FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Messerlian, C Wylie, BJ Minguez-Alarcon, L Williams, PL Ford, JB Souter, IC Calafat, AM Hauser, R AF Messerlian, Carmen Wylie, Blair J. Minguez-Alarcon, Lidia Williams, Paige L. Ford, Jennifer B. Souter, Irene C. Calafat, Antonia M. Hauser, Russ CA Earth Study Team TI Urinary Concentrations of Phthalate Metabolites and Pregnancy Loss Among Women Conceiving with Medically Assisted Reproduction SO EPIDEMIOLOGY LA English DT Article ID ENDOCRINE-DISRUPTING CHEMICALS; N-BUTYL PHTHALATE; BISPHENOL-A; MATERNAL EXPOSURE; MISCARRIAGE; RATS; CONCEPTION; HEALTH; RISK; MICE AB Background: Animal studies demonstrate that several phthalates are embryofetotoxic and are associated with increased pregnancy loss and malformations. Results from human studies on phthalates and pregnancy loss are inconsistent. Methods: We examined pregnancy loss prospectively in relation to urinary phthalate metabolite concentrations among women undergoing medically assisted reproduction. We used data from 256 women conceiving 303 pregnancies recruited between 2004 and 2012 from the Massachusetts General Hospital Fertility Center. We quantified 11 phthalate metabolite concentrations and calculated the molar sum of four di(2-ethylhexyl) phthalate (DEHP) metabolites (Sigma DEHP). We estimated risk ratios (RRs) and 95% confidence intervals for biochemical loss and total pregnancy loss (<20 weeks' gestation) across quartiles using repeated measures log-binomial models, adjusted for age, body mass index, smoking and infertility diagnosis. Results: Of the 303 pregnancies, 83 (27%) ended in loss less than 20 weeks' gestation and among these, 31 (10%) ended in biochemical loss. Although imprecise, the RRs for biochemical loss increased across quartiles of SDEHP and three individual DEHP metabolites. For SDEHP, the RRs (confidence intervals) were 2.3 (0.63, 8.5), 2.0 (0.58, 7.2), and 3.4 (0.97, 11.7) for quartiles two, three, and four, compared with one, respectively (P trend = 0.04). RRs for total pregnancy loss were elevated in the highest quartiles of SDEHP and three DEHP metabolites. The remaining seven phthalate metabolite concentrations evaluated were not associated with either outcome. Conclusions: We found a suggestive pattern of association between conception cycle-specific urinary concentrations of DEHP metabolites and biochemical and total pregnancy loss among women undergoing medically assisted reproduction. C1 [Messerlian, Carmen; Wylie, Blair J.; Minguez-Alarcon, Lidia; Ford, Jennifer B.; Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Wylie, Blair J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA USA. [Williams, Paige L.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Williams, Paige L.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Souter, Irene C.] Harvard Med Sch, Dept Obstet & Gynecol, Massachusetts Gen Hosp, Fertil Ctr, Boston, MA USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Hauser, Russ] Harvard Med Sch, Boston, MA USA. RP Messerlian, C (reprint author), Harvard TH Chan Sch Publ Hlth, 665 Huntington Ave,FXB 102A, Boston, MA 02115 USA. EM cmesser@hsph.harvard.edu FU National Institute of Environmental Health Sciences (NIEHS) [ES009718, ES022955, ES000002, T32ES007069]; National Institute of Environmental Health Sciences [NIH K23 ES021471]; Canadian Institutes of Health Research FX This work is supported by Grants ES009718, ES022955, and ES000002, T32ES007069 from the National Institute of Environmental Health Sciences (NIEHS). BJW was supported by the National Institute of Environmental Health Sciences (NIH K23 ES021471). CM was supported by a post-doctoral fellowship award from the Canadian Institutes of Health Research. NR 55 TC 1 Z9 1 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD NOV PY 2016 VL 27 IS 6 BP 879 EP 888 DI 10.1097/EDE.0000000000000525 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EF3UZ UT WOS:000390251500018 PM 27299194 ER PT J AU Kristensen, SL Martinez, F Jhund, PS Arango, JL Belohlavek, J Boytsov, S Cabrera, W Gomez, E Hagege, AA Huang, J Kiatchoosakun, S Kim, KS Mendoza, I Senni, M Squire, IB Vinereanu, D Wong, RCC Gong, JJ Lefkowitz, MP Rizkala, AR Rouleau, JL Shi, VC Solomon, SD Swedberg, K Zile, MR Packer, M McMurray, JJV AF Kristensen, Soren Lund Martinez, Felipe Jhund, Pardeep S. Arango, Juan Luis Belohlavek, Jan Boytsov, Sergey Cabrera, Walter Gomez, Efrain Hagege, Albert A. Huang, Jun Kiatchoosakun, Songsak Kim, Kee-Sik Mendoza, Ivan Senni, Michele Squire, Iain B. Vinereanu, Dragos Wong, Raymond Ching-Chiew Gong, Jianjian Lefkowitz, Martin P. Rizkala, Adel R. Rouleau, Jean L. Shi, Victor C. Solomon, Scott D. Swedberg, Karl Zile, Michael R. Packer, Milton McMurray, John J. V. TI Geographic variations in the PARADIGM-HF heart failure trial SO EUROPEAN HEART JOURNAL LA English DT Article DE Heart failure; Treatment outcome; Geographical variation; Clinical trial; Prognosis ID REDUCED EJECTION FRACTION; CLINICAL-TRIALS; ATRIAL-FIBRILLATION; GLOBAL VARIATION; OUTCOMES; MANAGEMENT; MORTALITY; EFFICACY; PROGRAM; EUROPE AB Aims The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treatment effects. We investigated these further in PARADIGM-HF, the largest and most globally representative trial in heart failure (HF) to date. Methods and results We looked at five regions: North America (NA) 602 (8%), Western Europe (WE) 1680 (20%), Central/Eastern Europe/Russia (CEER) 2762 (33%), Latin America (LA) 1433 (17%), and Asia-Pacific (AP) 1487 (18%). Notable differences included: WE patients (mean age 68 years) and NA (65 years) were older than AP (58 years) and LA (63 years) and had more coronary disease; NA and CEER patients had the worst signs, symptoms, and functional status. North American patients were the most likely to have a defibrillating-device (54 vs. 2% AP) and least likely prescribed a mineralocorticoid receptor antagonist (36 vs. 65% LA). Other evidence-based therapies were used most frequently in NA and WE. Rates of the primary composite outcome of cardiovascular (CV) death or HF hospitalization (per 100 patient-years) varied among regions: NA 13.6 (95% CI 11.7-15.7) WE 9.6 (8.6-10.6), CEER 12.3 (11.4-13.2), LA 11.2 (10.0-12.5), and AP 12.5 (11.3-13.8). After adjustment for prognostic variables, relative to NA, the risk of CV death was higher in LA and AP and the risk of HF hospitalization lower in WE. The benefit of sacubitril/valsartan was consistent across regions. Conclusion There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan. C1 [Kristensen, Soren Lund; Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [Kristensen, Soren Lund] Rigshosp, Dept Cardiol, Copenhagen, Denmark. [Martinez, Felipe] Univ Nacl Cordoba, Med, Cordoba, Argentina. [Arango, Juan Luis] Guatemalan Heart Inst, Guatemala City, Guatemala. [Belohlavek, Jan] Charles Univ Prague, Gen Univ Hosp, Dept Med 2, Cardiovasc Med, Prague, Czech Republic. [Belohlavek, Jan] Charles Univ Prague, Med Sch 1, Prague, Czech Republic. [Boytsov, Sergey] Natl Res Ctr Prevent Med, Moscow, Russia. [Cabrera, Walter] Clin Vesalio, Lima, Peru. [Gomez, Efrain] Clin Shaio, Bogota, Colombia. [Hagege, Albert A.] Paris Descartes Univ, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Dept Cardiol,Sorbonne Paris Cite,INSERM U970,Pari, Paris, France. [Huang, Jun] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China. [Kiatchoosakun, Songsak] Khon Kaen Univ, Cardiol, Med, Khon Kaen, Thailand. [Kim, Kee-Sik] Daegu Catholic Univ Hosp, Daegu, South Korea. [Mendoza, Ivan] Cent Univ Venezuela, Venezuela Inst Trop Med, Caracas, Venezuela. [Senni, Michele] Azienda Osped Papa Giovanni XXIII, Cardiol Scompenso & Trapianti Cuore 1, Bergamo, Italy. [Squire, Iain B.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. [Squire, Iain B.] Glenfield Hosp, NIHR Cardiovasc Biomed Res Unit, Leicester, Leics, England. [Vinereanu, Dragos] Univ Med & Pharm Carol Davila, Univ & Emergency Hosp, Bucharest, Romania. [Wong, Raymond Ching-Chiew] Natl Univ Heart Ctr, Dept Cardiol, Singapore, Singapore. [Gong, Jianjian; Lefkowitz, Martin P.; Rizkala, Adel R.; Shi, Victor C.] Novartis Pharmaceut, E Hanover, NJ USA. [Rouleau, Jean L.] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada. [Solomon, Scott D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Swedberg, Karl] Univ Gothenburg, Gothenburg, Sweden. [Swedberg, Karl] Imperial Coll, Natl Heart & Lung Inst, London, England. [Zile, Michael R.] Med Univ South Carolina, Charleston, SC USA. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Packer, Milton] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA. RP McMurray, JJV (reprint author), Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. EM john.mcmurray@glasgow.ac.uk FU Novartis; Danish Independent Research Council; Heart Failure Association of the European Society of Cardiology (ESC) FX The study was funded by Novartis. S.L.K. is supported by a Postdoctoral grant from the Danish Independent Research Council, and a Research Fellowship from the Heart Failure Association of the European Society of Cardiology (ESC). NR 24 TC 4 Z9 4 U1 7 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD NOV 1 PY 2016 VL 37 IS 41 BP 3167 EP + DI 10.1093/eurheartj/ehw226 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EF4MR UT WOS:000390303700013 PM 27354044 ER PT J AU Ionescu, DF Shelton, RC Baer, L Meade, KH Swee, MB Fava, M Papakostas, GI AF Ionescu, Dawn F. Shelton, Richard C. Baer, Lee Meade, Kathryn H. Swee, Michaela B. Fava, Maurizio Papakostas, George I. TI Ziprasidone augmentation for anxious depression SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE anxiolytic; anxious depression; psychopharmacology; treatment-resistant depression; ziprasidone augmentation ID STAR-ASTERISK-D; NONANXIOUS DEPRESSION; DISORDER ANALYSIS; METAANALYSIS; OUTPATIENTS; DIFFERENCE; EFFICACY; FEATURES AB Previously, we found an anxiolytic effect of ziprasidone augmentation to escitalopram (compared with placebo augmentation) in patients with depression in an 8-week, randomized, double-blind, parallel-group, placebo-controlled trial. Here, we carried out a post-hoc analysis, comparing changes in the Hamilton Depression and Anxiety Rating Scales between patients with anxious depression versus nonanxious depression, using a moderator analysis. Hamilton Depression Rating Scales total change scores from baseline and endpoint were not significantly different (interaction term P = 0.91) in patients with anxious depression on ziprasidone augmentation (n = 19; -9.1 +/- 4.9) or placebo (n = 19; -6.1 +/- 8.9) versus patients without anxious depression on ziprasidone (n = 52; -5.5 +/- 6.7) or placebo (n = 49; -2.3 +/- 4.5). There was a trend toward statistical significance (interaction term P = 0.1) in favor of patients without anxious depression for a difference in Hamilton Anxiety Rating Scale total change scores from baseline to endpoint [patients with anxious depression on ziprasidone augmentation (n = 19; -2.7 +/- 5.3) or placebo (n = 19; -3.3 +/- 5.8) versus patients without anxious depression on ziprasidone (n = 51;-3.9 +/- 6.6) or placebo (n = 44; -0.9 +/- 4.7)]. Ziprasidone augmentation was equally efficacious in treating depression in patients with versus without anxious depression. However, the observed anxiolytic effect for patients with higher anxiety was not clinically significant. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Ionescu, Dawn F.; Baer, Lee; Meade, Kathryn H.; Swee, Michaela B.; Fava, Maurizio; Papakostas, George I.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Ionescu, Dawn F.; Baer, Lee; Fava, Maurizio; Papakostas, George I.] Harvard Med Sch, Boston, MA USA. [Shelton, Richard C.] Univ Alabama Birmingham, Off Psychiat Clin Res, Dept Psychiat, Birmingham, AL USA. RP Ionescu, DF (reprint author), Massachusetts Gen Hosp, DCRP, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM dionescu@mgh.harvard.edu FU National Institute for Mental Health (NIMH) [R01MH081235] FX The authors would like to acknowledge the National Institute for Mental Health (NIMH) for funding through an R01 mechanism (R01MH081235 awarded to G.I.P.), Pfizer Inc. (for providing free blinded ziprasidone/placebo pills), and Forest Laboratories Inc. (for providing free escitalopram). NR 22 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0268-1315 EI 1473-5857 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD NOV PY 2016 VL 31 IS 6 BP 341 EP 346 DI 10.1097/YIC.0000000000000133 PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA EF3TL UT WOS:000390247200006 PM 27306192 ER PT J AU Lancaster, CL Teeters, JB Gros, DF Back, SE AF Lancaster, Cynthia L. Teeters, Jenni B. Gros, Daniel F. Back, Sudie E. TI Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment SO JOURNAL OF CLINICAL MEDICINE LA English DT Review DE posttraumatic stress disorder; evidence based; empirically supported; assessment; psychotherapy; pharmacotherapy; prolonged exposure; cognitive processing therapy; eye movement desensitization and reprocessing; selective serotonin reuptake inhibitors ID COGNITIVE-PROCESSING THERAPY; EYE-MOVEMENT DESENSITIZATION; RANDOMIZED CONTROLLED-TRIAL; PROLONGED EXPOSURE; REPROCESSING EMDR; RAPE VICTIMS; LIFE EVENTS; PSYCHOMETRIC PROPERTIES; SCREENING INSTRUMENT; SERTRALINE TREATMENT AB Posttraumatic stress disorder (PTSD) is a chronic psychological disorder that can develop after exposure to a traumatic event. This review summarizes the literature on the epidemiology, assessment, and treatment of PTSD. We provide a review of the characteristics of PTSD along with associated risk factors, and describe brief, evidence-based measures that can be used to screen for PTSD and monitor symptom changes over time. In regard to treatment, we highlight commonly used, evidence-based psychotherapies and pharmacotherapies for PTSD. Among psychotherapeutic approaches, evidence-based approaches include cognitive-behavioral therapies (e.g., Prolonged Exposure and Cognitive Processing Therapy) and Eye Movement Desensitization and Reprocessing. A wide variety of pharmacotherapies have received some level of research support for PTSD symptom alleviation, although selective serotonin reuptake inhibitors have the largest evidence base to date. However, relapse may occur after the discontinuation of pharmacotherapy, whereas PTSD symptoms typically remain stable or continue to improve after completion of evidence-based psychotherapy. After reviewing treatment recommendations, we conclude by describing critical areas for future research. C1 [Lancaster, Cynthia L.; Teeters, Jenni B.; Gros, Daniel F.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Lancaster, Cynthia L.; Teeters, Jenni B.; Gros, Daniel F.; Back, Sudie E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29401 USA. RP Back, SE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.; Back, SE (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29401 USA. EM lancascy@musc.edu; teeters@musc.edu; grosd@musc.edu; backs@musc.edu NR 95 TC 1 Z9 1 U1 22 U2 22 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD NOV PY 2016 VL 5 IS 11 AR 105 DI 10.3390/jcm5110105 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA EF1QC UT WOS:000390098800013 ER PT J AU McCarthy, CJ Behravesh, S Naidu, SG Oklu, R AF McCarthy, Colin J. Behravesh, Sasan Naidu, Sailendra G. Oklu, Rahmi TI Air Embolism: Practical Tips for Prevention and Treatment SO JOURNAL OF CLINICAL MEDICINE LA English DT Review DE Air embolism; endovascular; catheter; embolization ID ARTERIAL GAS EMBOLISM; HYPERBARIC-OXYGEN; TOO AB Air embolism is a rarely encountered but much dreaded complication of surgical procedures that can cause serious harm, including death. Cases that involve the use of endovascular techniques have a higher risk of air embolism; therefore, a heightened awareness of this complication is warranted. In particular, central venous catheters and arterial catheters that are often placed and removed in most hospitals by a variety of medical practitioners are at especially high risk for air embolism. With appropriate precautions and techniques it can be preventable. This article reviews the causes of air embolism, clinical management and prevention techniques. C1 [McCarthy, Colin J.] Harvard Med Sch, Massachusetts Gen Hosp, Div Intervent Radiol, 55 Fruit St,GRB-290A, Boston, MA USA. [Behravesh, Sasan; Naidu, Sailendra G.; Oklu, Rahmi] Mayo Clin Arizona, Div Vasc & Intervent Radiol, Phoenix, AZ 85054 USA. RP Oklu, R (reprint author), Mayo Clin Arizona, Div Vasc & Intervent Radiol, Phoenix, AZ 85054 USA. EM colin.mccarthy@mgh.harvard.edu; Behravesh.sasan@mayo.edu; Naidu.Sailen@mayo.edu; oklu.rahmi@mayo.edu OI Oklu, Rahmi/0000-0003-4984-1778 NR 26 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD NOV PY 2016 VL 5 IS 11 AR 93 DI 10.3390/jcm5110093 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA EF1QC UT WOS:000390098800001 ER PT J AU Switzer, GE Bruce, J Kiefer, DM Kobusingye, H Drexler, R Besser, RM Confer, DL Horowitz, MM King, RJ Shaw, BE van Walraven, SM Wiener, L Packman, W Varni, JW Pulsipher, MA AF Switzer, Galen E. Bruce, Jessica Kiefer, Deidre M. Kobusingye, Hati Drexler, Rebecca Besser, RaeAnne M. Confer, Dennis L. Horowitz, Mary M. King, Roberta J. Shaw, Bronwen E. van Walraven, Suzanna M. Wiener, Lori Packman, Wendy Varni, James W. Pulsipher, Michael A. TI Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors SO JOURNAL OF PEDIATRICS LA English DT Article ID BONE-MARROW DONATION; SIBLING DONOR; THE-LITERATURE; EXPERIENCE; TRANSPLANTATION; PEDSQL(TM)-4.0; RELIABILITY; VALIDITY; HARVEST; SAFETY AB Objectives To examine health-related quality of life (HRQoL) among sibling pediatric hematopoietic stem cell donors from predonation through 1 year postdonation, to compare donor-reported HRQoL scores with proxy-reports by parents/guardians and those of healthy norms, and to identify predonation factors (including donor age) potentially associated with postdonation HRQoL, to better understand the physical and psychosocial effects of pediatric hematopoietic stem cell donation. Study design A random sample of 105 pediatric donors from US centers and a parent/guardian were interviewed by telephone predonation and 4 weeks and 1 year postdonation. The interview included sociodemographic, psychosocial, and HRQoL items. A sample of healthy controls matched to donors by age, gender, and race/ethnicity was generated. Results Key findings included (1) approximately 20% of donors at each time point had very poor HRQoL; (2) child self-reported HRQoL was significantly lower than parent proxy-reported HRQoL at all 3 time points and significantly lower than that of norms at predonation and 4 weeks postdonation; and (3) younger children were at particular risk of poor HRQoL. Conclusions Additional research to identify the specific sources of poorer HRQoL among at-risk donors (eg, the donation experience vs having a chronically ill sibling) and the reasons that parents may be overestimating HRQoL in their donor children is critical and should lead to interventions and policy changes that ensure positive experiences for these minor donors. C1 [Switzer, Galen E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Switzer, Galen E.; Bruce, Jessica] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kiefer, Deidre M.; Kobusingye, Hati; Drexler, Rebecca; Besser, RaeAnne M.; Confer, Dennis L.; King, Roberta J.] Natl Marrow Donor Program Be Match, Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Horowitz, Mary M.; Shaw, Bronwen E.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [van Walraven, Suzanna M.] Sanquin Blood Supply, Dept Donor Serv, Amsterdam, Netherlands. [van Walraven, Suzanna M.] Leiden Univ, Med Ctr, Dept Pediat Stem Cell Transplantat, Willem Alexander Childrens Hosp, Leiden, Netherlands. [Wiener, Lori] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Packman, Wendy] Palo Alto Univ, Dept Psychol, Palo Alto, CA USA. [Varni, James W.] Texas A&M Univ, Dept Pediat, College Stn, TX USA. [Varni, James W.] Texas A&M Univ, Ctr Hlth Syst & Design, Dept Landscape Architecture & Urban Planning, College Stn, TX USA. [Pulsipher, Michael A.] Childrens Hosp Los Angeles, Div Hematol Oncol & Bone Marrow Transplantat, Los Angeles, CA 90027 USA. RP Switzer, GE (reprint author), Univ Pittsburgh, 3501 Forbes Ave,Oxford Bldg,Suite 410, Pittsburgh, PA 15213 USA. EM SwitzerGE@upmc.edu FU National Heart, Lung, and Blood Institute [R01 HL085707]; Mapi Research Trust FX Supported by the National Heart, Lung, and Blood Institute (R01 HL085707). J.V. holds the copyright and the trademark for the Pediatric Quality of Life Inventory and receives financial compensation from the Mapi Research Trust, which is a nonprofit research institute that charges distribution fees to for-profit companies that use the Pediatric Quality of Life Inventory. The other authors declare no conflicts of interest. NR 27 TC 1 Z9 1 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD NOV PY 2016 VL 178 BP 164 EP + DI 10.1016/j.jpeds.2016.07.009 PG 8 WC Pediatrics SC Pediatrics GA EF0ON UT WOS:000390025400031 PM 27522440 ER PT J AU Sindhar, S Lugo, M Levin, MD Danback, JR Brink, BD Yu, E Dietzen, DJ Clark, AL Purgert, CA Waxler, JL Elder, RW Pober, BR Kozel, BA AF Sindhar, Sampat Lugo, Michael Levin, Mark D. Danback, Joshua R. Brink, Benjamin D. Yu, Eric Dietzen, Dennis J. Clark, Amy L. Purgert, Carolyn A. Waxler, Jessica L. Elder, Robert W. Pober, Barbara R. Kozel, Beth A. TI Hypercalcemia in Patients with Williams-Beuren Syndrome SO JOURNAL OF PEDIATRICS LA English DT Article ID INFANTILE HYPERCALCEMIA; VITAMIN-D; CALCIUM; PAMIDRONATE; CHROMOSOME-7; MANAGEMENT; DIAGNOSIS; DELETIONS; INFUSION; ADULTS AB Objective To evaluate the timing, trajectory, and implications of hypercalcemia in Williams-Beuren syndrome ( WBS) through a multicenter retrospective study. Study design Data on plasma calcium levels from 232 subjects with WBS aged 0-67.1 years were compared with that in controls and also with available normative data. Association testing was used to identify relevant comorbidities. Results On average, individuals with WBS had higher plasma calcium levels than controls, but 86.7% of values were normal. Nonpediatric laboratories overreport hypercalcemia in small children. When pediatric reference intervals were applied, the occurrence of hypercalcemia dropped by 51% in infants and by 38% in toddlers. Across all ages, 6.1% of the subjects had actionable hypercalcemia. In children, actionable hypercalcemia was seen in those aged 5-25 months. In older individuals, actionable hypercalcemia was often secondary to another disease process. Evidence of dehydration, hypercalciuria, and nephrocalcinosis were common in both groups. Future hypercalcemia could not be reliably predicted by screening calcium levels. A subgroup analysis of 91 subjects found no associations between hypercalcemia and cardiovascular disease, gastrointestinal complaints, or renal anomalies. Analyses of electrogradiography data showed an inverse correlation of calcium concentration with corrected QT interval, but no acute life-threatening events were reported. Conclusions Actionable hypercalcemia in patients with WBS occurs infrequently. Although irritability and lethargy were commonly reported, no mortality or acute life-threatening events were associated with hypercalcemia and the only statistically associated morbidities were dehydration, hypercalciuria, and nephrocalcinosis. C1 [Sindhar, Sampat; Lugo, Michael; Danback, Joshua R.; Dietzen, Dennis J.; Clark, Amy L.; Purgert, Carolyn A.; Kozel, Beth A.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. [Levin, Mark D.; Kozel, Beth A.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Brink, Benjamin D.; Yu, Eric; Pober, Barbara R.] Quinnipiac Univ, Frank H Netter Sch Med, North Haven, CT USA. [Waxler, Jessica L.; Pober, Barbara R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Elder, Robert W.] Yale Univ, Sch Med, Dept Pediat, Sect Cardiol, New Haven, CT 06510 USA. [Elder, Robert W.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiol, New Haven, CT 06510 USA. [Pober, Barbara R.] Harvard Med Sch, Boston, MA USA. RP Kozel, BA (reprint author), NHLBI, Bldg 10,8N-110, Bethesda, MD 20892 USA. EM beth.kozel@nih.gov FU Children's Discovery Institute (Washington University School of Medicine/St. Louis Children's Hospital) [CH-FR-2011-169]; Division of Intramural Research of the National Heart, Lung, and Blood Institute; National Institutes of Health [T32HD043010, T35DK074375] FX Funded by the Children's Discovery Institute (CH-FR-2011-169 at Washington University School of Medicine/St. Louis Children's Hospital [to B.K.]) and the Division of Intramural Research of the National Heart, Lung, and Blood Institute. A.C. is supported by the National Institutes of Health (T32HD043010). S.S. was supported by the National Institutes of Health (T35DK074375). The authors declare no conflicts of interest. NR 35 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD NOV PY 2016 VL 178 BP 254 EP + DI 10.1016/j.jpeds.2016.08.027 PG 11 WC Pediatrics SC Pediatrics GA EF0ON UT WOS:000390025400045 PM 27574996 ER PT J AU Flaherty, MR Raybould, T Jamal-Allial, A Kaafarani, HMA Lee, J Gervasini, A Ginsburg, R Mandell, M Donelan, K Masiakos, PT AF Flaherty, Michael R. Raybould, Toby Jamal-Allial, Aziza Kaafarani, Haytham M. A. Lee, Jarone Gervasini, Alice Ginsburg, Richard Mandell, Mark Donelan, Karen Masiakos, Peter T. TI Impact of a State Law on Physician Practice in Sports-Related Concussions SO JOURNAL OF PEDIATRICS LA English DT Article ID PRIMARY-CARE; KNOWLEDGE; MEDICINE; CHILDREN; REST; PROVIDERS; SYMPTOMS; INJURIES; HEADS AB Objective To determine physician-reported adherence to and support of the 2010 Massachusetts youth concussion law, as well as barriers to care and clinical practice in the context of legislation. Study design Primary care physicians (n = 272) in a large pediatric network were eligible for a cross-sectional survey in 2014. Survey questions addressed key policy and practice provisions: concussion knowledge, state regulations and training, practice patterns, referrals, patient characteristics, and barriers to care. Analyses explored relationships between practice and policy, adjusting for physician demographic and practice characteristics. Results The survey response rate was 64% among all responders (173 of 272). A total of 146 respondents who had evaluated, treated, or referred patients with a suspected sports-related concussion in the previous year were eligible for analysis. The vast majority (90%) of providers agreed that the current Massachusetts laws regarding sports concussions are necessary and support the major provisions. Three-quarters (74%) had taken a required clinician training course on concussions. Those who took training courses were significantly more likely to develop individualized treatment plans (OR, 3.6; 95% CI, 1.1-11.0). Physician training did not improve screening of youth with concussion for depression or substance use. Most physicians (77%) advised patients to refrain from computer, telephone, or television for various time periods. Physicians reported limited communication with schools. Conclusions Primary care physicians report being comfortable with the diagnosis and management of concussions, and support statewide regulations; however, adherence to mandated training and specific legal requirements varied. Broader and more frequent training may be necessary to align current best evidence with clinical care and state-mandated practice. C1 [Flaherty, Michael R.; Mandell, Mark] Massachusetts Gen Hosp, Dept Pediat Crit Care, Boston, MA 02114 USA. [Flaherty, Michael R.; Kaafarani, Haytham M. A.; Lee, Jarone; Gervasini, Alice; Ginsburg, Richard; Mandell, Mark; Donelan, Karen; Masiakos, Peter T.] Harvard Med Sch, Boston, MA USA. [Raybould, Toby; Jamal-Allial, Aziza; Kaafarani, Haytham M. A.; Lee, Jarone; Gervasini, Alice] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Serv & Surg Crit Care, Boston, MA 02114 USA. [Ginsburg, Richard] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Donelan, Karen] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Masiakos, Peter T.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. RP Flaherty, MR (reprint author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, 175 Cambridge St, Boston, MA 02114 USA. EM mrflaherty@partners.org NR 25 TC 0 Z9 0 U1 5 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD NOV PY 2016 VL 178 BP 268 EP 274 DI 10.1016/j.jpeds.2016.08.025 PG 7 WC Pediatrics SC Pediatrics GA EF0ON UT WOS:000390025400047 PM 27597735 ER PT J AU Quenon, L Dricot, L Woodard, JL Hanseeuw, B Gilis, N Lhommel, R Ivanoiu, A AF Quenon, Lisa Dricot, Laurence Woodard, John L. Hanseeuw, Bernard Gilis, Nathalie Lhommel, Renaud Ivanoiu, Adrian TI Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE FCSRT; Cue efficiency; Free-recall; Alzheimer's disease; Amyloid; Hippocampal volume; Cortical thickness ID MILD COGNITIVE IMPAIRMENT; CORTICAL THICKNESS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; AMNESTIC SYNDROME; ELDERLY SUBJECTS; BETA DEPOSITION; MEMORY DEFICITS; FUNCTIONAL MRI AB Objectives: Relatively few studies have investigated relationships between performance on clinical memory measures and indexes of underlying neuropathology related to Alzheimer's disease (AD). This study investigated predictive relationships between Free and Cued Selective Reminding Test (FCSRT) cue efficiency (CE) and free-recall (FR) measures and brain amyloid levels, hippocampal volume (HV), and regional cortical thickness. Methods: Thirty-one older controls without memory complaints and 60 patients presenting memory complaints underwent the FCSRT, amyloid imaging using [F-18]-flutemetamol positron emission tomography, and surface-based morphometry (SBM) using brain magnetic resonance imaging. Three groups were considered: patients with high (A beta+P) and low (A beta- P) amyloid load and controls with low amyloid load (A beta- C). Results: A beta+P showed lower CE than both A beta- groups, but the A beta- groups did not differ significantly. In contrast, FR discriminated all groups. SBM analyses revealed that CE indexes were correlated with the cortical thickness of a wider set of left-lateralized temporal and parietal regions than FR. Regression analyses demonstrated that amyloid load and left HV independently predicted FCSRT scores. Moreover, CE indexes were predicted by the cortical thickness of some regions involved in early AD, such as the entorhinal cortex. Conclusions: Compared to FR measures, CE indexes appear to be more specific for differentiating persons on the basis of amyloid load. Both CE and FR performance were predicted independently by brain amyloid load and reduced left HV. However, CE performance was also predicted by the cortical thickness of regions known to be atrophic early in AD. C1 [Quenon, Lisa; Dricot, Laurence; Woodard, John L.; Hanseeuw, Bernard; Ivanoiu, Adrian] Catholic Univ Louvain, Inst Neurosci, Brussels, Belgium. [Woodard, John L.] Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA. [Hanseeuw, Bernard; Ivanoiu, Adrian] Catholic Univ Louvain, St Luc Univ Hosp, Neurol Dept, Brussels, Belgium. [Hanseeuw, Bernard] Harvard Med Sch, Massachusetts Gen Hosp, Neurol Dept, Boston, MA USA. [Gilis, Nathalie] Citadelle Reg Hosp Ctr, Neurosurg Dept, Liege, Belgium. [Lhommel, Renaud] Catholic Univ Louvain, St Luc Univ Hosp, Nucl Med Dept, Brussels, Belgium. RP Quenon, L (reprint author), Ctr Revalidat Neuropsychol, Ave Hippocrate 10, B-1200 Woluwe St Lambert, Belgium. EM lisa.quenon@uclouvain.be FU Belgian Foundation for Scientific Research [A 2/5 -MCF/DM]; Saint-Luc Foundation FX This research was supported by the Belgian Foundation for Scientific Research (LQ, FNRS grant number A 2/5 -MCF/DM) and Saint-Luc Foundation (BH: Bourse Ordre de Malte Oeuvre du Calvaire). We are grateful to the firm GE Healthcare Ltd. for having supplied with [18F]flutemetamol for the PET scan imaging according to a convention with our Clinic. The authors do not have any potential conflict of interest to declare. NR 66 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD NOV PY 2016 VL 22 IS 10 SI SI BP 991 EP 1004 DI 10.1017/S1355617716000813 PG 14 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA EF4WM UT WOS:000390332700005 PM 27903329 ER PT J AU Seidman, LJ Pousada-Casal, A Scala, S Meyer, EC Stone, WS Thermenos, HW Molokotos, E Agnew-Blais, J Tsuang, MT Faraone, SV AF Seidman, Larry J. Pousada-Casal, Andrea Scala, Silvia Meyer, Eric C. Stone, William S. Thermenos, Heidi W. Molokotos, Elena Agnew-Blais, Jessica Tsuang, Ming T. Faraone, Stephen V. TI Auditory Vigilance and Working Memory in Youth at Familial Risk for Schizophrenia or Affective Psychosis in the Harvard Adolescent Family High Risk Study SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Review DE Familial high-risk; Vigilance; Working memory; Psychopathology; Schizophrenia; Affective psychoses; Endophenotypes ID NEW-ENGLAND FAMILY; CONSENSUS COGNITIVE BATTERY; CONTINUOUS PERFORMANCE-TEST; PHENOTYPES B-SNIP; BIPOLAR DISORDER; NEUROPSYCHOLOGICAL FUNCTION; NONPSYCHOTIC RELATIVES; 1ST-DEGREE RELATIVES; SUSTAINED ATTENTION; MAJOR DEPRESSION AB Background: The degree of overlap between schizophrenia (SCZ) and affective psychosis (AFF) has been a recurring question since Kraepelin's subdivision of the major psychoses. Studying nonpsychotic relatives allows a comparison of disorder-associated phenotypes, without potential confounds that can obscure distinctive features of the disorder. Because attention and working memory have been proposed as potential endophenotypes for SCZ and AFF, we compared these cognitive features in individuals at familial high-risk (FHR) for the disorders. Methods: Young, unmedicated, first-degree relatives (ages, 13-25 years) at FHR-SCZ (n=41) and FHR-AFF (n=24) and community controls (CCs, n=54) were tested using attention and working memory versions of the Auditory Continuous Performance Test. To determine if schizotypal traits or current psychopathology accounted for cognitive deficits, we evaluated psychosis proneness using three Chapman Scales, Revised Physical Anhedonia, Perceptual Aberration, and Magical Ideation, and assessed psychopathology using the Hopkins Symptom Checklist -90 Revised. Results: Compared to controls, the FHR-AFF sample was significantly impaired in auditory vigilance, while the FHR-SCZ sample was significantly worse in working memory. Both FHR groups showed significantly higher levels of physical anhedonia and some psychopathological dimensions than controls. Adjusting for physical anhedonia, phobic anxiety, depression, psychoticism, and obsessive-compulsive symptoms eliminated the FHR-AFF vigilance effects but not the working memory deficits in FHR-SCZ. Conclusions: The working memory deficit in FHR-SZ was the more robust of the cognitive impairments after accounting for psychopathological confounds and is supported as an endophenotype. Examination of larger samples of people at familial risk for different psychoses remains necessary to confirm these findings and to clarify the role of vigilance in FHR-AFF. C1 [Seidman, Larry J.; Pousada-Casal, Andrea; Scala, Silvia; Stone, William S.; Thermenos, Heidi W.; Molokotos, Elena; Tsuang, Ming T.] Harvard Med Sch, Dept Psychiat, Massachusetts Mental Hlth Ctr, Div Publ Psychiat,Beth Israel Deaconess Med Ctr, Boston, MA USA. [Seidman, Larry J.; Thermenos, Heidi W.] Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA. [Pousada-Casal, Andrea] St Louis Univ, Madrid, Spain. [Scala, Silvia] Univ Verona, Sect Psychiat & Clin Psychol, Dept Publ Hlth & Community Med, Ple LA Scuro, Verona, Italy. [Meyer, Eric C.] VA VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX USA. [Meyer, Eric C.] Cent Texas Vet Healthcare Syst, Temple, TX USA. [Meyer, Eric C.] Texas A&M Hlth Sci Ctr, Coll Med, College Stn, TX USA. [Agnew-Blais, Jessica] Kings Coll London, MRC Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England. [Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genom, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Inst Genom Med, La Jolla, CA USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. RP Seidman, LJ (reprint author), Massachusetts Mental Hlth Ctr, Commonwealth Res Ctr, 5th Floor,75 Fenwood Rd, Boston, MA 02115 USA. EM lseidman@bidmc.harvard.edu NR 108 TC 0 Z9 0 U1 5 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD NOV PY 2016 VL 22 IS 10 SI SI BP 1026 EP 1037 DI 10.1017/S1355617716000242 PG 12 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA EF4WM UT WOS:000390332700008 PM 27903327 ER PT J AU Chung, J Valentine, W Sharath, SE Pathak, A Barshes, NR Pisimisis, G Kougias, P Mills, JL AF Chung, Jayer Valentine, Wilmer Sharath, Sherene E. Pathak, Amite Barshes, Neal R. Pisimisis, George Kougias, Panagiotis Mills, Joseph L. TI Percutaneous intervention for carotid in-stent restenosis does not improve outcomes compared with nonoperative management SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ULTRASOUND VELOCITY CRITERIA; RECURRENT STENOSIS; ARTERY STENOSIS; ENDARTERECTOMY; ANGIOPLASTY; STROKE; DISEASE; RISK; TRIAL AB Background: The appropriateness of percutaneous intervention for moderate to severe carotid in-stent restenosis (C-ISR) is unclear. We therefore sought to compare stroke/death/myocardial infarction (MI) rates between percutaneous interventions and nonoperative management for 50% C-ISR. Methods: We performed a single-center retrospective review of consecutive patients presenting with 50% C-ISR to the vascular surgery service. Demographics, comorbidities, and intraoperative and postoperative variables were obtained. The degree of stenosis was verified by review of digital subtraction or computed tomography angiograms. The primary outcome was stroke/death/MI after the diagnosis of 50% C-ISR. x2, Kruskal-Wallis, and Kaplan-Meier analysis was used to quantify outcomes of the patients treated percutaneously vs nonoperatively. Results: During a 13-year period, 59 patients (75 C-ISRs) presented with 50% C-ISRs (n = 58 male [98%]; n = 57 C-ISRs asymptomatic [76%]) with a median age of 67.5 years (62.8-74.6). The initial pathologic process underlying the original stent was atherosclerosis in 33 (70%), radiation induced in 10 (21%), prior carotid endarterectomy in 4 (9%), and unknown in 28 (37%). Forty C-ISRs underwent a percutaneous intervention (19 percutaneous angioplasty only [48%]; 21 repeated stent and percutaneous angioplasty [52%]). Median follow-up for the entire cohort was 948 days (283-2322) and similar between the intervention and nonintervention arms. There were no significant differences between the arms with respect to age (P=.16), medical comorbidities (P>.05), original stent type (P=.46), or clopidogrel use (P=.74). At 30 days, there was one stroke and subsequent death in the intervention arm and none in the nonintervention arm. During the follow-up period, a median of 1.0 procedure was required to maintain patency. By Kaplan-Meier analysis, there were no statistically significant differences between the intervention and nonintervention arms with respect to stroke/death/MI as a composite or any of the individual components at last follow-up (P =.82). Kaplan-Meier estimated patency was not significantly superior in the intervention vs the nonintervention arm (8.0 years 1.1 vs 5.3 years 0.7; P =.14). Conclusions: Over 13 years, percutaneous interventions for 50% C-ISR were safe and durable. However, interventions fail to improve long-term stroke/death/MI or patency rates relative to nonintervention. Intervention for C-ISR may not be necessary, although future appropriately powered, prospective trials will be necessary to confirm these findings and to determine the appropriateness of interventions for C-ISR. C1 [Chung, Jayer; Valentine, Wilmer; Sharath, Sherene E.; Pathak, Amite; Barshes, Neal R.; Pisimisis, George; Kougias, Panagiotis; Mills, Joseph L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. RP Chung, J (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM jayer.chung@bcm.edu OI Mills, Joseph/0000-0002-4955-4384 FU Michael E. DeBakey Department of Surgery at Baylor College of Medicine FX The work was funded by intramural funding from the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. NR 31 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD NOV PY 2016 VL 64 IS 5 BP 1286 EP + DI 10.1016/j.jvs.2016.05.086 PG 10 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EF0UQ UT WOS:000390042100013 PM 27462003 ER PT J AU Klarin, D Lancaster, RT Ergul, E Bertges, D Goodney, P Schermerhorn, ML Cambria, RP Patel, VI AF Klarin, Derek Lancaster, Robert T. Ergul, Emel Bertges, Daniel Goodney, Philip Schermerhorn, Marc L. Cambria, Richard P. Patel, Virendra I. CA Vasc Study Grp New England TI Perioperative and long-term impact of chronic kidney disease on carotid artery interventions SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID CHRONIC RENAL-INSUFFICIENCY; BYPASS-SURGERY; ENDARTERECTOMY; OUTCOMES; STENOSIS; RISK; REVASCULARIZATION; PREDICTION; MORTALITY; SURVIVAL AB Objective: Chronic kidney disease (CKD) increases morbidity and mortality after vascular procedures and adversely affects late survival of patients. The presence of CKD also confers increased risk of stroke in patients with asymptomatic carotid stenosis. Patients undergoing carotid intervention in the Vascular Study Group of New England database were stratified by CKD status referable to periprocedural and late outcomes. Methods: All carotid artery stenting and carotid endarterectomies (CEAs) performed from 2003 to 2013 were stratified by CKD severity as mild (estimated glomerular filtration rate [eGFR] >60 mL/min/1.73 m2), moderate (eGFR 30-59), and severe (eGFR <30). The impact of CKD on outcomes of carotid procedures was evaluated using univariate and multivariate methods. Results: Of 12,568 patients identified, 11,746 (93%) underwent CEA and 822 (7%) underwent carotid artery stenting. Procedures were performed for symptomatic disease in 40%. CI) severity was mild in 58%, moderate in 35%, and severe in 7%. The 30-day stroke rate was very low across all CKD groups (1.76% mild vs 1.84% moderate and 1.34% severe; P =.009). The 30-day mortality increased with worsening renal function (0.4% mild vs 0.9% moderate and 0.9% severe; P =.01). Independent predictors of 30-day stroke or death included American Society of Anesthesiologists (ASA) class 4 or 5 (odds ratio, 2.3; 95% confidence interval [CI], 1.5-3.4; P =.0001). Multivariable Cox hazards regression showed that severe CKD (hazard ratio [HR], 1.8; 95% CI, 1.3-2.6), ASA class 4 or 5 (HR, 1.7; 95% CI, 1.3-2.2), preoperative cortical symptoms (HR, 1.5; 95% CI, 1.2-1.8), history of diabetes (HR, 1.4; 95% CI, 1.1-1.7), and age (HR, 1.03/y; 95% CI, 1.02-1.04) independently (all P <.01) predicted neurologic events or death at median follow-up of 12.7 months (interquartile range, 10.3-15.2 months). CKD did not increase the risk of neurologic events at 1-year follow-up. Predictors (P <.05) of late death included moderate CM) (HR, 1.3; 95% CI, 1.01-1.7), severe CKD (HR, 2.2; 95% CI, 1.6-2.9), ASA class 4 or 5 (HR, 1.6; 95% CI, 1.2-2.0), history of diabetes (HR, 1.4; 95% CI, 1.2-1.7), chronic obstructive pulmonary disease (HR, 1.4; 95% CI, 1.1-1.8), and cortical symptoms (HR, 1.3; 95% CI, 1.05-1.6). The 1-, 5-, and 10-year survival rates decreased with worsening renal function (log-rank test, P <.001), but patients with severe CKD maintained a 71% survival at 5 years. Conclusions: CKD severity increases risk of perioperative mortality as well as late mortality. Patients with CKD benefit from stroke-free survival especially after CEA. Unlike patients with peripheral arterial occlusive disease, for whom severe CKD reduces median survival to 2.5 years, patients with CKD and carotid disease exhibit much longer survival. This suggests that carotid interventions have utility in carefully selected patients with moderate and severe CI= 3 or selected prolonged grade 2 adverse events (AEs), the dose can be reduced by 10 mg decrements to a minimum of 20 mg. Here, we evaluate the influence of afatinib dose reduction on AEs, pharmacokinetics and progression-free survival (PFS) in the phase III LUX-Lung 3 and 6 (LL3/6) trials. Treatment-na < ve patients with advancedEGFR mutation-positive NSCLC in LL3 (global) and LL6 (China, Thailand, South Korea) were randomized to afatinib or chemotherapy. All afatinib-treated patients (LL3,n = 229; LL6,n = 239) were included in thepost hoc analyses. Incidence and severity of common AEs before and after afatinib dose reduction were assessed. Afatinib plasma concentrations were compared in patients who reduced to 30 mg versus those remaining at 40 mg. PFS was compared between patients who dose reduced within the first 6 months of treatment and those who did not. Dose reductions occurred in 53.3% (122/229) and 28.0% (67/239) of patients in LL3 and LL6, respectively; most (86.1% and 82.1%) within the first 6 months of treatment. Dose reduction led to decreases in the incidence of drug-related AEs, and was more likely in patients with higher afatinib plasma concentrations. On day 43, patients who dose reduced to 30 mg (n = 59) had geometric mean afatinib plasma concentrations of 23.3 ng/ml, versus 22.8 ng/ml in patients who remained on 40 mg (n = 284). The median PFS was similar in patients who dose reduced during the first 6 months versus those who did not {LL3: 11.3 versus 11.0 months [hazard ratio (HR) 1.25]; LL6: 12.3 versus 11.0 months (HR 1.00)}. Tolerability-guided dose adjustment is an effective measure to reduce afatinib-related AEs without affecting therapeutic efficacy. Clinicaltrials.gov identifiers: NCT00949650 and NCT0112393. C1 [Yang, J. C. -H.] Natl Taiwan Univ Hosp, Taipei, Taiwan. [Yang, J. C. -H.] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan. [Sequist, L. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sequist, L. V.] Harvard Med Sch, Boston, MA USA. [Zhou, C.] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China. [Schuler, M.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany. [Geater, S. L.] Prince Songkla Univ, Hat Yai, Thailand. [Mok, T.] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China. [Hu, C. -P.] Cent S Univ, Xiangya Hosp, Changsha, Peoples R China. [Yamamoto, N.] Wakayama Med Univ, Wakayama, Japan. [Feng, J.] Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China. [O'Byrne, K.] Princess Alexandra Hosp, Brisbane, Qld, Australia. [O'Byrne, K.] Queensland Univ Technol, Brisbane, Qld, Australia. [Lu, S.] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China. [Hirsh, V.] McGill Univ, Montreal, PQ, Canada. [Huang, Y.] Kunming Med Univ, Affiliated Hosp 3, Yunnan Tumor Hosp, Kunming, Yunnan Province, Peoples R China. [Sebastian, M.] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany. [Okamoto, I.] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan. [Dickgreber, N.] Mathias Spital Rheine, Thorac Oncol & Resp Care Med, Rheine, Germany. [Shah, R.] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England. [Maerten, A.] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. [Massey, D.] Boehringer Ingelheim Ltd UK, Bracknell, Berks, England. [Wind, S.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. [Wu, Y. -L.] Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China. [Wu, Y. -L.] Guangdong Acad Med Sci, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China. RP Wu, YL (reprint author), Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.; Wu, YL (reprint author), Guangdong Acad Med Sci, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China. EM syylwu@live.cn FU Boehringer Ingelheim; Caroline Allinson of GeoMed; Ashfield Company, part of UDG Healthcare plc FX This work was supported by Boehringer Ingelheim. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Caroline Allinson of GeoMed, an Ashfield Company, part of UDG Healthcare plc, during the preparation of this article. There is no applicable grant number for this work. NR 26 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2016 VL 27 IS 11 BP 2103 EP 2110 DI 10.1093/annonc/mdw322 PG 8 WC Oncology SC Oncology GA ED0JN UT WOS:000388528900019 PM 27601237 ER PT J AU Liu, JF Moore, KN Birrer, MJ Berlin, S Matulonis, UA Infante, JR Wolpin, B Poon, KA Firestein, R Xu, J Kahn, R Wang, Y Wood, K Darbonne, WC Lackner, MR Kelley, SK Lu, X Choi, YJ Maslyar, D Humke, EW Burris, HA AF Liu, J. F. Moore, K. N. Birrer, M. J. Berlin, S. Matulonis, U. A. Infante, J. R. Wolpin, B. Poon, K. A. Firestein, R. Xu, J. Kahn, R. Wang, Y. Wood, K. Darbonne, W. C. Lackner, M. R. Kelley, S. K. Lu, X. Choi, Y. J. Maslyar, D. Humke, E. W. Burris, H. A. TI Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer SO ANNALS OF ONCOLOGY LA English DT Article DE MUC16; antibody-drug conjugate; DMUC5754a; ovarian cancer; pancreatic cancer ID MONOCLONAL-ANTIBODY; CA125; MUC16; ANTIGEN; EXPRESSION; CARCINOMA; VEDOTIN; TUMORS; MUCIN AB MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody-drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE). This phase I study evaluated safety, pharmacokinetics (PK), and pharmacodynamics of DMUC5754A given every 3 weeks (Q3W, 0.3-3.2 mg/kg) or weekly (Q1W, 0.8-1.6 mg/kg) to patients with advanced recurrent platinum-resistant OC or unresectable PC. Biomarker studies were also undertaken. Patients (66 OC, 11 PC) were treated with DMUC5754A (54 Q3W, 23 Q1W). Common related adverse events (AEs) in > 20% of patients (all grades) over all dose levels were fatigue, peripheral neuropathy, nausea, decreased appetite, vomiting, diarrhea, alopecia, and pyrexia in Q3W patents, and nausea, vomiting, anemia, fatigue, neutropenia, alopecia, decreased appetite, diarrhea, and hypomagnesemia in Q1W patients. Grade >= 3-related AE in >= 5% of patients included neutropenia (9%) and fatigue (7%) in Q3W patients, and neutropenia (17%), diarrhea (9%), and hyponatremia (9%) in Q1W patients. Plasma antibody-conjugated MMAE (acMMAE) and serum total antibody exhibited non-linear PK across tested doses. Minimal accumulation of acMMAE, total antibody, or unconjugated MMAE was observed. Confirmed responses (1 CR, 6 PRs) occurred in OC patients whose tumors were MUC16-positive by IHC (2+ or 3+). Two OC patients had unconfirmed PRs; six OC patients had stable disease lasting > 6 months. For CA125, a cut-off of >= 70% reduction was more suitable for monitoring treatment response due to the binding and clearance of serum CA125 by MUC16 ADC. We identified circulating HE4 as a potential novel surrogate biomarker for monitoring treatment response of MUC16 ADC and other anti-MUC16 therapies in OC. DMUC5754A has an acceptable safety profile and evidence of anti-tumor activity in patients with MUC16-expressing tumors. Objective responses were only observed in MUC16-high patients, although prospective validation is required. NCT01335958. C1 [Liu, J. F.; Berlin, S.; Matulonis, U. A.; Wolpin, B.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Moore, K. N.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA. [Birrer, M. J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA. [Berlin, S.] New England Canc Care Specialists, Dept Oncol, Kennebunk, ME USA. [Infante, J. R.; Burris, H. A.] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. [Poon, K. A.; Firestein, R.; Xu, J.; Kahn, R.; Wang, Y.; Wood, K.; Darbonne, W. C.; Lackner, M. R.; Kelley, S. K.; Lu, X.; Choi, Y. J.; Maslyar, D.; Humke, E. W.] Genentech Inc, Early Dev, San Francisco, CA USA. RP Liu, JF (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Gynecol Oncol Program, 450 Brookline Ave, Boston, MA 02215 USA. EM joyce_liu@dfci.harvard.edu FU Genentech, Inc., South San Francisco, CA FX This study was funded by Genentech, Inc., South San Francisco, CA. No grant number is applicable. NR 15 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2016 VL 27 IS 11 BP 2124 EP 2130 DI 10.1093/annonc/mdw401 PG 7 WC Oncology SC Oncology GA ED0JN UT WOS:000388528900022 PM 27793850 ER PT J AU Shahian, DM AF Shahian, David M. TI Envisioning Excellence SO ANNALS OF THORACIC SURGERY LA English DT Editorial Material ID THORACIC SURGEONS; PERFORMANCE; SOCIETY; VOLUME C1 [Shahian, David M.] Massachusetts Gen Hosp, Dept Surg & Ctr Qual & Safety, 55 Fruit St, Boston, MA 02114 USA. RP Shahian, DM (reprint author), Massachusetts Gen Hosp, Dept Surg & Ctr Qual & Safety, 55 Fruit St, Boston, MA 02114 USA. EM dshahian@partners.org NR 16 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD NOV PY 2016 VL 102 IS 5 BP 1428 EP 1431 DI 10.1016/j.athoracsur.2016.06.039 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EE4AR UT WOS:000389544600035 PM 27772569 ER PT J AU Gaissert, HA Fernandez, FG Allen, MS Burfeind, WR Block, MI Donahue, JM Mitchell, JD Schipper, PH Onaitis, MW Kosinski, AS Jacobs, JP Shahian, DM Kozower, BD Edwards, FH Conrad, EA Patterson, GA AF Gaissert, Henning A. Fernandez, Felix G. Allen, Mark S. Burfeind, William R. Block, Mark I. Donahue, James M. Mitchell, John D. Schipper, Paul H. Onaitis, Mark W. Kosinski, Andrzej S. Jacobs, Jeffrey P. Shahian, David M. Kozower, Benjamin D. Edwards, Fred H. Conrad, Emily A. Patterson, G. Alexander TI The Society of Thoracic Surgeons General Thoracic Surgery Database: 2016 Update on Research SO ANNALS OF THORACIC SURGERY LA English DT Article ID LUNG-CANCER RESECTION; PROPENSITY-MATCHED ANALYSIS; LONG-TERM SURVIVAL; THORACOSCOPIC LOBECTOMY; ESOPHAGEAL CANCER; STS DATABASE; STAGE-I; MORBIDITY; OUTCOMES; MORTALITY AB The Society of Thoracic Surgeons General Thoracic Surgery Database has grown to more than 500,000 case records. Clinical research supported by the database is increasingly used to advance patient outcomes. This research review from the General Thoracic Surgery Database in 2014 and 2015 discusses 6 recent publications and an ongoing study on longitudinal outcomes in lung cancer surgery from The Society of Thoracic Surgeons Task Force for Linked Registries and Longitudinal Follow-up. A lack of database variables specific for certain uncommon procedures limits the ability to study these operations; inclusion of clinical descriptors for selected infrequent but clinically important thoracic disorders is suggested. (C) 2016 by The Society of Thoracic Surgeons C1 [Gaissert, Henning A.; Fernandez, Felix G.; Allen, Mark S.; Burfeind, William R.; Block, Mark I.; Donahue, James M.; Mitchell, John D.; Schipper, Paul H.; Onaitis, Mark W.; Kosinski, Andrzej S.; Jacobs, Jeffrey P.; Shahian, David M.; Kozower, Benjamin D.; Edwards, Fred H.; Conrad, Emily A.; Patterson, G. Alexander] Massachusetts Gen Hosp, Harvard Med Sch, Blake 1570,55 Fruit St, Boston, MA 02114 USA. Emory Univ, Atlanta, GA 30322 USA. Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA. St Lukes Univ Hosp, Bethlehem, PA 18015 USA. Mem Healthcare Syst, Hollywood, FL 33021 USA. Univ Maryland, Baltimore, MD 21201 USA. Univ Colorado, Aurora, CO 80309 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Duke Univ, Med Ctr, Durham, NC 27708 USA. Duke Clin Res Inst, Durham, NC 27705 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. Washington Univ, Sch Med, St Louis, MO 63130 USA. Univ Florida, Coll Med, Jacksonville, FL 32611 USA. Soc Thorac Surg, Chicago, IL USA. RP Gaissert, HA (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Blake 1570,55 Fruit St, Boston, MA 02114 USA. EM hgaissert@partners.org NR 25 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD NOV PY 2016 VL 102 IS 5 BP 1444 EP 1451 DI 10.1016/j.athoracsur.2016.09.014 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EE4AR UT WOS:000389544600038 PM 27772572 ER PT J AU Keeling, WB Sundt, T Leacche, M Okita, Y Binongo, J Lasajanak, Y Aklog, L Lattouf, OM AF Keeling, W. Brent Sundt, Thor Leacche, Marzia Okita, Yutaka Binongo, Jose Lasajanak, Yi Aklog, Lishan Lattouf, Omar M. CA SPEAR Working Grp TI Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study SO ANNALS OF THORACIC SURGERY LA English DT Article ID EXTRACORPOREAL MEMBRANE-OXYGENATION; DEEP-VEIN THROMBOSIS; MANAGEMENT AB Background. Surgical pulmonary embolectomy (SPE) has been sparingly used for the successful treatment of massive and submassive pulmonary emboli. To date, all data regarding SPE have been limited to single-center experiences. The purpose of this study was to document short-term outcomes after SPE for acute pulmonary emboli (PE) at four high-volume institutions. Methods. A retrospective review of multiple local Society of Thoracic Surgeons databases of adults undergoing SPE from 1998 to 2014 for acute PE was performed (n = 214). Demographic, operative, and outcomes data were collected and analyzed. Patients were summarily categorized as having either massive or submassive PEs based on the presence or absence of preoperative vasopressors. Results. A total of 214 patients with acute PE were treated by SPE. The mean age was 56.0 +/- 14.5 years, and 92 (43.6%) patients were female. Of those, 176 (82.2%) PEs were submassive and 38 (17.8%) were massive. Fifteen (7.0%) patients underwent concomitant cardiac procedures, with 10 (4.7%) having simultaneous valvular interventions and 5 (2.4%) undergoing concomitant bypass grafting. Cardiopulmonary bypass (CPB) was used for all cases. Cardioplegic arrest was used for 80 (37.4%) patients. The median CPB and aortic cross clamp times were 71.5 (interquartile range [IQR], 47.0-109.5) and 46.0 (IQR, 26.0-74.5), respectively. Notably, only 25 (11.7%) patients died in the hospital. Mortality was highest among the 28 patients who experienced preoperative cardiac arrest (9, 32.1%) Conclusions. These data represent the first multicenter experience with SPE for acute pulmonary emboli. Surgical pulmonary embolectomy for acute massive and submassive PE is safe and can be performed with acceptable in-hospital outcomes; the procedure should be included in the multimodality treatment of life-threatening pulmonary emboli. (C) 2016 by The Society of Thoracic Surgeons C1 Emory Univ, Div Cardiothorac Surg, Atlanta, GA 30322 USA. Massachusetts Gen Hosp, Div Cardiothorac Surg, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Cardiothorac Surg, 75 Francis St, Boston, MA 02115 USA. Kobe Univ, Div Cardiothorac Surg, Kobe, Hyogo, Japan. Pavil Holdings Grp, New York, NY USA. RP Keeling, WB (reprint author), 49 Jesse Hill Dr, Atlanta, GA 30303 USA. EM brent.keeling@emory.edu NR 16 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD NOV PY 2016 VL 102 IS 5 BP 1498 EP 1502 DI 10.1016/j.athoracsur.2016.05.004 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EE4AR UT WOS:000389544600045 PM 27373187 ER PT J AU Hucker, WJ Saini, H Lubitz, SA Ellinor, PT AF Hucker, William J. Saini, Harsimran Lubitz, Steven A. Ellinor, Patrick T. TI Atrial Fibrillation Genetics: Is There a Practical Clinical Value Now or in the Future? SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Review ID OF-FUNCTION MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; CHROMOSOME 4Q25 VARIANTS; EARLY-ONSET; FAMILIAL AGGREGATION; SMALL-CONDUCTANCE; ISCHEMIC-STROKE; SINOATRIAL NODE; INCREASED RISK; RARE VARIANTS AB Atrial fibrillation (AF) is the most common sustained arrhythmia and has significant clinical impact. Over the last decade, our understanding of the genetics of AF has expanded dramatically. After a heritable predisposition for AF was identified, many investigators have in turn identified both common and rare variants associated with AF. Ongoing work is focused on translating these variants into disease pathways and novel therapeutic modalities. In this review, we focus on our understanding of the current concepts behind the genetics of AF and outline a vision for the incorporation of genetic data into clinical practice. C1 Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP Ellinor, PT (reprint author), Broad Inst Harvard & MIT, Program Med & Populat Genet, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,Gray 109, Boston, MA 02114 USA.; Ellinor, PT (reprint author), Broad Inst Harvard & MIT, Program Med & Populat Genet, Massachusetts Gen Hosp, Cardiovasc Res Ctr, 55 Fruit St,Gray 109, Boston, MA 02114 USA. EM ellinor@mgh.harvard.edu FU American Heart Association [12FTF11350014]; National Institutes of Health [1RO1HL092577, R01HL128914, K24HL105780]; Established Investigator Award from the American Heart Association [13EIA14220013]; Fondation Leducq [14CVD01]; National Heart, Lung, And Blood Institute [T32HL007208] FX S.A.L. is supported by an American Heart Association Fellow-to-Faculty award 12FTF11350014. P.T.E. is supported by grants from the National Institutes of Health (1RO1HL092577, R01HL128914, K24HL105780). He is also supported by an Established Investigator Award from the American Heart Association (13EIA14220013) and by the Fondation Leducq (14CVD01). W.J.H. was supported by Award Number T32HL007208 from the National Heart, Lung, And Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. NR 58 TC 3 Z9 3 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X EI 1916-7075 J9 CAN J CARDIOL JI Can. J. Cardiol. PD NOV PY 2016 VL 32 IS 11 BP 1300 EP 1305 DI 10.1016/j.cjca.2016.02.032 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EE3SF UT WOS:000389517700009 PM 27094126 ER PT J AU Li, Y Stone, JR AF Li, Yu Stone, James R. TI The impact of splenectomy on human coronary artery atherosclerosis and vascular macrophage distribution SO CARDIOVASCULAR PATHOLOGY LA English DT Article DE Atherosclerosis; Splenectomy; Spleen; Macrophages; Inflammation; Autopsy ID HEREDITARY SPHEROCYTOSIS; LIPID-METABOLISM; PHYSICAL HEALTH; SPLEEN; VETERANS; PATHOGENESIS; CHOLESTEROL; MONOCYTES; IMMUNITY; LESIONS AB Background: Splenectomy can potentially impact atherosclerosis through multiple mechanisms including altered lipid homeostasis, increased coagulation, and altered macrophage recruitment to the plaque. In patients, splenectomy has been associated with increased rates of coronary artery events, while in experimental mice, splenectomy causes increased atherosclerosis but reduces systemic monocyte supply. In this study, the direct impact of splenectomy on human coronary artery atherosclerotic plaque severity and macrophage content was investigated. Methods: Coronary artery atherosclerotic plaque severity was determined at autopsy in 18 long-term (>= 10 years) splenectomy patients and 90 matched control patients. Coronary artery macrophage content was evaluated in mild atherosclerotic plaques of 11 mid-to long-term (>= 1 year) splenectomy patients and 11 matched control patients. Results: Splenectomy was associated with reduced coronary artery atherosclerosis (P = .03). The association was most pronounced for the subgroup of patients who had undergone splenectomy 20 years or more prior to death (P = .02). There was no difference in the density of macrophages in the plaque, media, or adventitia upon comparing splenectomy and control patients. In the control group, there was no correlation between the macrophage densities in the three arterial layers. However, in the splenectomy patients, there was a strong correlation in the macrophage densities across the plaque, media, and adventitia (P = .0002), with resulting slopes that were significantly greater than seen in the control patients (P = .0007-.011). Conclusions: These findings indicate that, in humans, splenectomy is associated with lower coronary artery atherosclerotic plaque severity and altered coronary artery macrophage distribution. These results suggest that the spleen can modulate the recruitment of macrophages into human coronary arteries and the progression of atherosclerosis. (C) 2016 Elsevier Inc. All rights reserved. C1 [Li, Yu] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Li, Yu; Stone, James R.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Stone, James R.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Stone, JR (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,Room 8236,185 Cambridge St CPZN, Boston, MA 02114 USA. EM jrstone@partners.org NR 38 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-8807 EI 1879-1336 J9 CARDIOVASC PATHOL JI Cardiovasc. Pathol. PD NOV-DEC PY 2016 VL 25 IS 6 BP 453 EP 460 DI 10.1016/j.carpath.2016.08.001 PG 8 WC Cardiac & Cardiovascular Systems; Pathology SC Cardiovascular System & Cardiology; Pathology GA EE3SU UT WOS:000389519500002 PM 27614166 ER PT J AU Vargas, LA Pinilla, OA Diaz, RG Sepulveda, DE Swenson, ER Perez, NG Alvarez, BV AF Vargas, Lorena A. Pinilla, Oscar A. Diaz, Romina G. Sepulveda, Diana E. Swenson, Erik R. Perez, Nestor G. Alvarez, Bernardo V. TI Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats SO CARDIOVASCULAR PATHOLOGY LA English DT Article DE Heart failure; Carbonic anhydrase inhibitors; Intracellular pH; Myocardial infarction ID HEART-FAILURE; MYOCARDIAL-INFARCTION; CARDIOMYOCYTE HYPERTROPHY; EXCHANGE INHIBITION; ENHANCED ACTIVITY; INTRACELLULAR PH; IN-VIVO; IX; HYPOXIA; ACTIVATION AB Background: Two potent carbonic anhydrase (CA) inhibitors with widely differing membrane permeability, poorly diffusible benzolamide (BZ), and highly diffusible ethoxzolamide (ETZ) were assessed to determine whether they can reduce cardiac dysfunction in rats subjected to coronary artery ligation (CAL)-induced myocardial infarction. Methods and results: Rats with evidence of heart failure (HF) at 32 weeks following a permanent left anterior coronary artery occlusion were treated with placebo, BZ, or ETZ (4 mg kg day(-1)) for 4 weeks at which time left ventricular function and structure were evaluated. Lung weight/body weight (LW/BW) ratio increased in CAL rats by 17 +/- 1% vs. control, suggesting pulmonary edema. There was a trend for BZ and ETZ to ameliorate the increase in LW/BW by almost 50% (9 +/- 5% and 9 +/- 8%, respectively, versus CAL) (P=.16, NS). Echocardiographic assessment showed decreased left ventricular midwall shortening in HF rats, 21 +/- 1% vs. control 32 +/- 1%, which was improved by BZ to 29 +/- 1% and ETZ to 27 +/- 1%, and reduced endocardial shortening in HF rats 38 +/- 3% vs. control 62 +/- 1%, partially restored by BZ and ETZ to similar to 50%. Expression of the hypoxia-inducible membrane-associated CAIX isoform increased by similar to 60% in HF rat hearts, and this effect was blocked by ETZ. Conclusions: We conclude that CAL-induced myocardial interstitial fibrosis and associated decline in left ventricular function were diminished with BZ or ETZ treatment. The reductions in cardiac remodeling in HF with both ETZ and BZ CA inhibitors suggest that inhibition of a membrane-bound CA appears to be the critical site for this protection. (C) 2016 Elsevier Inc. All rights reserved. C1 [Vargas, Lorena A.; Pinilla, Oscar A.; Diaz, Romina G.; Perez, Nestor G.; Alvarez, Bernardo V.] Univ Nacl La Plata, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, Ctr Invest Cardiovasc, RA-1900 La Plata, Buenos Aires, Argentina. [Sepulveda, Diana E.] Univ Favaloro, Dept Patol, Buenos Aires, DF, Argentina. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med Pulm & Crit Care Med, Seattle, WA 98108 USA. Fac Ciencias Med, RA-1900 La Plata, Buenos Aires, Argentina. RP Alvarez, BV (reprint author), Fac Ciencias Med, Calle 60 & 120, RA-1900 La Plata, Buenos Aires, Argentina. EM balvarez@med.unlp.edu.ar FU Agencia Nacional de Promocion Cientifica y Tecnologica (FONCyT, PICT) [1976]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Type II Postdoctoral Fellowship) FX This work was funded by a grant from Agencia Nacional de Promocion Cientifica y Tecnologica to BVA (FONCyT, PICT2013 No. 1976). LAV was a recipient of a fellowship from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Type II Postdoctoral Fellowship). NR 51 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-8807 EI 1879-1336 J9 CARDIOVASC PATHOL JI Cardiovasc. Pathol. PD NOV-DEC PY 2016 VL 25 IS 6 BP 468 EP 477 DI 10.1016/j.carpath.2016.08.003 PG 10 WC Cardiac & Cardiovascular Systems; Pathology SC Cardiovascular System & Cardiology; Pathology GA EE3SU UT WOS:000389519500004 PM 27614168 ER PT J AU Olabisi, O Al-Romaih, K Henderson, J Tomar, R Drummond, I MacRae, C Pollak, M AF Olabisi, Opeyemi Al-Romaih, Khaldoun Henderson, Joel Tomar, Ritu Drummond, Iain MacRae, Calum Pollak, Martin TI From man to fish: What can Zebrafish tell us about ApoL1 nephropathy? SO CLINICAL NEPHROLOGY LA English DT Article; Proceedings Paper CT 10th International Conference on Kidney Disease in Disadvantaged Populations held as a Satellite Meeting of the International-Society-of-Nephrology (ISN) / World Congress of Nephrology (WCN) CY MAR 17-18, 2015 CL Cape Town, SOUTH AFRICA SP Int Soc Nephrol, Comm Kidney Hlth Disadvantaged Populat DE apolipoprotein L1; chronic kidney disease; focal segmental glomerulosclerosis; zebrafish ID HIV-ASSOCIATED NEPHROPATHY; CHRONIC KIDNEY-DISEASE; RISK VARIANTS; FAILURE AB Background: Risk variant Apolipoprotein L1 (G1/G2) are strongly associated with a spectrum of kidney disease in people of recent African descent. The mechanism of ApoL1 nephropathy is unknown. Podocytes and/or endothelial cells are the presumed target kidney cells. Given the close homology in structure and function of zebrafish (ZF) pronephros and human nephron, we studied the effect of podocyte-specific or endothelium-specific expression of ApoL1 (G0, G1, or G2) on the structure and function of ZF pronephros. Methods: Wild type (G0) or risk variant ApoL1 (G1/G2) were expressed in podocyte-specific or endothelium-specific under podocin/Flk promoters, respectively, using Gal4-UAS system. Structural pronephric changes were studied with light and electron microscopy (EM). Proteinuria was assayed by measuring renal excretion of GFP-vitamin D binding protein. Puromycin aminonucleoside (PAN) was used as inducer of podocyte injury. Results: Endothelial-specific transgenic expression of G1/G2 is associated with endothelial injury indicated by endothelial cell swelling, segmental early double contours, and loss of endothelium fenestrae. Podocyte specific expression of G1 is associated with segmental podocyte foot process effacement and irregularities relative to G0. Despite the histological changes, the expression of G1/G2 alone in podocyte or endothelium compartment is not associated with edema, proteinuria, or gross whole fish phenotype. Moreover, PAN produced equal pericardial edema in all transgenic fish as well as nontransgenic controls. Conclusions: Transgenic expression human ApoL1 (G1/G2) is associated with histologic abnormalities in ZF glomeruli but is insufficient to cause quantifiable renal dysfunction. This finding supports the necessity of a "second hit" in the pathogenesis/progression of ApoL1-associated nephropathy. C1 [Olabisi, Opeyemi; Tomar, Ritu; Drummond, Iain] Massachusetts Gen Hosp, Div Renal, Boston, MA 02114 USA. [Olabisi, Opeyemi; Al-Romaih, Khaldoun; Pollak, Martin] Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA. [MacRae, Calum] Brigham & Womens Hosp, Div Cardiol, 75 Francis St, Boston, MA 02115 USA. [Olabisi, Opeyemi; Al-Romaih, Khaldoun; Tomar, Ritu; Drummond, Iain; MacRae, Calum; Pollak, Martin] Harvard Med Sch, Boston, MA USA. [Al-Romaih, Khaldoun] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia. [Henderson, Joel] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. RP Pollak, M (reprint author), 99 Brookline Ave, Boston, MA 02215 USA. NR 13 TC 2 Z9 2 U1 0 U2 0 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD NOV PY 2016 VL 86 SU 1 BP S114 EP S118 DI 10.5414/CNP86S116 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA EE4RM UT WOS:000389592800025 PM 27509583 ER PT J AU O'Neil, PM Garvey, WT Gonzalez-Campoy, JM Mora, P Ortiz, RV Guerrero, G Claudius, B Pi-Sunyer, X AF O'Neil, Patrick M. Garvey, W. Timothy Gonzalez-Campoy, J. Michael Mora, Pablo Ortiz, Rafael Violante Guerrero, German Claudius, Birgitte Pi-Sunyer, Xavier CA Satiety Clin Adiposity Liraglutide TI EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HISPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS SO ENDOCRINE PRACTICE LA English DT Article ID LIFE-STYLE INTERVENTION; CLINICAL-TRIAL; OBESITY; ADULTS; OVERWEIGHT; MANAGEMENT; SAFETY; TOLERABILITY; LORCASERIN; PREVALENCE AB Objective: Scarce data exist on pharmacotherapy for obesity in Hispanic individuals. This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups. Methods: We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m(2) with at least 1 comorbidity, or a minimum BMI of 30 kg/m(2), at clinical research sites worldwide. In this analysis, we investigated possible differences in treatment effects between 534 Hispanics (10.4% of the population) and 4,597 non-Hispanics (89.6%) through statistical tests of interaction between subgroups and treatment. Variables examined included mean and categorical weight change, cardiovascular risk markers, and safety data. Results: Both subgroups achieved clinically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg versus placebo: Hispanics 7.0% versus 1.5%, treatment difference -5.1% (95% CI, -6.2 to -4.0); non-Hispanics 7.5% versus 2.3%, -5.2% (95% CI, -5.5 to -4.8). More individuals in both subgroups lost >= 5%, >10%, and >15% of their baseline weight with liraglutide 3.0 mg than with placebo. Efficacy endpoints generally did not vary with ethnicity (P>.05). Adverse events were comparable between ethnic subgroups, with more gastrointestinal disorders reported with liraglutide 3.0 mg than placebo. Conclusion: Efficacy and safety were largely similar between Hispanic and non-Hispanic subgroups. Results support that liraglutide 3.0 mg, used with a reduced-calorie diet and physical activity, can facilitate Weight loss in Hispanic individuals. C1 [O'Neil, Patrick M.] Med Univ South Carolina, Charleston, SC 29425 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Gonzalez-Campoy, J. Michael] Minnesota Ctr Obes Metab & Endocrinol, Eagan, MN USA. [Mora, Pablo] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Ortiz, Rafael Violante] Inst Mexicano Segura Social, Dept Endocrinol, Cuidad Madero, Mexico. [Guerrero, German] Novo Nordisk Inc, Plainsboro, NJ USA. [Claudius, Birgitte] Novo Nordisk AS, Soborg, Denmark. [Pi-Sunyer, Xavier] Columbia Univ, New York, NY USA. RP O'Neil, PM (reprint author), Med Univ South Carolina, Weight Management Ctr, Dept Psychiat & Behav Sci, IOP South, 67 President St Suite 410 POB 250861, Charleston, SC 29425 USA. EM oneilp@musc.edu FU Novo Nordisk; Novo Nordisk A/S FX We gratefully acknowledge the contribution of all trial participants and the trial site personnel who assisted with the trials. We also thank Ana-Paula Canino, M.D., M.Sc. (Novo Nordisk) for researching data and contributing to the manuscript, Henrik F. Thomsen, Ph.D. (Novo Nordisk) for assistance with the statistical analyses, as well as Angela Stocks, Ph.D. (Larix A/S, funded by Novo Nordisk) for editorial and medical writing contributions. Under the direction of the authors and according to an agreed outline, Angela Stocks drafted the initial version of the manuscript; all authors reviewed all drafts and revisions of the manuscript and commented and/or provided edits.; Novo Nordisk A/S funded the trials and provided the trial products. Novo Nordisk provided overall management of the trials, performed the statistical analyses, and verified the accuracy of the data presented. Novo Nordisk was also responsible for the overall trial designs. They provided a formal review of the manuscript, but the authors had final authority, including journal choice. The studies included in the pooled analysis are registered with ClinicalTrials.gov (NCT01272219, NCT00781937, NCT00781937, and NCT01557166). NR 33 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD NOV PY 2016 VL 22 IS 11 BP 1277 EP 1287 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EE7ZB UT WOS:000389842900003 PM 27482610 ER PT J AU Faingold, CL Randall, M Zeng, C Peng, SF Long, XY Feng, HJ AF Faingold, Carl L. Randall, Marcus Zeng, Chang Peng, Shifang Long, Xiaoyan Feng, Hua-Jun TI Serotonergic agents act on 5-HT3 receptors in the brain to block seizure-induced respiratory arrest in the DBA/1 mouse model of SUDEP SO EPILEPSY & BEHAVIOR LA English DT Article DE 5-HT; SSRIs; Antagonist; Audiogenic seizures; Intracerebroventricular ID SUDDEN UNEXPECTED DEATH; REUPTAKE INHIBITORS; ANTIDEPRESSANT-LIKE; ICTAL HYPOXEMIA; EPILEPSY SUDEP; MICE; MECHANISMS; NEURONS; MODULATION; PREVENTION AB Drugs that enhance the action of serotonin (5-hydroxytrypamine, 5-HT), including several selective serotonin reuptake inhibitors (SSRIs), reduce susceptibility to seizure-induced respiratory arrest (S-IRA) that leads to death in the DBA/1 mouse model of sudden unexpected death in epilepsy (SUDEP). However, it is not clear if specific 5-HT receptors are important in the action of these drugs and whether the brain is the major site of action of these agents in this SUDEP model. The current study examined the actions of agents that affect the 5-HT3 receptor subtype on S-IRA and whether intracerebroventricular (ICV) microinjection of an SSRI would reduce S-IRA susceptibility in DBA/1 mice. The data indicate that systemic administration of SR 57227, a 5-HT3 agonist, was effective in blocking S-IRA in doses that did not block seizures, and the S-IRA blocking effect of the SSRI, fluoxetine, was abolished by coadministration of a 5-HT3 antagonist, ondansetron. Intracerebroventricular administration of fluoxetine in the present study was also able to block S-IRA without blocking seizures. These findings suggest that 5-HT3 receptors play an important role in the block of S-IRA by serotonergic agents, such as SSRIs, which is consistent with the abnormal expression of 5-HT3 receptors in the brainstem of DBA mice observed previously. Taken together, these data indicate that systemically administered serotonergic agents act, at least, in part, in the brain, to reduce S-IRA susceptibility in DBA/1 mice and that 5-HT3 receptors may be important to this effect. (C) 2016 Elsevier Inc. All rights reserved. C1 [Faingold, Carl L.; Randall, Marcus] Southern Illinois Univ, Sch Med, Dept Pharmacol & Neurol, Springfield, IL 62702 USA. [Zeng, Chang; Feng, Hua-Jun] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Zeng, Chang; Feng, Hua-Jun] Harvard Med Sch, Boston, MA 02115 USA. [Zeng, Chang; Peng, Shifang] Cent S Univ, Hlth Management Ctr, Xiangya Hosp, Changsha, Hunan, Peoples R China. [Long, Xiaoyan] Cent S Univ, Dept Neurol, Xiangya Hosp, Changsha, Hunan, Peoples R China. RP Faingold, CL (reprint author), Southern Illinois Univ, Sch Med, Dept Pharmacol & Neurol, Springfield, IL 62702 USA.; Feng, HJ (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.; Feng, HJ (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM cfaingold@siumed.edu; feng.huajun@mgh.harvard.edu FU Epilepsy Foundation; CURE (Citizens United for Research in Epilepsy) foundation grant [R03NS078591]; Department of Anesthesia, Critical Care and Pain Medicine at Massachusetts General Hospital FX This study was supported by Epilepsy Foundation (CF) and R03NS078591, CURE (Citizens United for Research in Epilepsy) foundation grant, and fund from the Department of Anesthesia, Critical Care and Pain Medicine at Massachusetts General Hospital (HJF). NR 54 TC 0 Z9 0 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD NOV PY 2016 VL 64 BP 166 EP 170 DI 10.1016/j.yebeh.2016.09.034 PN A PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA EE6PN UT WOS:000389734800028 PM 27743549 ER PT J AU Schreiber, DR Shoji, K Imel, J Tighe, CA Dautovich, N AF Schreiber, D. R. Shoji, K. Imel, J. Tighe, C. A. Dautovich, N. TI SLEEP PREDICTS EMOTION-FOCUSED COPING ACROSS THE ADULT LIFESPAN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Schreiber, D. R.; Imel, J.; Dautovich, N.] Virginia Commonwealth Univ, Psychol, Richmond, VA USA. [Shoji, K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Tighe, C. A.] Univ Alabama, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 63 EP 63 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000231 ER PT J AU Hall, KS Gregg, J Bosworth, H Beckham, J Sloane, R Hoerster, K Morey, M AF Hall, K. S. Gregg, J. Bosworth, H. Beckham, J. Sloane, R. Hoerster, K. Morey, M. TI PROMOTING PHYSICAL AND PSYCHOLOGICAL RESILIENCE IN OLDER VETERANS WITH PTSD: A CASE FOR EXERCISE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hall, K. S.; Bosworth, H.; Beckham, J.; Sloane, R.; Morey, M.] Duke Univ, Med Ctr, Med, Durham, NC USA. [Hoerster, K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hall, K. S.; Gregg, J.; Bosworth, H.; Beckham, J.; Morey, M.] Vet Affairs Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 88 EP 88 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000317 ER PT J AU Kim, G Parmelee, P Bryant, A Crowther, M Park, S Parton, JM Chae, D AF Kim, G. Parmelee, P. Bryant, A. Crowther, M. Park, S. Parton, J. M. Chae, D. TI PERCEIVED RACIAL DISCRIMINATION AND PSYCHIATRIC DISORDERS AMONG BLACK ELDERS: THE ROLE OF GEOGRAPHY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kim, G.; Parmelee, P.; Crowther, M.; Park, S.; Parton, J. M.] Univ Alabama, Dept Psychol, Alabama Res Inst Aging, Box 870348, Tuscaloosa, AL 35487 USA. [Bryant, A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Chae, D.] Univ Maryland, College Pk, MD 20742 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 93 EP 93 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000332 ER PT J AU Espinoza, S Quiben, M Hazuda, H AF Espinoza, S. Quiben, M. Hazuda, H. TI ONSET OF FRAILTY CHARACTERISTICS IN A BI-ETHNIC COHORT: THE SAN ANTONIO LONGITUDINAL STUDY OF AGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espinoza, S.; Hazuda, H.] Univ Texas Hlth Sci Ctr San Antonio, Med, San Antonio, TX 78229 USA. [Espinoza, S.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Quiben, M.] Univ North Texas, Hlth Sci Ctr, Ft Worth, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 175 EP 175 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000641 ER PT J AU Lee, L Spiro, A AF Lee, L. Spiro, A. TI LONGITUDINAL-SURVIVAL MODELS OF CARDIOMETABOLIC RISK TRAJECTORIES: THE VA NORMATIVE AGING STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lee, L.; Spiro, A.] Boston Univ, Sch Med, Psychiat, Arlington, MA USA. [Lee, L.; Spiro, A.] VA Boston Healthcare Syst, Boston, MA USA. [Spiro, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 183 EP 183 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000667 ER PT J AU Wagers, AJ AF Wagers, A. J. TI STRATEGIES TO ENHANCE THE REGENERATIVE FUNCTIONS OF AGING STEM CELLS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Wagers, A. J.] Harvard Univ, Cambridge, MA 02138 USA. [Wagers, A. J.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Wagers, A. J.] Harvard Stem Cell Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 198 EP 198 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000724 ER PT J AU Tyzik, AL Lee, L Spiro, A AF Tyzik, A. L. Lee, L. Spiro, A. TI IMPACT OF EARLY LIFE EXPERIENCES ON LATER-LIFE WELL-BEING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lee, L.; Spiro, A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Lee, L.; Spiro, A.] VA Boston Healthcare Syst, Boston, MA USA. [Tyzik, A. L.; Spiro, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 237 EP 237 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001129 ER PT J AU Roberts, T Gilmore-Bykovskyi, A Lor, M Liebzeit, D Saliba, D Crnich, C AF Roberts, T. Gilmore-Bykovskyi, A. Lor, M. Liebzeit, D. Saliba, D. Crnich, C. TI IMPORTANT DAILY CARE AND ACTIVITY PREFERENCES AMONG NURSING HOME RESIDENTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Roberts, T.; Gilmore-Bykovskyi, A.; Crnich, C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Roberts, T.; Gilmore-Bykovskyi, A.; Lor, M.; Liebzeit, D.] Univ Wisconsin, Madison Sch Nursing, Madison, WI USA. [Saliba, D.] VA GLAHS GRECC & HSR&D Ctr Innovat, Los Angeles, CA USA. [Saliba, D.] UCLA JH Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, D.] RAND Corp, Santa Monica, CA USA. [Crnich, C.] Univ Wisconsin, Madison Sch Med & Publ Hlth, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 263 EP 264 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001237 ER PT J AU Gerolimatos, L Naik, A Amspoker, A Mulligan, EA Moye, J AF Gerolimatos, L. Naik, A. Amspoker, A. Mulligan, E. A. Moye, J. TI MODELING WORRY IN A LONGITUDINAL SAMPLE OF CANCER SURVIVORS: THE CRITICAL ROLE OF HEALTH ANXIETY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Gerolimatos, L.] APA AAAS, Washington, DC USA. [Gerolimatos, L.; Mulligan, E. A.; Moye, J.] VA Boston Healthcare Syst, Boston, MA USA. [Naik, A.; Amspoker, A.] Michael E DeBakey VAMC, Houston, TX USA. [Naik, A.; Amspoker, A.] Baylor Coll Med, Houston, TX 77030 USA. [Mulligan, E. A.; Moye, J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 324 EP 324 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001489 ER PT J AU Poole, V Jordan, AJ Manor, B Iloputaife, I Esterman, M Lipsitz, L AF Poole, V. Jordan, A. J. Manor, B. Iloputaife, I. Esterman, M. Lipsitz, L. TI EXECUTIVE BRAIN REGIONS UNDERLIE ASSOCIATIONS BETWEEN NEUROVASCULAR COUPLING AND GAIT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Poole, V.; Jordan, A. J.; Manor, B.; Iloputaife, I.; Lipsitz, L.] Harvard Med Sch, Boston, MA USA. [Poole, V.; Esterman, M.] VA Boston Healthcare Syst, Boston, MA USA. [Poole, V.; Jordan, A. J.; Manor, B.; Iloputaife, I.; Lipsitz, L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Jordan, A. J.; Manor, B.; Iloputaife, I.; Lipsitz, L.] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 335 EP 335 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001526 ER PT J AU Romo, R AF Romo, R. TI THE "SURPRISE" QUESTION: PREDICTING DEATH OR THE NEED FOR CARE? A SYSTEMATIC REVIEW SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Romo, R.] San Francisco VA Med Ctr, Geriatr Extended & Pallait Care, San Jose, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 341 EP 342 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001549 ER PT J AU Romo, R AF Romo, R. TI WHAT IS KNOWN ABOUT THE PATIENT EXPERIENCE AFTER LIVE DISCHARGE FROM HOSPICE? NOT MUCH SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Romo, R.] San Francisco VA Med Ctr, Geriatr Extended & Pallait Care, San Jose, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 342 EP 342 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001551 ER PT J AU Tighe, CA Imel, J Shoji, K Schreiber, DR Allen, RS Dautovich, N AF Tighe, C. A. Imel, J. Shoji, K. Schreiber, D. R. Allen, R. S. Dautovich, N. TI THE LINK BETWEEN SLEEP IMPAIRMENT AND FUTURE TIME PERSPECTIVE ACROSS ADULTHOOD SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Tighe, C. A.; Shoji, K.; Allen, R. S.] Univ Alabama, Psychol, Tuscaloosa, AL USA. [Imel, J.; Schreiber, D. R.; Dautovich, N.] Virginia Commonwealth Univ, Richmond, VA USA. [Shoji, K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 360 EP 361 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001613 ER PT J AU Quach, L Dugan, E Gagnon, D Burr, J AF Quach, L. Dugan, E. Gagnon, D. Burr, J. TI SOCIAL DETERMINANTS OF FALLS AMONG OLDER ADULTS: THE ROLE OF SOCIAL SUPPORT AND DEPRESSION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Quach, L.; Dugan, E.; Gagnon, D.; Burr, J.] Univ Massachusetts, Dept Gerontol, Boston, MA 02125 USA. [Quach, L.] VA Boston Healthcare Syst, Boston, MA USA. [Gagnon, D.] Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 366 EP 366 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001632 ER PT J AU Byers, A Li, Y Barnes, D Boscardin, J Seal, K Yaffe, K AF Byers, A. Li, Y. Barnes, D. Boscardin, J. Seal, K. Yaffe, K. TI MILD TRAUMATIC BRAIN INJURY AND RISK OF MORTALITY IN LATE LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A.; Barnes, D.; Boscardin, J.; Seal, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, A.; Li, Y.; Barnes, D.; Boscardin, J.; Seal, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 440 EP 440 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002088 ER PT J AU Feng, M Catlin, C AF Feng, M. Catlin, C. TI DEVELOPMENT OF AN ACCEPTANCE AND COMMITMENT THERAPY GROUP TO TREAT CHRONIC PAIN IN ELDERLY VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Feng, M.] Execut Mental Hlth, Los Angeles, CA USA. [Catlin, C.] Boston VA Res Inst Inc, Boston, MA USA. [Catlin, C.] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 447 EP 448 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002118 ER PT J AU Mulligan, EA Moye, J AF Mulligan, E. A. Moye, J. TI DEVELOPMENT OF A TIME-LIMITED GROUP THERAPY PROGRAM IN A VA GERIATRIC MENTAL HEALTH CLINIC SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mulligan, E. A.] San Francisco VA Hlth Care Syst, San Francisco, CA USA. [Moye, J.] VA Boston Healthcare Syst, Boston, MA USA. [Moye, J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 447 EP 447 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002117 ER PT J AU Kong, J AF Kong, J. TI TAI CHI CHUAN MODULATION OF BRAIN RESTING STATE FUNCTIONAL CONNECTIVITY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kong, J.] Massachusetts Gen Hosp, Psychiat, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 480 EP 480 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002254 ER PT J AU Haran, JP Wilsterman, E Zeoli, T Hibberd, P Tjia, J AF Haran, J. P. Wilsterman, E. Zeoli, T. Hibberd, P. Tjia, J. TI ELDERLY PATIENTS ARE AT AN INCREASED RISK OF TREATMENT FAILURE IN OUTPATIENT ABSCESSES MANAGEMENT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hibberd, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Haran, J. P.; Wilsterman, E.; Zeoli, T.; Tjia, J.] Univ Massachusetts, Sch Med, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 524 EP 525 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002442 ER PT J AU Haran, JP Wu, X Hibberd, P Tjia, J AF Haran, J. P. Wu, X. Hibberd, P. Tjia, J. TI RISK OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN LONG-TERM CARE AND COMMUNITY-DWELLING ELDERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Haran, J. P.] Univ Massachusetts, Sch Med, Emergency Med, Worcester, MA USA. [Hibberd, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wu, X.; Tjia, J.] Univ Massachusetts, Sch Med, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 547 EP 547 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002517 ER PT J AU McCaskill, GM Burgio, K AF McCaskill, G. M. Burgio, K. TI "OLD FOOTBALL KNEES:" PAIN AS A BARRIER AND A FACILITATOR TO PHYSICAL ACTIVITY AMONG OLDER VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McCaskill, G. M.; Burgio, K.] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [McCaskill, G. M.; Burgio, K.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 597 EP 598 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002707 ER PT J AU Pardasaney, P Ingber, M Broyles, I Deutsch, A Clayton, D Frank, J Haines, E McMullen, T AF Pardasaney, P. Ingber, M. Broyles, I. Deutsch, A. Clayton, D. Frank, J. Haines, E. McMullen, T. TI ASSESSING DISCHARGE TO COMMUNITY OUTCOMES IN POST-ACUTE CARE SETTINGS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Pardasaney, P.; Ingber, M.; Broyles, I.; Deutsch, A.; Clayton, D.; Frank, J.; Haines, E.] RTI Int, Qual Measures & Hlth Policy, Waltham, MA USA. [McMullen, T.] Ctr Med Serv, Baltimore, MD USA. [McMullen, T.] Ctr Medicaid Serv, Baltimore, MD USA. [Ingber, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 599 EP 599 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002714 ER PT J AU OConnor, M Moriarty, H Hoban, M Bowles, K AF OConnor, M. Moriarty, H. Hoban, M. Bowles, K. TI HOW DO WE KNOW THEY ARE READY? DETERMINING READINESS FOR DISCHARGE FROM SKILLED HOME HEALTH SERVICES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [OConnor, M.; Moriarty, H.] Villanova Univ, Villanova, PA 19085 USA. [Hoban, M.] Main Line Hlth Home Care & Hosp, Radnor, PA USA. [Bowles, K.] Univ Penn, Philadelphia, PA 19104 USA. [Moriarty, H.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Bowles, K.] Visiting Nurse Serv New York, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 628 EP 628 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003033 ER PT J AU Whiteman, KL Lohman, M Batsis, J Di Napoli, E Bruce, M Bartels, S AF Whiteman, K. L. Lohman, M. Batsis, J. Di Napoli, E. Bruce, M. Bartels, S. TI DISPARITIES IN PATIENT HEALTHCARE EXPERIENCE AMONG OLDER ADULTS WITH SERIOUS MENTAL ILLNESS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Whiteman, K. L.; Lohman, M.; Batsis, J.; Bruce, M.; Bartels, S.] Dartmouth Ctr Hlth & Aging, Lebanon, NH USA. [Di Napoli, E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Whiteman, K. L.; Lohman, M.; Batsis, J.; Bruce, M.; Bartels, S.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Whiteman, K. L.; Lohman, M.; Batsis, J.; Bruce, M.; Bartels, S.] CDC Hlth Promot Res Ctr Dartmouth, Lebanon, NH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 642 EP 642 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003094 ER PT J AU Elliott, M Martsolf, GR Haviland, AM Burkhart, Q Orr, NE Gaillot, S Saliba, D AF Elliott, M. Martsolf, G. R. Haviland, A. M. Burkhart, Q. Orr, N. E. Gaillot, S. Saliba, D. TI HEALTH CARE EXPERIENCES AMONG MEDICARE BENEFICIARIES WITH AND WITHOUT A PERSONAL PHYSICIAN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Elliott, M.; Martsolf, G. R.; Burkhart, Q.; Orr, N. E.; Saliba, D.] RAND Corp, Santa Monica, CA USA. [Haviland, A. M.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Gaillot, S.] Ctr Medicare Serv, Baltimore, MD USA. [Gaillot, S.] Ctr Medicaid Serv, Baltimore, MD USA. [Saliba, D.] US Dept Vet Affairs, Los Angeles, CA USA. [Saliba, D.] Univ Calif Los Angeles, Borun Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 663 EP 663 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003180 ER PT J AU Tappen, R Luckmann, R Cooley, ME AF Tappen, R. Luckmann, R. Cooley, M. E. TI OLDER ADULTS' PREFERENCES FOR INFORMATION TO SUPPORT HEALTH CARE DECISIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Tappen, R.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Cooley, M. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Luckmann, R.] Umass Mem Med Ctr, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 663 EP 663 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003179 ER PT J AU Jacob, ME Travison, T Ward, R Leveille, SG Jette, A Bean, JF AF Jacob, M. E. Travison, T. Ward, R. Leveille, S. G. Jette, A. Bean, J. F. TI UNRAVELING DISABLEMENT: DO IMPAIRMENTS AUGMENT SPPB'S CAPACITY TO PREDICT DISABILITY? SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Jacob, M. E.; Bean, J. F.] Harvard Univ, Boston, MA 02115 USA. [Jacob, M. E.; Ward, R.] VA Boston Healthcare Syst, New England GRECC, Boston, MA USA. [Jacob, M. E.; Jette, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Travison, T.] Hebrew Senior Life, Boston, MA USA. [Leveille, S. G.] Univ Massachusetts, Boston, MA 02125 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 688 EP 688 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003276 ER PT J AU Hung, WW Rossi, M Thielke, S Caprio, T Barczi, S Espinoza, S Garner, K Moo, L AF Hung, W. W. Rossi, M. Thielke, S. Caprio, T. Barczi, S. Espinoza, S. Garner, K. Moo, L. TI TELEMEDICINE APPROACHES TO EXTEND GERIATRIC CARE TO RURAL AREAS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.] James J Peters VA Med Ctr, Bronx, NY USA. [Rossi, M.] Univ Pittsburgh, Pittsburgh, PA USA. [Thielke, S.] Univ Washington, Seattle, WA 98195 USA. [Caprio, T.] Univ Rochester, Rochester, NY USA. [Barczi, S.] William S Middleton VA Med Ctr, Madison, WI USA. [Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Garner, K.] Univ Arkansas, Little Rock, AR 72204 USA. [Moo, L.] Bedford VA Med Ctr, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 694 EP 694 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003299 ER PT J AU Cigolle, C Quinones, A Nagel, C AF Cigolle, C. Quinones, A. Nagel, C. TI PATIENTS' UNCERTAINTY ABOUT THEIR CHRONIC DISEASE DIAGNOSES: THE HEALTH AND RETIREMENT STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Cigolle, C.] Univ Michigan, Ann Arbor, MI 48109 USA. [Cigolle, C.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Quinones, A.; Nagel, C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Quinones, A.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 703 EP 703 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003332 ER PT J AU Wright, RS Waldstein, S Gerassimakis, C Sprung, M Moody, DLB Taylor, A Evans, MK Zonderman, AB AF Wright, R. S. Waldstein, S. Gerassimakis, C. Sprung, M. Moody, D. L. Beatty Taylor, A. Evans, M. K. Zonderman, A. B. TI PREDICTORS OF NEUROCOGNITIVE PERFORMANCE AMONG AFRICAN AMERICANS ENROLLED IN THE HANDLS STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Wright, R. S.; Gerassimakis, C.] Univ Delaware, Sch Nursing, Newark, DE USA. [Waldstein, S.; Moody, D. L. Beatty; Taylor, A.] Univ Maryland Baltimore Cty, Baltimore, MD 21228 USA. [Sprung, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Evans, M. K.; Zonderman, A. B.] NIA, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 733 EP 734 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003446 ER PT J AU Bamonti, P Smith, H Smith, H Gaworski, L AF Bamonti, P. Smith, H. Smith, H. Gaworski, L. TI Exploring the Relation Between Cognitive Emotion Regulation and Burnout in Nursing Staff in Geriatric Settings SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bamonti, P.] VA Boston Healthcare Syst, Boston, MA USA. [Smith, H.] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA. [Smith, H.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Gaworski, L.] Wisconsin Sch Profess Psychol, Milwaukee, WI USA. NR 0 TC 0 Z9 0 U1 11 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003561 ER PT J AU Kirn, DR Buckley, RF Amariglio, RE Hanseeuw, B Sperling, R Johnson, KA Buckley, RF Amariglio, RE Sperling, R Buckley, RF Amariglio, RE Sperling, R Johnson, KA Johnson, KA AF Kirn, D. R. Buckley, R. F. Amariglio, R. E. Hanseeuw, B. Sperling, R. Johnson, K. A. Buckley, R. F. Amariglio, R. E. Sperling, R. Buckley, R. F. Amariglio, R. E. Sperling, R. Johnson, K. A. Johnson, K. A. TI Gait Speed and Alzheimer's Disease Pathology in Older Adults From the Harvard Aging Brain Study SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kirn, D. R.; Buckley, R. F.; Amariglio, R. E.; Hanseeuw, B.; Sperling, R.; Johnson, K. A.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Buckley, R. F.; Amariglio, R. E.; Sperling, R.] Harvard Med Sch, Boston, MA USA. [Buckley, R. F.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia. [Amariglio, R. E.; Sperling, R.; Johnson, K. A.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. [Johnson, K. A.] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585003603 ER PT J AU Gavlovsky, PJ Tonnerre, P Guitton, C Charreau, B AF Gavlovsky, Pierre-Jean Tonnerre, Pierre Guitton, Christophe Charreau, Beatrice TI Expression of MHC class I-related molecules MICA, HLA-E and EPCR shape endothelial cells with unique functions in innate and adaptive immunity SO HUMAN IMMUNOLOGY LA English DT Article DE MHC; HLA-E; MICA; EPCR; Endothelial cells ID PROTEIN-C RECEPTOR; DELTA T-CELLS; E-RESTRICTED RECOGNITION; DIFFERENTIAL EXPRESSION; KIDNEY-TRANSPLANTATION; TRANSMEMBRANE REGION; CONFERS PROTECTION; SURFACE EXPRESSION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS AB Endothelial cells (ECs) located at the interface of blood and tissues display regulatory activities toward coagulation, inflammation and vascular homeostasis. By expressing MHC class I and II antigens, ECs also contribute to immune responses. In transplantation, graft ECs are both trigger and target of alloimmune responses. ECs express a set of MHC class I-like or structural related molecules such as HLA-E, MHC class I related chain A (MICA) and the endothelial protein C receptor (EPCR) that provide multiple and unique functions to ECs. HLA-E is a low polymorphic ligand for the CD94/NKG2A/C receptors, and triggers HLA-E-restricted CD8(+)alpha beta T cell responses against viral and bacterial peptides. MICA is a highly polymorphic ligand for NKG2D activating NK and costimulating CD8(+)T cells and a ligand for tissue-resident V delta 1 gamma delta T subsets. More intriguing is the role of EPCR, a key regulator of coagulation, as a ligand for a circulating subset of V delta 2(-) gamma delta T cells. Coexpression of this set of MHC class I-related molecules that allow ECs to activate a subtle array of immune responses upon stress and infection may also influence transplant out come. Here, the respective structure, expression, and functions of HLA-E, MICA and EPCR as well as the impact of their polymorphism are reviewed. (C) 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. C1 [Gavlovsky, Pierre-Jean; Tonnerre, Pierre; Guitton, Christophe; Charreau, Beatrice] INSERM, UMR1064, LabEx Transplantex, F-44000 Nantes, France. [Gavlovsky, Pierre-Jean] IHU CESTI, F-44000 Nantes, France. [Gavlovsky, Pierre-Jean; Guitton, Christophe; Charreau, Beatrice] CHU Nantes, Inst Transplantat & Rech Transplantat Urol Nephro, ITUN, F-44000 Nantes, France. [Gavlovsky, Pierre-Jean; Tonnerre, Pierre; Guitton, Christophe; Charreau, Beatrice] LUNAM Univ Nantes, Fac Med, F-44000 Nantes, France. [Tonnerre, Pierre] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA. [Tonnerre, Pierre] Harvard Med Sch, Boston, MA USA. RP Charreau, B (reprint author), INSERM UMR1064, 30 Bd J Monnet, F-44093 Nantes 01, France. EM Beatrice.Charreau@univ-nantes.fr NR 87 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 EI 1879-1166 J9 HUM IMMUNOL JI Hum. Immunol. PD NOV PY 2016 VL 77 IS 11 SI SI BP 1084 EP 1091 DI 10.1016/j.humimm.2016.02.007 PG 8 WC Immunology SC Immunology GA EE4II UT WOS:000389565100012 PM 26916837 ER PT J AU Bala, H Venkatesh, V Venkatraman, S Bates, J AF Bala, Hillol Venkatesh, Viswanath Venkatraman, Srinivasan Bates, Jack TI If the Worst Happens: Five Strategies for Developing and Leveraging Information Technology-Enabled Disaster Response in Healthcare SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS LA English DT Article DE Disaster response; information technology (IT) strategy; IT architecture; natural disaster; universal data repository (UDR) ID US AB Natural disasters, such as hurricanes, tornadoes, cyclones, earthquakes, volcanic eruptions, wildfires, and floods, have a profound impact on healthcare by limiting healthcare providers' ability to effectively provide patient care in the affected areas and respond to myriad healthcare needs of the affected population. The situation can potentially be exacerbated if healthcare providers do not have effective mechanisms in place for disaster response. The response to Hurricane Katrina, a Category 3 hurricane that made landfall in August 2005 and affected several states in the southwestern U.S., was a vivid example of how the lack of effective planning and responsiveness can affect healthcare services. In this paper, based on an extensive case study, which included a rigorous examination of the Veterans Health Administration's information technology (IT) infrastructure and its response to Hurricane Katrina, we present five strategies that healthcare organizations can undertake to develop and leverage IT-enabled disaster response. These include the development of: 1) an integrated IT architecture; 2) a universal data repository; 3) web-based disaster communication and coordination; 4) an IT-enabled disaster support system; and 5) standardized and integrated IT-enabled disaster response processes. We discuss how these strategies can help healthcare providers manage continuity and offer quality healthcare during natural disasters. C1 [Bala, Hillol] Indiana Univ, Kelley Sch Business, Dept Operat & Decis Technol, Bloomington, IN 47401 USA. [Venkatesh, Viswanath] Univ Arkansas, Walton Coll Business, Dept Informat Syst, Fayetteville, AR 72701 USA. [Bates, Jack] US Dept Vet Affairs, Business Intelligence Serv, Washington, DC 20420 USA. RP Bala, H (reprint author), Indiana Univ, Kelley Sch Business, Dept Operat & Decis Technol, Bloomington, IN 47401 USA. EM hbala@indiana.edu; vvenkatesh@vvenkatesh.us; srini@srinivenkatraman.com; jack.bates@va.gov NR 25 TC 0 Z9 0 U1 7 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2194 J9 IEEE J BIOMED HEALTH JI IEEE J. Biomed. Health Inform. PD NOV PY 2016 VL 20 IS 6 BP 1545 EP 1551 DI 10.1109/JBHI.2015.2477371 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Medical Informatics SC Computer Science; Mathematical & Computational Biology; Medical Informatics GA EE8AN UT WOS:000389846700010 PM 26357415 ER PT J AU Brugger, SD Troxler, LJ Rufenacht, S Frey, PM Morand, B Geyer, R Muhlemann, K Hock, S Thormann, W Furrer, J Christen, S Hilty, M AF Brugger, Silvio D. Troxler, Lukas J. Rufenacht, Susanne Frey, Pascal M. Morand, Brigitte Geyer, Rudolf Muhlemann, Kathrin Hock, Stefan Thormann, Wolfgang Furrer, Julien Christen, Stephan Hilty, Markus TI Polysaccharide Capsule Composition of Pneumococcal Serotype 19A Subtypes Is Unaltered among Subtypes and Independent of the Nutritional Environment SO INFECTION AND IMMUNITY LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; ANION-EXCHANGE CHROMATOGRAPHY; PULSED-AMPEROMETRIC DETECTION; FLUORESCENT ANTHRANILIC ACID; STREPTOCOCCUS-PNEUMONIAE; CRYPTOCOCCUS-NEOFORMANS; CONJUGATE VACCINE; REPEATING UNITS; SEROLOGICAL CHARACTERIZATION; QUANTITATIVE-DETERMINATION AB Serotype 19A strains have emerged as a cause of invasive pneumococcal disease after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), and serotype 19A has now been included in the recent 13-valent vaccine (PCV13). Genetic analysis has revealed at least three different capsular serotype 19A subtypes, and nutritional environment-dependent variation of the 19A capsule structure has been reported. Pneumococcal vaccine effectiveness and serotyping accuracy might be impaired by structural differences in serotype 19A capsules. We therefore analyzed the distribution of 19A subtypes collected within a Swiss national surveillance program and determined capsule composition under different nutritional conditions with high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) spectroscopy. After the introduction of PCV7, a significant relative increase of subtype 19A-II and decrease of 19A-I occurred. Chemical analyses showed no difference in the composition as well as the linkage of 19A subtype capsular saccharides grown in defined and undefined growth media, which is consistent with a trisaccharide repeat unit composed of rhamnose, Nacetyl- mannosamine, and glucose. In summary, our study suggests that no structural variance dependent of the nutritional environment or the subtype exists. The serotype 19A subtype shift observed after the introduction of the PCV7 can therefore not be explained by selection of a capsule structure variant. However, capsule composition analysis of emerging 19A clones is recommended in cases where there is no other explanation for a selective advantage, such as antibiotic resistance or loss or acquisition of other virulence factors. C1 [Brugger, Silvio D.; Troxler, Lukas J.; Rufenacht, Susanne; Frey, Pascal M.; Morand, Brigitte; Muhlemann, Kathrin; Thormann, Wolfgang; Christen, Stephan; Hilty, Markus] Univ Bern, Inst Infect Dis, Bern, Switzerland. [Troxler, Lukas J.] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland. [Frey, Pascal M.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Gen Internal Med, Bern, Switzerland. [Geyer, Rudolf] Univ Giessen, Inst Biochem, Fac Med, Giessen, Germany. [Furrer, Julien] Univ Bern, Dept Chem & Biochem, Bern, Switzerland. [Hock, Stefan] ZHAW Zurich Univ Appl Sci, Inst Chem & Biotechnol, Sch Life Sci & Facil Management, Wadenswil, Switzerland. [Muhlemann, Kathrin; Hilty, Markus] Univ Bern, Univ Hosp Bern, Inselspital, Dept Infect Dis, Bern, Switzerland. [Brugger, Silvio D.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA. [Brugger, Silvio D.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA. [Christen, Stephan] Univ Zurich, Dept Mol Mechanisms Dis, Zurich, Switzerland. RP Hilty, M (reprint author), Univ Bern, Inst Infect Dis, Bern, Switzerland.; Hilty, M (reprint author), Univ Bern, Univ Hosp Bern, Inselspital, Dept Infect Dis, Bern, Switzerland. EM markus.hilty@ifik.unibe.ch RI Christen, Stephan/B-8602-2009 FU Swiss National Science Foundation [320000-113912, 323500-119214, 315230-146161, 310030-120725] FX This work, including the efforts of Kathrin Muhlemann, was funded by Swiss National Science Foundation (320000-113912). This work, including the efforts of Silvio D. Brugger, was funded by Swiss National Science Foundation (323500-119214). This work, including the efforts of Wolfgang Thormann, was funded by Swiss National Science Foundation (315230-146161). This work, including the efforts of Stephan Christen, was funded by Swiss National Science Foundation (310030-120725). NR 50 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD NOV PY 2016 VL 84 IS 11 BP 3152 EP 3160 DI 10.1128/IAI.00474-16 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EE8US UT WOS:000389902300007 PM 27550933 ER PT J AU Bastani, R Viswanath, K Lee, C Ramirez, A AF Bastani, R. Viswanath, K. Lee, C. Ramirez, A. TI POPULATION LEVEL IMPLEMENTATION OF INTERVENTIONS TO ENHANCE CANCER OUTCOMES: CHALLENGES AND SUCCESSES SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Bastani, R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Viswanath, K.] Harvard Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA USA. [Lee, C.] Univ Queensland, Sch Psychol, St Lucia, Qld, Australia. [Ramirez, A.] Univ Texas Hlth Sci Ctr San Antonio, Natl Latino Canc Res Network, Inst Hlth Promot Res, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. EM bastani@ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 EI 1532-7558 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD NOV PY 2016 VL 23 SU 1 MA S427 BP S139 EP S139 PG 1 WC Psychology, Clinical SC Psychology GA ED6CV UT WOS:000388943400438 ER PT J AU Lee, JH Jeon, HJ AF Lee, Jae-Hon Jeon, Hong Jin TI ASSOCIATION BETWEEN OCCUPATIONAL STRESS AND HUMAN ERRORS IN EXPERIENCED TRAIN DRIVERS: A POPULATION-BASED NATIONWIDE STUDY IN SOUTH KOREA SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lee, Jae-Hon] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Lee, Jae-Hon; Jeon, Hong Jin] Sungkyunkwan Univ, Samsung Seoul Hosp, Sch Med, Dept Psychiat, Seoul, South Korea. [Jeon, Hong Jin] Harvard Med Sch, Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 EI 1532-7558 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD NOV PY 2016 VL 23 SU 1 MA O199 BP S64 EP S65 PG 2 WC Psychology, Clinical SC Psychology GA ED6CV UT WOS:000388943400209 ER PT J AU Viswanath, K Minsky, S Lora, V Ramanadhan, S AF Viswanath, K. Minsky, S. Lora, V. Ramanadhan, S. TI BEYOND BEHAVIORAL INTERVENTIONS: PROMOTING PUBLIC AGENDA TO ADDRESS HEALTH DISPARITIES SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Viswanath, K.] Harvard Sch Publ Hlth, Boston, MA USA. [Viswanath, K.; Minsky, S.; Ramanadhan, S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lora, V.] YMCA Greater Lawrence, Lawrence, MA USA. EM vish_viswanath@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 EI 1532-7558 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD NOV PY 2016 VL 23 SU 1 MA S428 BP S139 EP S140 PG 2 WC Psychology, Clinical SC Psychology GA ED6CV UT WOS:000388943400439 ER PT J AU Kocaba, V Damour, O Auxenfans, C Burillon, C AF Kocaba, V. Damour, O. Auxenfans, C. Burillon, C. TI Limbal stem cell deficiency management. A review SO JOURNAL FRANCAIS D OPHTALMOLOGIE LA French DT Review DE Cornea; Limbus; Limbal stem cell deficiency; Cellular therapy; Limbal reconstruction ID OCULAR-SURFACE DISORDERS; STEVENS-JOHNSON-SYNDROME; EPITHELIAL TRANSPLANTATION; AMNIOTIC-MEMBRANE; CONJUNCTIVAL TRANSPLANTATION; AUTOGRAFT TRANSPLANTATION; PENETRATING KERATOPLASTY; KERATOLIMBAL ALLOGRAFTS; CORNEAL EPITHELIUM; CLINICAL-OUTCOMES AB Limbal stem cell deficiency is predominantly caused by severe eye burns resulting in a decreased or a complete ablation of the regenerative potential of these stem cells. The inability to reconstruct the corneal epithelium further leads conjunctivalization of the gimbal-epithelial barrier. These abnormalities collectively result in the progressive opacification of the cornea responsible for blindness that is driven by chronic corneal ulceration and neovascularization. The underlying pathology of the cornea affects the homeostasis of the neighboring conjunctiva, eyelids, and tear film. Therefore, the ocular reconstruction to treat limbal stem cell deficiency is quite prolonged and involves a continued treatment plan. The managementof limbal stem cell deficiency has undergone a multitude of changes over the past several decades. The understanding of limbal anatomy and physiology, as well as therapeutic advances in the stem cell field have propelled the development of new treatments offering new hope to severely disabled patients. Cultivated limbal epithelial and oral mucosal epithelial transplantations are therefore viable alternatives that could be utilized for the treatment of limbal stem cell deficiency. (C) 2016 Elsevier Masson SAS. All rights reserved. C1 [Kocaba, V.] Harvard Med Sch, Cornea Ctr Excellence, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. [Kocaba, V.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. [Kocaba, V.; Damour, O.; Auxenfans, C.; Burillon, C.] Hosp Civils Lyon, Hop Edouard Herriot, Banque Cornee Lyon, Pavil 1,5 Pl Arsonval, F-69003 Lyon, France. [Kocaba, V.; Burillon, C.] Hop Edouard Herriot, Serv Ophtalmol, Pavil C,5 Pl Arsonval, F-69003 Lyon, France. [Kocaba, V.; Burillon, C.] Univ Claude Bernard Lyon I, 43 Blvd 11 Novembre 1918, F-69100 Villeurbanne, France. RP Kocaba, V (reprint author), Harvard Med Sch, Cornea Ctr Excellence, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.; Kocaba, V (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.; Kocaba, V (reprint author), Hosp Civils Lyon, Hop Edouard Herriot, Banque Cornee Lyon, Pavil 1,5 Pl Arsonval, F-69003 Lyon, France.; Kocaba, V (reprint author), Hop Edouard Herriot, Serv Ophtalmol, Pavil C,5 Pl Arsonval, F-69003 Lyon, France.; Kocaba, V (reprint author), Univ Claude Bernard Lyon I, 43 Blvd 11 Novembre 1918, F-69100 Villeurbanne, France. EM viridianakocaba@meei.harvard.edu OI Kocaba, Viridiana/0000-0002-3044-5057 NR 68 TC 0 Z9 0 U1 4 U2 4 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0181-5512 EI 1773-0597 J9 J FR OPHTALMOL JI J. Fr. Ophthamol. PD NOV PY 2016 VL 39 IS 9 BP 791 EP 803 DI 10.1016/j.jfo.2016.08.001 PG 13 WC Ophthalmology SC Ophthalmology GA EE6MS UT WOS:000389726000022 PM 27742136 ER PT J AU Walter, JE Farmer, JR Foldvari, Z Torgerson, TR Cooper, MA AF Walter, Jolan E. Farmer, Jocelyn R. Foldvari, Zsofia Torgerson, Troy R. Cooper, Megan A. TI Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Review DE Primary immunodeficiencies (PIDs); Treatment; Autoimmunity; Cytopenias; Arthritis; Vasculitis; Lupus; Autoimmune enteropathy (AIE); Inflammatory bowel disease (IBD) ID COMMON VARIABLE IMMUNODEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; X-LINKED AGAMMAGLOBULINEMIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; STEM-CELL TRANSPLANTATION; WISKOTT-ALDRICH-SYNDROME; 22Q11.2 DELETION SYNDROME; REGULATORY T-CELLS; CHRONIC MUCOCUTANEOUS CANDIDIASIS; LYMPHOPROLIFERATIVE SYNDROME ALPS AB A broad spectrum of autoimmunity is now well described in patients with primary immunodeficiencies (PIDs). Management of autoimmune disease in the background of PID is particularly challenging given the seemingly discordant goals of immune support and immune suppression. Our growing ability to define the molecular underpinnings of immune dysregulation has facilitated novel targeted therapeutics. This review focuses on mechanism-based treatment strategies for the most common autoimmune and inflammatory complications of PID including autoimmune cytopenias, rheumatologic disease, and gastrointestinal disease. We aim to provide guidance regarding the rational use of these agents in the complex PID patient population. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma& Immunology. This is an open access article under the CC BY-NC-ND license. C1 [Walter, Jolan E.] Univ S Florida, Johns Hopkins All Childrens Hosp, Dept Pediat & Med, St Petersburg, FL 33701 USA. [Walter, Jolan E.] Massachusetts Gen Hosp Children, Div Pediat Allergy & Immunol, Boston, MA USA. [Walter, Jolan E.] Boston Childrens Hosp, Div Immunol, Boston, MA USA. [Farmer, Jocelyn R.] Massachusetts Gen Hosp, Dept Allergy & Immunol, Boston, MA 02114 USA. [Foldvari, Zsofia] Oslo Univ Hosp, Dept Canc Immunol, Radiumhosp, Oslo, Norway. [Foldvari, Zsofia] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Canc Immunotherapy & Inflammat Res, Oslo, Norway. [Torgerson, Troy R.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Cooper, Megan A.] Washington Univ, Sch Med, Dept Pediat, Div Rheumatol, St Louis, MO 63110 USA. RP Walter, JE (reprint author), Univ S Florida, Johns Hopkins All Childrens Hosp, 601 4th St South CRI 4008, St Petersburg, FL 33701 USA. EM jolanwalter@health.usf.edu FU Jeffrey Modell Foundation; Baxalta Biosciences; CSL Behring; NIH; Questcor Pharmaceuticals; Robert Wood Johnson Foundation; [5K08AI103035] FX J. E. Walter has been supported by grant number 5K08AI103035 and the Jeffrey Modell Foundation. J. R. Farmer is employed by Massachusetts General Hospital. T. R. Torgerson has consultancy arrangements with Baxalta Biosciences, CSL Behring, and ADMA Biologics; has received one or more grants from or has one or more grants pending with Baxalta Biosciences, CSL Behring, and the NIH; and has received one or more payments for the development of educational presentations for Baxalta Biosciences, CSL Behring, Questcor Pharmaceuticals, and Robert Wood Johnson Foundation. The rest of the authors declare that they have no relevant conflicts of interest. NR 188 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD NOV-DEC PY 2016 VL 4 IS 6 BP 1089 EP 1100 DI 10.1016/j.jaip.2016.08.004 PG 12 WC Allergy; Immunology SC Allergy; Immunology GA EE4ZA UT WOS:000389613300008 PM 27836058 ER PT J AU Shah, NH Schneider, TR Yeh, DD Cahill, KN Laidlaw, TM AF Shah, Neelam H. Schneider, Thomas R. Yeh, Doreen DeFaria Cahill, Katherine N. Laidlaw, Tanya M. TI Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Article DE Eosinophilia; Vasospasm; Aspirin-exacerbated respiratory disease; AERD; Steroid; Chest pain ID CHURG-STRAUSS-SYNDROME; MYOCARDIAL-INFARCTION; KOUNIS SYNDROME; ANGINA; SPASM AB BACKGROUND: Some patients with aspirin-exacerbated respiratory disease (AERD) and eosinophilia report angina-type chest pain that occurs at rest and responds to corticosteroid therapy. The frequency of eosinophilia-associated coronary artery vasospasm in patients with AERD, a disease characterized by blood and respiratory tissue eosinophilia, however, is unknown. OBJECTIVE: The objective of this study was to understand the cause of the chest pain described above and determine the most appropriate treatment for it. METHODS: A chart review of 153 patients with AERD who are followed at Brigham and Women's Hospital was performed. Patients who reported any type of chest pain were assessed for the presence of cardiac risk factors, eosinophilia, and response of chest pain to a variety of treatments. Two patients with AERD and eosinophilia who had recurrent chest pain due to suspected vasospasm are described in detail, and 8 other cases are also summarized. RESULTS: Of the 153 patients reviewed, 10 had a history of chest pain concerning for ischemia. Of the 10 patients with chest pain, 8 had undergone aspirin desensitization and initiated high-dose aspirin therapy; of these, 6 reported an increase in the frequency or severity of chest pain while on high-dose aspirin with improvement after aspirin discontinuation or dose reduction. Many patients had traditional cardiac risk factors, but none had any evidence of coronary atherosclerosis; almost all had significant eosinophilia. Their chest pain did not improve with typical antianginal treatments but did respond to corticosteroid therapy. CONCLUSIONS: Although uncommon, patients with AERD can develop eosinophilia-associated coronary artery vasospasm, which is occasionally worsened by high-dose aspirin. Patients with AERD who present with symptoms of ischemic chest pain should be screened for eosinophilia, as early treatment with corticosteroids can be life-saving. (C) 2016 American Academy of Allergy, Asthma & Immunology C1 [Shah, Neelam H.; Cahill, Katherine N.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Shah, Neelam H.] Boston Childrens Hosp, Dept Med, Boston, MA USA. [Shah, Neelam H.] Boston Med Ctr, Dept Pediat, Boston, MA USA. [Schneider, Thomas R.; Cahill, Katherine N.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA. [Yeh, Doreen DeFaria] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Yeh, Doreen DeFaria; Cahill, Katherine N.; Laidlaw, Tanya M.] Harvard Med Sch, Dept Med, Boston, MA USA. RP Shah, NH (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. EM nhshah@partners.org FU NIH [1R01HL128241-01, K23HL111113-02, K23 AI118804-01] FX This work was supported by NIH grants 1R01HL128241-01, K23HL111113-02, K23 AI118804-01 and by generous contributions from the Vinik Family and Kaye Family. NR 18 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD NOV-DEC PY 2016 VL 4 IS 6 BP 1215 EP 1219 DI 10.1016/j.jaip.2016.04.028 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA EE4ZA UT WOS:000389613300026 PM 27396680 ER PT J AU Drucker, AM Li, WQ Cho, EY Li, T Flint, AJ Camargo, CA Qureshi, AA AF Drucker, Aaron M. Li, Wen-Qing Cho, Eunyoung Li, Tricia Flint, Alan J. Camargo, Carlos A. Qureshi, Abrar A. TI Atopic conditions are associated with food addiction in US women SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Letter ID OBESITY; ASTHMA; SCALE C1 [Drucker, Aaron M.; Li, Wen-Qing; Cho, Eunyoung; Qureshi, Abrar A.] Warren Alpert Med Sch, Dept Dermatol, Providence, RI USA. [Drucker, Aaron M.; Qureshi, Abrar A.] Rhode Isl Hosp, Dept Dermatol, 593 Eddy St,APC 10, Providence, RI 02903 USA. [Drucker, Aaron M.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA. [Li, Wen-Qing; Cho, Eunyoung; Qureshi, Abrar A.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Cho, Eunyoung; Li, Tricia; Camargo, Carlos A.; Qureshi, Abrar A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Cho, Eunyoung; Li, Tricia; Camargo, Carlos A.; Qureshi, Abrar A.] Harvard Med Sch, Boston, MA USA. [Flint, Alan J.; Camargo, Carlos A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Flint, Alan J.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Camargo, Carlos A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Qureshi, AA (reprint author), Rhode Isl Hosp, Dept Dermatol, 593 Eddy St,APC 10, Providence, RI 02903 USA. EM abrar_qureshi@brown.edu FU NCI NIH HHS [UM1 CA176726] NR 9 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD NOV-DEC PY 2016 VL 4 IS 6 BP 1246 EP + DI 10.1016/j.jaip.2016.06.007 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA EE4ZA UT WOS:000389613300033 PM 27421898 ER PT J AU Lamoureux, L Radhakrishnan, J Mason, TG Kraut, JA Gazmuri, RJ AF Lamoureux, Lorissa Radhakrishnan, Jeejabai Mason, Thomas G. Kraut, Jeffrey A. Gazmuri, Raul J. TI Adverse postresuscitation myocardial effects elicited by buffer-induced alkalemia ameliorated by NHE-1 inhibition in a rat model of ventricular fibrillation SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE buffer agents; cardiopulmonary resuscitation; CO2-consuming buffer; cytochrome c; sodium-hydrogen exchanger isoform-1; ventricular fibrillation ID CLOSED-CHEST RESUSCITATION; MITOCHONDRIAL BIOENERGETIC FUNCTION; HYDROGEN EXCHANGER ISOFORM-1; AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; HYPERCARBIC ACIDOSIS; NA+/H+ EXCHANGE; REPERFUSION INJURY; BLOOD-FLOW; CARIPORIDE AB Major myocardial abnormalities occur during cardiac arrest and resuscitation including intracellular acidosis-partly caused by CO2 accumulation-and activation of the Na+-H+ exchanger isoform-1 (NHE-1). We hypothesized that a favorable interaction may result from NHE-1 inhibition during cardiac resuscitation followed by administration of a CO2-consuming buffer upon return of spontaneous circulation (ROSC). Ventricular fibrillation was electrically induced in 24 male rats and left untreated for 8 min followed by defibrillation after 8 min of cardiopulmonary resuscitation (CPR). Rats were randomized 1:1:1 to the NHE-1 inhibitor zoniporide or vehicle during CPR and disodium carbonate/ sodium bicarbonate buffer or normal saline (30 ml/ kg) after ROSC. Survival at 240 min declined from 100% with Zoniporide/ Saline to 50% with Zoniporide/ Buffer and 25% with Vehicle/ Buffer (P = 0.004), explained by worsening postresuscitation myocardial dysfunction. Marked alkalemia occurred after buffer administration along with lactatemia that was maximal after Vehicle/ Buffer, attenuated by Zoniporide/ Buffer, and minimal with Zoniporide/ Saline [ 13.3 +/- 4.8 (SD), 9.2 +/- 4.6, and 2.7 +/- 1.0 mmol/ l; P <= 0.001]. We attributed the intense postresuscitation lactatemia to enhanced glycolysis consequent to severe buffer-induced alkalemia transmitted intracellularly by an active NHE-1. We attributed the worsened postresuscitation myocardial dysfunction also to severe alkalemia intensifying Na+ entry via NHE-1 with consequent Ca2+ overload injuring mitochondria, evidenced by increased plasma cytochrome c. Both buffer-induced effects were ameliorated by zoniporide. Accordingly, buffer-induced alkalemia after ROSC worsened myocardial function and survival, likely through enhancing NHE-1 activity. Zoniporide attenuated these effects and uncovered a complex postresuscitation acid-base physiology whereby blood pH drives NHE-1 activity and compromises mitochondrial function and integrity along with myocardial function and survival. C1 [Lamoureux, Lorissa; Radhakrishnan, Jeejabai; Gazmuri, Raul J.] Rosalind Franklin Univ Med & Sci, Resuscitat Inst, 3333 Green Bay Rd, N Chicago, IL 60064 USA. [Gazmuri, Raul J.] Captain James A Lovell Fed Hlth Care Ctr, Sect Crit Care Med, N Chicago, IL USA. [Mason, Thomas G.] Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90024 USA. [Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Los Angeles, CA USA. [Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA USA. [Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Nephrol, Los Angeles, CA USA. [Kraut, Jeffrey A.] David Geffen Sch Med, Los Angeles, CA USA. RP Gazmuri, RJ (reprint author), Rosalind Franklin Univ Med & Sci, Resuscitat Inst, 3333 Green Bay Rd, N Chicago, IL 60064 USA. EM raul.gazmuri@rosalindfranklin.edu FU Friends Medical Research Institute; Veterans Administration; UCLA Academic Senate; Department of Medicine at Rosalind Franklin University of Medicine and Science FX This work was supported by funds from the Friends Medical Research Institute (J. A. Kraut and R. J. Gazmuri), the Veterans Administration (J. A. Kraut), the UCLA Academic Senate (J. A. Kraut and T. G. Mason), a gift in memory of U.S. Navy Retired SKC Robert W. Ply by Monica Ply for research in heart disease and Parkinson's disease (R. J. Gazmuri), and a discretionary fund from the Department of Medicine at Rosalind Franklin University of Medicine and Science (R. J. Gazmuri). NR 59 TC 0 Z9 0 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV 1 PY 2016 VL 121 IS 5 BP 1160 EP 1168 DI 10.1152/japplphysiol.00336.2016 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA EE5MH UT WOS:000389651700015 PM 27633736 ER PT J AU Mihos, CG Capoulade, R Yucel, E Melnitchouk, S Hung, J AF Mihos, Christos G. Capoulade, Romain Yucel, Evin Melnitchouk, Serguei Hung, Judy TI Combined papillary muscle sling and ring annuloplasty for moderate-to-severe secondary mitral regurgitation SO JOURNAL OF CARDIAC SURGERY LA English DT Article ID ISCHEMIC CARDIOMYOPATHY; HEART-FAILURE; VALVE SURGERY; RESTRICTIVE ANNULOPLASTY; SUBVALVULAR REPAIR; RECURRENCE; INSIGHTS; APPROXIMATION; DYSFUNCTION AB BACKGROUND: There is a 30-60% incidence of recurrent mitral regurgitation (MR) after mitral valve annuloplasty (Ring) for secondary MR. A concomitant papillary muscle sling (Ring+Sling) may improve valve repair by providing a more physiologic geometry of the mitral apparatus. METHODS: We retrospectively identified 58 consecutive patients with moderate-to-severe secondary MR who underwent a Ring+Sling repair, between March 2008 and May 2015. A Ring+Sling consisted of combined annuloplasty and papillary muscle approximation, utilizing a 4-mm polytetrafluoroethylene graft placed around the base of each muscle. Comparison of echocardiographic variables with patients who underwent a Ring only was performed utilizing 2: 1 propensity-score matching (Ring+Sling = 34; Ring = 17). RESULTS: The baseline demographics were similar between the groups. The mean time to follow-up echocardiogram was 10.1 months (range 0.25-42 months). At follow-up, a Ring+Sling repair was associated with a lower mitral valve tenting height (p = 0.005), mitral valve tenting area (p = 0.009), and interpapillary muscle distance (p = 0.001); a smaller posterior leaflet tethering angle (p = 0.003); and a greater leaflet coaptation length (p = 0.002), when compared with Ring only. Recurrence of moderate or greater MR occurred significantly less in the Ring+Sling group (14.7%), as compared with Ring only (35.3%) (p < 0.001). Finally, actuarial survival at three years was 87% for Ring+Sling, and 82% for Ring only (p = 0.49). CONCLUSIONS: A Ring+Sling for secondary MR results in favorable changes in the mitral valve apparatus geometry, and is associated with less MR recurrence in the early postoperative period. Longer-term follow-up is needed to assess its durability and effects on left ventricular remodeling and survival. C1 [Mihos, Christos G.; Capoulade, Romain; Yucel, Evin; Hung, Judy] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Boston, MA 02114 USA. [Mihos, Christos G.] Columbia Univ, Mt Sinai Heart Inst, Miami Beach, FL USA. [Melnitchouk, Serguei] Harvard Med Sch, Massachusetts Gen Hosp, Dept Cardiac Surg, Boston, MA USA. RP Mihos, CG (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Boston, MA 02114 USA. EM cmihos@mgh.harvard.edu FU American Medical Association Foundation Seed Grant; Canadian Institute of Health Research FX American Medical Association Foundation Seed Grant (CGM) and Post-Doctoral Fellowship Grant-Canadian Institute of Health Research (RC) NR 35 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0886-0440 EI 1540-8191 J9 J CARDIAC SURG JI J. Card. Surg. PD NOV PY 2016 VL 31 IS 11 BP 664 EP 671 DI 10.1111/jocs.12843 PG 8 WC Cardiac & Cardiovascular Systems; Surgery SC Cardiovascular System & Cardiology; Surgery GA EE1CV UT WOS:000389319300001 PM 27620350 ER PT J AU Woodhouse, E AF Woodhouse, Erik TI TOXIC MEGACOLON: A REVIEW FOR EMERGENCY DEPARTMENT CLINICIANS SO JOURNAL OF EMERGENCY NURSING LA English DT Review ID CLOSTRIDIUM-DIFFICILE INFECTION; SURGICAL-MANAGEMENT; ULCERATIVE-COLITIS; ETIOLOGY; DISEASES; UPDATE C1 [Woodhouse, Erik] William S Middleton Mem Vet Adm Med Ctr, Emergency Dept, Madison, WI USA. RP Woodhouse, E (reprint author), 418 S Livingston St, Madison, WI 53703 USA. EM ewoodhouse@wisc.edu NR 24 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0099-1767 EI 1527-2966 J9 J EMERG NURS JI J. Emerg. Nurs. PD NOV PY 2016 VL 42 IS 6 BP 481 EP 486 DI 10.1016/j.jen.2016.04.007 PG 6 WC Emergency Medicine; Nursing SC Emergency Medicine; Nursing GA EE3YU UT WOS:000389539300010 PM 27185628 ER PT J AU Wang, LJ Wu, LP Lai, SC Fu, JF Pan, J Chung, DC AF Wang, Liangjing Wu, Lunpo Lai, Sanchuan Fu, Jianfei Pan, Jie Chung, Daniel C. TI Survival outcomes of well-differentiated small intestinal neuroendocrine tumors: A retrospective cohort study based on National SEER database SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Meeting Abstract C1 [Wang, Liangjing; Wu, Lunpo] Zhejiang Univ, Inst Gastroenterol, Sch Med, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China. [Wang, Liangjing; Wu, Lunpo; Lai, Sanchuan] Zhejiang Univ, Sch Med, Hosp, Inst Gastroenterol, Hangzhou, Zhejiang, Peoples R China. [Fu, Jianfei] Zhejiang Univ, Jinhua Hosp, Dept Oncol, Hangzhou, Zhejiang, Peoples R China. [Pan, Jie] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Endocrinol, Hangzhou, Zhejiang, Peoples R China. [Chung, Daniel C.] Harvard Med Sch, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 EI 1440-1746 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD NOV PY 2016 VL 31 SU 3 MA 2030 BP 120 EP 121 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA6YV UT WOS:000386776001033 ER PT J AU Arora, U Ananthakrishnan, AN Kedia, S Bopana, S Mouli, PV Yadav, DP Makharia, GK Yajnik, V Ahuja, V AF Arora, Umang Ananthakrishnan, Ashwin N. Kedia, Saurabh Bopana, Sawan Mouli, P. V. Yadav, Dawesh P. Makharia, Govind K. Yajnik, Vijay Ahuja, Vineet TI Oral tobacco use and smoking do not affect disease outcomes in Indian patients with Crohn's disease SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Meeting Abstract C1 [Arora, Umang; Kedia, Saurabh; Bopana, Sawan; Mouli, P. V.; Yadav, Dawesh P.; Makharia, Govind K.; Ahuja, Vineet] All India Inst Med Sci, Dept Gastroenterol, Delhi, India. [Ananthakrishnan, Ashwin N.; Yajnik, Vijay] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 EI 1440-1746 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD NOV PY 2016 VL 31 SU 3 MA 1165 BP 166 EP 167 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA6YV UT WOS:000386776001168 ER PT J AU Mattox, R Battaglia, PJ Welk, AB Maeda, Y Haun, DW Kettner, NW AF Mattox, Ross Battaglia, Patrick J. Welk, Aaron B. Maeda, Yumi Haun, Daniel W. Kettner, Norman W. TI Reference Values for the Scalene Interval Width During Varying Degrees of Glenohumeral Abduction Using Ultrasonography SO JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS LA English DT Article DE Thoracic Outlet Syndrome; Ultrasonography; Brachial Plexus; Reference Values ID THORACIC OUTLET SYNDROME; CROSS-SECTIONAL AREA; BRACHIAL-PLEXUS; SYMPTOMATIC POPULATIONS; ANATOMY; TRIANGLE; SPACE; TESTS AB Objective: The aim of this study was to establish reference values for the width of the interval between the anterior and middle scalene muscles using ultrasonography during varying degrees of glenohumeral joint (GH) abduction. Reliability and body mass index (BMI) data were also assessed. Methods: Interscalene triangles of asymptomatic participants were scanned bilaterally in the transverse plane. Images were obtained at 0 degrees, 90 degrees, and 150 degrees of GH abduction with the participant seated. Width measurements were taken between the anterior and middle scalene muscle borders by bisecting the C6 nerve root as it passed superficial to the posterior tubercle of the C7 transverse process. Intra-and interexaminer reliability and BMI correlation were studied. Statistical significance was defined as P <= .05. Results: Images of 42 scalene intervals were included from 21 participants (11 female). Mean participant age was 25.3 +/- 3.9 years; mean BMI was 25.4 +/- 2.7 kg/m(2). Scalene interval measurements at 0 degrees, 90 degrees, and 150 degrees of GH abduction were 4.5 +/- 0.5 mm, 4.6 +/- 0.5 mm, and 4.4 +/- 0.7 mm, respectively, without a significant difference (P = .07). Intraexaminer reliability was excellent (0 degrees: intraclass correlation coefficient [ICC] = 0.82; 90 degrees: ICC = 0.89; 150 degrees: ICC = 0.90). Interexaminer reliability was good to excellent (0 degrees: ICC = 0.59; 90 degrees: ICC = 0.85; 150 degrees: ICC = 0.89). Body mass index was positively correlated only at 0 degrees of GH abduction. Conclusions: This study establishes previously unreported reference ultrasonography values for the width of the scalene interval. Intraexaminer reliability was excellent at all glenohumeral positions, and interexaminer reliability was determined to be good to excellent. Body mass index was positively correlated only at 0 degrees of GH abduction. C1 [Mattox, Ross; Battaglia, Patrick J.; Welk, Aaron B.; Maeda, Yumi; Haun, Daniel W.; Kettner, Norman W.] Logan Univ, Dept Radiol, 1851 Schoettler Rd, Chesterfield, MO 63006 USA. [Maeda, Yumi] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Mattox, R (reprint author), Logan Univ, Dept Radiol, 1851 Schoettler Rd, Chesterfield, MO 63006 USA. EM ross.mattox@logan.edu NR 34 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-4754 J9 J MANIP PHYSIOL THER JI J. Manip. Physiol. Ther. PD NOV-DEC PY 2016 VL 39 IS 9 BP 662 EP 667 DI 10.1016/j.jmpt.2016.08.002 PG 6 WC Health Care Sciences & Services; Integrative & Complementary Medicine; Rehabilitation SC Health Care Sciences & Services; Integrative & Complementary Medicine; Rehabilitation GA EE5EQ UT WOS:000389628600007 PM 28327294 ER PT J AU Selvi, F Messina, J Faquin, WC Keith, DA AF Selvi, Firat Messina, Justin Faquin, William C. Keith, David A. TI Relapsing Polychondritis Concomitant With Synovial Chondromatosis of the Temporomandibular Joint SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID II COLLAGEN AB Relapsing polychondritis (RP) is a rare, multisystem autoimmune disease characterized by inflammation, structural damage, and impaired function of cartilaginous tissues throughout the body. In the craniofacial region, this rare disease has been reported to affect structures of the ear and nose; however, reports of temporomandibular joint (TMJ) involvement are scarce. A second uncommon disorder of cartilage is synovial chondromatosis (SC), a progressive and proliferative disorder of the synovial membrane associated with the formation of variably sized cartilaginous and calcified loose bodies, often causing dysfunction of the joints and enlargement of the joint capsule. It commonly affects the larger joints; TMJ involvement is uncommon. We present the case of a 45-year-old woman with previously diagnosed RP in whom right TMJ pathology subsequently developed, undergoing arthroscopy and biopsy followed by arthroplasty, which was proved to be SC, likely due to her autoimmune disease. To our knowledge, this is the first case describing concomitant SC of the TMJ presumably from pre-existing RP. (C) 2016 American Association of Oral and Maxillofacial Surgeons C1 [Selvi, Firat; Messina, Justin] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. [Selvi, Firat; Messina, Justin] Harvard Sch Dent Med, Boston, MA USA. Istanbul Univ, Dept Oral Surg, Fac Dent, Oral Surg, Istanbul, Turkey. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Pathol, Boston, MA 02114 USA. [Faquin, William C.] Harvard Med Sch, Boston, MA USA. [Keith, David A.] Harvard Sch Dent Med, Oral & Maxillofacial Surg, Boston, MA USA. [Keith, David A.] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. RP Keith, DA (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM dkeith@mgh.harvard.edu NR 27 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD NOV PY 2016 VL 74 IS 11 BP 2207 EP 2215 DI 10.1016/j.joms.2016.04.035 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3QY UT WOS:000389512200027 PM 27292528 ER PT J AU Graves, LL Giaconi, JA Mallya, SM Chang, TI Friedlander, AH AF Graves, Lindsay L. Giaconi, Joann A. Mallya, Sanjay M. Chang, Tina I. Friedlander, Arthur H. TI Facial Trauma: Delayed Development of a Subluxated Traumatic Cataract as Visualized on a Panoramic Image SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article AB The immediate and long-term consequences of blunt orbital trauma leading to a subluxated lens and its subsequent calcification and opacification are reviewed. The accompanying panoramic image documents the process. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons C1 [Graves, Lindsay L.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Dent Serv, Los Angeles, CA USA. [Giaconi, Joann A.] Vet Affairs Greater Los Angeles Healthcare Syst, Ophthalmol, Los Angeles, CA USA. [Giaconi, Joann A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Giaconi, Joann A.] UCLA Jules Stein Eye Inst, Los Angeles, CA USA. [Mallya, Sanjay M.] UCLA Sch Dent, Sect Oral & Maxillofacial Radiol, Los Angeles, CA USA. [Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Fellowship & Inpatient Oral & Maxillofacial S, Los Angeles, CA USA. [Chang, Tina I.] UCLA Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] UCLA Sch Dent, Oral & Maxillofacial Surg, Residence, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Qual Assurance, Hosp Dent Serv, Los Angeles, CA 90073 USA. RP Friedlander, AH (reprint author), Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Arthur.Friedlander@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD NOV PY 2016 VL 74 IS 11 DI 10.1016/j.joms.2016.07.025 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3QY UT WOS:000389512200031 ER PT J AU Kim, H Wei, Y Lee, JY Wu, Y Zheng, Y Moskowitz, MA Chen, JW AF Kim, HyeonJu Wei, Ying Lee, Ji Yong Wu, Yue Zheng, Yi Moskowitz, Michael A. Chen, John W. TI Myeloperoxidase Inhibition Increases Neurogenesis after Ischemic Stroke SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ADULT SUBVENTRICULAR ZONE; FOCAL CEREBRAL-ISCHEMIA; NEURAL STEM-CELLS; ACUTE LUNG INJURY; NEUROTROPHIC FACTOR; STIMULATES NEUROGENESIS; INFLAMMATORY RESPONSE; NEUROBLASTS MIGRATE; THERAPEUTIC TARGET AB The relationship between inflammation and neurogenesis in stroke is currently not well understood. Focal ischemia enhances cell proliferation and neurogenesis in the neurogenic regions, including the subventricular zone (SVZ), dentate gyrus, as well as the non-neurogenic striatum, and cortex in the ischemic hemisphere. Myeloperoxidase (MPO) is a potent oxidizing enzyme secreted during inflammation by activated leukocytes, and its enzymatic activity is highly elevated after stroke. In this study, we investigated whether the inhibition of MPO activity by a specific irreversible inhibitor, 4-aminobenzoic acid hydrazide (ABAH) (MPO-/- mice) can increase neurogenesis after transient middle cerebral artery occlusion in mice. ABAH administration increased the number of proliferating bromodeoxyuridine (BrdU)-positive cells expressing markers for neural stems cells, astrocytes, neuroprogenitor cells (Nestin), and neuroblasts (doublecortin) in the ischemic SVZ, anterior SVZ, striatum, and cortex. MPO inhibition also increased levels of brain-derived neurotrophic factor, phosphorylation of cAMP response element-binding protein (Ser133), acetylated H3, and NeuN to promote neurogenesis in the ischemic SVZ. ABAH treatment also increased chemokine CXC receptor 4 expression in the ischemic SVZ. MPO-deficient mice treated with vehicle or ABAH both showed similar effects on the number of BrdU(+) cells in the ischemic hemisphere, demonstrating that ABAH is specific to MPO. Taken together, our results underscore a detrimental role of MPO activity to postischemia neurogenesis and that a strategy to inhibit MPO activity can increase cell proliferation and improve neurogenesis after ischemic stroke. C1 [Kim, HyeonJu; Lee, Ji Yong; Chen, John W.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA USA. [Kim, HyeonJu; Lee, Ji Yong; Chen, John W.] Harvard Med Sch, Massachusetts Gen Hosp, Inst Innovat Imaging, Boston, MA USA. [Wei, Ying; Wu, Yue; Zheng, Yi; Moskowitz, Michael A.] Harvard Med Sch, Massachusetts Gen Hosp, Neurosci Ctr, Boston, MA USA. RP Chen, JW (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Richard B Simches Res Ctr, 185 Cambridge St, Boston, MA 02114 USA. EM Jwchen@mgh.harvard.edu FU National Institutes of Health [R01-NS070835, R01-NS-0721267] FX This study was supported by National Institutes of Health [Grants R01-NS070835 and R01-NS-0721267]. NR 66 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD NOV 1 PY 2016 VL 359 IS 2 BP 262 EP 272 DI 10.1124/jpet.116.235127 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EE4WE UT WOS:000389605500005 PM 27550713 ER PT J AU Beyer-Berjot, L Berdah, S Hashimoto, DA Darzi, A Aggarwal, R AF Beyer-Berjot, Laura Berdah, Stephane Hashimoto, Daniel A. Darzi, Ara Aggarwal, Rajesh TI A Virtual Reality Training Curriculum for Laparoscopic Colorectal Surgery SO JOURNAL OF SURGICAL EDUCATION LA English DT Article DE simulation; education; colorectal; laparoscopy; advanced surgery ID RANDOMIZED-CONTROLLED-TRIAL; OPERATING-ROOM; NISSEN FUNDOPLICATION; SURGICAL RESIDENTS; LEARNING-CURVES; SKILLS; SIMULATION; COLECTOMY; MODEL; RELIABILITY AB OBJECTIVE: Training within a competency-based curriculum (CBC) outside the operating room enhances performance during real basic surgical procedures. This study aimed to design and validate a virtual reality CBC for an advanced laparoscopic procedure: sigmoid colectomy. DESIGN: This was a multicenter randomized study. Novice (surgeons who had performed <5 laparoscopic colorectal resections as primary operator), intermediate (between 10 and 20), and experienced surgeons ( > 50) were enrolled. Validity evidence for the metrics given by the virtual reality simulator, the LAP Mentor, was based on the second attempt of each task in between groups. The tasks assessed were 3 modules of a laparoscopic sigmoid colectomy (medial dissection [MD], lateral dissection [LD], and anastomosis) and a full procedure (FP). Novice surgeons were randomized to 1 of 2 groups to perform 8 further attempts of all 3 modules or FP, for learning curve analysis. SETTING: Two academic tertiary care centers division of surgery of St. Mary's campus, Imperial College Healthcare NHS Trust, London and Nord Hospital, Assistance Publique-Hopitaux de Marseille, Aix-Marseille Universite, Marseille, were involved. PARTICIPANTS: Novice surgeons were residents in digestive surgery at St. Mary's and Nord Hospitals. Intermediate and experienced surgeons were board-certified academic surgeons. RESULTS: A total of 20 novice surgeons, 7 intermediate surgeons, and 6 experienced surgeons were enrolled. Evidence for validity based on experience was identified in MD, LD, and FP for time (p = 0.005, p = 0.003, and p = 0.001, respectively), number of movements (p = 0.013, p = 0.005, and p = 0.001, respectively), and path length (p = 0.03, p = 0.017, and p = 0.001, respectively), and only for time (p = 0.03) and path length (p = 0.013) in the anastomosis module. Novice surgeons' performance significantly improved through repetition for time, movements, and path length in MD, LD, and FP. Experienced surgeons' benchmark criteria were defined for all construct metrics showing validity evidence. CONCLUSIONS: A CBC in laparoscopic colorectal surgery has been designed. Such training may reduce the learning curve during real colorectal resections in the operating room. (C) 2016 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved. C1 [Beyer-Berjot, Laura; Darzi, Ara] Imperial Coll Healthcare NHS Trust, Dept Surg & Canc, Div Surg, St Marys Campus, London, England. [Beyer-Berjot, Laura; Berdah, Stephane] Aix Marseille Univ, Ctr Surg Teaching & Res CERC, Marseille, France. [Hashimoto, Daniel A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Aggarwal, Rajesh] McGill Univ, Fac Med, Arnold & Blema Steinberg Med Simulat Ctr, Montreal, PQ, Canada. [Aggarwal, Rajesh] McGill Univ, Dept Surg, Fac Med, Montreal, PQ, Canada. RP Beyer-Berjot, L (reprint author), Aix Marseille Univ, Ctr Surg Teaching Res CERC, Fac Med Sect Nord, 51 Blvd Pierre Dramard, F-13015 Marseille, France. EM laura.beyer@ap-hm.fr OI Beyer-Berjot, Laura/0000-0002-6594-6935 FU French research project PHRC [00-11] FX The authors would like to thank the participants for their time and generosity. They also thank Simbionix for kindly lending the LAP Mentor used on the French research project PHRC 2008 no. 00-11. NR 37 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-7204 EI 1878-7452 J9 J SURG EDUC JI J. Surg. Educ. PD NOV-DEC PY 2016 VL 73 IS 6 BP 932 EP 941 DI 10.1016/j.jsurg.2016.05.012 PG 10 WC Education, Scientific Disciplines; Surgery SC Education & Educational Research; Surgery GA EE4FR UT WOS:000389558200002 PM 27342755 ER PT J AU Langer, CJ Gadgeel, SM Borghaei, H Papadimitrakopoulou, VA Patnaik, A Powell, SF Gentzler, RD Martins, RG Stevenson, JP Jalal, SI Panwalkar, A Yang, JCH Gubens, M Sequist, LV Awad, MM Fiore, J Ge, Y Raftopoulos, H Gandhi, L AF Langer, Corey J. Gadgeel, Shirish M. Borghaei, Hossein Papadimitrakopoulou, Vassiliki A. Patnaik, Amita Powell, Steven F. Gentzler, Ryan D. Martins, Renato G. Stevenson, James P. Jalal, Shadia I. Panwalkar, Amit Yang, James Chih-Hsin Gubens, Matthew Sequist, Lecia V. Awad, Mark M. Fiore, Joseph Ge, Yang Raftopoulos, Harry Gandhi, Leena CA KEYNOTE-021 Investigators TI Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study SO LANCET ONCOLOGY LA English DT Article ID 1ST-LINE TREATMENT; ANTICANCER AGENTS; CONTROLLED-TRIAL; NIVOLUMAB; BEVACIZUMAB; THERAPY; CHEMOTHERAPY; DOCETAXEL; CISPLATIN; SURVIVAL AB Background Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting. The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced non-squamous NSCLC. Methods In this randomised, open-label, phase 2 cohort of a multicohort study (KEYNOTE-021), patients were enrolled at 26 medical centres in the USA and Taiwan. Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1: 1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs >= 1%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. The primary endpoint was the proportion of patients who achieved an objective response, defined as the percentage of patients with radiologically confirmed complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1 assessed by masked, independent central review, in the intention-to-treat population, defined as all patients who were allocated to study treatment. Significance threshold was p<0.025 (one sided). Safety was assessed in the as-treated population, defined as all patients who received at least one dose of the assigned study treatment. This trial, which is closed for enrolment but continuing for follow-up, is registered with ClinicalTrials.gov, number NCT02039674. Findings Between Nov 25, 2014, and Jan 25, 2016, 123 patients were enrolled; 60 were randomly assigned to the pembrolizumab plus chemotherapy group and 63 to the chemotherapy alone group. 33 (55%; 95% CI 42-68) of 60 patients in the pembrolizumab plus chemotherapy group achieved an objective response compared with 18 (29%; 18-41) of 63 patients in the chemotherapy alone group (estimated treatment difference 26% [95% CI 9-42%]; p=0.0016). The incidence of grade 3 or worse treatment-related adverse events was similar between groups (23 [39%] of 59 patients in the pembrolizumab plus chemotherapy group and 16 [26%] of 62 in the chemotherapy alone group). The most common grade 3 or worse treatment-related adverse events in the pembrolizumab plus chemotherapy group were anaemia (seven [12%] of 59) and decreased neutrophil count (three [5%]); an additional six events each occurred in two (3%) for acute kidney injury, decreased lymphocyte count, fatigue, neutropenia, and sepsis, and thrombocytopenia. In the chemotherapy alone group, the most common grade 3 or worse events were anaemia (nine [15%] of 62) and decreased neutrophil count, pancytopenia, and thrombocytopenia (two [3%] each). One (2%) of 59 patients in the pembrolizumab plus chemotherapy group experienced treatment-related death because of sepsis compared with two (3%) of 62 patients in the chemotherapy group: one because of sepsis and one because of pancytopenia. Interpretation Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. This finding is being further explored in an ongoing international, randomised, double-blind, phase 3 study. C1 [Langer, Corey J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Gadgeel, Shirish M.] Karmanos Canc Inst, Detroit, MI USA. [Gadgeel, Shirish M.] Wayne State Univ, Detroit, MI USA. [Borghaei, Hossein] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Papadimitrakopoulou, Vassiliki A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Patnaik, Amita] South Texas Accelerated Res Therapeut, San Antonio, TX USA. [Powell, Steven F.] Sanford Canc Ctr, Sioux Falls, SD USA. [Gentzler, Ryan D.] Univ Virginia, Charlottesville, VA USA. [Martins, Renato G.] Univ Washington, Seattle, WA 98195 USA. [Martins, Renato G.] Seattle Canc Care Alliance, Seattle, WA USA. [Stevenson, James P.] Cleveland Clin, Cleveland, OH 44106 USA. [Jalal, Shadia I.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Panwalkar, Amit] Sanford Roger Maris Canc Ctr, Fargo, ND USA. [Yang, James Chih-Hsin] Natl Taiwan Univ Hosp, Taipei, Taiwan. [Yang, James Chih-Hsin] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan. [Gubens, Matthew] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Sequist, Lecia V.] Harvard Med Sch, Boston, MA USA. [Awad, Mark M.; Gandhi, Leena] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gandhi, Leena] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA. [Fiore, Joseph; Ge, Yang; Raftopoulos, Harry] Merck & Co Inc, Kenilworth, NJ USA. RP Langer, CJ (reprint author), Univ Penn, Abramson Canc Ctr, Dept Thorac Oncol, Philadelphia, PA 19104 USA. EM corey.langer@uphs.upenn.edu OI Gandhi, Leena/0000-0002-2398-9179 FU Merck Co. FX Merck & Co. NR 29 TC 19 Z9 19 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2016 VL 17 IS 11 BP 1497 EP 1508 DI 10.1016/S1470-2045(16)30498-3 PG 12 WC Oncology SC Oncology GA EE3YF UT WOS:000389537600043 PM 27745820 ER PT J AU Hodi, FS Chesney, J Pavlick, AC Robert, C Grossmann, KF McDermott, DF Linette, GP Meyer, N Giguere, JRK Agarwala, SS Shaheen, M Ernstoff, MS Minor, DR Salama, AK Taylor, MH Ott, PA Horak, C Gagnier, P Jiang, J Wolchok, JD Postow, MA AF Hodi, F. Stephen Chesney, Jason Pavlick, Anna C. Robert, Caroline Grossmann, Kenneth F. McDermott, David F. Linette, Gerald P. Meyer, Nicolas Giguere, Jeff Rey K. Agarwala, Sanjiv S. Shaheen, Montaser Ernstoff, Marc S. Minor, David R. Salama, April K. Taylor, Matthew H. Ott, Patrick A. Horak, Christine Gagnier, Paul Jiang, Joel Wolchok, Jedd D. Postow, Michael A. TI Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial SO LANCET ONCOLOGY LA English DT Article ID UNTREATED MELANOMA; METASTATIC MELANOMA; III TRIAL; PEMBROLIZUMAB; CHEMOTHERAPY AB Background Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma. Methods In this multicentre, double-blind, randomised, controlled, phase 2 trial (CheckMate 069) we recruited patients from 19 specialist cancer centres in two countries (France and the USA). Eligible patients were aged 18 years or older with previously untreated, unresectable stage III or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 2: 1 to receive an intravenous infusion of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg or ipilimumab 3 mg/kg plus placebo, every 3 weeks for four doses. Subsequently, patients assigned to nivolumab plus ipilimumab received nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity, whereas patients allocated to ipilimumab alone received placebo every 2 weeks during this phase. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by BRAF mutation status. The study funder, patients, investigators, and study site staff were masked to treatment assignment. The primary endpoint, which has been reported previously, was the proportion of patients with BRAF(V600) wild-type melanoma achieving an investigator-assessed objective response. Overall survival was an exploratory endpoint and is reported in this Article. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all treated patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01927419, and is ongoing but no longer enrolling patients. Findings Between Sept 16, 2013, and Feb 6, 2014, we screened 179 patients and enrolled 142, randomly assigning 95 patients to nivolumab plus ipilimumab and 47 to ipilimumab alone. In each treatment group, one patient no longer met the study criteria following randomisation and thus did not receive study drug. At a median follow-up of 24.5 months (IQR 9.1-25.7), 2-year overall survival was 63.8% (95% CI 53.3-72.6) for those assigned to nivolumab plus ipilimumab and 53.6% (95% CI 38.1-66.8) for those assigned to ipilimumab alone; median overall survival had not been reached in either group (hazard ratio 0.74, 95% CI 0.43-1.26; p=0.26). Treatment-related grade 3-4 adverse events were reported in 51 (54%) of 94 patients who received nivolumab plus ipilimumab compared with nine (20%) of 46 patients who received ipilimumab alone. The most common treatment-related grade 3-4 adverse events were colitis (12 [13%] of 94 patients) and increased alanine aminotransferase (ten [11%]) in the combination group and diarrhoea (five [11%] of 46 patients) and hypophysitis (two [4%]) in the ipilimumab alone group. Serious grade 3-4 treatment-related adverse events were reported in 34 (36%) of 94 patients who received nivolumab plus ipilimumab (including colitis in ten [11%] of 94 patients, and diarrhoea in five [5%]) compared with four (9%) of 46 patients who received ipilimumab alone (including diarrhoea in two [4%] of 46 patients, colitis in one [2%], and hypophysitis in one [2%]). No new types of treatment-related adverse events or treatment-related deaths occurred in this updated analysis. Interpretation Although follow-up of the patients in this study is ongoing, the results of this analysis suggest that the combination of first-line nivolumab plus ipilimumab might lead to improved outcomes compared with first-line ipilimumab alone in patients with advanced melanoma. The results suggest encouraging survival outcomes with immunotherapy in this population of patients. C1 [Hodi, F. Stephen; Ott, Patrick A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chesney, Jason] Univ Louisville, Louisville, KY 40292 USA. [Pavlick, Anna C.] NYU, New York, NY USA. [Robert, Caroline] Gustave Roussy, INSERM U981, Paris, France. [Grossmann, Kenneth F.] Huntsman Canc Inst, Salt Lake City, UT USA. [McDermott, David F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Linette, Gerald P.] Washington Univ, Sch Med, St Louis, MO USA. [Meyer, Nicolas] Inst Univ Canc, Toulouse, France. [Giguere, Jeff Rey K.] Greenville Hlth Syst Canc Inst, Greenville, SC USA. [Agarwala, Sanjiv S.] St Lukes Canc Ctr, Bethlehem, PA USA. [Agarwala, Sanjiv S.] Temple Univ, Bethlehem, PA USA. [Shaheen, Montaser] Univ New Mexico, Albuquerque, NM 87131 USA. [Ernstoff, Marc S.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Minor, David R.] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA. [Salama, April K.] Duke Univ, Med Ctr, Durham, NC USA. [Taylor, Matthew H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Horak, Christine; Gagnier, Paul; Jiang, Joel] Bristol Myers Squibb, Princeton, NJ USA. [Wolchok, Jedd D.; Postow, Michael A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Wolchok, Jedd D.; Postow, Michael A.] Weill Cornell Med Coll, New York, NY USA. RP Hodi, FS (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM stephen_hodi@dfci.harvard.edu FU Bristol-Myers Squibb FX Bristol-Myers Squibb. NR 19 TC 13 Z9 13 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2016 VL 17 IS 11 BP 1558 EP 1568 DI 10.1016/S1470-2045(16)30366-7 PG 11 WC Oncology SC Oncology GA EE3YF UT WOS:000389537600048 PM 27622997 ER PT J AU Yee, AJ Bensinger, WI Supko, JRG Voorhees, PM Berdeja, JG Richardson, PG Libby, EN Wallace, EE Birrer, NE Burke, JN Tamang, DL Yang, M Jones, SS Wheeler, CA Markelewicz, RJ Raje, NS AF Yee, Andrew J. Bensinger, William I. Supko, Jeff Rey G. Voorhees, Peter M. Berdeja, Jesus G. Richardson, Paul G. Libby, Edward N. Wallace, Ellen E. Birrer, Nicole E. Burke, Jill N. Tamang, David L. Yang, Min Jones, Simon S. Wheeler, Catherine A. Markelewicz, Robert J. Raje, Noopur S. TI Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial SO LANCET ONCOLOGY LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; C-MYC; COMBINATION; VORINOSTAT; BORTEZOMIB; TUBULIN; PANOBINOSTAT; EXPRESSION; PLACEBO AB Background Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. Motivated by findings from preclinical studies showing potent synergistic activity with ricolinostat and lenalidomide, our goal was to assess the safety and preliminary activity of the combination of ricolinostat with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Methods In this multicentre phase 1b trial, we recruited patients aged 18 years or older with previously treated relapsed or refractory multiple myeloma from five cancer centres in the USA. Inclusion criteria included a Karnofsky Performance Status score of at least 70, measureable disease, adequate bone marrow reserve, adequate hepatic function, and a creatinine clearance of at least 50 mL per min. Exclusion criteria included previous exposure to HDAC inhibitors; previous allogeneic stem-cell transplantation; previous autologous stem-cell transplantation within 12 weeks of baseline; active systemic infection; malignancy within the last 5 years; known or suspected HIV, hepatitis B, or hepatitis C infection; a QTc Fridericia of more than 480 ms; and substantial cardiovascular, gastrointestinal, psychiatric, or other medical disorders. We gave escalating doses (from 40-240 mg once daily to 160 mg twice daily) of oral ricolinostat according to a standard 3 + 3 design according to three different regimens on days 1-21 with a conventional 28 day schedule of oral lenalidomide (from 15 mg [in one cohort] to 25 mg [in all other cohorts] once daily) and oral dexamethasone (40 mg weekly). Primary outcomes were dose-limiting toxicities, the maximum tolerated dose of ricolinostat in this combination, and the dose and schedule of ricolinostat recommended for further phase 2 investigation. Secondary outcomes were the pharmacokinetics and pharmacodynamics of ricolinostat in this combination and the preliminary anti-tumour activity of this treatment. The trial is closed to accrual and is registered at ClinicalTrials.gov, number NCT01583283. Findings Between July 12, 2012, and Aug 20, 2015, we enrolled 38 patients. We observed two dose-limiting toxicities with ricolinostat 160 mg twice daily: one (2%) grade 3 syncope and one (2%) grade 3 myalgia event in different cohorts. A maximum tolerated dose was not reached. We chose ricolinostat 160 mg once daily on days 1-21 of a 28 day cycle as the recommended dose for future phase 2 studies in combination with lenalidomide 25 mg and dexamethasone 40 mg. The most common adverse events were fatigue (grade 1-2 in 14 [37%] patients; grade 3 in seven [18%]) and diarrhoea (grade 1-2 in 15 [39%] patients; grade 3 in two [5%]). Our pharmacodynamic studies showed that at clinically relevant doses, ricolinostat selectively inhibits HDAC6 while retaining a low and tolerable level of class I HDAC inhibition. The pharmacokinetics of ricolinostat and lenalidomide were not affected by co-administration. In a preliminary assessment of antitumour activity, 21 (55% [95% CI 38-71]) of 38 patients had an overall response. Interpretation The findings from this study provide preliminary evidence that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma. C1 [Yee, Andrew J.; Supko, Jeff Rey G.; Wallace, Ellen E.; Birrer, Nicole E.; Burke, Jill N.; Raje, Noopur S.] Harvard Med Sch, Ctr Canc, Massachusetts Gen Hosp, Boston, MA USA. [Bensinger, William I.; Libby, Edward N.] Univ Washington, Seattle, WA 98195 USA. [Voorhees, Peter M.] Univ N Carolina, Chapel Hill, NC USA. [Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA. [Richardson, Paul G.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Tamang, David L.; Yang, Min; Jones, Simon S.; Wheeler, Catherine A.; Markelewicz, Robert J.] Acetylon Pharmaceut, Boston, MA USA. RP Raje, NS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. EM nraje@mgh.harvard.edu FU Acetylon Pharmaceuticals FX Acetylon Pharmaceuticals. NR 31 TC 4 Z9 4 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2016 VL 17 IS 11 BP 1569 EP 1578 DI 10.1016/S1470-2045(16)30375-8 PG 10 WC Oncology SC Oncology GA EE3YF UT WOS:000389537600049 PM 27646843 ER PT J AU Ledermann, JA Harter, P Gourley, C Friedlander, M Vergote, I Rustin, G Scott, C Meier, W Shapira-Frommer, R Safra, T Matei, D Fielding, A Spencer, S Rowe, P Lowe, E Hodgson, D Sovak, MA Matulonis, U AF Ledermann, Jonathan A. Harter, Philipp Gourley, Charlie Friedlander, Michael Vergote, Ignace Rustin, Gordon Scott, Clare Meier, Werner Shapira-Frommer, Ronnie Safra, Tamar Matei, Daniela Fielding, Anitra Spencer, Stuart Rowe, Philip Lowe, Elizabeth Hodgson, Darren Sovak, Mika A. Matulonis, Ursula TI Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial SO LANCET ONCOLOGY LA English DT Article ID POLY(ADP-RIBOSE) POLYMERASE; THERAPY; INHIBITORS AB Background In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo. We assessed the effect of maintenance olaparib on overall survival in patients with platinum-sensitive recurrent serous ovarian cancer, including those with BRCA1 and BRCA2 mutations (BRCAm). Methods In this randomised, placebo-controlled, double-blind, phase 2 trial involving 82 sites across 16 countries, patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more courses of platinum-based chemotherapy and had responded to their latest regimen were randomly assigned (1: 1) using a computer-generated sequence to receive oral maintenance olaparib (as capsules; 400 mg twice a day) or a matching placebo by an interactive voice response system. Patients were stratified by ancestry, time to progression on penultimate platinum, and response to most recent platinum. Patients and investigators were masked to treatment assignment by the use of unique identifiers generated during randomisation. The primary endpoint of the trial was progression-free survival. In this updated analysis, we present data for overall survival, a secondary endpoint, from the third data analysis after more than 5 years' follow-up (intention-to-treat population). We did the updated overall survival analysis, described in this Article at 77% data maturity, using a two-sided a of 0.95%. As the study was not powered to assess overall survival, this analysis should be regarded as descriptive and the p values are nominal. We analysed randomly assigned patients for overall survival and all patients who received at least one dose of treatment for safety. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT00753545. Findings Between Aug 28, 2008, and Feb 9, 2010, 265 patients were randomly assigned to olaparib (n=136) or placebo (n=129). 136 patients had deleterious BRCAm. The data cutoff for this analysis was Sept 30, 2015. An overall survival advantage was seen with maintenance olaparib versus placebo in all patients (hazard ratio [HR] 0.73 [95% CI 0.55-0.96]; nominal p=0.025, which did not meet the required threshold for statistical significance [p<0.0095]; median overall survival was 29.8 months [95% CI 26.9-35.7] for those treated with olaparib vs 27.8 months [24.9-33.7] for those treated with placebo), and in patients with BRCAm (HR 0.62 [95% CI 0.41-0.94] nominal p=0.025; 34.9 months [95% CI 29.2-54.6] vs 30.2 months [23.1-40.7]). The overall survival data in patients with BRCA wild-type were HR 0.83 (95% CI 0.55-1.24, nominal p=0.37; 24.5 months [19.8-35.0] for those treated with olaparib vs 26.6 months [23.1-32.5] for those treated with placebo). 11 (15%) of 74 patients with BRCAm received maintenance olaparib for 5 years or more. Overall, common grade 3 or worse adverse events in the olaparib and placebo groups were fatigue (11 [8%] of 136 patients vs four [3%] of 128) and anaemia (eight [6%] vs one [1%]). 30 (22%) of 136 patients in the olaparib group and 11 (9%) of 128 patients in the placebo group reported serious adverse events. In patients treated for 2 years or more, adverse events in the olaparib and placebo groups included low-grade nausea (24 [75%] of 32 patients vs two [40%] of five), fatigue (18 [56%] of 32 vs two [40%] of five), vomiting (12 [38%] of 32 vs zero), and anaemia (eight [25%] of 32 vs one [20%] of five); generally, events were initially reported during the first 2 years of treatment. Interpretation Despite not reaching statistical significance, patients with BRCA-mutated platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy after platinum-based chemotherapy appeared to have longer overall survival, supporting the reported progression-free survival benefit. Clinically useful long-term exposure to olaparib was seen with no new safety signals. Taken together, these data support both the long-term clinical benefit and tolerability of maintenance olaparib in patients with BRCA-mutated platinum-sensitive recurrent serous ovarian cancer. C1 [Ledermann, Jonathan A.] UCL, UCL Canc Inst, London, England. [Ledermann, Jonathan A.] UCL Hosp, London, England. [Harter, Philipp] Kliniken Essen Mitte, Essen, Germany. [Gourley, Charlie] Univ Edinburgh, Canc Res UK Ctr, MRC, Inst Genet & Mol Med,Western Gen Hosp, Edinburgh, Midlothian, Scotland. [Friedlander, Michael] Univ New South Wales, Sch Clin, Prince Wales Hosp, Randwick, NSW, Australia. [Vergote, Ignace] Univ Leuven, Leuven, Belgium. [Rustin, Gordon] Mt Vernon Hosp, Northwood, Middx, England. [Scott, Clare] Royal Melbourne Hosp, Parkville, Vic, Australia. [Meier, Werner] Evangel Krankenhaus, Dusseldorf, Germany. [Shapira-Frommer, Ronnie] Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Safra, Tamar] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel. [Matei, Daniela] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Fielding, Anitra; Spencer, Stuart; Rowe, Philip; Hodgson, Darren] AstraZeneca, Alderley Pk, Macclesfield, Cheshire, England. [Lowe, Elizabeth; Sovak, Mika A.] AstraZeneca, Gaithersburg, MD USA. [Matulonis, Ursula] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ledermann, JA (reprint author), Canc Res UK, London W1T 4TJ, England.; Ledermann, JA (reprint author), UCL Canc Trials Ctr, London W1T 4TJ, England. EM j.ledermann@ucl.ac.uk FU AstraZeneca FX AstraZeneca. NR 23 TC 6 Z9 6 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2016 VL 17 IS 11 BP 1579 EP 1589 DI 10.1016/S1470-2045(16)30376-X PG 11 WC Oncology SC Oncology GA EE3YF UT WOS:000389537600050 PM 27617661 ER PT J AU Sharma, P Callahan, MK Bono, P Kim, J Spiliopoulou, P Calvo, E Pillai, RN Ott, PA de Braud, F Morse, M Le, DT Jaeger, D Chan, E Harbison, C Lin, CS Tschaika, M Azrilevich, A Rosenberg, JE AF Sharma, Padmanee Callahan, Margaret K. Bono, Petri Kim, Joseph Spiliopoulou, Pavlina Calvo, Emiliano Pillai, Rathi N. Ott, Patrick A. de Braud, Filippo Morse, Michael Le, Dung T. Jaeger, Dirk Chan, Emily Harbison, Chris Lin, Chen-Sheng Tschaika, Marina Azrilevich, Alex Rosenberg, Jonathan E. TI Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial SO LANCET ONCOLOGY LA English DT Article ID CELL LUNG-CANCER; RANDOMIZED-TRIAL; BLADDER; CHEMOTHERAPY; CONFIDENCE; DOCETAXEL; BLOCKADE; THERAPY; PLUS; GEMCITABINE AB Background Few effective treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-based chemotherapy. We assessed the activity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after previous platinum-based chemotherapy. Methods In this phase 1/2, multicentre, open-label study, we enrolled patients (age >= 18 years) with urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra at 16 sites in Finland, Germany, Spain, the UK, and the USA. Patients were not selected by PD-L1 expression, but tumour PD-L1 membrane expression was assessed retrospectively. Patients received nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or treatment discontinuation because of unacceptable toxicity or other protocol-defined reasons, whichever occurred later. The primary endpoint was objective response by investigator assessment. All patients who received at least one dose of the study drug were included in the analyses. We report an interim analysis of this ongoing trial. CheckMate 032 is registered with ClinicalTrials.gov, NCT01928394. Findings Between June 5, 2014, and April 24, 2015, 86 patients with metastatic urothelial carcinoma were enrolled in the nivolumab monotherapy group and 78 received at least one dose of treatment. At data cutoff(March 24, 2016), the minimum follow-up was 9 months (median 15.2 months, IQR 12.9-16.8). A confirmed investigator-assessed objective response was achieved in 19 (24.4%, 95% CI 15.3-35.4) of 78 patients. Grade 3-4 treatment-related adverse events occurred in 17 (22%) of 78 patients; the most common were elevated lipase (four [5%]), elevated amylase (three [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decreased neutrophil count (two [3%] each). Serious adverse events were reported in 36 (46%) of 78 patients and eight (10%) had a serious adverse event judged to be treatment related. Two (3%) of 78 patients discontinued because of treatment-related adverse events (grade 4 pneumonitis and grade 4 thrombocytopenia) and subsequently died. Interpretation Nivolumab monotherapy was associated with a substantial and durable clinical response and a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma. These data support further investigation of nivolumab monotherapy in advanced urothelial carcinoma. C1 [Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Dept Genitourinary Med Oncol, Houston, TX 77030 USA. [Callahan, Margaret K.; Rosenberg, Jonathan E.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Bono, Petri] Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Oncol, Helsinki, Finland. [Bono, Petri] Univ Helsinki, Helsinki, Finland. [Kim, Joseph] Yale Canc Ctr, Prostate & Urol Canc Program, New Haven, CT USA. [Kim, Joseph] Yale Canc Ctr, Early Drug Dev Program, New Haven, CT USA. [Spiliopoulou, Pavlina] Beatson West Scotland Canc Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland. [Calvo, Emiliano] Ctr Integral Oncol Clara Campal, START Madrid, Div Med Oncol, Madrid, Spain. [Pillai, Rathi N.] Emory Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA USA. [Ott, Patrick A.] Dana Farber Canc Inst, Melanoma Ctr, Ctr Immunooncol, Boston, MA 02115 USA. [de Braud, Filippo] Univ Milan, Ist Nazl Tumori, Dept Med Oncol, Milan, Italy. [Morse, Michael] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA. [Le, Dung T.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Div Oncol Gastrointestinal Canc, Baltimore, MD USA. [Jaeger, Dirk] Univ Heidelberg Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany. [Chan, Emily] Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, Dept Med, Nashville, TN USA. [Harbison, Chris] Bristol Myers Squibb, NIVO IPI LCM Biomarkers, Princeton, NJ USA. [Lin, Chen-Sheng] Bristol Myers Squibb, Clin Biostat, Princeton, NJ USA. [Tschaika, Marina; Azrilevich, Alex] Bristol Myers Squibb, Global Clin Res Oncol, Princeton, NJ USA. RP Sharma, P (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Dept Genitourinary Med Oncol, Houston, TX 77030 USA. EM padsharma@mdanderson.org RI de Braud, Filippo/B-9997-2017 OI de Braud, Filippo/0000-0003-0103-730X FU Bristol-Myers Squibb FX Bristol-Myers Squibb. NR 30 TC 7 Z9 7 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2016 VL 17 IS 11 BP 1590 EP 1598 DI 10.1016/S1470-2045(16)30496-X PG 9 WC Oncology SC Oncology GA EE3YF UT WOS:000389537600051 PM 27733243 ER PT J AU Zhao, SG Chang, SL Spratt, DE Erho, N Yu, MG Ashab, HAD Alshalalfa, M Speers, C Tomlins, SA Davicioni, E Dicker, AP Carroll, PR Cooperberg, MR Freedland, SJ Karnes, RJ Ross, AE Schaeffer, EM Den, RB Nguyen, PL Feng, FY AF Zhao, Shuang G. Chang, S. Laura Spratt, Daniel E. Erho, Nicholas Yu, Menggang Ashab, Hussam Al-Deen Alshalalfa, Mohammed Speers, Corey Tomlins, Scott A. Davicioni, Elai Dicker, Adam P. Carroll, Peter R. Cooperberg, Matthew R. Freedland, Stephen J. Karnes, R. Jeffrey Ross, Ashley E. Schaeffer, Edward M. Den, Robert B. Nguyen, Paul L. Feng, Felix Y. TI Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis SO LANCET ONCOLOGY LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; RADICAL PROSTATECTOMY; BREAST-CANCER; ADJUVANT RADIOTHERAPY; SALVAGE RADIOTHERAPY; GENOMIC CLASSIFIER; GENE; RISK; PROGRESSION; RECURRENCE AB Background Postoperative radiotherapy has an important role in the treatment of prostate cancer, but personalised patient selection could improve outcomes and spare unnecessary toxicity. We aimed to develop and validate a gene expression signature to predict which patients would benefit most from postoperative radiotherapy. Methods Patients were eligible for this matched, retrospective study if they were included in one of five published US studies (cohort, case-cohort, and case-control studies) of patients with prostate adenocarcinoma who had radical prostatectomy (with or without postoperative radiotherapy) and had gene expression analysis of the tumour, with long-term follow-up and complete clinicopathological data. Additional treatment after surgery was at the treating physician's discretion. In each cohort, patients who had postoperative radiotherapy were matched with patients who had not had radiotherapy using Gleason score, prostate-specific antigen concentration, surgical margin status, extracapsular extension, seminal vesicle invasion, lymph node invasion, and androgen deprivation therapy. We constructed a matched training cohort using patients from one study in which we developed a 24-gene Post-Operative Radiation Therapy Outcomes Score (PORTOS). We generated a pooled matched validation cohort using patients from the remaining four studies. The primary endpoint was the development of distant metastasis. Findings In the training cohort (n=196), among patients with a high PORTOS (n=39), those who had radiotherapy had a lower incidence of distant metastasis than did patients who did not have radiotherapy, with a 10-year metastasis rate of 5% (95% CI 0-14) in patients who had radiotherapy (n=20) and 63% (34-80) in patients who did not have radiotherapy (n=19; hazard ratio [HR] 0.12 [95% CI 0.03-0.41], p<0.0001), whereas among patients with a low PORTOS (n=157), those who had postoperative radiotherapy (n=78) had a greater incidence of distant metastasis at 10 years than did their untreated counterparts (n=79; 57% [44-67] vs 31% [20-41]; HR 2.5 [1.6-4.1], p<0.0001), with a significant treatment interaction (p(interaction) <0.0001). The finding that PORTOS could predict outcome due to radiotherapy treatment was confirmed in the validation cohort (n=330), which showed that patients who had radiotherapy had a lower incidence of distant metastasis compared with those who did not have radiotherapy, but only in the high PORTOS group (high PORTOS [n=82]: 4% [95% CI 0-10] in the radiotherapy group [n=57] vs 35% [95% CI 7-54] in the no radiotherapy group [n=25] had metastasis at 10 years; HR 0.15 [95% CI 0.04-0.60], p=0.0020; low PORTOS [n=248]: 32% [95% CI 19-43] in the radiotherapy group [n=108] vs 32% [95% CI 22-40] in the no radiotherapy group [n=140]; HR 0.92 [95% CI 0.56-1.51], p=0.76), with a significant interaction (p(interaction) =0.016). The conventional prognostic tools Decipher, CAPRA-S, and microarray version of the cell cycle progression signature did not predict response to radiotherapy (p(interaction) >0.05 for all). Interpretation Patients with a high PORTOS who had postoperative radiotherapy were less likely to have metastasis at 10 years than those who did not have radiotherapy, suggesting that treatment with postoperative radiotherapy should be considered in this subgroup. PORTOS should be investigated further in additional independent cohorts. C1 [Zhao, Shuang G.; Chang, S. Laura; Spratt, Daniel E.; Speers, Corey; Feng, Felix Y.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Tomlins, Scott A.] Univ Michigan, Dept Pathol, Dept Urol, Ann Arbor, MI 48109 USA. [Tomlins, Scott A.; Feng, Felix Y.] Univ Michigan, Michigan Ctr Translat Pathol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Erho, Nicholas; Ashab, Hussam Al-Deen; Alshalalfa, Mohammed; Davicioni, Elai] GenomeDx Biosci, Vancouver, BC, Canada. [Yu, Menggang] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Dicker, Adam P.; Den, Robert B.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA. [Carroll, Peter R.; Cooperberg, Matthew R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Feng, Felix Y.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA. [Feng, Felix Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Carroll, Peter R.; Cooperberg, Matthew R.; Feng, Felix Y.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Freedland, Stephen J.] Cedars Sinai Med Ctr, Dept Urol, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. [Karnes, R. Jeffrey] Mayo Clin, Dept Urol, Rochester, MN USA. [Ross, Ashley E.] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA. [Schaeffer, Edward M.] Northwestern Univ, Dept Urol, Evanston, IL 60208 USA. [Nguyen, Paul L.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Nguyen, Paul L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Feng, FY (reprint author), Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA. EM felix.feng@ucsf.edu FU Prostate Cancer Foundation; Evans Foundation; V Foundation for Cancer Research; A Alfred Taubman Medical Research Institute at the University of Michigan; GenomeDx Biosciences; Patient-Centered Outcomes Research Institute (PCORI) [ME-1409-21219] FX GenomeDx provided access to data from samples. The authors were funded by the Prostate Cancer Foundation, the Evans Foundation, the V Foundation for Cancer Research, the A Alfred Taubman Medical Research Institute at the University of Michigan, GenomeDx Biosciences, and a Patient-Centered Outcomes Research Institute (PCORI) Award (ME-1409-21219). The views in this publication are solely the responsibility of the authors and do not necessarily represent the views of the PCORI, its Board of Governors or Methodology Committee. We thank Steven Kronenberg for assistance with figure preparation. NR 36 TC 4 Z9 4 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2016 VL 17 IS 11 BP 1612 EP 1620 DI 10.1016/S1470-2045(16)30491-0 PG 9 WC Oncology SC Oncology GA EE3YF UT WOS:000389537600053 PM 27743920 ER PT J AU Lang, HN Nishimoto, E Xing, YZ Brown, LN Noble, KV Barth, JL LaRue, AC Ando, K Schulte, BA AF Lang, Hainan Nishimoto, Eishi Xing, Yazhi Brown, LaShardai N. Noble, Kenyaria V. Barth, Jeremy L. LaRue, Amanda C. Ando, Kiyoshi Schulte, Bradley A. TI Contributions of Mouse and Human Hematopoietic Cells to Remodeling of the Adult Auditory Nerve After Neuron Loss SO MOLECULAR THERAPY LA English DT Article ID SPIRAL GANGLION NEURONS; MARROW-DERIVED CELLS; BONE-MARROW; STEM-CELLS; GERBIL COCHLEA; INNER-EAR; ACOUSTIC TRAUMA; SDF-1/CXCR4 INTERACTIONS; MICROGLIAL CELLS; TISSUE-REPAIR AB The peripheral auditory nerve (AN) carries sound information from sensory hair cells to the brain. The present study investigated the contribution of mouse and human hematopoietic stem cells (HSCs) to cellular diversity in the AN following the destruction of neuron cell bodies, also known as spiral ganglion neurons (SGNs). Exposure of the adult mouse cochlea to ouabain selectively killed type I SGNs and disrupted the blood-labyrinth barrier. This procedure also resulted in the upregulation of genes associated with hematopoietic cell homing and differentiation, and provided an environment conducive to the tissue engraftment of circulating. stem/progenitor cells into the AN. Experiments were performed using both a mouse-mouse bone marrow transplantation model and a severely immune-incompetent mouse model transplanted with human CD34(+) cord blood cells. Quantitative immunohistochemical analysis of recipient mice demonstrated that ouabain injury promoted an increase in the number of both HSC-derived macrophages and HSC-derived nonmacrophages in the AN. Although rare, a few HSC-derived cells in the injured AN exhibited glial-like qualities. These results suggest that human hematopoietic cells participate in remodeling of the AN after neuron cell body loss and that hematopoietic cells can be an important resource for promoting AN repair/regeneration in the adult inner ear. C1 [Lang, Hainan; Nishimoto, Eishi; Xing, Yazhi; Brown, LaShardai N.; Noble, Kenyaria V.; LaRue, Amanda C.; Schulte, Bradley A.] Med Univ South Carolina, Dept Pathol & Lab Med, 765 Ashley Ave,POB 250908, Charleston, SC 29425 USA. [Barth, Jeremy L.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC USA. [LaRue, Amanda C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Ando, Kiyoshi] Tokai Univ, Sch Med, Div Hematopoiesis, Res Ctr Regenerat Med, Tokyo, Japan. RP Lang, HN (reprint author), Med Univ South Carolina, Dept Pathol & Lab Med, 765 Ashley Ave,POB 250908, Charleston, SC 29425 USA. EM langh@musc.edu FU National Institutes of Health [R01DC012058, P50DC00422]; MUSC's Office of the Vice President for Research; [GM103342]; [GM103499] FX This work has been supported by National Institutes of Health Grants R01DC012058 (H.L.), and P50DC00422 (H.L., B.A.S.). J.L.B. and microarray data analyses were additionally supported through GM103342, GM103499, and MUSC's Office of the Vice President for Research. We thank Makio Ogawa for preliminary planning of this project, Meenal Mehrotra for her help with the hematopoietic cell transplantation, Juhong Zhu for cochlear tissue preparations, and Mary Bridges, Clarisse Panganiban, and Linda McCarson for their critical comments on the manuscript. The authors declare no competing financial interests. NR 78 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1525-0016 EI 1525-0024 J9 MOL THER JI Mol. Ther. PD NOV PY 2016 VL 24 IS 11 BP 2000 EP 2011 DI 10.1038/mt.2076.174 PG 12 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EE6PL UT WOS:000389734600016 PM 27600399 ER PT J AU Xiong, XF Zhang, H Underwood, CR Harpsoe, K Gardella, TJ Woldike, MF Mannstadt, M Gloriam, DE Brauner-Osborne, H Stromgaard, K AF Xiong, Xiao-Feng Zhang, Hang Underwood, Christina R. Harpsoe, Kasper Gardella, Thomas J. Woldike, Mie F. Mannstadt, Michael Gloriam, David E. Brauner-Osborne, Hans Stromgaard, Kristian TI Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors SO NATURE CHEMISTRY LA English DT Article ID PLATELET-AGGREGATION INHIBITOR; CHROMOBACTERIUM SP QS3666; ARDISIA-CRENATA SIMS; CYCLIC DEPSIPEPTIDE; ADP-RIBOSYLATION; ADENYLATE-CYCLASE; YM-254890; DEHYDROALANINE; CYSTEINE; FR900359 AB G proteins are key mediators of G protein-coupled receptor signalling, which facilitates a plethora of important physiological processes. The cyclic depsipeptides YM-254890 and FR900359 are the only known specific inhibitors of the G(q) subfamily of G proteins; however, no synthetic route has been reported previously for these complex natural products and they are not easily isolated from natural sources. Here we report the first total synthesis of YM-254890 and FR900359, as well as of two known analogues, YM-385780 and YM-385781. The versatility of the synthetic approach also enabled the design and synthesis of ten analogues, which provided the first structure-activity relationship study for this class of compounds. Pharmacological characterization of all the compounds at G(q)-, G(i)- and G(s)-mediated signalling provided succinct information on the structural requirements for inhibition, and demonstrated that both YM-254890 and FR900359 are highly potent inhibitors of Gq signalling, with FR900359 being the most potent. These natural products and their analogues represent unique tools for explorative studies of G protein inhibition. C1 [Xiong, Xiao-Feng; Zhang, Hang; Underwood, Christina R.; Harpsoe, Kasper; Woldike, Mie F.; Gloriam, David E.; Brauner-Osborne, Hans; Stromgaard, Kristian] Univ Copenhagen, Dept Drug Design & Pharmacol, DK-2100 Copenhagen, Denmark. [Gardella, Thomas J.; Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Gardella, Thomas J.; Mannstadt, Michael] Harvard Med Sch, Boston, MA 02114 USA. RP Stromgaard, K (reprint author), Univ Copenhagen, Dept Drug Design & Pharmacol, DK-2100 Copenhagen, Denmark. EM kristian.stromgaard@sund.ku.dk OI Brauner-Osborne, Hans/0000-0001-9495-7388; Gloriam, David/0000-0002-4299-7561; Harpsoe, Kasper/0000-0002-9326-9644; Underwood, Christina Rye/0000-0002-2333-2177 FU Lundbeck Foundation; National Institutes of Health (NIH) [R01-DK100584, P01-DK11794]; Center for Skeletal Research Core [NIH P30 AR066261] FX We thank C. A. Olsen for constructive comments on the manuscript, and D. Staerk for performing the HRMS. H.B. O. and K.S. acknowledge financial support from the Lundbeck Foundation. X.-F.X. thanks the Novo Nordisk Foundation, H.Z. thanks the Chinese Scholarship Council, C.R.U. acknowledges financial support from the Lundbeck Foundation, D.E.G. thanks the European Research Commission (DE-ORPHAN 639125) and the Lundbeck Foundation (R163-2013-16327), M.M. was supported by the National Institutes of Health (NIH) grant R01-DK100584, T.J.G. by NIH P01-DK11794, Project I, and M.M. and T.J.G. by the Center for Skeletal Research Core (NIH P30 AR066261). NR 42 TC 2 Z9 2 U1 16 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1755-4330 EI 1755-4349 J9 NAT CHEM JI Nat. Chem. PD NOV PY 2016 VL 8 IS 11 BP 1035 EP 1041 DI 10.1038/NCHEM.2577 PG 7 WC Chemistry, Multidisciplinary SC Chemistry GA ED9WS UT WOS:000389224800015 PM 27768111 ER PT J AU Spahillari, A Mukamal, KJ DeFilippi, C Kizer, JR Gottdiener, JS Djousse, L Lyles, MF Bartz, TM Murthy, VL Shah, RV AF Spahillari, A. Mukamal, K. J. DeFilippi, C. Kizer, J. R. Gottdiener, J. S. Djousse, L. Lyles, M. F. Bartz, T. M. Murthy, V. L. Shah, R. V. TI The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES LA English DT Article DE DEXA; Fat; Lean mass; Cardiovascular mortality; All-cause mortality; Cardiovascular Health Study ID MUSCLE MASS; FOLLOW-UP; WAIST CIRCUMFERENCE; SARCOPENIC OBESITY; REGRESSION-MODELS; NATIONAL-HEALTH; INDEX; OVERWEIGHT; MEN; POPULATION AB Background and aims: Understanding contributions of lean and fat tissue to cardiovascular and non-cardiovascular mortality may help clarify areas of prevention in older adults. We aimed to define distributions of lean and fat tissue in older adults and their contributions to cause-specific mortality. Methods and results: A total of 1335 participants of the Cardiovascular Health Study (CHS) who underwent dual-energy x-ray absorptiometry (DEXA) scans were included. We used principal components analysis (PCA) to define two independent sources of variation in DEXA-derived body composition, corresponding to principal components composed of lean ("lean PC") and fat ("fat PC") tissue. We used Cox proportional hazards regression using these PCs to investigate the relationship between body composition with cardiovascular and non-cardiovascular mortality. Mean age was 76.2 perpendicular to 4.8 years (56% women) with mean body mass index 27.1 perpendicular to 4.4 kg/m(2). A greater lean PC was associated with lower all-cause (HR = 0.91, 95% CI 0.84-0.98, P = 0.01) and cardiovascular mortality (HR = 0.84, 95% CI 0.74-0.95, P = 0.005). The lowest quartile of the fat PC (least adiposity) was associated with a greater hazard of all-cause mortality (HR = 1.24, 95% CI 1.04-1.48, P = 0.02) relative to fat PCs between the 25th-75th percentile, but the highest quartile did not have a significantly greater hazard (P = 0.70). Conclusion: Greater lean tissue mass is associated with improved cardiovascular and overall mortality in the elderly. The lowest levels of fat tissue mass are linked with adverse prognosis, but the highest levels show no significant mortality protection. Prevention efforts in the elderly frail may be best targeted toward improvements in lean muscle mass. (C) 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. C1 [Spahillari, A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02114 USA. [Mukamal, K. J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02114 USA. [DeFilippi, C.] Univ Maryland, Sch Med, Dept Med, Div Cardiovasc Med, Baltimore, MD 21201 USA. [Kizer, J. R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Gottdiener, J. S.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Djousse, L.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Lyles, M. F.] Wake Forest Sch Med, Dept Med, Sect Gerontol & Geriatr, Winston Salem, NC USA. [Bartz, T. M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Murthy, V. L.] Univ Michigan, Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA. [Murthy, V. L.] Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. [Shah, R. V.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. RP Murthy, VL (reprint author), Univ Michigan, Dept Internal Med Cardiovasc Med, Cardiovasc Ctr 1338, 1500 East Med Ctr Dr,SPC 5873, Ann Arbor, MI 48109 USA.; Shah, RV (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Cardiol & Med, 55 Fruit St, Boston, MA 02114 USA. EM aspahill@bidmc.harvard.edu; kmukamal@bidmc.harvard.edu; cdefilip@medicine.umaryland.edu; jorge.kizer@einstein.yu.edu; jgottdie@medicine.umaryland.edu; ldjousse@partners.org; mlyles@wakehealth.edu; bartzt@uw.edu; vlmurthy@med.umich.edu; rvshah@partners.org RI Djousse, Luc/F-5033-2017; OI Djousse, Luc/0000-0002-9902-3047; Murthy, Venkatesh/0000-0002-7901-1321 FU National Institutes of Health [K23HL127099]; American Heart Association [16SFRN31740000] FX Dr. Shah is funded by grants from the National Institutes of Health (K23HL127099) and the American Heart Association (16SFRN31740000). There are no relationships with industry. NR 39 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0939-4753 EI 1590-3729 J9 NUTR METAB CARDIOVAS JI Nutr. Metab. Carbiovasc. Dis. PD NOV PY 2016 VL 26 IS 11 BP 1039 EP 1047 DI 10.1016/j.numecd.2016.06.011 PG 9 WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition & Dietetics SC Cardiovascular System & Cardiology; Endocrinology & Metabolism; Nutrition & Dietetics GA EE3SH UT WOS:000389518000011 PM 27484755 ER PT J AU Esselen, KM Cronin, AM Bixel, K Bookman, MA Burger, RA Cohn, DE Cristea, M Griggs, JJ Levenback, CF Mantia-Smaldone, G Meyer, LA Matulonis, UA Niland, JC Sun, C O'Malley, DM Wright, AA AF Esselen, Katharine M. Cronin, Angel M. Bixel, Kristin Bookman, Michael A. Burger, Robert A. Cohn, David E. Cristea, Mihaela Griggs, Jennifer J. Levenback, Charles F. Mantia-Smaldone, Gina Meyer, Larissa A. Matulonis, Ursula A. Niland, Joyce C. Sun, Charlotte O'Malley, David M. Wright, Alexi A. TI Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Esselen, Katharine M.] Beth Israel Deaconess Med Ctr, Dept Obstet Gynecol, Div Gynecol Oncol, Boston, MA 02215 USA. [Esselen, Katharine M.; Cronin, Angel M.; Matulonis, Ursula A.; Wright, Alexi A.] Harvard Med Sch, Boston, MA 02115 USA. [Cronin, Angel M.; Matulonis, Ursula A.; Wright, Alexi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bixel, Kristin; Cohn, David E.; O'Malley, David M.] Ohio State Univ, Ctr Comprehens Canc, Dept Obstet & Gynecol, Div Gynecol Oncol, Columbus, OH 43210 USA. [Bookman, Michael A.] US Oncol Res, Tucson, AZ USA. [Bookman, Michael A.] Arizona Oncol, Tucson, AZ USA. [Burger, Robert A.] Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA. [Cristea, Mihaela; Niland, Joyce C.] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA. [Griggs, Jennifer J.] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA. [Griggs, Jennifer J.] Univ Michigan, Ctr Comprehens Canc, Dept Hlth Management & Policy, Div Hematol & Oncol, Ann Arbor, MI 48109 USA. [Levenback, Charles F.; Meyer, Larissa A.; Sun, Charlotte] Univ Texas MD Anderson Canc Ctr, Dept Gynecol & Reprod Med, Div Surg, Houston, TX 77030 USA. [Mantia-Smaldone, Gina] Fox Chase Canc Ctr, Dept Surg Oncol, Div Gynecol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. RP Esselen, KM (reprint author), Beth Israel Deaconess Med Ctr, Dept Obstet Gynecol, Div Gynecol Oncol, Boston, MA 02215 USA.; Esselen, KM (reprint author), Harvard Med Sch, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD NOV PY 2016 VL 71 IS 11 BP 660 EP 661 DI 10.1097/OGX.0000000000000377 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE0DY UT WOS:000389245100014 ER PT J AU Farland, LV Tamimi, RM Eliassen, AH Spiegelman, D Hankinson, SE Chen, WY Missmer, SA AF Farland, Leslie V. Tamimi, Rulla M. Eliassen, A. Heather Spiegelman, Donna Hankinson, Susan E. Chen, Wendy Y. Missmer, Stacey A. TI Laparoscopically Confirmed Endometriosis and Breast Cancer in the Nurses' Health Study II SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID HOSPITAL DISCHARGE DIAGNOSIS; IOWA WOMENS HEALTH; MEDICAL CONDITIONS; RECEPTOR STATUS; RISK; ESTROGEN; PROGESTERONE; INFLAMMATION; OVARIAN; ASSOCIATION AB OBJECTIVE: To investigate the association between laparoscopically confirmed endometriosis and the risk of breast cancer. Previous research on endometriosis and breast cancer has reported mixed results. METHODS: Our prospective cohort study included 116,430 women from the Nurses' Health Study II cohort followed from 1989 until 2013. Our primary analysis investigated the association between self-reported laparoscopically confirmed endometriosis and the risk of breast cancer. Breast cancer diagnosis was verified through medical records. Multivariable adjusted Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Breast cancer was further classified by menopausal status at the time of diagnosis and tumor hormone receptor status verified through tissue microarrays when available and medical records. RESULTS: At baseline, 5,389 (5%) women reported laparoscopically confirmed endometriosis. Over 24 years of follow-up, 4,979 (3%) incident breast cancer cases were diagnosed. Women with endometriosis were not at higher risk for overall (adjusted HR 0.96, 95% CI 0.88-1.06), premenopausal (adjusted HR 1.05, 95% CI 0.89-1.23), or postmenopausal breast cancer (adjusted HR 0.93, 95% CI 0.80-1.07). However, associations varied by tumor hormone receptor status (P value, test for heterogeneity: .001), although women with endometriosis were not at increased risk of estrogen-and progesterone receptor-positive (ER+/PR+) tumors (adjusted HR 1.00, 95% CI 0.87-1.14) or ER- and PR- tumors (adjusted HR 0.90, 95% CI 0.67-1.21). Women with endometriosis reported 2.87 ER+/PR- breast cancer cases per 10,000 person-years compared with women without endometriosis (1.32/10,000 person-years), which resulted in nearly a twofold increased risk of ER+/PR- breast cancers (adjusted HR 1.90, 95% CI 1.44-2.50). CONCLUSION: Endometriosis was not found to be associated with overall risk of breast cancer in this study; however, endometriosis was significantly associated with an increased risk of ER+/PR- breast tumors, which should be interpreted cautiously. C1 [Farland, Leslie V.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA. Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA. RP Farland, LV (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA. EM lfarland@mail.harvard.edu FU National Institutes of Health, National Cancer Institute [UM1 CA176726, 3R25CA057711]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [HD57210, T32HD060454]; Dana Farber and Harvard Cancer Center FX Supported by the National Institutes of Health, National Cancer Institute (UM1 CA176726, 3R25CA057711 to L.V.F.), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD57210, T32HD060454 to L.V.F.), and the Dana Farber and Harvard Cancer Center Mazzone Award. NR 40 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2016 VL 128 IS 5 BP 1025 EP 1031 DI 10.1097/AOG.0000000000001684 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE0GA UT WOS:000389251000018 PM 27741204 ER PT J AU Wylie, BJ Hauptman, M Woolf, AD Goldman, RH AF Wylie, Blair J. Hauptman, Marissa Woolf, Alan D. Goldman, Rose H. TI Insect Repellants During Pregnancy in the Era of the Zika Virus SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID PERMETHRIN; REPELLENTS; SAFETY; DEET; EFFICACY; EXPOSURE; NEUROTOXICITY; ABSORPTION; UNIFORMS; AEDES AB Health care providers must be equipped to provide appropriate advice to reproductive-aged patients for protection against the potentially devastating consequences of prenatal Zika virus exposure. The goal of this commentary is to summarize what is known about the safety and toxicity of N,N-diethyl-meta-toluamide (DEET) as a topical insect repellant and the pyrethroid permethrin for treatment of fabric, endorsed in the fight against Zika virus. Reviews assessing the safety and toxicity of DEET conducted by the U.S. Environmental Protection Agency and the Canadian Pest Management Regulatory Agency conclude that DEET has low acute toxicity and does not appear to pose a significant health concern to humans when used as directed. Some experimental animal and limited epidemiologic data suggest that prenatal pyrethroid exposure may adversely affect learning and behavior, but this level of evidence pales in comparison to the known risks of Zika virus to the fetal brain. The available evidence has led to the strong recommendation by the Centers for Disease Control and Prevention for use of these products by pregnant women as personal protection against mosquito bites in the fight against Zika virus infection. This message has been affirmed by our obstetrics and gynecology professional organizations. Because Zika virus is unlikely to be the last disease requiring vector control, those with environmental health expertise must continue to join with infectious disease specialists to communicate the potential vulnerability of our youngest (fetuses, infants, and young children) to vector-borne disease, both to the disease itself and to the strategies employed to mitigate the spread of such disease. C1 Harvard Med Sch, Massachusetts Gen Hosp, Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. Boston Childrens Hosp, Boston, MA USA. Cambridge Hlth Alliance, Cambridge, MA USA. RP Wylie, BJ (reprint author), Mass Gen Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, 55 Fruit St, Boston, MA 02114 USA. EM bwylie@mgh.harvard.edu FU American Academy of Pediatrics (AAP); Agency for Toxic Substances and Disease Registry (ATSDR) [FAIN: 1U61TS000237-02]; U.S. Environmental Protection Agency (EPA) [DW-75-95877701]; National Institute of Environmental Health Sciences [NIH K23 ES021471] FX Supported by the American Academy of Pediatrics (AAP) and funded (in part) by the cooperative agreement FAIN: 1U61TS000237-02 from the Agency for Toxic Substances and Disease Registry (ATSDR). The U.S. Environmental Protection Agency (EPA) supports the PEHSU by providing partial funding to the Agency for Toxic Substances and Diseases Registry (ATSDR) under Inter- Agency Agreement number DW-75-95877701. Neither EPA nor ATSDR endorse the purchase of any commercial products or services mentioned in PEHSU publications. Blair J. Wylie is supported by the National Institute of Environmental Health Sciences (NIH K23 ES021471). NR 35 TC 0 Z9 0 U1 12 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2016 VL 128 IS 5 BP 1111 EP 1115 DI 10.1097/AOG.0000000000001685 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE0GA UT WOS:000389251000030 PM 27548647 ER PT J AU Pasquale, LR Hyman, L Wiggs, JL Rosner, BA Joshipura, K McEvoy, M McPherson, ZE Danias, J Kang, JH AF Pasquale, Louis R. Hyman, Leslie Wiggs, Janey L. Rosner, Bernard A. Joshipura, Kaumudi McEvoy, Mark McPherson, Zachary E. Danias, John Kang, Jae H. TI Prospective Study of Oral Health and Risk of Primary Open-Angle Glaucoma in Men Data from the Health Professionals Follow-up Study SO OPHTHALMOLOGY LA English DT Article ID VISUAL-FIELD LOSS; ENDOTHELIAL DYSFUNCTION; PERIODONTAL-DISEASE; SYSTEMIC-DISEASES; ASSOCIATION; MICROBIOME; VALIDITY; REASONS; PATTERN AB Purpose: Tooth loss or periodontal disease is associated with systemic endothelial dysfunction, which has been implicated in primary open-angle glaucoma (POAG). The relationship between oral health and POAG has received limited attention. Thus, we evaluated the association between oral health history and risk of POAG and POAG subtypes. Design: Prospective cohort study. Participants: Health Professionals Follow-up Study participants (40 536 men) followed biennially from 1986 to 2012. At each 2-year risk period, eligible participants were aged 40+ years, were free of POAG, and reported eye examinations. Methods: By using validated questions, we updated participants' status on number of natural teeth, teeth lost, periodontal disease with bone loss, and root canal treatments. Main Outcome Measures: During follow-up, 485 incident cases of POAG were confirmed with medical records and classified into subtypes defined by intraocular pressure (IOP; >= or < 22 mmHg) or visual field (VF) loss pattern at diagnosis (peripheral loss only or early paracentral loss). Multivariable relative risks (MVRRs) and 95% confidence intervals (CIs) were estimated. Results: Number of natural teeth, periodontal disease, and root canal treatment were not associated with POAG. However, compared with no report of tooth loss, a report of losing teeth within the past 2 years was associated with a 1.45-fold increased risk of POAG (95% CI, 1.06-1.97); in particular, a report within the past 2 years of both losing teeth and having a prevalent diagnosis of periodontal disease was associated with a 1.85-fold increased risk of POAG (95% CI, 1.07-3.18). The associations with recent tooth loss were not significantly different for the POAG subtypes (P for heterogeneity >= 0.36), although associations were strongest in relation to the POAG subtypes with IOP < 22 mmHg (MVRR, 1.93; 95% CI, 1.09-3.43) and early paracentral VF loss (MVRR, 2.27; 95% CI, 1.32-3.88). Conclusions: Although thenumber of natural teeth was not associated with risk of POAG, recent tooth loss was associated with an increased risk of POAG. Because these findings may be due to chance, they need confirmation in larger studies. (C) 2016 by the American Academy of Ophthalmology. C1 [Pasquale, Louis R.; Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Boston, MA 02114 USA. [Pasquale, Louis R.; Wiggs, Janey L.; Rosner, Bernard A.; Kang, Jae H.] Harvard Med Sch, Boston, MA USA. [Pasquale, Louis R.; Rosner, Bernard A.; Kang, Jae H.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Hyman, Leslie] SUNY Stony Brook, Dept Prevent Med, Div Epidemiol, Stony Brook, NY 11794 USA. [Rosner, Bernard A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Joshipura, Kaumudi] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Joshipura, Kaumudi] Univ Puerto Rico MSC, Ctr Clin Res & Hlth Promot, San Juan, PR USA. [McEvoy, Mark; McPherson, Zachary E.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia. [Danias, John] Suny Downstate Med Ctr, Dept Ophthalmol, Glaucoma Serv, Brooklyn, NY 11203 USA. RP Kang, JH (reprint author), Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM nhjhk@channing.harvard.edu FU National Institutes of Health [UM1 CA167552, EY09611, EY015473, R21 EY022766]; Arthur Ashley Foundation; Harvard Glaucoma Center of Excellence; Harvard Medical Distinguished Ophthalmology FX Supported by Grants UM1 CA167552, EY09611, EY015473 (L.R.P.), and R21 EY022766 (J.L.W.) from the National Institutes of Health and the Arthur Ashley Foundation. L.R.P. and J.L.W.: are supported by the Harvard Glaucoma Center of Excellence. Supported by a Harvard Medical Distinguished Ophthalmology Scholar award to L.R.P. NR 38 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD NOV PY 2016 VL 123 IS 11 BP 2318 EP 2327 DI 10.1016/j.ophtha.2016.07.014 PG 10 WC Ophthalmology SC Ophthalmology GA EE3QK UT WOS:000389509500016 PM 27554035 ER PT J AU Kalpathy-Cramer, J Campbell, JP Erdogmus, D Tian, P Kedarisetti, D Moleta, C Reynolds, JD Hutcheson, K Shapiro, MJ Repka, MX Ferrone, P Drenser, K Horowitz, J Sonmez, K Swan, R Ostmo, S Jonas, KE Chan, RVP Chiang, MF AF Kalpathy-Cramer, Jayashree Campbell, J. Peter Erdogmus, Deniz Tian, Peng Kedarisetti, Dharanish Moleta, Chace Reynolds, James D. Hutcheson, Kelly Shapiro, Michael J. Repka, Michael X. Ferrone, Philip Drenser, Kimberly Horowitz, Jason Sonmez, Kemal Swan, Ryan Ostmo, Susan Jonas, Karyn E. Chan, R. V. Paul Chiang, Michael F. CA Imaging Informatics Retinopathy TI Plus Disease in Retinopathy of Prematurity Improving Diagnosis by Ranking Disease Severity and Using Quantitative Image Analysis SO OPHTHALMOLOGY LA English DT Article ID EXPERT DIAGNOSIS; TELEMEDICINE; ACCURACY; FELLOWS; TORTUOSITY; AGREEMENT; GRADERS; CARE AB Purpose: To determine expert agreement on relative retinopathy of prematurity (ROP) disease severity and whether computer-based image analysis can model relative disease severity, and to propose consideration of a more continuous severity score for ROP. Design: We developed 2 databases of clinical images of varying disease severity (100 images and 34 images) as part of the Imaging and Informatics in ROP (i-ROP) cohort study and recruited expert physician, nonexpert physician, and nonphysician graders to classify and perform pairwise comparisons on both databases. Participants: Six participating expert ROP clinician-scientists, each with a minimum of 10 years of clinical ROP experience and 5 ROP publications, and 5 image graders (3 physicians and 2 nonphysician graders) who analyzed images that were obtained during routine ROP screening in neonatal intensive care units. Methods: Images in both databases were ranked by average disease classification (classification ranking), by pairwise comparison using the Elo rating method (comparison ranking), and by correlation with the i-ROP computer-based image analysis system. Main Outcome Measures: Interexpert agreement (weighted kappa statistic) compared with the correlation coefficient (CC) between experts on pairwise comparisons and correlation between expert rankings and computer-based image analysis modeling. Results: There was variable interexpert agreement on diagnostic classification of disease (plus, preplus, or normal) among the 6 experts (mean weighted kappa, 0.27; range, 0.06-0.63), but good correlation between experts on comparison ranking of disease severity (mean CC, 0.84; range, 0.74-0.93) on the set of 34 images. Comparison ranking provided a severity ranking that was in good agreement with ranking obtained by classification ranking (CC, 0.92). Comparison ranking on the larger dataset by both expert and nonexpert graders demonstrated good correlation (mean CC, 0.97; range, 0.95-0.98). The i-ROP system was able to model this continuous severity with good correlation (CC, 0.86). Conclusions: Experts diagnose plus disease on a continuum, with poor absolute agreement on classification but good relative agreement on disease severity. These results suggest that the use of pairwise rankings and a continuous severity score, such as that provided by the i-ROP system, may improve agreement on disease severity in the future. (C) 2016 by the American Academy of Ophthalmology. C1 [Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Campbell, J. Peter; Moleta, Chace; Ostmo, Susan; Chiang, Michael F.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA. [Erdogmus, Deniz; Tian, Peng; Kedarisetti, Dharanish] Northeastern Univ, Cognit Syst Lab, Boston, MA 02115 USA. [Reynolds, James D.] SUNY Buffalo, Ross Eye Inst, Dept Ophthalmol, Buffalo, NY USA. [Hutcheson, Kelly] Sidra Med & Res Ctr, Dept Ophthalmol, Doha, Qatar. [Shapiro, Michael J.] Retina Consultants, Chicago, IL USA. [Repka, Michael X.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA. [Ferrone, Philip] Long Isl Vitreoretinal Consultants, Great Neck, NY USA. [Drenser, Kimberly] Oakland Univ, Associated Retinal Consultants, Royal Oak, MI USA. [Horowitz, Jason] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA. [Sonmez, Kemal; Swan, Ryan; Chiang, Michael F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. [Jonas, Karyn E.; Chan, R. V. Paul] Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL USA. RP Chiang, MF (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.; Chiang, MF (reprint author), Oregon Hlth & Sci Univ, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM chiangm@ohsu.edu OI Jonas, Karyn /0000-0001-9038-6979 FU National Institutes of Health, Bethesda, Maryland [R01 EY19474, P30 EY010572, R21 EY022387, T32 EY23211]; National Center for Advancing Translational Sciences at the National Institutes of Health (Bethesda, MD) (Oregon Clinical and Translational Research Institute grant) [TL1TR000129]; Research to Prevent Blindness, New York, New York; iNsight Foundation (New York, NY) FX Supported by the National Institutes of Health, Bethesda, Maryland (grant nos.: R01 EY19474 [J.K.C., D.E., S.O., K.E.J., R.V.P.C., M.F.C.], P30 EY010572 [J.P.C., S.O., M.F.C.], R21 EY022387 [J.K.C., D.E., M.F.C.], and T32 EY23211 [M.F.C., R.S.]); the National Center for Advancing Translational Sciences at the National Institutes of Health (Bethesda, MD) (Oregon Clinical and Translational Research Institute grant no.: TL1TR000129); Research to Prevent Blindness, New York, New York (J.P.C., S.N.P., J.D.R., M.X.R., S.O., K.E.J., R.V.P.C., M.F.C.); and the iNsight Foundation (New York, NY) (R.V.P.C., K.E.J.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. No funding organizations had any role in the design or conduct of this research. M.F.C. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 37 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD NOV PY 2016 VL 123 IS 11 BP 2345 EP 2351 DI 10.1016/j.ophtha.2016.07.020 PG 7 WC Ophthalmology SC Ophthalmology GA EE3QK UT WOS:000389509500019 PM 27566853 ER PT J AU Graves, LL Friedlander, AH Chang, TI AF Graves, Lindsay L. Friedlander, Arthur H. Chang, Tina I. TI Differences in the risk of osteoporotic femur fractures among Japanese and white women as predicted by carotid artery calcification visualized on panoramic images SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Letter ID GEOMETRY C1 [Graves, Lindsay L.; Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg, Dent Serv, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. RP Graves, LL (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg, Dent Serv, Los Angeles, CA 90073 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 EI 1528-395X J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD NOV PY 2016 VL 122 IS 5 BP 654 EP 655 DI 10.1016/j.oooo.2016.06.097 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3WT UT WOS:000389532400025 PM 27765337 ER PT J AU Aitken, J Youlden, D Ward, L Thursfield, V Baade, P Hallahan, A Green, A Valery, P Gupta, S Frazier, L AF Aitken, J. Youlden, D. Ward, L. Thursfield, V. Baade, P. Hallahan, A. Green, A. Valery, P. Gupta, S. Frazier, L. TI From Theory to Practice: Implementation of the Toronto Consensus Principles and Guidelines for the Recording of Paediatric Cancer Stage SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Aitken, J.; Youlden, D.; Baade, P.] Viertel Canc Res Ctr, Canc Council Queensland, Brisbane, Qld, Australia. [Ward, L.] Australian Paediat Canc Registry, Canc Council Queensland, Brisbane, Qld, Australia. [Thursfield, V.] Victorian Canc Registry, Canc Council Victoria, Melbourne, Vic, Australia. [Hallahan, A.] Lady Cilento Childrens Hosp, Childrens Hlth Queensland, Brisbane, Qld, Australia. [Green, A.; Valery, P.] QIMR Berghofer Med Res Inst, Canc & Populat Studies, Brisbane, Qld, Australia. [Gupta, S.] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada. [Frazier, L.] Dana Farber Canc Inst, Paediat Rare Tumors Program, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0258 BP S149 EP S149 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800302 ER PT J AU Cohen, K Bandopadhayay, P London, W Susan, C Kieran, M AF Cohen, K. Bandopadhayay, P. London, W. Susan, C. Kieran, M. TI Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Cohen, K.] Johns Hopkins Univ SOM, Paediat Oncol, Baltimore, MD USA. [Bandopadhayay, P.; London, W.; Susan, C.; Kieran, M.] Dana Farber Canc Inst, Paediat Neurooncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0166 BP S131 EP S131 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800210 ER PT J AU Daw, NC Chi, YY Mullen, EA Kalapurakal, JA Tian, J Khanna, G Geller, JI Perlman, EJ Ehrlich, PF Warwick, AB Fernandez, CV Grundy, PE Dome, JS AF Daw, N. C. Chi, Y. Y. Mullen, E. A. Kalapurakal, J. A. Tian, J. Khanna, G. Geller, J. I. Perlman, E. J. Ehrlich, P. F. Warwick, A. B. Fernandez, C. V. Grundy, P. E. Dome, J. S. TI Treatment of Stage I Focal or Diffuse Anaplastic Wilms Tumour: A Report from the Children's Oncology Group SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Daw, N. C.] Univ Texas MD Anderson Canc Ctr, Div Paediat, Houston, TX 77030 USA. [Chi, Y. Y.; Tian, J.] Childrens Oncol Grp, Stat, Gainesville, FL USA. [Mullen, E. A.] Dana Farber Canc Inst, Paediat Haematol Oncol, Boston, MA 02115 USA. [Kalapurakal, J. A.] Ann & Robert H Lurie Childrens Hosp Chicago, Radiat Oncol, Chicago, IL 60611 USA. [Khanna, G.] Washington Univ, Sch Med, Paediat Radiol, St Louis, MO USA. [Geller, J. I.] Cincinnati Childrens Hosp Med Ctr, Haematol Oncol, Cincinnati, OH 45229 USA. [Perlman, E. J.] Ann & Robert H Lurie Childrens Hosp Chicago, Pathol, Chicago, IL 60611 USA. [Ehrlich, P. F.] Univ Michigan, CS Mott Childrens Hosp, Paediat Surg, Ann Arbor, MI 48109 USA. [Warwick, A. B.] Walter Reed Natl Mil Med Ctr, Paediat Haematol Oncol, Bethesda, MD USA. [Fernandez, C. V.] IWK Hlth Ctr, Paediat & Bioeth, Halifax, NS, Canada. [Grundy, P. E.] Univ Alberta Hosp, Paediat, Edmonton, AB, Canada. [Dome, J. S.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-118 BP S35 EP S35 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800453 ER PT J AU Dix, DB Gratias, E Seibel, NL Chi, YY Tian, J Mullen, E Geller, J Khanna, G Kalapurakal, J Perlman, EJ Ehrlich, P Malogolowkin, M Grundy, P Dome, JS AF Dix, D. B. Gratias, E. Seibel, N. L. Chi, Y. Y. Tian, J. Mullen, E. Geller, J. Khanna, G. Kalapurakal, J. Perlman, E. J. Ehrlich, P. Malogolowkin, M. Grundy, P. Dome, J. S. TI Treatment of Stage IV Favorable Histology Wilms Tumour with Extra-Pulmonary Metastases: A Report from Children's Oncology Group Study AREN0533 SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Dix, D. B.] British Columbia Childrens Hosp, Haematol Oncol, Vancouver, BC, Canada. [Gratias, E.] Evicore Healthcare, Med Oncol, Bluffton, SC USA. [Seibel, N. L.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Chi, Y. Y.; Tian, J.] COG Data Ctr, Childrens Oncol Grp, Gainesville, FL USA. [Mullen, E.] Dana Farber Harvard Canc Ctr, Paediat Haematol Oncol, Boston, MA USA. [Geller, J.] Cincinnati Childrens Hosp Med Ctr, Haematol Oncol, Cincinnati, OH 45229 USA. [Khanna, G.] Washington Univ, Sch Med, Paediat Radiol, St Louis, MO USA. [Kalapurakal, J.] Ann & Robert H Lurie Childrens Hosp Chicago, Radiat Oncol, Chicago, IL 60611 USA. [Perlman, E. J.] Ann & Robert H Lurie Childrens Hosp Chicago, Pathol, Chicago, IL 60611 USA. [Ehrlich, P.] CS Mott Childrens Hosp, Pediatrc Surg, Ann Arbor, MI USA. [Malogolowkin, M.] Univ Calif Davis, Ctr Comprehens Canc, Paediat Haematol Oncol, Sacramento, CA 95817 USA. [Grundy, P.] Univ Alberta Hosp, Paediat Haematol Oncol, Edmonton, AB, Canada. [Dome, J. S.] Childrens Natl Med Ctr, Div Oncol, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-139 BP S93 EP S94 PG 2 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800026 ER PT J AU Eaton, B Yock, T Goldberg, S MacDonald, S Tarbell, N AF Eaton, B. Yock, T. Goldberg, S. MacDonald, S. Tarbell, N. TI Long-Term Health Related Quality of Life (HRQOL) and School Functioning among Children Treated with Proton Therapy for Intracranial Ependymoma at Age <= 3 Years SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Eaton, B.] Emory Univ, Radiat Oncol, Atlanta, GA 30322 USA. [Yock, T.; Goldberg, S.; MacDonald, S.; Tarbell, N.] Massachusetts Gen Hosp, Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-023 BP S12 EP S12 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800358 ER PT J AU Gentile, M Yeap, B Goebel, C Gaudet, D Gallotto, S Weyman, E MacDonald, S Giantsoudi, D Adams, J Paganetti, H Tarbell, N Kooy, H Yock, T Morgan, M AF Gentile, M. Yeap, B. Goebel, C. Gaudet, D. Gallotto, S. Weyman, E. MacDonald, S. Giantsoudi, D. Adams, J. Paganetti, H. Tarbell, N. Kooy, H. Yock, T. Morgan, M. TI Incidence of Brainstem Injury in Paediatric Patients with Posterior Fossa Tumors SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Gentile, M.; Goebel, C.; Gaudet, D.; Gallotto, S.; Weyman, E.; MacDonald, S.; Giantsoudi, D.; Adams, J.; Paganetti, H.; Tarbell, N.; Kooy, H.; Yock, T.; Morgan, M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Yeap, B.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-015 BP S68 EP S68 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800609 ER PT J AU Hess, CB Nartowicz, J MacDonald, SM Marcus, KJ Huang, MS Friedmann, A Ebb, DH Chen, YLE DeLaney, TF Tarbell, NJ Yock, TI AF Hess, C. B. Nartowicz, J. MacDonald, S. M. Marcus, K. J. Huang, M. S. Friedmann, A. Ebb, D. H. Chen, Y. L. E. DeLaney, T. F. Tarbell, N. J. Yock, T. I. TI Preliminary Results of a Phase II Prospective Trial of Proton Therapy for non-Metastatic Paediatric non-Rhabdomyosarcoma Soft Tissue and Bone Sarcoma SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Hess, C. B.; MacDonald, S. M.; Chen, Y. L. E.; DeLaney, T. F.; Tarbell, N. J.; Yock, T. I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Nartowicz, J.] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Marcus, K. J.] Boston Childrens Hosp, Boston, MA USA. [Marcus, K. J.] Blood Disorders Ctr, Div Radiat Oncol, Boston, MA USA. [Huang, M. S.; Friedmann, A.; Ebb, D. H.] MassGen Hosp Children, Paediat Haematol Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-150 BP S96 EP S96 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800037 ER PT J AU Indelicato, D MacDonald, S Hartsell, W Perkins, S Hill-Kayser, C Majahan, A Bradley, J Rotondo, R Yock, T AF Indelicato, D. MacDonald, S. Hartsell, W. Perkins, S. Hill-Kayser, C. Majahan, A. Bradley, J. Rotondo, R. Yock, T. TI Early Ependymoma Outcomes from the Paediatric Proton Consortium Registry SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Indelicato, D.; Bradley, J.; Rotondo, R.] Univ Florida, Proton Therapy Inst, Radiat Oncol, Jacksonville, FL USA. [MacDonald, S.; Yock, T.] Massachusetts Gen Hosp, Radiat Oncol, Boston, MA 02114 USA. [Hartsell, W.] Cadence Hlth, Radiat Oncol, Chicago, IL USA. [Perkins, S.] Washington Univ, Radiat Oncol, St Louis, MO USA. [Hill-Kayser, C.] Univ Penn, Radiat Oncol, Philadelphia, PA 19104 USA. [Majahan, A.] Univ Texas MD Anderson Canc Ctr, Radiat Oncol, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-022 BP S12 EP S12 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800357 ER PT J AU Irwin, MS Naranjo, A Van Ryn, C Cohn, SL London, WB Gastier-Foster, JM Matthay, KK Attiyeh, EF Maris, JM Bagatell, R Park, JR Hogarty, MD AF Irwin, M. S. Naranjo, A. Van Ryn, C. Cohn, S. L. London, W. B. Gastier-Foster, J. M. Matthay, K. K. Attiyeh, E. F. Maris, J. M. Bagatell, R. Park, J. R. Hogarty, M. D. TI Revised Children's Oncology Group (COG) Risk Stratification Incorporating the International Neuroblastoma Risk Group Staging System SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Irwin, M. S.] Hosp Sick Children, Haematol Oncol, Toronto, ON, Canada. [Naranjo, A.; Van Ryn, C.] Stat & Data Ctr, Childrens Oncol Grp, Gainesville, FL USA. [Cohn, S. L.] Univ Chicago, Paediat, Chicago, IL 60637 USA. [London, W. B.] Boston Childrens Canc & Blood Disorders Ctr, Dana Farber Canc Inst, Boston, MA USA. [Gastier-Foster, J. M.] Nationwide Childrens Hosp, Biopathol Ctr, Columbus, OH USA. [Matthay, K. K.] Univ Calif San Francisco, Paediat, San Francisco, CA 94143 USA. [Attiyeh, E. F.; Maris, J. M.; Bagatell, R.; Hogarty, M. D.] Childrens Hosp Philadelphia, Oncol, Philadelphia, PA 19104 USA. [Park, J. R.] Seattle Childrens Hosp, Haematol Oncol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-096 BP S29 EP S29 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800431 ER PT J AU MacDonald, S Giantsoudi, D Eaton, B Yock, T Tarbell, N Adams, J Paganetti, H AF MacDonald, S. Giantsoudi, D. Eaton, B. Yock, T. Tarbell, N. Adams, J. Paganetti, H. TI Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in CSI of in Growing Paediatric Patients SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [MacDonald, S.; Giantsoudi, D.; Eaton, B.; Yock, T.; Tarbell, N.; Adams, J.; Paganetti, H.] Harvard Med Sch, Massachusetts Gen Hosp, Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0195 BP S137 EP S137 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800239 ER PT J AU Maloney, KW Friedmann, A Devidas, M Mattano, L Budkley, P Borowitz, MJ Carroll, AJ Gastier-Foster, JM Heerema, NA Kadan-Lottick, N Loh, ML Matloub, YH Marshall, DT Stork, L Raetz, EA Wood, B Winick, NJ Hunger, SP Carroll, WL AF Maloney, K. W. Friedmann, A. Devidas, M. Mattano, L. Budkley, P. Borowitz, M. J. Carroll, A. J. Gastier-Foster, J. M. Heerema, N. A. Kadan-Lottick, N. Loh, M. L. Matloub, Y. H. Marshall, D. T. Stork, L. Raetz, E. A. Wood, B. Winick, N. J. Hunger, S. P. Carroll, W. L. TI Very Favorable Complete Continueous Remission (CCR) and Overall Survival (OS) for Standard-Risk High (SRH) Acute Lymphoblastic Leukemia (ALL) Patients Treated on Cog AALL0331 SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Maloney, K. W.] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO USA. [Friedmann, A.] Massachusetts Gen Hosp, Ctr Canc, Paediat Haematol Oncol, Boston, MA USA. [Devidas, M.] Univ Florida, Biostat, Gainesville, FL USA. [Mattano, L.] HARP Pharma Consulting, Mystic, CT USA. [Budkley, P.] Duke Univ, Med Ctr, Pathol, Durham, NC 27706 USA. [Borowitz, M. J.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Pathol, Baltimore, MD USA. [Carroll, A. J.] Childrens Hosp Alabama, Genet, Birmingham, AL USA. [Gastier-Foster, J. M.] Nationwide Childrens Hosp, Lab Med, Columbus, OH USA. [Heerema, N. A.] Nationwide Childrens Hosp, Cytogenet, Columbus, OH USA. [Kadan-Lottick, N.] Yale Univ, Paediat Hem Onc, New Haven, CT USA. [Loh, M. L.] UCSF Med Ctr Mission Bay, Paediat Heme Onc, San Francisco, CA USA. [Matloub, Y. H.] Rainbow Babies & Childrens Hosp, Paediat Haematol Oncol, 2101 Adelbert Rd, Cleveland, OH 44106 USA. [Marshall, D. T.] Med Univ South Carolina, Radiat Oncol, Charleston, SC USA. [Stork, L.] Oregon Hlth & Sci Univ, Paediat Haematol Oncol, Portland, OR 97201 USA. [Raetz, E. A.] Primary Childrens Med Ctr, Paediat Haematol Oncol, Salt Lake City, UT USA. [Wood, B.] Seattle Childrens Hosp, Lab Med, Seattle, WA USA. [Winick, N. J.] UT Southwestern Simmons Canc Ctr Dallas, Pediatri Hem Onc, Dallas, TX USA. [Hunger, S. P.] Childrens Hosp Philadelphia, Paediat Hem Onc, Philadelphia, PA 19104 USA. [Carroll, W. L.] NYU Lagone Hassenfeld Childrens Ctr, Haematol Oncol, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-103 BP S31 EP S31 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800438 ER PT J AU Manley, P Trippett, T Smith, AA Macy, ME Leary, SE Boklan, J Cohen, KJ Goldman, S Kilbrun, LB Dhall, G Devin, J Herzog, CE Bernard, JP Chi, SN AF Manley, P. Trippett, T. Smith, A. A. Macy, M. E. Leary, S. E. Boklan, J. Cohen, K. J. Goldman, S. Kilbrun, L. B. Dhall, G. Devin, J. Herzog, C. E. Bernard, J. P. Chi, S. N. TI Phase 2 Study of Cabazitaxel in Paediatric Patients with Recurrent or Refractory High Grade Glioma or Diffuse Instrinsic Pontine Glioma: A Poetic Group Study SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Manley, P.; Chi, S. N.] Dana Farber Canc Inst, Paediat Oncol, Boston, MA 02115 USA. [Trippett, T.] Mem Sloan Kettering Canc Ctr, Paediat Dev Therapeut Program, 1275 York Ave, New York, NY 10021 USA. [Smith, A. A.] Arnold Palmer Hosp Children, Paediat Neurooncol, Orlando, FL USA. [Macy, M. E.] Childrens Hosp Colorado, Paediat Heme Onc & Bone Marrow Transplantat, Aurora, CO USA. [Leary, S. E.] Seattle Childrens Hosp, Canc & Blood Disorders Ctr, Seattle, WA USA. [Boklan, J.] Phoenix Childrens Hosp, Clin Oncol Res, Phoenix, AZ USA. [Cohen, K. J.] Johns Hopkins Childrens Ctr, Paediat Neurooncol, Baltimore, MD USA. [Goldman, S.] Lurie Childrens Hosp Chicago, Paediat Neurooncol, Chicago, IL USA. [Kilbrun, L. B.] Childrens Natl Med Ctr, Neurooncol, Washington, DC 20010 USA. [Dhall, G.] Childrens Hosp Los Angeles, Haematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90027 USA. [Devin, J.] Sanofi, Biostat & Programming, Cambridge, MA USA. [Herzog, C. E.] Univ Texas MD Anderson Canc Ctr, Paediat, Houston, TX 77030 USA. [Bernard, J. P.] Sanofi, Oncol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-010 BP S9 EP S9 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800345 ER PT J AU McManus, J Foley, E Stavros, D Houlahan, K AF McManus, J. Foley, E. Stavros, D. Houlahan, K. TI Surgical Procedures Outside the Operating Room among Paediatric Oncology Patients SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [McManus, J.; Foley, E.; Stavros, D.; Houlahan, K.] Dana Farber Canc Inst, Jimmy Fund Clin, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0968 BP S286 EP S286 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818801672 ER PT J AU O'Neill, AF Towbin, AJ McCarville, MB Meyers, RL McGahren, ED Tiao, GM Dunn, SP Langham, MR Weldon, CB Finegold, M Ranganathan, S Furman, WL Malogolowkin, M Rodriguez-Galindo, C Katzenstein, HM AF O'Neill, A. F. Towbin, A. J. McCarville, M. B. Meyers, R. L. McGahren, E. D. Tiao, G. M. Dunn, S. P. Langham, M. R., Jr. Weldon, C. B. Finegold, M. Ranganathan, S. Furman, W. L. Malogolowkin, M. Rodriguez-Galindo, C. Katzenstein, H. M. TI Characterization of Pulmonary Metastases in Children with Hepatoblastoma SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [O'Neill, A. F.] Dana Farber Canc Inst, Boston, MA 02115 USA. [O'Neill, A. F.] Harvard Med Sch, Paediat Oncol, Boston, MA USA. [Towbin, A. J.] Cincinnati Childrens Hosp, Radiol, Cincinnati, OH USA. [McCarville, M. B.] St Jude Childrens Res Hosp, Radiol, 332 N Lauderdale St, Memphis, TN 38105 USA. [Meyers, R. L.] Primary Childrens Med Ctr, Salt Lake City, UT USA. [Meyers, R. L.] Univ Utah, Surg, Salt Lake City, UT USA. [McGahren, E. D.] Univ Virginia, Childrens Hosp, Charlottesville, VA USA. [McGahren, E. D.] Univ Virginia, Surg, Charlottesville, VA USA. [Tiao, G. M.] Cincinnati Childrens Hosp, Surg, Cincinnati, OH USA. [Dunn, S. P.] duPont Hosp Children, Philadelphia, PA USA. [Dunn, S. P.] Thomas Jefferson Univ, Surg, Philadelphia, PA 19107 USA. [Langham, M. R., Jr.] Le Bonheur Childrens Hosp, Memphis, TN USA. [Langham, M. R., Jr.] Univ Tennessee, Surg, Memphis, TN USA. [Weldon, C. B.] Boston Childrens Hosp, Boston, MA USA. [Weldon, C. B.] Dana Farber Canc Inst, Surg, Boston, MA 02115 USA. [Finegold, M.] Baylor Coll Med, Pathol, Houston, TX 77030 USA. [Ranganathan, S.] UPMC, Pathol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Furman, W. L.; Rodriguez-Galindo, C.] St Jude Childrens Res Hosp, Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA. [Malogolowkin, M.] Univ Calif Davis, Ctr Comprehens Canc, Oncol, Sacramento, CA 95817 USA. [Katzenstein, H. M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Katzenstein, H. M.] Monroe Carell Jr Childrens Hosp, Oncol, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-111 BP S33 EP S33 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800446 ER PT J AU Peyrl, A Chocholous, M Azizi, A Kieran, M Nysom, K Sterba, J Sabel, M Czech, T Dieckmann, K Haberler, C Schmook, M Leiss, U Slavc, I AF Peyrl, A. Chocholous, M. Azizi, A. Kieran, M. Nysom, K. Sterba, J. Sabel, M. Czech, T. Dieckmann, K. Haberler, C. Schmook, M. Leiss, U. Slavc, I. TI Memmat - A Phase II Study of Metronomic and Targeted Anti-Angiogenesis Therapy for Children with Recurrent/Progressive Medulloblastoma SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Peyrl, A.; Chocholous, M.; Azizi, A.; Leiss, U.; Slavc, I.] Med Univ Vienna, Paediat, Vienna, Austria. [Kieran, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kieran, M.] Boston Childrens Hosp, Paediat Neurooncol, Boston, MA USA. [Nysom, K.] Univ Copenhagen, Rigshosp, Paediat & Adolescent Med, Copenhagen, Denmark. [Sterba, J.] Univ Hosp Brno, Dept Paediat Oncol, Brno, Czech Republic. [Sabel, M.] Queen Silvia Childrens Hosp, Childrens Canc Ctr, Gothenburg, Sweden. [Czech, T.] Med Univ Vienna, Neurosurg, Vienna, Austria. [Dieckmann, K.] Med Univ Vienna, Radiotherapy, Vienna, Austria. [Haberler, C.] Med Univ Vienna, Inst Neurol, Vienna, Austria. [Schmook, M.] Med Univ Vienna, Radiol, Vienna, Austria. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0206 BP S139 EP S139 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800250 ER PT J AU Rao, A Ermoian, R Alcorn, S Figueiredo, ML Chen, M Dieckmann, K MacDonald, S Ladra, M Kobyzeva, D Nechesnyuk, A Nilsson, K Winey, B Villar, R Terezakis, S AF Rao, A. Ermoian, R. Alcorn, S. Figueiredo, M. L. Chen, M. Dieckmann, K. MacDonald, S. Ladra, M. Kobyzeva, D. Nechesnyuk, A. Nilsson, K. Winey, B. Villar, R. Terezakis, S. TI Practice Patterns of Palliative Radiation Therapy in Paediatric Oncology Patients Amongst An International Paediatric Research Consortium SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Rao, A.; Alcorn, S.; Terezakis, S.] Johns Hopkins Univ, Radiat Oncol, Baltimore, MD USA. [Ermoian, R.] Univ Washington, Med Ctr, Radiat Oncol, Seattle, WA 98195 USA. [Figueiredo, M. L.; Chen, M.] Grp Apoio Adolescente & Crianca Com Canc, Radiat Oncol, Sao Paulo, Brazil. [Dieckmann, K.] Med Univ Vienna, Radiat Oncol, Vienna, Austria. [MacDonald, S.; Winey, B.] Harvard Univ, Massachusetts Gen Hosp, Radiat Oncol, Boston, MA 02115 USA. [Ladra, M.] Provis Ctr Proton Therapy, Radiat Oncol, Nashville, TN USA. [Nechesnyuk, A.] Fed Res & Clin Ctr Paediat Haematol Oncol & Immun, Radiat Oncol, Moscow, Russia. [Nilsson, K.] Uppsala Univ, Radiat Oncol, Uppsala, Sweden. [Villar, R.] Ctr Infantil Boldrini, Radiat Oncol, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-253 BP S63 EP S64 PG 2 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800587 ER PT J AU Rubagumya, F Xu, MJ May, M Driscoll, C Uwizeye, FR Shyirambere, C Umuhizi, DG Mpunga, T Shulman, LN Lehmann, L AF Rubagumya, F. Xu, M. Jue May, M. Driscoll, C. Uwizeye, F. R. Shyirambere, C. Umuhizi, D. G. Mpunga, T. Shulman, L. N. Lehmann, L. TI Outcomes of a Graduated Intensity Treatment for Acute Lymphoblastic Leukemia (ALL) at Butaro Cancer Center of Excellence in Rwanda SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Rubagumya, F.; Umuhizi, D. G.; Mpunga, T.] Minist Hlth, Oncol, Kigali, Rwanda. [Xu, M. Jue] Harvard Med Sch, Sch Med, Boston, MA USA. [May, M.] Boston Childrens Hosp, Peadiat, Boston, MA USA. [Driscoll, C.] Icahn Sch Med Mt Sinai, Sch Med, New York, NY 10029 USA. [Uwizeye, F. R.] IT, Hlth, Kigali, Rwanda. [Shulman, L. N.] Univ Penn, Oncol, Philadelphia, PA 19104 USA. [Lehmann, L.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0096 BP S117 EP S117 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800140 ER PT J AU Santacroce, E AF Santacroce, E. TI Standardizing Nursing Education for Ambulatory Paediatric Oncology Patients SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Santacroce, E.] Dana Farber Canc Inst, Paediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0610 BP S218 EP S218 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818801318 ER PT J AU Shah, R Xia, C Krailo, M Amatruda, JF Arul, SG Billmire, DF Brady, WE Covens, A Gershenson, DM Hurteau, J Hale, JP Murray, MJ Nicholson, JC Olson, TA Pashankar, F Rodriguez-Galindo, C Shaikh, F Stark, D Frazier, LA Stoneham, S AF Shah, R. Xia, C. Krailo, M. Amatruda, J. F. Arul, S. G. Billmire, D. F. Brady, W. E. Covens, A. Gershenson, D. M. Hurteau, J. Hale, J. P. Murray, M. J. Nicholson, J. C. Olson, T. A. Pashankar, F. Rodriguez-Galindo, C. Shaikh, F. Stark, D. Frazier, L. A. Stoneham, S. TI Dysgerminoma in Children, Adolescent and Young Adults: A Report from the Malignant Germ Cell Tumour International Collaborative (MAGIC) SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Shah, R.] Cincinnati Childrens Hosp Med Ctr, Paediat Oncol, Cincinnati, OH 45229 USA. [Xia, C.] Childrens Oncol Grp, Biostat, Los Angeles, CA USA. [Krailo, M.] Univ Southern Calif, Childrens Oncol Grp, Prevent Med Biostat, Los Angeles, CA USA. [Amatruda, J. F.] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr, Paediat Haematol Oncol, Dallas, TX 75390 USA. [Arul, S. G.] Birmingham Childrens Hosp NHS Fdn Trust, Paediat Surg, Birmingham, W Midlands, England. [Billmire, D. F.] Riley Hosp Children, Surg, Indiana, PA USA. [Brady, W. E.] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, New York, NY USA. [Covens, A.] Univ Toronto, Gynecol Oncol, Toronto, ON, Canada. [Gershenson, D. M.] Univ Texas MD Anderson Canc Ctr, Gynecol Oncol, Houston, TX 77030 USA. [Hurteau, J.] North Shore Univ Hlth Syst, Gynecol Oncol, Evanston, IL USA. [Hale, J. P.] Newcastle Upon Tyne Hosp Trust, Dept Paediat Oncol, Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England. [Murray, M. J.] Cambridge Univ Hosp NHS Fdn Trust, Pathol, Cambridge, England. [Nicholson, J. C.] Cambridge Univ Hosp NHS Fdn Trust, Paediat Oncol & Haematol, Cambridge, England. [Olson, T. A.] Emory Univ, Paediat Haematol Oncol, Childrens Healthcare Atlanta, Aflac Canc Ctr, Atlanta, GA 30322 USA. [Pashankar, F.] Yale Univ, Sch Med, Paediat Haematol Oncol, New Haven, CT 06520 USA. [Rodriguez-Galindo, C.; Frazier, L. A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodriguez-Galindo, C.; Frazier, L. A.] Boston Childrens Hosp, Paediat Oncol, Boston, MA USA. [Shaikh, F.] Univ Toronto, Paediat Oncol, Toronto, ON, Canada. [Stark, D.] Leeds Inst Oncol, Leeds Inst Canc Studies & Pathol, Leeds, W Yorkshire, England. [Stark, D.] St James Univ Hosp, Pathol, Leeds, W Yorkshire, England. [Stoneham, S.] Univ Coll London Hosp Trusts, Paediat Oncol, Childrens Canc Serv, London, England. [Stoneham, S.] Univ Coll London Hosp Trusts, Paediat Oncol, Young Persons Canc Serv, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-040 BP S73 EP S74 PG 2 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800634 ER PT J AU Slayton, W Schultz, K Chang, B Kairalla, J Devidas, M Gastier-Foster, J Raetz, E Loh, M Silverman, L Winick, N Carroll, W Schultz, K Hunger, S AF Slayton, W. Schultz, K. Chang, B. Kairalla, J. Devidas, M. Gastier-Foster, J. Raetz, E. Loh, M. Silverman, L. Winick, N. Carroll, W. Schultz, K. Hunger, S. TI BCR/ABL1 Point Mutations are Uncommon in Children with Ph plus Acute Lymphoblastic Leukemia Receiving Dasatinib Plus Multiagent Chemotherapy: A Report from Children's Oncology Group Trial AALL0622 SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Slayton, W.] Univ Florida, Paediat, Gainesville, FL USA. [Schultz, K.] Univ British Columbia, Paediat, Vancouver, BC, Canada. [Chang, B.] Univ Oregon, Paediat, Portland, OR USA. [Kairalla, J.; Devidas, M.] Univ Florida, Biostat, Gainesville, FL USA. [Gastier-Foster, J.] Nationwide Childrens Hosp, Clin Pathol, Columbus, OH USA. [Raetz, E.] Univ Utah, Paediat, Salt Lake City, UT USA. [Loh, M.] Univ Calif San Francisco, Paediat, San Francisco, CA 94143 USA. [Silverman, L.] Dana Farber Canc Inst, Paediat, Boston, MA 02115 USA. [Winick, N.] Univ Texas Southwestern, Paediat, Dallas, TX USA. [Carroll, W.] NYU, Paediat, New York, NY USA. [Schultz, K.] Univ British Columbia, Paediat, Vancouver, BC, Canada. [Hunger, S.] Childrens Hosp Philadelphia, Paediat, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-033 BP S14 EP S14 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800368 ER PT J AU Tomlinson, D Sung, L McFatrich, M Hinds, P Freyer, D Mack, J Baker, J Martens, C Withycombe, J Weaver, M Waldron, M Mowbray, C Jacobs, S Maurer, S Gibson, D Palma, D Wilcox, R Gagne, J Gattuso, J Reeve, B AF Tomlinson, D. Sung, L. McFatrich, M. Hinds, P. Freyer, D. Mack, J. Baker, J. Martens, C. Withycombe, J. Weaver, M. Waldron, M. Mowbray, C. Jacobs, S. Maurer, S. Gibson, D. Palma, D. Wilcox, R. Gagne, J. Gattuso, J. Reeve, B. TI Can Seven Year-Old Children with Cancer Understand and Report their Symptoms? SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Tomlinson, D.; Sung, L.] Hosp Sick Children, CHES, Toronto, ON, Canada. [Sung, L.] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada. [McFatrich, M.; Reeve, B.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Hinds, P.] Childrens Natl Med Ctr, Div Nursing, Washington, DC 20010 USA. [Freyer, D.] CHLA, Childrens Ctr Canc & Blood Dis, Los Angeles, CA USA. [Mack, J.] Dana Farber Canc Inst, Populat Sci Paediat Haematol Oncol, Boston, MA 02115 USA. [Baker, J.; Gibson, D.; Wilcox, R.] St Jude Childrens Res Hosp, Div Qual Life & Palliat Care, 332 N Lauderdale St, Memphis, TN 38105 USA. [Martens, C.] Northwestern Univ, Med Social Sci, Chicago, IL 60611 USA. [Withycombe, J.] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA. [Weaver, M.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA. [Waldron, M.] Childrens Natl Med Ctr, Dept Nursing Res & Qual Outcomes, Washington, DC 20010 USA. [Mowbray, C.; Jacobs, S.] Childrens Natl Med Ctr, Div Oncol, Washington, DC 20010 USA. [Maurer, S.] UPMC, Childrens Hosp Pittsburgh, Div Paediat Haematol Oncol, Pittsburg, KS USA. [Palma, D.] Univ Southern Calif, Off Protect Res Subjects, Los Angeles, CA USA. [Gagne, J.] Dana Farber Canc Inst, Survey & Data Management Core, Boston, MA 02115 USA. [Gattuso, J.] St Jude Childrens Res Hosp, Div Nursing Res, 332 N Lauderdale St, Memphis, TN 38105 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-204 BP S53 EP S53 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800538 ER PT J AU Trobaugh-Lotrario, A Malogolowkin, M Dunn, S Langham, M McCarville, B Tiao, G Towbin, A Weldon, C Katzenstein, H Meyers, R AF Trobaugh-Lotrario, A. Malogolowkin, M. Dunn, S. Langham, M. McCarville, B. Tiao, G. Towbin, A. Weldon, C. Katzenstein, H. Meyers, R. TI Novel PRETEXT/POST-TEXT Based Scoring System Developed to Evaluate Anatomic Response to Chemotherapy in Hepatoblastoma: A Report from the Children's Oncology Group AHEP0731 Study SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Trobaugh-Lotrario, A.] Providence Sacred Heart Childrens Hosp, Paediat Haematol Oncol, Spokane, WA USA. [Malogolowkin, M.] Univ Calif Davis, Ctr Comprehens Canc, Paediat Haematol Oncol, Sacramento, CA 95817 USA. [Dunn, S.] Alfred I duPont Hosp Children, Paediat Surg, Wilmington, DE USA. [Langham, M.] St Jude Childrens Res Hosp, Div Paediat Surg, 332 N Lauderdale St, Memphis, TN 38105 USA. [McCarville, B.] St Jude Childrens Res Hosp, Radiol Sci, 332 N Lauderdale St, Memphis, TN 38105 USA. [Tiao, G.] Cincinnati Childrens Hosp Med Ctr, Paediat Surg, Cincinnati, OH 45229 USA. [Towbin, A.] Cincinnati Childrens Hosp Med Ctr, Radiol, Cincinnati, OH 45229 USA. [Weldon, C.] Dana Farber Harvard Canc Ctr, Surg, Boston, MA USA. [Katzenstein, H.] Vanderbilt Univ, Ingram Canc Ctr, Paediat Haematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Meyers, R.] Primary Childrens Med Ctr, Paediat Surg, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-063 BP S78 EP S78 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800657 ER PT J AU Vatner, R Goldberg, S Gaudet, D Gallotto, S Goebel, C MacDonald, S Friedmann, A Tarbell, N Kuhlthau, K Yock, T AF Vatner, R. Goldberg, S. Gaudet, D. Gallotto, S. Goebel, C. MacDonald, S. Friedmann, A. Tarbell, N. Kuhlthau, K. Yock, T. TI A Prospective Assessment of Health-Related Quality of Life (HRQOL) Outcomes in Patients with Rhabdomyosarcoma Treated with Proton Radiotherapy SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Vatner, R.; Goldberg, S.; Gaudet, D.; Gallotto, S.; Goebel, C.; MacDonald, S.; Tarbell, N.; Yock, T.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Friedmann, A.] Massachusetts Gen Hosp, Dept Paediat Oncol, Boston, MA 02114 USA. [Kuhlthau, K.] Massachusetts Gen Hosp, Dept Paediat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA P-0849 BP S264 EP S264 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818801555 ER PT J AU Wakefield, C Georgiou, G McGill, B Fardell, J Signorelli, C Hanlon, L Tucker, K Patenaude, A Cohn, R AF Wakefield, C. Georgiou, G. McGill, B. Fardell, J. Signorelli, C. Hanlon, L. Tucker, K. Patenaude, A. Cohn, R. TI Genetic Testing for Childhood Cancer Survivors' Risk of Late Effects: Consumer Understanding, Acceptance and Willingness-To-Pay SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Wakefield, C.; Georgiou, G.; McGill, B.; Fardell, J.; Signorelli, C.; Hanlon, L.] Univ NSW, Sch Womens & Childrens Hlth, Sydney, NSW, Australia. [Tucker, K.] Univ NSW, Prince Wales Clin Sch, Sydney, NSW, Australia. [Patenaude, A.] Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Dept Psychiat, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Cohn, R.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-112 BP S88 EP S88 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800705 ER PT J AU Wiener, L Zadeh, S Battles, H Pelletier, W Muriel, A AF Wiener, L. Zadeh, S. Battles, H. Pelletier, W. Muriel, A. TI Understanding the Perceived Influence of Childhood Cancer on the Parents' Relationship SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Wiener, L.; Zadeh, S.; Battles, H.] NCI, Paediat Oncol Branch, Bethesda, MD 20892 USA. [Pelletier, W.] Alberta Childrens Prov Gen Hosp, Paediat Oncol, Calgary, AB, Canada. [Muriel, A.] Dana Farber Canc Inst, Paediat Psychosocial Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-231 BP S59 EP S59 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800565 ER PT J AU Withycombe, J Reeve, B McFatrich, M Mack, J Weaver, M Jacobs, S Sung, L Baker, J Pinheiro, L Mowbray, C Palma, D Freyer, D Gibson, D Tomlinson, D Lukshis, J Levine, A Jackson, K Waldon, M Lollar, S Hinds, PS AF Withycombe, J. Reeve, B. McFatrich, M. Mack, J. Weaver, M. Jacobs, S. Sung, L. Baker, J. Pinheiro, L. Mowbray, C. Palma, D. Freyer, D. Gibson, D. Tomlinson, D. Lukshis, J. Levine, A. Jackson, K. Waldon, M. Lollar, S. Hinds, P. S. TI Evaluation of Reading Level and Children's Ability to Complete the Paediatric Patient-Reported Outcome Common Terminology Criteria for Adverse Events (Paediatric PRO-CTCAE) SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Withycombe, J.] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA. [Reeve, B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [McFatrich, M.; Pinheiro, L.; Jackson, K.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Mack, J.; Levine, A.] Dana Farber Canc Inst, Paediat Oncol, Boston, MA USA. [Weaver, M.] NIH, Palliat Care, Bldg 10, Bethesda, MD 20892 USA. [Jacobs, S.] Childrens Natl, Oncol, Washington, DC USA. [Sung, L.] Hosp Sick Children, Haematol Oncol, Toronto, ON, Canada. [Baker, J.] St Jude Childrens Res Hosp, Oncol & Paediat Med, 332 N Lauderdale St, Memphis, TN 38105 USA. [Mowbray, C.; Waldon, M.; Hinds, P. S.] Childrens Natl, Nursing Res, Washington, DC USA. [Palma, D.] Univ Southern Calif, Res, Los Angeles, CA USA. [Freyer, D.] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA USA. [Gibson, D.] St Jude Childrens Res Hosp, Nursing, Memphis, TN USA. [Tomlinson, D.] Hosp Sick Children, Clin Res, Toronto, ON, Canada. [Lukshis, J.] Childrens Hosp, Palmetto Hlth, Columbia, SC USA. [Lollar, S.] Palmetto Hlth, Clin Trials, Columbia, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA PD-156 BP S97 EP S98 PG 2 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800043 ER PT J AU Wright, KD Bandopadhayay, P Goldman, S Rubin, J Leary, SE Gardner, S Elster, JD Wang, ZJ Bowers, D Robison, NJ Bendel, A MacDonald, TJ Sandler, ES Khatib, Z Jabado, N Goumnerova, L Ligon, K Prados, M Gupta, N Kieran, M AF Wright, K. D. Bandopadhayay, P. Goldman, S. Rubin, J. Leary, S. E. Gardner, S. Elster, J. D. Wang, Z. J. Bowers, D. Robison, N. J. Bendel, A. MacDonald, T. J. Sandler, E. S. Khatib, Z. Jabado, N. Goumnerova, L. Ligon, K. Prados, M. Gupta, N. Kieran, M. TI Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG): Feasibility and Safety Update SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Wright, K. D.; Kieran, M.] Dana Farber Harvard Canc Ctr, Oncol, Boston, MA USA. [Bandopadhayay, P.; Ligon, K.] Dana Farber Harvard Canc Inst, Boston, MA USA. [Bandopadhayay, P.] Broad Inst, Oncol, Boston, MA USA. [Goldman, S.] Ann & Robert H Lurie Childrens Hosp Chicago, Paediat Oncol, Chicago, IL 60611 USA. [Rubin, J.] Washington Univ, Med Ctr, Pediat Oncol, St Louis, MO 63130 USA. [Leary, S. E.] Seattle Childrens, Pediat Oncol, Seattle, WA USA. [Gardner, S.] NYU, Paediat Oncol, New York, NY USA. [Elster, J. D.] Kosair Childrens Hosp, Paediat Oncol, Louisville, KY USA. [Wang, Z. J.] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Wang, Z. J.] Wayne State Univ, Paediat Oncol, Detroit, MI USA. [Bowers, D.] UT Southwestern, Paediat Oncol, Dallas, TX USA. [Robison, N. J.] Childrens Hosp Los Angeles, Paediat Oncol, Los Angeles, CA 90027 USA. [Bendel, A.] Childrens Hosp & Clin Minnesota, Paediat Oncol, Minneapolis, MN USA. [MacDonald, T. J.] Childrens Hlth Care Atlanta, Paediat Oncol, Atlanta, GA USA. [Sandler, E. S.] Nemours Childrens Specialty Care, Paediat Oncol, Jacksonville, FL USA. [Khatib, Z.] Miami Childrens Hosp, Paediat Oncol, Miami, FL USA. [Jabado, N.] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Paediat Oncol, Montreal, PQ, Canada. [Goumnerova, L.] Dana Farber Harvard Canc Ctr, Neurosurg, Boston, MA USA. [Ligon, K.] Broad Inst, Boston, MA USA. [Prados, M.; Gupta, N.] Univ Calif San Francisco, Neurosurg, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-108 BP S32 EP S32 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800443 ER PT J AU Yock, T Goldberg, S Stone, JF Gaudet, DE Gallotto, SL Saran, F Zacharoulis, S Wharram, B Weyman, EA MacDonald, SM Ebb, DH Tarbell, NJ Nartowicz, JA Kuhlthau, KA Mandeville, HC AF Yock, T. Goldberg, S. Stone, J. F. Gaudet, D. E. Gallotto, S. L. Saran, F. Zacharoulis, S. Wharram, B. Weyman, E. A. MacDonald, S. M. Ebb, D. H. Tarbell, N. J. Nartowicz, J. A. Kuhlthau, K. A. Mandeville, H. C. TI A Comparison of PedsQL HRQoL Outcomes in Medulloblastoma Patients Treated with Modern Photon (XRT) or Proton Radiotherapy (PT) SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Yock, T.; Goldberg, S.; Gaudet, D. E.; Gallotto, S. L.; Weyman, E. A.; MacDonald, S. M.; Tarbell, N. J.; Nartowicz, J. A.] Massachusetts Gen Hosp, Radiat Oncol, Boston, MA 02114 USA. [Stone, J. F.; Saran, F.; Wharram, B.; Mandeville, H. C.] Royal Marsden Hosp, Radiat Oncol, London, England. [Zacharoulis, S.] Royal Marsden Hosp, Neurooncol, London, England. [Ebb, D. H.] Massachusetts Gen Hosp, Paediat Oncol, Boston, MA 02114 USA. [Kuhlthau, K. A.] Massachusetts Gen Hosp, Paediat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD NOV PY 2016 VL 63 SU 3 MA O-260 BP S65 EP S65 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA DY0XF UT WOS:000384818800594 ER PT J AU O'Neill, AF Hanto, DW Katzenstein, HM AF O'Neill, Allison F. Hanto, Douglas W. Katzenstein, Howard M. TI Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation SO PEDIATRIC TRANSPLANTATION LA English DT Editorial Material ID ONCOLOGY-GROUP; CHILDREN; SOCIETY; TUMORS C1 [O'Neill, Allison F.] Boston Childrens Hosp, Div Hematol Oncol, Dana Farber Canc Inst, Boston, MA USA. [O'Neill, Allison F.] Harvard Med Sch, Boston, MA USA. [Hanto, Douglas W.] Vanderbilt Univ, Sch Med, Monroe Carell Jr Childrens Hosp, Vanderbilt Transplant Ctr, Nashville, TN 37212 USA. [Hanto, Douglas W.] Vanderbilt Univ, Sch Med, Monroe Carell Jr Childrens Hosp, Dept Surg, Nashville, TN 37212 USA. [Katzenstein, Howard M.] Vanderbilt Univ, Sch Med, Div Pediat Hematol Oncol, Monroe Carell Jr Childrens Hosp, Nashville, TN 37212 USA. RP O'Neill, AF (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Dana Farber Canc Inst, Boston, MA USA.; O'Neill, AF (reprint author), Harvard Med Sch, Boston, MA USA. NR 13 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1397-3142 EI 1399-3046 J9 PEDIATR TRANSPLANT JI Pediatr. Transplant. PD NOV PY 2016 VL 20 IS 7 BP 878 EP 879 DI 10.1111/petr.12781 PG 2 WC Pediatrics; Transplantation SC Pediatrics; Transplantation GA ED9GE UT WOS:000389177400002 PM 27726261 ER PT J AU Sumner, JA Kubzansky, LD Roberts, AL Gilsanz, P Chen, Q Winning, A Forman, JP Rimm, EB Koenen, KC AF Sumner, J. A. Kubzansky, L. D. Roberts, A. L. Gilsanz, P. Chen, Q. Winning, A. Forman, J. P. Rimm, E. B. Koenen, K. C. TI Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middle-aged women SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Epidemiology; hypertension; post-traumatic stress disorder; trauma; women ID NATIONAL COMORBIDITY SURVEY; SHORT SCREENING SCALE; INCIDENT HYPERTENSION; SLEEP DURATION; BLOOD-PRESSURE; NURSES HEALTH; PTSD; ASSOCIATION; DEPRESSION; VETERANS AB Background. Post-traumatic stress disorder (PTSD) has been linked to hypertension, but most research on PTSD and hypertension is cross-sectional, and potential mediators have not been clearly identified. Moreover, PTSD is twice as common in women as in men, but understanding of the PTSD-hypertension relationship in women is limited. We examined trauma exposure and PTSD symptoms in relation to incident hypertension over 22 years in 47 514 civilian women in the Nurses' Health Study II. Method. We used proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for new-onset hypertension (N = 15 837). Results. PTSD symptoms assessed with a screen were modestly associated with incident hypertension in a doseresponse fashion after adjusting for potential confounders. Compared to women with no trauma exposure, women with 6-7 PTSD symptoms had the highest risk of developing hypertension (HR 1.20, 95% CI 1.12-1.30), followed by women with 4-5 symptoms (HR 1.17, 95% CI 1.10-1.25), women with 1-3 symptoms (HR 1.12, 95% CI 1.06-1.18), and trauma-exposed women with no symptoms (HR 1.04, 95% CI 1.00-1.09). Findings were maintained, although attenuated, adjusting for hypertension-relevant medications, medical risk factors, and health behaviors. Higher body mass index and antidepressant use accounted for 30% and 21% of the PTSD symptom-hypertension association, respectively. Conclusions. Screening for hypertension and reducing unhealthy lifestyle factors, particularly obesity, in women with PTSD may hold promise for offsetting cardiovascular risk. C1 [Sumner, J. A.] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 W 168th St,PH9-315, New York, NY 10032 USA. [Sumner, J. A.; Rimm, E. B.; Koenen, K. C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Kubzansky, L. D.; Roberts, A. L.; Gilsanz, P.; Winning, A.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Chen, Q.] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Forman, J. P.] Harvard Med Sch, Brigham & Womens Hosp, Div Renal, Boston, MA USA. [Forman, J. P.; Rimm, E. B.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA. [Rimm, E. B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Koenen, K. C.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Koenen, K. C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Koenen, K. C.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. RP Sumner, JA (reprint author), Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 W 168th St,PH9-315, New York, NY 10032 USA. EM js4456@cumc.columbia.edu FU National Institutes of Health [R01MH078928, R01MH101269, K01HL130650, T32MH017119, UM1CA176726]; Yerby Postdoctoral Fellowship FX We acknowledge the Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School for managing the NHS II. This study was supported by the National Institutes of Health grants R01MH078928, R01MH101269, K01HL130650, T32MH017119, and UM1CA176726; and the Yerby Postdoctoral Fellowship. NR 47 TC 1 Z9 1 U1 4 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD NOV PY 2016 VL 46 IS 15 BP 3105 EP 3116 DI 10.1017/S0033291716001914 PG 12 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA EE6FQ UT WOS:000389704800004 PM 27534802 ER PT J AU Johnson, TM Arya, S AF Johnson, Theodore M., II Arya, Shipra TI Untitled SO UROLOGY LA English DT Editorial Material ID OLDER-ADULTS; DISCHARGE; FRAILTY; CARE; SURGERY C1 [Johnson, Theodore M., II] US Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA 30033 USA. [Johnson, Theodore M., II] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Johnson, Theodore M., II] Emory Univ, Dept Family & Prevent Med, Atlanta, GA 30322 USA. [Arya, Shipra] Emory Univ, Sch Med, Div Vasc Surg, Atlanta, GA USA. [Arya, Shipra] US Dept Vet Affairs, Atlanta VA Med Ctr, Decatur, GA USA. RP Johnson, TM (reprint author), US Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA 30033 USA.; Johnson, TM (reprint author), Emory Univ, Dept Med, Atlanta, GA 30322 USA.; Johnson, TM (reprint author), Emory Univ, Dept Family & Prevent Med, Atlanta, GA 30322 USA. NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2016 VL 97 BP 31 EP 32 DI 10.1016/j.urology.2016.03.074 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA EE4CS UT WOS:000389550300018 PM 27492668 ER PT J AU Barry, MJ AF Barry, Michael J. TI Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia COMMENT SO UROLOGY LA English DT Editorial Material C1 [Barry, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Barry, Michael J.] Harvard Med Sch, Boston, MA 02115 USA. RP Barry, MJ (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Barry, MJ (reprint author), Harvard Med Sch, Boston, MA 02115 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2016 VL 97 BP 217 EP 217 DI 10.1016/j.urology.2016.03.071 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA EE4CS UT WOS:000389550300066 PM 27443796 ER PT J AU Valeshabad, AK Walsh, A Lloyd, GL AF Valeshabad, Ali Kord Walsh, Anne Lloyd, Granville L. TI An Important Mimic of Inguinal Hernia SO UROLOGY LA English DT Editorial Material AB Spermatic cord malignancy is a rare and challenging diagnosis, often misdiagnosed as an inguinal hernia or cord lipoma. In these images, we show a 61-year-old male for whom laparoscopic repair of clinically diagnosed hernia was attempted. Laparoscopy revealed closed internal ring without hernia. Imaging showed large paratesticular mass; radical inguinal excision of testicle, cord, and mass was performed. Pathology showed mixed low-grade and high-grade sarcoma. Liposarcoma should be considered in cases of unusual inguinal mass; appropriate imaging can guide surgical approach and optimize outcomes. Published by Elsevier Inc. C1 Univ Illinois, Dept Radiol, Chicago, IL USA. Univ Illinois, Dept Radiol, Aurora, CO USA. Univ Colorado Denver, Dept Surg, Aurora, CO USA. Univ Wisconsin, Dept Urol, Madison, WI USA. [Lloyd, Granville L.] Univ Colorado, Sch Med, Denver Vet Affairs Hosp, Dept Surg,Div Urol, 1055 Clermont St, Denver, CO 80220 USA. RP Lloyd, GL (reprint author), Univ Colorado, Sch Med, Denver Vet Affairs Hosp, Dept Surg,Div Urol, 1055 Clermont St, Denver, CO 80220 USA. EM granville.lloyd@ucdenver.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2016 VL 97 BP E11 EP E11 DI 10.1016/j.urology.2016.08.001 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA EE4CS UT WOS:000389550300005 PM 27502033 ER PT J AU Ji, C Sharma, I Pratihar, D Hudson, LL Maura, D Guney, T Rahme, LG Pesci, EC Coleman, JP Tan, DS AF Ji, Cheng Sharma, Indrajeet Pratihar, Debarshi Hudson, L. Lynn Maura, Damien Guney, Tezcan Rahme, Laurence G. Pesci, Everett C. Coleman, James P. Tan, Derek S. TI Designed Small-Molecule Inhibitors of the Anthranilyl-CoA Synthetase PqsA Block Quinolone Biosynthesis in Pseudomonas aeruginosa SO ACS CHEMICAL BIOLOGY LA English DT Article ID BACTERIAL MENAQUINONE BIOSYNTHESIS; VIRULENCE FACTOR EXPRESSION; TO-CELL COMMUNICATION; MYCOBACTERIUM-TUBERCULOSIS; SIDEROPHORE BIOSYNTHESIS; NUCLEOSIDE ANTIBIOTICS; REACTION INTERMEDIATE; ADENYLATION DOMAINS; BACILLUS-ANTHRACIS; ACID ADENYLATION AB The Gram-negative bacterial pathogen Pseudomonas aeruginosa uses three interconnected intercellular signaling systems regulated by the transcription factors LasR, Rh1R, and MvfR (PqsR), which mediate bacterial cell cell communication via small-molecule natural products and control the production of a variety of virulence factors. The MvfR system is activated by and controls the biosynthesis of the quinolone quorum sensing factors HHQ and PQS. A key step in the biosynthesis of these quinolones is catalyzed by the anthranilyl-CoA synthetase PqsA. To develop inhibitors of PqsA as novel potential antivirulence antibiotics, we report herein the design and synthesis of sulfonyladeonsine-based mimics of the anthranilyl-AMP reaction intermediate that is bound tightly by PqsA. Biochemical, microbiological, and pharmacological studies identified two potent PqsA inhibitors, anthranilyl-AMS (1) and anthranilyl-AMSN (2), that decreased HHQ and PQS production in P. aeruginosa strain PA14. However, these compounds did not inhibit production of the virulence factor pyocyanin. Moreover, they exhibited limited bacterial penetration in compound accumulation studies. This work provides the most potent PqsA inhibitors reported to date and sets the stage for future efforts to develop analogues with improved cellular activity to investigate further the complex relationships between quinolone biosynthesis and virulence factor production in P. aeruginosa and the therapeutic potential of targeting PqsA. C1 [Ji, Cheng; Sharma, Indrajeet; Pratihar, Debarshi; Guney, Tezcan; Tan, Derek S.] Mem Sloan Kettering Canc Ctr, Chem Biol Program, 1275 York Ave,Box 422, New York, NY 10065 USA. [Tan, Derek S.] Mem Sloan Kettering Canc Ctr, Triinst Res Program, 1275 York Ave,Box 422, New York, NY 10065 USA. [Hudson, L. Lynn; Pesci, Everett C.; Coleman, James P.] East Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, 600 Moye Blvd, Greenville, NC 27834 USA. [Maura, Damien; Rahme, Laurence G.] Harvard Med Sch, Dept Surg, 50 Blossom St, Boston, MA 02114 USA. [Maura, Damien; Rahme, Laurence G.] Massachusettts Gen Hosp, 50 Blossom St, Boston, MA 02114 USA. [Rahme, Laurence G.] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA. [Rahme, Laurence G.] Shriners Hosp Children Boston, Boston, MA 02114 USA. RP Tan, DS (reprint author), Mem Sloan Kettering Canc Ctr, Chem Biol Program, 1275 York Ave,Box 422, New York, NY 10065 USA.; Tan, DS (reprint author), Mem Sloan Kettering Canc Ctr, Triinst Res Program, 1275 York Ave,Box 422, New York, NY 10065 USA. EM tand@mskcc.org FU National Institutes of Health [R21/R33 AI098802, R01 AI068038, R21/R33 AI105902, R01 AI076272, P30 CA008748]; Lucille Castori Center for Microbes, Inflammation, and Cancer FX We thank G. Chiosis and T. Taldone (MSKCC) for providing access to LC-MS/MS instrumentation and G. Sukenick, R. Wang, H. Liu, H. Fang, and S. Rusli (MSKCC) for expert mass spectrometry support. Financial support from the National Institutes of Health (R21/R33 AI098802 to D.S.T. and L.G.R, R01 AI068038 to D.S.T., R21/R33 AI105902 to L.G.R., R01 AI076272 to E.C.P. and J.P.C., Cancer Center Support Grant P30 CA008748 to C. B. Thompson) and the Lucille Castori Center for Microbes, Inflammation, and Cancer (postdoctoral fellowship to I. S.) is gratefully acknowledged. NR 78 TC 1 Z9 1 U1 7 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD NOV PY 2016 VL 11 IS 11 BP 3061 EP 3067 DI 10.1021/acschembio.6b00575 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EC8YX UT WOS:000388430100013 PM 27658001 ER PT J AU Edwards, AL Meijer, DH Guerra, RM Molenaar, RJ Alberta, JA Bernal, F Bird, GH Stiles, CD Walensky, LD AF Edwards, Amanda L. Meijer, Dimphna H. Guerra, Rachel M. Molenaar, Remco J. Alberta, John A. Bernal, Federico Bird, Gregory H. Stiles, Charles D. Walensky, Loren D. TI Challenges in Targeting a Basic Helix-Loop-Helix Transcription Factor with Hydrocarbon-Stapled Peptides SO ACS CHEMICAL BIOLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; DNA-BINDING; NEURAL PROGENITORS; MALIGNANT GLIOMA; E47 DIMERIZATION; CANCER-THERAPY; FACTOR OLIG2; BH3 HELIX; C-MYC; INHIBITOR AB Basic helix-loop-helix (bHLH) transcription factors play critical roles in organism development and disease by regulating cell proliferation and differentiation. Transcriptional activity, whether by bHLH homo- or heterodimerization, is dependent on protein protein and protein DNA interactions mediated by a-helices. Thus, alpha-helical decoys have been proposed as potential targeted therapies for pathologic bHLH transcription. Here, we developed a library of stabilized alpha-helices of OLIG2 (SAH-OLIG2) to test the capacity of hydrocarbon-stapled peptides to disrupt OLIG2 homodimerization, which drives the development and chemoresistance of glioblastoma multiforme, one of the deadliest forms of human brain cancer. Although stapling successfully reinforced the alpha-helical structure of bHLH constructs of varying length, sequence-specific dissociation of OLIG2 dimers from DNA was not achieved. Re-evaluation of the binding determinants for OLIG2 self-association and stability revealed an unanticipated role of the C-terminal domain. These data highlight potential pitfalls in peptide-based targeting of bHLH transcription factors given the liabilities of their positively charged amino acid sequences and multifactorial binding determinants. C1 [Edwards, Amanda L.; Guerra, Rachel M.; Bernal, Federico; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Edwards, Amanda L.; Guerra, Rachel M.; Bernal, Federico; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02215 USA. [Meijer, Dimphna H.; Molenaar, Remco J.; Alberta, John A.; Stiles, Charles D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. RP Walensky, LD (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.; Walensky, LD (reprint author), Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02215 USA.; Stiles, CD (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. EM Charles_Stiles@dfci.harvard.edu; Loren_Walensky@dfci.harvard.edu FU National Institutes of Health [5P01CA142536]; Leukemia and Lymphoma Scholar Award; NSF FX We thank S. Lee and E. Smith for figure preparation, A. Dricot for technical assistance with the yeast two-hybrid screen, and Y. Nakatani for helpful discussions. This work was supported by National Institutes of Health grant 5P01CA142536 to C.D.S. and L.D.W., a Leukemia and Lymphoma Scholar Award to L.D.W., and an NSF predoctoral award to A.L.E. NR 40 TC 0 Z9 0 U1 2 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD NOV PY 2016 VL 11 IS 11 BP 3146 EP 3153 DI 10.1021/acschembio.6b00465 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EC8YX UT WOS:000388430100023 PM 27643505 ER PT J AU Canellas, R Mehrkhani, F Patino, M Kambadakone, A Sahani, D AF Canellas, Rodrigo Mehrkhani, Farhad Patino, Manuel Kambadakone, Avinash Sahani, Dushyant TI Characterization of Portal Vein Thrombosis (Neoplastic Versus Bland) on CT Images Using Software-Based Texture Analysis and Thrombus Density (Hounsfield Units) SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE bland thrombus; CT; neoplastic thrombus; portal vein thrombosis; texture analysis ID FINE-NEEDLE-ASPIRATION; HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; BENIGN; CLASSIFICATION; ULTRASOUND; DIAGNOSIS; DIFFERENTIATION; HETEROGENEITY; PREDICTION AB OBJECTIVE. The purpose of this study was to investigate the role of CT texture analysis and thrombus density (measured in Hounsfield units) in distinguishing between neoplastic and bland portal vein thrombosis (PVT) on portal venous phase CT. MATERIALS AND METHODS. In this retrospective study, 117 contrast-enhanced CT studies of 109 patients were included for characterization of PVT. Assessment of PVT was performed by estimation of CT textural features using CT texture analysis software and measurement of attenuation values. For CT texture analysis, filtered and unfiltered images were assessed to quantify heterogeneity using a set of predefined histogram-based texture parameters. The Mann-Whitney U test and binary logistic regression were applied for statistical significance. ROC curves were used to identify accuracy and optimal cutoff values. RESULTS. Of the 117 CT studies, 63 neoplastic thrombi and 54 bland thrombi were identified on the images. The two most discriminative CT texture analysis parameters to differentiate neoplastic from bland thrombus were mean value of positive pixels (without filtration, p < 0.001) and entropy (with fine filtration, p < 0.001). Mean thrombus density values could also reliably distinguish neoplastic (81.39 HU) and bland (32.88 HU) thrombi (p < 0.001). The AUCs were 0.97 for mean value of positive pixels (p < 0.001), 0.93 for entropy (p < 0.001), 0.99 for the model combining mean value of positive pixels and entropy (p < 0.001), 0.91 for thrombus density (p < 0.001), and 0.61 for the radiologist's subjective evaluation (p = 0.037). The optimal cutoffs values were 56.9 for mean value of positive pixels, 4.50 for entropy, and 54.0 HU for thrombus density. CONCLUSION. CT texture analysis and CT attenuation values allow reliable differentiation between neoplastic and bland thrombi on a single portal venous phase CT examination. C1 [Canellas, Rodrigo; Mehrkhani, Farhad; Patino, Manuel; Kambadakone, Avinash; Sahani, Dushyant] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Dept Radiol, White 270,55 Fruit St, Boston, MA 02114 USA. RP Sahani, D (reprint author), Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Dept Radiol, White 270,55 Fruit St, Boston, MA 02114 USA. EM dsahani@partners.org NR 34 TC 0 Z9 0 U1 2 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD NOV PY 2016 VL 207 IS 5 BP W81 EP W87 DI 10.2214/AJR.15.15928 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB3TN UT WOS:000387289200001 PM 27490095 ER PT J AU Deml, C Kaiser, P van Leeuwen, WF Zitterl, M Euler, SA Doz, P AF Deml, Christian Kaiser, Peter van Leeuwen, Wouter F. Zitterl, Magdalena Euler, Simon A. Doz, Priv TI The J-Shaped Bone Graft for Anatomic Glenoid Reconstruction A 10-Year Clinical Follow-up and Computed Tomography-Osteoabsorptiometry Study SO AMERICAN JOURNAL OF SPORTS MEDICINE LA English DT Article DE density distribution; glenoid; instability; CT-OAM; shoulder; bone graft ID ANTERIOR SHOULDER INSTABILITY; SKELETAL STRUCTURAL ADAPTATIONS; MECHANICAL USAGE SATMU; REDEFINING WOLFF LAW; SUBCHONDRAL MINERALIZATION; GLENOHUMERAL INSTABILITY; LATARJET PROCEDURE; DISLOCATION; DEFECTS; OSTEOARTHRITIS AB Background: The J-shaped bone graft procedure is one of the recommended methods to reconstruct significant glenoid rim defects. Purpose: To evaluate long-term (minimum 10-year) clinical outcomes and show further details of the remodeling effects on the articular cavity of the glenoid after J-shaped bone grafting. Study Design: Case series; Level of evidence, 4. Methods: A total of 14 patients treated with a J-shaped bone graft procedure were observed clinically. Additionally, bilateral pre-operative and postoperative follow-up computed tomography (CT) scans were used for CT-osteoabsorptiometry (OAM) to evaluate the bony remodeling processes. Results: The follow-up rate was 93% at a mean follow-up time of 10.7 years (range, 10.08-11.75 years). Patients exhibited a mean Constant score of 92.5 (range, 80-100) on the clinical evaluation. All patients had free range of motion and were pain free without any recurrence of instability. Based on CT-OAM, comparable and almost anatomically reconstructed, bilaterally equal glenoid cavities were found postoperatively. The distribution patterns of glenoid subchondral mineralization were bilaterally equal in 85.7% of the patients. Conclusion: The surgical treatment of recurrent shoulder instability with a significant bony Bankart lesion using the J-shaped bone graft procedure provided excellent long-term results. This study lends evidence to support the capability of the J-shaped bone graft procedure to restore the normal glenoid shape due to physiological remodeling processes. C1 [Deml, Christian; Kaiser, Peter; van Leeuwen, Wouter F.; Zitterl, Magdalena; Euler, Simon A.; Doz, Priv] Med Univ Innsbruck, Innsbruck, Austria. [Deml, Christian; Kaiser, Peter; Zitterl, Magdalena; Euler, Simon A.] Med Univ Innsbruck, Dept Trauma Surg, Anichstr 35, A-6020 Innsbruck, Austria. [Deml, Christian; van Leeuwen, Wouter F.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Cambridge, MA USA. RP Euler, SA (reprint author), Med Univ Innsbruck, Dept Trauma Surg, Anichstr 35, A-6020 Innsbruck, Austria. EM simon.euler@tirol-kliniken.at NR 41 TC 1 Z9 1 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0363-5465 EI 1552-3365 J9 AM J SPORT MED JI Am. J. Sports Med. PD NOV PY 2016 VL 44 IS 11 BP 2778 EP 2783 DI 10.1177/0363546516665816 PG 6 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA EB4RE UT WOS:000387359900030 PM 27634468 ER PT J AU Eichinger, JK Massimini, DF Kim, J Higgins, LD AF Eichinger, Josef K. Massimini, Daniel F. Kim, Jungryul Higgins, Laurence D. TI Biomechanical Evaluation of Glenoid Version and Dislocation Direction on the Influence of Anterior Shoulder Instability and Development of Hill-Sachs Lesions SO AMERICAN JOURNAL OF SPORTS MEDICINE LA English DT Article DE anatomy; morphology; glenohumeral; mechanism; subluxation ID GLENOHUMERAL JOINT; POSTERIOR INSTABILITY; CONTACT PRESSURES; PECTORALIS MAJOR; RISK-FACTORS; DEFECTS; RECONSTRUCTION; ARTHROPLASTY; TOMOGRAPHY; STABILITY AB Background: Abnormal glenoid version is a risk factor for shoulder instability. However, the degree to which the variance in version (both anteversion and retroversion) affects one's predisposition for instability is not well understood. Purpose: To determine the influence of glenoid version on anterior shoulder joint stability and to determine if the direction of the humeral head dislocation is a stimulus for the development of Hill-Sachs lesions. Study Design: Controlled laboratory study. Methods: Ten human cadaveric shoulders (mean age, 59.4 +/- 4.3 years) were tested using a custom shoulder dislocation device placed in a position of apprehension (90 degrees of abduction with 90 degrees of external rotation). Glenoid version was adjusted in 5 degrees increments for a total of 6 version angles tested: +10 degrees, +5 degrees, 0 degrees, 25 degrees, -10 degrees, and -15 degrees (anteversion angles are positive, and retroversion angles are negative). Two humeral dislocation directions were tested. The first direction was true anterior through the anterior-posterior glenoid axis. The second dislocation direction was 35 degrees inferior from the anterior-posterior glenoid axis based on the deforming force role of the pectoralis major. The force and energy to dislocate were recorded. Results: Changes in glenoid version manifested a linear effect on the dislocation force. The energy to dislocate increased as a second-order polynomial as a function of increasing glenoid retroversion. Glenoid version of +10 degrees anteversion and -15 degrees retroversion was highly unstable, resulting in spontaneous dislocation in one-quarter (10/40) and one-half (25/40) of the specimens anteriorly and posteriorly, respectively, in the absence of an applied dislocation force. The greater tuberosity was observed to engage with the anterior glenoid rim, consistent with Hill-Sachs lesions, 40% more frequently when the dislocation direction was true anterior compared with 35 degrees inferior from the anterior-posterior glenoid axis. The engagement of the greater tuberosity caused an increase in the energy required to dislocate. Conclusion: Glenoid version has a direct effect on the force required for a dislocation. An anterior-inferior dislocation direction requires less energy for a dislocation and results in a lower risk of the development of a Hill-Sachs lesion than a direct anterior dislocation direction. Clinical Relevance: Consideration should be given to glenoid version when choosing a surgical treatment option for anterior shoulder instability. C1 [Eichinger, Josef K.; Massimini, Daniel F.; Kim, Jungryul; Higgins, Laurence D.] Massachusetts Gen Hosp, Shoulder Biomot Lab, Boston, MA 02114 USA. [Kim, Jungryul; Higgins, Laurence D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA. [Eichinger, Josef K.] Med Univ South Carolina, Dept Orthopaed Surg, Charleston, SC USA. [Massimini, Daniel F.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [Kim, Jungryul] CHA Univ, Dept Orthopaed Surg, CHA Bundang Med Ctr, Seongnam, South Korea. RP Higgins, LD (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA. EM ldhiggins@partners.org NR 50 TC 1 Z9 1 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0363-5465 EI 1552-3365 J9 AM J SPORT MED JI Am. J. Sports Med. PD NOV PY 2016 VL 44 IS 11 BP 2792 EP 2799 DI 10.1177/0363546516659281 PG 8 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA EB4RE UT WOS:000387359900029 PM 27496904 ER PT J AU Pejo, E Zhou, XJ Husain, SS Raines, DE AF Pejo, Ervin Zhou, Xiaojuan Husain, S. Shaukat Raines, Douglas E. TI Sedative-hypnotic Binding to 11 beta-hydroxylase SO ANESTHESIOLOGY LA English DT Article ID CYCLOPROPYL-METHOXYCARBONYL METOMIDATE; CRITICALLY-ILL PATIENTS; ADRENAL STEROIDOGENESIS; ADRENOCORTICAL-FUNCTION; CARDIAC-SURGERY; INTENSIVE-CARE; ETOMIDATE; DEXMEDETOMIDINE; PROPOFOL; ANALOG AB Background: Etomidate potently suppresses adrenocortical steroid synthesis with potentially deleterious consequences by binding to 11 beta-hydroxylase and inhibiting its function. The authors hypothesized that other sedative-hypnotics currently in clinical use or under development (or their metabolites) might bind to the same site at clinically relevant concentrations. The authors tested this hypothesis by defining etomidate's affinity for this site and the potencies with which other sedative-hypnotics (and their metabolites) inhibit etomidate binding. Methods: 3H-etomidate's binding to adrenal membranes from Sprague-Dawley rats was characterized with a filtration assay, and its dissociation constant was defined using saturation and homologous ligand competition approaches. Half-inhibitory concentrations of sedative-hypnotics and metabolites were determined from the reduction in specific 3H-etomidate binding measured in the presence of ranging sedative-hypnotic and metabolite concentrations. Results: Saturation and homologous competition studies yielded 3H-etomidate dissociation constants of 40 and 21 nM, respectively. Half-inhibitory concentrations of etomidate and cyclopropyl methoxycarbonyl metomidate (CPMM) differed significantly (26 vs. 143 nM, respectively; P < 0.001), and those of the carboxylic acid (CA) metabolites etomidate-CA and CPMM-CA were greater than or equal to 1,000x higher than their respective parent hypnotics. The half-inhibitory concentration of dexme-detomidine was 2.2 mu M, whereas those of carboetomidate, ketamine, and propofol were greater than or equal to 50 mu M. Conclusion: Etomidate's in vitro dissociation constant for 11 beta-hydroxylase closely approximates its in vivo adrenocortical half-inhibitory concentration. CPMM produces less adrenocortical suppression than etomidate not only because it is metabolized faster but also because it binds to 11 beta-hydroxylase with lower affinity. Other sedative-hypnotics and metabolites bind to 11 beta-hydroxylase and inhibit etomidate binding only at suprahypnotic concentrations. C1 [Pejo, Ervin; Zhou, Xiaojuan; Husain, S. Shaukat; Raines, Douglas E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB444, Boston, MA 02114 USA. RP Raines, DE (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB444, Boston, MA 02114 USA. EM draines@partners.org FU National Institutes of Health, Bethesda, Maryland [R01-GM087316]; Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts FX Supported by grant R01-GM087316 from the National Institutes of Health, Bethesda, Maryland, and the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. NR 45 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD NOV PY 2016 VL 125 IS 5 BP 943 EP 951 DI 10.1097/ALN.0000000000001304 PG 9 WC Anesthesiology SC Anesthesiology GA ED8PW UT WOS:000389134400021 PM 27541316 ER PT J AU Muenster, S Beloiartsev, A Yu, BL Abidi, S Dao, M Fabry, G Graw, JA Wepler, M Malhotra, R Fernandez, BO Feelisch, M Bloch, KD Bloch, DB Zapol, WM AF Muenster, Stefan Beloiartsev, Arkadi Yu, Binglan Abidi, Sabia Dao, Ming Fabry, Gregor Graw, Jan A. Wepler, Martin Malhotra, Rajeev Fernandez, Bernadette O. Feelisch, Martin Bloch, Kenneth D. Bloch, Donald B. Zapol, Warren M. TI Exposure of Stored Packed Erythrocytes to Nitric Oxide Prevents Transfusion-associated Pulmonary Hypertension SO ANESTHESIOLOGY LA English DT Article ID RED-BLOOD-CELLS; CRITICALLY-ILL; FREE HEMOGLOBIN; STORAGE; AGE; BIOAVAILABILITY; PNEUMONIA; INCREASES; SURVIVAL; THERAPY AB Background: Transfusion of packed erythrocytes stored for a long duration is associated with increased pulmonary arterial pressure and vascular resistance. Prolonged storage decreases erythrocyte deformability, and older erythrocytes are rapidly removed from the circulation after transfusion. The authors studied whether treating stored packed ovine erythrocytes with NO before transfusion could prevent pulmonary vasoconstriction, enhance erythrocyte deformability, and prolong erythrocyte survival after transfusion. Methods: Ovine leukoreduced packed erythrocytes were treated before transfusion with either NO gas or a short-lived NO donor. Sheep were transfused with autologous packed erythrocytes, which were stored at 4 degrees C for either 2 ("fresh blood") or 40 days ("stored blood"). Pulmonary and systemic hemodynamic parameters were monitored before, during, and after transfusion. Transfused erythrocytes were labeled with biotin to measure their circulating lifespan. Erythrocyte deformability was assessed before and after NO treatment using a microfluidic device. Results: NO treatment improved the deformability of stored erythrocytes and increased the number of stored erythrocytes circulating at 1 and 24 h after transfusion. NO treatment prevented transfusion-associated pulmonary hypertension (mean pulmonary arterial pressure at 30 min of 21 +/- 1 vs. 15 +/- 1 mmHg in control and NO-treated packed erythrocytes, P < 0.0001). Washing stored packed erythrocytes before transfusion did not prevent pulmonary hypertension. Conclusions: NO treatment of stored packed erythrocytes before transfusion oxidizes cell-free oxyhemoglobin to methemoglobin, prevents subsequent NO scavenging in the pulmonary vasculature, and limits pulmonary hypertension. NO treatment increases erythrocyte deformability and erythrocyte survival after transfusion. NO treatment might provide a promising therapeutic approach to prevent pulmonary hypertension and extend erythrocyte survival. C1 [Muenster, Stefan; Beloiartsev, Arkadi; Yu, Binglan; Fabry, Gregor; Graw, Jan A.; Wepler, Martin; Bloch, Kenneth D.; Bloch, Donald B.; Zapol, Warren M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, 55 Fruit St,Thier 503, Boston, MA 02114 USA. [Muenster, Stefan; Beloiartsev, Arkadi; Yu, Binglan; Fabry, Gregor; Graw, Jan A.; Wepler, Martin; Malhotra, Rajeev; Bloch, Kenneth D.; Bloch, Donald B.; Zapol, Warren M.] Harvard Med Sch, 55 Fruit St,Thier 503, Boston, MA 02114 USA. [Muenster, Stefan] Univ Hosp Bonn, Dept Anesthesiol & Crit Care Med, Bonn, Germany. [Abidi, Sabia; Dao, Ming] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA. [Malhotra, Rajeev; Bloch, Kenneth D.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, 55 Fruit St,Thier 503, Boston, MA 02114 USA. [Malhotra, Rajeev; Bloch, Kenneth D.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, 55 Fruit St,Thier 503, Boston, MA 02114 USA. [Fernandez, Bernadette O.; Feelisch, Martin] Univ Southampton, Fac Med Clin & Expt Sci, Southampton, Hants, England. [Bloch, Donald B.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 55 Fruit St,Thier 503, Boston, MA 02114 USA. [Bloch, Donald B.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol Gen Med Serv, 55 Fruit St,Thier 503, Boston, MA 02114 USA. RP Zapol, WM (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, 55 Fruit St,Thier 503, Boston, MA 02114 USA.; Zapol, WM (reprint author), Harvard Med Sch, 55 Fruit St,Thier 503, Boston, MA 02114 USA. EM wzapol@mgh.harvard.edu RI Dao, Ming/B-1602-2008; OI Malhotra, Rajeev/0000-0003-0120-4630 FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts; National Institutes of Health (Bethesda, Maryland) [U01HL114476, R01DK082971]; German Academic Exchange Service (Deutscher Akademischer Austauschdienst), Bonn, Germany; Deutsche Forschungsgemeinschaft, Bonn, Germany [GR 4446/1-1, WE 5471/2-1]; National Heart, Lung and Blood Institute, Bethesda, Maryland [K08HL111210]; Leducq Foundation, Paris, France FX Supported by funds from the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts; National Institutes of Health (Bethesda, Maryland) grants U01HL114476 (to Drs. Du and Dao) and R01DK082971 (to Drs. K.D. Bloch and D.B. Bloch); German Academic Exchange Service (Deutscher Akademischer Austauschdienst), Bonn, Germany (to Mr. Fabry); grants GR 4446/1-1 (to Dr. Graw) and WE 5471/2-1 (to Dr. Wepler) from the Deutsche Forschungsgemeinschaft, Bonn, Germany; grant K08HL111210 from the National Heart, Lung and Blood Institute, Bethesda, Maryland (to Dr. Malhotra); and a grant from the Leducq Foundation, Paris, France (to Drs. K.D. Bloch and D.B. Bloch). NR 40 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD NOV PY 2016 VL 125 IS 5 BP 952 EP 963 DI 10.1097/ALN.0000000000001294 PG 12 WC Anesthesiology SC Anesthesiology GA ED8PW UT WOS:000389134400022 PM 27517645 ER PT J AU Wellman, TJ de Prost, N Tucci, M Winkler, T Baron, RM Filipczak, P Raby, B Chu, JH Harris, RS Musch, G Falcao, LFD Capelozzi, V Venegas, JG Melo, MFV AF Wellman, Tyler J. de Prost, Nicolas Tucci, Mauro Winkler, Tilo Baron, Rebecca M. Filipczak, Piotr Raby, Benjamin Chu, Jen-hwa Harris, R. Scott Musch, Guido dos Reis Falcao, Luiz F. Capelozzi, Vera Venegas, Jose G. Melo, Marcos F. Vidal TI Lung Metabolic Activation as an Early Biomarker of Acute Respiratory Distress Syndrome and Local Gene Expression Heterogeneity SO ANESTHESIOLOGY LA English DT Article ID MECHANICAL VENTILATION; PULMONARY PERFUSION; F-18-FDG UPTAKE; INJURY; INFLAMMATION; SEPSIS; PRESSURE; SHEEP; PET; KINETICS AB Background: Acute respiratory distress syndrome (ARDS) is an inflammatory condition comprising diffuse lung edema and alveolar damage. ARDS frequently results from regional injury mechanisms. However, it is unknown whether detectable inflammation precedes lung edema and opacification and whether topographically differential gene expression consistent with heterogeneous injury occurs in early ARDS. The authors aimed to determine the temporal relationship between pulmonary metabolic activation and density in a large animal model of early ARDS and to assess gene expression in differentially activated regions. Methods: The authors produced ARDS in sheep with intravenous lipopolysaccharide (10 ng . kg(-1) . h(-1)) and mechanical ventilation for 20 h. Using positron emission tomography, the authors assessed regional cellular metabolic activation with 2-deoxy-2-[(18)F]fluoro-D-glucose, perfusion and ventilation with (NN)-N-13-saline, and aeration using transmission scans. Species-specific microarray technology was used to assess regional gene expression. Results: Metabolic activation preceded detectable increases in lung density (as required for clinical diagnosis) and correlated with subsequent histologic injury, suggesting its predictive value for severity of disease progression. Local time courses of metabolic activation varied, with highly perfused and less aerated dependent lung regions activated earlier than nondependent regions. These regions of distinct metabolic trajectories demonstrated differential gene expression for known and potential novel candidates for ARDS pathogenesis. Conclusions: Heterogeneous lung metabolic activation precedes increases in lung density in the development of ARDS due to endotoxemia and mechanical ventilation. Local differential gene expression occurs in these early stages and reveals molecular pathways relevant to ARDS biology and of potential use as treatment targets. C1 [Wellman, Tyler J.; Tucci, Mauro; Winkler, Tilo; Musch, Guido; dos Reis Falcao, Luiz F.; Venegas, Jose G.; Melo, Marcos F. Vidal] Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. [Harris, R. Scott] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Pulm & Crit Care, Boston, MA USA. [de Prost, Nicolas] Hop Henri Mondor, Assistance Publ Hop Paris, Med Intens Care Unit, Creteil, France. [Baron, Rebecca M.; Filipczak, Piotr] Harvard Med Sch, Brigham & Womens Hosp, Dept Med Pulm & Crit Care, Boston, MA USA. [Raby, Benjamin; Chu, Jen-hwa] Harvard Med Sch, Brigham & Womens Hosp, Channing Lab, Boston, MA USA. [Capelozzi, Vera] Univ Sao Paulo, Lab Histomorphometry & Lung Genom, Sao Paulo, Brazil. RP Melo, MFV (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM VidalMelo.Marcos@mgh.harvard.edu FU National Heart, Lung, and Blood Institute (Bethesda, Maryland) [HL086827, HL121228]; National Heart, Lung, and Blood Institute [R01HL094639] FX Supported by R01 grants HL086827 and HL121228 from the National Heart, Lung, and Blood Institute (Bethesda, Maryland; to Dr. Vidal Melo). Dr. Musch was funded by R01HL094639 from the National Heart, Lung, and Blood Institute. NR 53 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD NOV PY 2016 VL 125 IS 5 BP 992 EP 1004 DI 10.1097/ALN.0000000000001334 PG 13 WC Anesthesiology SC Anesthesiology GA ED8PW UT WOS:000389134400025 PM 27611185 ER PT J AU Zhang, DF Gomez, JE Chien, JY Haseley, N Desjardins, CA Earl, AM Hsueh, PR Hung, DT AF Zhang, Danfeng Gomez, James E. Chien, Jung-Yien Haseley, Nathan Desjardins, Christopher A. Earl, Ashlee M. Hsueh, Po-Ren Hung, Deborah T. TI Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; PULMONARY TUBERCULOSIS; RAPID DETECTION; SEQUENCE DATA; MOXIFLOXACIN; MUTATIONS; HETERORESISTANCE; EXPOSURE; REGIMENS; PATIENT AB Fluoroquinolones (FQs) are effective second-line drugs for treating antibiotic-resistant tuberculosis (TB) and are being considered for use as first-line agents. Because FQs are used to treat a range of infections, in a setting of undiagnosed TB, there is potential to select for drug-resistant Mycobacterium tuberculosis mutants during FQ-based treatment of other infections, including pneumonia. Here we present a detailed characterization of ofloxacin-resistant M. tuberculosis samples isolated directly from patients in Taiwan, which demonstrates that selection for FQ resistance can occur within patients who have not received FQs for the treatment of TB. Several of these samples showed no mutations in gyrA or gyrB based on PCR-based molecular assays, but genome-wide next-generation sequencing (NGS) revealed minority populations of gyrA and/ or gyrB mutants. In other samples with PCR-detectable gyrA mutations, NGS revealed subpopulations containing alternative resistance-associated genotypes. Isolation of individual clones from these apparently heterogeneous samples confirmed the presence of the minority drug-resistant variants suggested by the NGS data. Further NGS of these purified clones established evolutionary links between FQ-sensitive and-resistant clones derived from the same patient, suggesting de novo emergence of FQ-resistant TB. Importantly, most of these samples were isolated from patients without a history of FQ treatment for TB. Thus, selective pressure applied by FQ monotherapy in the setting of undiagnosed TB infection appears to be able to drive the full or partial emergence of FQ-resistant M. tuberculosis, which has the potential to confound diagnostic tests for antibiotic susceptibility and limit the effectiveness of FQs in TB treatment. C1 [Zhang, Danfeng; Gomez, James E.; Haseley, Nathan; Desjardins, Christopher A.; Earl, Ashlee M.; Hung, Deborah T.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Zhang, Danfeng] Minnan Normal Univ, Sch Biol Sci & Biotechnol, Zhangzhou, Peoples R China. [Chien, Jung-Yien] Natl Taiwan Univ Med Coll, Grad Inst Clin Med, Taipei, Taiwan. [Chien, Jung-Yien; Hsueh, Po-Ren] Natl Taiwan Univ Med Coll, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan. [Hsueh, Po-Ren] Natl Taiwan Univ Med Coll, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan. [Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Hung, Deborah T.] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA. RP Hung, DT (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Hung, DT (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.; Hung, DT (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.; Hung, DT (reprint author), Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA. EM hung@molbio.mgh.harvard.edu OI CHIEN, JUNG-YIEN/0000-0002-7718-0594 FU National Science Council of Taiwan [NSC 102-2314-B-002-165]; Pershing Square Foundation; Broad Institute Tuberculosis Donor Group; HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [U19AI110818]; HHS \ NIH \ National Human Genome Research Institute (NHGRI) [HG002295]; Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) [2015J01145]; Doris Duke Charitable Foundation (DDCF) [2008046] FX This work, including the efforts of Po-Ren Hsueh, was funded by National Science Council of Taiwan (NSC 102-2314-B-002-165). This work, including the efforts of Deborah T. Hung, was funded by Pershing Square Foundation. This work, including the efforts of Deborah T. Hung, was funded by Broad Institute Tuberculosis Donor Group. This work, including the efforts of Christopher A. Desjardins and Ashlee M. Earl, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (U19AI110818). This work, including the efforts of Nathan Hasely, was funded by HHS vertical bar NIH vertical bar National Human Genome Research Institute (NHGRI) (HG002295). This work, including the efforts of Danfeng Zhang, was funded by Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) (2015J01145). This work, including the efforts of Deborah T. Hung, was funded by Doris Duke Charitable Foundation (DDCF) (2008046). NR 41 TC 1 Z9 1 U1 4 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2016 VL 60 IS 11 BP 6600 EP 6608 DI 10.1128/AAC.00664-16 PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7QH UT WOS:000389063500018 PM 27572408 ER PT J AU Kadosh, D Najvar, LK Bocanegra, R Olivo, M Kirkpatrick, WR Wiederhold, NP Patterson, TF AF Kadosh, David Najvar, Laura K. Bocanegra, Rosie Olivo, Marcos Kirkpatrick, William R. Wiederhold, Nathan P. Patterson, Thomas F. TI Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID SYSTEMIC CANDIDIASIS; PURIFIED DIETS; INFANT MICE; ALBICANS; COLONIZATION; MUCOSAL; SUSCEPTIBILITY; PATHOGENESIS; NEUTROPENIA; CANDIDEMIA AB Candida albicans, normally found as a commensal in the gut, is a major human fungal pathogen responsible for both mucosal and systemic infections in a wide variety of immunocompromised individuals, including cancer patients and organ transplant recipients. The gastrointestinal tract represents a major portal of entry for the establishment of disseminated candidiasis in many of these individuals. Here we report the development of a diet-based mouse model for disseminated candidiasis acquired via the gastrointestinal tract. Using this model, as well as an appropriate immunosuppression regimen, we demonstrate that dissemination of C. albicans from the gastrointestinal tract can result in mortality within 30 days postinfection. We also show a significant increase in fungal burden in systemic organs, but not gastrointestinal tract organs, upon immunosuppression. Importantly, we demonstrate that the administration of two widely used antifungals, fluconazole and caspofungin, either pre-or postimmunosuppression, significantly reduces fungal burdens. This model should prove to be of significant value for testing the ability of both established and experimental therapeutics to inhibit C. albicans dissemination from the gastrointestinal tract in an immunocompromised host as well as the subsequent mortality that can result from disseminated candidiasis. C1 [Kadosh, David] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kadosh, D (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA. EM kadosh@uthscsa.edu FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272201000038I]; Voelcker Young Investigator Award from the Max and Minnie Tomerlin Voelcker Fund (Voelcker Fund) FX This work, including the efforts of Thomas F. Patterson, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) Task Order A13 (HHSN272201000038I). This work, including the efforts of David Kadosh, was funded by a Voelcker Young Investigator Award from the Max and Minnie Tomerlin Voelcker Fund (Voelcker Fund). NR 40 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2016 VL 60 IS 11 BP 6703 EP 6708 DI 10.1128/AAC.01144-16 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7QH UT WOS:000389063500029 PM 27572393 ER PT J AU Velasquez, GE Calderon, RI Mitnick, CD Becerra, MC Huang, CC Zhang, ZB Contreras, CC Yataco, RM Galea, JT Lecca, LW Murray, MB AF Velasquez, Gustavo E. Calderon, Roger I. Mitnick, Carole D. Becerra, Mercedes C. Huang, Chuan-Chin Zhang, Zibiao Contreras, Carmen C. Yataco, Rosa M. Galea, Jerome T. Lecca, Leonid W. Murray, Megan B. TI Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; RIFAMPIN RESISTANCE; DRUG-RESISTANCE; LIQUID CULTURE; SUSCEPTIBILITY; MUTATIONS; METAANALYSIS; THERAPY; COHORT; TESTS AB Phenotypic drug susceptibility testing is the current "gold standard" for detecting Mycobacterium tuberculosis susceptibility to antituberculous drugs. Pyrazinamide is one antituberculous drug for which the correlation between in vitro resistance and clinical outcomes remains unclear. Here we performed latent class analysis (LCA) to develop a consensus gold standard definition of pyrazinamide resistance using three paired standard pyrazinamide resistance assays. We then compared this consensus measure to the 2-month culture results for patients with multidrug-resistant tuberculosis (MDR-TB) who were treated for 2 months with first-line antituberculous drugs before their resistance results were known. Among 121 patients with MDR-TB, 60 (49.6%) were resistant to pyrazinamide by the Wayne method (L. G. Wayne, Am Rev Respir Dis 109: 147-151, 1974), 71 (58.7%) were resistant by the Bactec MGIT 960 method, and 68 (56.2%) were resistant by pncA sequencing. LCA grouped isolates with positive results by at least two assays into a category which we considered the "consensus gold standard" for pyrazinamide resistance. The sensitivity and specificity for this consensus gold standard were 82.4% and 92.5%, respectively, for the Wayne method; 95.6% and 88.7%, respectively, for the Bactec MGIT 960 method; and 92.6% and 90.6%, respectively, for pncA sequencing. After we adjusted for other factors associated with poor outcomes, including age, sex, alcohol use, and baseline ethambutol resistance, patients whose isolates were resistant by the LCA-derived consensus gold standard were more likely to be culture positive at 2 months with an odds ratio of 1.95 (95% confidence interval, 0.74 to 5.11), but this result was not statistically significant. These findings underscore the need for improved diagnostics for routine use in programmatic settings. C1 [Velasquez, Gustavo E.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. [Velasquez, Gustavo E.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Velasquez, Gustavo E.] Harvard Med Sch, Dept Med, Boston, MA USA. [Calderon, Roger I.; Mitnick, Carole D.; Becerra, Mercedes C.; Contreras, Carmen C.; Yataco, Rosa M.; Galea, Jerome T.; Lecca, Leonid W.; Murray, Megan B.] Partners Hlth Socios Salud, Boston, MA USA. [Calderon, Roger I.; Mitnick, Carole D.; Becerra, Mercedes C.; Contreras, Carmen C.; Yataco, Rosa M.; Galea, Jerome T.; Lecca, Leonid W.; Murray, Megan B.] Partners Hlth Socios Salud, Lima, Peru. [Mitnick, Carole D.; Becerra, Mercedes C.; Murray, Megan B.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA. [Mitnick, Carole D.; Becerra, Mercedes C.; Zhang, Zibiao; Murray, Megan B.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA USA. [Huang, Chuan-Chin] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA. [Murray, Megan B.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Murray, MB (reprint author), Partners Hlth Socios Salud, Boston, MA USA.; Murray, MB (reprint author), Partners Hlth Socios Salud, Lima, Peru.; Murray, MB (reprint author), Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA.; Murray, MB (reprint author), Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA USA.; Murray, MB (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. EM megan_murray@hms.harvard.edu OI Velasquez, Gustavo/0000-0003-1438-0692 FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [U19 AI076217, U01 AI057786, T32 AI007433, L30 AI120170] FX This work, including the efforts of Megan B. Murray, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (U19 AI076217). This work, including the efforts of Mercedes C. Becerra, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (U01 AI057786). This work, including the efforts of Gustavo E. Velasquez, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (T32 AI007433). This work, including the efforts of Gustavo E. Velasquez, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (L30 AI120170). NR 36 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2016 VL 60 IS 11 BP 6766 EP 6773 DI 10.1128/AAC.00632-16 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7QH UT WOS:000389063500037 PM 27600032 ER PT J AU Goel, S AF Goel, Shom TI BREAST CANCER IN 2016: WHERE TO FROM HERE? SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Goel, Shom] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goel, Shom] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 BP 67 EP 67 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900002 ER PT J AU Goel, S AF Goel, Shom TI ADVANCES IN THE MANAGEMENT OF HER2-POSITIVE BREAST CANCER SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Goel, Shom] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goel, Shom] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 BP 68 EP 68 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900006 ER PT J AU Goel, S AF Goel, Shom TI TARGETING THERAPEUTIC RESISTANCE IN HER2-POSITIVE BREAST CANCER SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Goel, Shom] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goel, Shom] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 56 BP 82 EP 82 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900057 ER PT J AU Goel, S AF Goel, Shom TI CDK4/6 INHIBITION IN BREAST CANCER: THE LATE HARVEST CYCLE BEGINS SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Goel, Shom] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goel, Shom] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 107 BP 96 EP 96 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900106 ER PT J AU Seah, D Robinson, D Churilov, L Lin, NU Lim, E AF Seah, Davinia Robinson, Danielle Churilov, Leonid Lin, Nancy U. Lim, Elgene TI ATTITUDES OF PATIENTS WITH METASTATIC CANCER TOWARD RESEARCH BIOPSIES SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Seah, Davinia] St Vincents Hosp Sydney, Sacred Heart Support & Palliat Care Serv, Darlinghurst, NSW, Australia. [Seah, Davinia] Univ Notre Dame Australia, Sch Med, Sydney, NSW, Australia. [Seah, Davinia; Lim, Elgene] Univ New South Wales, Sydney, NSW, Australia. [Robinson, Danielle] Austin Hlth, Heidelberg, Vic, Australia. [Churilov, Leonid] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia. [Lin, Nancy U.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lin, Nancy U.] Harvard Med Sch, Boston, MA USA. [Lim, Elgene] St Vincents Hosp, Med Oncol, Sydney, NSW, Australia. [Lim, Elgene] Garvan Inst Med Res, Sydney, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 188 BP 107 EP 108 PG 2 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900139 ER PT J AU Sznol, M Ferrucci, P Hogg, D Atkins, M Wolter, P Guidoboni, M Lebbe, C Kirkwood, J Schachter, J Daniels, G Hassel, J Cebon, J Gerritsen, W Atkinson, V Thomas, L Mccaffrey, J Power, D Jiang, J Hodi, S Wolchok, J AF Sznol, Mario Ferrucci, Pier Hogg, David Atkins, Michael Wolter, Pascal Guidoboni, Massimo Lebbe, Celeste Kirkwood, John Schachter, Jacob Daniels, Gregory Hassel, Jessica Cebon, Jonathan Gerritsen, Winald Atkinson, Victoria Thomas, Luc Mccaffrey, John Power, Derek Jiang, Joel Hodi, Stephen Wolchok, Jedd TI SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL) SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Sznol, Mario] Yale Canc Ctr, New Haven, CT USA. [Ferrucci, Pier] Ist Europeo Oncol, Milan, Italy. [Hogg, David] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Atkins, Michael] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. [Wolter, Pascal] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium. [Guidoboni, Massimo] IRCCS IRST, Immunotherapy & Somat Cell Therapy Unit, Meldola, Italy. [Lebbe, Celeste] Hop St Louis, Paris, France. [Kirkwood, John] Hillman Canc Ctr, Pittsburgh, PA USA. [Schachter, Jacob] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel. [Daniels, Gregory] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Hassel, Jessica] Univ Heidelberg Hosp, Dept Dermatol, Heidelberg, Germany. [Cebon, Jonathan] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Vic, Australia. [Gerritsen, Winald] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands. [Atkinson, Victoria] Gallipoli Med Res Fdn, Woolloongabba, Qld, Australia. [Atkinson, Victoria] Princess Alexandra Hosp, Woolloongabba, Qld, Australia. [Thomas, Luc] Ctr Hosp Lyon Sud, Dept Dermatol, Pierre Benite, France. [Mccaffrey, John] Irish Clin Oncol Res Grp, Dublin, Ireland. [Power, Derek] Irish Clin Onocl Reserach Grp, Cork, Ireland. [Jiang, Joel] Bristol Myers Squibb, Princeton, NJ USA. [Hodi, Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wolchok, Jedd] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 216 BP 118 EP 118 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900166 ER PT J AU Chapman, PB Sznol, M Lao, CD Gonzalez, R Daniels, GA Thompson, JA Kudchadkar, RR Sharfman, WH Atkins, MB Pavlick, AC Infante, JR Kim, KB Weber, JS Nair, S Cowey, L Lipson, EJ Lee, S Avila, A Hodi, S AF Chapman, Paul B. Sznol, Mario Lao, Christopher D. Gonzalez, Rene Daniels, Gregory A. Thompson, John A. Kudchadkar, Ragini R. Sharfman, William H. Atkins, Michael B. Pavlick, Anna C. Infante, Jeffrey R. Kim, Kevin B. Weber, Jeffrey S. Nair, Suresh Cowey, Lance Lipson, Evan J. Lee, Sue Avila, Alexandre Hodi, Stephen TI SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL) SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Chapman, Paul B.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Sznol, Mario] Yale Canc Ctr, New Haven, CT USA. [Lao, Christopher D.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Gonzalez, Rene] Univ Colorado, Ctr Canc, Denver, CO 80262 USA. [Daniels, Gregory A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Thompson, John A.] Univ Washington, Seattle, WA 98195 USA. [Kudchadkar, Ragini R.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Sharfman, William H.; Lipson, Evan J.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. [Pavlick, Anna C.] NYU, New York, NY USA. [Infante, Jeffrey R.] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. [Kim, Kevin B.] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA. [Weber, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Nair, Suresh] Lehigh Valley Hosp, Allentown, PA USA. [Cowey, Lance] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA. [Lee, Sue; Avila, Alexandre] Bristol Myers Squibb, Princeton, NJ USA. [Hodi, Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 219 BP 119 EP 119 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900169 ER PT J AU Chawla, S Offski, PS Grignani, G Blay, JY Maki, RG D'Adamo, DR Janevski, M Guo, M Demetri, GD AF Chawla, Sant Offski, Patrick Sch Grignani, Giovanni Blay, Jean-Yves Maki, Robert G. D'Adamo, David R. Janevski, Mile Guo, Matthew Demetri, George D. TI SUBTYPE-SPECIFIC ACTIVITY IN LIPOSARCOMA (LPS) PATIENTS (PTS) FROM A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF ERIBULIN (ERI) VERSUS DACARBAZINE (DTIC) IN PTS WITH ADVANCED LPS AND LEIOMYOSARCOMA (LMS) SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Chawla, Sant] Sarcoma Oncol Ctr, Santa Monica, CA USA. [Offski, Patrick Sch] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium. [Grignani, Giovanni] Fdn Piemonte Oncol IRCC, Dept Med Oncol, Turin, Italy. [Blay, Jean-Yves] Univ Claude Bernard, Lyon, France. [Blay, Jean-Yves] Ctr Leon Berard, Lyon, France. [Maki, Robert G.] Mt Sinai Med Ctr, Tisch Canc Inst, New York, NY 10029 USA. [D'Adamo, David R.; Guo, Matthew] Eisai Inc, Woodcliff Lake, NJ USA. [Janevski, Mile] Eisai Australia, Melbourne, Vic, Australia. [Demetri, George D.] Dana Farber Canc Inst, Sarcoma Ctr, Boston, MA 02115 USA. [Demetri, George D.] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA. [Demetri, George D.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 230 BP 123 EP 123 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900180 ER PT J AU Long, G Larkin, J Ascierto, P Hodi, S Rutkowski, P Chiarion-Selini, V Hassel, J Lebbe, C Pavlick, A Wagstaff, J Schadendorf, D Dummer, R Hogg, D Haanen, J Corrie, P Hoeller, C Horak, C Wolchok, J Robert, C AF Long, Georgina Larkin, James Ascierto, Paolo Hodi, Stephen Rutkowski, Piotr Chiarion-Selini, Vanna Hassel, Jessica Lebbe, Celeste Pavlick, Anna Wagstaff, John Schadendorf, Dirk Dummer, Reinhard Hogg, David Haanen, John Corrie, Pippa Hoeller, Christopher Horak, Christine Wolchok, Jedd Robert, Caroline TI PD-L1 EXPRESSION AS A BIOMARKER FOR NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) AND NIVO ALONE IN ADVANCED MELANOMA (MEL): A POOLED ANALYSIS SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Long, Georgina] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia. [Long, Georgina] Royal North Shore Hosp, Sydney, NSW, Australia. [Long, Georgina] Mater Hosp, Sydney, NSW, Australia. [Larkin, James] Royal Marsden Hosp, London, England. [Ascierto, Paolo] Ist Nazl Tumori Fdn Pascale, Naples, Italy. [Hodi, Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rutkowski, Piotr] Inst Im Marii Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland. [Chiarion-Selini, Vanna] Inst Oncol, Padua, Italy. [Hassel, Jessica] Univ Heidelberg Hosp, Dept Dermatol, Heidelberg, Germany. [Lebbe, Celeste] Hop St Louis, Paris, France. [Pavlick, Anna] NYU, New York, NY USA. [Wagstaff, John] South West Wales Canc Inst, Swansea, W Glam, Wales. [Wagstaff, John] Swansea Univ, Coll Med, Swansea, W Glam, Wales. [Schadendorf, Dirk] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany. [Dummer, Reinhard] Univ Spital, Zurich, Switzerland. [Hogg, David] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Haanen, John] Netherlands Canc Inst, Amsterdam, Netherlands. [Corrie, Pippa] Addenbrookes Hosp, Cambridge, England. [Hoeller, Christopher] Med Univ Vienna, Dept Dermatol, Vienna, Austria. [Horak, Christine] Bristol Myers Squibb, Princeton, NJ USA. [Wolchok, Jedd] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Robert, Caroline] Canc Inst Gustave Roussy, Villejuif, France. [Robert, Caroline] Paris Sud Univ, Villejuif, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 240 BP 126 EP 126 PG 1 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900189 ER PT J AU Wolchok, JD Chiarion-Sileni, V Gonzalez, R Rutkowski, P Grob, JJ Cowey, CL Lao, CD Schadendorf, D Ferrucci, PF Smylie, M Dummer, R Hill, A Haanen, J Maio, M McArthur, G Walker, D Jiang, J Horak, C Larkin, J Hodi, S AF Wolchok, Jedd D. Chiarion-Sileni, Vanna Gonzalez, Rene Rutkowski, Piotr Grob, Jean-Jacques Cowey, C. Lance Lao, Christopher D. Schadendorf, Dirk Ferrucci, Pier F. Smylie, Michael Dummer, Reinhard Hill, Andrew Haanen, John Maio, Michele McArthur, Grant Walker, Dana Jiang, Joel Horak, Christine Larkin, James Hodi, Stephen TI UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067) SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Chiarion-Sileni, Vanna] Oncol Inst Veneto IRCCS, Padua, Italy. [Gonzalez, Rene] Univ Colorado, Ctr Canc, Denver, CO USA. [Rutkowski, Piotr] Inst Im Marii Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland. [Grob, Jean-Jacques] Hop La Timone, Marseille, France. [Cowey, C. Lance] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA. [Lao, Christopher D.] Univ Michigan, Ann Arbor, MI 48109 USA. [Schadendorf, Dirk] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany. [Ferrucci, Pier F.] European Inst Oncol, Milan, Italy. [Smylie, Michael] Cross Canc Inst, Edmonton, AB, Canada. [Dummer, Reinhard] Univ Spital, Zurich, Switzerland. [Hill, Andrew] Tasman Oncol Res, Southport Gold Coast, Qld, Australia. [Haanen, John] Netherlands Canc Inst, Amsterdam, Netherlands. [Maio, Michele] Univ Hosp Siena, Siena, Italy. [McArthur, Grant] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Walker, Dana; Jiang, Joel; Horak, Christine] Bristol Myers Squibb, Princeton, NJ USA. [Larkin, James] Royal Marsden Hosp, London, England. [Hodi, Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 244 BP 127 EP 128 PG 2 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900193 ER PT J AU Postow, MA Chesney, J Pavlick, AC Robert, C Grossmann, K McDermott, D Linette, G Meyer, N Giguere, J Agarwala, SS Shaheen, M Ernstoff, MS Minor, DR Salama, A Taylor, MH Ott, PA Jiang, J Horak, C Wolchok, JD Hodi, S AF Postow, Michael A. Chesney, Jason Pavlick, Anna C. Robert, Caroline Grossmann, Kenneth McDermott, David Linette, Gerald Meyer, Nicolas Giguere, Jeffrey Agarwala, Sanjiv S. Shaheen, Montaser Ernstoff, Marc S. Minor, David R. Salama, April Taylor, Matthew H. Ott, Patrick A. Jiang, Joel Horak, Christine Wolchok, Jedd D. Hodi, Stephen TI TWO-YEAR OVERALL SURVIVAL (OS) RATES FROM A RANDOMIZED PHASE 2 TRIAL EVALUATING THE COMBINATION OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) VERSUS IPI IN PATIENTS WITH ADVANCED MELANOMA (MEL) SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Postow, Michael A.; Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Chesney, Jason] Univ Louisville, J Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Pavlick, Anna C.] NYU, New York, NY USA. [Robert, Caroline] Canc Inst Gustave Roussy, Villejuif, France. [Grossmann, Kenneth] Huntsman Canc Inst, Salt Lake City, UT USA. [McDermott, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Linette, Gerald] Washington Univ, St Louis, MO USA. [Meyer, Nicolas] Inst Univ Canc, Toulouse, France. [Giguere, Jeffrey] Greenville Hlth Syst, Greenville, SC USA. [Agarwala, Sanjiv S.] St Lukes Canc Ctr, Bethlehem, PA USA. [Shaheen, Montaser] Univ New Mexico, Albuquerque, NM 87131 USA. [Ernstoff, Marc S.] Cleveland Clin, Cleveland, OH 44106 USA. [Minor, David R.] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA. [Salama, April] Duke Univ, Med Ctr, Durham, NC USA. [Taylor, Matthew H.] Oregon Hlth & Sci Univ, Portland, OR USA. [Ott, Patrick A.; Hodi, Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jiang, Joel; Horak, Christine] Bristol Myers Squibb, Princeton, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 253 BP 130 EP 131 PG 2 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900202 ER PT J AU Robinson, B Schlumberger, M Wirth, LJ Dutcus, C Binder, T Guo, M Taylor, MH Kim, SB Krzyzanowska, MK Capdevila, J Sherman, SI Young, L Tahara, M AF Robinson, Bruce Schlumberger, Martin Wirth, Lori J. Dutcus, Corina Binder, Terri Guo, Matthew Taylor, Matthew H. Kim, Sung-Bae Krzyzanowska, Monika K. Capdevila, Jaume Sherman, Steven I. Young, Louise Tahara, Makoto TI RESPONSES IN SPECIFIC METASTASES FOLLOWING TREATMENT WITH LENVATINIB: RESULTS FROM THE PHASE 3 SELECT TRIAL SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Robinson, Bruce] Univ Sydney, Kolling Inst Med Res, Sydney, NSW, Australia. [Schlumberger, Martin] Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Villejuif, France. [Schlumberger, Martin] Univ Paris Sud, Villejuif, France. [Wirth, Lori J.] Massachusetts Gen Hosp, Dept Med, Boston, MA USA. [Dutcus, Corina; Binder, Terri; Guo, Matthew] Eisai Inc, Woodcliff Lake, NJ USA. [Taylor, Matthew H.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Kim, Sung-Bae] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea. [Krzyzanowska, Monika K.] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada. [Capdevila, Jaume] Vall dHebron Univ Hosp, VHIO, Med Oncol Dept, Barcelona, Spain. [Sherman, Steven I.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Div Internal Med, Houston, TX 77030 USA. [Young, Louise] Eisai Australia Pty Ltd, Melbourne, Vic, Australia. [Tahara, Makoto] Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, Kashiwa, Chiba, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD NOV PY 2016 VL 12 SU S5 MA 264 BP 134 EP 135 PG 2 WC Oncology SC Oncology GA EC0EE UT WOS:000387769900213 ER PT J AU Martin, J Walters, R Demontis, D Mattheisen, M Lee, H O'Donovan, M Robinson, E Franke, B Borglum, A Faraone, S Thapar, A Neale, B AF Martin, Joanna Walters, Raymond Demontis, Ditte Mattheisen, Manuel Lee, Hong O'Donovan, Michael Robinson, Elise Franke, Barbara Borglum, Anders Faraone, Stephen Thapar, Anita Neale, Benjamin TI Sex-specific genome-wide common variant analyses of attention deficit hyperactivity disorder SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 46th Annual Meeting of the Behavior-Genetics-Association CY JUN 20-23, 2016 CL Brisbane, AUSTRALIA SP Behav Genet Assoc C1 [Martin, Joanna; Walters, Raymond] Broad Inst, Cambridge, MA USA. [Demontis, Ditte; Mattheisen, Manuel; Borglum, Anders] Aarhus Univ, Aarhus, Denmark. [Lee, Hong] Queensland Inst Med Res, Brisbane, Qld, Australia. [O'Donovan, Michael; Thapar, Anita] Cardiff Univ, Cardiff, S Glam, Wales. [Robinson, Elise; Neale, Benjamin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Franke, Barbara] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands. [Faraone, Stephen] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. FU Wellcome Trust [106047] FX Wellcome Trust Grant No. 106047. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 EI 1573-3297 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2016 VL 46 IS 6 BP 795 EP 795 PG 1 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA EA6AJ UT WOS:000386706600084 ER PT J AU Neale, B AF Neale, Benjamin TI Challenges of scale in genetic analysis SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 46th Annual Meeting of the Behavior-Genetics-Association CY JUN 20-23, 2016 CL Brisbane, AUSTRALIA SP Behav Genet Assoc C1 [Neale, Benjamin] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 EI 1573-3297 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2016 VL 46 IS 6 BP 798 EP 798 PG 1 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA EA6AJ UT WOS:000386706600095 ER PT J AU Walters, R Mattheisen, M Demontis, D Daly, M Borglum, A Faraone, S Middeldorp, C Boomsma, D Neale, B AF Walters, Raymond Mattheisen, Manuel Demontis, Ditte Daly, Mark Borglum, Anders Faraone, Stephen Middeldorp, Christel Boomsma, Dorret Neale, Benjamin TI Integrating GWAS of ADHD and continuous ADHD-related traits SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 46th Annual Meeting of the Behavior-Genetics-Association CY JUN 20-23, 2016 CL Brisbane, AUSTRALIA SP Behav Genet Assoc C1 [Walters, Raymond] Broad Inst, Cambridge, MA USA. [Mattheisen, Manuel; Demontis, Ditte; Borglum, Anders] Aarhus Univ, Aarhus, Denmark. [Daly, Mark; Neale, Benjamin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Faraone, Stephen] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Middeldorp, Christel] Vrije Univ Amsterdam, Amsterdam, Netherlands. [Boomsma, Dorret] Vrije Univ Amsterdam, Amsterdam, Netherlands. NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 EI 1573-3297 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2016 VL 46 IS 6 BP 812 EP 813 PG 2 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA EA6AJ UT WOS:000386706600143 ER PT J AU Zheng, J Haycock, P Hemani, G Elsworth, B Shihab, H Laurin, C Erzurumluoglu, M Howe, L Wade, K Warrington, N Finucane, H Price, A Anttila, V Paternoster, L Martin, R Relton, C Gaunt, T Smith, GD Neale, B Evans, D AF Zheng, Jie Haycock, Philip Hemani, Gibran Elsworth, Benjamin Shihab, Hashem Laurin, Charles Erzurumluoglu, Mesut Howe, Laurence Wade, Kaitlin Warrington, Nicole Finucane, Hilary Price, Alkes Anttila, Verneri Paternoster, Lavinia Martin, Richard Relton, Caroline Gaunt, Tom Smith, George Davey Neale, Benjamin Evans, David TI LD hub and MR-base: online platforms for preforming LD score regression and Mendelian randomization analysis using GWAS summary data SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 46th Annual Meeting of the Behavior-Genetics-Association CY JUN 20-23, 2016 CL Brisbane, AUSTRALIA SP Behav Genet Assoc C1 [Zheng, Jie; Haycock, Philip; Hemani, Gibran; Elsworth, Benjamin; Shihab, Hashem; Laurin, Charles; Howe, Laurence; Wade, Kaitlin; Martin, Richard; Relton, Caroline; Gaunt, Tom; Smith, George Davey] Univ Bristol, Bristol, Avon, England. [Erzurumluoglu, Mesut] Univ Leicester, Leicester, Leics, England. [Warrington, Nicole; Evans, David] Univ Queensland, Brisbane, Qld, Australia. [Finucane, Hilary; Price, Alkes; Anttila, Verneri] MIT, Cambridge, MA 02139 USA. [Paternoster, Lavinia] Univ Bristol, MRC IEU, Bristol, Avon, England. [Neale, Benjamin] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 EI 1573-3297 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2016 VL 46 IS 6 BP 815 EP 815 PG 1 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA EA6AJ UT WOS:000386706600151 ER PT J AU Koo, H Hahn, SK Yun, SH AF Koo, Heebeom Hahn, Sei Kwang Yun, Seok Hyun TI Controlled Detachment of Chemically Glued Cells SO BIOCONJUGATE CHEMISTRY LA English DT Article ID CLICK CHEMISTRY; IN-VIVO; DELIVERY; MICELLES; RELEASE AB We demonstrate a chemically detachable cell glue system based on linkers containing disulfide bonds as well as functional groups for metabolic glycoengineering and bioorthogonal click chemistry. Azide groups are generated on the cell surface by metabolic glycoengineering, and they are further modified into tetrazine (Tz) or trans-cyclooctene (TCO) using rationally designed cross-linkers. When the Tz-modified and TCO-modified cells are mixed together, cell gluing between these two cell groups is established by Tz-TCO click chemistry. This artificial cell cell adhesion can be broken by the administration of glutathione (5 mM), which triggers the degradation of disulfide bonds. Both the gluing and detachment processes are rapid (<10 min) and minimally cytotoxic. C1 [Koo, Heebeom; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA. [Koo, Heebeom; Yun, Seok Hyun] Harvard Med Sch, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA. [Koo, Heebeom] Catholic Univ Korea, Coll Med, Dept Med Lifesci, 222 Banpo Daero, Seoul 137701, South Korea. [Hahn, Sei Kwang] Pohang Univ Sci & Technol, Dept Mat Sci & Engn, Kyungbuk 790784, South Korea. RP Yun, SH (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA.; Yun, SH (reprint author), Harvard Med Sch, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA. EM synn@hms.harvard.edu FU U.S. National Institutes of Health [R01-CA192878, P41-EB015903]; National Science Foundation [ECCS-1562863]; Department of Defense [FA9550-11-1-0331]; Future Planning [NRF-2011-0031644]; Basic Science Research Program by the Ministry of Education [2016R1C1B3013951]; Midcareer Researcher Program by the Ministry of Science through the National Research Foundation of Korea; National IT Industry Promotion Agency (IT Consilience Creative Program) [NIPA-2014-H0201-14-1001] FX This work was supported in part by the U.S. National Institutes of Health (R01-CA192878, P41-EB015903), National Science Foundation (ECCS-1562863), Department of Defense (FA9550-11-1-0331), the Future Planning (NRF-2011-0031644), Basic Science Research Program by the Ministry of Education (2016R1C1B3013951), and Midcareer Researcher Program by the Ministry of Science through the National Research Foundation of Korea, and National IT Industry Promotion Agency (IT Consilience Creative Program, NIPA-2014-H0201-14-1001). NR 20 TC 0 Z9 0 U1 4 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD NOV PY 2016 VL 27 IS 11 BP 2601 EP 2604 DI 10.1021/acs.bioconjchem.6b00546 PG 4 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA EC8ZD UT WOS:000388430700004 PM 27779857 ER PT J AU Blankenship, JC Abbott, BG Lindenfeld, J Wiegers, SE Rosenfield, K AF Blankenship, James C. Abbott, Brian G. Lindenfeld, Joann Wiegers, Susan E. Rosenfield, Ken TI Multi-Society Presidents' Page: The Value of Membership in Your Sub-Specialty Society SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material C1 [Blankenship, James C.] Geisinger Med Ctr, Soc Cardiovasc Angiog & Intervent, Dept Cardiol, Danville, PA 17822 USA. [Abbott, Brian G.] Cardiovasc Inst, Amer Soc Nucl Cardiol, East Greenwich, RI USA. [Lindenfeld, Joann] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Heart Failure Soc Amer, Nashville, TN USA. [Wiegers, Susan E.] Temple Univ, Lewis Katz Sch Med, Amer Soc Echocardiog, Philadelphia, PA 19122 USA. [Rosenfield, Ken] Massachusetts Gen Hosp, Soc Cardiovasc Angiog & Intervent, Boston, MA 02114 USA. RP Blankenship, JC (reprint author), Geisinger Med Ctr, Dept Cardiol, Danville, PA 17822 USA. EM jblan-kenship@geisinger.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD NOV PY 2016 VL 88 IS 5 BP 671 EP 673 DI 10.1002/ccd.26560 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7BV UT WOS:000388291700005 PM 27604039 ER PT J AU Feldman, DN Aronow, HD Swaminathan, RV Abbott, JD Tremmel, JA Kapur, NK Breinholt, JP Asgar, AW Pinto, DS Tu, TM Rosenfield, KM Naidu, SS AF Feldman, Dmitriy N. Aronow, Herbert D. Swaminathan, Rajesh V. Abbott, J. Dawn Tremmel, Jennifer A. Kapur, Navin K. Breinholt, John P. Asgar, Anita W. Pinto, Duane S. Tu, Thomas M. Rosenfield, Kenneth M. Naidu, Srihari S. TI Investing in our future: Update on the SCAI Emerging Leader Mentorship (ELM) Program SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material C1 [Feldman, Dmitriy N.] Weill Cornell Med Coll, New York, NY USA. [Aronow, Herbert D.; Abbott, J. Dawn] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Swaminathan, Rajesh V.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Tremmel, Jennifer A.] Stanford Univ, Med Ctr, Dept Med Cardiovasc, Stanford, CA 94305 USA. [Kapur, Navin K.] Tufts Med Ctr, Boston, MA USA. Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Asgar, Anita W.] Montreal Heart Inst, Montreal, PQ, Canada. [Pinto, Duane S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Tu, Thomas M.] Louisville Cardiol Grp, Intervent Cardiol, Louisville, KY USA. [Rosenfield, Kenneth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Naidu, Srihari S.] Winthrop Univ Hosp, Mineola, NY 11501 USA. RP Naidu, SS (reprint author), Winthrop Univ Hosp, Mineola, NY 11501 USA. EM SSNaidu@Winthrop.org NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD NOV PY 2016 VL 88 IS 5 BP 674 EP 677 DI 10.1002/ccd.26814 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7BV UT WOS:000388291700006 PM 27865069 ER PT J AU Chatterjee, S Yeh, RW Sardar, P Virk, HU Mukherjee, D Parikh, SA Kumbhani, DJ Kirtane, A Bashir, R Cohen, H Kolansky, DM Wilensky, RL Giri, J AF Chatterjee, Saurav Yeh, Robert W. Sardar, Partha Virk, Hafeez Ul Hassan Mukherjee, Debabrata Parikh, Sahil A. Kumbhani, Dharam J. Kirtane, Ajay Bashir, Riyaz Cohen, Howard Kolansky, Daniel M. Wilensky, Robert L. Giri, Jay TI Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE acute myocardial infarction; multi-vessel disease; percutaneous coronary intervention ID PERCUTANEOUS CORONARY INTERVENTION; 2011 ACCF/AHA/SCAI GUIDELINE; SEGMENT ELEVATION; RANDOMIZED-TRIALS; CLINICAL-OUTCOMES; DISEASE; REVASCULARIZATION; METAANALYSIS; CULPRIT; ANGIOPLASTY AB ObjectivesAppraisal of evidence for recommendations for multivessel coronary intervention in ST-elevation myocardial infarction (STEMI). BackgroundMulti-vessel disease (MVD) is common in patients with ST-segment elevation myocardial infarction (STEMI). Published observational data has suggested that multi-vessel percutaneous coronary intervention (MVPCI) at the time of initial hospitalization for STEMI may be harmful in contrast to evidence from recent randomized trials. MethodsWe queried the nationwide inpatient sample (NIS) to identify characteristics of hemodynamically stable STEMI patients undergoing MVPCI on index admission and subsequent mortality in raw and adjusted models. To compare our results with published observational data, we searched multiple databases from inception through July 15, 2015. ResultsFrom 2009-2012, excluding cardiac arrest or cardiogenic shock, there were 11,454 MVPCI and 157,011 single-vessel PCI (SVPCI) for STEMI patients in the NIS. Compared to SVPCI, MVPCI on index admission was not associated with higher in-hospital mortality in unadjusted or propensity-adjusted models (MVPCI 1.91% vs. SVPCI 5.32%, P<0.001). Our analysis of index hospitalization MVPCI versus infarct-related artery (IRA)only PCI in the meta-analysis of observational studies (19 studies, N=76,399) demonstrated no difference in in-hospital mortality with MVPCI compared with IRA-only PCI (OR 0.87, 95% CI 0.65-1.17; P=0.37), with confirmation in study sequential analysis. ConclusionsMVPCI is uncommonly performed during index hospitalization in hemodynamically stable STEMI patients, likely reflecting widespread adherence to prior guidelines. Based on observational data, there does not appear to be early harm associated with MVPCI on the index admission in hemodynamically stable STEMI patients. (c) 2016 Wiley Periodicals, Inc. C1 [Chatterjee, Saurav; Virk, Hafeez Ul Hassan] St Lukes Roosevelt Hosp Mt Sinai Hlth Syst, Div Cardiol, New York, NY USA. [Yeh, Robert W.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Sardar, Partha] Univ Utah, Div Cardiol, Salt Lake City, UT 84112 USA. [Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, El Paso, TX USA. [Parikh, Sahil A.] Univ Hosp Case Med Ctr, Harrington Heart & Vasc Inst, Cardiovasc Med Div, Cleveland, OH USA. [Parikh, Sahil A.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Kumbhani, Dharam J.] Univ Texas Southwestern Med Sch, Div Cardiol, Dallas, TX USA. [Kirtane, Ajay] Columbia Univ Med Ctr, New York Presbyterian Hosp, Herbert & Sandi Feinberg Intervent Cardiol & Hear, New York, NY USA. [Cohen, Howard] Temple Univ, Sch Med, Div Cardiol, Philadelphia, PA 19122 USA. [Kolansky, Daniel M.; Wilensky, Robert L.; Giri, Jay] Univ Penn, Perelman Sch Med, Cardiovasc Med Div, Philadelphia, PA 19104 USA. RP Giri, J (reprint author), Hosp Univ Penn, Cardiovasc Med Div, Gates Pavilion,9th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM giri.jay@gmail.com FU Abbott Vascular; Medtronic; Boston Scientific; Abiomed; St. Jude Medical; TriReme Medical; CR Bard; Medtronic Cardiovascular; Vascular Dynamics; Eli Lilly FX Dr. Yeh is on the advisory board for Abbott Vascular, is a consultant for Gilead Sciences, and is an investigator at the Harvard Clinical Research Institute. Dr. Parikh is a consultant and speaker for Abbott Vascular, Medtronic, Boston Scientific, Abiomed, CR Bard, AstraZeneca, Spectranetics and St. Jude Medical. He has received institutional research grants (to University Hospitals Case Medical Center) from Abbott Vascular, Medtronic, Boston Scientific, Abiomed, St. Jude Medical, TriReme Medical, and CR Bard. Dr. Kumbhani is a consultant for the American College of Cardiology. Dr. Kirtane has received institutional research grants (to Columbia University) from Medtronic Cardiovascular, Boston Scientific, Abiomed, Abbott Vascular, Vascular Dynamics, St. Jude Medical, and Eli Lilly. Dr. Wilensky is a member of the scientific advisory boards of Cardiostem, GenWay, Soteria, and Vascular Magnetics and has equity interest in Johnson & Johnson, Inc. Drs. Chatterjee, Virk, Sardar, Mukherjee, Bashir, Cohen, Kolansky and Giri have nothing relevant to disclose. NR 29 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD NOV PY 2016 VL 88 IS 5 BP 697 EP 707 DI 10.1002/ccd.26643 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7BV UT WOS:000388291700010 PM 27341605 ER PT J AU Meller, SM Al-Damluji, MS Gutierrez, A Stilp, E Mena-Hurtado, C AF Meller, Stephanie M. Al-Damluji, Mohammed Salim Gutierrez, Alejandra Stilp, Erik Mena-Hurtado, Carlos TI Carotid stenting versus endarterectomy for the treatment of carotid artery stenosis: Contemporary results from a large single center study SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE carotid artery revascularization; carotid artery stenosis; endovascular therapy ID EMBOLIC PROTECTION; CEREBRAL PROTECTION; HIGH-RISK; TRIAL; ANGIOPLASTY; REVASCULARIZATION; POPULATION; INFARCTION; OUTCOMES; DEVICES AB ObjectiveTo compare the complication rates associated with carotid endarterectomy (CEA) versus carotid artery stenting (CAS). BackgroundCarotid stenosis is a well-known cause of stroke and increased mortality. The safety of carotid revascularization may be related to symptom status, medical comorbidities, use of embolic protection devices, as well as operator experience and these factors may vary across patient populations within a single operating center. MethodsWe retrospectively analyzed patients with carotid artery stenosis admitted to our hospital for carotid revascularization between January 1, 2007 and December 1, 2013. The primary end point was a composite endpoint of periprocedural death, stroke, and myocardial infarction (MI). ResultsOf the 718 patients admitted for carotid revascularization 525 (73.1%) underwent CEA and 193 (26.9%) underwent CAS. Both groups demonstrated similar rates of the composite endpoint, MI, and death; the stenting group demonstrated a higher rate of stroke (4.2% vs. 1.3%; P=0.020). Adjusting for baseline medical comorbidities and symptom status mitigated this difference (P=0.091 and 0.113, respectively). When stratified by department performing CAS, there was a significant difference in the occurrence of stroke (P=0.033), which likewise disappeared in the multivariate regression analysis. ConclusionThe risk of the composite endpoint did not differ significantly between those undergoing CAS versus CEA. The stenting group demonstrated a higher rate of periprocedural stroke, which was also apparent when patients were stratified by stenting department. These differences were likely driven by variation in baseline medical comorbidities and symptom status. (c) 2016 Wiley Periodicals, Inc. C1 [Meller, Stephanie M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA. [Al-Damluji, Mohammed Salim] Univ Connecticut, Dept Internal Med, Farmington, CT USA. [Gutierrez, Alejandra; Stilp, Erik; Mena-Hurtado, Carlos] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, 333 Cedar St,DANA3 Cardiol, New Haven, CT 06510 USA. RP Mena-Hurtado, C (reprint author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, 333 Cedar St,DANA3 Cardiol, New Haven, CT 06510 USA. EM carlos.mena-hurtado@yale.edu NR 32 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD NOV PY 2016 VL 88 IS 5 BP 822 EP 830 DI 10.1002/ccd.26593 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7BV UT WOS:000388291700030 PM 27219323 ER PT J AU Boockvar, KS AF Boockvar, Kenneth S. TI Reducing Sedative-hypnotic Medication Use in Older Adults with Sleep Problems SO CLINICAL THERAPEUTICS LA English DT Editorial Material C1 [Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Boockvar, Kenneth S.] New Jewish Home, New York, NY 10025 USA. RP Boockvar, KS (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.; Boockvar, KS (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.; Boockvar, KS (reprint author), New Jewish Home, New York, NY 10025 USA. EM Kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2330 EP 2331 DI 10.1016/j.clinthera.2016.10.003 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000002 PM 27789042 ER PT J AU Culver, NC Song, YS McGowan, SK Fung, CH Mitchell, MN Rodriguez, JC Dzierzewski, JM Josephson, KR Jouldjian, S Washington, DL Yano, EM Schweizer, CA Alessi, CA Martin, JL AF Culver, Najwa C. Song, Yeonsu McGowan, Sarah Kate Fung, Constance H. Mitchell, Michael N. Carlos Rodriguez, Juan Dzierzewski, Joseph M. Josephson, Karen R. Jouldjian, Stella Washington, Donna L. Yano, Elizabeth M. Schweizer, C. Amanda Alessi, Cathy A. Martin, Jennifer L. TI Acceptability of Medication and Nonmedication Treatment for Insomnia Among Female Veterans: Effects of Age, Insomnia Severity, and Psychiatric Symptoms SO CLINICAL THERAPEUTICS LA English DT Article DE cognitive-behavioral therapy; female veterans; insomnia; medications; sleep; treatment acceptability ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; PHARMACOLOGICAL THERAPIES; PATIENT PREFERENCE; GOOD SLEEPERS; PREVALENCE; DEPRESSION; DISORDERS; DISSEMINATION AB Purpose: Female veterans are at high risk for sleep problems, and there is a need to provide effective treatment for this population who experience insomnia. This study's primary goal was to compare the acceptability of medication versus nonmedication treatments for insomnia among female veterans. In addition, we examined the role of patient age, severity of sleep disturbance, and psychiatric symptoms on acceptability of each treatment approach and on the differences in acceptability between these approaches. Methods: A large nationwide postal survey was sent to a random sample of 4000 female veterans who had received health care at a Veterans Administration (VA) facility in the previous 6 months (May 29, 2012 November 28, 2012). A total of 1559 completed surveys were returned. Survey items used for the current analyses included: demographic characteristics, sleep quality, psychiatric symptoms, military service experience, and acceptability of medication and non medication treatments for insomnia. For analysis, only ratings of "very acceptable" were used to indicate an interest in the treatment approach (vs ratings of "not at all acceptable," "a little acceptable," "somewhat acceptable," and "no opinion/don't know"). Findings: In the final sample of 1538 women with complete data, 57.7% rated nonmedication treatment as very acceptable while only 33.5% rated medication treatment as very acceptable. This difference was statistically significant for the group as a whole and when examining subgroups of patients based on age, sleep quality, psychiatric symptoms, and military experience. The percentage of respondents rating medication treatment as very acceptable was higher for women who were younger, had more severe sleep disturbances, had more psychiatric symptoms, who were not combat exposed, and who had experienced military sexual trauma. By contrast, the percentage of respondents rating nonmedication treatment as very acceptable differed only by age (younger women were more likely to find nonmedication treatment acceptable) and difficulty falling asleep. Implications: Female veterans are more likely to find nonmedication insomnia treatment acceptable compared with medication treatment. Thus, it is important to match these patients with effective behavioral interventions such as cognitive behavioral therapy for insomnia. Efforts to educate providers about these preferences and about the efficacy of cognitive behavioral therapy for insomnia may serve to connect female veterans who have insomnia to the treatment they prefer. These findings also suggest that older female veterans may be less likely to find either approach as acceptable as their younger counterparts. Published by Elsevier HS Journals, Inc. C1 [Culver, Najwa C.; Song, Yeonsu; McGowan, Sarah Kate; Fung, Constance H.; Mitchell, Michael N.; Carlos Rodriguez, Juan; Dzierzewski, Joseph M.; Josephson, Karen R.; Jouldjian, Stella; Alessi, Cathy A.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Song, Yeonsu; Fung, Constance H.; Washington, Donna L.; Schweizer, C. Amanda; Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Carlos Rodriguez, Juan] Pontificia Univ Catolica Chile, Dept Med, Santiago, Region Metropol, Chile. [Dzierzewski, Joseph M.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA. [Washington, Donna L.; Yano, Elizabeth M.; Schweizer, C. Amanda] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv, Res & Dev Ctr Study Healthcare Innovat Implementa, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Culver, NC (reprint author), 11E,16111 Plummer St, North Hills, CA 91343 USA. EM najwa.culver@va.gov FU VA Quality Enhancement Research Initiative (QUERI) [RRP 12-189]; Research Services, of the VA Greater Los Angeles Healthcare System; VAGLAHS Geriatric Research, Education and Clinical Center; VA Health Services Research and Development Service (Senior Research Career Scientist Award) [RCS 05-195] FX This research was supported the VA Quality Enhancement Research Initiative (QUERI; RRP 12-189; Principal Investigator: Dr. Martin), Research Services, of the VA Greater Los Angeles Healthcare System and VAGLAHS Geriatric Research, Education and Clinical Center; VA Health Services Research and Development Service (Senior Research Career Scientist Award, RCS 05-195; Principal Investigator: Dr. Yano). Preparation of this publication was also supported by the Office of Academic Affiliations, Department of Veterans Affairs. The authors thank Julia Yosef, MA, RN, Simone Vukelich, and Sergio Martinez for their assistance with the study. They thank Terry Vandenberg, MA, posthumously, for her many contributions to this project as well. NR 41 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2373 EP 2385 DI 10.1016/j.clinthera.2016.09.019 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000005 PM 28314434 ER PT J AU Johnson, TM Vaughan, CP Goode, PS Bliwise, DL Markland, AD Huisingh, C Redden, DT McGwin, G Eisenstein, R Ouslander, JG Issa, M Burgio, KL AF Johnson, Theodore M., II Vaughan, Camille P. Goode, Patricia S. Bliwise, Donald L. Markland, Alayne D. Huisingh, Carrie Redden, David T. McGwin, Gerald, Jr. Eisenstein, Rina Ouslander, Joseph G. Issa, Muta Burgio, Kathryn L. TI Pilot Results from a Randomized Trial in Men Comparing Alpha-Adrenergic Antagonist versus Behavior and Exercise for Nocturia and Sleep SO CLINICAL THERAPEUTICS LA English DT Article DE alpha-blocker; behavioral treatment and exercise therapy; nocturia; sleep disorder ID BENIGN PROSTATIC HYPERPLASIA; DWELLING OLDER-ADULTS; OVERACTIVE BLADDER; INCONTINENCE; ASSOCIATION; THERAPY; WOMEN; INDEX AB Purpose: Nocturia and sleep problems are common in older adults. We developed and tested a novel intervention, multicomponent behavioral treatment and exercise therapy (M-BET), that may reduce nocturia and improve sleep in men. We compared reductions in nocturia and improvement in sleep in men with M-BET versus an active drug comparator (alpha-blocker) used alone or in combination (M-BET + alpha-blocker) Methods: This randomized, controlled trial was conducted in the ambulatory setting in 2 US Department of Veterans Affairs medical centers in men at least 40 years of age with nocturia (defined as >= 2 nightly episodes). Participants were randomized to receive either M-BET, including pelvic floor muscle training, urge-suppression techniques, delayed voiding, fluid management, sleep hygiene, and peripheral edema management; an active comparator of known efficacy (the alpha-blocker tamsulosin, one 0.4-mg tablet nightly); or both therapies combined. Participants received interventions over 12 weeks. Outcomes were assessed via voiding diaries, wrist actigraphy, and validated questionnaires. The primary outcome was change in diary-recorded nocturia, assessed using ANCOVA for the between-group changes and paired t tests for within-group changes. Findings: A total of 72 men with a mean age of 65.8 years participated. At 12 weeks, mean diary recorded nocturia changed with M-BET by 1.39 episodes/night (P < 0.001), with alpha-blocker therapy by -0.59 episodes/night (P < 0.01), and with combination therapy by -1.03 episodes/night (P < 0.01). Reductions were not statistically different across treatment groups (P = 0.41). M-BET also showed statistically significant improvements in sleep quality, bother from nocturia, and nocturia-specific quality of life. All treatment groups indicated global satisfaction with treatment. Implications: Behavioral therapy in men, alone or combined with a-blocker therapy, consistently showed large and statistically significant nocturia reductions and favorable effects on sleep and quality of life. Based on these findings, behavioral therapy, while not statistically superior to alpha-blocker therapy, may provide a meaningful treatment option for men with nocturia. Future research should include the development of behavioral treatment and exercise therapy interventions that could be more easily deployed. Published by Elsevier HS Journals, Inc. C1 [Johnson, Theodore M., II; Vaughan, Camille P.; Eisenstein, Rina; Ouslander, Joseph G.] Atlanta VAMC, Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Decatur, GA USA. [Johnson, Theodore M., II; Vaughan, Camille P.; Eisenstein, Rina; Ouslander, Joseph G.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Goode, Patricia S.; Markland, Alayne D.; Redden, David T.; McGwin, Gerald, Jr.; Burgio, Kathryn L.] Birmingham VAMC, Birmingham Atlanta GRECC, Birmingham, AL USA. [Goode, Patricia S.; Markland, Alayne D.; Burgio, Kathryn L.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Bliwise, Donald L.] Emory Univ, Sch Med, Dept Neurol, Program Sleep Aging & Chronobiol, Atlanta, GA 30322 USA. [Huisingh, Carrie; McGwin, Gerald, Jr.] Dept Epidemiol, Birmingham, AL USA. [Redden, David T.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Issa, Muta] Atlanta Vet Affairs Med Ctr VAMC, Dept Urol, Decatur, GA USA. RP Johnson, TM (reprint author), Birmingham Atlanta GRECC, Wesley Woods Ctr, Floor 5,1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM tmjohns@emory.edu OI Markland, Alayne/0000-0002-6567-6744 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Services [E6110-R] FX This work was funded by the US Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Services grant E6110-R (T.M.J., K.B., P.G., A.M., D.R., C.V.). The Department of Veterans Affairs did not exert control over the design and conduct of the study; the collection, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. NR 38 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2394 EP 2406 DI 10.1016/j.clinthera.2016.10.001 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000007 ER PT J AU Carballo, NJ Alessi, CA Martin, JL Mitchell, MN Hays, RD Col, N Patterson, ES Jouldjian, S Josephson, K Fung, CH AF Carballo, Nancy J. Alessi, Cathy A. Martin, Jennifer L. Mitchell, Michael N. Hays, Ron D. Col, Nananda Patterson, Emily S. Jouldjian, Stella Josephson, Karen Fung, Constance H. TI Perceived Effectiveness, Self-efficacy, and Social Support for Oral Appliance Therapy Among Older Veterans With Obstructive Sleep Apnea SO CLINICAL THERAPEUTICS LA English DT Article DE attitude to health; oral appliance therapy; patient reported measures; sleep apnea syndromes ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIALS; CPAP ADHERENCE; RATED HEALTH; METAANALYSIS; UPDATE; ADULTS; USERS AB Purpose: Obstructive sleep apnea is a prevalent sleep disorder among older adults. Oral appliances are increasingly prescribed as therapy for obstructive sleep apnea. Adherence to oral appliance therapy is highly variable. Based on value-expectancy theory and other social psychological theories, adherence to oral appliance therapy may be influenced by patients' perceived effectiveness of the therapy, self-efficacy, and availability of social support. We examined these perceptions among older adults with obstructive sleep apnea who were prescribed oral appliance therapy. Methods: We mailed surveys to all patients aged >= 65 years who had been prescribed oral appliance therapy for obstructive sleep apnea over the prior 36 months at a Veterans Affairs medical center. We examined frequencies of responses to items that assessed perceived effectiveness, self-efficacy, and social support for nightly use of oral appliances from friends, family, or health care staff. Findings: Thirty-nine individuals responded (response rate, 30%; mean [SD] age 71.4 [SD 6.3] years; 97% male). Thirty-six percent of the respondents perceived regular use of oral appliance therapy to be effective in managing obstructive sleep apnea; 39% agreed that they felt confident about using oral appliances regularly; 41% felt supported by people in their life in using oral appliance therapy; and 38% agreed that health care staff would help them to use their oral appliance regularly. These rates represented less than half of respondents despite the finding that 65% of patients believed that they would use their oral appliance regularly. Implications: Although oral appliance therapy is increasingly prescribed for obstructive sleep apnea, only about one third of older adults prescribed it perceived it to be an effective treatment, were confident about oral appliance use, and/or believed that they would receive needed support. Future research is needed to better understand older adults' perceptions so that interventions can be designed to improve the effectiveness of oral appliances, their self-efficacy for using oral appliances, and their social support for this therapy, which may, in turn, improve oral appliance therapy adherence. Published by Elsevier HS Journals, Inc. C1 [Carballo, Nancy J.; Alessi, Cathy A.; Martin, Jennifer L.; Mitchell, Michael N.; Jouldjian, Stella; Josephson, Karen; Fung, Constance H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Alessi, Cathy A.; Hays, Ron D.; Fung, Constance H.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Col, Nananda] Univ New England, Ctr Excellence Neurosci, Biddeford, ME USA. [Patterson, Emily S.] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA. [Carballo, Nancy J.; Alessi, Cathy A.; Martin, Jennifer L.; Fung, Constance H.] Univ Calif Los Angelesz, David Geffen Sch Med, Los Angeles, CA USA. RP Fung, CH (reprint author), Univ Calif Los Angeles, Los Angeles, CA USA.; Fung, CH (reprint author), VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. EM constance.fung@va.gov FU NIH National Institute on Aging (NIA) [K23AG045937]; Beeson Career Development in Aging Research Award Program; NIA; American Federation for Aging Research (AFAR) AFAR; John A. Hartford Foundation; Atlantic Philanthropies FX This work was supported by NIH National Institute on Aging (NIA) award K23AG045937 and the Beeson Career Development in Aging Research Award Program (supported by NIA, American Federation for Aging Research (AFAR) AFAR, the John A. Hartford Foundation, and the Atlantic Philanthropies). NR 23 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2016 VL 37 IS 11 BP 2407 EP 2415 DI 10.1016/j.clinthera.2016.09.008 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED9EM UT WOS:000389173000008 PM 27751674 ER PT J AU Ventura, MI Barnes, DE Ross, JM Lanni, KE Sigvardt, KA Disbrow, EA AF Ventura, Maria I. Barnes, Deborah E. Ross, Jessica M. Lanni, Kimberly E. Sigvardt, Karen A. Disbrow, Elizabeth A. TI A pilot study to evaluate multi-dimensional effects of dance for people with Parkinson's disease SO Contemporary Clinical Trials LA English DT Article DE Parkinson's disease; Dance; Rehabilitation; Quality of life ID QUALITY-OF-LIFE; TEST-RETEST RELIABILITY; MINI-MENTAL-STATE; EXERCISE; VALIDITY; MOTOR; INDIVIDUALS; VALIDATION; TRIAL; NEUROPLASTICITY AB Parkinson's disease (PD) is a progressive neurodegenerative disease associated with deficits in motor, cognitive, and emotion/quality of life (QOL) domains, yet most pharmacologic and behavioral interventions focus only on motor function. Our goal was to perform a pilot study of Dance for Parkinson's-a community-based program that is growing-in popularity in order to compare effect sizes across multiple outcomes and to inform selection of primary and secondary outcomes for a larger trial. Study participants were people with PD who self-enrolled in either Dance for Parkinson's classes (intervention group, N = 8) or PD support groups (control group, N = 7). Assessments of motor function (Timed-Up-and-Go, Gait Speed, Standing Balance Test), cognitive function (Test of Everyday Attention, Verbal Fluency, Alternate Uses, Digit Span Forward and Backward), and emotion/QOL (Geriatric Depression Scale, Falls Efficacy Scale-International, Parkinson's Disease Questionnaire-39 (total score and Activities of Daily Living subscale)) were performed in both groups at baseline and follow-up. Standardized effect sizes were calculated within each group and between groups for all 12 measures. Effect sizes were positive (suggesting improvement) for all 12 measures within the intervention group and 7 of 12 measures within the control group. The largest between-group differences were observed for the Test of Everyday Attention (a measure of cognitive switching), gait speed and falls efficacy. Our findings suggest that dance has potential to improve multiple outcomes in people with PD. Future trials should consider co-primary outcomes given potential benefits in motor, cognitive and emotion/QOL domains. (C) 2016 Elsevier Inc. All rights reserved. C1 [Ventura, Maria I.; Barnes, Deborah E.] UC, Dept Epidemiol & Biostat, San Francisco, CA USA. [Barnes, Deborah E.] UC San Francisco, Dept Psychiat, San Francisco, CA USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, Mental Hlth Res Serv, San Francisco, CA USA. [Ross, Jessica M.] UC Merced, Dept Cognit Sci, Merced, CA USA. [Lanni, Kimberly E.] William Jessup Univ, Dept Psychol, Rocklin, CA USA. [Sigvardt, Karen A.] Univ Calif Davis, Dept Neurol, Davis, CA USA. [Disbrow, Elizabeth A.] LSU Hlth Sci Ctr Shreveport, Dept Neurol, POB 33932, Shreveport, LA 71130 USA. RP Disbrow, EA (reprint author), LSU Hlth Sci Ctr Shreveport, Dept Neurol, POB 33932, Shreveport, LA 71130 USA. EM edisbr@lsuhsc.edu FU Neuroscience Scholars Program Fellowship; UC Office of the President Dissertation Year Fellowship (UC Davis Dept. of Psychology); NIH [5-T32-AG000212, 1-T32-AG049663]; NINDS [R01NS064040]; Department of Veterans Affairs [1I01RX000181, 1I01RX001507]; Alzheimer's Association [NPSASA-15-364656]; S.D. Bechtel, Jr. Foundation FX This study was performed as part of the first author's doctoral dissertation in Psychology/Cognitive Neuroscience at the University of California, Davis. The authors would like to thank all participants who graciously volunteered their time to take part in this study; Ruth Rosenberg, Artist Engagement Coordinator for the Robert & Margrit Mondavi Center for the Performing Arts; Pamela Trokanski, director of the Pamela Trokanski Dance Theatre; and our Dance for PD (R) supporters from the Mark Morris Dance Group. We would also like to thank Christine Lee, RN and Hoang Nguyen for their contributions to the project MIV was supported by a Neuroscience Scholars Program Fellowship, UC Office of the President Dissertation Year Fellowship (UC Davis Dept. of Psychology), NIH grants 5-T32-AG000212 and 1-T32-AG049663. EAD was supported by grants from the NINDS (R01NS064040) and the Department of Veterans Affairs (1I01RX000181). DEB was supported in part by the Alzheimer's Association (NPSASA-15-364656), Department of Veterans Affairs (1I01RX001507), the S.D. Bechtel, Jr. Foundation and philanthropic support from the Osher Center for Integrative Medicine at UCSF. NR 54 TC 1 Z9 1 U1 17 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2016 VL 51 BP 50 EP 55 DI 10.1016/j.cct.2016.10.001 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA ED9BW UT WOS:000389166100007 PM 27765693 ER PT J AU Kelmenson, LB Demoruelle, MK Deane, KD AF Kelmenson, Lindsay B. Demoruelle, M. Kristen Deane, Kevin D. TI The Complex Role of the Lung in the Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Rheumatoid arthritis; Lung; Anti-citrullinated protein antibodies; Rheumatoid factor ID RESOLUTION COMPUTED-TOMOGRAPHY; CYCLIC CITRULLINATED PEPTIDES; EXTRAARTICULAR MANIFESTATIONS; INTERSTITIAL PNEUMONIA; MUCOSAL INFLAMMATION; PULMONARY-FIBROSIS; INCREASED RISK; DISEASE; ANTIBODIES; AUTOANTIBODIES AB While the primary manifestation of rheumatoid arthritis (RA) is articular disease, extra-articular disease may also occur. In particular, pulmonary disease is a frequent extra-articular manifestation of seropositive RA and a leading cause of morbidity and mortality in this population. This review will highlight studies published in the last several years and will, in particular, discuss the relationship of antibodies to citrullinated protein/peptide antigens (ACPA) and lung disease in patients with RA. We will also review the data regarding the potential role of the lung and generation of RA-related autoantibodies in a period of disease development termed "preclinical RA." Finally, we will discuss the role of ACPA and other Abs in non-RA pulmonary diseases and discuss a research agenda for next steps in the understanding and management of the lung in RA. C1 [Kelmenson, Lindsay B.; Demoruelle, M. Kristen; Deane, Kevin D.] Univ Colorado Denver, Div Rheumatol, 1635 Aurora Court,MS F721, Aurora, CO 80045 USA. [Deane, Kevin D.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kelmenson, LB (reprint author), Univ Colorado Denver, Div Rheumatol, 1635 Aurora Court,MS F721, Aurora, CO 80045 USA. EM lindsay.kelmenson@ucdenver.edu FU NIH [AR-07534, AR066712]; Rheumatology Research & Education Foundation; VA Accreditation Council for Graduate Medical Education Enhancement Award FX LBK and MKD were supported by the NIH grants (AR-07534, AR066712) and the Rheumatology Research & Education Foundation. In addition, LBK was supported in part by funding through a VA Accreditation Council for Graduate Medical Education Enhancement Award. NR 76 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD NOV PY 2016 VL 18 IS 11 AR 69 DI 10.1007/s11926-016-0618-4 PG 10 WC Rheumatology SC Rheumatology GA ED4QX UT WOS:000388836400004 PM 27796844 ER PT J AU Chen, QJ Yang, ZY Wang, CY Dong, LM Zhang, YS Xie, C Chen, CZ Zhu, SK Yang, HJ Wu, HS Yang, C AF Chen, Qi-Jun Yang, Zhi-Yong Wang, Chun-You Dong, Li-Ming Zhang, Yu-Shun Xie, Chao Chen, Chang-Zhong Zhu, Shi-Kai Yang, Hong-Ji Wu, He-Shui Yang, Chong TI Hydroxyethyl starch resuscitation downregulate pro-inflammatory cytokines in the early phase of severe acute pancreatitis: A retrospective study SO EXPERIMENTAL AND THERAPEUTIC MEDICINE LA English DT Article DE hydroxyethyl starch; severe acute pancreatitis; cytokine; fluid balance; renal function ID CRITICALLY-ILL PATIENTS; INTRAABDOMINAL HYPERTENSION; FLUID RESUSCITATION; DISEASE SEVERITY; RINGERS ACETATE; SEVERE SEPSIS; INTERLEUKIN-6; METAANALYSIS; ASSOCIATION; ENDOTOXEMIA AB In the present study, we investigated the effects of hydroxyethyl starch (HES) 130/0.4 on serum pro-inflammatory variables, immunologic variables, fluid balance (FB)-negative(-) rate and renal function in severe acute pancreatitis (SAP) patients. From October, 2007 to November, 2008, a total of 120 SAP patients were enrolled in this retrospective study. Fifty-nine patients in the HES group received 6% HES 130/0.4 combined with crystalloid solution for fluid resuscitation (HES group). In the control group, 61 patients received only crystalloid solution after admission. Interleukin (IL)-1, IL-6, IL-8 and tumor necrosis factor (TNF)-alpha levels in serum were measured on days 1, 2, 4 and 8. The peripheral blood CD4(+)CD8(+) T lymphocyte rates, serum BUN and Cr values were also measured on days 1, 4 and 8. Patients with FB(-) rates were recorded from day 1 to 8. Interaction term analysis (hospital stay and fluid resuscitation methods) based on mixed-effects regression model revealed significantly lower levels of IL-1 and TNF-alpha in the HES group compared with the control group. The difference in curve's risk ratio was not significant for IL-6, CD4(+)CD8(+) T lymphocyte rate, BUN and Cr values (P>0.05). In the HES group, we detected a significantly higher rate of patients with FB(-) from day 4 to 8 (P<0.05). Thus, HES 130/0.4 resuscitation could decrease the IL-1 and IL-8 levels, shorten the duration of positive FB, and preserve the patient's immune status as well as renal function during the early phase of SAP. C1 [Chen, Qi-Jun; Yang, Zhi-Yong; Wang, Chun-You; Dong, Li-Ming; Zhang, Yu-Shun; Xie, Chao; Wu, He-Shui] Huazhong Univ Sci & Technol, Pancreat Dis Inst, Union Hosp, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China. [Chen, Chang-Zhong] Dana Farber Canc Inst, Microarray Core Facil, Boston, MA 02138 USA. [Zhu, Shi-Kai; Yang, Hong-Ji; Yang, Chong] Hosp Univ Elect Sci & Technol China, Organ Transplantat Ctr, 32 West Second Section First Ring Rd, Chengdu 610072, Sichuan, Peoples R China. [Zhu, Shi-Kai; Yang, Hong-Ji; Yang, Chong] Sichuan Prov Peoples Hosp, 32 West Second Section First Ring Rd, Chengdu 610072, Sichuan, Peoples R China. RP Wu, HS (reprint author), Huazhong Univ Sci & Technol, Pancreat Dis Inst, Union Hosp, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Yang, C (reprint author), Hosp Univ Elect Sci & Technol China, Organ Transplantat Ctr, 32 West Second Section First Ring Rd, Chengdu 610072, Sichuan, Peoples R China.; Yang, C (reprint author), Sichuan Prov Peoples Hosp, 32 West Second Section First Ring Rd, Chengdu 610072, Sichuan, Peoples R China. EM heshuiwu1@163.com; hong_yang1212@163.com NR 48 TC 0 Z9 0 U1 0 U2 0 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1792-0981 EI 1792-1015 J9 EXP THER MED JI Exp. Ther. Med. PD NOV PY 2016 VL 12 IS 5 BP 3213 EP 3220 DI 10.3892/etm.2016.3744 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED4ME UT WOS:000388822000065 PM 27882140 ER PT J AU Robertson, AL Avagyan, S Gansner, JM Zon, LI AF Robertson, Anne L. Avagyan, Serine Gansner, John M. Zon, Leonard I. TI Understanding the regulation of vertebrate hematopoiesis and blood disorders - big lessons from a small fish SO FEBS LETTERS LA English DT Review DE blood disorders; hematopoietic stem cells; zebrafish ID DIAMOND-BLACKFAN-ANEMIA; STEM-CELL EMERGENCE; ACUTE MYELOID-LEUKEMIA; RIBOSOMAL-PROTEIN S19; L-LEUCINE IMPROVES; CLASS-I GENES; DEFINITIVE HEMATOPOIESIS; TRANSCRIPTION FACTOR; HEMOGENIC ENDOTHELIUM; ZEBRAFISH EMBRYOS AB Hematopoietic stem cells (HSCs) give rise to all differentiated blood cells. Understanding the mechanisms that regulate self-renewal and lineage specification of HSCs is key for developing treatments for many human diseases. Zebrafish have emerged as an excellent model for studying vertebrate hematopoiesis. This review will highlight the unique strengths of zebrafish and important findings that have emerged from studies of blood development and disorders using this system. We discuss recent advances in our understanding of hematopoiesis, including the origin of HSCs, molecular control of their development, and key signaling pathways involved in their regulation. We highlight significant findings from zebrafish models of blood disorders and discuss their application for investigating stem cell dysfunction in disease and for the development of new therapeutics. C1 [Robertson, Anne L.; Avagyan, Serine] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Robertson, Anne L.; Gansner, John M.; Zon, Leonard I.] Harvard Med Sch, Boston, MA USA. [Avagyan, Serine] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gansner, John M.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA. [Zon, Leonard I.] Boston Childrens Hosp, Harvard Stem Cell Inst, Howard Hughes Med Inst, Boston, MA USA. RP Zon, LI (reprint author), Karp Res Bldg,7th Floor,300 Longwood Ave, Boston, MA 02115 USA. EM zon@enders.tch.harvard.edu FU NHLBI NIH HHS [T32 HL116324] NR 162 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-5793 EI 1873-3468 J9 FEBS LETT JI FEBS Lett. PD NOV PY 2016 VL 590 IS 22 SI SI BP 4016 EP 4033 DI 10.1002/1873-3468.12415 PG 18 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA ED4KN UT WOS:000388816900006 PM 27616157 ER PT J AU Chen, DD Taylor, KP Hall, Q Kaplan, JM AF Chen, Didi Taylor, Kelsey P. Hall, Qi Kaplan, Joshua M. TI The Neuropeptides FLP-2 and PDF-1 Act in Concert To Arouse Caenorhabditis elegans Locomotion SO GENETICS LA English DT Article DE Caenorhabditis elegans; orexin; PDF; sleep; lethargus ID SLEEP-LIKE STATE; C. ELEGANS; BEHAVIORAL QUIESCENCE; SOCIAL-BEHAVIOR; NERVOUS-SYSTEM; RECEPTOR; CIRCUIT; NEURONS; MECHANISMS; NARCOLEPSY AB During larval molts, Caenorhabditis elegans exhibits a sleep-like state (termed lethargus) that is characterized by the absence of feeding and profound locomotion quiescence. The rhythmic pattern of locomotion quiescence and arousal linked to the molting cycle is mediated by reciprocal changes in sensory responsiveness, whereby arousal is associated with increased responsiveness. Sensory neurons arouse locomotion via release of a neuropeptide (PDF-1) and glutamate. Here we identify a second arousing neuropeptide (FLP-2). We show that FLP-2 acts via an orexin-like receptor (FRPR-18), and that FLP-2 and PDF-1 secretion are regulated by reciprocal positive feedback. These results suggest that the aroused behavioral state is stabilized by positive feedback between two neuropeptides. C1 [Chen, Didi; Taylor, Kelsey P.; Hall, Qi; Kaplan, Joshua M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Chen, Didi; Taylor, Kelsey P.; Hall, Qi; Kaplan, Joshua M.] Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA. [Taylor, Kelsey P.; Kaplan, Joshua M.] Harvard Med Sch, Biol & Biomed Sci Program, Boston, MA 02115 USA. [Chen, Didi] UT Southwest Med Ctr, Dept Microbiol, Dallas, TX 75390 USA. RP Kaplan, JM (reprint author), Dept Mol Biol, Simches 7,185 Cambridge St, Boston, MA 02114 USA. EM Kaplan@molbio.mgh.harvard.edu FU National Science Foundation predoctoral fellowship; National Institutes of Health research grant [DK-80215] FX We thank the following for strains, advice, reagents, and comments on the manuscript: the Caenorhabditis Genetics Center (CGC) and S. Mitani for strains, O. Hobert for sharing the strains expressing the cho-1 and eat-4 reporter constructs, and members of the Kaplan lab for comments on the manuscript. This work was supported by a National Science Foundation predoctoral fellowship to K.P.T., and by a National Institutes of Health research grant to J.M.K. (DK-80215). NR 47 TC 0 Z9 0 U1 4 U2 4 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 EI 1943-2631 J9 GENETICS JI Genetics PD NOV PY 2016 VL 204 IS 3 BP 1151 EP + DI 10.1534/genetics.116.192898 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA EC9ZN UT WOS:000388502900026 PM 27585848 ER PT J AU Xu, JG Wang, HD Won, SJ Basu, J Kapfhamer, D Swanson, RA AF Xu, Jianguo Wang, Handong Won, Seok Joon Basu, Jayinee Kapfhamer, David Swanson, Raymond A. TI Microglial Activation Induced by the Alarmin S100B is Regulated by Poly(ADP-ribose) Polymerase-1 SO GLIA LA English DT Article DE stroke; trauma; astrocyte; PARP-1; nitric oxide; MMP9; veliparib ID TRAUMATIC BRAIN-INJURY; GENE-EXPRESSION; INHIBITION; NEUROINFLAMMATION; VELIPARIB; SIGNAL; PARPS; HMGB1 AB Brain injury resulting from stroke or trauma can be exacerbated by the release of proinflammatory cytokines, proteases, and reactive oxygen species by activated microglia. The microglial activation resulting from brain injury is mediated in part by alarmins, which are signaling molecules released from damaged cells. The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been shown to regulate microglial activation after brain injury, and here we show that signaling effects of the alarmin S100B are regulated by PARP-1. S100B is a protein localized predominantly to astrocytes. Exogenous S100B added to primary microglial cultures induced a rapid change in microglial morphology, upregulation of IL-1 beta, TNF alpha, and iNOS gene expression, and release of matrix metalloproteinase 9 and nitric oxide. Most, though not all of these effects were attenuated in PARP-1(-/-) microglia and in wild-type microglia treated with the PARP inhibitor, veliparib. Microglial activation and gene expression changes induced by S100B injected directly into brain were likewise attenuated by PARP-1 inhibition. The anti-inflammatory effects of PARP-1 inhibitors in acutely injured brain may thus be mediated in part through effects on S100B signaling pathways. C1 [Xu, Jianguo; Wang, Handong] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, Nanjing, Jiangsu, Peoples R China. [Xu, Jianguo; Won, Seok Joon; Basu, Jayinee; Kapfhamer, David; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Xu, Jianguo; Won, Seok Joon; Basu, Jayinee; Kapfhamer, David; Swanson, Raymond A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Swanson, RA (reprint author), VAMC, Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM Raymond.Swanson@ucsf.edu FU U.S. Department of Veterans Affairs; National Institutes of Health [NS041421]; China Scholarship Council FX Grant sponsor: U.S. Department of Veterans Affairs (RAS).; Grant sponsor: the National Institutes of Health; Grant numbers: NS041421 (RAS); the China Scholarship Council (JX) NR 40 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 EI 1098-1136 J9 GLIA JI Glia PD NOV PY 2016 VL 64 IS 11 BP 1869 EP 1878 DI 10.1002/glia.23026 PG 10 WC Neurosciences SC Neurosciences & Neurology GA EA6PR UT WOS:000386751600005 PM 27444121 ER PT J AU Melamed, A Hinchcliff, EM Clemmer, JT Bregar, AJ Uppal, S Bostock, I Schorge, JO del Carmen, MG Rauh-Hain, JA AF Melamed, Alexander Hinchcliff, Emily M. Clemmer, Joel T. Bregar, Amy J. Uppal, Shitanshu Bostock, Ian Schorge, John O. del Carmen, Marcela G. Rauh-Hain, J. Alejandro TI Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Neoadjuvant chemotherapy; Advanced ovarian cancer; Temporal trends ID PRIMARY DEBULKING SURGERY; GYNECOLOGIC-ONCOLOGY-GROUP; CYTOREDUCTIVE SURGERY; JOINPOINT REGRESSION; CHANGING PATTERNS; CARCINOMA; SURVIVAL; TRIAL AB Objective. Neoadjuvant chemotherapy and interval debulking surgery for the treatment of advanced ovarian cancer has remained controversial, despite the publication of two randomized trials comparing this modality. with primary cytoreductive surgery. This study describes temporal trends in the utilization of neoadjuvant chemotherapy and interval debulking surgery in clinical practice in the United States. Methods. We completed a time trend analysis of the National Cancer Data Base. We identified women with stage IIIC and IV epithelial ovarian cancer diagnosed between 2004 and 2013. We categorized subjects as having undergone one of four treatment modalities: primary cytoreductive surgery followed by adjuvant chemotherapy, neoadjuvant chemotherapy followed by interval debulking surgery, surgery only, and chemotherapy only. Temporal trends in the frequency of treatment modalities were evaluated using Joinpoint regression, and X-2 tests. Results. We identified 40,694 women meeting inclusion criteria, of whom 27,032 (66.4%) underwent primary cytoreductive surgery and adjuvant chemotherapy, 5429 (13.3%) received neoadjuvant chemotherapy and interval surgery, 5844 (15.4%) had surgery only, and 2389 (5.9%) received chemotherapy only. The proportion of women receiving neoadjuvant chemotherapy and surgery increased from 8.6% to 22.6% between 2004 and 2013 (p < 0.001), and adoption of this treatment modality occurred primarily after 2007 (95%CI 2006-2009; p = 0.001). During this period, the proportion of women who received primary cytoreductive surgery and chemotherapy declined from 68.1% to 60.8% (p < 0.001), and the proportion who underwent surgery only declined from 17.8% to 9.9% (p < 0.001). Conclusion. Between 2004 and 2013 the frequency of neoadjuvant chemotherapy and interval surgery increased significantly in the United States. (C) 2016 Elsevier Inc. All rights reserved. C1 [Melamed, Alexander; Hinchcliff, Emily M.; Clemmer, Joel T.; Bregar, Amy J.; Schorge, John O.; del Carmen, Marcela G.; Rauh-Hain, J. Alejandro] Harvard Med Sch, Div Gynecol Oncol Vincent Obstet & Gynecol, Massachusetts Gen Hosp, Boston, MA USA. [Uppal, Shitanshu] Univ Michigan, Div Gynecol Oncol Obstet & Gynecol, Ann Arbor, MI 48109 USA. [Bostock, Ian] Dartmouth Hitchcock Med Ctr, Dept Surg, Lebanon, NH 03766 USA. RP Melamed, A (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, 55 Fruit St,Founders 5, Boston, MA 02114 USA. EM amelamed@partners.org OI Melamed, Alexander/0000-0002-0654-0863 FU National Cancer Institute at the National Institutes of Health [R25CA092203]; Deborah Kelly Center for Outcomes Research at Massachusetts General Hospital FX This work is supported by grant R25CA092203 from the National Cancer Institute at the National Institutes of Health, and the Deborah Kelly Center for Outcomes Research at Massachusetts General Hospital. This study was presented at the Society for Gynecologic Oncology's Annual Meeting on Women's Cancer, San Diego, CA, March 19-22, 2016. NR 33 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD NOV PY 2016 VL 143 IS 2 BP 236 EP 240 DI 10.1016/j.ygyno.2016.09.002 PG 5 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EA6MS UT WOS:000386743900004 PM 27612977 ER PT J AU Hay, CM Courtney-Brooks, M Lefkowits, C Hagan, TL Edwards, RP Donovan, HS AF Hay, Casey M. Courtney-Brooks, Madeleine Lefkowits, Carolyn Hagan, Teresa L. Edwards, Robert P. Donovan, Heidi S. TI Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important? SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Symptom management; Recurrent ovarian cancer; Palliative; Communication ID COMMON TERMINOLOGY CRITERIA; ADVERSE EVENTS; QUESTIONNAIRE; TRIAL; CARE AB Objective. We sought to compare symptoms identified as a priority by patients with recurrent ovarian cancer to symptoms most frequently documented by their clinicians, and examine the association between clinician documentation of symptoms and subsequent clinical intervention. Methods. Single-institution, retrospective chart review of patients enrolled in WRITE Symptoms Study (GOG 259), a randomized controlled trial of internet-based recurrent ovarian cancer symptom management. As part of the trial, women completed the Symptom Representation Questionnaire for 28 symptoms and selected 3 priority symptoms (PS). We compared patient-reported PS to clinician documentation of symptoms and interventions over the time period corresponding to study enrollment. Results. At least one PS was documented in 92% of patients. Of 150 PS reported by patients, 53% were never documented by clinicians; these symptoms tended to be less directly related to disease or treatment status. Symptoms not identified by patients as PS were frequently documented by clinicians; these symptoms tended to relate to physiologic effects of disease and treatment toxicity. 58% of patients had at least one PS intervention. PS intervened for were documented at 2.58 visits vs 0.50 visits for PS not receiving intervention (p <= 0.0001). Conclusions. Discordance was identified between symptoms reported by patients as important and symptoms documented by clinicians. Symptoms more frequently documented were also more frequently intervened for. Our study illustrates the need to improve identification of symptoms important to patients, and suggests that improving communication between patients and clinicians could increase intervention rates to enhance quality of life in women with recurrent ovarian cancer. (C) 2016 Elsevier Inc. All rights reserved. C1 [Hay, Casey M.; Courtney-Brooks, Madeleine; Edwards, Robert P.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Div Gynecol Oncol,Dept Obstet Gynecol & Reprod Sc, 300 Halket St, Pittsburgh, PA 15213 USA. [Lefkowits, Carolyn] Univ Colorado Denver, Div Gynecol Oncol, 1665 Aurora Court, Aurora, CO 80045 USA. [Hagan, Teresa L.; Donovan, Heidi S.] Univ Pittsburgh, Sch Nursing, 415 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA. [Hagan, Teresa L.] Harvard Med Sch, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. RP Hay, CM (reprint author), Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Gynecol Oncol, 300 Halket St, Pittsburgh, PA 15213 USA. EM haycm2@upmc.edu FU NINR NIH HHS [R01 NR010735] NR 14 TC 1 Z9 1 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD NOV PY 2016 VL 143 IS 2 BP 367 EP 370 DI 10.1016/j.ygyno.2016.08.235 PG 4 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EA6MS UT WOS:000386743900025 PM 27531571 ER PT J AU Barber, SR Kozin, ED Dedmon, M Lin, BM Lee, K Sinha, S Black, N Remenschneider, AK Lee, DJ AF Barber, Samuel R. Kozin, Elliott D. Dedmon, Matthew Lin, Brian M. Lee, Kyuwon Sinha, Sumi Black, Nicole Remenschneider, Aaron K. Lee, Daniel J. TI 3D-printed pediatric endoscopic ear surgery simulator for surgical training SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY LA English DT Article DE Endoscopic ear surgery; Transcanal endoscopic ear surgery; Simulator; 3D printing; Surgical simulation ID RANDOMIZED-CONTROLLED-TRIAL; INGUINAL-HERNIA REPAIR; TEMPORAL BONE; VIRTUAL-REALITY; OPERATING-ROOM; PERFORMANCE; MODEL; PARTICIPATION; TECHNOLOGY; VALIDATION AB Introduction: Surgical simulators are designed to improve operative skills and patient safety. Transcanal Endoscopic Ear Surgery (TEES) is a relatively new surgical approach with a slow learning curve due to one-handed dissection. A reusable and customizable 3-dimensional (3D)-printed endoscopic ear surgery simulator may facilitate the development of surgical skills with high fidelity and low cost. Herein, we aim to design, fabricate, and test a low-cost and reusable 3D-printed TEES simulator. Methods: The TEES simulator was designed in computer-aided design (CAD) software using anatomic measurements taken from anthropometric studies. Cross sections from external auditory canal samples were traced as vectors and serially combined into a mesh construct. A modified tympanic cavity with a modular testing platform for simulator tasks was incorporated. Components were fabricated using calcium sulfate hemihydrate powder and multiple colored infiltrants via a commercial inkjet 3D-printing service. Results: All components of a left-sided ear were printed to scale. Six right-handed trainees completed three trials each. Mean trial time (n = 3) ranged from 23.03 to 62.77 s using the dominant hand for all dissection. Statistically significant differences between first and last completion time with the dominant hand (p < 0.05) and average completion time for junior and senior residents (p < 0.05) suggest construct validity. Conclusions: A 3D-printed simulator is feasible for TEES simulation. Otolaryngology training programs with access to a 3D printer may readily fabricate a TEES simulator, resulting in inexpensive yet highfidelity surgical simulation. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Barber, Samuel R.; Kozin, Elliott D.; Dedmon, Matthew; Lin, Brian M.; Lee, Kyuwon; Sinha, Sumi; Remenschneider, Aaron K.; Lee, Daniel J.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA USA. [Barber, Samuel R.; Kozin, Elliott D.; Dedmon, Matthew; Lin, Brian M.; Lee, Kyuwon; Sinha, Sumi; Remenschneider, Aaron K.; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Black, Nicole] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Black, Nicole] Harvard Univ, Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA. RP Kozin, ED (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Elliott_Kozin@meei.harvard.edu NR 25 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-5876 EI 1872-8464 J9 INT J PEDIATR OTORHI JI Int. J. Pediatr. Otorhinolaryngol. PD NOV PY 2016 VL 90 BP 113 EP 118 DI 10.1016/j.ijporl.2016.08.027 PG 6 WC Otorhinolaryngology; Pediatrics SC Otorhinolaryngology; Pediatrics GA EA6KM UT WOS:000386738100021 PM 27729115 ER PT J AU Carrico, AW Zepf, R Meanley, S Batchelder, A Stall, R AF Carrico, Adam W. Zepf, Roland Meanley, Steven Batchelder, Abigail Stall, Ronald TI When the Party is Over: A Systematic Review of Behavioral Interventions for Substance-Using Men Who Have Sex with Men SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Review DE alcohol use; behavioral interventions; HIV; men who have sex with men; substance use; systematic review ID RANDOMIZED CONTROLLED-TRIAL; HIV TRANSMISSION RISK; MULTICENTER AIDS COHORT; PSYCHOSOCIAL HEALTH-PROBLEMS; HUMAN-IMMUNODEFICIENCY-VIRUS; BISEXUAL MEN; STIMULANT USE; CONTINGENCY MANAGEMENT; DISEASE PROGRESSION; POSITIVE MEN AB Because problematic patterns of alcohol and other substance use are prevalent drivers of the HIV/AIDS epidemic, comprehensive interventions are needed for substance-using men who have sex with men (SUMSM). We conducted a systematic review of 12 randomized controlled trials (RCTs) of behavioral interventions for reducing condomless anal intercourse (CAI) in SUMSM. Three RCTs observed that cognitive behavioral or motivational interviewing interventions achieved a 24% to 40% decrease in CAI. Interventions also tended to demonstrate greater efficacy for reducing CAI and substance use among those who had lower severity of substance use disorder symptoms. Although behavioral interventions for SUMSM are one potentially important component of biobehavioral HIV/AIDS prevention, further research is needed to examine whether integrative approaches that cultivate resilience and target co-occurring syndemic conditions demonstrate greater efficacy. Multilevel intervention approaches are also needed to optimize the effectiveness of pre-exposure prophylaxis and HIV treatment as prevention with SUMSM. C1 [Carrico, Adam W.; Zepf, Roland] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Carrico, Adam W.] Univ Calif San Francisco, Sch Med, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. [Meanley, Steven; Stall, Ronald] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Sci, Pittsburgh, PA USA. [Batchelder, Abigail] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. RP Carrico, AW (reprint author), Univ Calif San Francisco, Sch Nursing, 2 Koret Way,N511M, San Francisco, CA 94143 USA. EM adam.carrico@ucsf.edu FU National Institute on Drug Abuse (NIDA) [R01-DA033854]; National Institute of Mental Health (NIMH) [T32-MH094174] FX Supported by the National Institute on Drug Abuse (NIDA), R01-DA033854 (Carrico & Moskowitz, PIs) and the National Institute of Mental Health (NIMH), T32-MH094174 (Stall, PI). NR 86 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2016 VL 73 IS 3 BP 299 EP 306 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7KV UT WOS:000389044000016 PM 27258233 ER PT J AU Roberts, ST Haberer, J Celum, C Mugo, N Ware, NC Cohen, CR Tappero, JW Kiarie, J Ronald, A Mujugira, A Tumwesigye, E Were, E Irungu, E Baeten, JM AF Roberts, Sarah T. Haberer, Jessica Celum, Connie Mugo, Nelly Ware, Norma C. Cohen, Craig R. Tappero, Jordan W. Kiarie, James Ronald, Allan Mujugira, Andrew Tumwesigye, Elioda Were, Edwin Irungu, Elizabeth Baeten, Jared M. CA Partners PrEP Study Team TI Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE intimate partner violence; pre-exposure prophylaxis; adherence; HIV prevention ID TENOFOVIR DISOPROXIL FUMARATE; POISSON REGRESSION APPROACH; CHILD SEXUAL-ABUSE; SUB-SAHARAN AFRICA; OF-THE-LITERATURE; ANTIRETROVIRAL PROPHYLAXIS; MEDICATION ADHERENCE; HEALTHY-VOLUNTEERS; DOMESTIC VIOLENCE; MICROBICIDE TRIAL AB Background: Intimate partner violence (IPV) is associated with higher HIV incidence, reduced condom use, and poor adherence to antiretroviral therapy and other medications. IPV may also affect adherence to pre-exposure prophylaxis (PrEP). Methods: We analyzed data from 1785 HIV-uninfected women enrolled in a clinical trial of PrEP among African HIV serodiscordant couples. Experience of verbal, physical, or economic IPV was assessed at monthly visits by face-to-face interviews. Low PrEP adherence was defined as clinic-based pill count coverage <80% or plasma tenofovir levels <40 ng/mL. The association between IPV and low adherence was analyzed using generalized estimating equations, adjusting for potential confounders. In-depth interview transcripts were examined to explain how IPV could impact adherence. Results: Sixteen percent of women reported IPV during a median of 34.8 months of follow-up (interquartile range 27.0-35.0). Overall, 7% of visits had pill count coverage <80%, and 32% had plasma tenofovir <40 ng/mL. Women reporting IPV in the past 3 months had increased risk of low adherence by pill count (adjusted risk ratio 1.49, 95% confidence interval: 1.17 to 1.89) and by plasma tenofovir (adjusted risk ratio 1.51, 95% confidence interval: 1.06 to 2.15). Verbal, economic, and physical IPV were all associated with low adherence. However, the impact of IPV diminished and was not statistically significant 3 months after the reported exposure. In qualitative interviews, women identified several ways in which IPV affected adherence, including stress and forgetting, leaving home without pills, and partners throwing pills away. Conclusions: Women who reported recent IPV in the Partners PrEP Study were at increased risk of low PrEP adherence. Strategies to mitigate PrEP nonadherence in the context of IPV should be evaluated. C1 [Roberts, Sarah T.; Celum, Connie; Mujugira, Andrew; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Haberer, Jessica] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Haberer, Jessica] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Haberer, Jessica; Ware, Norma C.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA. [Celum, Connie; Mugo, Nelly; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA. [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Mugo, Nelly] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Ware, Norma C.] Brigham & Womens Hosp, Dept Med, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA. [Cohen, Craig R.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kiarie, James] Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya. [Ronald, Allan] Univ Manitoba, Dept Med, Winnipeg, MB, Canada. [Tumwesigye, Elioda] Kabwohe Clin Res Ctr, Kabwohe, Uganda. [Were, Edwin] Moi Univ, Dept Reprod Hlth, Eldoret, Kenya. [Irungu, Elizabeth] Kenyatta Natl Hosp, Nairobi, Kenya. RP Roberts, ST (reprint author), Univ Washington, Int Clin Res Ctr, 325 Ninth Ave,Box 359927, Seattle, WA 98104 USA. EM str24@uw.edu FU Bill & Melinda Gates Foundation [OPP47674]; US National Institutes of Health [R01 MH095507, T32 AI007140, F31 MH107258]; ARCS Foundation Seattle Chapter Endowment Fund FX Supported by research Grants from the Bill & Melinda Gates Foundation (OPP47674), the US National Institutes of Health (R01 MH095507, T32 AI007140, F31 MH107258), and the ARCS Foundation Seattle Chapter Endowment Fund. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the National Institutes of Health or Centers for Disease Control and Prevention. NR 70 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2016 VL 73 IS 3 BP 313 EP 322 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7KV UT WOS:000389044000018 PM 27243900 ER PT J AU Smeltzer, SC Mitra, M Iezzoni, LI Long-Bellil, L Smith, LD AF Smeltzer, Suzanne C. Mitra, Monika Iezzoni, Lisa I. Long-Bellil, Linda Smith, Lauren D. TI Perinatal Experiences of Women With Physical Disabilities and Their Recommendations for Clinicians SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Article DE physical disabilities; pregnant women; unmet perinatal health care needs; women with disabilities ID QUALITATIVE DESCRIPTION; MOBILITY DISABILITY; CURRENT PREGNANCY; US WOMEN; HEALTH; CARE; ACCESSIBILITY AB Objective: To explore the perinatal experiences of women with physical disabilities (WWPD) and their associated recommendations for maternity care clinicians to improve care. Design: A mixed-methods study was conducted with a semistructured interview guide to identify the experiences of WWPD. This qualitative descriptive study was part of a larger study of the unmet needs and barriers to perinatal care experienced by WWPD Setting: Telephone interview. Participants: Twenty-five women with physical disabilities who gave birth within the last 10 years and were 21 to 55 years of age were recruited and agreed to participate in the study. Methods: Participants were asked about their interactions with clinicians during pregnancy and their recommendations for clinicians to improve perinatal care for women with physical disabilities. Content analysis was used to analyze transcribed interviews. Themes that emerged from analysis of the interviews were identified and coded. Kurasaski's coding was used to establish the reliability of the coding. Results: Three themes emerged from analysis of the interview data: Clinicians' lack of knowledge about pregnancy-related needs of WWPD; Clinicians' failure to consider women's knowledge, experience, and expertise about their own disabilities; and Clinicians' lack of awareness of the reproductive concerns of WWPD. Women provided recommendations that warrant attention from clinicians who provide perinatal care for women who live with physical disabilities. Conclusion: Participants experienced problematic interactions with clinicians related to pregnancy and identified recommendations for maternity care clinicians to address those problems with the goal of improving perinatal health care for WWPD. C1 [Smeltzer, Suzanne C.] Villanova Univ, Ctr Nursing Res, Coll Nursing, 800 Lancaster Ave, Villanova, PA 19085 USA. [Mitra, Monika; Smith, Lauren D.] Brandeis Univ, Lurie Inst Disabil Policy, Heller Sch Social Policy & Management, Waltham, MA USA. [Iezzoni, Lisa I.] Harvard Med Sch, Mongan Inst Hlth Policy, Massachusetts Gen Hosp, Boston, MA USA. [Long-Bellil, Linda] Univ Massachusetts, Ctr Hlth Policy & Res, Sch Med, Shrewsbury, MA USA. RP Smeltzer, SC (reprint author), Villanova Univ, Ctr Nursing Res, Coll Nursing, 800 Lancaster Ave, Villanova, PA 19085 USA. EM suzanne.smeltzer@villanova.edu FU NICHD NIH HHS [R01 HD074581] NR 26 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0884-2175 EI 1552-6909 J9 JOGNN-J OBST GYN NEO JI JOGNN PD NOV-DEC PY 2016 VL 45 IS 6 BP 781 EP 789 DI 10.1016/j.jogn.2016.07.007 PG 9 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA ED4UF UT WOS:000388846500005 PM 27619410 ER PT J AU Madanat, R Rolfson, O Donahue, GS Hussey, DK Potter, HG Wallace, R Muratoglu, OK Malchau, H AF Madanat, Rami Rolfson, Ola Donahue, Gabrielle S. Hussey, Daniel K. Potter, Hollis G. Wallace, Robert Muratoglu, Orhun K. Malchau, Henrik TI Medial Calcar Erosion Is Associated With Synovial Thickness in Patients With ASR XL Total Hip Arthroplasty SO JOURNAL OF ARTHROPLASTY LA English DT Article DE calcar erosion; synovial thickness; metal-on-metal; hip arthroplasty; adverse local tissue reaction ID MODULAR-NECK; IMAGING FINDINGS; CORROSION; TISSUE; MRI; REVISION AB Background: Medial calcar erosion is considered a late finding in patients with severe adverse local tissue reactions (ALTRs) after total hip arthroplasty (THA) with dual modular neck stems. Although calcar erosion has been associated with dual modular neck stems, one would expect similar findings in standard stems owing to analogous corrosion at the taper junction. The aim of this study was to evaluate whether medial calcar erosion is also associated with ALTR in patients with standard stems in metal-on-metal (MoM) THA. Methods: A total of 96 patients (108 hips) with MoM THA had radiographs and a magnetic resonance imaging of the hip performed at a mean time of 5.7 years after surgery. Calcar erosion was assessed from radiographs. ALTR Anderson grade, diameter, volume, and synovial thickness were assessed from magnetic resonance imaging. Results: Calcar erosion was present in 54 hips (50%) and was associated with ALTR synovial thickness but not with Anderson grade, diameter, or volume. Most of the hips with calcar erosion (n = 45) had an ALTR (positive predictive value 0.83, 95% confidence interval 0.70-0.92). The relative risk of having a synovial thickness > 3 mm increased by a factor of 3.0 (95% confidence interval 1.3-6.5) if calcar erosion was observed. Conclusion: Subtle erosions of the medial calcar after MoM THA may be an early indicator of an adverse reaction to wear particles warranting cross-sectional imaging. Synovial thickness may also be more relevant than absolute size in the classification of ALTR severity and collateral tissue damage. (C) 2016 Elsevier Inc. All rights reserved. C1 [Madanat, Rami; Rolfson, Ola; Donahue, Gabrielle S.; Hussey, Daniel K.; Muratoglu, Orhun K.; Malchau, Henrik] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Lab, Boston, MA 02114 USA. [Madanat, Rami; Rolfson, Ola; Muratoglu, Orhun K.; Malchau, Henrik] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA. [Potter, Hollis G.] Hosp Special Surg, Dept Radiol & Imaging, 535 E 70th St, New York, NY 10021 USA. [Wallace, Robert] Sportsmed SA, Dept Orthopaed Surg, Stepney, SA, Australia. RP Malchau, H (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, 55 Fruit St,GRJ 1126, Boston, MA 02114 USA. FU DePuy Orthopaedics, Warsaw, Indiana (MGH) [2012P000554] FX This study was supported by DePuy Orthopaedics, Warsaw, Indiana (MGH #2012P000554). The authors thank Clinical Research Project Manager Slav Lerner from MGH for his help with the study and Marc Bragdon from MGH for technical assistance. NR 20 TC 0 Z9 0 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD NOV PY 2016 VL 31 IS 11 BP 2588 EP 2592 DI 10.1016/j.arth.2016.04.005 PG 5 WC Orthopedics SC Orthopedics GA EA6OG UT WOS:000386747900040 PM 27178012 ER PT J AU van Leeuwen, WF van Hoorn, BTJA Chen, N Ring, D AF van Leeuwen, W. F. van Hoorn, B. T. J. A. Chen, N. Ring, D. TI Kirschner wire pin site infection in hand and wrist fractures: incidence rate and risk factors SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME LA English DT Article DE Kirschner wire; k-wire; fracture; skeletal fixation; percutaneous; infection; hand; wrist ID ANTIBIOTIC-PROPHYLAXIS; CLOSED REDUCTION; FIXATION; OUTCOMES; SURGERY; COMPLICATIONS AB Kirschner wires are widely used for skeletal fixation of unstable fractures, but the pin tracks create a potential pathway through the skin and into the bone for bacteria to cause an infection. We tested the null hypothesis that there are no demographic, patient-related, injury, or treatment variables independently associated with the occurrence of pin site infection after percutaneous fixation of hand and wrist fractures using Kirschner wires. A retrospective review of 1213 patients with one or more fractures of the hand and wrist treated with percutaneous Kirschner wire fixation identified 85 patients (7%) who had additional treatment with oral antibiotics, early pin removal, or reoperation related to a pin site infection. We found no factors were independently associated with higher or lower risks of pin site infection in multivariable logistic regression analysis. Pin site infections - most benign - occur in a notable number of patients and we could not identify any modifiable risk factors. Level of Evidence: III C1 [van Leeuwen, W. F.; van Hoorn, B. T. J. A.; Chen, N.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA USA. [Ring, D.] Univ Texas Austin, Dept Surg & Perioperat Care, Austin, TX USA. RP Ring, D (reprint author), Univ Texas Austin, Dept Surg & Perioperat Care, Dell Med Sch, 1400 Barbara Jordan Blvd,Suite 1-114AC,MC R1800, Austin, TX 78723 USA. EM david.ring@austin.utexas.edu NR 18 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-1934 EI 2043-6289 J9 J HAND SURG-EUR VOL JI J. Hand Surg.-Eur. Vol. PD NOV PY 2016 VL 41 IS 9 BP 990 EP 994 DI 10.1177/1753193416661280 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA EA7YH UT WOS:000386848600016 PM 27464583 ER PT J AU Weingarden, H Renshaw, KD Wilhelm, S Tangney, JP DiMauro, J AF Weingarden, Hilary Renshaw, Keith D. Wilhelm, Sabine Tangney, June P. DiMauro, Jennifer TI Anxiety and Shame as Risk Factors for Depression, Suicidality, and Functional Impairment in Body Dysmorphic Disorder and Obsessive Compulsive Disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Body dysmorphic disorder; obsessive compulsive disorder; shame; anxiety; depression ID SENSITIVITY COGNITIVE CONCERNS; STRESS SCALES DASS; QUALITY-OF-LIFE; CLINICAL-FEATURES; PSYCHOMETRIC PROPERTIES; COMORBID CONDITIONS; SYMPTOM DIMENSIONS; MAJOR DEPRESSION; MENTAL-HEALTH; SELF-REPORT AB Body dysmorphic disorder (BDD) and obsessive compulsive disorder (OCD) are associated with elevated depression, suicidality, functional impairment, and days housebound, yet little research has identified risk factors for these outcomes. Using path analysis, the present study examined anxiety and shame as risk factors for these outcomes across Internet-recruited self-report groups (BDD [n = 114], OCD[n = 114], and healthy control [HC; n = 133]). Paths from anxiety and shame to outcomes were similar and mostly significant across BDD and OCD, compared to non-significant paths for HCs, with one exception: the path from shame to depression was significant in the BDD group (b = 0.32) but non-significant in the OCD group (b = 0.07). Findings underscore similarities in BDD and OCD, supporting their reclassification into the same Obsessive Compulsive Related Disorders category. Results emphasize the importance of targeting shame, in addition to anxiety, in treatments for BDD and OCD. C1 [Weingarden, Hilary; Renshaw, Keith D.; Tangney, June P.; DiMauro, Jennifer] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA. [Weingarden, Hilary; Wilhelm, Sabine] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. RP Weingarden, H (reprint author), 185 Cambridge St,Suite 2000, Boston, MA 02114 USA. EM hilary_weingarden@mgh.harvard.edu FU NIMH of the National Institutes of Health [1F31MH100845-01A1] FX This research was supported by the NIMH of the National Institutes of Health under award number 1F31MH100845-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 72 TC 0 Z9 0 U1 10 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD NOV PY 2016 VL 204 IS 11 BP 832 EP 839 DI 10.1097/NMD.0000000000000498 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EC8QV UT WOS:000388408500006 PM 26998694 ER PT J AU Heit, JJ Gonzalez, RG Sabbag, D Brouwers, HB Rubiano, EGO Schaefer, PW Hirsch, JA Romero, JM AF Heit, Jeremy J. Gonzalez, R. Gilberto Sabbag, David Brouwers, H. Bart Rubiano, Edgar Gerardo Ordonez Schaefer, Pamela W. Hirsch, Joshua A. Romero, Javier M. TI Detection and characterization of intracranial aneurysms: a 10-year multidetector CT angiography experience in a large center SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article AB Background CT angiography (CTA) is increasingly used for the detection, characterization, and follow-up of intracranial aneurysms. A lower threshold to request a CT angiogram may render a patient population that differs from previous studies primarily evaluated with conventional angiography. Our objective was to broaden our knowledge of the factors associated with aneurysm rupture and patient mortality in this population. Methods All CTA studies performed over a 10-year period at a large neurovascular referral center were reviewed for the presence of an intracranial aneurysm. Patient demographics, mortality, CTA indication, aneurysm location, size, and rupture status were recorded. Results 2927 patients with aneurysms were identified among 29 003 CTAs. 17% of the aneurysms were ruptured at the time of imaging, 24% of aneurysms were incidentally identified, and multiple aneurysms were identified in 34% of patients. Aneurysms most commonly arose from the supraclinoid internal carotid artery (22%), the middle cerebral artery (18%), and the anterior communicating artery (13%). Male sex, age <50 years, aneurysms >6 mm, and aneurysms arising from the anterior communicating artery, posterior communicating artery, or the posterior circulation were independent predictors of aneurysm rupture. Independent mortality predictors included male sex, posterior circulation aneurysms, intraventricular hemorrhage, and intraparenchymal hemorrhage. Conclusions These results indicate that aneurysms detected on CTA that arise from the anterior communicating artery, posterior communicating artery, or the posterior circulation, measure >6 mm in size, occur in men, and in patients aged <50 years are associated with rupture. C1 [Heit, Jeremy J.] Stanford Univ Hosp, Intervent Neuroradiol Div, Dept Radiol, Stanford, CA 94305 USA. [Gonzalez, R. Gilberto; Schaefer, Pamela W.; Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Div, Boston, MA USA. [Sabbag, David] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Brouwers, H. Bart] Univ Med Ctr Utrecht, Dept Neurosurg, Brain Ctr Rudolf Magnus, Utrecht, Netherlands. [Brouwers, H. Bart] Univ Med Ctr Utrecht, Dept Radiol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands. [Rubiano, Edgar Gerardo Ordonez] Hosp Infantil Univ San Jose, Dept Neurosurg, Bogota, Colombia. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Neurointervent Radiol Div, Boston, MA USA. RP Heit, JJ (reprint author), Stanford Univ, Dept Radiol, Intervent Neuroradiol Div, 300 Pasteur Dr,Room S-047, Stanford, CA 94305 USA. EM jheit@stanford.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD NOV PY 2016 VL 8 IS 11 BP 1168 EP 1172 DI 10.1136/neurintsurg-2015-012082 PG 5 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA EA6NP UT WOS:000386746200016 PM 26553878 ER PT J AU Murthy, SB Urday, S Beslow, LA Dawson, J Lees, K Kimberly, WT Iadecola, C Kamel, H Hanley, DF Sheth, KN Ziai, WC AF Murthy, Santosh B. Urday, Sebastian Beslow, Lauren A. Dawson, Jesse Lees, Kennedy Kimberly, W. Taylor Iadecola, Costantino Kamel, Hooman Hanley, Daniel F. Sheth, Kevin N. Ziai, Wendy C. CA VISTA ICH Collaborators TI Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID BLOOD-PRESSURE REDUCTION; PERIHEMATOMAL EDEMA; PERIHEMORRHAGIC EDEMA; NATURAL-HISTORY; HEMATOMA; VOLUME; TRIAL; EVOLUTION; INTERACT AB Background Perihaematomal edema (PHE) expansion rate may be a predictor of outcome after intracerebral haemorrhage (ICH). We determined whether PHE expansion rate in the first 72 hours after ICH predicts outcome, and how it compares against other PHE measures. Methods We included patients from the Virtual International Stroke Trials Archive. We calculated PHE expansion rate using the equation: (PHE at 72 hours-PHE at baseline)/(time to 72-hour CT scan-time to baseline CT scan). Outcomes of interest were mortality and poor 90-day outcome (modified Rankin Scale score of >= 3). Logistic regression was used to assess relationships with outcome. Results A total of 596 patients with ICH were included. At baseline, median haematoma volume was 15.0 mL (IQR 7.9-29.2) with median PHE volume of 8.7 mL (IQR 4.5-15.5). Median PHE expansion rate was 0.31 mL/hour (IQR 0.12-0.55). The odds of mortality were greater with increasing PHE expansion rate (OR 2.63, CI 1.10 to 6.25), while the odds of poor outcome also increased with greater PHE growth (OR 1.67, CI 1.28 to 2.39). Female sex had an inverse relationship with PHE growth, but baseline haematoma volume had a direct correlation. Among other PHE measures, only interval increase in PHE correlated with poor outcome. There was no significant difference between the 2 measures of PHE volume expansion. Conclusions Rate of PHE growth over 72 hours was an independent predictor of mortality and poor functional outcomes following ICH. Baseline haematoma volume and gender appear to influence PHE growth. C1 [Murthy, Santosh B.; Iadecola, Costantino; Kamel, Hooman] Weill Cornell Med, Div Stroke & Neurocrit Care, Dept Neurol, New York, NY USA. [Murthy, Santosh B.; Iadecola, Costantino; Kamel, Hooman] Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY USA. [Urday, Sebastian; Beslow, Lauren A.; Sheth, Kevin N.] Yale Univ, Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, New Haven, CT 06510 USA. [Dawson, Jesse; Lees, Kennedy] Univ Glasgow, Dept Cerebrovasc Med, Glasgow, Lanark, Scotland. [Kimberly, W. Taylor] Harvard Med Sch, Massachusetts Gen Hosp, Div Neurocrit Care & Emergency Neurol, Dept Neurol,Ctr Human Genet Res, Boston, MA USA. [Hanley, Daniel F.] Johns Hopkins Univ, Sch Med, Div Brain Injury Outcomes, Baltimore, MD USA. [Ziai, Wendy C.] Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Baltimore, MD USA. RP Murthy, SB (reprint author), New York Presbyterian Hosp, Weill Cornell Med, Dept Neurol, 525 E 68th St,Suite 2-312, New York, NY 10065 USA. EM sam9200@med.cornell.edu FU American Brain Foundation; American Academy of Neurology; American Heart Association; NINDS [K23NS076597, K23NS082367]; NIH [R37NS089323-02, R01 NS034179-21, R01 NS037853-19, R01 NS073666-04]; Michael Goldberg Stroke Research Fund; [NIH-K12-NS049453]; [5U01NS062851]; [1U01NS08082] FX SBM is supported by the American Brain Foundation and American Academy of Neurology. S. Urday received the 2014 American Heart Association's Student Scholarship in Cerebrovascular Disease and Stroke. LAB was supported by NIH-K12-NS049453. WTK is supported by NINDS K23NS076597. CI is supported by NIH grants R37NS089323-02, R01 NS034179-21, R01 NS037853-19 and R01 NS073666-04. HK is supported by NINDS grant K23NS082367 and the Michael Goldberg Stroke Research Fund. DFH was awarded significant research support through grant numbers 5U01NS062851 for Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Haemorrhage III and for Minimally Invasive Surgery Plus r-tPA for Intracerebral Haemorrhage Evacuation (MISTIE) III 1U01NS08082. NR 18 TC 0 Z9 0 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 EI 1468-330X J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD NOV PY 2016 VL 87 IS 11 BP 1169 EP 1173 DI 10.1136/jnnp-2016-313653 PG 5 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA ED8WI UT WOS:000389151200005 PM 27466360 ER PT J AU Mackey, DC Lui, LY Cawthon, PM Ensrud, K Yaffe, K Cummings, SR AF Mackey, Dawn C. Lui, Li-Yung Cawthon, Peggy M. Ensrud, Kristine Yaffe, Kristine Cummings, Steven R. TI Life-Space Mobility and Mortality in Older Women: Prospective Results from the Study of Osteoporotic Fractures SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aged; mobility; death; independence; survival ID MILD COGNITIVE IMPAIRMENT; ALL-CAUSE MORTALITY; PROSPECTIVE COHORT; CARDIOVASCULAR-DISEASE; PHYSICAL PERFORMANCE; ADULTS; MEN; RISK; CONSTRICTION; ASSOCIATION AB ObjectivesTo evaluate the relationship between life-space mobility (extent, frequency, independence of movement) and mortality in older women. DesignProspective cohort study. SettingFour U.S. clinical sites. ParticipantsWomen (N = 1,498) aged 75 to 102 (mean 87.6) followed from 2006 to 2015. MeasurementsLife-space during the past 4 weeks was assessed in an interview, scored from 0 (daily restriction to bedroom) to 120 (daily trips outside town without assistance), and categorized (0-20, 21-40, 41-60, 61-80, 81-120). All-cause mortality was the primary outcome; noncancer, cardiovascular, cancer, and noncardiovascular noncancer mortality were secondary outcomes. ResultsOver a mean 5.2 years, 842 (56.2%) women died. Unadjusted risk of all-cause mortality was 82.6% in women with the lowest level of life-space (0-20 points) and 36.2% in those with the highest level (81-120 points). In multivariable proportional hazards models, there was a strong relationship between less life-space and greater risk of all-cause mortality (P-trend < .001). Women with the lowest level of life-space (0-20 points) had a risk of all-cause mortality that was 2.4 times as high (95% confidence interval (CI) = 1.5-4.0) as that of women with the highest level (81-120 points); women with life-space scores between 21 and 60 had a risk of all-cause mortality that was 1.5 times as high as that of women with the highest level. Each standard deviation decrease in life-space was associated with a 1.2 times greater (95% CI = 1.1-1.4) risk of all-cause mortality. Women unable to travel beyond their neighborhood without assistance had a risk of all-cause mortality that was 1.4 times (95% CI = 1.1-1.7) as high as that of women who could travel beyond their neighborhood without assistance. Results were similar for noncancer, cardiovascular, and other mortality and did not change after controlling for underlying disease or living arrangement. ConclusionLife-space scores of 60 or less were associated with mortality in older women independent of other strong risk factors. C1 [Mackey, Dawn C.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, K9625 Shrum Sci Ctr Bldg K,8888 Univ Dr, Burnaby, BC V5A 1S6, Canada. [Mackey, Dawn C.] Univ British Columbia, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada. [Lui, Li-Yung; Cawthon, Peggy M.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Ensrud, Kristine] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Mackey, DC (reprint author), Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, K9625 Shrum Sci Ctr Bldg K,8888 Univ Dr, Burnaby, BC V5A 1S6, Canada. EM dmackey@sfu.ca FU National Institutes of Health; National Institute on Aging [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576] FX SOF is supported by National Institutes of Health funding. The National Institute on Aging provides support under Grants R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. NR 35 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP 2226 EP 2234 DI 10.1111/jgs.14474 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600035 PM 27696354 ER PT J AU Berlowitz, DR Breaux-Shropshire, T Foy, CG Gren, LH Kazis, L Lerner, AJ Newman, JC Powell, JR Riley, WT Rosman, R Wadley, VG Williams, JA AF Berlowitz, Dan R. Breaux-Shropshire, Tonya Foy, Capri G. Gren, Lisa H. Kazis, Lewis Lerner, Alan J. Newman, Jill C. Powell, James R. Riley, William T. Rosman, Robert Wadley, Virginia G. Williams, Julie A. CA SPRINT Res Grp TI Hypertension Treatment and Concern About Falling: Baseline Data from the Systolic Blood Pressure Intervention Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hypertension; falls; concern about falling ID OLDER-PEOPLE; FES-I; FEAR; PREVALENCE; HEALTH; POPULATION; VALIDITY AB ObjectivesTo determine the extent of concern about falling in older adults with hypertension, whether lower blood pressure (BP) and greater use of antihypertensive medications are associated with greater concern about falling, and whether lower BP has a greater effect on concern about falling in older and more functionally impaired individuals. DesignSecondary analysis involving cross-sectional study of baseline characteristics of participants enrolled in the Systolic Blood Pressure Intervention Trial (SPRINT). SettingApproximately 100 outpatient sites. ParticipantsSPRINT enrollees aged 50 and older (mean age 69) diagnosed with hypertension (N=2,299). MeasurementsConcern about falling was determined using the shortened version of the Falls Efficacy Scale International as measured at the baseline examination. ResultsMild concern about falling was present in 29.3% of participants and moderate to severe concern in 17.9%. Neither low BP (systolic BP<120mmHg, diastolic BP <70mmHg) nor orthostatic hypotension was associated with concern about falling (P>.10). Participants with moderate to severe concern about falling were taking significantly more antihypertensive medications than those with mild or no concern. After adjusting for baseline characteristics, no associations were evident between BP, medications, and concern about falling. Results were similar in older and younger participants; interactions between BP and age and functional status were not significantly associated with concern about falling. ConclusionAlthough concern about falling is common in older adults with hypertension, it was not found to be associated with low BP or use of more antihypertensive medications in baseline data from SPRINT. C1 [Berlowitz, Dan R.; Kazis, Lewis] Bedford Vet Affairs Hosp, Bedford, MA USA. [Berlowitz, Dan R.; Kazis, Lewis] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA USA. [Breaux-Shropshire, Tonya] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Breaux-Shropshire, Tonya; Wadley, Virginia G.] Univ Alabama Birmingham, Birmingham, AL USA. [Foy, Capri G.; Newman, Jill C.] Wake Forest Univ, Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC USA. [Gren, Lisa H.] Univ Utah, Sch Med, Dept Family & Prevent Med, Salt Lake City, UT USA. [Lerner, Alan J.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH USA. [Powell, James R.] East Carolina Univ, Brody Sch Med, Div Gen Internal Med, Greenville, NC USA. [Riley, William T.] NIH, Off Behav & Social Sci Res, Bethesda, MD USA. [Rosman, Robert] Univ Illinois, Div Acad Internal Med & Geriatr, Coll Med, Chicago, IL USA. [Williams, Julie A.] Wake Forest Univ, Sch Med, Sect Gerontol & Geriatr Med, Winston Salem, NC USA. RP Berlowitz, DR (reprint author), Bedford VA Hosp, 200 Springs Rd, Bedford, MA 01730 USA. EM dan.berlowitz@va.gov FU National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C]; CTSAs funded by NCATS [UL1TR000439, UL1RR025755, UL1RR024134, UL1TR000003, UL1RR025771, UL1TR000093, UL1RR025752, UL1TR000073, UL1TR001064, UL1TR000050, UL1TR000005, 9U54TR 000017-06, UL1TR000105-05, UL1TR000445, UL1TR000075, UL1TR000002, UL1TR000064, UL1TR000433, P30GM103337]; [A-HL-13-002-001] FX SPRINT is funded with funds from the National Institutes of Health (NIH), including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS), under Contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, and Inter-Agency Agreement A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. The investigators designed and implemented all components of the SPRINT protocol. The investigative team collected, analyzed, and interpreted the data. For a full list of contributors to SPRINT, please see the supplementary acknowledgment list. We also acknowledge the support from the following CTSAs funded by NCATS: CWRU: UL1TR000439, OSU: UL1RR025755, U Penn: UL1RR024134 & UL1TR000003, U Boston: UL1RR025771, U Stanford: UL1TR000093, U Tufts: UL1RR025752, UL1TR000073 & UL1TR001064, University of Illinois: UL1TR000050, University of Pittsburgh: UL1TR000005, UT Southwestern: 9U54TR 000017-06, University of Utah: UL1TR000105-05, Vanderbilt University: UL1TR000445, George Washington University: UL1TR000075, University of CA, Davis: UL1TR000002, University of Florida: UL1TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM103337 COBRE Award NIGMS. NR 18 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP 2302 EP 2306 DI 10.1111/jgs.14441 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600045 PM 27640987 ER PT J AU Kramer, BJ Creekmur, B Howe, JL Trudeau, S Douglas, JR Garner, K Bales, C Callaway-Lane, C Barczi, S AF Kramer, B. Josea Creekmur, Beth Howe, Judith L. Trudeau, Scott Douglas, Joseph R. Garner, Kimberly Bales, Connie Callaway-Lane, Carol Barczi, Steven TI Veterans Affairs Geriatric Scholars Program: Enhancing Existing Primary Care Clinician Skills in Caring for Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE education; VA; continuing professional development; rural ID CONTINUING MEDICAL-EDUCATION; OUTCOMES; BEHAVIOR; IMPACT; MODEL AB The Veterans Affairs Geriatric Scholars Program (GSP) is a continuing professional development program to integrate geriatrics into the clinical practices of primary care providers and select associated health professions that support primary care teams. GSP uses a blended program educational format, and the minimal requirements are to attend an intensive course in geriatrics, participate in an interactive workshop on quality improvement (QI), and initiate a local QI project to demonstrate application of new knowledge to benefit older veterans. Using a retrospective post/pre survey design, the effect of GSP on clinical practices and behaviors and variation of that effect on clinicians working in rural and nonrural settings were evaluated. Significant improvement was found in the frequency of using evidence-based brief standardized assessments, clinical decision-making, and standards of care. Significant subgroup differences were observed in peer-to-peer information sharing between rural and nonrural clinicians. Overall, 77% of the sample reported greater job satisfaction after participating in GSP. The program is a successful model for advancing postgraduate education in geriatrics and a model that might be replicated to increase access to quality health care, particularly in rural areas. C1 [Kramer, B. Josea; Creekmur, Beth; Douglas, Joseph R.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Kramer, B. Josea] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA USA. [Howe, Judith L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Vet Integrated Serv Network 2, Bronx, NY USA. [Howe, Judith L.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY USA. [Howe, Judith L.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA. [Trudeau, Scott] Bedford Vet Affairs Med Ctr, New England Geriatr Res Educ & Clin Ctr, Bedford, MA USA. [Trudeau, Scott] Tufts Univ, Dept Occupat Therapy, Medford, MA USA. [Trudeau, Scott] Amer Occupat Therapy Assoc, Prod Aging & Collaborat Practice, Bethesda, MD USA. [Garner, Kimberly] Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Vet Integrated Serv Network 16, Little Rock, AR USA. [Garner, Kimberly] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR USA. [Bales, Connie] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Bales, Connie] Duke Univ, Sch Med, Durham, NC USA. [Callaway-Lane, Carol] Vanderbilt Univ, Sch Nursing, Nashville, TN USA. [Callaway-Lane, Carol] Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Barczi, Steven] William S Middleton Memorial Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Barczi, Steven] Univ Wisconsin, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA. RP Kramer, BJ (reprint author), Greater Angeles Healthcare Syst GREGG, 16111 Plummer St 11E, Sepulveda, CA 91343 USA. EM josea.kramer@va.gov OI Creekmur, Beth/0000-0001-7802-1125 FU VA FX The VA funding sources for the Geriatric Scholars Program had no role in the design, methods, subject recruitment, data collection, analysis, or preparation of this paper. NR 28 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP 2343 EP 2348 DI 10.1111/jgs.14382 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600052 PM 27696341 ER PT J AU Andy, UU Vaughan, CP Burgio, KL Alli, FM Goode, PS Markland, AD AF Andy, Uduak U. Vaughan, Camille P. Burgio, Kathryn L. Alli, Foluke M. Goode, Patricia S. Markland, Alayne D. TI Shared Risk Factors for Constipation, Fecal Incontinence, and Combined Symptoms in Older US Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE constipation; fecal incontinence; epidemiology; older adults; geriatrics ID QUALITY-OF-LIFE; PREVALENCE; WOMEN; IMPACT; POPULATION; COMMUNITY; EPIDEMIOLOGY; MORTALITY; SEVERITY; HOME AB ObjectivesTo estimate the prevalence of constipation, fecal incontinence (FI), and combined symptoms and to identify shared factors associated with bowel symptoms in older U.S. men and women DesignPopulation-based cross-sectional study. SettingNational Health and Nutrition Examination Survey (2005-2010). ParticipantsWomen and men aged 50 and older. MeasurementsConstipation was defined as hard stool consistency on the validated Bristol Stool Form Scale or stool frequency of fewer than three bowel movements per week. FI was defined as at least monthly loss of solid, liquid, or mucus stool. Combined symptoms was defined as constipation and FI. Multinomial multivarible models adjusted for age, race, socioeconomic status, education, self-rated health, depression, impairments in activities of daily living, and number of comorbidities. ResultsWomen (n = 3,078) reported higher prevalence of bowel symptoms than men (constipation 11.8% vs 4.7%%, FI 11.2% vs 8.6%, combined symptoms 1.4% vs 0.4%). In adjusted models, women had greater odds of having constipation (odds ratio (OR) = 3.0, 95% confidence interval (CI) = 2.3-3.8), FI (OR = 1.4, 95% CI = 1.1-1.8), and combined symptoms (OR = 4.6, 95% CI = 2.0-10.2) than men. Shared risk factors included poor self-rated health and depression symptoms (constipation: OR = 1.8, 95% CI = 1.4-2.4 and OR = 1.8, 95% CI = 1.0-3.2; FI: OR = 1.6, 95% CI = 1.2-2.2 and OR = 2.3 95% CI = 1.4-3.6; combined symptoms: OR = 2.6 95% CI = 1.5-4.8 and OR = 4.6, 95% CI = 1.3-16.4). ConclusionWhen defining constipation and FI using validated instruments, women had a much higher prevalence of constipation than men, whereas men had a higher prevalence of FI than constipation. Shared risk factors reflect the negative effect that bowel symptoms have on quality of life. C1 [Andy, Uduak U.] Univ Penn, Sch Med, Dept Obstet & Gynecol, Div Urogynecol, Philadelphia, PA 19104 USA. [Vaughan, Camille P.] Atlanta Vet Affairs Med Ctr, Birmingham Atlanta Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Decatur, GA USA. [Vaughan, Camille P.] Emory Univ, Dept Med, Div Gen Med & Geriatr, Atlanta, GA 30322 USA. [Burgio, Kathryn L.; Alli, Foluke M.; Goode, Patricia S.; Markland, Alayne D.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham Atlanta Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Burgio, Kathryn L.; Goode, Patricia S.; Markland, Alayne D.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. RP Andy, UU (reprint author), Div Urogynecol, 1000 Courtyard Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM uduakumoh.andy@uphs.upenn.edu OI Markland, Alayne/0000-0002-6567-6744 FU National Institute of Diabetes and Digestive and Kidney Diseases [R21 D096201]; Veterans Health Administration Career Development Award from Rehabilitation Research and Development [1 IK2 RX000747-01] FX Support was received from the National Institute of Diabetes and Digestive and Kidney Diseases (R21 D096201; PI: Markland). Dr. Vaughan is supported by a Veterans Health Administration Career Development Award from Rehabilitation Research and Development (1 IK2 RX000747-01). NR 26 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP E183 EP E188 DI 10.1111/jgs.14521 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600011 PM 27783401 ER PT J AU Brody, AA Gibson, B Tresner-Kirsch, D Kramer, H Thraen, I Coarr, ME Rupper, R AF Brody, Abraham A. Gibson, Bryan Tresner-Kirsch, David Kramer, Heidi Thraen, Iona Coarr, Matthew E. Rupper, Randall TI High Prevalence of Medication Discrepancies Between Home Health Referrals and Centers for Medicare and Medicaid Services Home Health Certification and Plan of Care and Their Potential to Affect Safety of Vulnerable Elderly Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE safety; medication reconciliation; care coordination; home health; transitional care ID TRANSITIONS; RECONCILIATION; COMMUNICATION; ADHERENCE; RECORDS AB ObjectivesTo describe the prevalence of discrepancies between medication lists that referring providers and home healthcare (HH) nurses create. DesignThe active medication list from the hospital at time of HH initiation was compared with the HH agency's plan of care medication list. An electronic algorithm was developed to compare the two lists for discrepancies. SettingSingle large hospital and HH agency in the western United States. ParticipantsIndividuals referred for HH from the hospital in 2012 (N = 770, 96.3% male, median age 71). MeasurementsPrevalence was calculated for discrepancies, including medications missing from one list or the other and differences in dose, frequency, or route for medications contained on both lists. ResultsParticipants had multiple medical problems (median 16 active problems) and were taking a median of 15 medications (range 1-93). Every participant had at least one discrepancy; 90.1% of HH lists were missing at least one medication that the referring provider had prescribed, 92.1% of HH lists contained medications not on the referring provider's list, 89.8% contained medication naming errors. 71.0% contained dosing discrepancies, and 76.3% contained frequency discrepancies. ConclusionDiscrepancies between HH and referring provider lists are common. Future work is needed to address possible safety and care coordination implications of discrepancies in this highly complex population. C1 [Brody, Abraham A.] James J Peters Bronx Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Brody, Abraham A.] NYU, Coll Nursing, Harttord Inst Geriatr Nursing, 433 First Ave, New York, NY 10010 USA. [Gibson, Bryan; Kramer, Heidi] George E Wahlen Vet Affairs Med Ctr, Informat Decis Enhancement & Analyt Sci, Salt Lake City, UT USA. [Gibson, Bryan; Kramer, Heidi] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA. [Tresner-Kirsch, David; Coarr, Matthew E.] Mitre Corp, Burlington Rd, Bedford, MA 01730 USA. [Tresner-Kirsch, David] Brandeis Univ, Waltham, MA USA. [Thraen, Iona; Rupper, Randall] George E Wahlen Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA. [Thraen, Iona] Univ Utah, Coll Social Work, Salt Lake City, UT USA. [Rupper, Randall] Univ Utah, Dept Geriatr, Salt Lake City, UT USA. RP Brody, AA (reprint author), NYU, Coll Nursing, Harttord Inst Geriatr Nursing, 433 First Ave, New York, NY 10010 USA. EM ab.brody@nyu.edu OI Brody, Abraham/0000-0002-3405-7043 FU Department of Veterans Affairs Office of Rural Health FX This research was funded by a grant from the Department of Veterans Affairs Office of Rural Health. NR 20 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2016 VL 64 IS 11 BP E166 EP E170 DI 10.1111/jgs.14457 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC7QO UT WOS:000388335600008 PM 27673753 ER PT J AU Udelsman, BV Eaton, J Muniappan, A Morse, CR Wright, CD Mathisen, DJ AF Udelsman, Brooks V. Eaton, Jessica Muniappan, Ashok Morse, Christopher R. Wright, Cameron D. Mathisen, Douglas J. TI Repair of large airway defects with bioprosthetic materials SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE large airway defects; acellular dermal matrix; aortic homograft; bioprosthetic ID TRACHEOESOPHAGEAL FISTULA; NONMALIGNANT TRACHEOESOPHAGEAL; AORTIC HOMOGRAFT; RECONSTRUCTION; MANAGEMENT; ALLODERM; CLOSURE; ESOPHAGECTOMY; EXPERIENCE; RESECTION AB Objective: Patients with complicated airway defects that exceed the limits of primary repair represent a challenging clinical problem and require alternative techniques for repair. The aim of this study was to evaluate bioprosthetic reconstruction of large tracheal and bronchial defects. Methods: Retrospective chart review of patients treated at a single tertiary center from 2008 to 2015 who underwent repair of tracheal or bronchial defects with a bioprosthetic device, namely aortic homograft or acellular dermal matrix. Results: Eight patients, 3 men and 5 women with a mean age of 54 +/- 13 years, underwent closure of complex central airway defects with bioprosthetic material. All but 1 patient underwent prior operative or stenting procedures. Three patients had isolated airway defects, whereas 5 had fistulas between the airway and enteric tract. Defects involved the membranous wall of the trachea (n = 5), the anterior wall of the trachea (n = 1), or the main stem bronchus (n = 2). Five reconstructions were with aortic homograft and 3 with acellular dermal matrix. Bioprosthetic material was buttressed with muscle flap (n = 4), omentum (n = 2), or left unbuttressed (n = 2). The airway defect was successfully closed in all patients. There was no postoperative mortality or recurrence of the airway defect in short-term follow-up. Two patients required debridement of granulation tissue and 1 additional patient required airway balloon dilation. Progression of underlying metastatic disease explained the majority of long-term mortality (75%). Conclusions: Bioprosthetic materials represent a viable option for management of large airway defects, including airway-enteric fistulae, that exceed the limits of primary repair. C1 [Udelsman, Brooks V.] Massachusetts Gen Hosp, Div Gen Surg, 55 Fruit St, Boston, MA 02114 USA. [Muniappan, Ashok; Morse, Christopher R.; Wright, Cameron D.; Mathisen, Douglas J.] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA. [Eaton, Jessica] Univ Louisville, Sch Med, Louisville, KY 40292 USA. RP Udelsman, BV (reprint author), Massachusetts Gen Hosp, Div Gen Surg, 55 Fruit St, Boston, MA 02114 USA. EM budelsman@partners.org NR 24 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD NOV PY 2016 VL 152 IS 5 BP 1388 EP 1396 DI 10.1016/j.jtcvs.2016.07.074 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EA6OY UT WOS:000386749700043 PM 27751243 ER PT J AU Huynh, TG Morales-Oyarvide, V Campo, MJ Gainor, JF Bozkurtlar, E Uruga, H Zhao, L Gomez-Caraballo, M Hata, AN Mark, EJ Lanuti, M Engelman, JA Mino-Kenudson, M AF Huynh, Tiffany G. Morales-Oyarvide, Vicente Campo, Meghan J. Gainor, Justin F. Bozkurtlar, Emine Uruga, Hironori Zhao, Ling Gomez-Caraballo, Maria Hata, Aaron N. Mark, Eugene J. Lanuti, Michael Engelman, Jeffrey A. Mino-Kenudson, Mad TI Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE KRAS mutation; Lung adenocarcinoma; PD-L1; Smoking; Tumor microenvironment ID PD-L1 EXPRESSION; CANCER-PATIENTS; PHASE-II; COLORECTAL-CANCER; KRAS MUTATIONS; SAFETY; EGFR; NIVOLUMAB; MPDL3280A; DOCETAXEL AB Introduction: Programmed cell death ligand 1 (PD-L1) expression on tumor cells can be upregulated via activation of CD8(+) cytotoxic T lymphocytes (CTLs) or the T helper cell (Th1) pathway, counterbalancing the CTL/Th1 microenvironment. However, PD-L1 expression in association with subtypes of tumor-associated lymphocytes and molecular alterations has not been well characterized in lung adenocarcinomas. Methods: PD-L1 expression was evaluated in 261 resected lung adenocarcinomas using tissue microarrays and various scoring systems, and was correlated with clinicopathologic/molecular features, including the extent/subtype of tumor associated lymphocytes (i.e., CD8, T-bet [Th1 transcription factor], and GATA3 [Th2 transcription factor]), and patient outcomes. Results: PD-L1 expression was present in 129 (49%), 95 (36.5%), and 62 (24%) cases using cutoffs of >= 1%, >= 5%, and >= 50%, respectively, 98 (38%) by H score and 72 (28%) by immune score. PD-L1 expression was associated with abundant CD8(+) and/or T-bet(+) tumor-infiltrating lymphocytes and EGFR wild-type, significant smoking history, and aggressive pathologic features. In addition, concurrent PD-L1 expression and abundant CD8(+) tumor-associated lymphocytes were seen in 25% of KRAS mutants or cases with no alterations by clinical molecular testing as opposed to only 7.4% of EGFR mutants. PD-L1 expression was significantly associated with decreased progression-free and overall survival rates by univariate analysis, but not by multivariate analysis. Conclusion: PD-L1 expression in resected lung adenocarcinomas is frequently observed in the presence of CTL/Th1 microenvironment, in particular in those with KRAS mutations or no common molecular alterations, suggesting that blockade of the PD-1/PD-L1 axis may be a promising treatment strategy to reinstitute active immune response for at least a subset of such patient populations. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. C1 [Huynh, Tiffany G.; Bozkurtlar, Emine; Uruga, Hironori; Zhao, Ling; Mark, Eugene J.; Mino-Kenudson, Mad] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. [Morales-Oyarvide, Vicente] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA USA. [Campo, Meghan J.; Gainor, Justin F.; Gomez-Caraballo, Maria; Hata, Aaron N.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Gainor, Justin F.; Hata, Aaron N.; Engelman, Jeffrey A.] Harvard Med Sch, Dept Med, Boston, MA USA. [Mark, Eugene J.; Mino-Kenudson, Mad] Harvard Med Sch, Dept Pathol, Boston, MA USA. [Lanuti, Michael] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA. [Lanuti, Michael] Harvard Med Sch, Dept Surg, Boston, MA USA. RP Mino-Kenudson, M (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. EM mminokenudson@partners.org FU Stand Up To Cancer-American Cancer Society Dream Team Translation Research Grant FX Supported by a Stand Up To Cancer-American Cancer Society Dream Team Translation Research Grant (J.F.G., J.A.E., M.M.K.). NR 47 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2016 VL 11 IS 11 BP 1869 EP 1878 DI 10.1016/j.jtho.2016.08.134 PG 10 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EA6NI UT WOS:000386745500008 PM 27568346 ER PT J AU Campo, M Gerber, D Gainor, JF Heist, RS Temel, JS Shaw, AT Fidias, P Muzikansky, A Engelman, JA Sequist, LV AF Campo, Meghan Gerber, David Gainor, Justin F. Heist, Rebecca S. Temel, Jennifer S. Shaw, Alice T. Fidias, Panos Muzikansky, Alona Engelman, Jeffrey A. Sequist, Lecia V. TI Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Non-small cell lung cancer; EGFR mutation; Afatinib; Acquired resistance; T790M; Progression biopsy ID CELL LUNG-CANCER; EGFR MUTATIONS; ADENOCARCINOMA; TRIAL; CHEMOTHERAPY AB Objectives: The mechanisms of acquired resistance to the irreversible EGFR inhibitor afatinib are not well documented. We performed this prospective clinical trial to determine the prevalence of the mutation T790M in afatinib-resistant patients. Methods: Eligible patients had EGFR mutations; they were tyrosine kinase inhibitor-naive and were treated with afatinib, 40 mg daily. At enrollment, patients consented to a future repeat biopsy at the time of acquired resistance. Results: A total of 24 patients were enrolled. The objective response rate was 58% (95% confidence interval [CI]: 37-78) with a median progression-free survival of 11.4 months (95% CI: 5.9-13.7) and median overall survival of 20.8 months (95% CI: 15.1-40.5). Of the 24 patients enrolled, 23 progressed and only 14 completed repeat biopsy at time of progression, with 11 samples sufficient for molecular analysis. Of those 11 patients, four (36% [95% CI: 10.9-69.2]) harbored T790M. Conclusions: T790M is likely a common resistance mechanism in patients treated with first-line afatinib. Although repeat biopsies at progression are crucial in elucidating resistance mechanisms, this study suggests that clinical and technical issues often limit their feasibility, highlighting the importance of developing noninvasive tumor-genotyping strategies. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. C1 [Campo, Meghan; Gainor, Justin F.; Heist, Rebecca S.; Temel, Jennifer S.; Shaw, Alice T.; Fidias, Panos; Muzikansky, Alona; Engelman, Jeffrey A.; Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Campo, Meghan; Gainor, Justin F.; Heist, Rebecca S.; Temel, Jennifer S.; Shaw, Alice T.; Fidias, Panos; Muzikansky, Alona; Engelman, Jeffrey A.; Sequist, Lecia V.] Harvard Med Sch, Boston, MA USA. [Gerber, David] Univ Texas Southwestern Med Sch, Dallas, TX USA. RP Sequist, LV (reprint author), 32 Fruit St,Yawkey 7B, Boston, MA 02114 USA. EM lvsequist@partners.org FU Boeheringer-Ingelheim Pharmaceuticals, Inc. FX This work was supported by Boeheringer-Ingelheim Pharmaceuticals, Inc. NR 13 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2016 VL 11 IS 11 BP 2022 EP 2026 DI 10.1016/j.jtho.2016.06.032 PG 5 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EA6NI UT WOS:000386745500023 PM 27553514 ER PT J AU Lin, JJ Kennedy, E Sequist, LV Brastianos, PK Goodwin, KE Stevens, S Wanat, AC Stober, LL Digumarthy, SR Engelman, JA Shaw, AT Gainor, JF AF Lin, Jessica J. Kennedy, Elizabeth Sequist, Lecia V. Brastianos, Priscilla K. Goodwin, Kelly E. Stevens, Sara Wanat, Alexandra C. Stober, Lisa L. Digumarthy, Subba R. Engelman, Jeffrey A. Shaw, Alice T. Gainor, Justin F. TI Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Alectinib; RET; Tyrosine kinase inhibitor; Lung cancer; NSCLC ID CRIZOTINIB; ADENOCARCINOMA; PATIENT; FUSIONS; GENE AB Introduction: Chromosomal rearrangements involving rearranged during transfection gene (RET) occur in 1% to 2% of NSCLCs and may confer sensitivity to rearranged during transfection (RET) inhibitors. Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. The clinical activity of alectinib in patients with RET-rearranged NSCLC has not yet been reported. Methods: We have described four patients with advanced RET-rearranged NSCLC who were treated with alectinib (600 mg twice daily [n = 3] or 900 mg twice daily [n = 1]) as part of single-patient compassionate use protocols or off label use of the commercially available drug. Results: Four patients with metastatic RET-rearranged NSCLC were identified. Three of the four had received prior RET TKIs, including cabozantinib and experimental RET inhibitors. In total, we observed two (50%) objective radiographic responses after treatment with alectinib (one confirmed and one unconfirmed), with durations of therapy of 6 months and more than 5 months (treatment ongoing), respectively. Notably, one of these two patients had his dose of alectinib escalated to 900 mg twice daily and had clinical improvement in central nervous system metastases. In addition, one patient (25%) experienced a best response of stable disease lasting approximately 6 weeks (the drug discontinued for toxicity). A fourth patient who was RET TKI-naive had primary progression while receiving alectinib. Conclusions: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors. Larger prospective studies with longer follow-up are needed to assess the efficacy of alectinib in RET-rearranged NSCLC and other RET-driven malignancies. In parallel, development of more selective, potent RET TKIs is warranted. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. C1 [Lin, Jessica J.; Kennedy, Elizabeth; Sequist, Lecia V.; Brastianos, Priscilla K.; Goodwin, Kelly E.; Stevens, Sara; Wanat, Alexandra C.; Stober, Lisa L.; Engelman, Jeffrey A.; Shaw, Alice T.; Gainor, Justin F.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Digumarthy, Subba R.] Massachusetts Gen Hosp, Dept Thorac Imaging & Intervent, Boston, MA 02114 USA. RP Gainor, JF (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM jgainor@partners.org FU Be a Piece of the Solution; LungStrong advocacy groups FX Alectinib was provided to two patients on a compassionate use basis by Genentech/Roche. We thank the members of the Massachusetts General Hospital Cancer Center Protocol Office for their assistance and the Be a Piece of the Solution and LungStrong advocacy groups for their support. NR 16 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2016 VL 11 IS 11 BP 2027 EP 2032 DI 10.1016/j.jtho.2016.08.126 PG 6 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EA6NI UT WOS:000386745500024 PM 27544060 ER PT J AU San-Miguel, JF Hungria, VTM Yoon, SS Beksac, M Dimopoulos, MA Elghandour, A Jedrzejczak, WW Gunther, A Nakorn, TN Siritanaratkul, N Schlossman, RL Hou, J Moreau, P Lonial, S Lee, JH Einsele, H Sopala, M Bengoudifa, BR Binlich, F Richardson, PG AF San-Miguel, Jesus F. Hungria, Vania T. M. Yoon, Sung-Soo Beksac, Meral Dimopoulos, Meletios A. Elghandour, Ashraf Jedrzejczak, Wieslaw W. Guenther, Andreas Nakorn, Thanyaphong N. Siritanaratkul, Noppadol Schlossman, Robert L. Hou, Jian Moreau, Philippe Lonial, Sagar Lee, Jae H. Einsele, Hermann Sopala, Monika Bengoudifa, Bourras-Rezki Binlich, Florence Richardson, Paul G. TI Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial SO Lancet Haematology LA English DT Article ID END-POINTS; LENALIDOMIDE; COMBINATION; MULTICENTER; OUTCOMES; LBH589; RISK AB Background Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus bortezomib and dexamethasone in the phase 3 PANORAMA 1 trial. Here, we present the final overall survival analysis for this trial. Methods PANORAMA 1 is a randomised, placebo-controlled, double-blind, phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma with one to three previous treatments. Patients were randomly assigned (1:1) to receive panobinostat (20 mg orally) or placebo, with bortezomib (1.3 mg/m(2) intravenously) and dexamethasone (20 mg orally), over two distinct treatment phases. In treatment phase 1 (eight 3-week cycles), patients received: panobinostat or placebo on days 1, 3, 5, 8, 10, and 12; bortezomib on days 1, 4, 8, and 11; and dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12. During treatment phase 2 (four 6-week cycles with a 2 weeks on, 1 week off schedule), panobinostat or placebo was given three times a week, bortezomib was administered once a week, and dexamethasone was given on the days of and following bortezomib administration. The primary endpoint was progression-free survival; overall survival was a key secondary endpoint. This study is registered at ClinicalTrials.gov, NCT01023308. Findings Between Jan 21, 2010, and Feb 29, 2012, 768 patients were enrolled into the study and randomly assigned to receive either panobinostat (n=387) or placebo (n=381), plus bortezomib and dexamethasone. At data cutoff (June 29, 2015), 415 patients had died. Median overall survival was 40.3 months (95% CI 35.0-44.8) in those who received panobinostat, bortezomib, and dexamethasone versus 35.8 months (29.0-40.6) in those who received placebo, bortezomib, and dexamethasone (hazard ratio [HR] 0.94, 95% CI 0.78-1.14; p=0.54). Of patients who had received at least two previous regimens including bortezomib and an immunomodulatory drug, median overall survival was 25.5 months (95% CI 19.6-34.3) in 73 patients who received panobinostat, bortezomib, and dexamethasone versus 19.5 months (14.1-32.5) in 74 who received placebo (HR 1.01, 95% CI 0.68-1.50). Interpretation The overall survival benefit with panobinostat over placebo with bortezomib and dexamethasone was modest. However, optimisation of the regimen could potentially prolong treatment duration and improve patients' outcomes, although further trials will be required to confirm this. C1 [San-Miguel, Jesus F.] Univ Navarra Clin, CIMA, IDISNA, Pamplona 31008, Spain. [Hungria, Vania T. M.] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil. [Yoon, Sung-Soo] Seoul Natl Univ Hosp, Seoul, South Korea. [Beksac, Meral] Ankara Univ, Sch Med, Ankara, Turkey. [Dimopoulos, Meletios A.] Univ Athens, Athens, Greece. [Elghandour, Ashraf] Univ Alexandria, Alexandria, Egypt. [Jedrzejczak, Wieslaw W.] Med Univ Warsaw, Warsaw, Poland. [Guenther, Andreas] Univ Kiel, Kiel, Germany. [Nakorn, Thanyaphong N.] King Chulalongkorn Mem Hosp, Bangkok, Thailand. [Nakorn, Thanyaphong N.] Chulalongkorn Univ, Bangkok, Thailand. [Siritanaratkul, Noppadol] Siriraj Hosp, Bangkok, Thailand. [Schlossman, Robert L.; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hou, Jian] Shanghai Changzheng Hosp, Shanghai, Peoples R China. [Moreau, Philippe] Univ Hosp Nantes, Nantes, France. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Lee, Jae H.] Gachon Univ, Gil Med Ctr, Inchon, South Korea. [Einsele, Hermann] Univ Hosp Wurzburg, Wurzburg, Germany. [Sopala, Monika; Bengoudifa, Bourras-Rezki] Novartis Pharma AG, Basel, Switzerland. [Binlich, Florence] Novartis Pharma SAS, Rueil Malmaison, France. RP San-Miguel, JF (reprint author), Univ Navarra Clin, CIMA, IDISNA, Pamplona 31008, Spain. EM sanmiguel@unav.es RI richard, chrystelle/K-8595-2015 FU Novartis Pharmaceuticals FX Novartis Pharmaceuticals. NR 26 TC 2 Z9 2 U1 5 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2352-3026 J9 LANCET HAEMATOL JI Lancet Haematol. PD NOV PY 2016 VL 3 IS 11 BP E506 EP E515 DI 10.1016/S2352-3026(16)30147-8 PG 10 WC Hematology SC Hematology GA ED7ST UT WOS:000389071200007 PM 27751707 ER PT J AU Safren, SA Bedoya, CA O'Cleirigh, C Biello, KB Pinkston, MM Stein, MD Traeger, L Kojic, E Robbins, GK Lerner, JA Herman, DS Mimiaga, MJ Mayer, KH AF Safren, Steven A. Bedoya, C. Andres O'Cleirigh, Conall Biello, Katie B. Pinkston, Megan M. Stein, Michael D. Traeger, Lara Kojic, Erna Robbins, Gregory K. Lerner, Jonathan A. Herman, Debra S. Mimiaga, Matthew J. Mayer, Kenneth H. TI Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial SO Lancet HIV LA English DT Article ID CBT-AD; INTERPERSONAL PSYCHOTHERAPY; ANTIRETROVIRAL THERAPY; NONADHERENCE; PROGRESSION; MEDICATION; OUTCOMES AB Background Depression is highly prevalent in people with HIV and has consistently been associated with poor antiretroviral therapy (ART) adherence. Integrating cognitive behavioural therapy (CBT) for depression with adherence counselling using the Life-Steps approach (CBT-AD) has an emerging evidence base. The aim of this study was to test the efficacy of CBT-AD. Methods In this three-arm randomised controlled trial in HIV-positive adults with depression, we compared CBT-AD with information and supportive psychotherapy plus adherence counselling using the Life-Steps approach (ISP-AD), and with enhanced treatment as usual (ETAU) including Life-Steps adherence counselling only. Participants were recruited from three sites in New England, USA (two hospital settings and one community health centre). Patients were randomly assigned (2: 2: 1) to receive CBT-AD (one Life-Steps session plus 11 weekly integrated sessions lasting up to 1 h each), ISP-AD (one Life-Steps session plus 11 weekly integrated sessions lasting up to 1 h each), or ETAU (one Life-Steps session and five assessment visits roughly every 2 weeks), randomisation was done with allocation software, in pairs, and stratified by three variables: study site, whether or not participants had been prescribed antidepressant medication, and whether or not participants had a history of injection drug use. The primary outcome was ART adherence at the end of treatment (4 month assessment) assessed via electronic pill caps (Medication Event Monitoring System [MEMS]) with correction for pocketed doses, analysed by intention to treat. Findings Patients were recruited from Feb 26, 2009, to June 21, 2012. Patients who were assigned to CBT-AD (94 randomly assigned, 83 completed assessment) had greater improvements in adherence (estimated difference 1.00 percentage point per visit, 95% CI 0.34 to 1.66, p=0.003) and depression (Center for Epidemiological Studies depression [CESD] score estimated difference -0.41, -0.66 to -0.16, p=0.001; Montgomery-Asberg depression rating scale [MADRS] score -4.69, -8.09 to -1.28, p=0.007; clinical global impression [CGI] score -0.66, -1.11 to -0.21, p=0.005)than did patients who had ETAU (49 assigned, 46 completed assessment) after treatment (4 months). No significant differences in adherence were noted between CBT-AD and ISP-AD (97 assigned, 87 completed assessment). No study-related adverse events were reported. Interpretation Integrating evidenced-based treatment for depression with evidenced-based adherence counselling is helpful for individuals living with HIV/AID Sand depression. Future efforts should examine how to best disseminate effective psychosocial depression treatments such as CBT-AD to people living with HIV/AIDS and examine the cost-effectiveness of such approaches. C1 [Safren, Steven A.] Univ Miami, Dept Psychol, Miami, FL USA. [Safren, Steven A.; Bedoya, C. Andres; O'Cleirigh, Conall; Traeger, Lara; Lerner, Jonathan A.] Massachusetts Gen Hosp, Behav Med Psychiat, Boston, MA 02114 USA. [Robbins, Gregory K.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Safren, Steven A.; Bedoya, C. Andres; O'Cleirigh, Conall; Traeger, Lara; Lerner, Jonathan A.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Robbins, Gregory K.; Mayer, Kenneth H.] Harvard Med Sch, Dept Med, Boston, MA USA. [Safren, Steven A.; O'Cleirigh, Conall; Biello, Katie B.; Mimiaga, Matthew J.; Mayer, Kenneth H.] Fenway Inst Fenway Hlth, Boston, MA USA. [Biello, Katie B.; Mimiaga, Matthew J.] Brown Univ, Sch Publ Hlth, Dept Behav & Social Hlth Sci & Epidemiol, Providence, RI 02912 USA. [Biello, Katie B.; Mimiaga, Matthew J.] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Biello, Katie B.; Mimiaga, Matthew J.] Brown Univ, Inst Community Hlth Promot, Providence, RI 02912 USA. [Pinkston, Megan M.] Brown Univ, Immunol & Infect Dis, Providence, RI 02912 USA. [Stein, Michael D.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA USA. [Pinkston, Megan M.; Kojic, Erna] Miriam Hosp, Providence, RI 02906 USA. [Herman, Debra S.] Butler Hosp, Dept Psychiat & Human Behav, Providence, RI 02906 USA. [Mimiaga, Matthew J.] TH Chan Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. RP Safren, SA (reprint author), Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA. EM ssafren@miami.edu FU National Institute of Mental Health [R01MH084757]; National Institute of Allergy and Infectious Diseases (NIAID) [5P30AI060354, P30AI042853] FX This study was funded by a National Institute of Mental Health grant R01MH084757 to SAS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. Some of the author time, and resources for statistical consultation, were also supported by grants National Institute of Allergy and Infectious Diseases (NIAID) 5P30AI060354 and P30AI042853. We thank study interventionists, assessors, and research assistants working on daily study operations, quality assurance, recruitment, and other study coordination tasks; the Harvard Center for AIDS Research (CFAR) and Heather Ribaudo specifically for statistical consultation; the participants for their time and effort to complete the study assessments and procedures; and the Community Advisory Board at Fenway Health who gave input regarding the design and the recruitment of participants. NR 28 TC 1 Z9 1 U1 8 U2 8 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD NOV PY 2016 VL 3 IS 11 BP E529 EP E538 DI 10.1016/S2352-3018(16)30053-4 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7TB UT WOS:000389072300010 PM 27658881 ER PT J AU Armato, SG Blyth, KG Keating, JJ Katz, S Tsim, S Coolen, J Gudmundsson, E Opitz, I Nowak, AK AF Armato, Samuel G., III Blyth, Kevin G. Keating, Jane J. Katz, Sharyn Tsim, Selina Coolen, Johan Gudmundsson, Eyjolfur Opitz, Isabelle Nowak, Anna K. TI Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group SO LUNG CANCER LA English DT Review DE Near-infrared imaging; Perfusion MRI; Dynamic contrast-enhanced CT; Tumor response assessment; Tumor volume; Modified RECIST ID THORACIC CT SCANS; RESPONSE EVALUATION; TUMOR VOLUME; MALIGNANT MESOTHELIOMA; PATIENT RESPONSE; RECIST CRITERIA; PERFUSION CT; SOLID TUMORS; LUNG-CANCER; EXPERIENCE AB Imaging plays an important role in the detection, diagnosis, staging, response assessment, and surveillance of malignant pleural mesothelioma. The etiology, biology, and growth pattern of mesothelioma present unique challenges for each modality used to capture various aspects of this disease. Clinical implementation of imaging techniques and information derived from images continue to evolve based on active research in this field worldwide. This paper summarizes the imaging-based research presented orally at the 2016 International Conference of the International Mesothelioma Interest Group (iMig) in Birmingham, United Kingdom, held May 1-4, 2016. Presented topics included intraoperative near-infrared imaging of mesothelioma to aid the assessment of resection completeness, an evaluation of tumor enhancement improvement with increased time delay between contrast injection and image acquisition in standard clinical magnetic resonance imaging (MRI) scans, the potential of early contrast enhancement analysis to provide MRI with a role in mesothelioma detection, the differentiation of short and long-term survivors based on MRI tumor volume and histogram analysis, the response-assessment potential of hemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans, the correlation of CT-based tumor volume with post-surgical tumor specimen weight, and consideration of the need to update the mesothelioma tumor response assessment paradigm. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Armato, Samuel G., III] Univ Chicago, Dept Radiol, 5841 South Maryland Ave MC 2026, Chicago, IL 60637 USA. [Blyth, Kevin G.; Tsim, Selina] Queen Elizabeth Univ Hosp, Dept Resp Med, Glasgow, Lanark, Scotland. [Blyth, Kevin G.; Tsim, Selina] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland. [Keating, Jane J.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Keating, Jane J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Keating, Jane J.] Univ Penn, Abramson Canc Ctr, Ctr Precis Surg, Pearlman Sch Med, Philadelphia, PA 19104 USA. [Katz, Sharyn] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Coolen, Johan] Univ Hosp Leuven, Dept Radiol, Leuven, Belgium. [Opitz, Isabelle] Univ Zurich Hosp, Div Thorac Surg, Zurich, Switzerland. [Nowak, Anna K.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia. [Nowak, Anna K.] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia. [Nowak, Anna K.] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia. RP Armato, SG (reprint author), Univ Chicago, Dept Radiol, 5841 South Maryland Ave MC 2026, Chicago, IL 60637 USA. EM s-armato@uchicago.edu RI Nowak, Anna/B-2487-2013 OI Nowak, Anna/0000-0002-9317-9526 FU National Institutes of Health [R0I CA193556]; Belgian Foundation against Cancer [ARC211]; Kazan Law Firm's Charitable Foundation; Paul C. Hodges Alumni Society, Department of Radiology, The University of Chicago; University of Chicago; National Health and Medical Research Council of Australia; National Research Scotland Career Research Fellowship FX JJK would like to thank Jarrod D. Predina, M.D., Sarah Nims, Ollin Venegas, John C. Kucharczuk, M.D., Charuhas Deshpande, M.D., Ryan Zeh, Sunil Singhal, M.D. The study of JJK was supported by National Institutes of HealthR0I CA193556.; JC acknowledges F. De Keyzer, P. Nafteux, W. De Weyer, E. Verbeken, J. Vansteenkiste, K. Nackaerts, and J. Verschakelen. The mesothelioma study of JC was supported by a grant (#ARC211) from the Belgian Foundation against Cancer.; EG would like to thank Samuel G. Armato III, Ph.D., Zacariah E. Labby, Ph.D., Christopher Straus, M.D., Feng Li, M.D., Ph.D., Buerkley Rose, R.N., and Hedy L. Kindler, M.D. EG was funded in part by the Kazan Law Firm's Charitable Foundation and the Paul C. Hodges Alumni Society, Department of Radiology, The University of Chicago.; SGA receives royalties and licensing fees through The University of Chicago for computer-aided diagnosis technology. SGA is a consultant for Aduro Biotech, Inc.; AKN acknowledges the National Health and Medical Research Council of Australia for funding the National Centre for Asbestos Related Diseases Centre of Research Excellence.; KGB is funded by a National Research Scotland Career Research Fellowship. NR 48 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD NOV PY 2016 VL 101 BP 48 EP 58 DI 10.1016/j.lungcan.2016.09.003 PG 11 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EC3SN UT WOS:000388046700009 PM 27794408 ER PT J AU Frost, R Hess, AT Okell, TW Chappell, MA Tisdall, MD van der Kouwe, AJW Jezzard, P AF Frost, Robert Hess, Aaron T. Okell, Thomas W. Chappell, Michael A. Tisdall, M. Dylan van der Kouwe, Andre J. W. Jezzard, Peter TI Prospective Motion Correction and Selective Reacquisition Using Volumetric Navigators for Vessel-Encoded Arterial Spin Labeling Dynamic Angiography SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE prospective motion correction; volumetric navigator; pseudo-continuous arterial spin labeling; magnetic resonance angiography; vessel-encoded angiography; reacquisition ID IMAGE-BASED TRACKING; HEAD MOTION; BLOOD-FLOW; K-SPACE; MRI; FMRI; ARTIFACTS; ECHOES AB Purpose: The aim of this study was to improve robustness to motion in a vessel-encoded angiography sequence used for patient scans. The sequence is particularly sensitive to motion between imaging segments, which causes ghosting and blurring that propagates to the final angiogram. Methods: Volumetric echo planar imaging (EPI) navigators acquired in 275 ms were inserted after the imaging readout in a vessel-encoded pseudo-continuous arterial spin labeling (VEPCASL) sequence. The effects of movement between segments on the images were tested with phantom experiments. Deliberate motion experiments with healthy volunteers were performed to compare prospective motion correction (PMC) with reacquisition versus no correction. Results: In scans without motion, the addition of the EPI navigator to the sequence did not affect the quality of the angiograms in comparison with the original sequence. PMC and reacquisition improved the visibility of vessels in the angiograms compared with the scans without correction. The reacquisition strategy was shown to be important for complete correction of imaging artifacts. Conclusion: We have demonstrated an effective method to correct motion in vessel-encoded angiography. For reacquisition of 15 segments, the technique requires approximately 30 s of additional scanning (similar to 25%). (C) 2015 International Society for Magnetic Resonance in Medicine C1 [Frost, Robert; Okell, Thomas W.; Chappell, Michael A.; Jezzard, Peter] Univ Oxford, Nuffield Dept Clin Neurosci, FMRIB Ctr, Oxford, England. [Hess, Aaron T.] Univ Oxford, Div Cardiovasc Med, Radcliffe Dept Med, Oxford Ctr Clin Magnet Resonance Res, Oxford, England. [Chappell, Michael A.] Univ Oxford, Inst Biomed Engn, Oxford, England. [Tisdall, M. Dylan; van der Kouwe, Andre J. W.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Tisdall, M. Dylan; van der Kouwe, Andre J. W.] Harvard Med Sch, Dept Radiol, Boston, MA USA. RP Frost, R (reprint author), John Radcliffe Hosp, FMRIB Ctr, Oxford OX3 9DU, England. EM robert.frost@ndcn.ox.ac.uk OI Chappell, Michael/0000-0003-1802-4214 FU National Institute for Health Research Oxford Biomedical Research Centre; Royal Academy of Engineering; Dunhill Medical Trust FX We are grateful to the National Institute for Health Research Oxford Biomedical Research Centre and the Royal Academy of Engineering for funding and for the facilities provided by the Acute Vascular Imaging Centre. We thank James Kennedy, George Harston, Davide Carone, Juliet Semple, and Peter Manley for helpful discussions and assistance with data acquisition. We also thank the Dunhill Medical Trust for support. NR 37 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD NOV PY 2016 VL 76 IS 5 BP 1420 EP 1430 DI 10.1002/mrm.26040 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ED8NB UT WOS:000389127100008 PM 26567122 ER PT J AU Graedel, NN Polimeni, JR Guerin, B Gagoski, B Bonmassar, G Wald, LL AF Graedel, Nadine N. Polimeni, Jonathan R. Guerin, Bastien Gagoski, Borjan Bonmassar, Giorgio Wald, Lawrence L. TI Anatomically Realistic Temperature Phantom for Radiofrequency Heating Measurements (vol 73, pg 442, 2015) SO MAGNETIC RESONANCE IN MEDICINE LA English DT Correction C1 [Graedel, Nadine N.; Polimeni, Jonathan R.; Guerin, Bastien; Bonmassar, Giorgio; Wald, Lawrence L.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Polimeni, Jonathan R.; Bonmassar, Giorgio; Wald, Lawrence L.] Harvard Med Sch, Boston, MA USA. [Gagoski, Borjan] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Wald, Lawrence L.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA. RP Guerin, B (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. EM guerin@nmr.mgh.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD NOV PY 2016 VL 76 IS 5 BP 1642 EP 1642 DI 10.1002/mrm.26363 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ED8NB UT WOS:000389127100032 PM 27747939 ER PT J AU Gao, J Kong, XY Li, ZM Wang, TY Li, YN AF Gao, Jun Kong, Xiangyi Li, Zhimin Wang, Tianyu Li, Yongning TI Surgical treatments on adult tethered cord syndrome A retrospective study SO MEDICINE LA English DT Article DE microsurgery; tethered cord syndrome; tumor ID OF-THE-LITERATURE; SPINAL-CORD; EXPERIENCE; MANAGEMENT AB To investigate effects of surgical treatment on adult tethered cord syndrome (TCS). A retrospective analysis of 82 adult patients (17 male cases, 82% and 24 female cases, 59%) with TCS treated by surgery was conducted between March, 2005 and December, 2015, with an average age of 31.6 years and average disease course of 6.7 years. All the 82 cases of patients received nerve electrophysiology monitoring assisted microsurgery. After surgery, all patients were followed up for an average of 2.5 years. Surgical effects were evaluated according to Hoffman grading system. As this is just a retrospective study that does not involve any interventions, ethical approval was not necessary according to the rules of the hospital. All patients were followed up, no death occurred. According to Hoffman grading system, the neurologic symptoms were improved in 22 patients (27%), stabilized in 60 patients (73%). Of 10 cases with lipoma tethered spinal cord, corresponding symptoms were improved in 2 cases. Of 32 cases with tethered spinal cord caused by dermoid cyst and epidermoid cyst, the symptoms were improved in 6 cases. Of 40 cases without occupying lesions of tethered spinal cord, the symptoms were improved in 14 cases. Besides, there was no deteriorated case. Surgical treatment on adult patients with TCS can improve the neurologic deficits which are associated with the course of disease, early treatment has much better curative effect. C1 [Gao, Jun; Kong, Xiangyi; Li, Zhimin; Wang, Tianyu; Li, Yongning] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, 1 Shuaifuyuan, Beijing 100730, Peoples R China. [Kong, Xiangyi] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Harvard Med Sch, Boston, MA USA. RP Li, YN (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, 1 Shuaifuyuan, Beijing 100730, Peoples R China. EM 13901078229@139.com FU Peking Union Medical College Youth Research Funds [3332016010]; Peking Union Medical College Graduate Student Innovation Fund [2015-1002-02-09] FX This study was supported by Peking Union Medical College Youth Research Funds (2016) (project no. 3332016010; grant recipient: XK) and Peking Union Medical College Graduate Student Innovation Fund (2015) (project no. 2015-1002-02-09; grant recipient: XK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD NOV PY 2016 VL 95 IS 46 AR e5454 DI 10.1097/MD.0000000000005454 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA ED3DV UT WOS:000388730500067 PM 27861396 ER PT J AU Taylor, MV Priefer, BA Alt-White, AC AF Taylor, Melissa V. Priefer, Beverly A. Alt-White, Anna C. TI Evidence-based practice: Embracing integration SO NURSING OUTLOOK LA English DT Article DE Evidence-based practice; EBP process; Evidence; Patient preferences; Clinical expertise; Leadership; Nurses; Education; Culture; Infrastructure ID SHARED DECISION-MAKING; HEALTH-CARE; CLINICAL-PRACTICE; COMPETENCES AB Background: The Veterans Health Administration's Office of Nursing Services launched several initiatives to support evidence-based practice (EBP) initiatives throughout its system. From evaluation of these initiatives and reflection on discussions with nurse leaders and direct care nurses, our thinking about and approach to EBP has evolved from a project-focused to a practice-focused interpretation. Purpose: (a) Offer an expanded view that moves beyond interpreting EBP as process-driven projects to a "way of practicing" where nurses assume ownership for a practice that integrates best available evidence, clinical expertise, and patient preferences, and (b) describe and generate discussion on the educational, cultural, and role modeling implications of this expanded view. Methods: We illustrate EBP integration using a point-of-care interaction scenario. Conclusion: Commitment to EBP is reflected at the point-of-care where each nurse demonstrates the ability to integrate evidence-based interventions, patient preferences, and clinical expertise to arrive at patient-centric health care decisions. C1 [Taylor, Melissa V.] VA Pittsburgh Healthcare Syst, Patient Care Serv, Univ Dr, Pittsburgh, PA 15240 USA. [Priefer, Beverly A.] Off Nursing Serv, Dept Vet Affairs, Fitchburg, WI USA. [Alt-White, Anna C.] Off Nursing Serv, Dept Vet Affairs, Washington, DC USA. RP Taylor, MV (reprint author), VA Pittsburgh Healthcare Syst, Patient Care Serv, Univ Dr, Pittsburgh, PA 15240 USA. EM melissa.taylor5@va.gov NR 27 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD NOV-DEC PY 2016 VL 64 IS 6 BP 575 EP 582 DI 10.1016/j.outlook.2016.04.004 PG 8 WC Nursing SC Nursing GA EE0VH UT WOS:000389296500010 PM 27318385 ER PT J AU O'Neil, PM Miller-Kovach, K Tuerk, PW Becker, LE Wadden, TA Fujioka, K Hollander, PL Kushner, RF Garvey, WT Rubino, DM Malcolm, RJ Weiss, D Raum, WJ Salyer, JL Hermayer, KL Rost, SL Veliko, JL Sora, ND AF O'Neil, Patrick M. Miller-Kovach, Karen Tuerk, Peter W. Becker, Lynne E. Wadden, Thomas A. Fujioka, Ken Hollander, Priscilla L. Kushner, Robert F. Garvey, W. Timothy Rubino, Domenica M. Malcolm, Robert J. Weiss, Daniel Raum, William J. Salyer, Jonny L. Hermayer, Kathie L. Rost, Stephanie L. Veliko, Jan L. Sora, Nicoleta D. TI Randomized Controlled Trial of a Nationally Available Weight Control Program Tailored for Adults with Type 2 Diabetes SO Obesity LA English DT Article ID LIFE-STYLE INTERVENTION; CARDIOVASCULAR RISK-FACTORS; SELF-MANAGEMENT EDUCATION; OBESE-PATIENTS; CLINICAL-TRIAL; UNITED-STATES; NUTRITION; METAANALYSIS; PREVALENCE; OVERWEIGHT AB Objective: Modest weight loss from clinical interventions improves glycemic control in type 2 diabetes (T2DM). Data are sparse on the effects of weight loss via commercial weight loss programs. This study examined the effects on glycemic control and weight loss of the standard Weight Watchers program, combined with telephone and email consultations with a certified diabetes educator (WW), compared with standard diabetes nutrition counseling and education (standard care, SC). Methods: In a 12-month randomized controlled trial at 16 U.S. research centers, 563 adults with T2DM (HbA(1c) 7-11%; BMI 27-50 kg/m(2)) were assigned to either the commercially available WW program (regular community meetings, online tools), plus telephone and email counseling from a certified diabetes educator, or to SC (initial in-person diabetes nutrition counseling/education, with follow-up informational materials). Results: Follow-up rate was 86%. Twelve-month HbA(1c) changes for WW and SC were 20.32 and 10.16, respectively; 24% of WW versus 14% of SC achieved HbA(1c) <7.0% (P = 0.004). Weight losses were -4.0% for WW and -1.9% for SC (Ps < 0.001). 26% of WW versus 12% of SC reduced diabetes medications (P < 0.001). WW participants had greater reductions in waist circumference (P < 0.001) and C-reactive protein (P = 0.02) but did not differ on other cardiovascular risk factors. Conclusions: Widely available commercial weight loss programs with community and online components, combined with scalable complementary diabetes education, may represent accessible and effective components of management plans for adults with overweight/obesity and T2DM. C1 [O'Neil, Patrick M.; Tuerk, Peter W.; Becker, Lynne E.; Malcolm, Robert J.] Med Univ South Carolina, Weight Management Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Miller-Kovach, Karen; Rost, Stephanie L.; Veliko, Jan L.] Weight Watchers Int, New York, NY USA. [Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Wadden, Thomas A.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Fujioka, Ken] Scripps Clin Res, La Jolla, CA USA. [Hollander, Priscilla L.] Baylor Endocrine Ctr, Dallas, TX USA. [Kushner, Robert F.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Rubino, Domenica M.] Washington Ctr Weight Management & Res, Arlington, VA USA. [Weiss, Daniel] Your Diabet Endocrine Nutr Grp, Mentor, OH USA. [Raum, William J.] Oregon Weight Loss Surg, Portland, OR USA. [Salyer, Jonny L.] Lovelace Sci Resources, Albuquerque, NM USA. [Hermayer, Kathie L.; Sora, Nicoleta D.] Med Univ South Carolina, Div Endocrinol Diabet & Med Genet, Coll Med, Charleston, SC USA. RP O'Neil, PM (reprint author), Med Univ South Carolina, Weight Management Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM oneilp@musc.edu FU Weight Watchers International (WWI) FX This study was funded by a grant from Weight Watchers International (WWI) to the Medical University of South Carolina (MUSC). NR 33 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD NOV PY 2016 VL 24 IS 11 BP 2269 EP 2277 DI 10.1002/oby.21616 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA ED8VG UT WOS:000389148400004 PM 27804264 ER PT J AU Good, MM Riad, FS Good, CB Shalaby, AA AF Good, Meghan M. Riad, Fady S. Good, Chester B. Shalaby, Alaa A. TI Provider Response to QTc Prolongation on Standard 12-Lead EKG: Do We Notice or Do We Care? SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE QTc; EKG; drug interaction ID AMERICAN-HEART-ASSOCIATION; OF-CARDIOLOGY FOUNDATION; IN-HOSPITAL SETTINGS; TORSADE-DE-POINTES; INTERVAL PROLONGATION; SCIENTIFIC STATEMENT; CLINICAL CARDIOLOGY; MEDICATION ERRORS; PATIENT SAFETY; RISK AB Background: Drugs and electrolyte imbalances are widely recognized as common triggers of a prolonged QT interval. We conducted a chart review to assess provider response to prolonged QT reported on a standard 12-lead electrocardiogram (EKG). Methods: We identified all Veterans Affairs Pittsburgh Healthcare System patients in a 6-month period with an EKG reporting a corrected QT (QTc) >500 ms. We excluded confounding or uninterpretable EKGs. Charts were reviewed to assess medications and electrolytes at the time of the EKG as well as the setting (inpatient vs outpatient) in which the EKG was obtained. Provider documentation of QTc and any corrective measures were sought. Results: After exclusions, 106 patients were included in this analysis (87 [82%] inpatient and 19 [18%] outpatient). Most were male (101, 95%) with a mean age of 63.5 +/- 10.6 years. At the time of index EKG, most patients were receiving at least one (72, 68%), and frequently two or more (35, 33%), QTc prolonging medications. Providers documented QTc prolongation in 20 inpatients (19%). Drugs were adjusted or discontinued in only two inpatients (2%). There were 14 patients (14%) with potassium level <3.6 mmol/L and 10 of 69 (14%) patients had a magnesium level <1.7 mg/dL. Conclusion: Patients with prolonged QTc on EKG were more likely to be inpatients than outpatients. Inpatients were more likely to be receiving multiple types and classes of QTc prolonging medications. In the vast majority of cases, providers did not address the prolonged QTc and only rarely initiated remedial actions. C1 [Good, Meghan M.] Vet Affairs Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA USA. [Riad, Fady S.; Good, Chester B.; Shalaby, Alaa A.] Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA USA. [Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.; Shalaby, Alaa A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Shalaby, Alaa A.] Vet Affairs Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. RP Shalaby, AA (reprint author), 111C Univ Dr, Pittsburgh, PA 15240 USA. EM Alaa.Shalaby@va.gov OI Riad, Fady/0000-0001-7874-2328 NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0147-8389 EI 1540-8159 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD NOV PY 2016 VL 39 IS 11 BP 1174 EP 1180 DI 10.1111/pace.12951 PG 7 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA ED8US UT WOS:000389147000002 PM 27628760 ER PT J AU Hummel, JD Coppess, MA Osborn, JS Yee, R Fung, JWH Augostini, R Li, S Hine, D Singh, JP AF Hummel, John D. Coppess, Mark A. Osborn, Jeffrey S. Yee, Raymond Fung, Jeffrey W. H. Augostini, Ralph Li, Shelby Hine, Douglas Singh, Jagmeet P. TI Real-World Assessment of Acute Left Ventricular Lead Implant Success and Complication Rates: Results from the Attain Success Clinical Trial SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE left ventricular lead; cardiac resynchronization; coronary sinus ID CARDIAC-RESYNCHRONIZATION THERAPY; ADVANCED HEART-FAILURE AB Background: Left ventricular lead (LVL) implant success rates have historically ranged between 70.5% and 95.5%. To date, there are few large studies that evaluate LVL implant success utilizing a single family of delivery catheters and leads. The Attain Success study was a prospective nonrandomized multicenter global study with the main objectives of assessing single-system LVL implant success and complication rates. Methods: Patients undergoing cardiac resynchronization therapy implantation were eligible for enrollment. There was no prespecified level of experience for investigator participation. LVL implant success and complication rates were assessed though 3 months of follow-up. Results: A total of 2,014 patients (69.1 +/- 12.0 years, 71% male and 38% atrial fibrillation) were enrolled from 114 centers with a follow-up of 3.5 +/- 2.1 months. Coronary sinus cannulation success rate was 96.4% with Attain Family delivery catheters. Implant success rate for Attain Family leads using Attain Family catheters was 94.0%; overall LVL implant success rate was 97.1%. Median procedure time was 4 minutes for cannulation and 9 minutes for LVL placement. Median fluoroscopy time was 17 minutes and median contrast used was 25 cc. There were 55 catheter or LVL-related complications in 53 subjects; the majority were LVL dislodgements (34, 1.7%) and extracardiac stimulation (11, 0.5%). The Kaplan-Meier estimate of the 3-month complication probability was 2.6%. Conclusion: This study represents the largest prospective evaluation of LVL implantation to date, revealing a high LVL implant success rate and low complication rate using a single family of leads and delivery catheters. C1 [Hummel, John D.; Augostini, Ralph] Ohio State Univ, Columbus, OH 43210 USA. [Coppess, Mark A.] Stern Cardiovasc Ctr, Germantown, TN USA. [Osborn, Jeffrey S.] Intermt Med Ctr, Murray, UT USA. [Yee, Raymond] London Hlth Sci Ctr, London, ON, Canada. [Fung, Jeffrey W. H.] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China. [Li, Shelby; Hine, Douglas] Medtronic, Mounds View, MN USA. [Singh, Jagmeet P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Hummel, JD (reprint author), Ohio State Univ, Davis Heart & Lung Res Inst, 473 West 12th Ave,Ste 200, Columbus, OH 43210 USA. EM John.Hummel@osumc.edu NR 13 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0147-8389 EI 1540-8159 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD NOV PY 2016 VL 39 IS 11 BP 1246 EP 1253 DI 10.1111/pace.12939 PG 8 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA ED8US UT WOS:000389147000010 PM 27549013 ER PT J AU Cohen, JV Tawbi, H Margolin, KA Amravadi, R Bosenberg, M Brastianos, PK Chiang, VL de Groot, J Glitza, IC Herlyn, M Holmen, SL Jilaveanu, LB Lassman, A Moschos, S Postow, MA Thomas, R Tsiouris, JA Wen, P White, RM Turnham, T Davies, MA Kluger, HM AF Cohen, Justine V. Tawbi, Hussain Margolin, Kim A. Amravadi, Ravi Bosenberg, Marcus Brastianos, Priscilla K. Chiang, Veronica L. de Groot, John Glitza, Isabella C. Herlyn, Meenhard Holmen, Sheri L. Jilaveanu, Lucia B. Lassman, Andrew Moschos, Stergios Postow, Michael A. Thomas, Reena Tsiouris, John A. Wen, Patrick White, Richard M. Turnham, Timothy Davies, Michael A. Kluger, Harriet M. TI Melanoma central nervous system metastases: current approaches, challenges, and opportunities SO PIGMENT CELL & MELANOMA RESEARCH LA English DT Review DE brain metastasis; leptomeningeal disease; tumor microenvironment; clinical trials; experimental models ID WHOLE-BRAIN RADIOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; RANDOMIZED CONTROLLED-TRIAL; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; QUALITY-OF-LIFE; PHASE-II TRIAL; OPEN-LABEL; STEREOTACTIC RADIOSURGERY; LEPTOMENINGEAL METASTASES AB Melanoma central nervous system metastases are increasing, and the challenges presented by this patient population remain complex. In December 2015, the Melanoma Research Foundation and the Wistar Institute hosted the First Summit on Melanoma Central Nervous System (CNS) Metastases in Philadelphia, Pennsylvania. Here, we provide a review of the current status of the field of melanoma brain metastasis research; identify key challenges and opportunities for improving the outcomes in patients with melanoma brain metastases; and set a framework to optimize future research in this critical area. C1 [Cohen, Justine V.; Bosenberg, Marcus; Chiang, Veronica L.; Jilaveanu, Lucia B.; Kluger, Harriet M.] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA. [Tawbi, Hussain; Glitza, Isabella C.; Davies, Michael A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA. [Margolin, Kim A.] City Hope Canc Ctr, Dept Med Oncol Therapeut Res, Duarte, CA USA. [Amravadi, Ravi] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Brastianos, Priscilla K.] Massachusetts Gen Hosp, Div Neuro Oncol, Boston, MA 02114 USA. [de Groot, John] Univ Texas MD Anderson Canc Ctr, Div Neurooncol, Houston, TX 77030 USA. [Herlyn, Meenhard] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA. [Holmen, Sheri L.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT USA. [Lassman, Andrew] Columbia Univ, Med Ctr, Ctr Canc, Dept Neurol & Herbert Irving Comprehens, New York, NY USA. [Moschos, Stergios] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Postow, Michael A.] Mem Sloan Kettering Canc Ctr & Weill Cornell Med, Dept Oncol, New York, NY USA. [Thomas, Reena] Stanford Univ, Dept Neurol, Div Neurooncol, Stanford, CA 94305 USA. [Tsiouris, John A.] New York Presbyterian Hosp Weill Cornell Med, Dept Radiol, New York, NY USA. [Wen, Patrick] Dana Farber Canc Inst, Dept Neuro Oncol, Boston, MA 02115 USA. [White, Richard M.] Mem Sloan Kettering Canc Ctr & Weill Cornell Med, Dept Canc Biol Genet, New York, NY USA. [Turnham, Timothy] Melanoma Res Fdn, Washington, DC USA. RP Kluger, HM (reprint author), Yale Sch Med, Yale Canc Ctr, New Haven, CT USA.; Davies, MA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA. EM mdavies@mdanderson.org; harriet.kluger@yale.edu FU BMS; Novartis; Merck; Agios; Angiochem; Astra Zeneca; Exelixis; Genentech/Roche; GlaxosmithKline; Karyopharm; ORIC Pharmaceuticals; Sanofi-Aventis; Regeneron Pharmaceuticals Inc.; Vascular Biogenics; Roche/Genentech; Myriad; Oncothyreon FX HT receives research funding from BMS, Novartis, and Merck and has consulted for BMS, Novartis, and Genentech/Roche. PKB has consulted for Genentech and has received Speaker's Honoraria for Genentech and Merck. SM has received a travel grant from Novartis and research funding from Merck. MAP has received honoraria from BMS and Merck and receives research grant support from BMS. He sits on the advisory board of BMS. PW has research support from Agios, Angiochem, Astra Zeneca, BMS, Exelixis, Genentech/Roche, GlaxosmithKline, Karyopharm, Novartis, ORIC Pharmaceuticals, Sanofi-Aventis, Regeneron Pharmaceuticals Inc., Vascular Biogenics. He sits on the advisory boards of AbbVie, Cavion, Celldex, Genentech/Roche, Midatech, Momenta, Novartis, Novocure, SigmaTau, and Vascular Biogenics and on the speaker's bureau of Merck. MAD has served on advisory boards for Novartis, Glaxosmithkline, Roche/Genentech, and Sanofi-Aventis and has received research funding from Glaxosmithkline, Roche/Genentech, Sanofi-Aventis, Myriad, and Oncothyreon. HMK has received research funding from Merck. She has consulted for Regeneron, Alexion, and Prometheus. NR 141 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-1471 EI 1755-148X J9 PIGM CELL MELANOMA R JI Pigment Cell Melanoma Res. PD NOV PY 2016 VL 29 IS 6 BP 627 EP 642 DI 10.1111/pcmr.12538 PG 16 WC Oncology; Cell Biology; Dermatology SC Oncology; Cell Biology; Dermatology GA EC7JH UT WOS:000388312900006 PM 27615400 ER PT J AU Izar, B Joyce, CE Goff, S Cho, NL Shah, PM Sharma, G Li, JJ Ibrahim, N Gold, J Hodi, FS Garraway, LA Novina, CD Bertagnolli, MM Yoon, CH AF Izar, Benjamin Joyce, Cailin E. Goff, Stephanie Cho, Nancy L. Shah, Parin M. Sharma, Gaurav Li, Jingjing Ibrahim, Nageatte Gold, Jason Hodi, F. Stephen Garraway, Levi A. Novina, Carl D. Bertagnolli, Monica M. Yoon, Charles H. TI Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation SO PIGMENT CELL & MELANOMA RESEARCH LA English DT Article DE melanoma; tumor stroma; CAFs; metastasis; TGF; EGFR ID CARCINOMA-ASSOCIATED FIBROBLASTS; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; TUMOR MICROENVIRONMENT; STROMAL FIBROBLASTS; COLORECTAL-CANCER; MESENCHYMAL TRANSITION; METASTATIC MELANOMA; PANCREATIC-CANCER; POOR-PROGNOSIS AB Tumor-stroma interactions are critical for epithelial-derived tumors, and among the stromal cell types, cancer-associated fibroblasts (CAFs) exhibit multiple functions that fuel growth, dissemination, and drug resistance. However, these interactions remain insufficiently characterized in non-epithelial tumors such as malignant melanoma. We generated monocultures of melanoma cells and matching CAFs from patients' metastatic lesions, distinguished by oncogenic drivers and immunoblotting of characteristic markers. RNA sequencing of CAFs revealed a homogenous epigenetic program that strongly resembled the signatures from epithelial cancers, including enrichment for an epithelial-to-mesenchymal transition (EMT). Melanoma CAFs in monoculture displayed robust invasive behavior while patient-derived melanoma monocultures showed very little invasiveness. Instead, melanoma cells showed increased invasion when co-cultured with CAFs. In turn, CAFs showed increased proliferation when exposed to melanoma conditioned media (CM), mediated in part by melanoma-secreted transforming growth factor-alpha that acted on CAFs via the epidermal growth factor receptor. This study provides evidence that bidirectional interactions between melanoma and CAFs regulate progression of metastatic melanoma. C1 [Izar, Benjamin; Goff, Stephanie; Cho, Nancy L.; Sharma, Gaurav; Bertagnolli, Monica M.; Yoon, Charles H.] Brigham & Womens Hosp, Div Surg Oncol, Dept Surg, 75 Francis St, Boston, MA 02115 USA. [Izar, Benjamin; Joyce, Cailin E.; Shah, Parin M.; Garraway, Levi A.; Novina, Carl D.] Broad Inst & Harvard, Cambridge, MA USA. [Izar, Benjamin; Shah, Parin M.; Li, Jingjing; Ibrahim, Nageatte; Hodi, F. Stephen; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Joyce, Cailin E.; Novina, Carl D.] Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA. [Gold, Jason] VA Boston Hlth Care Serv, Surg Serv, Dept Surg, West Roxbury, MA USA. [Goff, Stephanie] Natl Canc Inst, Surg Branch, NIH, 10-3940,10 Ctr Dr,MSC 1201, Bethesda, MD 20892 USA. [Ibrahim, Nageatte] Merck Res Labs, Oncol, 351 North Sumneytown Pike, N Wales, PA 19454 USA. RP Yoon, CH (reprint author), Brigham & Womens Hosp, Div Surg Oncol, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM chyoon@bics.bwh.harvard.edu NR 65 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-1471 EI 1755-148X J9 PIGM CELL MELANOMA R JI Pigment Cell Melanoma Res. PD NOV PY 2016 VL 29 IS 6 BP 656 EP 668 DI 10.1111/pcmr.12513 PG 13 WC Oncology; Cell Biology; Dermatology SC Oncology; Cell Biology; Dermatology GA EC7JH UT WOS:000388312900008 PM 27482935 ER PT J AU Jeon, HJ Woo, JM Kim, HJ Fava, M Mischoulon, D Cho, SJ Chang, SM Park, DH Kim, JW Yoo, I Heo, JY Hong, JP AF Jeon, Hong Jin Woo, Jong-Min Kim, Hyo-Jin Fava, Maurizio Mischoulon, David Cho, Seong Jin Chang, Sung Man Park, Doo-Heum Kim, Jong Woo Yoo, Ikki Heo, Jung-Yoon Hong, Jin Pyo TI Gender Differences in Somatic Symptoms and Current Suicidal Risk in Outpatients with Major Depressive Disorder SO PSYCHIATRY INVESTIGATION LA English DT Article DE Somatic symptom; Suicidality; Gender difference; Chest pain ID MELANCHOLIC FEATURES; PAIN; ASSOCIATION; PSYCHOPATHOLOGY; COMORBIDITY; COMPLETION; PREVALENCE; VALIDATION; PREDICTORS; HOSTILITY AB Objective Although somatic symptoms are common complaints of patients with major depressive disorder (MDD), their associations with suicide are still unclear. Methods A total of 811 MDD outpatients of aged between 18 to 64 years were enrolled nationwide in Korea with the suicidality module of the Mini-International Neuropsychiatric Interview (MINI) and the Depression and Somatic Symptom Scale (DSSS). Results On stepwise regression analysis, current suicidality scores were most strongly associated with chest pain in men, and neck or shoulder pain in women. Severe chest pain was associated with higher current suicidality scores in men than in women, whereas severe neck or shoulder pain showed no significant differences between the genders. In conclusion, MDD patients of both sexes with suicidal ideation showed significantly more frequent and severe somatic symptoms than those without. Current suicidal risk was associated with chest pain in men, and neck or shoulder pain in women. Conclusion We suggest that clinicians pay attention to patients' somatic symptoms in real world practice. C1 [Jeon, Hong Jin; Yoo, Ikki; Heo, Jung-Yoon; Hong, Jin Pyo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul, South Korea. [Jeon, Hong Jin; Fava, Maurizio; Mischoulon, David] Harvard Med Sch, Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA USA. [Woo, Jong-Min] Inje Univ, Sch Med, Seoul Paik Hosp, Dept Psychiat, Seoul, South Korea. [Woo, Jong-Min] Inje Univ, Stress Res Inst, Seoul, South Korea. [Kim, Hyo-Jin] Pfizer Korea, Corp Affairs Hlth & Value Div, OR RWD Team, Seoul, South Korea. [Cho, Seong Jin] Gachon Med Sch, Gil Med Ctr, Dept Psychiat, Inchon, South Korea. [Chang, Sung Man] Kyungpook Natl Univ, Sch Med, Kyungpook Natl Univ Hosp, Dept Psychiat, Daegu, South Korea. [Park, Doo-Heum] Konkuk Univ, Sch Med, Dept Psychiat, Seoul, South Korea. [Kim, Jong Woo] Kyung Hee Univ, Coll Med, Kyung Hee Univ Hosp, Dept Psychiat, Seoul, South Korea. RP Hong, JP (reprint author), Sungkynkwan Univ, Dept Psychiat, Sch Med, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea. EM suhurhong@gmail.com FU Pfizer Pharmaceuticals Korea Ltd.; Basic Science Research Program through the National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology [2011-0013064]; Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A120051] FX This study was supported by Pfizer Pharmaceuticals Korea Ltd. and the Basic Science Research Program through the National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology (No. 2011-0013064). This study was also supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120051 suicide prevention research center). NR 40 TC 0 Z9 0 U1 4 U2 4 PU KOREAN NEUROPSYCHIATRIC ASSOC PI SEOUL PA RN 522, G-FIVE CENTRAL PLAZA 1685-8 SEOCHO 4-DONG, SEOCHO-GU, SEOUL, 137-882, SOUTH KOREA SN 1738-3684 EI 1976-3026 J9 PSYCHIAT INVEST JI Psychiatry Investig. PD NOV PY 2016 VL 13 IS 6 BP 609 EP 615 DI 10.4306/pi.2016.13.6.609 PG 7 WC Psychiatry SC Psychiatry GA ED3XU UT WOS:000388782600005 PM 27909451 ER PT J AU Wortmann, JH Jordan, AH Weathers, FW Resick, PA Dondanville, KA Hall-Clark, B Foa, EB Young-McCaughan, S Yarvis, JS Hembree, EA Mintz, J Peterson, AL Litz, BT AF Wortmann, Jennifer H. Jordan, Alexander H. Weathers, Frank W. Resick, Patricia A. Dondanville, Katherine A. Hall-Clark, Brittany Foa, Edna B. Young-McCaughan, Stacey Yarvis, Jeffrey S. Hembree, Elizabeth A. Mintz, Jim Peterson, Alan L. Litz, Brett T. CA STRONG STAR Consortium TI Psychometric Analysis of the PTSD Checklist-5 (PCL-5) Among Treatment-Seeking Military Service Members SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE PTSD; PCL-5; military; psychometrics ID POSTTRAUMATIC-STRESS-DISORDER; CLINICAL-SIGNIFICANCE; DIMENSIONAL STRUCTURE; NATIONAL-HEALTH; SYMPTOMS; VETERANS; DSM-5; VALIDITY; SCALE; EXPERIENCES AB ` The Posttraumatic Stress Disorder Checklist (PCL-5; Weathers et al., 2013) was recently revised to reflect the changed diagnostic criteria for posttraumatic stress disorder (PTSD) in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 2013). We investigated the psychometric properties of PCL-5 scores in a large cohort (N = 912) of military service members seeking PTSD treatment while stationed in garrison. We examined the internal consistency, convergent and discriminant validity, and DSM-5 factor structure of PCL-5 scores, their sensitivity to clinical change relative to PTSD Symptom Scale-Interview (PSS-I; Foa, Riggs, Dancu, & Rothbaum, 1993) scores, and their diagnostic utility for predicting a PTSD diagnosis based on various measures and scoring rules. PCL-5 scores exhibited high internal consistency. There was strong agreement between the order of hypothesized and observed correlations among PCL-5 and criterion measure scores. The best-fitting structural model was a 7-factor hybrid model (Armour et al., 2015), which demonstrated closer fit than all other models evaluated, including the DSM-5 model. The PCL-5's sensitivity to clinical change, pre-to posttreatment, was comparable with that of the PSS-I. Optimally efficient cut scores for predicting PTSD diagnosis were consistent with prior research with service members (Hoge, Riviere, Wilk, Herrell, & Weathers, 2014). The results indicate that the PCL-5 is a psychometrically sound measure of DSM-5 PTSD symptoms that is useful for identifying provisional PTSD diagnostic status, quantifying PTSD symptom severity, and detecting clinical change over time in PTSD symptoms among service members seeking treatment. C1 [Wortmann, Jennifer H.; Jordan, Alexander H.; Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Jamaica Plain, MA USA. [Wortmann, Jennifer H.; Jordan, Alexander H.; Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Weathers, Frank W.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Resick, Patricia A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. [Dondanville, Katherine A.; Hall-Clark, Brittany] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Foa, Edna B.; Hembree, Elizabeth A.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Young-McCaughan, Stacey; Mintz, Jim; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Yarvis, Jeffrey S.] Carl R Darnall Army Med Ctr, Dept Behav Hlth, Ft Hood, TX USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Peterson, Alan L.] South Texas Vet Hlth Care Syst, Off Res & Dev, San Antonio, TX USA. RP Wortmann, JH (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave 151 MAV, Boston, MA 02130 USA. EM jennifer.wortmann@va.gov FU U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command; Congressionally Directed Medical Research Programs; Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-02-109, W81XWH-08-02-0111, W81XWH-08-02-0114, W81XWH-08-02-0116] FX This material is the result of work supported with resources and the use of facilities at the VA Boston Healthcare System and South Texas Veterans Health Care System. The views expressed in this article are solely those of the authors and do not reflect an endorsement by or the official policy of the U.S. Army, the Department of Defense, the Department of Veterans Affairs, or the U.S. Government. Dr. Foa receives royalties from the sale of Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences Therapist Guide and Reclaiming Your Life From a Traumatic Experience Workbook by Oxford University Press (New York, NY). Dr. Foa also receives payment for training she conducts on prolonged exposure therapy. Funding for this work was made possible by the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-02-109 (Alan Peterson), W81XWH-08-02-0111 (Edna Foa), W81XWH-08-02-0114 (Brett Litz), and W81XWH-08-02-0116 (Patricia Resick). We thank Robert A. Lew, PhD, for his consultation on the clinical change analyses. NR 55 TC 2 Z9 2 U1 13 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD NOV PY 2016 VL 28 IS 11 BP 1392 EP 1403 DI 10.1037/pas0000260 PG 12 WC Psychology, Clinical SC Psychology GA EE0YY UT WOS:000389307800005 PM 26751087 ER PT J AU Feemster, L AF Feemster, L. TI E-CIGARETTES UPDATE SO RESPIROLOGY LA English DT Meeting Abstract C1 [Feemster, L.] Univ Washington, VA Puget Sound HCS, Med Pulm & Crit Care, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 SU 3 SI SI MA APSR6-0839 BP 7 EP 7 PG 1 WC Respiratory System SC Respiratory System GA EC0NJ UT WOS:000387797600018 ER PT J AU Feemster, L AF Feemster, L. TI FACILITATING ADOPTION OF COPD EVIDENCE BASED CARE IN OUTPATIENT SETTINGS (FACES) SO RESPIROLOGY LA English DT Meeting Abstract C1 [Feemster, L.] Univ Washington, VA Puget Sound HCS, Med Pulm & Crit Care, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 SU 3 SI SI MA APSR6-0840 BP 15 EP 15 PG 1 WC Respiratory System SC Respiratory System GA EC0NJ UT WOS:000387797600045 ER PT J AU Mcgarvey, L Calverley, PM Metzdorf, N Mueller, A Wise, RA Anzueto, A Dusser, D AF Mcgarvey, L. Calverley, P. M. Metzdorf, N. Mueller, A. Wise, R. A. Anzueto, A. Dusser, D. TI PRODUCTIVE COUGH AS A PREDICTOR OF MORTALITY, EXACERBATIONS AND CARDIAC EVENTS IN THE TIOSPIR (R) TRIAL SO RESPIROLOGY LA English DT Meeting Abstract C1 [Mcgarvey, L.] Queens Univ, Ctr Infect & Immun, Belfast, Antrim, North Ireland. [Calverley, P. M.] Univ Liverpool, Ctr Clin Sci, Inst Ageing & Chron Dis, Liverpool, Merseyside, England. [Metzdorf, N.] Boehringer Ingelheim Pharma GmbH & Co KG, Resp Med, Ingelheim, Germany. [Mueller, A.] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci Europe, Biberach, Germany. [Wise, R. A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, Pulm Crit Care, San Antonio, TX USA. [Dusser, D.] Univ Paris 05, Hosp Cochin, AP HP, Dept Pneumol, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD NOV PY 2016 VL 21 SU 3 SI SI MA APSR6-0703 BP 120 EP 120 PG 1 WC Respiratory System SC Respiratory System GA EC0NJ UT WOS:000387797600357 ER PT J AU Zhou, IY Fuss, TL Igarashi, T Jiang, WP Zhou, X Cheng, LL Sun, PZ AF Zhou, Iris Yuwen Fuss, Taylor L. Igarashi, Takahiro Jiang, Weiping Zhou, Xin Cheng, Leo L. Sun, Phillip Zhe TI Tissue Characterization with Quantitative High-Resolution Magic Angle Spinning Chemical Exchange Saturation Transfer Z-Spectroscopy SO ANALYTICAL CHEMISTRY LA English DT Article ID NUCLEAR OVERHAUSER ENHANCEMENT; ENCODED CEST SPECTROSCOPY; AMIDE PROTON-TRANSFER; MRI CONTRAST AGENTS; MAGNETIZATION-TRANSFER; IN-VIVO; NMR-SPECTROSCOPY; H-1-NMR SPECTROSCOPY; SINGLE-SCAN; HUMAN BRAIN AB Chemical exchange saturation transfer (CEST) provides sensitive magnetic resonance (MR) contrast for probing dilute compounds via exchangeable protons, serving as an emerging molecular imaging methodology. CEST Z-spectrum is often acquired by sweeping radiofrequency saturation around bulk water resonance, offset by offset, to detect CEST effects at characteristic chemical shift offsets, which requires prolonged acquisition time. Herein, combining high-resolution magic angle spinning (HRMAS) with concurrent application of gradient and rf saturation to achieve fast Z-spectral acquisition, we demonstrated the feasibility of fast quantitative HRMAS CEST Z-spectroscopy. The concept was validated with phantoms, which showed excellent agreement with results obtained from conventional HRMAS MR spectroscopy (MRS). We further utilized the HRMAS Z-spectroscopy for fast ex vivo quantification of ischemic injury with rodent brain tissues after ischemic stroke. This method allows rapid and quantitative CEST characterization of biological tissues and shows potential for a host of biomedical applications. C1 [Zhou, Iris Yuwen; Fuss, Taylor L.; Igarashi, Takahiro; Jiang, Weiping; Cheng, Leo L.; Sun, Phillip Zhe] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Zhou, Iris Yuwen; Fuss, Taylor L.; Igarashi, Takahiro; Jiang, Weiping; Cheng, Leo L.; Sun, Phillip Zhe] Harvard Med Sch, Charlestown, MA 02129 USA. [Fuss, Taylor L.; Cheng, Leo L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Fuss, Taylor L.; Cheng, Leo L.] Harvard Med Sch, Boston, MA 02114 USA. [Igarashi, Takahiro] Nihon Univ, Sch Med, Dept Neurol Surg, Div Neurosurg, Tokyo 1738610, Japan. [Jiang, Weiping; Zhou, Xin] Chinese Acad Sci, Wuhan Inst Phys & Math, Natl Ctr Magnet Resonance Wuhan, State Key Lab Magnet Resonance & Atom & Mol Phys, Wuhan 430071, Peoples R China. RP Sun, PZ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.; Sun, PZ (reprint author), Harvard Med Sch, Charlestown, MA 02129 USA. EM pzhesun@mgh.harvard.edu RI Zhou, Iris Yuwen/A-2089-2017 OI Zhou, Iris Yuwen/0000-0002-4351-7398 FU NIH/NINDS Grant [1R21NS085574, 1R01NS083654]; PHS NIH Grant [CA115746]; NSFC Grant [81227902] FX This study was supported in part by grants from NIH/NINDS Grant 1R21NS085574 (P.Z.S.), NIH/NINDS Grant 1R01NS083654 (P.Z.S.), PHS NIH Grant CA115746 (L.L.C.), and NSFC Grant 81227902 (X. Z.). NR 50 TC 0 Z9 0 U1 5 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD NOV 1 PY 2016 VL 88 IS 21 BP 10379 EP 10383 DI 10.1021/acs.analchem.6b03137 PG 5 WC Chemistry, Analytical SC Chemistry GA EA9UW UT WOS:000386991200009 PM 27709896 ER PT J AU Lao, LF Shen, J Tian, HJ Yao, QQ Li, YW Qian, L Murray, SS Wang, JC AF Lao, Lifeng Shen, Jia Tian, Haijun Yao, Qingqiang Li, Yawei Qian, Lie Murray, Samuel S. Wang, Jeffrey C. TI Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2 SO ANTICANCER RESEARCH LA English DT Article DE Prostate cancer; bone morphogenetic protein 2; secreted phosphoprotein 24 kD; bone metastasis ID BONE MORPHOGENETIC PROTEIN-2; TUMOR-GROWTH; SPP24; EXPRESSION; METASTASIS; ACTIVATION; LESIONS AB Background/Aim: Secreted phosphoprotein 24 kD (spp24) has been shown to inhibit bone morphogenetic protein 2 (BMP2)-induced cancer growth in several tumor models. In this study, we aimed to investigate the effects spp24 on the growth of prostate cancer caused by BMP2 in vitro and in vivo. Materials and Methods: The effects of BMP2 and spp24 on PC-3 cell viability were analyzed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. A subcutaneous tumor model and intratibial tumor model was established using PC-3 cells. Tumor growth was assessed through gross examination and radiography during the experiment. Then, after sacrifice, tumor cell apoptosis and tumor cell proliferation were assessed by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and immunochemical analysis. Results: BMP2 stimulated the PC-3 cell proliferation in vitro and spp24 could abolish the effect of BMP2. In a xeneograft tumor model, BMP2 promoted the subcutaneous and intratibial tumor growth, while spp24 dramatically inhibited the tumor growth induced by BMP2. Histological examination showed that spp24 also abolished the BMP2-induced proliferating cell nuclear antigen (PCNA) expression and promoted tumor cell apoptosis. Conclusion: Spp24 can inhibit the growth of prostate cancer and its bone metastasis induced by BMP2; spp24 may have great potential to be a therapeutic agent in clinical situations. C1 [Lao, Lifeng; Qian, Lie] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, 160 Pujian Rd, Shanghai 200127, Peoples R China. [Shen, Jia; Tian, Haijun; Yao, Qingqiang; Li, Yawei] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA. [Murray, Samuel S.] VA Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. [Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Murray, Samuel S.] Univ Calif Los Angeles, Biomed Engn Interdept Program, Los Angeles, CA USA. [Wang, Jeffrey C.] Univ Southern Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA USA. RP Qian, L (reprint author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, 160 Pujian Rd, Shanghai 200127, Peoples R China. EM lqianrj@sina.com FU Shanghai Pujiang Program [15PJD026]; Medical-Engineering Joint Fund of Shanghai Jiao Tong University [YG2014MS51]; Shanghai Fund for Young Physician Development [20141051]; Incubating Program for Clinical Research and Innovation of Renji Hospital [PYXJS16-006] FX This research was funded by Shanghai Pujiang Program (NO. 15PJD026), Medical-Engineering Joint Fund of Shanghai Jiao Tong University (NO. YG2014MS51), Shanghai Fund for Young Physician Development (NO. 20141051), Incubating Program for Clinical Research and Innovation of Renji Hospital (NO. PYXJS16-006). NR 30 TC 1 Z9 1 U1 0 U2 0 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD NOV PY 2016 VL 36 IS 11 SI SI BP 5773 EP 5780 DI 10.21873/anticanres.11161 PG 8 WC Oncology SC Oncology GA EC9TI UT WOS:000388486700020 PM 27793899 ER PT J AU Hecht, PM Hudson, M Connors, SL Tilley, MR Liu, XD Beversdorf, DQ AF Hecht, Patrick M. Hudson, Melissa Connors, Susan L. Tilley, Michael R. Liu, Xudong Beversdorf, David Q. TI Maternal serotonin transporter genotype affects risk for ASD with exposure to prenatal stress SO AUTISM RESEARCH LA English DT Article DE autism spectrum disorders; serotonin; stress; prenatal stress; development; environmental influences ID OBSESSIVE-COMPULSIVE DISORDER; POLYMORPHISM 5-HTTLPR; BRAIN-DEVELOPMENT; AUTISM; GENE; ASSOCIATION; DEPRESSION; SLC6A4; REGION; MICE AB Stress exposure during gestation is implicated in several neuropsychiatric conditions, including autism spectrum disorder (ASD). Previous research showed that prenatal stress increases risk for ASD with peak exposure during the end of the second and the beginning of the third trimester. However, exposures to prenatal stress do not always result in ASD, suggesting that other factors may interact with environmental stressors to increase ASD risk. The present study examined a maternal genetic variation in the promoter region of the serotonin transporter gene (5-HTTLPR) affecting stress tolerance and its interaction with the effect of environmental stressors on risk for ASD. Two independent cohorts of mothers of ASD children recruited by the University of Missouri and Queen's University were surveyed regarding the prenatal environment and genotyping on 5-HTTLPR was performed to explore this relationship. In both samples, mothers of children with ASD carrying the stress susceptible short allele variant of 5-HTTLPR experienced a greater number of stressors and greater stress severity when compared to mothers carrying the long allele variant. The temporal peak of stressors during gestation in these mothers was consistent with previous findings. Additionally, increased exposure to prenatal stress was not reported in the pregnancies of typically developing siblings from the same mothers, regardless of maternal genotype, suggesting against the possibility that the short allele might increase the recall of stress during pregnancy. The present study provides further evidence of a specific maternal polymorphism that may affect the risk for ASD with exposure to prenatal stress. Autism Res2016, 9: 1151-1160. (c) 2016 International Society for Autism Research, Wiley Periodicals, Inc. C1 [Hecht, Patrick M.; Beversdorf, David Q.] Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO USA. [Hecht, Patrick M.; Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorder, Columbia, MO USA. [Hecht, Patrick M.; Beversdorf, David Q.] Univ Missouri, Ctr Translat Neurosci, Columbia, MO USA. [Hudson, Melissa; Liu, Xudong] Queens Univ, Dept Psychiat, Kingston, ON, Canada. [Connors, Susan L.] Harvard Med Sch, Massachusetts Gen Hosp, Lurie Ctr Autism, Dept Med, Lexington, MA USA. [Connors, Susan L.] Harvard Med Sch, Massachusetts Gen Hosp, Lurie Ctr Autism, Dept Pediat, Lexington, MA USA. [Tilley, Michael R.] Cent Methodist Univ, Dept Biol Sci, Fulton, MO USA. [Beversdorf, David Q.] Univ Missouri, Dept Psychol Sci, Columbia, MO USA. [Beversdorf, David Q.] Univ Missouri, Dept Radiol, Columbia, MO USA. [Beversdorf, David Q.] Univ Missouri, Dept Neurol, Columbia, MO USA. RP Beversdorf, DQ (reprint author), William & Nancy Thompson Chair Radiol, Dept Radiol, DC069-10,One Hosp Dr, Columbia, MO 65212 USA.; Liu, XD (reprint author), Queens Univ, Dept Psychiat, Ongwanada Resource Ctr, 191 Portsmouth Ave, Kingston, ON K7M 8A6, Canada. EM liux@queensu.ca; beversdorfd@health.missouri.edu FU Mizzou Advantage Initiative; University of Missouri College of Medicine Mission Enhancement Fund; Ongwanada Fund FX The authors are grateful to the late Dr. Jeanette Holden for her critical role in this collaborative work. We also thank Lauren Welby and Eloise Jones for their assistance in genotyping and data entry. We also thank Jonathan Hegarty, Bradley Ferguson, and Rachel Zamzow for their helpful comments. This research was supported by the Mizzou Advantage Initiative (DB), and the University of Missouri College of Medicine Mission Enhancement Fund (DB). This work was also supported by an Ongwanada Fund (XL). The authors are very grateful to the families who participated in this research through ASD-CARC (www.autismresearch.com). NR 53 TC 3 Z9 3 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1939-3792 EI 1939-3806 J9 AUTISM RES JI Autism Res. PD NOV PY 2016 VL 9 IS 11 BP 1151 EP 1160 DI 10.1002/aur.1629 PG 10 WC Behavioral Sciences; Psychology, Developmental SC Behavioral Sciences; Psychology GA ED1CH UT WOS:000388581000003 PM 27091118 ER PT J AU Charidimou, A AF Charidimou, Andreas TI Defining retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations SO BRAIN LA English DT Editorial Material ID SMALL VESSEL DISEASE AB This scientific commentary refers to 'Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations', by Stam et al. C1 [Charidimou, Andreas] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. RP Charidimou, A (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. EM andreas.charidimou.09@ucl.ac.uk NR 5 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD NOV PY 2016 VL 139 BP 2819 EP 2821 DI 10.1093/brain/aww253 PN 11 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ED0WV UT WOS:000388564400010 ER PT J AU Chai, LR Mattar, MG Blank, IA Fedorenko, E Bassett, DS AF Chai, Lucy R. Mattar, Marcelo G. Blank, Idan Asher Fedorenko, Evelina Bassett, Danielle S. TI Functional Network Dynamics of the Language System SO CEREBRAL CORTEX LA English DT Article DE angular gyrus; dynamic networks; flexibility; language; language comprehension; lateralization; modularity; networks ID ANTERIOR TEMPORAL-LOBE; HUMAN BRAIN NETWORKS; RIGHT-HEMISPHERE; SPLIT-BRAIN; COMMUNITY STRUCTURE; FMRI; CONNECTIVITY; LATERALIZATION; COMPREHENSION; PATTERNS AB During linguistic processing, a set of brain regions on the lateral surfaces of the left frontal, temporal, and parietal cortices exhibit robust responses. These areas display highly correlated activity while a subject rests or performs a naturalistic language comprehension task, suggesting that they form an integrated functional system. Evidence suggests that this system is spatially and functionally distinct from other systems that support high-level cognition in humans. Yet, how different regions within this system might be recruited dynamically during task performance is not well understood. Here we use network methods, applied to fMRI data collected from 22 human subjects performing a language comprehension task, to reveal the dynamic nature of the language system. We observe the presence of a stable core of brain regions, predominantly located in the left hemisphere, that consistently coactivate with one another. We also observe the presence of a more flexible periphery of brain regions, predominantly located in the right hemisphere, that coactivate with different regions at different times. However, the language functional ROIs in the angular gyrus and the anterior temporal lobe were notable exceptions to this trend. By highlighting the temporal dimension of language processing, these results suggest a trade-off between a region's specialization and its capacity for flexible network reconfiguration. C1 [Chai, Lucy R.; Mattar, Marcelo G.; Bassett, Danielle S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Mattar, Marcelo G.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [Blank, Idan Asher; Fedorenko, Evelina] MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA. [Blank, Idan Asher; Fedorenko, Evelina] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA. [Fedorenko, Evelina] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Bassett, Danielle S.] Univ Penn, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA. RP Bassett, DS (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Bassett, DS (reprint author), Univ Penn, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA. EM dsb@seas.upenn.edu FU Rachleff Scholars Program of the University of Pennsylvania; NSF award [BCS-1430087]; Psychology Graduate Group of the University of Pennsylvania; NICHD [K99/R00, HD057522]; John D. and Catherine T. MacArthur Foundation; Alfred P. Sloan Foundation; Army Research Laboratory from the U.S. Army Research Office [W911NF-10-2-0022]; U.S. Army Research Office [W911NF-14-1-0679]; National Science Foundation [BCS-1430087, BCS-1441502] FX L.R.C. acknowledges support from the Rachleff Scholars Program of the University of Pennsylvania, and from NSF award #BCS-1430087 to D.S.B. M.M. acknowledges support from the Psychology Graduate Group of the University of Pennsylvania. E.F. was funded by a K99/R00 award HD057522 from NICHD. DSB acknowledges support from the John D. and Catherine T. MacArthur Foundation, the Alfred P. Sloan Foundation, the Army Research Laboratory through contract no. W911NF-10-2-0022 from the U.S. Army Research Office, the U.S. Army Research Office through contract no. W911NF-14-1-0679, and the National Science Foundation award #BCS-1441502 and #BCS-1430087. NR 71 TC 1 Z9 1 U1 13 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD NOV PY 2016 VL 26 IS 11 BP 4148 EP 4159 DI 10.1093/cercor/bhw238 PG 12 WC Neurosciences SC Neurosciences & Neurology GA ED0KV UT WOS:000388532300003 ER PT J AU Kim, J Di Franco, A Seoane, T Srinivasan, A Kampaktsis, PN Geevarghese, A Goldburg, SR Khan, SA Szulc, M Ratcliffe, MB Levine, RA Morgan, AE Maddula, P Rozenstrauch, M Shah, T Devereux, RB Weinsaft, JW AF Kim, Jiwon Di Franco, Antonino Seoane, Tania Srinivasan, Aparna Kampaktsis, Polydoros N. Geevarghese, Alexi Goldburg, Samantha R. Khan, Saadat A. Szulc, Massimiliano Ratcliffe, Mark B. Levine, Robert A. Morgan, Ashley E. Maddula, Pooja Rozenstrauch, Meenakshi Shah, Tara Devereux, Richard B. Weinsaft, Jonathan W. TI Right Ventricular Dysfunction Impairs Effort Tolerance Independent of Left Ventricular Function Among Patients Undergoing Exercise Stress Myocardial Perfusion Imaging SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Article DE echocardiography; exercise; exercise test; exercise tolerance; heart failure ID EMISSION COMPUTED-TOMOGRAPHY; CARDIAC MAGNETIC-RESONANCE; CORONARY-ARTERY-DISEASE; ALL-CAUSE MORTALITY; EJECTION FRACTION; HEART-FAILURE; SYSTOLIC DYSFUNCTION; ECHOCARDIOGRAPHIC-ASSESSMENT; MITRAL REGURGITATION; PROGNOSTIC-SIGNIFICANCE AB Background-Right ventricular (RV) and left ventricular (LV) function are closely linked due to a variety of factors, including common coronary blood supply. Altered LV perfusion holds the potential to affect the RV, but links between LV ischemia and RV performance, and independent impact of RV dysfunction on effort tolerance, are unknown. Methods and Results-The population comprised 2051 patients who underwent exercise stress myocardial perfusion imaging and echo (5.5 +/- 7.9 days), among whom 6% had echo-evidenced RV dysfunction. Global summed stress scores were approximate to 3-fold higher among patients with RV dysfunction, attributable to increments in inducible and fixed LV perfusion defects (all P <= 0.001). Regional inferior and lateral wall ischemia was greater among patients with RV dysfunction (both P<0.01), without difference in corresponding anterior defects (P=0.13). In multivariable analysis, inducible inferior and lateral wall perfusion defects increased the likelihood of RV dysfunction (both P<0.05) independent of LV function, fixed perfusion defects, and pulmonary artery pressure. Patients with RV dysfunction demonstrated lesser effort tolerance whether measured by exercise duration (6.7 +/- 2.8 versus 7.9 +/- 2.9 minutes; P<0.001) or peak treadmill stage (2.6 +/- 0.9 versus 3.1 +/- 1.0; P<0.001), paralleling results among patients with LV dysfunction (7.0 +/- 2.9 versus 8.0 +/- 2.9; P<0.001 vertical bar 2.7 +/- 1.0 versus 3.1 +/- 1.0; P<0.001 respectively). Exercise time decreased stepwise in relation to both RV and LV dysfunction (P<0.001) and was associated with each parameter independent of age or medication regimen. Conclusions-Among patients with known or suspected coronary artery disease, regional LV ischemia involving the inferior and lateral walls confers increased likelihood of RV dysfunction. RV dysfunction impairs exercise tolerance independent of LV dysfunction. C1 [Kim, Jiwon; Seoane, Tania; Srinivasan, Aparna; Kampaktsis, Polydoros N.; Geevarghese, Alexi; Goldburg, Samantha R.; Khan, Saadat A.; Szulc, Massimiliano; Maddula, Pooja; Rozenstrauch, Meenakshi; Shah, Tara; Devereux, Richard B.; Weinsaft, Jonathan W.] Weill Cornell Med Coll, Dept Med, Greenberg Cardiol Div, 525 E 68th St, New York, NY 10021 USA. [Di Franco, Antonino] Weill Cornell Med Coll, Dept Cardiothorac Surg, 525 E 68th St, New York, NY 10021 USA. [Ratcliffe, Mark B.; Morgan, Ashley E.] Univ Calif San Francisco, Dept Surg, Div Cardiol, San Francisco, CA USA. [Ratcliffe, Mark B.; Morgan, Ashley E.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA USA. [Ratcliffe, Mark B.; Morgan, Ashley E.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Levine, Robert A.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. RP Weinsaft, JW (reprint author), Weill Cornell Med Coll, Cardiac MRI Programs, Nucl Cardiol, 525 E 68th St, New York, NY 10021 USA. EM jww2001@med.cornell.edu FU [1R01HL128278-01] FX This study was supported by a grant 1R01HL128278-01 (to J.W. Weinsaft). NR 37 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD NOV PY 2016 VL 9 IS 11 AR e005115 DI 10.1161/CIRCIMAGING.116.005115 PG 11 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EC9RS UT WOS:000388482500006 ER PT J AU Khalil, DN Postow, MA Ibrahim, N Ludwig, DL Cosaert, J Kambhampati, SRP Tang, S Grebennik, D Kauh, JSW Lenz, HJ Flaherty, KT Hodi, FS Lawrence, DP Wolchok, JD AF Khalil, Danny N. Postow, Michael A. Ibrahim, Nageatte Ludwig, Dale L. Cosaert, Jan Kambhampati, Siva Rama Prasad Tang, Shande Grebennik, Dmitri Kauh, John Sae Wook Lenz, Heinz-Josef Flaherty, Keith T. Hodi, F. Stephen Lawrence, Donald P. Wolchok, Jedd D. TI An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma SO CLINICAL CANCER RESEARCH LA English DT Article ID MEDIATED CYTOTOXICITY; CANCER PATIENTS; TRIAL; TRASTUZUMAB; IPILIMUMAB; IMMUNITY; THERAPY; PROTEIN AB Purpose: Tyrosinase-related protein-1 (TYRP1) is a transmembrane glycoprotein that is specifically expressed in melanocytes and melanoma cells. Preclinical data suggest that mAbs targeting TYRP1 confer antimelanoma activity. IMC-20D7S is a recombinant human IgG1 mAb targeting TYRP1. Here, we report the first-in-human phase I/Ib trial of IMC-20D7S. Experimental Design: The primary objective of this study was to establish the safety profile and the MTD of IMC-20D7S. Patients with advanced melanoma who progressed after or during at least one line of treatment or for whom standard therapy was not indicated enrolled in this standard 3 + 3 dose-escalation, open-label study. IMC-20D7S was administered intravenously every 2 or 3 weeks. Results: Twenty-seven patients were enrolled. The most common adverse events were fatigue and constipation experienced by nine (33%) and eight (30%) patients, respectively. There were no serious adverse events related to treatment, no discontinuations of treatment due to adverse events, and no treatment-related deaths. Given the absence of dose-limiting toxicities, an MTD was not defined, but a provisional MTD was established at the 20 mg/kg every 2-week dose based on serum concentration and safety data. One patient experienced a complete response. A disease control rate, defined as stable disease or better, of 41% was observed. Conclusion: IMC-20D7S is well tolerated among patients with advanced melanoma with evidence of antitumor activity. Further investigation of this agent as monotherapy in selected patients or as part of combination regimens is warranted. (C) 2016 AACR. C1 [Khalil, Danny N.; Postow, Michael A.; Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA. [Ibrahim, Nageatte] Merck Res Labs, N Wales, PA USA. [Ludwig, Dale L.; Kambhampati, Siva Rama Prasad; Tang, Shande; Kauh, John Sae Wook] Eli Lilly & Co, New York, NY USA. [Cosaert, Jan] Sotio, Prague, Czech Republic. [Grebennik, Dmitri] Kyowa Hakko Kirin Pharma Inc, Princeton, NJ USA. [Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA. [Flaherty, Keith T.; Lawrence, Donald P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Wolchok, JD (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA. EM wolchokj@mskcc.org FU NIH [P30CA008748]; American Association for Cancer Research; Amgen; Conquer Cancer Foundation; American Society of Clinical Oncology FX This work was supported by an NIH grant P30CA008748. D. Khalil is currently supported by a fellowship in Clinical/Translational Cancer Research from the American Association for Cancer Research and Amgen, in Clinical Investigation from the American Philosophical Society, and through a Young Investigator Award from the Conquer Cancer Foundation and the American Society of Clinical Oncology. NR 22 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 1 PY 2016 VL 22 IS 21 BP 5204 EP 5210 DI 10.1158/1078-0432.CCR-16-1241 PG 7 WC Oncology SC Oncology GA EB5VY UT WOS:000387450000009 PM 27797971 ER PT J AU Trivedi, S Srivastava, RM Concha-Benavente, F Ferrone, S Garcia-Bates, TM Li, J Ferris, RL AF Trivedi, Sumita Srivastava, Raghvendra M. Concha-Benavente, Fernando Ferrone, Soldano Garcia-Bates, Tatiana M. Li, Jing Ferris, Robert L. TI Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients SO CLINICAL CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; LABEL PHASE-2 TRIAL; WILD-TYPE KRAS; CHEMOTHERAPY PLUS; RANDOMIZED-TRIAL; NATURAL-KILLER; CETUXIMAB; PANITUMUMAB; CARCINOMA AB Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab (IgG1 isotype) inhibits downstream signaling of EGFR and activates antitumor, cellular immune mechanisms. As panitumumab (IgG2 isotype) may inhibit downstream EGFR signaling similar to cetuximab, it might also induce adaptive immunity. Experimental Design: We measured in vitro activation of cellular components of the innate and adaptive immune systems. We also studied the in vivo activation of components of the adaptive immune system in patient specimens from two recent clinical trials using cetuximab or panitumumab. Results: Both monoclonal antibodies (mAb) primarily activate natural killer (NK) cells, although cetuximab is significantly more potent than panitumumab. Cetuximab-activated neutrophils mediate antibody-dependent cellular cytotoxicity (ADCC) against head and neck squamous cell carcinomas (HNSCC) tumor cells, and interestingly, this effect was Fc gamma RIIa- and Fc gamma RIIIa genotype-dependent. Panitumumab may activate monocytes through CD32 (Fc gamma RIIa); however, monocytes activated by either mAb are not able to mediate ADCC. Cetuximab enhanced dendritic cell (DC) maturation to a greater extent than panitumumab, which was associated with improved tumor antigen cross-presentation by cetuximab compared with panitumumab. This correlated with increased EGFR-specific cytotoxic CD8(+) T cells in patients treated with cetuximab compared with those treated with panitumumab. Conclusions: Although panitumumab effectively inhibits EGFR signaling to a similar extent as cetuximab, it is less effective at triggering antitumor, cellular immune mechanisms which may be crucial for effective therapy of HNSCC. (C) 2016 AACR. C1 [Trivedi, Sumita; Srivastava, Raghvendra M.; Ferris, Robert L.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA USA. [Concha-Benavente, Fernando] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA. [Ferrone, Soldano] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. [Garcia-Bates, Tatiana M.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA. [Li, Jing] Tsinghua Univ, Sch Med, Dept Pharmacol & Pharmaceut Sci, Beijing, Peoples R China. [Ferris, Robert L.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Ferris, Robert L.] Univ Pittsburgh, Inst Canc, Canc Immunol Program, Pittsburgh, PA USA. RP Ferris, RL (reprint author), Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA. EM ferrrl@upmc.edu FU NIH [R01 DE019727, P50 CA097190, T32 CA060397]; University of Pittsburgh Cancer Institute award [P30 CA047904] FX This work was supported by NIH grants R01 DE019727, P50 CA097190, T32 CA060397 and used the University of Pittsburgh Cancer Institute award P30 CA047904. NR 33 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 1 PY 2016 VL 22 IS 21 BP 5229 EP 5237 DI 10.1158/1078-0432.CCR-15-2971 PG 9 WC Oncology SC Oncology GA EB5VY UT WOS:000387450000012 PM 27217441 ER PT J AU Lyle, LT Lockman, PR Adkins, CE Mohammad, AS Sechrest, E Hua, E Palmieri, D Liewehr, DJ Steinberg, SM Kloc, W Izycka-Swieszewska, E Duchnowska, R Nayyar, N Brastianos, PK Steeg, PS Gril, B AF Lyle, L. Tiffany Lockman, Paul R. Adkins, Chris E. Mohammad, Afroz Shareef Sechrest, Emily Hua, Emily Palmieri, Diane Liewehr, David J. Steinberg, Seth M. Kloc, Wojciech Izycka-Swieszewska, Ewa Duchnowska, Renata Nayyar, Naema Brastianos, Priscilla K. Steeg, Patricia S. Gril, Brunilde TI Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID NERVOUS-SYSTEM METASTASES; PHASE-II; MESENCHYMAL TRANSITION; CAPECITABINE; GROWTH; COLONIZATION; ANGIOGENESIS; TEMOZOLOMIDE; INTEGRITY; SURVIVAL AB Purpose: The blood-brain barrier (BBB) is modified to a blood-tumor barrier (BTB) as a brain metastasis develops from breast or other cancers. We (i) quantified the permeability of experimental brain metastases, (ii) determined the composition of the BTB, and (iii) identified which elements of the BTB distinguished metastases of lower permeability from those with higher permeability. Experimental Design: A SUM190-BR3 experimental inflammatory breast cancer brain metastasis subline was established. Experimental brain metastases from this model system and two previously reported models (triple-negative MDA-231-BR6, HER2(+) JIMT-1-BR3) were serially sectioned; low- and high-permeability lesions were identified with systemic 3-kDa Texas Red dextran dye. Adjoining sections were used for quantitative immunofluorescence to known BBB and neuroinflammatory components. One-sample comparisons against a hypothesized value of one were performed with the Wilcoxon signed-rank test. Results: When uninvolved brain was compared with any brain metastasis, alterations in endothelial, pericytic, astrocytic, and microglial components were observed. When metastases with relatively low and high permeability were compared, increased expression of a desmin(+) subpopulation of pericytes was associated with higher permeability (231-BR6 P = 0.0002; JIMT-1-BR3 P = 0.004; SUM190-BR3 P = 0.008); desmin(+) pericytes were also identified in human craniotomy specimens. Trends of reduced CD13(+) pericytes (231-BR6 P = 0.014; JIMT-1-BR3 P = 0.002, SUM190-BR3, NS) and laminin alpha 2 (231-BR6 P = 0.001; JIMT-1-BR3 P = 0.049; SUM190-BR3 P = 0.023) were also observed with increased permeability. Conclusions: We provide the first account of the composition of the BTB in experimental brain metastasis. Desmin(+) pericytes and laminin a2 are potential targets for the development of novel approaches to increase chemotherapeutic efficacy. (C) 2016 AACR. C1 [Hua, Emily; Palmieri, Diane; Steeg, Patricia S.; Gril, Brunilde] NCI, Ctr Canc Res, Womens Malignancies Branch, Bethesda, MD 20892 USA. [Lockman, Paul R.; Adkins, Chris E.; Mohammad, Afroz Shareef; Sechrest, Emily] West Virginia Univ, Hlth Sci Ctr, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA. [Lyle, L. Tiffany; Liewehr, David J.; Steinberg, Seth M.] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA. [Kloc, Wojciech] Univ Varmia & Masuria Univ, Dept Neurol, Olsztyn, Poland. [Kloc, Wojciech] Univ Varmia & Masuria Univ, Dept Neurosurg, Olsztyn, Poland. [Kloc, Wojciech] Copernicus Hosp Gdansk, Dept Neurosurg, Gdansk, Poland. [Izycka-Swieszewska, Ewa] Med Univ Gdansk, Dept Pathol, Gdansk, Poland. [Izycka-Swieszewska, Ewa] Med Univ Gdansk, Dept Neuropathol, Gdansk, Poland. [Izycka-Swieszewska, Ewa] Copernicus Hosp, Dept Pathomorphol, Gdansk, Poland. [Duchnowska, Renata] Mil Inst Med, Dept Oncol, Warsaw, Poland. [Nayyar, Naema; Brastianos, Priscilla K.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Div Neurooncol, Boston, MA USA. [Palmieri, Diane] NCI, Ctr Res Strategy, NIH, Bethesda, MD 20892 USA. [Lyle, L. Tiffany] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47906 USA. RP Gril, B (reprint author), NCI, 37-1126 NIH, Bethesda, MD 20892 USA. EM grilbrun@mail.nih.gov FU Intramural Program of the NCI; U.S. Department of Defense Breast Cancer Research Program [W81 XWH-062-0033]; Inflammatory Breast Cancer Research Foundation FX This work was supported by the Intramural Program of the NCI, U.S. Department of Defense Breast Cancer Research Program, grant number: W81 XWH-062-0033, and a research grant from the Inflammatory Breast Cancer Research Foundation. NR 42 TC 2 Z9 2 U1 7 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 1 PY 2016 VL 22 IS 21 BP 5287 EP 5299 DI 10.1158/1078-0432.CCR-15-1836 PG 13 WC Oncology SC Oncology GA EB5VY UT WOS:000387450000018 PM 27245829 ER PT J AU Olow, A Mueller, S Yang, XD Hashizume, R Meyerowitz, J Weiss, W Resnick, AC Waanders, AJ Stalpers, LJA Berger, MS Gupta, N James, CD Petritsch, CK Haas-Kogan, DA AF Olow, Aleksandra Mueller, Sabine Yang, Xiaodong Hashizume, Rintaro Meyerowitz, Justin Weiss, William Resnick, Adam C. Waanders, Angela J. Stalpers, Lukas J. A. Berger, Mitchel S. Gupta, Nalin James, C. David Petritsch, Claudia K. Haas-Kogan, Daphne A. TI BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas SO CLINICAL CANCER RESEARCH LA English DT Article ID LOW-GRADE ASTROCYTOMAS; RAF INHIBITOR RESISTANCE; MAPK PATHWAY ACTIVATION; MEK INHIBITION; HUMAN CANCER; GENE; MUTATIONS; KINASE; BRAF(V600E); DUPLICATION AB Purpose: Alteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade gliomas (PLGGs), and mTOR activation has been documented in the majority of these tumors. We investigated combinations of MEK1/2, BRAF(V600E) and mTOR inhibitors in gliomas carrying specific genetic alterations of the MAPK pathway. Experimental Design: We used human glioma lines containing BRAF(V600E) (adult high-grade: AM-38, DBTRG, PLGG: BT40), or wild-type BRAF (pediatric high-grade: SF188, SF9427, SF8628) and isogenic systems of KIAA1549: BRAF-expressing NIH/3T3 cells and BRAF(V600E)- expressing murine brain cells. Signaling inhibitors included everolimus (mTOR), PLX4720 (BRAF(V600E)), and AZD6244 (MEK1/2). Proliferation was determined using ATP-based assays. In vivo inhibitor activities were assessed in the BT40 PLGG xenograft model. Results: In BRAF(V600E) cells, the three possible doublet combinations of AZD6244, everolimus, and PLX4720 exhibited significantly greater effects on cell viability. In BRAF(WT) cells, everolimus + AZD6244 was superior compared with respective monotherapies. Similar results were found using isogenic murine cells. In KIAA1549: BRAF cells, MEK1/2 inhibition reduced cell viability and S-phase content, effects that were modestly augmented by mTOR inhibition. In vivo experiments in the BRAF(V600E) pediatric xenograft model BT40 showed the greatest survival advantage in mice treated with AZD6244 + PLX4720 (P < 0.01). Conclusions: In BRAF(V600E) tumors, combination of AZD6244 + PLX4720 is superior to monotherapy and to other combinatorial approaches. In BRAFWT pediatric gliomas, everolimus + AZD6244 is superior to either agent alone. KIAA1549: BRAF-expressing tumors display marked sensitivity to MEK1/2 inhibition. Application of these results to PLGG treatment must be exercised with caution because the dearth of PLGG models necessitated only a single patient-derived PLGG (BT40) in this study. (C) 2016 AACR. C1 [Olow, Aleksandra] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Mueller, Sabine; Yang, Xiaodong; Meyerowitz, Justin; Weiss, William; Berger, Mitchel S.; Gupta, Nalin; Haas-Kogan, Daphne A.] Univ Calif San Francisco, Helen Diller Canc Diller Canc Res Ctr, Brain Tumor Res Ctr, San Francisco, CA 94143 USA. [Mueller, Sabine; Weiss, William] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Mueller, Sabine; Weiss, William] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Mueller, Sabine; Berger, Mitchel S.; Gupta, Nalin; Petritsch, Claudia K.; Haas-Kogan, Daphne A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Hashizume, Rintaro; James, C. David] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg Biochem & Mol Genet, Chicago, IL 60611 USA. [Resnick, Adam C.; Waanders, Angela J.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Stalpers, Lukas J. A.] Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, Amsterdam, Netherlands. [Haas-Kogan, Daphne A.] Harvard Med Sch, Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiat Oncol, 450 Brookline Ave D1622, Boston, MA 02215 USA. RP Haas-Kogan, DA (reprint author), Harvard Med Sch, Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiat Oncol, 450 Brookline Ave D1622, Boston, MA 02215 USA. EM dhaas-kogan@lroc.harvard.edu FU National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI [KL2TR000143]; NIH Brain Tumor SPORE [P50 CA097257]; NINDS [R01NS080619, 1R01NS091620]; Matthew Larson Foundation; Grand Philanthropic Fund; University of California Cancer Research Coordinating Committee FX This research was supported in part by the National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI grant KL2TR000143 (S. Mueller), NIH Brain Tumor SPORE grant P50 CA097257 (S. Mueller, D.A. Haas-Kogan, W. Weiss, M. S. Berger), NINDS R01NS080619 (C.D. James, C.K. Petritsch), NINDS 1R01NS091620 (D.A. Haas- Kogan, W. Weiss, A.C. Resnick), the Matthew Larson Foundation (S. Mueller), Grand Philanthropic Fund (D.A. Haas-Kogan), and the University of California Cancer Research Coordinating Committee (S. Mueller and A. Haas-Kogan). NR 36 TC 2 Z9 2 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 1 PY 2016 VL 22 IS 21 BP 5312 EP 5321 DI 10.1158/1078-0432.CCR-15-1101 PG 10 WC Oncology SC Oncology GA EB5VY UT WOS:000387450000020 PM 27217440 ER PT J AU Nathenson, MJ Ravi, V Fleming, N Wang, WL Conley, A AF Nathenson, Michael J. Ravi, Vinod Fleming, Nicole Wang, Wei-Lien Conley, Anthony TI Uterine Adenosarcoma: a Review SO CURRENT ONCOLOGY REPORTS LA English DT Review DE Sarcoma; Uterine; Adenosarcoma; Review; Ovarian; Soft tissue sarcoma ID EXTRAGENITAL MULLERIAN ADENOSARCOMA; GYNECOLOGIC-ONCOLOGY-GROUP; FEMALE GENITAL-TRACT; OF-THE-LITERATURE; GEMCITABINE PLUS DOCETAXEL; BREAST-CANCER PATIENTS; GRANULOSA-CELL TUMOR; SARCOMATOUS OVERGROWTH; OVARIAN ADENOSARCOMA; CLINICOPATHOLOGICAL ANALYSIS AB Adenosarcomas are rare malignancies of the female genital tract, accounting for approximately 5 % of uterine sarcomas. Occasionally, adenosarcoma occurs in the ovaries or in extra-uterine tissue, which may be related to endometriosis. These tumors are characterized by benign epithelial elements and a malignant mesenchymal component. Pathologic diagnosis is dependent on the identification of the characteristic morphologic features. The most common immunohistochemical markers for adenosarcoma are CD10 and WT1, but these are not specific. The most frequent presenting symptom is abnormal uterine bleeding. The majority of patients present with stage I disease, with a 5-year overall survival of 60 to 80 %. Survival is influenced by the presence of myometrial invasion, sarcomatous overgrowth, lymphovascular invasion, necrosis, and the presence of heterologous elements including rhabdomyoblastic differentiation. Patients with sarcomatous overgrowth have significantly increased risk of recurrence 23 versus 77 % and decreased 5-year overall survival 50 to 60 %. Standard of care treatment is total hysterectomy with bilateral salpingo-oophorectomy without lymphadenectomy, as the incidence of lymph node metastasis is rare. Retrospective data does not support the use of adjuvant pelvic radiotherapy in uterine adenosarcomas as no survival benefit is seen. Insufficient data exists to recommend routinely neoadjuvant or adjuvant chemotherapy for uterine adenosarcomas. Limited evidence exists for the role of hormonal therapy in uterine adenosarcomas. The PIK3/AKT/PTEN pathway is mutated in similar to 70% of adenosarcomas, and this may represent a possible therapeutic target. This article reviews the current state of knowledge concerning uterine adenosarcoma and discusses the management of this rare tumor. C1 [Nathenson, Michael J.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. [Ravi, Vinod; Conley, Anthony] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, 1515 Holcombe Blvd Unit 450, Houston, TX 77030 USA. [Fleming, Nicole] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, 1515 Holcombe Blvd Unit 450, Houston, TX 77030 USA. [Wang, Wei-Lien] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 450, Houston, TX 77030 USA. RP Nathenson, MJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM mjnathenson@gmail.com FU NCI NIH HHS [P30 CA008748] NR 181 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3790 EI 1534-6269 J9 CURR ONCOL REP JI Curr. Oncol. Rep. PD NOV PY 2016 VL 18 IS 11 AR 68 DI 10.1007/s11912-016-0552-7 PG 17 WC Oncology SC Oncology GA ED1QA UT WOS:000388618800004 PM 27718181 ER PT J AU Braunberger, T Lynn, D Reimer, C Doctor, M Hill, MK Mounessa, J Dunnick, CA AF Braunberger, Taylor Lynn, Darren Reimer, Christie Doctor, Monica Hill, Mary K. Mounessa, Jessica Dunnick, Cory A. TI Disease Severity and Quality of Life Measurements in Contact Dermatitis: A Systematic Review 2005-2015 SO DERMATITIS LA English DT Review ID SODIUM-LAURYL-SULFATE; TRANSEPIDERMAL WATER-LOSS; CUMULATIVE SKIN IRRITATION; LASER-DOPPLER FLOWMETRY; RANDOMIZED CLINICAL-TRIAL; NICKEL ALLERGY SYNDROME; GLOBAL ASSESSMENT IGA; DOUBLE-BLIND; STRATUM-CORNEUM; IN-VIVO AB Background: Contact dermatitis (CD) has been assessed by numerous disease severity indices resulting in heterogeneity across published research. Objective: This study aims to evaluate published CD severity scales and identify a criterion standard for assessment. Methods: Scopus and Ovid MEDLINE were searched for human randomized controlled trials (RCTs) on CD severity measures published during a 10-year period. Eligible studies were English-language RCTs reporting disease severity outcome measures for CD in humans. Studies were excluded if they were duplicates, not available in English, not related to CD, not RCTs, not conducted on human subjects, or did not report relevant outcome measures. Results: A total of 22 disease outcome measures were used in 81 included RCTs. Instrument-based measures were used in 40 (49.4%) studies, and visual assessments were used in 66 (81.5%) RCTs. Only 5 (6.2%) studies reported quality of life (QoL) outcomes. Two (2.5%) studies used a clinical severity scale, which combined both QoL and visual assessments. Limitations: This study was limited by the exclusion of non-RCTs and gray literature. Conclusions: Wide variation in CD outcome measures exists including instrument-based measures, visual assessments, and QoL outcomes. A standardized outcome measure must be generated to reduce heterogeneity. C1 [Braunberger, Taylor] Univ North Dakota, Sch Med, Grand Forks, ND USA. [Lynn, Darren; Hill, Mary K.] Univ Colorado, Sch Med, Aurora, CO USA. [Reimer, Christie] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Doctor, Monica] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Mounessa, Jessica; Dunnick, Cory A.] Univ Colorado Denver, Dept Dermatol, 1665 Aurora Ct,MS 703, Aurora, CO 80045 USA. [Dunnick, Cory A.] Denver Vet Affairs Med Ctr, Dept Dermatol, Denver, CO USA. RP Dunnick, CA (reprint author), Univ Colorado Denver, Dept Dermatol, 1665 Aurora Ct,MS 703, Aurora, CO 80045 USA. EM cory.dunnick@ucdenver.edu NR 111 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1710-3568 EI 2162-5220 J9 DERMATITIS JI Dermatitis PD NOV-DEC PY 2016 VL 27 IS 6 BP 362 EP 371 DI 10.1097/DER.0000000000000235 PG 10 WC Dermatology SC Dermatology GA ED1KG UT WOS:000388603700007 PM 27775978 ER PT J AU Gerken, AT McGahee, S Keuroghlian, AS Freudenreich, O AF Gerken, Adrienne T. McGahee, Shunda Keuroghlian, Alex S. Freudenreich, Oliver TI Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE acquired immunodeficiency syndrome; clozapine; gender identity; hepatitis C; HIV; psychotic disorders; schizophrenia; transgender persons ID FEMALE TRANSGENDER PERSONS; IMMUNODEFICIENCY-VIRUS-INFECTION; SEXUAL RISK BEHAVIORS; SUBSTANCE USE; SAN-FRANCISCO; MENTAL-HEALTH; UNITED-STATES; ANTIPSYCHOTIC-DRUGS; PUBLIC-HEALTH; WEIGHT-GAIN C1 [Gerken, Adrienne T.; Keuroghlian, Alex S.; Freudenreich, Oliver] Harvard Med Sch, Boston, MA USA. [Gerken, Adrienne T.; Keuroghlian, Alex S.; Freudenreich, Oliver] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gerken, Adrienne T.] McLean Hosp, 115 Mill St, Belmont, MA 02478 USA. [McGahee, Shunda] Massachusetts Mental Hlth Ctr, Boston, MA 02115 USA. [Keuroghlian, Alex S.] Fenway Hlth, Boston, MA USA. [Freudenreich, Oliver] Lindemann Mental Hlth Ctr, Boston, MA USA. RP Gerken, AT (reprint author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA. EM agerken@partners.org NR 100 TC 0 Z9 0 U1 8 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1067-3229 EI 1465-7309 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD NOV-DEC PY 2016 VL 24 IS 6 BP 406 EP 415 DI 10.1097/HRP.0000000000000120 PG 10 WC Psychiatry SC Psychiatry GA ED3AG UT WOS:000388720900003 PM 27824636 ER PT J AU Ross, RA Mandelblat-Cerf, Y Verstegen, AMJ AF Ross, Rachel A. Mandelblat-Cerf, Yael Verstegen, Anne M. J. TI Interacting Neural Processes of Feeding, Hyperactivity, Stress, Reward, and the Utility of the Activity-Based Anorexia Model of Anorexia Nervosa SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE activity-based anorexia (ABA) animal model; anorexia; feeding; hyperactivity; neurobiology; reward; stress ID MELANIN-CONCENTRATING HORMONE; PITUITARY-ADRENAL AXIS; AMPHETAMINE-REGULATED TRANSCRIPT; CORTICOTROPIN-RELEASING HORMONE; AGOUTI-RELATED PROTEIN; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; VENTRAL TEGMENTAL AREA; SEMISTARVATION-INDUCED HYPERACTIVITY; CONDITIONED PLACE PREFERENCE; ADIPOSE-TISSUE THERMOGENESIS AB Anorexia nervosa (AN) is a psychiatric illness with minimal effective treatments and a very high rate of mortality. Understanding the neurobiological underpinnings of the disease is imperative for improving outcomes and can be aided by the study of animal models. The activity-based anorexia rodent model (ABA) is the current best parallel for the study of AN. This review describes the basic neurobiology of feeding and hyperactivity seen in both ABA and AN, and compiles the research on the role that stress- response and reward pathways play in modulating the homeostatic drive to eat and to expend energy, which become dysfunctional in ABA and AN. C1 [Ross, Rachel A.] Harvard Med Sch, Boston, MA USA. [Ross, Rachel A.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Mandelblat-Cerf, Yael; Verstegen, Anne M. J.] Beth Israel Deaconess Med Ctr, Div Endocrinol, Dept Med, Boston, MA 02215 USA. [Ross, Rachel A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Ross, RA (reprint author), Beth Israel Deaconess Med Ctr, 718 Gryzmysh,330 Brookline Ave, Boston, MA 02115 USA. EM rross4@partners.org NR 364 TC 1 Z9 1 U1 9 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1067-3229 EI 1465-7309 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD NOV-DEC PY 2016 VL 24 IS 6 BP 416 EP 436 DI 10.1097/HRP.0000000000000111 PG 21 WC Psychiatry SC Psychiatry GA ED3AG UT WOS:000388720900004 PM 27824637 ER PT J AU Lindsay, RW George, R Herberg, ME Jackson, P Brietzke, S AF Lindsay, Robin W. George, Ryan Herberg, Matthew E. Jackson, Paula Brietzke, Scott TI Reliability of a Standardized Nasal Anatomic Worksheet and Correlation With Subjective Nasal Airway Obstruction SO JAMA FACIAL PLASTIC SURGERY LA English DT Article ID SLEEP APNEA/HYPOPNEA SYNDROME; FUNCTIONAL RHINOPLASTY; CLASSIFICATION-SYSTEM; COMPUTED-TOMOGRAPHY; SEPTAL DEVIATION; DISEASE; SEPTOPLASTY; SEVERITY; OUTCOMES; VALIDATION AB IMPORTANCE Nasal obstruction is a common chief concern; however, a comprehensive standardized worksheet for evaluating nasal obstruction has not been developed. OBJECTIVE To evaluate the interrater reliability between staff surgeons and otolaryngology residents using a worksheet-based standardized nasal examination and to identify specific examination findings correlated with the Nasal Obstruction Symptom Evaluation quality-of-life score. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study conducted from June to July 2012 involved 50 adults presenting to an otolaryngology clinic at a tertiary care hospital. The patients were examined by 2 board-certified facial plastic surgeons and 2 otolaryngology residents. EXPOSURES The inferior turbinates, septum, and internal and external nasal valve narrowing and collapse were graded bilaterally from a scale of 0 to 3 with the aid of a standardized nasal anatomy worksheet. The findings were compared between the attending staff, residents, and the entire group. MAIN OUTCOMES AND MEASURES The Cohen. coefficient for interrater reliability was calculated for each of the graded metrics. The Nasal Obstruction Symptom Evaluation scores were correlated with anatomic scores. RESULTS Of the 49 patients included in the final analysis, the mean age was 43.6 years (range, 21-82 years), and 31 were male (66.3%). Among all attending and resident examiners, a moderate to fair, statistically significant interrater reliability coefficient (P<.001) was observed in the following nasal anatomic measurements: left and right Cottle (kappa = 0.582 [95% CI, 0.463-0.700] and kappa = 0.580 [95% CI, 0.461-0.698], respectively), modified Cottle (kappa = 0.491 [95% CI, 0.373-0.609] and kappa = 0.560 [95% CI, 0.442-0.679], respectively), dynamic internal nasal valve collapse (kappa = 0.204 [95% CI, 0.118-0.290] and kappa = 0.232 [95% CI, 0.140-0.323], respectively), and inferior turbinate hypertrophy (kappa = 0.252 [95% CI, 0.152-0.352] and kappa = 0.235 [95% CI, 0.153-0.317], respectively). The trend of examination interrater reliability was similar for attending staff and the otolaryngology residents. The Nasal Obstruction Symptom Evaluation score correlated with the mean total anatomic worksheet score (Spearman rho = 0.301; P=.048). CONCLUSIONS AND RELEVANCE Interrater reliability is high in both residents and attending staff for dynamic nasal airway examinations evaluating the internal and external nasal valves and for turbinate hypertrophy assessment. The total nasal anatomic score using a standardized worksheet correlates to patient-reported nasal-specific quality of life. C1 [Lindsay, Robin W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Lindsay, Robin W.] Harvard Med Sch, Boston, MA USA. [George, Ryan; Herberg, Matthew E.; Jackson, Paula; Brietzke, Scott] Walter Reed Natl Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, Bethesda, MD USA. RP Lindsay, RW (reprint author), Massachusetts Eye & Ear Infirm, Div Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA. EM robin_lindsay@meei.harvard.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6076 EI 2168-6092 J9 JAMA FACIAL PLAST SU JI JAMA Facial Plast. Surg. PD NOV-DEC PY 2016 VL 18 IS 6 BP 449 EP 454 DI 10.1001/jamafacial.2016.0721 PG 6 WC Surgery SC Surgery GA ED3FS UT WOS:000388735600008 PM 27415032 ER PT J AU Morotti, A Charidimou, A Phuah, CL Jessel, MJ Schwab, K Ayres, AM Romero, JM Viswanathan, A Gurol, ME Greenberg, SM Anderson, CD Rosand, J Goldstein, JN AF Morotti, Andrea Charidimou, Andreas Phuah, Chia-Ling Jessel, Michael J. Schwab, Kristin Ayres, Alison M. Romero, Javier M. Viswanathan, Anand Gurol, M. Edip Greenberg, Steven M. Anderson, Christopher D. Rosand, Jonathan Goldstein, Joshua N. TI Association Between Serum Calcium Level and Extent of Bleeding in Patients With Intracerebral Hemorrhage SO JAMA NEUROLOGY LA English DT Article ID ANGIOGRAPHY SPOT SIGN; PREDICTS HEMATOMA EXPANSION; HEALTH-CARE PROFESSIONALS; STROKE ASSOCIATION; MANAGEMENT; RELAXATION; GUIDELINES; ALBUMIN; SPARKS; VOLUME AB IMPORTANCE Calcium is a key cofactor of the coagulation cascade and may play a role in the pathophysiology of intracerebral hemorrhage (ICH). OBJECTIVE To investigate whether a low serum calcium level is associated with an increase in the extent of bleeding in patients with ICH as measured by baseline hematoma volume and risk of hematoma expansion. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 2103 consecutive patients with primary ICH ascertained during the period between 1994 and 2015 at an academic medical center. The statistical analysis was performed in January 2016. MAIN OUTCOMES AND MEASURES Total calcium levelwas measured on admission, and hypocalcemia was defined as a serum calcium level of less than 8.4mg/dL. Baseline and follow-up hematoma volumes, detected by noncontrast computed tomography, were measured using a computer-assisted semiautomatic analysis. Hematoma expansion was defined as an increase of more than 30% or 6mL from baseline ICH volume. Associations between serum calcium level and baseline hematoma volume and between serum calcium level and ICH expansion were investigated in multivariable linear and logistic regression models, respectively. RESULTS A total of 2123 patients with primary ICH were screened, and 2103 patients met the inclusion criteria (mean [SD] age, 72.7 [12.5] years; 54.3% male patients), of whom 229 (10.9%) had hypocalcemia on admission. Hypocalcemic patients had a higher median baseline hematoma volume than did normocalcemic patients (37mL [IQR, 15-72 mL] vs 16 mL [IQR, 6-44 mL]; P <.001). Low calcium levels were independently associated with higher baseline ICH volume (alpha = -0.13, SE =.03, P <.001). A total of 1393 patients underwent follow-up noncontrast computed tomography and were included in the ICH expansion analysis. In this subgroup, a higher serum calcium level was associated with reduced risk of ICH expansion (odds ratio, 0.55 [95% CI, 0.35-0.86]; P =.01), after adjusting for other confounders. CONCLUSIONS AND RELEVANCE Hypocalcemia correlates with the extent of bleeding in patients with ICH. A low calcium levelmay be associated with a subtle coagulopathy predisposing to increased bleeding and might therefore be a promising therapeutic target for acute ICH treatment trials. C1 [Morotti, Andrea] Univ Brescia, Dept Clin & Expt Sci, Neurol Unit, Brescia, Italy. [Morotti, Andrea; Phuah, Chia-Ling; Anderson, Christopher D.; Rosand, Jonathan; Goldstein, Joshua N.] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA 02114 USA. [Morotti, Andrea; Charidimou, Andreas; Phuah, Chia-Ling; Jessel, Michael J.; Schwab, Kristin; Ayres, Alison M.; Viswanathan, Anand; Gurol, M. Edip; Greenberg, Steven M.; Anderson, Christopher D.; Rosand, Jonathan; Goldstein, Joshua N.] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, 175 Cambridge St,Ste 300, Boston, MA 02114 USA. [Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Serv Neuroradiol, Boston, MA USA. [Goldstein, Joshua N.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Morotti, A (reprint author), Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, 175 Cambridge St,Ste 300, Boston, MA 02114 USA. EM a.morotti@ymail.com OI Anderson, Christopher/0000-0002-0053-2002 FU National Institute of Neurological Disorders and Stroke [R01NS073344, K23AG02872605, K23NS086873, R01NS059727] FX This study was supported by National Institute of Neurological Disorders and Stroke grants R01NS073344 (Dr Goldstein), K23AG02872605 (Dr Viswanathan), K23NS086873 (Dr Anderson), and R01NS059727 (Dr Rosand). NR 28 TC 2 Z9 2 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD NOV 1 PY 2016 VL 73 IS 11 BP 1285 EP 1290 DI 10.1001/jamaneurol.2016.2252 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA ED1BL UT WOS:000388578600008 PM 27598746 ER PT J AU Gomperts, SN Locascio, JJ Makaretz, SJ Schultz, A Caso, C Vasdev, N Sperling, R Growdon, JH Dickerson, BC Johnson, K AF Gomperts, Stephen N. Locascio, Joseph J. Makaretz, Sara J. Schultz, Aaron Caso, Christina Vasdev, Neil Sperling, Reisa Growdon, John H. Dickerson, Bradford C. Johnson, Keith TI Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases SO JAMA NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; DIAGNOSTIC-CRITERIA; DEMENTIA; BODIES; PATHOLOGY; BURDEN; BRAIN AB IMPORTANCE The causes of cognitive impairment in dementia with Lewy bodies (DLB) and Parkinson disease (PD) are multifactorial. Tau pathologic changes are commonly observed at autopsy in individuals with DLB and PD dementia, but their contribution to these diseases during life is unknown. OBJECTIVE To contrast tau aggregation in DLB, cognitively impaired persons with PD (PD-impaired), cognitively normal individuals with PD (PD-normal), and healthy persons serving as control participants, and to evaluate the association between tau aggregation, amyloid deposition, and cognitive function. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional studywas conducted from January 1, 2014, to April 28, 2016, in a tertiary care center's memory and movement disorders units. Twenty-four patients with Lewy body disease (7 DLB, 8 PD-impaired, and 9 PD-normal) underwent multimodal brain imaging, cognitive testing, and neurologic evaluation, and imaging measures were compared with those of an independently acquired group of 29 controls with minimal brain amyloid burden as measured with carbon 11-labeled Pittsburgh Compound B ([C-11] PiB) positron emission tomography (PET). EXPOSURES Imaging with fluorine 18-labeled AV-1451 ([F-18] AV-1451) (formerly known as [F-18] T807), [C-11] PiB PET, magnetic resonance imaging (MRI), neurologic examination, and detailed cognitive testing using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating scale. MAIN OUTCOMES AND MEASURES Main outcomeswere differentiation of diagnostic groups on the basis of [F-18] AV-1451 binding, the association of [F-18] AV-1451 binding with [C-11] PiB binding, and the association of [F-18] AV-1451 binding with cognitive impairment. All but 3 individuals underwent amyloid imaging with [C-11] PiB PET. The hypotheses being tested were formulated before data collection. Mini-Mental State Examination (range, 0-30, with 30 being best) and Clinical Dementia Rating scale sum-of-boxes scale (range, 0-18, with 0 being best) were used for assessment of cognitive function. RESULTS In patients with DLB, cortical [F-18] AV-1451 uptake was highly variable and greater than in the controls, particularly in the inferior temporal gyrus and precuneus. Foci of increased [F-18] AV-1451 binding in the inferior temporal gyrus and precuneus were also evident in PD-impaired patients. Elevated cortical [F-18] AV-1451 binding was observed in 4 of 17 patients with Lewy body disease with low cortical [C-11] PiB retention. For DLB and PD-impaired patients, greater [F-18] AV-1451 uptake in the inferior temporal gyrus and precuneus was associated with increased cognitive impairment as measured with the MMSE and the Clinical Dementia Rating scale sum-of-boxes score. CONCLUSIONS AND RELEVANCE Patients with Lewy body disease manifest a spectrum of tau pathology. Cortical aggregates of tau are common in patients with DLB and in PD-impaired patients, even in those without elevated amyloid levels. When present, tau deposition is associated with cognitive impairment. These findings support a role for tau copathology in the Lewy body diseases. C1 [Gomperts, Stephen N.] MassGen Inst Neurodegenerat Dis, 114 16th St,Room 2004, Charlestown, MA 02129 USA. [Gomperts, Stephen N.; Locascio, Joseph J.; Sperling, Reisa; Growdon, John H.; Dickerson, Bradford C.; Johnson, Keith] Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Ctr, Charlestown, MA USA. [Gomperts, Stephen N.; Locascio, Joseph J.; Makaretz, Sara J.; Schultz, Aaron; Caso, Christina; Sperling, Reisa; Growdon, John H.; Dickerson, Bradford C.; Johnson, Keith] Harvard Med Sch, Charlestown, MA USA. [Makaretz, Sara J.; Caso, Christina; Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Disorders Unit, Dept Neurol, Charlestown, MA USA. [Schultz, Aaron; Sperling, Reisa; Dickerson, Bradford C.; Johnson, Keith] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Vasdev, Neil; Sperling, Reisa; Johnson, Keith] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA USA. [Vasdev, Neil; Sperling, Reisa; Johnson, Keith] Harvard Med Sch, Boston, MA USA. RP Gomperts, SN (reprint author), MassGen Inst Neurodegenerat Dis, 114 16th St,Room 2004, Charlestown, MA 02129 USA. EM gomperts.stephen@mgh.harvard.edu FU NIH/National Institute of Neurological Disorders and Stroke [R21 NS 090243, R21 NS084156]; National Institute on Aging [R01 AG046396, P01 AG036694, P50 AG00513421]; National Parkinson's Foundation FX This study was supported by grants R21 NS 090243 and R21 NS084156 from the NIH/National Institute of Neurological Disorders and Stroke; R01 AG046396, P01 AG036694, and P50 AG00513421 from the National Institute on Aging; and the National Parkinson's Foundation. NR 51 TC 2 Z9 2 U1 7 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD NOV 1 PY 2016 VL 73 IS 11 BP 1334 EP 1341 DI 10.1001/jamaneurol.2016.3338 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA ED1BL UT WOS:000388578600014 PM 27654968 ER PT J AU Amini, A Waxweiler, TV Brower, JV Jones, BL McDermott, JD Raben, D Ghosh, D Bowles, DW Karam, SD AF Amini, Arya Waxweiler, Timothy V. Brower, Jeffrey V. Jones, Bernard L. McDermott, Jessica D. Raben, David Ghosh, Debashis Bowles, Daniel W. Karam, Sana D. TI Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma Data From the National Cancer Data Base SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; POSTOPERATIVE RADIATION-THERAPY; ADENOID CYSTIC CARCINOMA; LOCALLY ADVANCED HEAD; PROGNOSTIC-FACTORS; NECK-CANCER; PHASE-II; MALIGNANT-TUMORS; CONCURRENT CHEMORADIOTHERAPY; CONCOMITANT CHEMOTHERAPY AB IMPORTANCE Data on adjuvant concurrent chemoradiotherapy (CRT) after resection of salivary gland carcinomas (SGCs) are limited. OBJECTIVE To examine overall survival (OS) outcomes of patients who receive CRT vs radiotherapy (RT) alone after resection of SGCs. DESIGN, SETTING, AND PARTICIPANTS The National Cancer Data Base (NCDB), a hospital-based registry that represents 70% of all cancer cases in the United States, was queried for patients who underwent resection of major SGCs with at least 1 high-risk feature (T3-T4 stage, N1-N3 stage, or positive margins). Included patients had histologic findings for malignant SGC with grades 2 to 3 disease and at least 1 high-risk feature. All patients underwent resection with postoperative CRT or RT alone. Patients were treated from 1998 to 2011. Data were analyzed from January to March 2016. EXPOSURES Patients received CRT, defined as chemotherapy start within 14 days of RT initiation, or RT alone. MAIN OUTCOMES AND MEASURES Univariate, multivariate, and propensity score-matched analyses were performed to compare OS for patients undergoing CRT vs RT alone. RESULTS Analyses included 2210 eligible patients (1372 men [62.1%] and 838 women [37.9%]; median age [range], 63 [18-90] years); of these, 1842 (83.3%) received RT alone and 368 (16.7%) received CRT. Median follow-up was 39 (range, 2-188) months. Most of the resected major SGCs occurred at the parotid gland (1852 [83.8%]), followed by the submandibular gland (276 [12.5%]), major gland not otherwise specified (66 [3.0%]), and sublingual gland (16 [0.7%]). Unadjusted 2-year OS was worse with adjuvant CRT vs RT alone (71.3% vs 80.2%), as was 5-year OS (38.5% vs 54.2%) (hazard ratio [HR], 1.51; 95% CI, 1.29-1.76; P < .001). Overall survival was inferior with adjuvant CRT on multivariate analysis (HR, 1.22; 95% CI, 1.03-1.44; P = .02) and propensity score-matched analysis (HR, 1.20; 95% CI, 0.98-1.47; P = .08) compared with RT alone. Subgroup analyses by age, comorbidity score, primary site, histologic type, grade, T stage, N stage, margin status, and chemotherapy (single agent vs multiagent) demonstrated equivalent or shorter OS with the addition of chemotherapy to RT. CONCLUSIONS AND RELEVANCE This large analysis compared survival outcomes between postoperative CRT and RT alone in patients undergoing resection of high-risk major SGCs using a nationally representative database. The addition of concurrent chemotherapy to RT in patients with high-risk major SGCs did not offer an advantage in OS. C1 [Amini, Arya; Waxweiler, Timothy V.; Jones, Bernard L.; Raben, David; Karam, Sana D.] Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Ct,Room 1032, Aurora, CO 80045 USA. [Brower, Jeffrey V.] Univ Wisconsin, Carbone Canc Ctr, Dept Human Oncol, Sch Med, Madison, WI 53706 USA. [McDermott, Jessica D.; Bowles, Daniel W.] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO USA. [McDermott, Jessica D.; Bowles, Daniel W.] Eastern Colorado Hlth Care Syst, Div Med Oncol, Dept Med, Denver Vet Affairs Med Ctr, Denver, CO USA. [Ghosh, Debashis] Univ Colorado, Sch Med, Dept Biostat, Aurora, CO 80045 USA. RP Karam, SD (reprint author), Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Ct,Room 1032, Aurora, CO 80045 USA. EM sana.karam@ucdenver.edu FU National Cancer Institute, National Institutes of Health; Cancer League of Colorado; Golfers Against Cancer FX This study was supported by a Paul Calabresi Career Development Award for Clinical Oncology K12 from the National Cancer Institute, National Institutes of Health (Dr Karam); by a grant from the Cancer League of Colorado; and by Golfers Against Cancer. NR 52 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD NOV PY 2016 VL 142 IS 11 BP 1100 EP 1110 DI 10.1001/jamaoto.2016.2168 PG 11 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA ED3GI UT WOS:000388737200013 PM 27541166 ER PT J AU Barysauskas, CM Hudgins, G Gill, KK Camuso, KM Bagley, J Rozanski, S Kadish, S AF Barysauskas, Constance M. Hudgins, Gina Gill, Katie Kupferberg Camuso, Kristen M. Bagley, Janet Rozanski, Sheila Kadish, Sarah TI Measuring Chemotherapy Appointment Duration and Variation Using Real-Time Location Systems SO JOURNAL FOR HEALTHCARE QUALITY LA English DT Article DE Real-time location systems; patient flow; variability; quality assurance; patient tracking ID I TRAUMA CENTER AB Introduction: Clinical schedules drive resource utilization, cost, and patient wait time. Accurate appointment duration allocation ensures appropriate staffing ratios to daily caseloads and maximizes scarce resources. Dana-Farber Cancer Institute (DFCI) infusion appointment duration is adjusted by regimen using a consensus method of experts including pharmacists, nurses, and administrators. Using real-time location system (RTLS), we examined the accuracy of observed appointment duration compared with the scheduled duration. Methods: Appointment duration was calculated using RTLS at DFCI between August 1, 2013, and September 30, 2013. Duration was defined as the total time a patient occupied an infusion chair. The top 10 administered infusion regimens were investigated (n = 805). Results: Median observed appointment durations were statistically different than the scheduled durations. Appointment durations were shorter than scheduled 98% (C), 95% (I), and 75% (F) of the time and longer than scheduled 77% (A) and 76% (G) of the time. Fifty-six percent of the longer than scheduled (A) appointments were at least 30 minute longer. Conclusion: RTLS provides reliable and unbiased data to improve schedule accuracy. Replacing consensus with system-based data may improve clinic flow, relieve staff stress, and increase patient satisfaction. Further investigation is warranted to elucidate factors that impact variation in appointment duration. C1 [Barysauskas, Constance M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Hudgins, Gina] Dana Farber Canc Inst, Dept Ambulatory Practice Management, Boston, MA 02115 USA. [Gill, Katie Kupferberg] Dana Farber Canc Inst, Dis Ctr Operat, Boston, MA 02115 USA. [Camuso, Kristen M.] Dana Farber Canc Inst, Qual & Patient Safety Dept, Boston, MA 02115 USA. [Bagley, Janet] Dana Farber Canc Inst, Dept Adult Ambulatory Serv, Nursing, Boston, MA 02115 USA. [Rozanski, Sheila] Dana Farber Canc Inst, Dept Adult Ambulatory Serv, Boston, MA 02115 USA. [Kadish, Sarah] Dana Farber Canc Inst, Performance Measures & Improvement, Boston, MA 02115 USA. RP Barysauskas, CM (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. EM barysaus@jimmy.harvard.edu NR 10 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1062-2551 EI 1945-1474 J9 J HEALTHC QUAL JI J. Healthc. Qual. PD NOV-DEC PY 2016 VL 38 IS 6 BP 353 EP 358 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA ED1TM UT WOS:000388627800010 PM 27049626 ER PT J AU Dryden-Peterson, S Bvochora-Nsingo, M Suneja, G Efstathiou, JA Grover, S Chiyapo, S Ramogola-Masire, D Kebabonye-Pusoentsi, M Clayman, R Mapes, AC Tapela, N Asmelash, A Medhin, H Viswanathan, AN Russell, AH Lin, LL Kayembe, MKA Mmalane, M Randall, TC Chabner, B Lockman, S AF Dryden-Peterson, Scott Bvochora-Nsingo, Memory Suneja, Gita Efstathiou, Jason A. Grover, Surbhi Chiyapo, Sebathu Ramogola-Masire, Doreen Kebabonye-Pusoentsi, Malebogo Clayman, Rebecca Mapes, Abigail C. Tapela, Neo Asmelash, Aida Medhin, Heluf Viswanathan, Akila N. Russell, Anthony H. Lin, Lilie L. Kayembe, Mukendi K. A. Mmalane, Mompati Randall, Thomas C. Chabner, Bruce Lockman, Shahin TI HIV Infection and Survival Among Women With Cervical Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-PAPILLOMAVIRUS INFECTION; PROTEASE INHIBITOR NELFINAVIR; ACTIVE ANTIRETROVIRAL THERAPY; CELL LUNG-CANCER; PHASE-I TRIAL; INTRAEPITHELIAL NEOPLASIA; NEGATIVE PATIENTS; RISK; DISEASE AB Purpose Cervical cancer is the leading cause of cancer death among the 20 million women with HIV worldwide. We sought to determine whether HIV infection affected survival in women with invasive cervical cancer. Patients and Methods We enrolled sequential patients with cervical cancer in Botswana from 2010 to 2015. Standard treatment included external beam radiation and brachytherapy with concurrent cisplatin chemotherapy. The effect of HIV on survival was estimated by using an inverse probability weighted marginal Cox model. Results A total of 348 women with cervical cancer were enrolled, including 231 (66.4%) with HIV and 96 (27.6%) without HIV. The majority (189 [81.8%]) of women with HIV received antiretroviral therapy before cancer diagnosis. The median CD4 cell count for women with HIV was 397 (interquartile range, 264 to 555). After a median follow-up of 19.7 months, 117 (50.7%) women with HIV and 40 (41.7%) without HIV died. One death was attributed to HIV and the remaining to cancer. Three-year survival for the women with HIV was 35% (95% CI, 27% to 44%) and 48% (95% CI, 35% to 60%) for those without HIV. In an adjusted analysis, HIV infection significantly increased the risk for death among all women (hazard ratio, 1.95; 95% CI, 1.20 to 3.17) and in the subset that received guideline-concordant curative treatment (hazard ratio, 2.63; 95% CI, 1.05 to 6.55). The adverse effect of HIV on survival was greater for women with a more-limited stage cancer (P = .035), those treated with curative intent (P = .003), and those with a lower CD4 cell count (P = .036). Advanced stage and poor treatment completion contributed to high mortality overall. Conclusion In the context of good access to and use of antiretroviral treatment in Botswana, HIV infection significantly decreases cervical cancer survival. (C) 2016 by American Society of Clinical Oncology C1 [Dryden-Peterson, Scott; Viswanathan, Akila N.; Lockman, Shahin] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Dryden-Peterson, Scott; Lockman, Shahin] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Dryden-Peterson, Scott; Efstathiou, Jason A.; Viswanathan, Akila N.; Russell, Anthony H.; Randall, Thomas C.; Chabner, Bruce; Lockman, Shahin] Harvard Med Sch, Boston, MA USA. [Efstathiou, Jason A.; Clayman, Rebecca; Russell, Anthony H.; Randall, Thomas C.; Chabner, Bruce] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Viswanathan, Akila N.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dryden-Peterson, Scott; Mapes, Abigail C.; Tapela, Neo; Asmelash, Aida; Mmalane, Mompati; Lockman, Shahin] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana. [Bvochora-Nsingo, Memory] Gaborone Private Hosp, Gaborone, Botswana. [Chiyapo, Sebathu] Princess Marina Hosp, Gaborone, Botswana. [Ramogola-Masire, Doreen] Botswana Univ Pennsylvania Partnership, Gaborone, Botswana. [Kebabonye-Pusoentsi, Malebogo; Tapela, Neo; Medhin, Heluf; Kayembe, Mukendi K. A.] Botswana Minist Hlth, Gaborone, Botswana. [Suneja, Gita] Univ Utah, Sch Med, Salt Lake City, UT USA. [Grover, Surbhi; Lin, Lilie L.] Univ Penn, Philadelphia, PA 19104 USA. RP Dryden-Peterson, S (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. EM scott_peterson@post.harvard.edu FU National Institutes of Health [P30AI060354, P30AI045008, K23AI091434]; National Cancer Institute Federal Share of program [C06CA059267]; Paul G. Allen Family Foundation [11689] FX Supported by National Institutes of Health Grants No. P30AI060354, P30AI045008, and K23AI091434; National Cancer Institute Federal Share of program income earned by Massachusetts General Hospital on C06CA059267; and the Paul G. Allen Family Foundation (11689). NR 48 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2016 VL 34 IS 31 BP 3749 EP + DI 10.1200/JCO.2016.67.9613 PG 13 WC Oncology SC Oncology GA ED5WP UT WOS:000388923800008 ER PT J AU Giacalone, NJ Wu, J Chen, MH Renshaw, A Loffredo, M Kantoff, PW D'Amico, AV AF Giacalone, Nicholas J. Wu, Jing Chen, Ming-Hui Renshaw, Andrew Loffredo, Marian Kantoff, Philip W. D'Amico, Anthony V. TI Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ANDROGEN DEPRIVATION THERAPY; RADIATION-THERAPY; RADICAL PROSTATECTOMY; FOLLOW-UP; RADIOTHERAPY; SUPPRESSION; DURATION; MORTALITY AB Purpose Physicians sometimes make management recommendations on the basis of early results from randomized controlled trials (RCTs) relating to reduced prostate-specific antigen (PSA) failure, yet whether this early end point is associated with all-cause mortality (ACM), particularly in men with competing risks, is unknown. Using a validated metric in men treated within the context of an RCT, we aimed to determine whether PSA failure is associated with the risk of ACM stratified by comorbidity score. Patients and Methods Between 1995 and 2001, 206 men with localized (T1b to 2b) intermediate-and high-risk prostate cancer (PC) were randomly assigned to receive radiation therapy or radiation therapy and 6 months of ADT. Cox regression analyses were performed to evaluate whether PSA failure modeled as a time-dependent covariate was associated with an increased risk of ACM among men with Adult Comorbidity Evaluation-27-defined no or minimal versus moderate-to-severe comorbidity adjusting for age, PC prognostic factors, and treatment. Results After a median follow-up of 16.62 years, 156 men (76%) died, 29 of whom (19%) died as a result of PC. PSA failure was associated with an increased ACM risk among men with no or minimal (adjusted hazard ratio, 1.59; 95% CI, 1.03 to 2.46; P = .04), but not moderate or severe comorbidity (adjusted hazard ratio, 1.75; 95% CI, 0.76 to 3.99; P = .19). Conclusion Recommending treatment on the basis of reduced PSA failure observed from early results of RCTs is unlikely to prolong survival in men with moderate-to-severe comorbidity but may prolong survival in men with no or minimal comorbidity, providing evidence to support discussing the early results with these men. (C) 2016 by American Society of Clinical Oncology C1 [Giacalone, Nicholas J.; Loffredo, Marian; D'Amico, Anthony V.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St,L-2 Level, Boston, MA 02115 USA. [Giacalone, Nicholas J.] Harvard Radiat Oncol Program, Boston, MA USA. [Wu, Jing; Chen, Ming-Hui] Univ Connecticut, Storrs, CT USA. [Renshaw, Andrew] Miami Baptist Hosp, Miami, FL USA. [Kantoff, Philip W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. RP Giacalone, NJ (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,L-2 Level, Boston, MA 02115 USA. EM ngiacalone@partners.org NR 27 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2016 VL 34 IS 31 BP 3781 EP + DI 10.1200/JCO.2016.68.4530 PG 7 WC Oncology SC Oncology GA ED5WP UT WOS:000388923800012 ER PT J AU Hasegawa, T Uno, H Wei, LJ AF Hasegawa, Takahiro Uno, Hajime Wei, Lee-Jen TI How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter C1 [Hasegawa, Takahiro] Shionogi & Co Ltd, Osaka, Japan. [Uno, Hajime] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wei, Lee-Jen] Harvard Univ, Boston, MA 02115 USA. RP Hasegawa, T (reprint author), Shionogi & Co Ltd, Osaka, Japan. NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2016 VL 34 IS 31 BP 3818 EP + DI 10.1200/JCO.2016.67.2055 PG 2 WC Oncology SC Oncology GA ED5WP UT WOS:000388923800018 ER PT J AU Rapalino, O Ratai, EM AF Rapalino, O. Ratai, E. M. TI Multiparametric Imaging Analysis: Magnetic Resonance Spectroscopy SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Magnetic resonance spectroscopy; N-acetyl aspartate; Choline; Glioma; Cerebral metastasis; Lactate; 2-Hydroxyglutarate; Brain tumor ID PROTON MR SPECTROSCOPY; TUMEFACTIVE DEMYELINATING LESIONS; LOW-GRADE GLIOMAS; POWER ADIABATIC PULSES; IN-VIVO DETECTION; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; CEREBRAL GLIOMAS; RADIATION-THERAPY; CHEMICAL-SHIFT AB Magnetic resonance spectroscopy (MRS) is a magnetic resonance based imaging modality that allows noninvasive sampling of metabolic changes in normal and abnormal brain parenchyma. MRS is particularly useful in the differentiation of developmental or non-neoplastic disorders from neoplastic processes. MRS is also useful during routine imaging follow-up after radiation treatment or during antiangiogenic treatment and for predicting outcomes and treatment response. The objective of this article is to provide a concise but thorough review of the basic physical principles, important applications of MRS in brain tumor imaging, and future directions. C1 [Rapalino, O.; Ratai, E. M.] Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Div, Boston, MA 02114 USA. [Ratai, E. M.] MGH HST Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St,Room 2301, Charlestown, MA 02129 USA. RP Ratai, EM (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Div, Bldg 149,13th St,Room 2301, Charlestown, MA 02129 USA.; Ratai, EM (reprint author), AA Martinos Ctr Biomed Imaging, Bldg 149,13th St,Room 2301, Charlestown, MA 02129 USA. EM eratai@mgh.harvard.edu NR 76 TC 0 Z9 0 U1 3 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD NOV PY 2016 VL 24 IS 4 BP 671 EP + DI 10.1016/j.mric.2016.06.001 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ED5OB UT WOS:000388900500004 PM 27742109 ER PT J AU Huang, RY Wen, PY AF Huang, Raymond Y. Wen, Patrick Y. TI Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE RANO; Response assessment; Endpoints; Gliomas; Brain metastases ID APPARENT DIFFUSION-COEFFICIENT; MAGNETIC-RESONANCE-SPECTROSCOPY; RECURRENT GLIOBLASTOMA PATIENTS; NEWLY-DIAGNOSED GLIOBLASTOMA; PROTON MR SPECTROSCOPY; CEREBRAL BLOOD-VOLUME; ACRIN 6677/RTOG 0625; HIGH-GRADE GLIOMAS; PHASE-II TRIAL; BEVACIZUMAB PLUS IRINOTECAN AB The Response Assessment in Neuro-Oncology (RANO) Working Group is an international multidisciplinary group whose goal is to improve response criteria and define endpoints for neuro-oncology trials. The RANO criteria for high-grade gliomas attempt to address the issues of pseudoprogression, pseudoresponse, and nonenhancing tumor progression. Incorporation of advanced MR imaging may eventually help improve the ability of these criteria to better define enhancing and nonenhancing disease. The RANO group has also developed criteria for neurologic response and evaluation of patients receiving immunologic therapies. RANO criteria have been developed for brain metastases and are in progress for meningiomas, leptomeningeal disease, spinal tumors, and pediatric tumors. C1 [Huang, Raymond Y.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Div Neuroradiol, 75 Francis St, Boston, MA 02115 USA. [Wen, Patrick Y.] Harvard Med, Brigham & Womens Hosp, Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol,Dept Neurol,Div Neurooncol, Boston, MA 02215 USA. RP Huang, RY (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Div Neuroradiol, 75 Francis St, Boston, MA 02115 USA. EM ryhuang@partners.org NR 112 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD NOV PY 2016 VL 24 IS 4 BP 705 EP + DI 10.1016/j.mric.2016.06.003 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ED5OB UT WOS:000388900500006 PM 27742111 ER PT J AU Karaa, A Cohen, BH Goldstein, A Vockley, G Haas, R AF Karaa, A. Cohen, B. H. Goldstein, A. Vockley, G. Haas, R. TI Mitochondrial Replacement Therapy SO MITOCHONDRION LA English DT Meeting Abstract C1 [Karaa, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cohen, B. H.] Akron Childrens Hosp, Akron, OH USA. [Haas, R.] Univ Calif San Diego, Sch Med, San Diego, CA USA. [Goldstein, A.; Vockley, G.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2016 VL 31 BP 90 EP 90 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA EC8ZL UT WOS:000388431500016 ER PT J AU Perales-Clemente, E Cook, AN Evans, JM Roellinger, S Secreto, F Emmanuele, V Oglesbee, D Mootha, VK Hirano, M Schon, EA Terzic, A Nelson, TJ AF Perales-Clemente, Ester Cook, Alexandra Nicole Evans, Jared Matthew Roellinger, Samantha Secreto, Frank Emmanuele, Valentina Oglesbee, Devin Mootha, Vamsi Krishna Hirano, Michio Schon, Eric Alan Terzic, Andre Nelson, Timothy James TI Amplification of rare, low-level heteroplasmic mtDNA mutations during nuclear reprogramming causes intra-person induced pluripotent stem cells variability SO MITOCHONDRION LA English DT Meeting Abstract C1 [Perales-Clemente, Ester; Terzic, Andre] Mayo Clin, Ctr Regenerat Med, Dept Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA. [Perales-Clemente, Ester; Terzic, Andre] Mayo Clin, Ctr Regenerat Med, Dept Med Genet, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Cook, Alexandra Nicole; Secreto, Frank; Nelson, Timothy James] Mayo Clin, Ctr Regenerat Med, Dept Med,Div Pediat Cardiol, Dept Mol Pharmacol & Expt Therapeut,Div Gen Inter, Rochester, MN 55905 USA. [Cook, Alexandra Nicole; Secreto, Frank; Nelson, Timothy James] Mayo Clin, Ctr Regenerat Med, Transplant Ctr, Rochester, MN 55905 USA. [Evans, Jared Matthew] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA. [Roellinger, Samantha; Oglesbee, Devin] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA. [Mootha, Vamsi Krishna] Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA. Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2016 VL 31 MA PA-0143 BP 92 EP 93 PG 2 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA EC8ZL UT WOS:000388431500022 ER PT J AU Parikh, S Karaa, A Goldstein, A Ng, YS Gorman, G Feigenbaum, A Christodoulou, J Haas, R Tarnopolsky, M Cohen, BH Dimmock, D Feyma, T Koenig, MK Mundy, H Niyazov, D Saneto, RP Wainwright, MS Wusthoff, C McFarland, R Scaglia, F AF Parikh, Sumit Karaa, Amel Goldstein, Amy Ng, Yi S. Gorman, Grainne Feigenbaum, Annette Christodoulou, John Haas, Richard Tarnopolsky, Mark Cohen, Bruce H. Dimmock, David Feyma, Tim Koenig, Mary K. Mundy, Helen Niyazov, David Saneto, Russell P. Wainwright, Mark S. Wusthoff, Courtney McFarland, Robert Scaglia, Fernando TI Solid organ transplantation in primary mitochondrial disease: Proceed with caution SO MITOCHONDRION LA English DT Meeting Abstract C1 [Parikh, Sumit] Cleveland Clin, Ctr Pediat Neurol, Neurogenet & Mitochondrial Dis, Cleveland, OH 44106 USA. [Karaa, Amel] Massachusetts Gen Hosp, Dept Med Genet, Boston, MA 02114 USA. [Goldstein, Amy] Childrens Hosp Pittsburgh, Ctr Pediat Neurol, Pittsburgh, PA 15213 USA. [Ng, Yi S.; Gorman, Grainne] Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Feigenbaum, Annette] Rady Childrens Hosp, Dept Med Genet, San Diego, CA USA. [Christodoulou, John] Childrens Hosp Westmead, Western Sydney Genet Program, Sydney, NSW, Australia. [Christodoulou, John] Univ Sydney, Disciplines Pediat & Child Hlth & Genet Med, Sydney, NSW, Australia. [Haas, Richard] Rady Childrens Hosp, Dept Pediat Neurol, San Diego, CA USA. [Tarnopolsky, Mark] McMaster Univ, Dept Pediat, Div Neuromuscular & Neurometabol Dis, Hamilton, ON, Canada. [Cohen, Bruce H.] Akron Childrens Hosp, Dept Pediat Neurol, Akron, OH USA. [Dimmock, David] Med Coll Wisconsin, Dept Med Genet, Milwaukee, WI 53226 USA. [Feyma, Tim] Gillette Childrens Specialty Healthcare, Dept Pediat Neurol, St Paul, MN USA. [Koenig, Mary K.] Univ Texas Houston, Sch Med, Dept Pediat, Div Child & Adolescent Neurol, Houston, TX USA. [Mundy, Helen] Evelina London Childrens Healthcare, Pediat Metab, London, England. [Niyazov, David] Ochsner Clin Fdn, Dept Pediat, Div Med Genet, New Orleans, LA USA. [Saneto, Russell P.] Seattle Childrens Hosp, Dept Pediat Neurol, Seattle, WA USA. [Wainwright, Mark S.] Lurie Childrens Hosp, Dept Pediat, Div Neurol, Chicago, IL USA. [Wusthoff, Courtney] Lucile Packard Childrens Hosp, Dept Pediat Neurol, Palo Alto, CA USA. [McFarland, Robert] Newcastle Univ, R Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England. [Scaglia, Fernando] Baylor Coll Med, Dept Mol & Human Genet, Baylor, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2016 VL 31 MA PA-014 BP 93 EP 94 PG 2 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA EC8ZL UT WOS:000388431500025 ER PT J AU Elsharkawi, I Balcells, C Karaa, A AF Elsharkawi, Ibrahim Balcells, Cristy Karaa, Amel TI Effect of pregnancy in females with mitochondrial disease/dysfunction: A retrospective study SO MITOCHONDRION LA English DT Meeting Abstract C1 [Elsharkawi, Ibrahim; Karaa, Amel] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Balcells, Cristy] MitoAction, POB 51474, Boston, MA 02205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2016 VL 31 MA 2016PA0163 BP 96 EP 96 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA EC8ZL UT WOS:000388431500031 ER PT J AU Sobti, N Liao, EC AF Sobti, Nikhil Liao, Eric C. TI Surgeon-Controlled Study and Meta-Analysis Comparing FlexHD and AlloDerm in Immediate Breast Reconstruction Outcomes SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID ACELLULAR DERMAL MATRIX; COMPLICATIONS; SLINGS; INFECTION; IMPLANTS; RISK AB Background: The use of acellular dermal matrix has facilitated immediate prosthesis-based breast reconstruction. However, few studies directly compare surgical outcomes following acellular dermal matrix-based reconstruction with two of the most commonly available materials, AlloDerm and FlexHD. Those studies that are available often do not adequately control for the surgeon as a variable. The authors hypothesize that complication rates will not differ significantly between AlloDerm and FlexHD when practice and surgeon variables are properly controlled. Methods: Retrospective review was conducted to identify consecutive implant-based reconstruction procedures performed at a tertiary academic medical institution by a single plastic surgeon over 6 years. Univariate and binomial regression analyses were conducted to compare patient characteristics and clinical endpoints across acellular dermal matrix groups (AlloDerm/AlloDerm ready-to-use versus FlexHD Pliable/Perforated). Results: Of the 233 patients that underwent matrix-based breast reconstruction, 11 (4.7 percent) developed surgical-site infection. The infection rate was not statistically different between patients who received FlexHD [n = 5 (5.0 percent)] versus AlloDerm [n = 6 (4.6 percent)] on either univariate (p = 0.89) or binomial regression analysis (p = 0.56). Likewise, there were no statistical differences in rates of seroma, hematoma, explantation, or delayed wound healing. Conclusions: Clinical endpoints of interest were all equivalent between acellular dermal matrix types. This study uniquely reports a single-surgeon case series comparing outcomes between different acellular dermal matrix types. Instead of focusing on acellular dermal matrix as a predictor of outcome, other patient and surgeon factors should be addressed to improve results and innovate better alternatives. C1 [Sobti, Nikhil; Liao, Eric C.] Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA. RP Liao, EC (reprint author), 15 Parkman St,WACC 435, Boston, MA 02114 USA. EM cliao@partners.org FU Musculoskeletal Transplant Foundation FX Dr. Liao serves as a consultant and principal investigator on a research study funded by Musculoskeletal Transplant Foundation and serves as a consultant for LifeCell Inc., manufacturers of FlexHD and AlloDerm, respectively. No funds were received for this clinical study. NR 40 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD NOV PY 2016 VL 138 IS 5 BP 959 EP 967 DI 10.1097/PRS.0000000000002616 PG 9 WC Surgery SC Surgery GA ED7HM UT WOS:000389033400039 PM 27782982 ER PT J AU Metrik, J Jackson, K Bassett, SS Zvolensky, MJ Seal, K Borsari, B AF Metrik, Jane Jackson, Kristina Bassett, Shayna S. Zvolensky, Michael J. Seal, Karen Borsari, Brian TI The Mediating Roles of Coping, Sleep, and Anxiety Motives in Cannabis Use and Problems Among Returning Veterans With PTSD and MDD SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE cannabis; motives; PTSD; depression; sleep ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; MARIJUANA USE MOTIVES; NATIONAL EPIDEMIOLOGIC SURVEY; COGNITIVE-BEHAVIORAL THERAPY; MENTAL-HEALTH DIAGNOSES; AFGHANISTAN VETERANS; MOTIVATIONAL MODEL; DISTRESS TOLERANCE; COMORBIDITY SURVEY AB Veterans with posttraumatic stress disorder (PTSD) and major depressive disorder (MDD), the 2 most prevalent mental health disorders in the Iraq and Afghanistan veterans, are at increased risk for cannabis use and problems including cannabis use disorder (CUD). The present study examined the relationship of PTSD and MDD with cannabis use frequency, cannabis problems, and CUD as well as the role of 3 coping-oriented cannabis use motives (coping with negative affect, situational anxiety, and sleep) that might underlie this relationship. Participants were veterans (N = 301) deployed post-9/11/2001 recruited from a Veterans Health Administration facility in the Northeast United States based on self-reported lifetime cannabis use. There were strong unique associations between PTSD and MDD and cannabis use frequency, cannabis problems, and CUD. Mediation analyses revealed the 3 motives accounted, in part, for the relationship between PTSD and MDD with 3 outcomes in all cases but for PTSD with cannabis problems. When modeled concurrently, sleep motives, but not situational anxiety or coping with negative affect motives, significantly mediated the association between PTSD and MDD with use. Together with coping motives, sleep motives also fully mediated the effects of PTSD and MDD on CUD and in part the effect of MDD on cannabis problems. Findings indicate the important role of certain motives for better understanding the relation between PTSD and MDD with cannabis use and misuse. Future work is needed to explore the clinical utility in targeting specific cannabis use motives in the context of clinical care for mental health and CUD. C1 [Metrik, Jane; Bassett, Shayna S.] Providence VA Med Ctr, Providence, RI USA. [Metrik, Jane; Jackson, Kristina] Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Bassett, Shayna S.] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Zvolensky, Michael J.] Univ Houston, Dept Behav Sci, Houston, TX 77004 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Seal, Karen; Borsari, Brian] San Francisco VA Med Ctr, San Francisco, CA USA. [Seal, Karen; Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Metrik, J (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA. EM Jane_Metrik@brown.edu FU National Institute on Drug Abuse [R01 DA033425]; [K02 AA13938] FX All authors contributed in a significant way to the manuscript and have all read and approved the final manuscript. This study was funded by a National Institute on Drug Abuse grant (R01 DA033425), awarded to Jane Metrik and Brian Borsari. Kristina Jackson's work on this project was supported by K02 AA13938. The funding sources had no other role other than financial support. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors have no financial relationship with the study sponsor. The authors gratefully acknowledge Cassandra Delapaix, Rebecca Swagger, Madeline Benz, Hannah Wheeler, Suzanne Sales, and Julie Evon for their contribution to the project. NR 85 TC 1 Z9 1 U1 10 U2 10 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD NOV PY 2016 VL 30 IS 7 BP 743 EP 754 DI 10.1037/adb0000210 PG 12 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA ED3HM UT WOS:000388740200004 PM 27786514 ER PT J AU Gros, DF Flanagan, JC Korte, KJ Mills, AC Brady, KT Back, SE AF Gros, Daniel F. Flanagan, Julianne C. Korte, Kristina J. Mills, Adam C. Brady, Kathleen T. Back, Sudie E. TI Relations Among Social Support, PTSD Symptoms, and Substance Use in Veterans SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE posttraumatic stress disorder; social support; alcohol; veterans ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-USE; DEPRESSIVE SYMPTOMS; ENDURING FREEDOM; EXPOSED ADULTS; IRAQI FREEDOM; COMORBIDITY; DEPENDENCE; RESILIENCE; NETWORKS AB Social support plays a significant role in the development, maintenance, and treatment of posttraumatic stress disorder (PTSD). However, there has been little investigation of social support with PTSD and its frequent comorbid conditions and related symptoms. Substance use disorders (SUDs) are 1 set of conditions that have yet to be investigated in combination with PTSD and social support. As compared with civilians, veterans are at increased risk for developing both PTSD and SUD. In this study, veterans (N = 171) with symptoms of PTSD (76% met diagnostic criteria) and SUD (83% met diagnostic criteria for any dependence) were recruited and completed clinician-rated and self-report measures of PTSD, SUD, and social support. Overall, low social support was reported in the sample. When controlled for the other disorder's symptoms, PTSD symptoms demonstrated a significant negative relation and SUD symptoms demonstrated a significant positive relation to social support. The PTSD findings are consistent with previous studies on PTSD and social support without SUD comorbidity. However, the SUD findings are inconsistent with previous studies, which focused primarily on older veterans. Together, these findings highlight the significance of social support in individuals with PTSD and SUD and promote future research within comorbid presentations. C1 [Gros, Daniel F.; Flanagan, Julianne C.; Korte, Kristina J.; Mills, Adam C.; Brady, Kathleen T.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Gros, Daniel F.; Flanagan, Julianne C.; Korte, Kristina J.; Mills, Adam C.; Brady, Kathleen T.; Back, Sudie E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU National Institute on Drug Abuse (NIDA) [DA030143]; Department of Veteran Affairs [CX000845]; National Institute on Child Health and Human Development; Office of Research on Women's Health [K12HD055885]; National Institute of Alcohol Abuse and Alcoholism [T32AA007474] FX This research was supported by the National Institute on Drug Abuse (NIDA) grant DA030143 (Principal Investigator [PI]: S. E. B.), the Department of Veteran Affairs Clinical Science Research and Development Career Development Award CX000845 (PI: D. F. G.), the National Institute on Child Health and Human Development and the Office of Research on Women's Health grant K12HD055885 (PI: J. C. F.), and by the National Institute of Alcohol Abuse and Alcoholism grant T32AA007474 (K. J. K.). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of NIDA, the Department of Veterans Affairs, or the U.S. government. NR 45 TC 1 Z9 1 U1 8 U2 8 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD NOV PY 2016 VL 30 IS 7 BP 764 EP 770 DI 10.1037/adb0000205 PG 7 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA ED3HM UT WOS:000388740200006 PM 27786511 ER PT J AU Montgomery, AE Szymkowiak, D Marcus, J Howard, P Culhane, DP AF Montgomery, Ann Elizabeth Szymkowiak, Dorota Marcus, Jessica Howard, Paul Culhane, Dennis P. TI Homelessness, Unsheltered Status, and Risk Factors for Mortality: Findings From the 100000 Homes Campaign SO PUBLIC HEALTH REPORTS LA English DT Article DE homeless; unsheltered; mortality ID FOSTER-CARE; PHYSICAL HEALTH; ADULTS; DEATH; BOSTON; SERVICES; BEHAVIOR; OUTCOMES; HISTORY; IMPACT AB Objectives: People who live in unsheltered situations, such as the streets, often have poorer health, less access to health care, and an increased risk of premature mortality as compared with their sheltered counterparts. The objectives of this study were to (1) compare the characteristics of people experiencing homelessness who were sleeping primarily in unsheltered situations with those who were accessing homeless shelters and other sheltered situations, (2) identify correlates of unsheltered status, and (3) assess the relationship between unsheltered status and increased risk of mortality. Methods: Using primary data collected as part of the 100000 Homes Campaigna national effort to help communities find homes for vulnerable and chronically homeless Americanswe estimated 2 generalized linear mixed models to understand the correlates of unsheltered status and risk factors for mortality. Independent variables included demographic characteristics; history of homelessness, incarceration, foster care, and treatment for mental illness or substance use; sources of income; and past and present medical conditions. The study sample comprised 25489 people experiencing homelessness who responded to an assessment of their housing and health as part of the 100000 Homes Campaign from 2008 to 2014. Results: In the full model, the following characteristics were associated with unsheltered status: being a veteran (adjusted odds ratio [aOR] = 1.10); having 5 years), incarceration (aOR = 1.32), or substance use (aOR = 1.10 for ever abusing drugs or alcohol, aOR = 1.13 for ever using intravenous drugs, aOR = 1.98 for drinking alcohol every day for past month). Being unsheltered (aOR = 1.12), being female (aOR = 1.22), or receiving entitlements (aOR = 1.63) increased respondents' odds of having risk factors for mortality. Conclusions: These findings highlight the need to assertively reach out to vulnerable populations and provide interventions to assist them during their transitionfor example, as they exit incarceration or age out of foster care. Such a response could prevent unsheltered homelessness and thereby address increased mortality risk. Connecting people with resources to increase their access to employment, benefits, and other sources of income is especially important. C1 [Montgomery, Ann Elizabeth] Birmingham Vet Affairs Med Ctr, Hlth Serv Res, Birmingham, AL USA. [Montgomery, Ann Elizabeth; Szymkowiak, Dorota; Culhane, Dennis P.] Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Montgomery, Ann Elizabeth] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Marcus, Jessica; Howard, Paul] Community Solut, Data & Performance Management, New York, NY USA. [Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Montgomery, AE (reprint author), Birmingham VA Med Ctr, Mail Stop 151 A Pickwick,700 South 19th St, Birmingham, AL 35233 USA. EM ann.montgomery2@va.gov NR 30 TC 0 Z9 0 U1 8 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 765 EP 772 DI 10.1177/0033354916667501 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400006 PM 28123222 ER PT J AU Hoffmire, C Stephens, B Morley, S Thompson, C Kemp, J Bossarte, RM AF Hoffmire, Claire Stephens, Brady Morley, Sybil Thompson, Caitlin Kemp, Janet Bossarte, Robert M. TI VA Suicide Prevention Applications Network: A National Health Care System-Based Suicide Event Tracking System SO PUBLIC HEALTH REPORTS LA English DT Article DE veterans; suicide; prevention AB Objectives: The US Department of Veterans Affairs' Suicide Prevention Applications Network (SPAN) is a national system for suicide event tracking and case management. The objective of this study was to assess data on suicide attempts among people using Veterans Health Administration (VHA) services. Methods: We assessed the degree of data overlap on suicide attempters reported in SPAN and the VHA's medical records from October 1, 2010, to September 30, 2014-overall, by year, and by region. Data on suicide attempters in the VHA's medical records consisted of diagnoses documented with E95 codes from the International Classification of Diseases, Ninth Revision. Results: Of 50 518 VHA patients who attempted suicide during the 4-year study period, data on fewer than half (41%) were reported in both SPAN and the medical records; nearly 65% of patients whose suicide attempt was recorded in SPAN had no data on attempted suicide in the VHA's medical records. Conclusion: Evaluation of administrative data suggests that use of SPAN substantially increases the collection of data on suicide attempters as compared with the use of medical records alone, but neither SPAN nor the VHA's medical records identify all suicide attempters. Further research is needed to better understand the strengths and limitations of both systems and how to best combine information across systems. C1 [Hoffmire, Claire] US Dept Vet Affairs, Rocky Mt Mental Illness Res Educ & Clin Ctr Suici, 1055 Clermont St, Denver, CO 80220 USA. [Stephens, Brady; Kemp, Janet] US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua, NY USA. [Morley, Sybil; Bossarte, Robert M.] US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth, Off Publ Hlth, Washington, DC USA. [Thompson, Caitlin] US Dept Vet Affairs, Suicide Prevent Program, Mental Hlth Serv, Washington, DC USA. RP Hoffmire, C (reprint author), US Dept Vet Affairs, Rocky Mt Mental Illness Res Educ & Clin Ctr Suici, 1055 Clermont St, Denver, CO 80220 USA. EM claire.hoffmire@va.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 816 EP 821 DI 10.1177/0033354916670133 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400012 PM 28123228 ER PT J AU Barth, SK Kang, HK Bullman, T AF Barth, Shannon K. Kang, Han K. Bullman, Tim TI All-Cause Mortality Among US Veterans of the Persian Gulf War: 13-Year Follow-up SO PUBLIC HEALTH REPORTS LA English DT Article DE gulf war; mortality; veterans ID POPULATION-BASED SURVEY; LOW-LEVEL SARIN; MULTISYMPTOM ILLNESS; CYCLOSARIN EXPOSURE; HEALTH-STATUS; FIRE SMOKE; I VETERANS; ARMY; KHAMISIYAH; ASTHMA AB Objective: We determined cause-specific mortality prevalence and risks of Gulf War deployed and nondeployed veterans to determine if deployed veterans were at greater risk than nondeployed veterans for death overall or because of certain diseases or conditions up to 13 years after conflict subsided. Methods: Follow-up began when the veteran left the Gulf War theater or May 1, 1991, and ended on the date of death or December 31, 2004. We studied 621901 veterans who served in the 1990-1991 Persian Gulf War and 746247 veterans who served but were not deployed during the Gulf War. We used Cox proportional hazard models to calculate rate ratios adjusted for age at entry to follow-up, length of follow-up, race, sex, branch of service, and military unit. We compared the mortality of (1) Gulf War veterans with non-Gulf War veterans and (2) Gulf War army veterans potentially exposed to nerve agents at Khamisiyah in March 1991 with those not exposed. We compared standardized mortality ratios of deployed and nondeployed Gulf War veterans with the US population. Results: Male Gulf War veterans had a lower risk of mortality than male non-Gulf War veterans (adjusted rate ratio [aRR] = 0.97; 95% confidence interval [CI], 0.95-0.99), and female Gulf War veterans had a higher risk of mortality than female non-Gulf War veterans (aRR = 1.15; 95% CI, 1.03-1.28). Khamisiyah-exposed Gulf War army veterans had >3 times the risk of mortality from cirrhosis of the liver than nonexposed army Gulf War veterans (aRR = 3.73; 95% CI, 1.64-8.48). Compared with the US population, female Gulf War veterans had a 60% higher risk of suicide and male Gulf War veterans had a lower risk of suicide (standardized mortality ratio = 0.84; 95% CI, 0.80-0.88). Conclusion: The vital status and mortality risk of Gulf War and non-Gulf War veterans should continue to be investigated. C1 [Barth, Shannon K.; Kang, Han K.; Bullman, Tim] US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Serv, Off Patient Care Serv,Vet Hlth Adm, Washington, DC USA. RP Barth, SK (reprint author), US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Serv 10P4Q, Off Patient Care Serv, 810 Vermont Ave NW, Washington, DC 20420 USA. EM shannon.barth@va.gov FU US Department of Veterans Affairs, Office of Research and Development [GWRA-019-04 S] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was based on work supported by merit review funding (GWRA-019-04 S) awarded by the US Department of Veterans Affairs, Office of Research and Development. NR 50 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 822 EP 830 DI 10.1177/0033354916676278 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400013 PM 28123229 ER PT J AU Kalinich, JF Kasper, CE AF Kalinich, John F. Kasper, Christine E. TI Are Internalized Metals a Long-term Health Hazard for Military Veterans? SO PUBLIC HEALTH REPORTS LA English DT Article DE heavy metal; inhalation; embedded fragments ID PARTICULATE MATTER; AIR-POLLUTION; SOFT-TISSUE; BRAIN; EXPOSURE; INJURY; URANIUM; RATS; INHALATION; FRAGMENTS C1 [Kalinich, John F.] Uniformed Serv Univ Hlth Sci, Armed Forces Radiobiol Res Inst, Internal Contaminat & Met Toxic Program, Bethesda, MD USA. [Kasper, Christine E.] US Dept Vet Affairs, Off Nursing Serv, Bethesda, MD USA. [Kasper, Christine E.] Uniformed Serv Univ Hlth Sci, Daniel K Inouye Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. RP Kasper, CE (reprint author), Uniformed Serv Univ Hlth Sci, Daniel K Inouye Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM christine.kasper@va.gov FU Veterans Affairs grant [B5044 R]; US Army Medical Research and Materiel Command [DAMD17-01-1-0821] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by Veterans Affairs grant B5044 R to C.E.K. and US Army Medical Research and Materiel Command grant DAMD17-01-1-0821 to J.F.K. NR 34 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 831 EP 833 DI 10.1177/0033354916669324 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400014 PM 28123230 ER PT J AU Dursa, EK Barth, SK Bossarte, RM Schneiderman, AI AF Dursa, Erin K. Barth, Shannon K. Bossarte, Robert M. Schneiderman, Aaron I. TI Demographic, Military, and Health Characteristics of VA Health Care Users and Nonusers Who Served in or During Operation Enduring Freedom or Operation Iraqi Freedom, 2009-2011 SO PUBLIC HEALTH REPORTS LA English DT Article DE OEF/OIF; veterans; Department of Veterans Affairs ID VETERANS AB An estimated 60% of all Operation Enduring Freedom / Operation Iraqi Freedom (OEF/OIF) veterans who have left the military had used the US Department of Veterans Affairs (VA) for health care services as of March 31, 2015. What is not known, however, are the differences in demographic, military, and health characteristics between OEF/OIF veterans who use the VA for health care and OEF/OIF veterans who do not. We used data from the 2009-2011 National Health Study for a New Generation of US Veterans to explore these differences. We found that VA health care users were more likely than non-VA health care users to be non-Hispanic black, to be unmarried, to have served on active duty and in the army, to have been deployed to OEF/OIF, and to have an annual income less than $35000. The prevalence of 21 chronic medical conditions was higher among VA health care users than among non-VA health care users. OEF/OIF veterans using the VA for health care differ from nonusers with respect to demographic, military, and health characteristics. These data may be useful for developing programs and policies to address observed health disparities and achieve maximum benefit for the VA beneficiary population. C1 [Dursa, Erin K.; Barth, Shannon K.; Bossarte, Robert M.; Schneiderman, Aaron I.] US Dept Vet Affairs, Postdeployment Hlth Epidemiol Serv, Off Patient Care Serv, 810 Vermont Ave NW,MS 10PQ4, Washington, DC 20420 USA. [Bossarte, Robert M.] Univ West Virginia, Sch Publ Hlth, Morgantown, WV 26506 USA. RP Dursa, EK (reprint author), US Dept Vet Affairs, Postdeployment Hlth Epidemiol Serv, Off Patient Care Serv, 810 Vermont Ave NW,MS 10PQ4, Washington, DC 20420 USA. EM erin.dursa2@va.gov FU US Department of Veterans Affairs FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the US Department of Veterans Affairs. NR 11 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 839 EP 843 DI 10.1177/0033354916676279 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400016 PM 28123232 ER PT J AU Holst, F Singer, CF AF Holst, Frederik Singer, Christian F. TI ESR1-Amplification-Associated Estrogen Receptor proportional to Activity in Breast Cancer SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Letter ID COPY-NUMBER ALTERATION; GENOMIC CHARACTERIZATION; ENDOCRINE-THERAPY C1 [Holst, Frederik] Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers, Bergen, Norway. [Holst, Frederik] Haukeland Hosp, Dept Gynecol & Obstet, Bergen, Norway. [Holst, Frederik] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Holst, Frederik] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02139 USA. [Singer, Christian F.] Med Univ Vienna, Dept Special Gynecol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. RP Holst, F (reprint author), Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers, Bergen, Norway.; Holst, F (reprint author), Haukeland Hosp, Dept Gynecol & Obstet, Bergen, Norway.; Holst, F (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.; Holst, F (reprint author), Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02139 USA. EM frederik.holst@ulb.no NR 12 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD NOV PY 2016 VL 27 IS 11 BP 751 EP 752 DI 10.1016/j.tem.2016.08.002 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA6LM UT WOS:000386740700001 PM 27595547 ER PT J AU Morris, BJ Chen, RD Donlon, TA Evans, DS Tranah, GJ Parimi, N Ehret, GB Newton-Cheh, C Seto, T Willcox, DC Masaki, KH Kamide, K Ryuno, H Oguro, R Nakama, C Kabayama, M Yamamoto, K Sugimoto, K Ikebe, K Masui, Y Arai, Y Ishizaki, T Gondo, Y Rakugi, H Willcox, BJ AF Morris, Brian J. Chen, Randi Donlon, Timothy A. Evans, Daniel S. Tranah, Gregory J. Parimi, Neeta Ehret, Georg B. Newton-Cheh, Christopher Seto, Todd Willcox, D. Craig Masaki, Kamal H. Kamide, Kei Ryuno, Hirochika Oguro, Ryosuke Nakama, Chikako Kabayama, Mai Yamamoto, Koichi Sugimoto, Ken Ikebe, Kazunori Masui, Yukie Arai, Yasumichi Ishizaki, Tatsuro Gondo, Yasuyuki Rakugi, Hiromi Willcox, Bradley J. TI Association Analysis of FOXO3 Longevity Variants With Blood Pressure and Essential Hypertension SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; essential hypertension; FoxO3 gene (FOXO3); genetic association analysis; hypertension; longevity gene ID FORKHEAD TRANSCRIPTION FACTORS; LIFE-SPAN; OXIDATIVE STRESS; DISEASE; METAANALYSIS; RESVERATROL; EXPRESSION; GENETICS; CELLS; IDENTIFICATION AB The minor alleles of 3 FOXO3 single nucleotide polymorphisms (SNPs)-rs2802292, rs2253310, and rs2802288-are associated with human longevity. The aim of the present study was to test these SNPs for association with blood pressure (BP) and essential hypertension (EHT). In a primary study involving Americans of Japanese ancestry drawn from the Family Blood Pressure Program II we genotyped 411 female and 432 male subjects aged 40-79 years and tested for statistical association by contingency table analysis and generalized linear models that included logistic regression adjusting for sibling correlation in the data set. Replication of rs2802292 with EHT was attempted in Japanese SONIC study subjects and of each SNP in a meta-analysis of genome-wide association studies of BP in individuals of European ancestry. In Americans of Japanese ancestry, women homozygous for the longevity-associated (minor) allele of each FOXO3 SNP had 6mm Hg lower systolic BP and 3mm Hg lower diastolic BP compared with major allele homozygotes (Bonferroni corrected P < 0.05 and > 0.05, respectively). Frequencies of minor allele homozygotes were 3.3-3.9% in women with EHT compared with 9.5-9.6% in normotensive women (P = 0.03-0.04; haplotype analysis P = 0.0002). No association with BP or EHT was evident in males. An association with EHT was seen for the minor allele of rs2802292 in the Japanese SONIC cohort (P = 0.03), while in European subjects the minor allele of each SNP was associated with higher systolic and diastolic BP. Longevity-associated FOXO3 variants may be associated with lower BP and EHT in Japanese women. C1 [Morris, Brian J.; Chen, Randi; Donlon, Timothy A.; Willcox, D. Craig; Masaki, Kamal H.; Willcox, Bradley J.] Kuakini Med Ctr, Dept Res, HAAS, HHP, Honolulu, HI USA. [Morris, Brian J.; Willcox, D. Craig; Masaki, Kamal H.; Willcox, Bradley J.] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96822 USA. [Morris, Brian J.] Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Sydney, NSW, Australia. [Morris, Brian J.] Univ Sydney, Bosch Inst, Sydney, NSW, Australia. [Evans, Daniel S.; Tranah, Gregory J.; Parimi, Neeta] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Ehret, Georg B.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Newton-Cheh, Christopher] Harvard Med Sch, Massachusetts Gen Hosp, Broad Inst Harvard & MIT, Boston, MA USA. [Seto, Todd] Queens Med Ctr, Dept Cardiol, Honolulu, HI USA. [Willcox, D. Craig] Okinawa Int Univ, Dept Human Welf, Ginowan, Okinawa, Japan. [Kamide, Kei; Ryuno, Hirochika; Kabayama, Mai] Osaka Univ, Grad Sch Med, Dept Hlth Sci, Suita, Osaka, Japan. [Kamide, Kei; Oguro, Ryosuke; Nakama, Chikako; Yamamoto, Koichi; Sugimoto, Ken; Rakugi, Hiromi] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka, Japan. [Ikebe, Kazunori] Osaka Univ, Grad Sch Dent, Dept Prosthodont Gerodontol & Oral Rehabil, Suita, Osaka, Japan. [Masui, Yukie; Ishizaki, Tatsuro] Tokyo Metropolitan Geriatr Hosp, Tokyo, Japan. [Masui, Yukie; Ishizaki, Tatsuro] Inst Gerontol, Tokyo, Japan. [Arai, Yasumichi] Keio Univ, Sch Med, Tokyo, Japan. [Gondo, Yasuyuki] Osaka Univ, Grad Sch Human Sci, Dept Clin Thanatol & Geriatr Behav Sci, Suita, Osaka, Japan. RP Morris, BJ (reprint author), Kuakini Med Ctr, Dept Res, HAAS, HHP, Honolulu, HI USA.; Morris, BJ (reprint author), Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96822 USA.; Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Sydney, NSW, Australia.; Morris, BJ (reprint author), Univ Sydney, Bosch Inst, Sydney, NSW, Australia. EM brian.morris@sydney.edu.au FU Kuakini Medical Center; US National Institutes of Health [N01-AG-4-2149, 5 U01 AG019349-05, 5R01AG027060, 5R01AG038707]; National Heart, Lung, and Blood Institute [NO1-HC-05102]; National Institute on Aging [NO1-AG-4-2149, U01-AG-019349, R01-AG-038707, R01-AG-027060, N01AG62101, N01AG62103, N01AG62106]; Hawaii Community Foundation [2004-0463]; Longevity Consortium [U19AG023122]; Intramural Research Program of the NIH, National Institute on Aging; NIA [1R01AG032098-01A1]; National Institutes of Health [HHSN268200782096C]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [T15K089100, A25253059c, 21330152, 24653194] FX This research was supported by the Kuakini Medical Center, the US National Institutes of Health contract N01-AG-4-2149, grants 5 U01 AG019349-05, 5R01AG027060 (Kuakini Hawaii Lifespan Study), and 5R01AG038707 (Kuakini Hawaii Healthspan Study), the National Heart, Lung, and Blood Institute (contract NO1-HC-05102), the National Institute on Aging contract NO1-AG-4-2149 and grants U01-AG-019349, R01-AG-038707, and R01-AG-027060, and Hawaii Community Foundation grant 2004-0463. The research of authors at the California Pacific Medical Center Research Institute was supported by the National Institutes of Aging contracts N01AG62101, N01AG62103, and N01AG62106, grant U19AG023122 from the Longevity Consortium, and in part by the Intramural Research Program of the NIH, National Institute on Aging (Health ABC study). The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract (number HHSN268200782096C) from the National Institutes of Health to the Johns Hopkins University. Support for the SONIC study involved grants T15K089100, A25253059c, 21330152, and 24653194 from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. NR 50 TC 1 Z9 1 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD NOV PY 2016 VL 29 IS 11 BP 1292 EP 1300 DI 10.1093/ajh/hpv171 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EC2PX UT WOS:000387967000012 ER PT J AU Waxman, DA Min, L Setodji, CM Hanson, M Wenger, NS Ganz, DA AF Waxman, Daniel A. Min, Lillian Setodji, Claude M. Hanson, Mark Wenger, Neil S. Ganz, David A. TI Does Medicare Advantage Enrollment Affect Home Healthcare Use? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID TRADITIONAL MEDICARE; GEOGRAPHIC-VARIATION; SERVICES; PLANS; RISK AB OBJECTIVES: To compare home health utilization and clinical outcomes between Medicare beneficiaries in the fee-for-service (FFS) and Medicare Advantage (MA) programs, and to compare regional variation. STUDY DESIGN: We used the 2010 and 2011 Outcome and Assessment Information Set to identify all home health episodes begun in 2010 and to measure 7 clinical home health outcomes that are defined by CMS for public reporting. METHODS: We modeled the probability of home health use, the duration of home health episodes, and each clinical outcome measure as a function of MA versus FFS enrollment and model-specific risk adjustors. Empirical Bayes predictions from generalized linear mixed models were aggregated by hospital referral region (HRR) to create standardized regional measures of home health utilization and mean episode duration. RESULTS: We identified 30,837,130 FFS and 10,594,658 MA beneficiaries (excluding those dually eligible for Medicaid). After adjusting for demographic and clinical patient characteristics, the odds of receiving home health among FFS enrollees were 1.83 times those of MA (95% CI, 1.82-1.84). Adjusted home health duration was 34% longer for FFS (95% CI, 32%-34%). Outcomes differences were small in magnitude and inconsistent across measures. Regional variations in use and duration were substantial for both FFS and MA enrollees. Within HRRs, correlations between FFS and MA utilization rates and between FFS and MA episode durations were 0.51 and 0.94, respectively. CONCLUSIONS: MA beneficiaries use less home health than their FFS counterparts, but regional factors affect utilization, independent of insurance status. C1 [Waxman, Daniel A.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA. [Wenger, Neil S.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Waxman, Daniel A.; Min, Lillian; Setodji, Claude M.; Hanson, Mark; Wenger, Neil S.; Ganz, David A.] RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. [Min, Lillian] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Min, Lillian] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Ganz, David A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Waxman, DA (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. EM dwaxman@rand.org FU CMS [HHSM-500-2005-00028I, HHSM-500-T0004]; HHS [HHSM-500-2005-00028I, HHSM-500-T0004] FX The analyses upon which this article is based were performed under contract HHSM-500-2005-00028I, task order number HHSM-500-T0004, entitled "Evaluation and Development of Outcome Measures for Quality Assessment in MAOs and SNPs," funded by CMS and HHS. The content of this article does not necessarily reflect the views or policies of HHS, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government. The author assumes full responsibility for the accuracy and completeness of the ideas presented. NR 19 TC 0 Z9 0 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2016 VL 22 IS 11 BP 714 EP 720 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EC7WP UT WOS:000388351800007 PM 27870545 ER PT J AU Linsky, A Simon, SR Stolzmann, K Bokhour, BG Meterko, M AF Linsky, Amy Simon, Steven R. Stolzmann, Kelly Bokhour, Barbara G. Meterko, Mark TI Prescribers' Perceptions of Medication Discontinuation: Survey Instrument Development and Validation SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID ADVERSE DRUG EVENTS; RESPONSE RATES; POLYPHARMACY; PHYSICIANS; CARE; QUESTIONNAIRE; THERAPY; GUIDE AB OBJECTIVES: Primary care providers (PCPs) and clinical pharmacists have concerns about the adverse consequences of using medications inappropriately and generally support the notion of reducing unnecessary drugs. Despite this attitude, many factors impede clinicians' ability to discontinue medication in clinical settings. We sought to develop a survey instrument that assesses PCPs' and pharmacists' experiences, attitudes, and beliefs toward medication discontinuation. STUDY DESIGN: Survey development and psychometric assessment. METHODS: Based on a conceptual framework, we developed a questionnaire and surveyed a national sample of Department of Veterans Affairs PCPs with prescribing privileges, including physicians, nurse practitioners, physician assistants, and clinical pharmacy specialists. We randomly divided respondents into derivation and validation samples and used iterations of multi-trait analysis to assess the psychometric properties of the proposed measures. Multivariable regression models identified factors associated with the outcome of self-rated comfort with medication discontinuation. RESULTS: Using established criteria for scale development, we identified 5 scales: Medication Characteristics, Current Patient Clinical Factors, Predictions of Future Health States, Patients' Resources to Manage Their Own Health, and Education and Experience. Three of these dimensions predicted providers' self-rated comfort with making decisions to discontinue medication (Current Patient Clinical Factors, Predictions of Future Health States, and Education and Experience). CONCLUSIONS: We developed a psychometrically sound instrument to measure prescribers' attitudes toward, and experiences with, medication discontinuation. This survey will enable identification of perceived barriers to, and facilitators of, proactive discontinuation-an important step toward developing interventions that improve the quality and safety of care in medication use. C1 [Linsky, Amy; Simon, Steven R.; Stolzmann, Kelly] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Gen Internal Med Sect, Boston, MA USA. [Bokhour, Barbara G.] Edith Nourse Rogers Mem Vet Affairs Med Ctr, Bedford, MA USA. [Linsky, Amy; Simon, Steven R.] Boston Med Ctr, Gen Internal Med Sect, Boston, MA USA. [Bokhour, Barbara G.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Hlth Law Policy & Management, Boston, MA USA. [Meterko, Mark] VHA Off Analyt & Business Intelligence, Performance Measurement, Bedford, MA USA. RP Linsky, A (reprint author), VA Boston Healthcare Syst, Gen Internal Med 152G, 150 S Huntington Ave, Boston, MA 02130 USA. EM amy.linsky@va.gov FU Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development Career Development Award [CDA12-166] FX The principal investigator (AL) was supported by a Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development Career Development Award (CDA12-166), and the study was conducted using resources of the VA Boston Healthcare System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication. NR 33 TC 0 Z9 0 U1 1 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2016 VL 22 IS 11 BP 747 EP 754 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EC7WP UT WOS:000388351800010 PM 27870547 ER PT J AU Roberts, AW Gellad, WF Skinner, AC AF Roberts, Andrew W. Gellad, Walid F. Skinner, Asheley Cockrell TI Lock-In Programs and the Opioid Epidemic: A Call for Evidence SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material C1 [Roberts, Andrew W.] Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Sci, Omaha, NE 68178 USA. [Roberts, Andrew W.] Creighton Univ, Ctr Hlth Serv Res & Patient Safety, Omaha, NE 68178 USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Skinner, Asheley Cockrell] Duke Univ, Duke Clin Res Inst, Durham, NC USA. RP Roberts, AW (reprint author), Creighton Univ, Dept Pharm Sci, 2500 Calif Plaza,Hixson Lied Room 166, Omaha, NE 68178 USA. EM drewroberts@creighton.edu RI Skinner, Asheley/Q-5793-2016 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2016 VL 106 IS 11 BP 1918 EP 1919 DI 10.2105/AJPH.2016.303404 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4IE UT WOS:000388090200016 PM 27715305 ER PT J AU Morgan, AU Grande, DT Carter, T Long, JA Kangovi, S AF Morgan, Anna U. Grande, David T. Carter, Tamala Long, Judith A. Kangovi, Shreya TI Penn Center for Community Health Workers: Step-by-Step Approach to Sustain an Evidence-Based Community Health Worker Intervention at an Academic Medical Center SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID LOW SOCIOECONOMIC-STATUS; CARE AB Community-engaged researchers who work with low-income communities can be reliant on grant funding. We use the illustrative case of the Penn Center for Community Health Workers (PCCHW) to describe a step-by-step framework for achieving financial sustainability for community-engaged research interventions. PCCHW began as a small grant-funded research project but followed an 8-step framework to engage both low-income patients and funders, determine outcomes, and calculate return on investment. PCCHW is now fully funded by Penn Medicine and delivers the Individualized Management for Patient-Centered Targets (IMPaCT) community health worker intervention to 2000 patients annually. C1 [Morgan, Anna U.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Grande, David T.; Kangovi, Shreya] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Grande, David T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Carter, Tamala; Kangovi, Shreya] Penn Ctr Community Hlth Workers, Philadelphia, PA USA. [Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Morgan, AU (reprint author), Robert Wood Johnson Clin Scholars Program, 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM amorga@mail.med.upenn.edu NR 11 TC 0 Z9 0 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2016 VL 106 IS 11 BP 1958 EP 1960 DI 10.2105/AJPH.2016.303366 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4IE UT WOS:000388090200026 PM 27631747 ER PT J AU Fleming, JN Taber, DJ Pilch, NA Srinivas, TR Chavin, KD AF Fleming, J. N. Taber, D. J. Pilch, N. A. Srinivas, T. R. Chavin, K. D. TI Yes, We Still Need IL-2 Receptor Antagonists SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Letter ID KIDNEY-TRANSPLANTATION C1 [Fleming, J. N.] Med Univ South Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. [Taber, D. J.; Chavin, K. D.] Med Univ South Carolina, Dept Surg, Charleston, SC USA. [Taber, D. J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Pilch, N. A.] Med Univ South Carolina, Transplant Ctr, Charleston, SC USA. [Srinivas, T. R.] Med Univ South Carolina, Dept Nephrol, Charleston, SC USA. RP Fleming, JN (reprint author), Med Univ South Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. EM fleminj@musc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD NOV PY 2016 VL 16 IS 11 BP 3308 EP 3309 DI 10.1111/ajt.13930 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA EC5VE UT WOS:000388204600037 PM 27321737 ER PT J AU Mull, HJ Rosen, AK Rivard, PE Itani, KMF AF Mull, Hillary J. Rosen, Amy K. Rivard, Peter E. Itani, Kamal M. F. TI Defining Outpatient Surgery: Perspectives of Surgical Staff in the Veterans Health Administration SO AMERICAN SURGEON LA English DT Article; Proceedings Paper CT Annual Meeting of the Association-of-VA-Surgeons CY MAY 03, 2015 CL Miami, FL SP Assoc VA Surg C1 [Mull, Hillary J.; Rosen, Amy K.; Rivard, Peter E.] VA Boston Healthcare Syst, CHOIR, 150 South Huntington Ave 152M, Boston, MA 02130 USA. [Mull, Hillary J.; Rosen, Amy K.; Itani, Kamal M. F.] Boston Univ, Sch Med, Dept Surg, Boston, MA USA. [Rivard, Peter E.] Suffolk Univ, Healthcare Adm Sawyer Business Sch, Boston, MA USA. [Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, West Roxbury, MA USA. [Itani, Kamal M. F.] Harvard Med Sch, Boston, MA USA. RP Mull, HJ (reprint author), VA Boston Healthcare Syst, CHOIR, 150 South Huntington Ave 152M, Boston, MA 02130 USA. EM hillary.mull@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD NOV PY 2016 VL 82 IS 11 BP 1142 EP 1145 PG 4 WC Surgery SC Surgery GA EC8CO UT WOS:000388368000034 PM 28206946 ER PT J AU Liu, GQ Boot, B Locascio, JJ Jansen, IE Winder-Rhodes, S Eberly, S Elbaz, A Brice, A Ravina, B van Hilten, JJ Cormier-Dequaire, F Corvol, JC Barker, RA Heutink, P Marinus, J Williams-Gray, CH Scherzer, CR AF Liu, Ganqiang Boot, Brendon Locascio, Joseph J. Jansen, Iris E. Winder-Rhodes, Sophie Eberly, Shirley Elbaz, Alexis Brice, Alexis Ravina, Bernard van Hilten, Jacobus J. Cormier-Dequaire, Florence Corvol, Jean-Christophe Barker, Roger A. Heutink, Peter Marinus, Johan Williams-Gray, Caroline H. Scherzer, Clemens R. CA Int Genetics Parkinson Dis TI Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's SO ANNALS OF NEUROLOGY LA English DT Article ID SOCIETY TASK-FORCE; GLUCOCEREBROSIDASE MUTATIONS; GBA MUTATIONS; INCIDENT COHORT; DISEASE; BIOMARKER; DEMENTIA; SCALE; ASSOCIATION; CAMPAIGN AB ObjectiveWe hypothesized that specific mutations in the -glucocerebrosidase gene (GBA) causing neuropathic Gaucher's disease (GD) in homozygotes lead to aggressive cognitive decline in heterozygous Parkinson's disease (PD) patients, whereas non-neuropathic GD mutations confer intermediate progression rates. MethodsA total of 2,304 patients with PD and 20,868 longitudinal visits for up to 12.8 years (median, 4.1) from seven cohorts were analyzed. Differential effects of four types of genetic variation in GBA on longitudinal cognitive decline were evaluated using mixed random and fixed effects and Cox proportional hazards models. ResultsOverall, 10.3% of patients with PD and GBA sequencing carried a mutation. Carriers of neuropathic GD mutations (1.4% of patients) had hazard ratios (HRs) for global cognitive impairment of 3.17 (95% confidence interval [CI], 1.60-6.25) and a hastened decline in Mini-Mental State Exam scores compared to noncarriers (p=0.0009). Carriers of complex GBA alleles (0.7%) had an HR of 3.22 (95% CI, 1.18-8.73; p=0.022). By contrast, the common, non-neuropathic N370S mutation (1.5% of patients; HR, 1.96; 95% CI, 0.92-4.18) or nonpathogenic risk variants (6.6% of patients; HR, 1.36; 95% CI, 0.89-2.05) did not reach significance. InterpretationMutations in the GBA gene pathogenic for neuropathic GD and complex alleles shift longitudinal cognitive decline in PD into high gear. These findings suggest a relationship between specific types of GBA mutations and aggressive cognitive decline and have direct implications for improving the design of clinical trials. Ann Neurol 2016;80:674-685 C1 [Liu, Ganqiang; Locascio, Joseph J.; Scherzer, Clemens R.] Harvard Med Sch, Neurogen Lab, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA. [Liu, Ganqiang; Locascio, Joseph J.; Scherzer, Clemens R.] Harvard Med Sch, Parkinson Personalized Med Program, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA. [Liu, Ganqiang; Locascio, Joseph J.; Scherzer, Clemens R.] Brigham & Womens Hosp, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA. [Liu, Ganqiang; Scherzer, Clemens R.] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA. [Boot, Brendon; Scherzer, Clemens R.] Harvard NeuroDiscovery Ctr, Biomarkers Program, Boston, MA USA. [Boot, Brendon; Scherzer, Clemens R.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. [Locascio, Joseph J.; Scherzer, Clemens R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Jansen, Iris E.; Heutink, Peter] Vrije Univ Amsterdam, Med Ctr, Dept Med Genom, Neurosci Campus Amsterdam, NL-HZ Amsterdam, Netherlands. [Jansen, Iris E.; Heutink, Peter] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany. [Winder-Rhodes, Sophie; Barker, Roger A.; Williams-Gray, Caroline H.] Univ Cambridge, Dept Clin Neurosci, John Van Geest Ctr Brain Repair, Cambridge, England. [Eberly, Shirley] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA. [Elbaz, Alexis] Ctr Res Epidemiol & Populat Hlth, INSERM, Epidemiol Ageing & Age Related Dis, U1018, Villejuif, France. [Elbaz, Alexis; Cormier-Dequaire, Florence; Corvol, Jean-Christophe] Univ Paris Sud, UMRS 1018, Villejuif, France. [Brice, Alexis; Cormier-Dequaire, Florence; Corvol, Jean-Christophe] Univ Pierre & Marie Curie Paris 06, Sorbonne Univ, Inst Natl Sante & Rech Med U 1127, UMR S 1127, Paris, France. [Brice, Alexis; Cormier-Dequaire, Florence; Corvol, Jean-Christophe] Hop La Pitie Salpetriere, AP HP, Ctr Natl Rech Sci U 7225,Dept Neurol Genet, Ctr Invest Clin 1422,Inst Cerveau & Moelle Epinie, Paris, France. [Ravina, Bernard] Voyager Therapeut, Clin Dev, Cambridge, MA USA. [van Hilten, Jacobus J.; Marinus, Johan] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands. RP Scherzer, CR (reprint author), Harvard Med Sch, Neurogen Lab, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA.; Scherzer, CR (reprint author), Harvard Med Sch, Parkinson Personalized Med Program, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA.; Scherzer, CR (reprint author), Brigham & Womens Hosp, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA. EM cscherzer@rics.bwh.harvard.edu RI corvol, jean-christophe/I-6387-2012 OI corvol, jean-christophe/0000-0001-7325-0199 FU Michael J. Fox Foundation; NIH [PDBP U01 NS082157, NS050095, NS24778]; Harvard NeuroDiscovery Center; U.S. Department of Defense; M.E.M.O. Hoffman Foundation; Parkinson's Disease Foundation; Wellcome Trust; MRC; Parkinson's UK; Cure-PD; Patrick Berthoud Trust; Van Geest Foundation; NIHR; Assistance Publique Hopitaux de Paris; French clinical research hospital program-PHRC [AOR08010]; 0"Investissements d'Avenir" [ANR-10-IAIHU-06]; Prinses Beatrix Fonds [WAR05-0120]; Stichting Alkemade-Keuls; Stichting ParkinsonFonds FX This study was supported by the Michael J. Fox Foundation (to C.R.S.); NIH grants PDBP U01 NS082157 (to C.R.S.), NS050095, and NS24778; Harvard NeuroDiscovery Center (to C.R.S.); U.S. Department of Defense (to C.R.S. and B.R.); M.E.M.O. Hoffman Foundation (to C.R.S.), Parkinson's Disease Foundation (to B.R.); Wellcome Trust, MRC, Parkinson's UK, Cure-PD, Patrick Berthoud Trust, Van Geest Foundation and NIHR (to R.A.B. and C.H.W.-G.); Assistance Publique Hopitaux de Paris, French clinical research hospital program-PHRC (code AOR08010), 0"Investissements d'Avenir" ANR-10-IAIHU-06 (to J.-C.C., A.E., and A.B.); Prinses Beatrix Fonds (Project No. WAR05-0120), Stichting Alkemade-Keuls, and Stichting ParkinsonFonds (to J.J.v.H. and J.M., P.H.). NR 50 TC 6 Z9 6 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2016 VL 80 IS 5 BP 674 EP 685 DI 10.1002/ana.24781 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ED0YS UT WOS:000388570800005 PM 27717005 ER PT J AU Anderson, CD Falcone, GJ Phuah, CL Radmanesh, F Brouwers, HB Battey, TWK Biffi, A Peloso, GM Liu, DJJ Ayres, AM Goldstein, JN Viswanathan, A Greenberg, SM Selim, M Meschia, JF Brown, DL Worrall, BB Silliman, SL Tirschwell, DL Flaherty, ML Kraft, P Jagiella, JM Schmidt, H Hansen, BM Jimenez-Conde, J Giralt-Steinhauer, E Elosua, R Cuadrado-Godia, E Soriano, C van Nieuwenhuizen, KM Klijn, CJM Rannikmae, K Samarasekera, N Salman, RA Sudlow, CL Deary, IJ Morotti, A Pezzini, A Pera, J Urbanik, A Pichler, A Enzinger, C Norrving, B Montaner, J Fernandez-Cadenas, I Delgado, P Roquer, J Lindgren, A Slowik, A Schmidt, R Kidwell, CS Kittner, SJ Waddy, SP Langefeld, CD Abecasis, G Willer, CJ Kathiresan, S Woo, D Rosand, J AF Anderson, Christopher D. Falcone, Guido J. Phuah, Chia-Ling Radmanesh, Farid Brouwers, H. Bart Battey, Thomas W. K. Biffi, Alessandro Peloso, Gina M. Liu, Dajiang J. Ayres, Alison M. Goldstein, Joshua N. Viswanathan, Anand Greenberg, Steven M. Selim, Magdy Meschia, James F. Brown, Devin L. Worrall, Bradford B. Silliman, Scott L. Tirschwell, David L. Flaherty, Matthew L. Kraft, Peter Jagiella, Jeremiasz M. Schmidt, Helena Hansen, Bjorn M. Jimenez-Conde, Jordi Giralt-Steinhauer, Eva Elosua, Roberto Cuadrado-Godia, Elisa Soriano, Carolina van Nieuwenhuizen, Koen M. Klijn, Catharina J. M. Rannikmae, Kristiina Samarasekera, Neshika Salman, Rustam Al-Shahi Sudlow, Catherine L. Deary, Ian J. Morotti, Andrea Pezzini, Alessandro Pera, Joanna Urbanik, Andrzej Pichler, Alexander Enzinger, Christian Norrving, Bo Montaner, Joan Fernandez-Cadenas, Israel Delgado, Pilar Roquer, Jaume Lindgren, Arne Slowik, Agnieszka Schmidt, Reinhold Kidwell, Chelsea S. Kittner, Steven J. Waddy, Salina P. Langefeld, Carl D. Abecasis, Goncalo Willer, Cristen J. Kathiresan, Sekar Woo, Daniel Rosand, Jonathan CA Global Lipids Genetics Consortium Int Stroke Genetics Consortium TI Genetic variants in CETP increase risk of intracerebral hemorrhage SO ANNALS OF NEUROLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; CHOLESTEROL LEVELS; AGGRESSIVE REDUCTION; STROKE PREVENTION; VASCULAR EVENTS; PLASMA-LIPIDS; DISEASE; METAANALYSIS; INHIBITORS; LOCATION AB ObjectiveIn observational epidemiologic studies, higher plasma high-density lipoprotein cholesterol (HDL-C) has been associated with increased risk of intracerebral hemorrhage (ICH). DNA sequence variants that decrease cholesteryl ester transfer protein (CETP) gene activity increase plasma HDL-C; as such, medicines that inhibit CETP and raise HDL-C are in clinical development. Here, we test the hypothesis that CETP DNA sequence variants associated with higher HDL-C also increase risk for ICH. MethodsWe performed 2 candidate-gene analyses of CETP. First, we tested individual CETP variants in a discovery cohort of 1,149 ICH cases and 1,238 controls from 3 studies, followed by replication in 1,625 cases and 1,845 controls from 5 studies. Second, we constructed a genetic risk score comprised of 7 independent variants at the CETP locus and tested this score for association with HDL-C as well as ICH risk. ResultsTwelve variants within CETP demonstrated nominal association with ICH, with the strongest association at the rs173539 locus (odds ratio [OR]=1.25, standard error [SE]=0.06, p=6.0x10(-4)) with no heterogeneity across studies (I-2=0%). This association was replicated in patients of European ancestry (p=0.03). A genetic score of CETP variants found to increase HDL-C by approximate to 2.85mg/dl in the Global Lipids Genetics Consortium was strongly associated with ICH risk (OR=1.86, SE=0.13, p=1.39x10(-6)). InterpretationGenetic variants in CETP associated with increased HDL-C raise the risk of ICH. Given ongoing therapeutic development in CETP inhibition and other HDL-raising strategies, further exploration of potential adverse cerebrovascular outcomes may be warranted. Ann Neurol 2016;80:730-740 C1 [Anderson, Christopher D.; Falcone, Guido J.; Phuah, Chia-Ling; Radmanesh, Farid; Brouwers, H. Bart; Battey, Thomas W. K.; Biffi, Alessandro; Peloso, Gina M.; Ayres, Alison M.; Kathiresan, Sekar; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St;CPZN 6818, Boston, MA 02114 USA. [Anderson, Christopher D.; Falcone, Guido J.; Phuah, Chia-Ling; Radmanesh, Farid; Brouwers, H. Bart; Battey, Thomas W. K.; Biffi, Alessandro; Ayres, Alison M.; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan] MGH, Dept Neurol, J Philip Kistler Stroke Res Ctr, Boston, MA USA. [Anderson, Christopher D.; Falcone, Guido J.; Phuah, Chia-Ling; Radmanesh, Farid; Brouwers, H. Bart; Battey, Thomas W. K.; Rosand, Jonathan] MGH, Div Neurocrit Care & Emergency Neurol, Dept Neurol, Boston, MA USA. [Anderson, Christopher D.; Falcone, Guido J.; Phuah, Chia-Ling; Radmanesh, Farid; Brouwers, H. Bart; Battey, Thomas W. K.; Biffi, Alessandro; Peloso, Gina M.; Kathiresan, Sekar; Rosand, Jonathan] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Falcone, Guido J.; Kraft, Peter] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Falcone, Guido J.; Kraft, Peter] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Biffi, Alessandro] MGH, Div Behav Neurol, Dept Neurol, Boston, MA USA. [Biffi, Alessandro] MGH, Dept Psychiat, Div Psychiat, Boston, MA USA. [Liu, Dajiang J.] Penn State Coll Med, Inst Personalized Med, Dept Publ Hlth Sci, Hershey, PA USA. [Goldstein, Joshua N.] MGH, Dept Emergency Med, Boston, MA USA. [Selim, Magdy] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Brown, Devin L.] Univ Michigan Hlth Syst, Dept Neurol, Stroke Program, Ann Arbor, MI USA. [Worrall, Bradford B.] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA. [Worrall, Bradford B.] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, Charlottesville, VA USA. [Silliman, Scott L.] Univ Florida, Coll Med, Dept Neurol, Jacksonville, FL USA. [Tirschwell, David L.] Univ Washington, Harborview Med Ctr, Stroke Ctr, 325 9Th Ave, Seattle, WA 98104 USA. [Flaherty, Matthew L.; Woo, Daniel] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA. [Jagiella, Jeremiasz M.; Pera, Joanna; Urbanik, Andrzej; Slowik, Agnieszka] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland. [Schmidt, Helena] Med Univ Graz, Inst Mol Biol & Biochem, Graz, Austria. [Hansen, Bjorn M.; Norrving, Bo; Lindgren, Arne] Lund Univ, Div Neurol, Dept Clin Sci Lund, Lund, Sweden. [Hansen, Bjorn M.; Norrving, Bo; Lindgren, Arne] Skane Univ Hosp, Div Neurol, Dept Neurol & Rehabil Med, Lund, Sweden. [Jimenez-Conde, Jordi; Giralt-Steinhauer, Eva; Elosua, Roberto; Cuadrado-Godia, Elisa; Soriano, Carolina; Roquer, Jaume] Autonomous Univ Barcelona, Municipal Inst Med Invest Hosp Sea, Dept Neurol, Neurovasc Res Unit, Barcelona, Spain. [Jimenez-Conde, Jordi; Giralt-Steinhauer, Eva; Elosua, Roberto; Cuadrado-Godia, Elisa; Soriano, Carolina; Roquer, Jaume] Autonomous Univ Barcelona, Municipal Inst Med Invest Hosp Sea, Program Inflammat & Cardiovasc Disorders, Barcelona, Spain. [van Nieuwenhuizen, Koen M.; Klijn, Catharina J. M.] Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, Brain Ctr Rudolf Magnus, Utrecht, Netherlands. [Klijn, Catharina J. M.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands. [Rannikmae, Kristiina; Samarasekera, Neshika; Salman, Rustam Al-Shahi; Sudlow, Catherine L.] Univ Edinburgh, Div Clin Brain Sci, Edinburgh, Midlothian, Scotland. [Sudlow, Catherine L.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland. [Deary, Ian J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland. [Morotti, Andrea; Pezzini, Alessandro] Univ Brescia, Dept Clin & Expt Sci, Neurol Clin, Brescia, Italy. [Pichler, Alexander; Enzinger, Christian; Schmidt, Reinhold] Med Univ Graz, Dept Neurol, Graz, Austria. [Enzinger, Christian; Slowik, Agnieszka] Med Univ Graz, Div Neuroradiol, Dept Radiol, Graz, Austria. [Montaner, Joan; Fernandez-Cadenas, Israel; Delgado, Pilar] Autonomous Univ Barcelona, Res Inst, Vall dHebron Hosp, Neurovasc Res Lab, Barcelona, Spain. [Montaner, Joan; Fernandez-Cadenas, Israel; Delgado, Pilar] Autonomous Univ Barcelona, Res Inst, Vall dHebron Hosp, Neurovasc Unit, Barcelona, Spain. [Fernandez-Cadenas, Israel] Terrassa Mutual Hosp, Stroke Pharmacogen & Genet Terrassa Mutual Teachi, Terrassa, Spain. [Kidwell, Chelsea S.] Univ Arizona, Dept Neurol, Tucson, AZ USA. [Kittner, Steven J.] Baltimore Vet Adm Med Ctr, Dept Neurol, Baltimore, MD USA. [Kittner, Steven J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Waddy, Salina P.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA. [Langefeld, Carl D.] Wake Forest Univ, Ctr Publ Hlth Genom, Winston Salem, NC 27109 USA. [Langefeld, Carl D.] Wake Forest Univ, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Abecasis, Goncalo] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA. [Willer, Cristen J.] Univ Michigan, Dept Internal Med, Sch Med, Div Cardiol, Ann Arbor, MI 48109 USA. [Willer, Cristen J.] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI USA. [Kathiresan, Sekar] MGH, Cardiovasc Dis Prevent Ctr, Boston, MA USA. RP Anderson, CD (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St;CPZN 6818, Boston, MA 02114 USA. EM cdanderson@mgh.harvard.edu RI Lee, Chaeyoung/C-7929-2012; Montaner, Joan/D-3063-2015; OI Lee, Chaeyoung/0000-0002-2940-1778; Anderson, Christopher/0000-0002-0053-2002 FU NIH National Institute of Neurological Disorders and Stroke (NINDS) [K23NS086873, R01NS059727, P50NS061343, R01NS36695, U01NS069 763, R01NS30678]; NIH National Institute on Aging [R01AG26484]; NIH National Heart, Lung, and Blood Institute [R01HL127564]; Swedish Heart and Lung Foundation; Skane University Hospital; Region Skane; Freemasons Lodge of Instruction EOS in Lund; King Gustaf V and Queen Victoria's Foundation; Lund University; Swedish Stroke Association; Spain's Ministry of Health (Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III FEDER) [RD12/0042/0020] FX This work was supported by the NIH National Institute of Neurological Disorders and Stroke (NINDS; K23NS086873, R01NS059727, P50NS061343, R01NS36695, U01NS069 763, R01NS30678) and the NIH National Institute on Aging (R01AG26484). Project support for the GLGC through C.J.W. and S.K. was provided by the NIH National Heart, Lung, and Blood Institute (R01HL127564). Lund Stroke Register has been supported by the Swedish Heart and Lung Foundation, Skane University Hospital, Region Skane, the Freemasons Lodge of Instruction EOS in Lund, King Gustaf V and Queen Victoria's Foundation, Lund University, the Swedish Stroke Association, and Spain's Ministry of Health (Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III FEDER, RD12/0042/0020). NR 47 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2016 VL 80 IS 5 BP 730 EP 740 DI 10.1002/ana.24780 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ED0YS UT WOS:000388570800010 PM 27717122 ER PT J AU Herranz, E Gianni, C Louapre, C Treaba, CA Govindarajan, ST Ouellette, R Loggia, ML Sloane, JA Madigan, N Izquierdo-Garcia, D Ward, N Mangeat, G Granberg, T Klawiter, EC Catana, C Hooker, JM Taylor, N Ionete, C Kinkel, RP Mainero, C AF Herranz, Elena Gianni, Costanza Louapre, Celine Treaba, Constantina A. Govindarajan, Sindhuja T. Ouellette, Russell Loggia, Marco L. Sloane, Jacob A. Madigan, Nancy Izquierdo-Garcia, David Ward, Noreen Mangeat, Gabriel Granberg, Tobias Klawiter, Eric C. Catana, Ciprian Hooker, Jacob M. Taylor, Norman Ionete, Carolina Kinkel, Revere P. Mainero, Caterina TI Neuroinflammatory component of gray matter pathology in multiple sclerosis SO ANNALS OF NEUROLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; TRANSLOCATOR PROTEIN; CORTICAL-LESIONS; PET RADIOLIGAND; WHITE-MATTER; GLIAL ACTIVATION; INFLAMMATION; BRAIN; DEMYELINATION AB ObjectiveIn multiple sclerosis (MS), using simultaneous magnetic resonance-positron emission tomography (MR-PET) imaging with C-11-PBR28, we quantified expression of the 18kDa translocator protein (TSPO), a marker of activated microglia/macrophages, in cortex, cortical lesions, deep gray matter (GM), white matter (WM) lesions, and normal-appearing WM (NAWM) to investigate the in vivo pathological and clinical relevance of neuroinflammation. MethodsFifteen secondary-progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched healthy controls underwent C-11-PBR28 MR-PET. MS subjects underwent 7T T2*-weighted imaging for cortical lesion segmentation, and neurological and cognitive evaluation. C-11-PBR28 binding was measured using normalized 60- to 90-minute standardized uptake values and volume of distribution ratios. ResultsRelative to controls, MS subjects exhibited abnormally high C-11-PBR28 binding across the brain, the greatest increases being in cortex and cortical lesions, thalamus, hippocampus, and NAWM. MS WM lesions showed relatively modest TSPO increases. With the exception of cortical lesions, where TSPO expression was similar, C-11-PBR28 uptake across the brain was greater in SPMS than in RRMS. In MS, increased C-11-PBR28 binding in cortex, deep GM, and NAWM correlated with neurological disability and impaired cognitive performance; cortical thinning correlated with increased thalamic TSPO levels. InterpretationIn MS, neuroinflammation is present in the cortex, cortical lesions, deep GM, and NAWM, is closely linked to poor clinical outcome, and is at least partly linked to neurodegeneration. Distinct inflammatory-mediated factors may underlie accumulation of cortical and WM lesions. Quantification of TSPO levels in MS could prove to be a sensitive tool for evaluating in vivo the inflammatory component of GM pathology, particularly in cortical lesions. Ann Neurol 2016;80:776-790 C1 [Herranz, Elena; Gianni, Costanza; Louapre, Celine; Treaba, Constantina A.; Govindarajan, Sindhuja T.; Ouellette, Russell; Loggia, Marco L.; Izquierdo-Garcia, David; Ward, Noreen; Mangeat, Gabriel; Granberg, Tobias; Catana, Ciprian; Hooker, Jacob M.; Mainero, Caterina] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. [Herranz, Elena; Gianni, Costanza; Louapre, Celine; Treaba, Constantina A.; Loggia, Marco L.; Sloane, Jacob A.; Madigan, Nancy; Izquierdo-Garcia, David; Granberg, Tobias; Klawiter, Eric C.; Catana, Ciprian; Hooker, Jacob M.; Taylor, Norman; Mainero, Caterina] Harvard Med Sch, Boston, MA USA. [Sloane, Jacob A.; Madigan, Nancy; Kinkel, Revere P.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Mangeat, Gabriel] Montreal Polytech, Inst Biomed Engn, Montreal, PQ, Canada. [Klawiter, Eric C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Taylor, Norman] Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02114 USA. [Ionete, Carolina] UMass Multiple Sclerosis Med Ctr, Worcester, MA USA. [Kinkel, Revere P.] Univ San Diego, San Diego, CA 92110 USA. RP Mainero, C (reprint author), AA Martinos Ctr Biomed Imaging, Bldg 149,Thirteenth St, Charlestown, MA 02129 USA. EM caterina@nmr.mgh.harvard.edu FU Clafin Award; National Multiple Sclerosis Society (NMSS) [RG 4729A2/1]; US Army, Department of Defense (DoD) [W81XWH-13-1-0112]; NMSS fellowship [FG-1507-05459]; ARSEP Foundation; Italian Multiple Sclerosis Foundation training fellowship [2012/B/04]; NIH [1R21NS087472-01A1]; DoD [W81XWH-14-1-0543] FX This study was supported by the Clafin Award; the National Multiple Sclerosis Society (NMSS; RG 4729A2/1); the US Army, Department of Defense (DoD; W81XWH-13-1-0112); an NMSS fellowship (FG-1507-05459; E.H.); the ARSEP Foundation (C.L.); an Italian Multiple Sclerosis Foundation training fellowship (2012/B/04; C.G.); the NIH (1R21NS087472-01A1; M.L.L.); and the DoD (W81XWH-14-1-0543) M.L.L. NR 49 TC 4 Z9 4 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2016 VL 80 IS 5 BP 776 EP 790 DI 10.1002/ana.24791 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ED0YS UT WOS:000388570800014 PM 27686563 ER PT J AU Roy-Chowdhuri, S Aisner, DL Allen, TC Beasley, MB Borczuk, A Cagle, PT Capelozzi, V Dacic, S Santos, GD Hariri, LP Kerr, KM Lantuejoul, S Mino-Kenudson, M Moreira, A Raparia, K Rekhtman, N Sholl, L Thunnissen, E Tsao, MS Vivero, M Yatabe, Y AF Roy-Chowdhuri, Sinchita Aisner, Dara L. Allen, Timothy Craig Beasley, Mary Beth Borczuk, Alain Cagle, Philip T. Capelozzi, Vera Dacic, Sanja Santos, Gilda da Cunha Hariri, Lida P. Kerr, Keith M. Lantuejoul, Sylvie Mino-Kenudson, Mari Moreira, Andre Raparia, Kirtee Rekhtman, Natasha Sholl, Lynette Thunnissen, Eric Tsao, Ming Sound Vivero, Marina Yatabe, Yasushi TI Biomarker Testing in Lung Carcinoma Cytology Specimens A Perspective From Members of the Pulmonary Pathology Society SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID GROWTH-FACTOR RECEPTOR; LIQUID-BASED CYTOLOGY; FINE-NEEDLE-ASPIRATION; SQUAMOUS-CELL CARCINOMA; EGFR MUTATIONS; CANCER PATIENTS; KRAS MUTATIONS; DIRECT SMEARS; SMALL-BIOPSY; FREE DNA AB The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era. C1 [Roy-Chowdhuri, Sinchita] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Aisner, Dara L.] Univ Colorado, Ctr Canc, Dept Pathol, Denver, CO 80262 USA. [Allen, Timothy Craig] Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA. [Beasley, Mary Beth] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA. [Borczuk, Alain; Cagle, Philip T.] Weill Cornell Med Coll, Dept Pathol, New York, NY USA. [Cagle, Philip T.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA. [Capelozzi, Vera] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil. [Dacic, Sanja] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Santos, Gilda da Cunha; Tsao, Ming Sound] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Pathol, Toronto, ON, Canada. [Santos, Gilda da Cunha; Tsao, Ming Sound] Univ Toronto, Toronto, ON, Canada. [Hariri, Lida P.; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Hariri, Lida P.; Mino-Kenudson, Mari] Harvard Med Sch, Boston, MA USA. [Kerr, Keith M.] Univ Aberdeen, Sch Med, Dept Pathol, Foresterhill, Aberdeen, Scotland. [Kerr, Keith M.] Aberdeen Royal Infirm, Foresterhill, Aberdeen, Scotland. [Lantuejoul, Sylvie] Ctr Leon Berard, Dept Biopathol, Lyon, France. [Lantuejoul, Sylvie] J Fourier Univ, INSERM, Inst Albert Bonniot, Lyon, France. [Moreira, Andre] NYU, Dept Pathol, 550 1St Ave, New York, NY 10016 USA. [Raparia, Kirtee] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA. [Rekhtman, Natasha] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. [Sholl, Lynette; Vivero, Marina] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Sholl, Lynette; Vivero, Marina] Harvard Med Sch, Boston, MA USA. [Thunnissen, Eric] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands. [Yatabe, Yasushi] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan. RP Allen, TC (reprint author), Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA. EM tcallen@utmb.edu NR 63 TC 1 Z9 1 U1 1 U2 1 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD NOV PY 2016 VL 140 IS 11 BP 1267 EP 1272 DI 10.5858/arpa.2016-0091-SA PG 6 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA EC7ZQ UT WOS:000388360100017 ER PT J AU Raparia, K Aisner, DL Allen, TC Beasley, MB Borczuk, A Cagle, PT Capelozzi, V Dacic, S Hariri, LP Kerr, KM Lantuejoul, S Mino-Kenudson, M Rekhtman, N Roden, AC Roy-Chowdhuri, S Sholl, L Smith, ML Thunnissen, E Tsao, MS Yatabe, Y AF Raparia, Kirtee Aisner, Dara L. Allen, Timothy Craig Beasley, Mary Beth Borczuk, Alain Cagle, Philip T. Capelozzi, Vera Dacic, Sanja Hariri, Lida P. Kerr, Keith M. Lantuejoul, Sylvie Mino-Kenudson, Mari Rekhtman, Natasha Roden, Anja C. Roy-Chowdhuri, Sinchita Sholl, Lynette Smith, Maxwell L. Thunnissen, Eric Tsao, Ming Sound Yatabe, Yasushi TI Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis A Perspective From Members of the Pulmonary Pathology Society SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID YIELD; BIOPSY AB Transbronchial lung cryobiopsy involves using a cryoprobe rather than forceps to obtain a bronchoscopic biopsy. Recent studies have shown that transbronchial cryobiopsy provides a larger specimen than conventional transbronchial forceps biopsy, and that the interobserver agreement in the interpretation of cryobiopsy specimens is comparable to that of a surgical lung biopsy. This is encouraging, and transbronchial lung cryobiopsy clearly has a role in the workup and diagnosis of interstitial lung diseases. However, very few patients who have been studied underwent both transbronchial lung cryobiopsy and surgical lung biopsy, and the available data suggest that the diagnostic accuracy of cryobiopsy may not be similar to that of surgical lung biopsy. Further study is needed before transbronchial lung biopsy can be recommended as a replacement for surgical lung biopsy. C1 [Raparia, Kirtee] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA. [Aisner, Dara L.] Univ Colorado, Ctr Canc, Dept Pathol, Denver, CO 80262 USA. [Allen, Timothy Craig] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Beasley, Mary Beth] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA. [Borczuk, Alain; Cagle, Philip T.] Weill Cornell Med Coll, Dept Pathol, New York, NY USA. [Cagle, Philip T.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA. [Capelozzi, Vera] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil. [Dacic, Sanja] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Hariri, Lida P.; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Hariri, Lida P.; Mino-Kenudson, Mari; Sholl, Lynette] Harvard Med Sch, Boston, MA USA. [Kerr, Keith M.] Univ Aberdeen, Sch Med, Dept Pathol, Foresterhill, Aberdeen, Scotland. [Kerr, Keith M.] Aberdeen Royal Infirm, Foresterhill, Aberdeen, Scotland. [Lantuejoul, Sylvie] Ctr Leon Berard, Dept Biopathol, Lyon, France. [Lantuejoul, Sylvie] J Fourier Univ, INSERM, U823, Inst A Bonniot, Lyon, France. [Rekhtman, Natasha] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. [Roden, Anja C.] Mayo Clin Rochester, Dept Lab Med & Pathol, Rochester, MN USA. [Roy-Chowdhuri, Sinchita] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Sholl, Lynette] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Smith, Maxwell L.] Mayo Clin Scottsdale, Dept Lab Med & Pathol, Scottsdale, AZ USA. [Thunnissen, Eric] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands. [Tsao, Ming Sound] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Pathol, Toronto, ON, Canada. [Tsao, Ming Sound] Univ Toronto, Toronto, ON, Canada. [Yatabe, Yasushi] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan. RP Allen, TC (reprint author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. EM tcallen@utmb.edu NR 14 TC 0 Z9 0 U1 2 U2 2 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD NOV PY 2016 VL 140 IS 11 BP 1281 EP 1284 DI 10.5858/arpa.2016-0258-SA PG 4 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA EC7ZQ UT WOS:000388360100019 ER PT J AU Berghorst, LH Kumar, P Greve, DN Deckersbach, T Ongur, D Dutra, SJ Pizzagalli, DA AF Berghorst, Lisa H. Kumar, Poornima Greve, Doug N. Deckersbach, Thilo Ongur, Dost Dutra, Sunny J. Pizzagalli, Diego A. TI Stress and reward processing in bipolar disorder: a functional magnetic resonance imaging study SO BIPOLAR DISORDERS LA English DT Article DE amygdala; bipolar disorder; functional magnetic resonance imaging (fMRI); Monetary Incentive Delay (MID); putamen; reward; stress ID LIFE EVENTS; CONSUMMATORY PHASES; DEPRESSION; BRAIN; AMYGDALA; SYMPTOMS; SCHIZOPHRENIA; SEGMENTATION; ANTICIPATION; METAANALYSIS AB Objectives: A link between negative life stress and the onset of mood episodes in bipolar disorder (BD) has been established, but processes underlying such a link remain unclear. Growing evidence suggests that stress can negatively affect reward processing and related neurobiological substrates, indicating that a dysregulated reward system may provide a partial explanation. The aim of this study was to test the impact of stress on reward-related neural functioning in BD. Methods: Thirteen euthymic or mildly depressed individuals with BD and 15 controls performed a Monetary Incentive Delay (MID) task while undergoing functional magnetic resonance imaging during no-stress and stress (negative psychosocial stressor involving poor performance feedback and threat of monetary deductions) conditions. Results: In hypothesis-driven region-of-interest analyses, a significant group-by-condition interaction emerged in the amygdala during reward anticipation. Relative to controls, while anticipating a potential reward, subjects with BD were characterized by amygdalar hyperactivation in the no-stress condition but hypoactivation during stress. Moreover, relative to controls, subjects with BD had significantly larger amygdala volumes. After controlling for structural differences, the effects of stress on amygdalar function remained, whereas groups no longer differed during the no-stress condition. During reward consumption, a group-by-condition interaction emerged in the putamen due to increased putamen activation in response to rewards in participants with BD during stress, but an opposite pattern in controls. Conclusions: Overall, findings highlight possible impairments in using reward-predicting cues to adaptively engage in goal-directed actions in BD, combined with stress-induced hypersensitivity to reward consumption. Potential clinical implications are discussed. C1 [Berghorst, Lisa H.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA. [Kumar, Poornima; Pizzagalli, Diego A.] McLean Hosp, Ctr Depress Anxiety & Stress Res, 115 Mill St, Belmont, MA 02478 USA. [Kumar, Poornima; Deckersbach, Thilo; Ongur, Dost; Pizzagalli, Diego A.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Greve, Doug N.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA. [Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Ongur, Dost] McLean Hosp, Schizophrenia & Bipolar Disorder Res Program, 115 Mill St, Belmont, MA 02178 USA. [Dutra, Sunny J.] Yale Univ, Dept Psychol, New Haven, CT USA. [Pizzagalli, Diego A.] McLean Hosp, McLean Imaging Ctr, 115 Mill St, Belmont, MA 02178 USA. RP Pizzagalli, DA (reprint author), McLean Hosp, Ctr Depress Anxiety & Stress Res, 115 Mill St, Belmont, MA 02478 USA. EM dap@mclean.harvard.edu FU NCRR NIH HHS [UL1 RR025758, M01 RR001066]; NIMH NIH HHS [R01 MH068376] NR 51 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD NOV PY 2016 VL 18 IS 7 BP 602 EP 611 DI 10.1111/bdi.12444 PG 10 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EC7HV UT WOS:000388308700006 PM 27870507 ER PT J AU Dizon, D AF Dizon, D. TI Sexual life in women after breast cancer SO BREAST LA English DT Meeting Abstract C1 [Dizon, D.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 EI 1532-3080 J9 BREAST JI Breast PD NOV PY 2016 VL 29 SU 1 MA IN21 BP S6 EP S6 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EC0KO UT WOS:000387789700015 ER PT J AU Partridge, AH AF Partridge, A. H. TI Any news in early breast cancer (EBC)? SO BREAST LA English DT Meeting Abstract C1 [Partridge, A. H.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 EI 1532-3080 J9 BREAST JI Breast PD NOV PY 2016 VL 29 SU 1 MA IN17 BP S5 EP S5 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EC0KO UT WOS:000387789700013 ER PT J AU Rosenberg, S Gelber, S Gelber, R Krop, E Korde, L Pagani, O Partridge, A AF Rosenberg, S. Gelber, S. Gelber, R. Krop, E. Korde, L. Pagani, O. Partridge, A. TI Oncology physicians' perspectives on practices and barriers to fertility preservation and the feasibility of a prospective study of pregnancy after breast cancer SO BREAST LA English DT Meeting Abstract C1 [Rosenberg, S.; Krop, E.; Partridge, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gelber, S.; Gelber, R.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Pagani, O.] Inst Oncol Southern Switzerland, Breast Unit, Bellinzona, Switzerland. [Korde, L.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 EI 1532-3080 J9 BREAST JI Breast PD NOV PY 2016 VL 29 SU 1 MA BP45 BP S14 EP S15 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EC0KO UT WOS:000387789700034 ER PT J AU del Carmen, MG Supko, JG Horick, NK Rauh-Hain, JA Clark, RM Campos, SM Krasner, CN Atkinson, T Birrer, MJ AF del Carmen, Marcela G. Supko, Jeff G. Horick, Nora K. Rauh-Hain, J. Alejandro Clark, Rachel M. Campos, Susana M. Krasner, Carolyn N. Atkinson, Tina Birrer, Michael J. TI Phase 1 and 2 Study of Carboplatin and Pralatrexate in Patients With Recurrent, Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer SO CANCER LA English DT Article DE carboplatin-pralatrexate; chemotherapy; pharmacokinetics; recurrent ovarian cancer ID GYNECOLOGIC-ONCOLOGY-GROUP; T-CELL LYMPHOMA; STAGE-III; TRIAL; PACLITAXEL; CISPLATIN; 10-PROPARGYL-10-DEAZAAMINOPTERIN; CHEMOTHERAPY; ANTIFOLATE; TOXICITY AB BACKGROUND: The objective of this phase 1 and 2 trial was to identify the appropriate dose of combined carboplatin and pralatrexate for patients with recurrent, platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer. METHODS: In phase 1, patients received carboplatin (at an area under the curve of 5) and increasing doses of pralatrexate until the maximum-tolerated dose (MTD) of pralatrexate was achieved. The primary endpoint was the response rate. Additional endpoints were safety, response duration, progression-free survival, overall survival, and pharmacokinetics. RESULTS: Thirty patients were enrolled in phase 1, and 20 were enrolled in phase 2. Of all 50 patients, 49 completed the study. The mean patient age was 59 years, and patients completed a median of 6 cycles. The MTD for pralatrexate was 105 mg/m(2). The clinical benefit rate (complete responses plus partial responses plus stable disease) was 86%. Of 26 patients who received the MTD, 12 had a partial response, 11 had stable disease, and 2 had disease progression. The progression-free survival rate at 3 and 6 months was 87% and 79%, respectively; and the overall survival rate was 98% at 6 and 12 months and 66% at 24 months. Of 30 patients, 18 (60%) in phase 1 experienced an adverse event of any grade; and, of those, 4 patients (13%) had a grade 3 or greater adverse event. In phase 2, 12 patients (60%) had an adverse event of any grade, and 4 (20%) had grade 3 or greater toxicity. There was a significant reduction in the total body clearance of pralatrexate when it was received concurrently with carboplatin. CONCLUSIONS: Most patients responded to carboplatin-pralatrexate combination. This regimen is well tolerated and effective in this patient population. (C) 2016 American Cancer Society. C1 [del Carmen, Marcela G.; Rauh-Hain, J. Alejandro; Clark, Rachel M.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Div Gynecol Oncol, Boston, MA USA. [Supko, Jeff G.; Krasner, Carolyn N.; Atkinson, Tina; Birrer, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA USA. [Horick, Nora K.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Campos, Susana M.] Harvard Med Sch, Dana Farber Canc Inst, Div Med Oncol, Boston, MA USA. RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM mdelcarmen@partners.org FU National Comprehensive Cancer Network (NCCN) Oncology Research Program from Allos Therapeutics FX This study was funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by Allos Therapeutics, a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. NR 30 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2016 VL 122 IS 21 BP 3297 EP 3306 DI 10.1002/cncr.30196 PG 10 WC Oncology SC Oncology GA EC6ZU UT WOS:000388286000009 PM 27421044 ER PT J AU Algazi, AP Tsai, KK Shoushtari, AN Munhoz, RR Eroglu, Z Piulats, JM Ott, PA Johnson, DB Hwang, J Daud, AI Sosman, JA Carvajal, RD Chmielowski, B Postow, MA Weber, JS Sullivan, RJ AF Algazi, Alain P. Tsai, Katy K. Shoushtari, Alexander N. Munhoz, Rodrigo R. Eroglu, Zeynep Piulats, Josep M. Ott, Patrick A. Johnson, Douglas B. Hwang, Jimmy Daud, Adil I. Sosman, Jeffrey A. Carvajal, Richard D. Chmielowski, Bartosz Postow, Michael A. Weber, Jeffrey S. Sullivan, Ryan J. TI Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies SO CANCER LA English DT Article DE atezolizumab; immunotherapy; nivolumab; pembrolizumab; uveal melanoma ID CELL LUNG-CANCER; UNTREATED MELANOMA; CTLA-4 BLOCKADE; PEMBROLIZUMAB; IPILIMUMAB; NIVOLUMAB; CHEMOTHERAPY; TRIAL; MUTATIONS; RESPONSES AB BACKGROUND: Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. METHODS: Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression-free survival (PFS), and overall survival (OS), were retrospectively determined. RESULTS: Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty-eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%-22.5%). Stable disease (>6 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4-2.8 months), and the median OS was 7.6 months (95% CI, 0.7-14.6 months). There was no association between prior treatment with ipilimumab or liver-directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity. CONCLUSIONS: PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. (C) 2016 American Cancer Society. C1 [Algazi, Alain P.; Tsai, Katy K.; Hwang, Jimmy; Daud, Adil I.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Shoushtari, Alexander N.; Munhoz, Rodrigo R.; Postow, Michael A.] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 1275 York Ave, New York, NY 10021 USA. [Eroglu, Zeynep] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Piulats, Josep M.] Spanish Melanoma Multidisciplinary Grp, Barcelona, Spain. [Ott, Patrick A.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Johnson, Douglas B.; Sosman, Jeffrey A.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Carvajal, Richard D.] Columbia Univ, Med Ctr, New York, NY USA. [Chmielowski, Bartosz] Univ Calif Los Angeles, Johansson Comprehens Canc Ctr, Los Angeles, CA USA. [Weber, Jeffrey S.] NYU Langone Med Ctr, Isaac Perlmutter Canc Ctr, New York, NY USA. [Sullivan, Ryan J.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. RP Algazi, AP (reprint author), UCSF Melanoma & Head & Neck Oncol, 1600 Divisadero St,A739, San Francisco, CA 94143 USA. EM alain.algazi@ucsf.edu FU Bristol-Myers Squibb; Merck; Genentech FX Bristol-Myers Squibb, Merck, and Genentech provided financial support for the conduct of the trials retrospectively analyzed in this article. NR 39 TC 4 Z9 4 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2016 VL 122 IS 21 BP 3344 EP 3353 DI 10.1002/cncr.30258 PG 10 WC Oncology SC Oncology GA EC6ZU UT WOS:000388286000014 PM 27533448 ER PT J AU Shoushtari, AN Munhoz, RR Kuk, D Ott, PA Johnson, DB Tsai, KK Rapisuwon, S Eroglu, Z Sullivan, RJ Luke, JJ Gangadhar, TC Salama, AKS Clark, V Burias, C Puzanov, I Atkins, MB Algazi, AP Ribas, A Wolchok, JD Postow, MA AF Shoushtari, Alexander N. Munhoz, Rodrigo R. Kuk, Deborah Ott, Patrick A. Johnson, Douglas B. Tsai, Katy K. Rapisuwon, Suthee Eroglu, Zeynep Sullivan, Ryan J. Luke, Jason J. Gangadhar, Tara C. Salama, April K. S. Clark, Varina Burias, Clare Puzanov, Igor Atkins, Michael B. Algazi, Alain P. Ribas, Antoni Wolchok, Jedd D. Postow, Michael A. TI The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma SO CANCER LA English DT Article DE acral melanoma; anti-programmed cell death receptor 1 (anti-PD-1); immunotherapy; mucosal melanoma; nivolumab; pembrolizumab ID UNTREATED MELANOMA; CTLA-4 BLOCKADE; PD-1 BLOCKADE; IPILIMUMAB; NIVOLUMAB; CANCER; BIOCHEMOTHERAPY; PEMBROLIZUMAB; SAFETY; TRIAL AB BACKGROUND: Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described. METHODS: A multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials. Objective responses were determined using investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival and overall survival were assessed using the Kaplan-Meier method. RESULTS: Sixty individuals were identified, including 25 (42%) with acral melanoma and 35 (58%) with mucosal melanoma. Fifty-one patients (85%) had received previous therapy, including 77% who had previously received ipilimumab. Forty patients (67%) received pembrolizumab at a dose of 2 mg/kg or 10mg/kg, and 20 (33%) received nivolumab at a doses ranging from 0.3 to 10 mg/kg every 2 to 3 weeks. The objective response rate was 32% (95% confidence interval, 15%-54%) in patients with acral melanoma and 23% (95% confidence interval, 10%-40%) in those with mucosal melanoma. After a median follow-up of 20 months in the acral melanoma group and 10.6 months in the mucosal melanoma group, the median progression-free survival was 4.1 months and 3.9 months, respectively. Only 2 patients (3%) discontinued treatment because of toxicity. CONCLUSIONS: Response rates to PD-1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. (C) 2016 American Cancer Society. C1 [Shoushtari, Alexander N.; Munhoz, Rodrigo R.; Clark, Varina; Burias, Clare; Wolchok, Jedd D.; Postow, Michael A.] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 300 East 66th St, New York, NY 10065 USA. [Shoushtari, Alexander N.; Wolchok, Jedd D.; Postow, Michael A.] Weill Cornell Med Coll, New York, NY USA. [Kuk, Deborah] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Ott, Patrick A.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Johnson, Douglas B.; Puzanov, Igor] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Tsai, Katy K.; Algazi, Alain P.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Rapisuwon, Suthee; Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. [Eroglu, Zeynep] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Sullivan, Ryan J.] Harvard Med Sch, Massachussetts Gen Hosp, Boston, MA USA. [Luke, Jason J.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA. [Gangadhar, Tara C.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Salama, April K. S.] Duke Univ, Sch Med, Durham, NC USA. [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. RP Shoushtari, AN (reprint author), Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 300 East 66th St, New York, NY 10065 USA. EM shoushta@mskcc.org FU Bristol-Myers Squibb (BMS); Merck; National Institutes of Health Cancer Center Support Grant [P30 CA008748] FX Bristol-Myers Squibb (BMS) and Merck provided financial support for the conduct of the trials analyzed retrospectively in this article. Alexander N. Shoushtari, Deborah Kuk, Jedd D. Wolchok, and Michael A. Postow receive support through the National Institutes of Health Cancer Center Support Grant (P30 CA008748). NR 39 TC 3 Z9 3 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2016 VL 122 IS 21 BP 3354 EP 3362 DI 10.1002/cncr.30259 PG 9 WC Oncology SC Oncology GA EC6ZU UT WOS:000388286000015 PM 27533633 ER PT J AU Mahal, BA Chen, YW Muralidhar, V Mahal, AR Choueiri, TK Hoffman, KE Hu, JC Sweeney, CJ Yu, JB Feng, FY Kim, SP Beard, CJ Martin, NE Trinh, QD Nguyen, PL AF Mahal, Brandon A. Chen, Yu-Wei Muralidhar, Vinayak Mahal, Amandeep R. Choueiri, Toni K. Hoffman, Karen E. Hu, Jim C. Sweeney, Christopher J. Yu, James B. Feng, Felix Y. Kim, Simon P. Beard, Clair J. Martin, Neil E. Quoc-Dien Trinh Nguyen, Paul L. TI National Sociodemographic Disparities in the Treatment of High-Risk Prostate Cancer: Do Academic Cancer Centers Perform Better Than Community Cancer Centers? SO CANCER LA English DT Article DE academic center; community center; disparities; National Cancer Data Base; patterns of care; prostatic neoplasm ID AFFORDABLE CARE ACT; QUALITY; TRENDS; BASE AB BACKGROUND: Most major cancer organizations seek to reduce sociodemographic disparities in high-risk cancers partly by increasing access to theoretically high-quality, academic-oriented cancer care. The objective of this study was to determine whether academic centers have less sociodemographic treatment disparities than community centers using high-risk prostate cancer as a test case. METHODS: The National Cancer Data Base was used to identify 138,019 patients who were diagnosed with nonmetastatic, high-risk prostate cancer from 2004 to 2012. Multivariable logistic analysis was used to identify independent determinants of definitive therapy. The Gray test and multivariable Cox regression were used to analyze the timing of therapy. All analyses were stratified by academic versus community cancer center. RESULTS: Compared with white or privately insured patients, black, Hispanic, and uninsured patients with prostate cancer were less likely to receive definitive therapy at both community centers (adjusted odds ratio: 0.60 [95% confidence interval (CI), 0.56-0.64], 0.69 [95% CI, 0.61-0.78], and 0.25 [95% CI, 0.22-0.30], respectively) and academic cancer centers (adjusted odds ratio: 0.50 [95% CI, 0.46-0.54], 0.56 [95% CI, 0.50-0.64], and 0.31 [95% CI, 0.28-0.36], respectively). Among patients who received definitive therapy, black, Hispanic, and uninsured patients were more likely to experience treatment delays at both community centers (>= 15, >= 10, and >= 19 days, respectively; all Gray P<.001) and academic centers (>= 19, >= 11, and >= 18 days, respectively); treatment delays were observed among the aforementioned groups even after multivariable Cox regression analysis (P<.001 for all adjusted hazard ratios). CONCLUSIONS: Nationally, academic cancer centers demonstrate similarly high rates of sociodemographic disparities in cancer treatment patterns as community cancer centers. Making community centers conform to academic center standards may not necessarily reduce treatment disparities. (C) 2016 American Cancer Society. C1 [Mahal, Brandon A.] Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02115 USA. [Mahal, Brandon A.; Muralidhar, Vinayak; Choueiri, Toni K.; Sweeney, Christopher J.; Beard, Clair J.; Martin, Neil E.; Quoc-Dien Trinh; Nguyen, Paul L.] Harvard Med Sch, Boston, MA USA. [Chen, Yu-Wei; Beard, Clair J.; Martin, Neil E.; Nguyen, Paul L.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. [Chen, Yu-Wei; Choueiri, Toni K.; Sweeney, Christopher J.; Beard, Clair J.; Martin, Neil E.; Nguyen, Paul L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Mahal, Amandeep R.; Yu, James B.] Yale Sch Med, Dept Therapeut Radiol Radiat Oncol, New Haven, CT USA. [Choueiri, Toni K.; Sweeney, Christopher J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hoffman, Karen E.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Hu, Jim C.] New York Presbyterian Hosp, Weill Cornel Med Ctr, Dept Urol, New York, NY USA. [Feng, Felix Y.] Univ Michigan Hlth Syst, Dept Radiat Oncol, Ann Arbor, MI USA. [Kim, Simon P.] Univ Hosp Case Western Reserve Univ, Sch Med, Dept Urol, Cleveland, OH USA. [Quoc-Dien Trinh] Harvard Med Sch, Brigham & Womens Hosp, Div Urol, Boston, MA USA. RP Nguyen, PL (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. EM pnguyen@LROC.harvard.edu FU Prostate Cancer Foundation; Fitz's Cancer Warriors; Anonymous family foundation FX This work is supported by David and Cynthia Chapin, the Prostate Cancer Foundation, Fitz's Cancer Warriors, Hugh Simons in honor of Frank and Anne Simons, The Scott Forbes and Gina Ventre Fund, The Campbell Family in honor of Joan Campbell, and a grant from an Anonymous family foundation. NR 17 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2016 VL 122 IS 21 BP 3371 EP 3377 DI 10.1002/cncr.30205 PG 7 WC Oncology SC Oncology GA EC6ZU UT WOS:000388286000017 PM 27434225 ER PT J AU Ibrahim, N Buchbinder, EI Granter, SR Rodig, SJ Giobbie-Hurder, A Becerra, C Tsiaras, A Gjini, E Fisher, DE Hodi, FS AF Ibrahim, Nageatte Buchbinder, Elizabeth I. Granter, Scott R. Rodig, Scott J. Giobbie-Hurder, Anita Becerra, Carla Tsiaras, Argyro Gjini, Evisa Fisher, David E. Hodi, F. Stephen TI A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma SO CANCER MEDICINE LA English DT Article DE HDAC; immunotherapy; LBH589; melanoma; MITF; panobinostat ID HISTONE DEACETYLASE INHIBITORS; CELL LUNG-CANCER; MHC CLASS-I; MALIGNANT-MELANOMA; UNTREATED MELANOMA; HDAC INHIBITORS; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; SURVIVAL AB Epigenetic alterations by histone/protein deacetylases (HDACs) are one of the many mechanisms that cancer cells use to alter gene expression and promote growth. HDAC inhibitors have proven to be effective in the treatment of specific malignancies, particularly in combination with other anticancer agents. We conducted a phase I trial of panobinostat in patients with unresectable stage III or IV melanoma. Patients were treated with oral panobinostat at a dose of 30 mg daily on Mondays, Wednesdays, and Fridays (Arm A). Three of the six patients on this dose experienced clinically significant thrombocytopenia requiring dose interruption. Due to this, a second treatment arm was opened and the dose was changed to 30 mg oral panobinostat three times a week every other week (Arm B). Six patients were treated on Arm A and 10 patients were enrolled to Arm B with nine patients treated. In nine patients treated on Arm B, the response rate was 0% (90% confidence interval [CI]: 0-28%) and the disease-control rate was 22% (90% CI: 4-55%). Among all 15 patients treated, the overall response rate was 0% (90% CI: 0-17%) and the disease-control rate was 27% (90% CI: 10-51%). There was a high rate of toxicity associated with treatment. Correlative studies suggest the presence of immune modifications after HDAC inhibition. Panobinostat is not active as a single agent in the treatment of melanoma. Further exploration of this agent in combination with other therapies may be warranted. C1 [Ibrahim, Nageatte; Buchbinder, Elizabeth I.; Becerra, Carla; Tsiaras, Argyro; Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ibrahim, Nageatte] Merck & Co Inc, Kenilworth, NJ USA. [Granter, Scott R.; Rodig, Scott J.; Gjini, Evisa] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA. [Fisher, David E.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Buchbinder, EI (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM Elizabeth_buchbinder@dfci.harvard.edu FU John Giblin Melanoma Research Fund at Dana-Farber Cancer Institute FX Novartis Pharmaceuticals Corporation provided clinical trial support, additional funding obtained through the John Giblin Melanoma Research Fund at Dana-Farber Cancer Institute. NR 34 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD NOV PY 2016 VL 5 IS 11 BP 3041 EP 3050 DI 10.1002/cam4.862 PG 10 WC Oncology SC Oncology GA EC8DH UT WOS:000388370000003 PM 27748045 ER PT J AU Chatterjee, NA Gold, MR Waggoner, AD Picard, MH Stein, KM Yu, YH Meyer, TE Wold, N Ellenbogen, KA Singh, JP AF Chatterjee, Neal A. Gold, Michael R. Waggoner, Alan D. Picard, Michael H. Stein, Kenneth M. Yu, Yinghong Meyer, Timothy E. Wold, Nicholas Ellenbogen, Kenneth A. Singh, Jagmeet P. TI Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy) SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Article DE cardiac resynchronization therapy; echocardiography; logistic models; papillary muscles; ventricular remodeling ID HEART-FAILURE; LEAD LOCATION; DYSSYNCHRONY; ECHOCARDIOGRAPHY; REDUCTION; RECOMMENDATIONS; PERFORMANCE; IMPROVEMENT; MORPHOLOGY; SEVERITY AB Background-Mitral regurgitation (MR) is associated with worse survival in those undergoing cardiac resynchronization therapy (CRT). Left ventricular (LV) lead position in CRT may ameliorate mechanisms of MR. We examine the association between a longer LV electric delay (QLV) at the LV stimulation site and MR reduction after CRT. Methods and Results-QLV was assessed retrospectively in 426 patients enrolled in the SMART-AV study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in CRT). QLV was defined as the time from QRS onset to the first large peak of the LV electrogram. Linear regression and logistic regression were used to assess the association between baseline QLV and MR reduction at 6 months (absolute change in vena contracta width and odds of >= 1 grade reduction in MR). At baseline, there was no difference in MR grade, LV dyssynchrony, or LV volumes in those with QLV above versus below the median (95 ms). After multivariable adjustment, increasing QLV was an independent predictor of MR reduction at 6 months as reflected by an increased odds of MR response (odds ratio: 1.13 [1.03-1.25]/10 ms increase QLV; P=0.02) and a decrease in vena contracta width (P<0.001). At 3 months, longer QLV (>= median) was associated with significant decrease in LV end-systolic volume (Delta LV end-systolic volume -28.2 +/- 38.9 versus -4.9 +/- 33.8 mL, P<0.001). Adjustment for 3-month Delta LV end-systolic volume attenuated the association between QLV and 6-month MR reduction. Conclusions-In patients undergoing CRT, longer QLV was an independent predictor of MR reduction at 6 months and associated with interval 3-month LV reverse remodeling. These findings provide a mechanistic basis for using an electric-targeting LV lead strategy at the time of CRT implant. C1 [Chatterjee, Neal A.; Singh, Jagmeet P.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Div Cardiol, Boston, MA USA. [Picard, Michael H.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Div Cardiol, Boston, MA USA. [Gold, Michael R.] Med Univ South Carolina, Div Cardiol, Charleston, SC USA. [Waggoner, Alan D.] Washington Univ, St Louis, MO USA. [Stein, Kenneth M.; Yu, Yinghong; Meyer, Timothy E.; Wold, Nicholas] Boston Sci, St Paul, MN USA. [Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Med Ctr, Div Cardiol, Richmond, VA 23284 USA. RP Singh, JP (reprint author), Massachusetts Gen Hosp, Ctr Heart, Cardiac Arrhythmia Serv, GRB 109,55 Fruit St, Boston, MA 02411 USA. EM jsingh@partners.org FU NHLBI [T-32 HL-007575]; Boston Scientific Corporation FX Dr Chatterjee was supported by NHLBI T-32 HL-007575 that does not represent a relevant disclosure but does support time for writing. The SMART-AV trial (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in CRT) was funded by Boston Scientific Corporation. NR 31 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3149 EI 1941-3084 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD NOV PY 2016 VL 9 IS 11 AR e004346 DI 10.1161/CIRCEP.116.004346 PG 17 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9UE UT WOS:000388489000010 ER PT J AU Groeneveld, PW Rumsfeld, JS AF Groeneveld, Peter W. Rumsfeld, John S. TI Can Big Data Fulfill Its Promise? SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE algorithms; analysis; database; machine learning; patient-specific modeling ID RISK; INDEX C1 [Groeneveld, Peter W.] Michael J Crescenz Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Groeneveld, Peter W.] Univ Penn, Dept Med, Div Gen Internal Med, Perelman Sch Med,Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Ctr Cardiovasc Outcomes Qual & Evaluat Res, Philadelphia, PA 19104 USA. [Rumsfeld, John S.] Univ Colorado, Sch Med, Aurora, CO USA. [Rumsfeld, John S.] Vet Affairs Eastern Colorado Hlth Syst, Denver, CO USA. [Rumsfeld, John S.] Amer Coll Cardiol, Washington, DC USA. RP Groeneveld, PW (reprint author), Univ Penn, Perelman Sch Med, 1201 Blockley Hall,423 Serv Dr, Philadelphia, PA 19104 USA. EM petergro@upenn.edu NR 14 TC 1 Z9 1 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2016 VL 9 IS 6 BP 679 EP 682 DI 10.1161/CIRCOUTCOMES.116.003097 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9VE UT WOS:000388491600010 PM 28263942 ER PT J AU Blewer, AL Putt, ME Becker, LB Riegel, BJ Li, JQ Leary, M Shea, JA Kirkpatrick, JN Berg, RA Nadkarni, VM Groeneveld, PW Abella, BS AF Blewer, Audrey L. Putt, Mary E. Becker, Lance B. Riegel, Barbara J. Li, Jiaqi Leary, Marion Shea, Judy A. Kirkpatrick, James N. Berg, Robert A. Nadkarni, Vinay M. Groeneveld, Peter W. Abella, Benjamin S. CA CHIP Study Grp TI Video-Only Cardiopulmonary Resuscitation Education for High-Risk Families Before Hospital Discharge A Multicenter Pragmatic Trial SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiopulmonary resuscitation; cardiovascular diseases; randomized controlled trial; resuscitation; heart arrest ID AMERICAN-HEART-ASSOCIATION; ACUTE CORONARY SYNDROMES; ELEVATION MYOCARDIAL-INFARCTION; CARDIAC-ARREST RESUSCITATION; CHEST COMPRESSION DEPTH; SELF-INSTRUCTION; LAY RESPONDERS; UNITED-STATES; CPR; OUTCOMES AB Background-Cardiopulmonary resuscitation (CPR) training rates in the United States are low, highlighting the need to develop CPR educational approaches that are simpler, with broader dissemination potential. The minimum training required to ensure long-term skill retention remains poorly characterized. We compared CPR skill retention among laypersons randomized to training with video-only (VO; no manikin) with those trained with a video self-instruction kit (VSI; with manikin). We hypothesized that VO training would be noninferior to the VSI approach with respect to chest compression (CC) rate. Methods and Results-We performed a prospective, cluster randomized trial of CPR education for family members of patients with high-risk cardiac conditions on hospital cardiac units, using a multicenter pragmatic design. Eight hospitals were randomized to offer either VO or VSI training before discharge using volunteer trainers. CPR skills were assessed 6 months post training. Mean CC rate among those trained with VO compared with those trained with VSI was assessed with a noninferiority margin set at 8 CC per min; as a secondary outcome, mean differences in CC depth were assessed. From February 2012 to May 2015, 1464 subjects were enrolled and 522 subjects completed a skills assessment. The mean CC rates were 87.7 (VO) CC per min and 89.3 (VSI) CC per min; we concluded noninferiority for VO based on a mean difference of -1.6 (90% confidence interval, -5.2 to 2.1). The mean CC depth was 40.2 mm (VO) and 45.8 mm (VSI) with a mean difference of -5.6 (95% confidence interval, -7.6 to -3.7). Results were similar after multivariate regression adjustment. Conclusions-In this large, prospective trial of CPR skill retention, VO training yielded a noninferior difference in CC rate compared with VSI training. CC depth was greater in the VSI group. These findings suggest a potential trade-off in efforts for broad dissemination of basic CPR skills; VO training might allow for greater scalability and dissemination, but with a potential reduction in CC depth. C1 [Blewer, Audrey L.; Becker, Lance B.; Leary, Marion; Abella, Benjamin S.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Blewer, Audrey L.; Becker, Lance B.; Leary, Marion; Abella, Benjamin S.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA. [Blewer, Audrey L.; Putt, Mary E.; Li, Jiaqi] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Riegel, Barbara J.; Leary, Marion] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Riegel, Barbara J.] Univ Penn, New Courtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Shea, Judy A.; Kirkpatrick, James N.; Groeneveld, Peter W.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Berg, Robert A.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Berg, Robert A.; Nadkarni, Vinay M.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Abella, BS (reprint author), Univ Penn, Dept Emergency Med, Ctr Resuscitat Sci, 3400 Spruce St, Philadelphia, PA 19104 USA. EM benjamin.abella@uphs.upenn.edu FU National Institutes of Health [R18HL107217]; American Heart Association FX This work was supported by grants from the National Institutes of Health (R18HL107217) and the American Heart Association (Clinical Research Program award). NR 38 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2016 VL 9 IS 6 BP 740 EP 748 DI 10.1161/CIRCOUTCOMES.116.002493 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9VE UT WOS:000388491600019 PM 27703033 ER PT J AU Jackevicius, CA Choi, K Krumholz, HM AF Jackevicius, Cynthia A. Choi, Katie Krumholz, Harlan M. TI Access to Evidence-Based Statins in Low-Cost Generic Drug Programs SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE drug costs; evidence-based medicine; generic drugs; 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors; prescription drugs ID RISK C1 [Jackevicius, Cynthia A.; Choi, Katie] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pharm, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Dept Pharm, Toronto, ON, Canada. Yale Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA. [Krumholz, Harlan M.] Dept Hlth Policy & Management, New Haven, CT USA. [Krumholz, Harlan M.] Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2016 VL 9 IS 6 BP 785 EP 787 DI 10.1161/CIRCOUTCOMES.116.002985 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC9VE UT WOS:000388491600024 PM 27803089 ER PT J AU McPherson, ZE Horvath-Puho, E Sorensen, HT Norgaard, M McElduff, P McElduff, S Agar, A Coroneo, M White, A Wang, JJ Francis, IC Craig, J Pasquale, LR Kang, JH Kellman, JC Walker, MM Talley, NJ Pettersson, S McEvoy, M AF McPherson, Zachary E. Horvath-Puho, Erzsebet Sorensen, Henrik T. Norgaard, Mette McElduff, Patrick McElduff, Simon Agar, Ashish Coroneo, Minas White, Andrew Wang, Jie Jin Francis, Ian C. Craig, Jamie Pasquale, Louis R. Kang, Jae H. Kellman, Julian C. Walker, Marjorie M. Talley, Nicholas J. Pettersson, Sven McEvoy, Mark TI IRRITABLE BOWEL SYNDROME IS A RISK FACTOR FOR GLAUCOMA; ANALYSIS OF TWO EUROPEAN POPULATION-BASED COHORT STUDIES SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY LA English DT Meeting Abstract C1 [McPherson, Zachary E.; McElduff, Patrick; McElduff, Simon; Walker, Marjorie M.; Talley, Nicholas J.; McEvoy, Mark] Univ Newcastle, Newcastle, NSW, Australia. [Pettersson, Sven] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore. [Horvath-Puho, Erzsebet; Sorensen, Henrik T.; Norgaard, Mette] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark. [Agar, Ashish; Coroneo, Minas; Francis, Ian C.] Prince Wales Hosp, Randwick, NSW, Australia. [White, Andrew] Westmead Hosp, Westmead, NSW, Australia. [Craig, Jamie] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia. [Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Pasquale, Louis R.; Kang, Jae H.] Harvard Med Sch, Boston, MA USA. [Kang, Jae H.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Walker, Marjorie M.; Talley, Nicholas J.] John Hunter Hosp, Newcastle, NSW, Australia. [Pettersson, Sven] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden. [White, Andrew; Wang, Jie Jin] Univ Sydney, Westmead Millenium Inst, Westmead, NSW, Australia. [Kellman, Julian C.] St Vincents Hosp, Darlinghurst, NSW, Australia. EM zacmcpherson93@gmail.com RI Wang, Jie Jin/P-1499-2014 OI Wang, Jie Jin/0000-0001-9491-4898 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1442-6404 EI 1442-9071 J9 CLIN EXP OPHTHALMOL JI Clin. Exp. Ophthalmol. PD NOV PY 2016 VL 44 SU 1 MA 2203 BP 50 EP 50 PG 1 WC Ophthalmology SC Ophthalmology GA EC0JY UT WOS:000387788100050 ER PT J AU Siggs, O Souma, T Tompson, S Thomson, B Kalaydjieva, L Azmanov, D Javadiyan, S Souzeau, E Zhou, T Hewitt, A Burdon, K Mackey, D Ruddle, J Wiggs, J Pasutto, F Quaggin, S Young, T Craig, J AF Siggs, Owen Souma, Tomokazu Tompson, Stuart Thomson, Benjamin Kalaydjieva, Luba Azmanov, Dimitar Javadiyan, Shahrbanou Souzeau, Emmanuelle Zhou, Tiger Hewitt, Alex Burdon, Kathryn Mackey, David Ruddle, Jonathan Wiggs, Janey Pasutto, Francesca Quaggin, Susan Young, Terri Craig, Jamie TI MUTATION OF THE ANGIOPOIETIN RECEPTOR TEK IS ASSOCIATED WITH PRIMARY CONGENITAL GLAUCOMA SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY LA English DT Meeting Abstract C1 [Siggs, Owen; Javadiyan, Shahrbanou; Souzeau, Emmanuelle; Zhou, Tiger; Craig, Jamie] Flinders Univ S Australia, Adelaide, SA, Australia. [Souma, Tomokazu; Thomson, Benjamin; Quaggin, Susan] Northwestern Univ, Chicago, IL 60611 USA. [Tompson, Stuart; Young, Terri] Univ Wisconsin Madison, Madison, WI USA. [Kalaydjieva, Luba; Azmanov, Dimitar] Harry Perkins Inst Med Res, Perth, WA, Australia. [Hewitt, Alex; Ruddle, Jonathan] Ctr Eye Res Australia, Melbourne, Australia. [Hewitt, Alex; Burdon, Kathryn; Mackey, David] Menzies Inst Med Res, Hobart, Tas, Australia. [Wiggs, Janey] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Mackey, David] Lions Eye Inst, Perth, WA, Australia. [Pasutto, Francesca] Friedrich Alexander Univ, Erlangen, Germany. EM sigg0005@flinders.edu.au NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1442-6404 EI 1442-9071 J9 CLIN EXP OPHTHALMOL JI Clin. Exp. Ophthalmol. PD NOV PY 2016 VL 44 SU 1 MA P0601 BP 56 EP 56 PG 1 WC Ophthalmology SC Ophthalmology GA EC0JY UT WOS:000387788100060 ER PT J AU Musher, DM AF Musher, Daniel M. TI Polymerase Chain Reaction for the tpp47 Gene: A New Test for Neurosyphilis SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE syphilis; neurosyphilis; syphilitic meningitis ID CEREBROSPINAL-FLUID; SYPHILIS; DIAGNOSIS C1 [Musher, Daniel M.] Baylor Coll Med, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey Med Ctr, Infect Dis Sect, Med Care Line, Houston, TX USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@va.gov NR 12 TC 0 Z9 0 U1 7 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2016 VL 63 IS 9 BP 1187 EP 1188 DI 10.1093/cid/ciw518 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC2WY UT WOS:000387986200011 PM 27585980 ER PT J AU Feinstein, MJ Bogorodskaya, M Bloomfield, GS Vedanthan, R Siedner, MJ Kwan, GF Longenecker, CT AF Feinstein, Matthew J. Bogorodskaya, Milana Bloomfield, Gerald S. Vedanthan, Rajesh Siedner, Mark J. Kwan, Gene F. Longenecker, Christopher T. TI Cardiovascular Complications of HIV in Endemic Countries SO CURRENT CARDIOLOGY REPORTS LA English DT Review DE Human immunodeficiency virus; HIV; Cardiovascular epidemiology; Risk factors; Health disparities; Global health ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INTIMA-MEDIA THICKNESS; PULMONARY ARTERIAL-HYPERTENSION; ACUTE MYOCARDIAL-INFARCTION; SUBCLINICAL CORONARY ATHEROSCLEROSIS; LEFT-VENTRICULAR DYSFUNCTION; POPULATION-BASED COHORT; SUB-SAHARAN AFRICA; T-CELL COUNTS AB Effective combination antiretroviral therapy (ART) has enabled human immunodeficiency virus (HIV) infection to evolve from a generally fatal condition to a manageable chronic disease. This transition began two decades ago in high-income countries and has more recently begun in lower income, HIV endemic countries (HIV-ECs). With this transition, there has been a concurrent shift in clinical and public health burden from AIDS-related complications and opportunistic infections to those associated with well-controlled HIV disease, including cardiovascular disease (CVD). In the current treatment era, traditional CVD risk factors and HIV-related factors both contribute to an elevated risk of myocardial infarction, stroke, heart failure, and arrhythmias. In HIV-ECs, the high prevalence of persons living with HIV and growing prevalence of CVD risk factors will contribute to a growing epidemic of HIV-associated CVD. In this review, we discuss the epidemiology and pathophysiology of cardiovascular complications of HIV and the resultant implications for public health efforts in HIV-ECs. C1 [Feinstein, Matthew J.] Northwestern Univ, Dept Med, Div Cardiovasc Dis, Feinberg Sch Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. [Bogorodskaya, Milana; Longenecker, Christopher T.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA. [Bogorodskaya, Milana] Univ Hosp, Dept Med, Case Med Ctr, Cleveland, OH USA. [Bloomfield, Gerald S.] Duke Univ, Duke Clin Res Inst, Dept Med, Div Cardiol, Durham, NC USA. [Vedanthan, Rajesh] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA. [Siedner, Mark J.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Kwan, Gene F.] Boston Univ, Sch Med, Dept Med, Sect Cardiovasc Med, Boston, MA 02118 USA. [Longenecker, Christopher T.] Univ Hosp, Dept Med, Div Cardiol, Case Med Ctr, Cleveland, OH USA. RP Feinstein, MJ (reprint author), Northwestern Univ, Dept Med, Div Cardiovasc Dis, Feinberg Sch Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. EM Matthewjfeinstein@northwestern.edu FU NIH [K23 HL123341]; American Heart Association [16 FTF 31200010] FX Christopher T. Longenecker reports grants from NIH (K23 HL123341). Matthew J. Feinstein reports grants from the American Heart Association (16 FTF 31200010) NR 139 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD NOV PY 2016 VL 18 IS 11 AR 113 DI 10.1007/s11886-016-0794-x PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC4TA UT WOS:000388125500010 PM 27730474 ER PT J AU Ganda, OP Mitri, J AF Ganda, Om P. Mitri, Joanna TI Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes SO CURRENT CARDIOLOGY REPORTS LA English DT Review DE Lipid guidelines; Blood pressure guidelines.; Diabetes and CVD; Guideline controversies; CVD clinical trials ID ACUTE CORONARY SYNDROME; BLOOD-PRESSURE CONTROL; CARDIOVASCULAR EVENTS; RANDOMIZED-TRIALS; RISK-FACTORS; LOWERING THERAPY; LDL CHOLESTEROL; REDUCING LIPIDS; STATIN THERAPY; METAANALYSIS AB Despite major advances, many patients with diabetes are currently achieving suboptimal control of lipids and blood pressure. The new cholesterol guidelines by the ACC/AHA have reignited the emphasis on more intensive treatment with statins in the population at high risk of CVD, including those with diabetes. While these guidelines do not include specific lipid goals, several other guidelines have retained previously defined risk-based LDL-C and non-HDL-C goals. More recent data indicate potential benefits in CVD outcomes with non-statin therapy added to statin therapy. On-going long-term trials with PCSK-9 inhibitors may help answer the question of the benefits and safety of very low LDL-C. Regarding the blood pressure guidelines, there remains an inconsistency of evidence for targets to reduce CVD outcomes. The ACCORD trial weighted heavily in the recent meta-analyses, leading to currently recommended goal of < 140/90 mmHg. Studies targeting blood pressure goals of <130 mmHg in younger patients with diabetes, including sub-populations of interest, may help solve the controversy. Until we have these data, perhaps it is time to shift our focus from a rigid blood pressure target to risk-based goals. C1 [Ganda, Om P.; Mitri, Joanna] Harvard Med Sch, Joslin Diabet Ctr, Adult Diabet & Clin Res, 1 Joslin Pl, Boston, MA 02215 USA. RP Ganda, OP (reprint author), Harvard Med Sch, Joslin Diabet Ctr, Adult Diabet & Clin Res, 1 Joslin Pl, Boston, MA 02215 USA. EM Om.ganda@joslin.harvard.edu FU NIH [P30DK36836] FX Supported in part by NIH Grant P30DK36836-Diabetes enrichment core. NR 56 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD NOV PY 2016 VL 18 IS 11 AR 114 DI 10.1007/s11886-016-0790-1 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC4TA UT WOS:000388125500011 PM 27747489 ER PT J AU Chakravarthy, K Nava, A Christo, PJ Williams, K AF Chakravarthy, Krishnan Nava, Andrew Christo, Paul J. Williams, Kayode TI Review of Recent Advances in Peripheral Nerve Stimulation (PNS) SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Review DE Peripheral nerve stimulation; Chronic pain; Peripheral neuromodulation; Clinical indications; Pain; Neuropathic pain ID TENS-INDUCED ANTIHYPERALGESIA; HIGH-FREQUENCY TENS; NEUROPATHIC PAIN; FIELD STIMULATION; ELECTRICAL-STIMULATION; OPIOID RECEPTORS; FIBER ACTIVATION; BRACHIAL-PLEXUS; SPINAL-CORD; RATS AB Peripheral nerve stimulation (PNS) for the treatment of chronic pain has become an increasingly important field in the arena of neuromodulation, given the ongoing advances in electrical neuromodulation technology since 1999 permitting minimally invasive approaches using an percutaneous approach as opposed to implantable systems. Our review aims to provide clinicians with the recent advances and studies in the field, with specific emphasis on clinical data and indications that have been accumulated over the last several years. In addition, we aim to address key basic science studies to further emphasize the importance of translational research outcomes driving clinical management. C1 [Chakravarthy, Krishnan] Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. [Nava, Andrew; Christo, Paul J.; Williams, Kayode] Johns Hopkins Univ, Sch Med, Div Pain Med, Dept Anesthesiol & Crit Care Med, 600 North Wolfe St, Baltimore, MD 21287 USA. [Nava, Andrew] Johns Hopkins Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA. RP Chakravarthy, K (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM kchakravarthy@mgh.harvard.edu FU Medtronic, Inc. FX Paul J. Christo and Kayode Williams declare grant support from Medtronic, Inc. NR 50 TC 0 Z9 0 U1 10 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1531-3433 EI 1534-3081 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD NOV PY 2016 VL 20 IS 11 AR 60 DI 10.1007/s11916-016-0590-8 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EC7AV UT WOS:000388289000002 PM 27671799 ER PT J AU Celano, CM Daunis, DJ Lokko, HN Campbell, KA Huffman, JC AF Celano, Christopher M. Daunis, Daniel J. Lokko, Hermioni N. Campbell, Kirsti A. Huffman, Jeff C. TI Anxiety Disorders and Cardiovascular Disease SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE Anxiety; Generalized anxiety disorder; Panic disorder; Post-traumatic stress disorder; Cardiovascular disease ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR ASSIST DEVICE; PANIC DISORDER; GENERALIZED ANXIETY; ARTERY-DISEASE; CARDIAC EVENTS AB Anxiety and its associated disorders are common in patients with cardiovascular disease and may significantly influence cardiac health. Anxiety disorders are associated with the onset and progression of cardiac disease, and in many instances have been linked to adverse cardiovascular outcomes, including mortality. Both physiologic (autonomic dysfunction, inflammation, endothelial dysfunction, changes in platelet aggregation) and health behavior mechanisms may help to explain the relationships between anxiety disorders and cardiovascular disease. Given the associations between anxiety disorders and poor cardiac health, the timely and accurate identification and treatment of these conditions is of the utmost importance. Fortunately, pharmacologic and psychotherapeutic interventions for the management of anxiety disorders are generally safe and effective. Further study is needed to determine whether interventions to treat anxiety disorders ultimately impact both psychiatric and cardiovascular health. C1 [Celano, Christopher M.; Daunis, Daniel J.; Lokko, Hermioni N.; Campbell, Kirsti A.; Huffman, Jeff C.] Harvard Med Sch, Boston, MA 02115 USA. [Celano, Christopher M.; Daunis, Daniel J.; Campbell, Kirsti A.; Huffman, Jeff C.] Massachusetts Gen Hosp, Dept Psychiat, Blake 11,55 Fruit St, Boston, MA 02114 USA. [Lokko, Hermioni N.] Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA. RP Celano, CM (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Celano, CM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Blake 11,55 Fruit St, Boston, MA 02114 USA. EM ccelano@partners.org FU National Heart Lung and Blood Institute [K23HL123607, R01HL113272] FX Time for article preparation was funded by the National Heart Lung and Blood Institute through grant K23HL123607 (to Dr. Celano) and R01HL113272 (to Dr. Huffman). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or other funders. NR 128 TC 0 Z9 0 U1 8 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD NOV PY 2016 VL 18 IS 11 AR 101 DI 10.1007/s11920-016-0739-5 PG 11 WC Psychiatry SC Psychiatry GA EC5II UT WOS:000388167600004 PM 27671918 ER PT J AU DiPasquale, DM AF DiPasquale, Dana M. TI Sex Differences in Diving: Fact or Folklore SO CURRENT SPORTS MEDICINE REPORTS LA English DT Editorial Material ID COLD-WATER EXPOSURE; VENOUS GAS EMBOLI; DECOMPRESSION-SICKNESS; MENSTRUAL-CYCLE; THERMOREGULATORY RESPONSES; THERMAL ADJUSTMENT; GENDER-DIFFERENCES; RISK-FACTORS; RESTING MEN; WOMEN C1 [DiPasquale, Dana M.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. RP DiPasquale, DM (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM dipasquale.dana@gmail.com NR 42 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1537-890X EI 1537-8918 J9 CURR SPORT MED REP JI Curr. Sport. Med. Rep. PD NOV-DEC PY 2016 VL 15 IS 6 BP 389 EP 391 DI 10.1249/JSR.0000000000000313 PG 3 WC Sport Sciences SC Sport Sciences GA EC6BI UT WOS:000388220700005 PM 27841809 ER PT J AU Morotti, A Goldstein, JN AF Morotti, Andrea Goldstein, Joshua N. TI New Oral Anticoagulants and Their Reversal Agents SO CURRENT TREATMENT OPTIONS IN NEUROLOGY LA English DT Review DE Direct oral anticoagulants; Factor Xa inhibitors; Thrombin inhibitors; Bleeding; Reversal ID NONVALVULAR ATRIAL-FIBRILLATION; ACUTE ISCHEMIC-STROKE; FACTOR XA INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; ACUTE VENOUS THROMBOEMBOLISM; HEALTH-CARE PROFESSIONALS; INTRACEREBRAL HEMORRHAGE; BLEEDING COMPLICATIONS; LABORATORY MEASUREMENT; EMERGENCY MANAGEMENT AB Direct oral anticoagulants (DOAC) are an attractive therapeutic option for anticoagulant treatment in the setting of venous thromboembolism or non-valvular atrial fibrillation. These drugs overall appear to have a lower risk of life-threatening hemorrhage than the vitamin K antagonists. In addition, they demonstrate more predictable and stable pharmacokinetics. Measurement of the degree of anticoagulation is desirable in patients with DOAC-associated hemorrhage, but commonly available coagulation assays show poor sensitivity for degree of DOAC effect. DOAC-specific tests are time consuming and not widely available. All coagulation tests should be interpreted considering the timing of last intake and renal function. When life-threatening bleeding occurs, hemostasis should be restored as rapidly as possible. Non-specific prohemostatic drugs may have a role in DOAC reversal, and specific antidotes are at different stages of development. In this review, we provide a summary of DOAC characteristics and an overview of the different therapeutic options available for DOAC reversal. C1 [Morotti, Andrea] Harvard Med Sch, JP Kistler Stroke Res Ctr, Massachusetts Gen Hosp, 175 Cambridge St,Suite 300, Boston, MA USA. [Goldstein, Joshua N.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. RP Morotti, A (reprint author), Harvard Med Sch, JP Kistler Stroke Res Ctr, Massachusetts Gen Hosp, 175 Cambridge St,Suite 300, Boston, MA USA. EM a.morotti@ymail.com FU Boehringer Ingelheim; Pfizer; Portola Pharmaceuticals; Bristol Myers Squibb; NINDS [5R01NS073344] FX Joshua N. Goldstein has received a research grant from Boehringer Ingelheim; a research grant from Pfizer; a research grant from Portola Pharmaceuticals; a consulting fee from Bristol Myers Squibb; and NINDS research funding 5R01NS073344. NR 82 TC 0 Z9 0 U1 1 U2 1 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1092-8480 EI 1534-3138 J9 CURR TREAT OPTION NE JI Curr. Treat. Options Neurol. PD NOV PY 2016 VL 18 IS 11 AR 47 DI 10.1007/s11940-016-0430-5 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA EC7BF UT WOS:000388290100001 PM 27696178 ER PT J AU Shields, AE Wise, LA Ruiz-Narvaez, EA Seddighzadeh, B Byun, HM Cozier, YC Rosenberg, L Palmer, JR Baccarelli, AA AF Shields, Alexandra E. Wise, Lauren A. Ruiz-Narvaez, Edward A. Seddighzadeh, Bobak Byun, Hyang-Min Cozier, Yvette C. Rosenberg, Lynn Palmer, Julie R. Baccarelli, Andrea A. TI Childhood abuse, promoter methylation of leukocyte NR3C1 and the potential modifying effect of emotional support SO EPIGENOMICS LA English DT Article DE abuse; African-Americans; child maltreatment; CpG island shore; DNA methylation; epigenetic epidemiology; glucocorticoid receptor; health disparities; NR3C1; violence ID GLUCOCORTICOID-RECEPTOR GENE; BORDERLINE PERSONALITY-DISORDER; CPG ISLAND SHORES; DNA METHYLATION; ADULT-ONSET; RISK; ASSOCIATIONS; HYPERMETHYLATION; MALTREATMENT; SEVERITY AB Aim: To investigate childhood abuse victimization in relation to adult DNA methylation levels in a novel region of NR3C1, with emotional support as a possible modifier. Materials & methods: 295 participants from the Black Women's Health Study. Multivariable linear regression models were used to compute differences in mean percent methylation levels. Results: Women reporting childhood abuse victimization exhibited higher mean NR3C1 methylation levels than nonabused women, with a clear dose-response relationship. Childhood emotional support appeared to attenuate associations only among women with the highest levels of physical and sexual abuse. Conclusion: NR3C1 mean methylation was higher among women who reported childhood abuse. Further research is warranted to clarify whether or the extent to which childhood emotional support buffers the association. C1 [Shields, Alexandra E.] Harvard Med Sch, 25 Shattuck St, Boston, MA 02114 USA. [Shields, Alexandra E.; Seddighzadeh, Bobak; Baccarelli, Andrea A.] Massachusetts Gen Hosp, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, 50 Staniford St,Suite 901, Boston, MA 02114 USA. [Wise, Lauren A.; Ruiz-Narvaez, Edward A.; Cozier, Yvette C.; Rosenberg, Lynn; Palmer, Julie R.] Boston Univ, Sch Publ Hlth, Talbot Bldg,715 Albany St, Boston, MA 02118 USA. [Wise, Lauren A.; Ruiz-Narvaez, Edward A.; Cozier, Yvette C.; Rosenberg, Lynn; Palmer, Julie R.] Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA. [Byun, Hyang-Min] Newcastle Univ, Inst Cellular Med, Human Nutr Res Ctr, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England. [Baccarelli, Andrea A.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 722 W 168th St, New York, NY 10032 USA. RP Shields, AE (reprint author), Harvard Med Sch, 25 Shattuck St, Boston, MA 02114 USA.; Shields, AE (reprint author), Massachusetts Gen Hosp, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, 50 Staniford St,Suite 901, Boston, MA 02114 USA. EM ashields@mgh.harvard.edu FU Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources) [UL1 TR001102]; Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH) [UL1 TR001102]; Harvard University; John Templeton Foundation [48424]; Black Women's Health Study [R01 CA 058420, UM1CA 164974] FX This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers (AA Baccarelli). This work was also supported by The John Templeton Foundation Grant #48424 (AE Shields) and the Black Women's Health Study (R01 CA 058420 and UM1CA 164974). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 55 TC 0 Z9 0 U1 1 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1750-1911 EI 1750-192X J9 EPIGENOMICS-UK JI Epigenomics PD NOV PY 2016 VL 8 IS 11 BP 1507 EP 1517 DI 10.2217/epi-2016-0074 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA EC0GH UT WOS:000387776300007 PM 27620456 ER PT J AU Liu, P Shen, JK Xu, JZ Trahan, CA Hornicek, FJ Duan, ZF AF Liu, Pei Shen, Jacson K. Xu, Jianzhong Trahan, Carol A. Hornicek, Francis J. Duan, Zhenfeng TI Aberrant DNA methylations in chondrosarcoma SO EPIGENOMICS LA English DT Article DE 5-azacytidine; 5-aza-2 '-deoxycytidine; chondrosarcoma; DNA methylation; epigenetics ID SWARM RAT CHONDROSARCOMA; CANCER-CELLS; GENE; EXPRESSION; HYPOMETHYLATION; EPIGENETICS; TUMORS; SOX9; BONE AB Chondrosarcoma (CS) is the second most common primary malignant bone tumor. Unlike other bone tumors, CS is highly resistant to conventional chemotherapy and radiotherapy, thus resulting in poor patient outcomes. There is an urgent need to establish alternative therapies for CS. However, the etiology and pathogenesis of CS still remain elusive. Recently, DNA methylation-associated epigenetic changes have been found to play a pivotal role in the initiation and development of human cancers, including CS, by regulating target gene expression in different cellular pathways. Elucidating the mechanisms of DNA methylation alteration may provide biomarkers for diagnosis and prognosis, as well as novel treatment options for CS. We have conducted a critical review to summarize the evidence regarding aberrant DNA methylation patterns as diagnostic biomarkers, predictors of progression and potential treatment strategies in CS. C1 [Liu, Pei; Shen, Jacson K.; Trahan, Carol A.; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Sarcoma Biol Lab, 55 Fruit St,Jackson 1115, Boston, MA 02114 USA. [Liu, Pei; Shen, Jacson K.; Trahan, Carol A.; Hornicek, Francis J.; Duan, Zhenfeng] Harvard Med Sch, 55 Fruit St,Jackson 1115, Boston, MA 02114 USA. [Liu, Pei; Xu, Jianzhong] Zhengzhou Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Zhengzhou 450052, Henan, Peoples R China. RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Sarcoma Biol Lab, 55 Fruit St,Jackson 1115, Boston, MA 02114 USA.; Duan, ZF (reprint author), Harvard Med Sch, 55 Fruit St,Jackson 1115, Boston, MA 02114 USA. EM zduan@mgh.harvard.edu FU Gattegno fund; Wechsler fund; Sarcoma Foundation of America (SFA); National Cancer Institute (NCI)/NIH [CA 151452-01]; Sarcoma SPORE/NIH; Academic Enrichment Fund of MGH Orthopaedics FX This work was supported, in part, by the Gattegno and Wechsler funds. Z Duan is supported, in part, through a grant from Sarcoma Foundation of America (SFA), a grant from National Cancer Institute (NCI)/NIH, UO1, CA 151452-01, a pilot grant from Sarcoma SPORE/NIH, and a grant from an Academic Enrichment Fund of MGH Orthopaedics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 46 TC 0 Z9 0 U1 0 U2 0 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1750-1911 EI 1750-192X J9 EPIGENOMICS-UK JI Epigenomics PD NOV PY 2016 VL 8 IS 11 BP 1519 EP 1525 DI 10.2217/epi-2016-0071 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA EC0GH UT WOS:000387776300008 PM 27686001 ER PT J AU Blanco-Centurion, C Liu, M Konadhode, RP Zhang, XB Pelluru, D van den Pol, AN Shiromani, PJ AF Blanco-Centurion, Carlos Liu, Meng Konadhode, Roda P. Zhang, Xiaobing Pelluru, Dheeraj van den Pol, Anthony N. Shiromani, Priyattam J. TI Optogenetic activation of melanin-concentrating hormone neurons increases non-rapid eye movement and rapid eye movement sleep during the night in rats SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE channelrhodopsin-2; melanin-concentrating hormone; rapid eye movement sleep; rat; recombinant adeno-associated virus ID LOCUS-COERULEUS NEURONS; MCH NEURONS; PARADOXICAL SLEEP; OREXIN NEURONS; DORSAL RAPHE; REM-SLEEP; PROJECTIONS; DISCHARGE; MICE; HYPOTHALAMUS AB Neurons containing melanin-concentrating hormone (MCH) are located in the hypothalamus. In mice, optogenetic activation of the MCH neurons induces both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep at night, the normal wake-active period for nocturnal rodents [R. R. Konadhode etal. (2013) J. Neurosci., 33, 10257-10263]. Here we selectively activate these neurons in rats to test the validity of the sleep network hypothesis in another species. Channelrhodopsin-2 (ChR2) driven by the MCH promoter was selectively expressed by MCH neurons after injection of rAAV-MCHp-ChR2-EYFP into the hypothalamus of Long-Evans rats. An invitro study confirmed that the optogenetic activation of MCH neurons faithfully triggered action potentials. In the second study, in Long-Evans rats, rAAV-MCH-ChR2, or the control vector, rAAV-MCH-EYFP, were delivered into the hypothalamus. Three weeks later, baseline sleep was recorded for 48h without optogenetic stimulation (0Hz). Subsequently, at the start of the lights-off cycle, the MCH neurons were stimulated at 5, 10, or 30Hz (1mW at tip; 1min on - 4min off) for 24h. Sleep was recorded during the 24-h stimulation period. Optogenetic activation of MCH neurons increased both REM and NREM sleep at night, whereas during the day cycle, only REM sleep was increased. Delta power, an indicator of sleep intensity, was also increased. In control rats without ChR2, optogenetic stimulation did not increase sleep or delta power. These results lend further support to the view that sleep-active MCH neurons contribute to drive sleep in mammals. C1 [Blanco-Centurion, Carlos; Liu, Meng; Konadhode, Roda P.; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 114 Doughty St,MSC 404-STB 404, Charleston, SC 29425 USA. [Zhang, Xiaobing; van den Pol, Anthony N.] Yale Univ, Dept Neurosurg, New Haven, CT USA. [Shiromani, Priyattam J.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Shiromani, PJ (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 114 Doughty St,MSC 404-STB 404, Charleston, SC 29425 USA.; Shiromani, PJ (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM shiroman@musc.edu RI ZHANG, XIAOBING /J-4076-2015 OI ZHANG, XIAOBING /0000-0002-5707-193X FU Medical Research Service of the Department of Veterans Affairs [101 BX000798]; NIH [1K01AG041520, NS052287, NS084477, NS079940, NS048476] FX We thank Wengxue Wang for assistance with the study and Dr. Amanda LaRue for use of the confocal microscope. This study was supported by Medical Research Service of the Department of Veterans Affairs (101 BX000798) and NIH grants 1K01AG041520 (to ML), NS052287, NS084477, NS079940, NS048476 (to AVP). NR 52 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD NOV PY 2016 VL 44 IS 10 BP 2846 EP 2857 DI 10.1111/ejn.13410 PG 12 WC Neurosciences SC Neurosciences & Neurology GA EC9YJ UT WOS:000388499900011 PM 27657541 ER PT J AU Goyal, N Emerick, KS Deschler, DG Lin, DT Yarlagadda, BB Rich, DL Durand, ML AF Goyal, Neerav Emerick, Kevin S. Deschler, Daniel G. Lin, Derrick T. Yarlagadda, Bharat B. Rich, Debbie L. Durand, Marlene L. TI Risk factors for surgical site infection after supraclavicular flap reconstruction in patients undergoing major head and neck surgery SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE supraclavicular flap; surgical site infections; fistula; head and neck cancer; reconstructive surgery ID ARTERY ISLAND FLAP; LENGTH-OF-STAY; MYOCUTANEOUS FLAP; CANCER-PATIENTS; EXPERIENCE; DISSECTION; DEFECTS AB Background. Surgical site infections can adversely affect flaps in head and neck reconstruction. The purpose of this study was to evaluate the risk factors of surgical site infections in supraclavicular artery island flap reconstructions. Methods. Records of patients undergoing head and neck surgery from 2011 to 2014 with supraclavicular artery island flap reconstruction at a single specialty hospital were reviewed; surgical site infections <= 30 days postoperatively were noted. Results. Of 64 patients, 86% underwent resection for malignancy, 55% previously received radiation. Sixty-three percent of surgeries were clean-contaminated. Seven patients (11%) developed recipient site surgical site infections, all in patients who underwent clean-contaminated surgery for malignancy. There was no complete flap loss. No significant differences in demographics or perioperative factors were noted. Oral cavity and laryngeal reconstructions (p=.014) and clean-contaminated surgery (p=.04) were factors associated with increased surgical site infection risk on univariate but not multivariate analysis. Patients with surgical site infections had longer hospitalizations (p=.003). Conclusion. The supraclavicular artery island flap can be used for head and neck reconstruction with a low rate of surgical site infection. (C) 2016 Wiley Periodicals, Inc. C1 [Goyal, Neerav; Emerick, Kevin S.; Deschler, Daniel G.; Lin, Derrick T.; Yarlagadda, Bharat B.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Harvard Med Sch, Boston, MA 02114 USA. [Goyal, Neerav] Penn State Milton S Hershey Med Ctr, Div Otolaryngol Head & Neck Surg, Hershey, PA 17033 USA. [Yarlagadda, Bharat B.] Lahey Hosp & Med Ctr, Dept Otolaryngol, Burlington, MA USA. [Rich, Debbie L.] Massachusetts Eye & Ear Infirm, Dept Nursing, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Goyal, N (reprint author), Penn State Milton S Hershey Med Ctr, Div Otolaryngol Head & Neck Surg, Hershey, PA 17033 USA. EM ngoyal1@hmc.psu.edu OI Goyal, Neerav/0000-0001-7783-1097 NR 28 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD NOV PY 2016 VL 38 IS 11 BP 1615 EP 1620 DI 10.1002/hed.24480 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EC8CG UT WOS:000388367200006 PM 27098679 ER PT J AU Namin, AW Varvares, MA AF Namin, Arya W. Varvares, Mark A. TI Functional outcomes of sensate versus insensate free flap reconstruction in oral and oropharyngeal reconstruction: A systematic review SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Review DE free flap reconstruction; sensate; insensate; innervated; functional outcome; glossectomy; mastication; swallowing; speech; 2-point discrimination ID FOREARM FREE FLAPS; ANTEROLATERAL THIGH FLAP; RADIAL FOREARM; SENSORY RECOVERY; TONGUE RECONSTRUCTION; GLOSSECTOMY DEFECTS; NECK RECONSTRUCTION; SWALLOWING FUNCTION; MICROVASCULAR RECONSTRUCTION; OROMANDIBULAR RECONSTRUCTION AB The purposes of this article were to review the literature regarding subjective outcomes, objective functional outcomes, and objective sensation return after sensate and/or insensate free flap reconstruction of the oral cavity and oropharynx. Sensate radial forearm and anterolateral thigh free flaps tend to have better static 2-point discrimination and pressure threshold sensitivity than insensate flaps. There is insufficient evidence to draw conclusions on whether sensate flaps improve functional speech and swallowing outcomes measured by videofluoroscopic swallowing studies and percentage of word intelligibility by a listener blinded to the study. These data highlight the complexity and number of variables affecting functional outcomes in patients who have undergone reconstructive surgery after oral and oropharyngeal cancer ablative operations. A prospective randomized multicenter study that properly and rigidly stratifies patients by defect, flap and recipient nerve choice, adjuvant therapies, and uses widely agreed upon pretreatment and posttreatment evaluation tools could help to answer this important question. (C) 2016 Wiley Periodicals, Inc. C1 [Namin, Arya W.] Univ Texas Southwestern Med Ctr, Dept Surg, Dallas, TX USA. [Varvares, Mark A.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA USA. [Varvares, Mark A.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA USA. RP Varvares, MA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM mark_varvares@meei.harvard.edu NR 52 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD NOV PY 2016 VL 38 IS 11 BP 1717 EP 1721 DI 10.1002/hed.24494 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EC8CG UT WOS:000388367200020 PM 27131049 ER PT J AU Edelman, EJ Gordon, KS Tate, JP Becker, WC Bryant, K Crothers, K Gaither, JR Gibert, CL Gordon, AJ Marshall, BDL Rodriguez-Barradas, MC Samet, JH Skanderson, M Justice, AC Fiellin, DA AF Edelman, E. J. Gordon, K. S. Tate, J. P. Becker, W. C. Bryant, K. Crothers, K. Gaither, J. R. Gibert, C. L. Gordon, A. J. Marshall, B. D. L. Rodriguez-Barradas, M. C. Samet, J. H. Skanderson, M. Justice, A. C. Fiellin, D. A. TI The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy SO HIV MEDICINE LA English DT Article DE analgesics; antiretroviral therapy; CD4 lymphocyte count; disease progression; HIV; opioid ID HUMAN-IMMUNODEFICIENCY-VIRUS; ILLICIT DRUG-USE; COMMUNITY-BASED COHORT; VETERANS AGING COHORT; DISEASE PROGRESSION; TREATMENT OUTCOMES; UNINFECTED PATIENTS; RHESUS MACAQUES; INDIGENT ADULTS; IMMUNE FUNCTION AB Objectives Certain prescribed opioids have immunosuppressive properties, yet their impact on clinically relevant outcomes, including antiretroviral therapy (ART) response among HIV-infected patients, remains understudied. Methods Using the Veterans Aging Cohort Study data, we conducted a longitudinal analysis of 4358 HIV-infected patients initiating ART between 2002 and 2010 and then followed them for 24 months. The primary independent variable was prescribed opioid duration, categorized using pharmacy data as none prescribed, short-term (< 90 days) and long-term (>= 90 days). Outcomes included CD4 cell count over time. Analyses adjusted for demographics, comorbid conditions, ART type and year of initiation, and overall disease severity [ascertained with the Veterans Aging Cohort Study (VACS) Index]. Sensitivity analyses examined whether effects varied according to baseline CD4 cell count, achievement of viral load suppression, and opioid properties (i.e. dose and known immunosuppressive properties). Results Compared to those with none, patients with short-term opioids had a similar increase in CD4 cell count (mean rise per year: 74 vs. 68 cells/mu L; P = 0.11), as did those with long-term prescribed opioids (mean rise per year: 74 vs. 75 cells/mu L; P = 0.98). In sensitivity analysis, compared with no opioids, the effects of short-term prescribed opioids were statistically significant among those with a baseline CD4 cell count >= 500 cells/mu L (mean rise per year: 52 cells/mu L for no opioids vs. 20 cells/mu L for short-term opioids; P = 0.04); findings were otherwise unchanged. Conclusions Despite immunosuppressive properties intrinsic to opioids, prescribed opioids appeared to have no effect on CD4 cell counts over 24 months among HIV-infected patients initiating ART. C1 [Edelman, E. J.; Tate, J. P.; Becker, W. C.; Gaither, J. R.; Justice, A. C.; Fiellin, D. A.] Yale Univ, Sch Med, POB 208025, New Haven, CT 06520 USA. [Edelman, E. J.; Justice, A. C.; Fiellin, D. A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA. [Gordon, K. S.; Tate, J. P.; Becker, W. C.; Gaither, J. R.; Skanderson, M.; Justice, A. C.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Bryant, K.] NIAAA, HIV AIDS Program, Bethesda, MD USA. [Crothers, K.] Univ Washington, Seattle, WA 98195 USA. [Gaither, J. R.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. [Gibert, C. L.] DC Vet Affairs Med Ctr, Washington, DC USA. [Gibert, C. L.] George Washington Univ, Washington, DC USA. [Gordon, A. J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, A. J.] Univ Pittsburgh, Pittsburgh, PA USA. [Marshall, B. D. L.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Houston, TX 77030 USA. [Samet, J. H.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Samet, J. H.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Edelman, EJ (reprint author), Yale Univ, Sch Med, POB 208025, New Haven, CT 06520 USA. EM ejennifer.edelman@yale.edu OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502 FU NCATS NIH HHS [UL1 TR000142]; NIAAA NIH HHS [U10 AA013566]; NIDA NIH HHS [K12 DA033312] NR 79 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD NOV PY 2016 VL 17 IS 10 BP 728 EP 739 DI 10.1111/hiv.12377 PG 12 WC Infectious Diseases SC Infectious Diseases GA EC9DA UT WOS:000388443100003 PM 27186715 ER PT J AU Patel, MS Mohebali, J Shah, JA Markmann, JF Vagefi, PA AF Patel, Madhukar S. Mohebali, Jahan Shah, Jigesh A. Markmann, James F. Vagefi, Parsia A. TI Readmission following liver transplantation: an unwanted occurrence but an opportunity to act SO HPB LA English DT Article ID HOSPITAL READMISSIONS; SURGERY AB Background: Liver transplant (LT) patients are at high risk for readmission. This study sought to identify predictors of readmission following liver transplantation and to evaluate their impact on survival in a region with prolonged waiting list times. Methods: A single center review of adult deceased donor LT's from 2005 to 2015 was performed, with linkage to the UNOS Standard Transplant Analysis and Research registry. Readmission was defined as hospitalization within 90 days of discharge. Logistic regression was used to identify independent predictors of readmission and Kaplan-Meier analysis for survival. Results: 325 patients underwent LT with an overall 90-day readmission rate of 46%. Upon adjusted analysis, predictors of readmission were age (OR 0.97 per year), male gender (OR 0.48), hospital length of stay (OR 1.03 per day), and hepatitis C liver failure (OR 2.37). Readmitted patients demonstrated a significantly lower 5-year survival (75% vs. 88%, p = 0.008) with only one patient (0.7%) dying during initial readmission. Conclusions: Nearly half of all patients are readmitted after LT. As readmission portents decreased survival, an emphasis should be placed on identifying and optimizing those at increased risk. If readmission does occur, however, it presents an opportunity to intervene, as virtually no patients died during initial readmission. C1 [Patel, Madhukar S.; Mohebali, Jahan; Shah, Jigesh A.; Markmann, James F.; Vagefi, Parsia A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Vagefi, PA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,White 521c, Boston, MA 02114 USA. EM mspatel1@partners.org; mohebali.jahan@mgh.harvard.edu; jashah@partners.org; jmarkmann@partners.org; pvagefi@mgh.harvard.edu NR 16 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1365-182X EI 1477-2574 J9 HPB JI HPB PD NOV PY 2016 VL 18 IS 11 BP 936 EP 942 DI 10.1016/j.hpb.2016.08.003 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA EC6LS UT WOS:000388248200011 PM 27642080 ER PT J AU Calabria, A Spinozzi, G Merelli, I Beretta, S Rancoita, P Benedicenti, F Brasca, S Tenderini, E Cesana, D Volpin, M Naldini, L Di Serio, C Milanesi, L Biffi, A Montini AF Calabria, A. Spinozzi, G. Merelli, I. Beretta, S. Rancoita, P. Benedicenti, F. Brasca, S. Tenderini, E. Cesana, D. Volpin, M. Naldini, L. Di Serio, C. Milanesi, L. Biffi, A. Montini TI Molecular characterization of hematopoietic system reconstitution in 7 metachromatic leukodystrophy patients following hematopoietic stem cell gene therapy SO HUMAN GENE THERAPY LA English DT Meeting Abstract CT Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy CY OCT 18-21, 2016 CL Florence, ITALY SP Int Soc Stem Cell Res, Assoc Biologia Cellulare & Differenziamento C1 [Calabria, A.; Spinozzi, G.; Benedicenti, F.; Brasca, S.; Tenderini, E.; Cesana, D.; Volpin, M.; Naldini, L.; Montini] San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy. [Spinozzi, G.; Beretta, S.] Univ Milano Bicocca, Milan, Italy. [Merelli, I.; Beretta, S.; Milanesi, L.] CNR, Inst Biomed Technol, Rome, Italy. [Rancoita, P.; Di Serio, C.] Univ Ctr Stat Biomed Sci, Naples, Italy. [Biffi, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Naldini, L.] Univ Vita Salute San Raffaele, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2016 VL 27 IS 11 MA P230 BP A115 EP A116 PG 2 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EC4QT UT WOS:000388119200383 ER PT J AU Downey, RJ Wu, HJ Riester, M Moreira, A Michor, F AF Downey, R. J. Wu, H. J. Riester, M. Moreira, A. Michor, F. TI A stem cell oriented phylogeny of cancers derived novel cancer gene expression signature in all undifferentiated cancers as a therapeutic target SO HUMAN GENE THERAPY LA English DT Meeting Abstract CT Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy CY OCT 18-21, 2016 CL Florence, ITALY SP Int Soc Stem Cell Res, Assoc Biologia Cellulare & Differenziamento C1 [Downey, R. J.; Riester, M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Wu, H. J.; Michor, F.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Moreira, A.] NYU Med Ctr, New York, NY 10016 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2016 VL 27 IS 11 MA OR36 BP A36 EP A37 PG 2 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EC4QT UT WOS:000388119200126 ER PT J AU Joung, JK AF Joung, J. K. TI Genome editing using CRISPR-Cas nucleases SO HUMAN GENE THERAPY LA English DT Meeting Abstract CT Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy CY OCT 18-21, 2016 CL Florence, ITALY SP Int Soc Stem Cell Res, Assoc Biologia Cellulare & Differenziamento C1 [Joung, J. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Joung, J. K.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2016 VL 27 IS 11 MA INV21 BP A7 EP A7 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EC4QT UT WOS:000388119200024 ER PT J AU Rothe, M Schwarzer, A Talbot, SR Dittrich-Breiholz, O Staal, FJT Havenga, MJ Thrasher, AJ Gaspar, HB Biasco, L Modlich, U Baum, C Schambach, A AF Rothe, M. Schwarzer, A. Talbot, S. R. Dittrich-Breiholz, O. Staal, F. J. T. Havenga, M. J. Thrasher, A. J. Gaspar, H. B. Biasco, L. Modlich, U. Baum, C. Schambach, A. TI New molecular surrogate assay for genotoxicity assessment (SAGA) SO HUMAN GENE THERAPY LA English DT Meeting Abstract CT Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy CY OCT 18-21, 2016 CL Florence, ITALY SP Int Soc Stem Cell Res, Assoc Biologia Cellulare & Differenziamento C1 [Rothe, M.; Schwarzer, A.; Talbot, S. R.; Dittrich-Breiholz, O.; Baum, C.; Schambach, A.] Hannover Med Sch, Hannover, Germany. [Staal, F. J. T.] Leiden Univ, Med Ctr, Leiden, Netherlands. [Thrasher, A. J.; Gaspar, H. B.; Biasco, L.] UCL, Inst Child Hlth, London, England. [Modlich, U.] Paul Ehrlich Inst, Langen, Hessen, Germany. [Havenga, M. J.] Batavia Biosci, Leiden, Netherlands. [Biasco, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2016 VL 27 IS 11 MA OR47 BP A40 EP A40 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EC4QT UT WOS:000388119200137 ER PT J AU Saha, D Martuza, RL Rabkin, SD AF Saha, D. Martuza, R. L. Rabkin, S. D. TI Immunovirotherapy in combination with immune checkpoint inhibitors for treating glioblastoma stem cell-derived tumors SO HUMAN GENE THERAPY LA English DT Meeting Abstract CT Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy CY OCT 18-21, 2016 CL Florence, ITALY SP Int Soc Stem Cell Res, Assoc Biologia Cellulare & Differenziamento C1 [Saha, D.; Martuza, R. L.; Rabkin, S. D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Saha, D.; Martuza, R. L.; Rabkin, S. D.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2016 VL 27 IS 11 MA OR21 BP A32 EP A32 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EC4QT UT WOS:000388119200111 ER PT J AU Sereni, L Castiello, MC Anselmo, A Marangoni, F Ferrua, F Inverso, D Aiolfi, R Draghici, E Thrasher, AJ Notarangelo, LD Iannacone, M Aiuti, A Bosticardo, M Villa, A AF Sereni, L. Castiello, M. C. Anselmo, A. Marangoni, F. Ferrua, F. Inverso, D. Aiolfi, R. Draghici, E. Thrasher, A. J. Notarangelo, L. D. Iannacone, M. Aiuti, A. Bosticardo, M. Villa, A. TI Intrinsic defect in Was-/- platelets: studies in conditional mouse model and WAS gene therapy treated patients SO HUMAN GENE THERAPY LA English DT Meeting Abstract CT Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy CY OCT 18-21, 2016 CL Florence, ITALY SP Int Soc Stem Cell Res, Assoc Biologia Cellulare & Differenziamento C1 [Sereni, L.; Castiello, M. C.; Draghici, E.; Aiuti, A.; Bosticardo, M.; Villa, A.] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy. [Sereni, L.; Ferrua, F.; Aiuti, A.] Univ Vita Salute San Raffaele, Milan, Italy. [Anselmo, A.] Humanitas Clin & Res Ctr, Milan, Italy. [Marangoni, F.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA USA. [Ferrua, F.; Aiuti, A.] IRCCS San Raffaele Sci Inst, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy. [Inverso, D.; Aiolfi, R.; Iannacone, M.] Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Milan, Italy. [Thrasher, A. J.] UCL, Inst Child Hlth, Mol Immunol Unit, London, England. [Notarangelo, L. D.] Harvard Med Sch, Childrens Hosp, Div Immunol, Boston, MA USA. [Villa, A.] CNR, Milan Unit, Ist Ric Genet & Biomed, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2016 VL 27 IS 11 MA OR53 BP A42 EP A42 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EC4QT UT WOS:000388119200143 ER PT J AU Briet, JP Houwert, RM Hageman, MGJS Hietbrink, F Ring, DC Verleisdonk, EJJM AF Briet, Jan Paul Houwert, Roderick M. Hageman, Michiel G. J. S. Hietbrink, Falco Ring, David C. Verleisdonk, Egbert Jan J. M. TI Factors associated with pain intensity and physical limitations after lateral ankle sprains SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Ankle sprain; Pain self-efficacy; Depression; Ankle ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CATASTROPHIZING SCALE; 2-ITEM QUESTIONNAIRE; ORTHOPEDIC TRAUMA; LIGAMENT INJURIES; ARM PAIN; DEPRESSION; DISABILITY; VALIDITY AB Background: Swelling, tenderness, and ecchymosis don't correlate with time to functional recovery in patients with a lateral ankle sprain. It is established that psychosocial factors such as symptoms of depression and low pain self-efficacy correlate with pain intensity and magnitude of limitations in patients with musculoskeletal disorders. Objective: We studied the correlation between pain self-efficacy or symptoms of depression and (1) ankle specific limitations and (2) pain intensity in patients with a lateral ankle sprain. Further we explored the correlation between estimation of sprain severity (grade) and (3) pain intensity or magnitude of ankle specific limitations. Design: Eighty-four patients with a lateral ankle sprain prospectively completed the Pain Self Efficacy Questionnaire, the Olerud Molander Ankle Score, Ordinal scale of Pain and the Patient Health Questionnaire-2 at enrollment and the Olerud Molander Ankle Score and the Ordinal scale of Pain three weeks after the injury. Factors associated with higher ankle specific limitations and symptoms were investigated in bivariable and multivariable analysis. Results: When accounting for confounding factors, greater self-efficacy (p = 0.01) and older age (p < 0.01) were significantly associated with greater ankle specific symptoms and limitations three weeks after the injury and explained 22% of the variability in ankle specific limitations and symptoms. There was no correlation between the grade of the sprain and pain intensity or ankle specific limitations or symptoms. Conclusions: Psychosocial factors (adaptiveness in response to pain in particular) explain more of the variation in symptoms and limitations after ankle sprain than the degree of pathophysiology. The influence of adaptive illness descriptions and recovery strategies based on methods for improving self-efficacy (i.e. cognitive behavioral therapy) might enhance and speed recovery from ankle injuries and merit additional investigation. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Briet, Jan Paul; Verleisdonk, Egbert Jan J. M.] Diakonessenhuis Utrecht, Dept Surg, Bosboomstr 1, NL-3582KE Utrecht, Netherlands. [Houwert, Roderick M.] Utrecht Traumactr, Utrecht, Netherlands. [Hageman, Michiel G. J. S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA. [Hietbrink, Falco] Dept Surg UMC Utrecht, Heidelberglaan 100,PO 85500, NL-3508 GA Utrecht, Netherlands. [Ring, David C.] New Dell Med Ctr, Dept Surg & Perioperat Care, Austin, TX USA. RP Briet, JP (reprint author), Diakonessenhuis Utrecht, Dept Surg, Bosboomstr 1, NL-3582KE Utrecht, Netherlands. EM jp.briet@gmail.com FU Cornelis Visser Foundation; Diakonessenhuis Utrecht and Zeist FX This study was supported by the Cornelis Visser Foundation. We would like to thank the Cast technicians form the Diakonessenhuis Utrecht and Zeist for their support and assistance in conducting this study. NR 46 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 EI 1879-0267 J9 INJURY JI Injury-Int. J. Care Inj. PD NOV PY 2016 VL 47 IS 11 BP 2565 EP 2569 DI 10.1016/j.injury.2016.09.016 PG 5 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA EC5IE UT WOS:000388167000026 PM 27659849 ER PT J AU Costa, SMR Isganaitis, E Matthews, TJ Hughes, K Daher, G Dreyfuss, JM da Silva, GAP Patti, ME AF Costa, S. M. R. Isganaitis, E. Matthews, T. J. Hughes, K. Daher, G. Dreyfuss, J. M. da Silva, G. A. P. Patti, M-E TI Maternal obesity programs mitochondrial and lipid metabolism gene expression in infant umbilical vein endothelial cells SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID INSULIN-RESISTANCE; OXIDATIVE-PHOSPHORYLATION; FETAL NUTRITION; ADIPOSE-TISSUE; IN-UTERO; ACID; MICE; DISEASE; PLASMA; LIFE AB BACKGROUND/OBJECTIVES: Maternal obesity increases risk for childhood obesity, but molecular mechanisms are not well understood. We hypothesized that primary umbilical vein endothelial cells (HUVEC) from infants of overweight and obese mothers would harbor transcriptional patterns reflecting offspring obesity risk. SUBJECTS/METHODS: In this observational cohort study, we recruited 13 lean (pre-pregnancy body mass index (BMI) <25.0 kg m(-2)) and 24 overweight-obese ('ov-ob', BMI >= 25.0 kg m(-2)) women. We isolated primary HUVEC, and analyzed both gene expression (Primeview, Affymetrix) and cord blood levels of hormones and adipokines. RESULTS: A total of 142 transcripts were differentially expressed in HUVEC from infants of overweight-obese mothers (false discovery rate, FDR<0.05). Pathway analysis revealed that genes involved in mitochondrial and lipid metabolism were negatively correlated with maternal BMI (FDR<0.05). To test whether these transcriptomic patterns were associated with distinct nutrient exposures in the setting of maternal obesity, we analyzed the cord blood lipidome and noted significant increases in the levels of total free fatty acids (lean: 95.5 +/- 37.1 mu g ml(-1), ov-ob: 124.1 +/- 46.0 mu g ml (-1), P = 0.049), palmitate (lean: 34.5 +/- 12.7 mu g ml(-1), ov-ob: 46.3 +/- 18.4 mu g ml(-1), P=0.03) and stearate (lean: 20.8 +/- 8.2 mu g ml -1, ov-ob: 29.7 +/- 17.2 mu g ml(-1), P = 0.04), in infants of overweight-obese mothers. CONCLUSIONS: Prenatal exposure to maternal obesity alters HUVEC expression of genes involved in mitochondrial and lipid metabolism, potentially reflecting developmentally programmed differences in oxidative and lipid metabolism. C1 [Costa, S. M. R.; da Silva, G. A. P.] Univ Fed Pernambuco, Recife, PE, Brazil. [Costa, S. M. R.; Isganaitis, E.; Matthews, T. J.; Hughes, K.; Daher, G.; Dreyfuss, J. M.; Patti, M-E] Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. [Costa, S. M. R.; Isganaitis, E.; Patti, M-E] Harvard Med Sch, Boston, MA USA. RP Isganaitis, E (reprint author), Joslin Diabet Ctr, Div Res, Dept Genet & Epidemiol, 1 Joslin Pl,Room 607, Boston, MA 02215 USA.; Isganaitis, E (reprint author), Harvard Med Sch, Div Pediat, 1 Joslin Pl,Room 607, Boston, MA 02215 USA. EM elvira.isganaitis@joslin.harvard.edu FU Fullbright Fellowship; NICHD K99/R00 Award [HD064793]; Diabetes Research Center (DRC) [DK036836]; National Council of Technological and Scientific Development of Brazil [CNPq 472031/2010] FX We are thankful for our research support. SMRC was supported by a Fullbright Fellowship. EI was supported by NICHD K99/R00 Award HD064793. JMD and the Joslin Bioinformatics Core are supported by a Diabetes Research Center (DRC) grant (DK036836). GAPdS was supported by a grant from the National Council of Technological and Scientific Development of Brazil (CNPq 472031/2010). We are grateful for the services of the Vanderbilt Lipid Core. NR 53 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD NOV PY 2016 VL 40 IS 11 BP 1627 EP 1634 DI 10.1038/ijo.2016.142 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EC4TT UT WOS:000388127600004 PM 27531045 ER PT J AU Ray, GT Kulldorff, M Asgari, MM AF Ray, G. Thomas Kulldorff, Martin Asgari, Maryam M. TI Geographic Clusters of Basal Cell Carcinoma in a Northern California Health Plan Population SO JAMA DERMATOLOGY LA English DT Article ID CUTANEOUS MELANOMA INCIDENCE; SKIN-CANCER; NEIGHBORHOOD DEPRIVATION; ULTRAVIOLET EXPOSURE; UNITED-STATES; US WOMEN; RISK; ASSOCIATION; RADIATION AB IMPORTANCE Rates of skin cancer, including basal cell carcinoma (BCC), the most common cancer, have been increasing over the past 3 decades. A better understanding of geographic clustering of BCCs can help target screening and prevention efforts. OBJECTIVE Present amethodology to identify spatial clusters of BCC and identify such clusters in a northern California population. DESIGN, SETTING, AND PARTICIPANTS This retrospective study used a BCC registry to determine rates of BCC by census block group, and used spatial scan statistics to identify statistically significant geographic clusters of BCCs, adjusting for age, sex, and socioeconomic status. The study population consisted of white, non-Hispanic members of Kaiser Permanente Northern California during years 2011 and 2012. MAIN OUTCOMES AND MEASURES Statistically significant geographic clusters of BCC as determined by spatial scan statistics. RESULTS Spatial analysis of 28 408 individuals who received a diagnosis of at least 1 BCC in 2011 or 2012 revealed distinct geographic areas with elevated BCC rates. Among the 14 counties studied, BCC incidence ranged from 661 to 1598 per 100 000 person-years. After adjustment for age, sex, and neighborhood socioeconomic status, a pattern of 5 discrete geographic clusters emerged, with a relative risk ranging from 1.12 (95% CI, 1.03-1.21; P = .006) for a cluster in eastern Sonoma and northern Napa Counties to 1.40 (95% CI, 1.15-1.71; P < .001) for a cluster in east Contra Costa and west San Joaquin Counties, compared with persons residing outside that cluster. CONCLUSIONS AND RELEVANCE In this study of a northern California population, we identified several geographic clusters with modestly elevated incidence of BCC. Knowledge of geographic clusters can help inform future research on the underlying etiology of the clustering including factors related to the environment, health care access, or other characteristics of the resident population, and can help target screening efforts to areas of highest yield. C1 [Ray, G. Thomas] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Kulldorff, Martin] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA. [Kulldorff, Martin; Asgari, Maryam M.] Harvard Med Sch, Boston, MA USA. [Asgari, Maryam M.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Ray, GT (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM tom.ray@kp.org FU National Cancer Institute (Cancer Research Network Across Health Care Systems) [U19CA79689]; National Cancer Institute [RO1CA165057] FX This study was supported in part by the National Cancer Institute (Cancer Research Network Across Health Care Systems) grant U19CA79689 (to Dr Asgari), and in part by National Cancer Institute grant RO1CA165057 (to Dr Kulldorff). NR 32 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD NOV PY 2016 VL 152 IS 11 BP 1218 EP 1224 DI 10.1001/jamadermatol.2016.2536 PG 7 WC Dermatology SC Dermatology GA EC6GO UT WOS:000388234700008 PM 27439152 ER PT J AU Das, A Maiti, A Sinha, S AF Das, Avash Maiti, Abhishek Sinha, Shirshendu TI Antidepressant Prescription in the Geriatric Population A Teachable Moment SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Das, Avash] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Maiti, Abhishek] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, 6431 Fannin,MSB 1-134, Houston, TX 77030 USA. [Sinha, Shirshendu] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA. RP Maiti, A (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, 6431 Fannin,MSB 1-134, Houston, TX 77030 USA. EM abhishek.maiti87@gmail.com NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2016 VL 176 IS 11 BP 1608 EP 1609 DI 10.1001/jamainternmed.2016.5535 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EC4KK UT WOS:000388097700008 PM 27668672 ER PT J AU Conley, J O'Brien, CW Leff, BA Bolen, S Zulman, D AF Conley, Jared O'Brien, Colin W. Leff, Bruce A. Bolen, Shari Zulman, Donna TI Alternative Strategies to Inpatient Hospitalization for Acute Medical Conditions A Systematic Review SO JAMA INTERNAL MEDICINE LA English DT Review ID ACUTE PULMONARY-EMBOLISM; COMMUNITY-ACQUIRED PNEUMONIA; DEEP-VEIN THROMBOSIS; SHORT-STAY UNITS; OUTPATIENT TREATMENT; EMERGENCY-DEPARTMENT; UNCOMPLICATED DIVERTICULITIS; FEBRILE NEUTROPENIA; CLINICAL-PRACTICE; EARLY DISCHARGE AB IMPORTANCE Determining innovative approaches that better align health needs to the appropriate setting of care remains a key priority for the transformation of US health care; however, to our knowledge, no comprehensive assessment exists of alternative management strategies to hospital admission for acute medical conditions. OBJECTIVE To examine the effectiveness, safety, and cost of managing acute medical conditions in settings outside of a hospital inpatient unit. EVIDENCE REVIEW MEDLINE, Scopus, CINAHL, and the Cochrane Database of Systematic Reviews (January 1995 to February 2016) were searched for English-language systematic reviews that evaluated alternative management strategies to hospital admission. Two investigators extracted data independently on trial design, eligibility criteria, clinical outcomes, patient experience, and health care costs. The quality of each review was assessed using the revised AMSTAR tool (R-AMSTAR) and the strength of evidence from primary studies was graded according to the Oxford Centre for Evidence-Based Medicine. FINDINGS Twenty-five systematic reviews (representing 123 primary studies) met inclusion criteria. For outpatient management strategies, several acute medical conditions had no significant difference in mortality, disease-specific outcomes, or patient satisfaction compared with inpatient admission. For quick diagnostic units, the evidence was more limited but did demonstrate low mortality rates and high patient satisfaction. For hospital-at-home, a variety of acute medical conditions had mortality rates, disease-specific outcomes, and patient and caregiver satisfaction that were either improved or no different compared with inpatient admission. For observation units, several acute medical conditions were found to have no difference in mortality, a decreased length of stay, and improved patient satisfaction compared to inpatient admission; results for some conditions were more limited. Across all alternative management strategies, cost data were heterogeneous but showed near-universal savings when assessed. CONCLUSIONS AND RELEVANCE For low-risk patients with a range of acute medical conditions, evidence suggests that alternative management strategies to inpatient care can achieve comparable clinical outcomes and patient satisfaction at lower costs. Further study and application of such opportunities for health system redesign is warranted. C1 [Conley, Jared] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA. [Conley, Jared] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [Conley, Jared] Stanford Univ, Clin Excellence Res Ctr, Stanford, CA 94305 USA. [Conley, Jared] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [O'Brien, Colin W.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Leff, Bruce A.] Johns Hopkins Univ, Sch Med, Div Geriatr Med, Ctr Transformat Geriatr Res, Baltimore, MD USA. [Bolen, Shari] Case Western Reserve Univ, MetroHlth, Ctr Hlth Care Res & Policy, Cleveland, OH 44106 USA. [Bolen, Shari] MetroHlth Med Ctr, Div Gen Internal Med, Cleveland, OH USA. [Bolen, Shari] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Zulman, Donna] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Zulman, Donna] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA. RP Conley, J (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA. EM jconley@mgh.harvard.edu FU Stanford University; Levy Foundation; VA Health Services Research and Development Service career development award FX This work was supported by Stanford University (Dr Conley and Mr O'Brien), the Levy Foundation (Dr Conley), and a VA Health Services Research and Development Service career development award (Dr Zulman). NR 48 TC 0 Z9 0 U1 5 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2016 VL 176 IS 11 BP 1693 EP 1702 DI 10.1001/jamainternmed.2016.5974 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA EC4KK UT WOS:000388097700025 PM 27695822 ER PT J AU Percac-Lima, S Atlas, SJ AF Percac-Lima, Sanja Atlas, Steven J. TI Patient Navigation for Comprehensive Cancer Screenings in High-Risk Patients Reply SO JAMA INTERNAL MEDICINE LA English DT Letter ID TRIAL; CARE C1 [Percac-Lima, Sanja; Atlas, Steven J.] Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. [Percac-Lima, Sanja] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, Chelsea, MA USA. RP Percac-Lima, S (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM spercaclima@mgh.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2016 VL 176 IS 11 BP 1726 EP 1726 DI 10.1001/jamainternmed.2016.6326 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EC4KK UT WOS:000388097700043 PM 27820646 ER PT J AU Schopfer, DW Takemoto, S Allsup, K Helfrich, CD Ho, PM Forman, DE Whooley, MA AF Schopfer, David W. Takemoto, Steven Allsup, Kelly Helfrich, Christian D. Ho, P. Michael Forman, Daniel E. Whooley, Mary A. TI Notice of Retraction and Replacement. Schopfer DW, et al. Cardiac Rehabilitation Use Among Veterans With Ischemic Heart Disease. JAMA Intern Med. 2014; 174(10): 1687-1689 SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Schopfer, David W.; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Schopfer, David W.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Takemoto, Steven] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA. [Allsup, Kelly; Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res & Clin Ctr, Pittsburgh, PA USA. [Helfrich, Christian D.] Vet Affairs Puget Sound Healthcare Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Ho, P. Michael] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA. RP Schopfer, DW (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM david.schopfer@ucsf.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2016 VL 176 IS 11 BP 1726 EP + DI 10.1001/jamainternmed.2016.5831 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EC4KK UT WOS:000388097700044 PM 27723859 ER PT J AU Schnipper, LE Abel, GA AF Schnipper, Lowell E. Abel, Gregory A. TI Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health SO JAMA ONCOLOGY LA English DT Editorial Material ID CANCER; IMPACT C1 [Schnipper, Lowell E.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA. [Schnipper, Lowell E.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA USA. [Abel, Gregory A.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. RP Schnipper, LE (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA. EM lschnipp@bidmc.harvard.edu NR 7 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV 1 PY 2016 VL 2 IS 11 BP 1397 EP 1398 DI 10.1001/jamaoncol.2016.2463 PG 2 WC Oncology SC Oncology GA EC6GU UT WOS:000388235300002 PM 27532895 ER PT J AU Vaz-Luis, I Burstein, HJ AF Vaz-Luis, Ines Burstein, Harold J. TI Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer SO JAMA ONCOLOGY LA English DT Editorial Material ID SURVIVAL; TRIAL C1 [Vaz-Luis, Ines; Burstein, Harold J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. RP Burstein, HJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM hal_burstein@dfci.harvard.edu NR 8 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV 1 PY 2016 VL 2 IS 11 BP 1399 EP 1400 DI 10.1001/jamaoncol.2016.3631 PG 2 WC Oncology SC Oncology GA EC6GU UT WOS:000388235300003 PM 27631400 ER PT J AU Esselen, KM Cronin, AM Bixel, K Bookman, MA Burger, RA Cohn, DE Cristea, M Griggs, JJ Levenback, CF Mantia-Smaldone, G Meyer, LA Matulonis, UA Niland, JC Sun, C O'Malley, DM Wright, AA AF Esselen, Katharine M. Cronin, Angel M. Bixel, Kristin Bookman, Michael A. Burger, Robert A. Cohn, David E. Cristea, Mihaela Griggs, Jennifer J. Levenback, Charles F. Mantia-Smaldone, Gina Meyer, Larissa A. Matulonis, Ursula A. Niland, Joyce C. Sun, Charlotte O'Malley, David M. Wright, Alexi A. TI Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer SO JAMA ONCOLOGY LA English DT Article ID POSTTREATMENT SURVEILLANCE; TRIAL; CARE; IMPACT; CA125; DIAGNOSIS; SURVIVAL; SOCIETY; WOMEN; COST AB IMPORTANCE A 2009 randomized clinical trial demonstrated that using cancer antigen 125 (CA-125) tests for routine surveillance in ovarian cancer increases the use of chemotherapy and decreases patients' quality of life without improving survival, compared with clinical observation. The Society of Gynecologic Oncology guidelines categorize CA-125 testing as optional and discourage the use of radiographic imaging for routine surveillance. To date, few studies have examined the use of CA-125 tests in clinical practice. OBJECTIVES To examine the use of CA-125 tests and computed tomographic (CT) scans in clinical practice before and after the 2009 randomized clinical trial and to estimate the economic effect of surveillance testing. DESIGN, SETTING, AND PARTICIPANTS A prospective cohort of 1241women with ovarian cancer in clinical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Cancer Institute-designated cancer centers between January 1, 2004, and December 31, 2011, was followed up through December 31, 2012, to study the use of CA-125 tests and CT scans before and after 2009. Data analysis was conducted from April 9, 2014, to March 28, 2016. MAIN OUTCOMES AND MEASURES The use of CA-125 tests and CT scans before and after 2009. Secondary outcomes included the time from CA-125 markers doubling to retreatment among women who experienced a rise in CA-125 markers before and after 2009, and the costs associated with surveillance testing using 2015 Medicare reimbursement rates. RESULTS Among 1241 women (mean [SD] age 59 [12] years; 1112 white [89.6%]), the use of CA-125 testing and CT scans was similar during the study period. During 12 months of surveillance, the cumulative incidence of patients undergoing 3 or more CA-125 tests was 86% in 2004-2009 vs 91% in 2010-2012 (P =.95), and the cumulative incidence of patients undergoing more than 1 CT scan was 81% in 2004-2009 vs 78% in 2010-2012 (P =.50). Among women whose CA-125 markers doubled (n = 511), there was no significant difference in the time to retreatment with chemotherapy before and after 2009 (median, 2.8 vs 3.5 months; P = 40). During a 12-month period, there was a mean of 4.6 CA-125 tests and 1.7 CT scans performed per patient, resulting in a US population surveillance cost estimate of $1 999 029 per year for CA-125 tests alone and $ 16 194 647 per year with CT scans added. CONCLUSIONS AND RELEVANCE CA-125 tests and CT scans are still routinely used for surveillance testing in patients with ovarian cancer, although their benefit has not been proven and their use may have significant implications for patients' quality of life as well as costs. C1 [Esselen, Katharine M.] Beth Israel Deaconess Med Ctr, Dept Obstet Gynecol, Div Gynecol Oncol, Boston, MA 02215 USA. [Esselen, Katharine M.] Harvard Med Sch, Boston, MA USA. [Cronin, Angel M.; Matulonis, Ursula A.; Wright, Alexi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Cronin, Angel M.; Matulonis, Ursula A.; Wright, Alexi A.] Harvard Med Sch, Boston, MA USA. [Bixel, Kristin; Cohn, David E.; O'Malley, David M.] Ohio State Univ, Ctr Comprehens Canc, Dept Obstet & Gynecol, Div Gynecol Oncol, Columbus, MS USA. [Bookman, Michael A.] US Oncol Res & Arizona Oncol, Tucson, AZ USA. [Burger, Robert A.] Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA. [Cristea, Mihaela; Niland, Joyce C.] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA. [Griggs, Jennifer J.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Div Hematol & Oncol, Ann Arbor, MI USA. [Griggs, Jennifer J.] Univ Michigan, Ctr Comprehens Canc, Div Hematol, Ann Arbor, MI USA. [Griggs, Jennifer J.] Univ Michigan, Ctr Comprehens Canc, Dept Hlth Management, Ann Arbor, MI USA. [Levenback, Charles F.; Meyer, Larissa A.; Sun, Charlotte] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Reprod Med, Div Surg, Houston, TX USA. [Mantia-Smaldone, Gina] Fox Chase Canc Ctr, Div Gynecol Oncol, Dept Surg Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. RP Esselen, KM (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Obstet Gynecol, Gynecol Oncol, 330 Brookline Ave, Boston, MA 02215 USA. EM kesselen@bidmc.harvard.edu FU NCI NIH HHS [K07 CA166210] NR 27 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV 1 PY 2016 VL 2 IS 11 BP 1427 EP 1433 DI 10.1001/jamaoncol.2016.1842 PG 7 WC Oncology SC Oncology GA EC6GU UT WOS:000388235300011 PM 27442965 ER PT J AU Shu, CA Pike, MC Jotwani, AR Friebel, TM Soslow, RA Levine, DA Nathanson, KL Konner, JA Arnold, AG Bogomolniy, F Dao, F Olvera, N Bancroft, EK Goldfrank, DJ Stadler, ZK Robson, ME Brown, CL Leitao, MM Abu-Rustum, NR Aghajanian, CA Blum, JL Neuhausen, SL Garber, JE Daly, MB Isaacs, C Eeles, RA Ganz, PA Barakat, RR Offit, K Domchek, SM Rebbeck, TR Kauff, ND AF Shu, Catherine A. Pike, Malcolm C. Jotwani, Anjali R. Friebel, Tara M. Soslow, Robert A. Levine, Douglas A. Nathanson, Katherine L. Konner, Jason A. Arnold, Angela G. Bogomolniy, Faina Dao, Fanny Olvera, Narciso Bancroft, Elizabeth K. Goldfrank, Deborah J. Stadler, Zsofia K. Robson, Mark E. Brown, Carol L. Leitao, Mario M., Jr. Abu-Rustum, Nadeem R. Aghajanian, Carol A. Blum, Joanne L. Neuhausen, Susan L. Garber, Judy E. Daly, Mary B. Isaacs, Claudine Eeles, Rosalind A. Ganz, Patricia A. Barakat, Richard R. Offit, Kenneth Domchek, Susan M. Rebbeck, Timothy R. Kauff, Noah D. TI Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations SO JAMA ONCOLOGY LA English DT Article ID PAPILLARY-SEROUS-CARCINOMA; BENIGN GYNECOLOGIC DISEASE; BREAST-CANCER; GERMLINE MUTATIONS; ENDOMETRIAL CANCER; OVARIAN-CANCER; PROSPECTIVE COHORT; CORPUS CANCER; TAMOXIFEN USE; CARRIERS AB IMPORTANCE The link between BRCA mutations and uterine cancer is unclear. Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations (BRCA+ women), the role of concomitant hysterectomy is controversial. OBJECTIVE To determine the risk for uterine cancer and distribution of specific histologic subtypes in BRCA+ women after RRSO without hysterectomy. DESIGN, SETTING, AND PARTICIPANTS This multicenter prospective cohort study included 1083 women with a deleterious BRCA1 or BRCA2 mutation identified from January 1, 1995, to December 31, 2011, at 9 academic medical centers in the United States and the United Kingdom who underwent RRSO without a prior or concomitant hysterectomy. Of these, 627 participants were BRCA1+; 453, BRCA2+; and 3, both. Participants were prospectively followed up for a median 5.1 (interquartile range [IQR], 3.0-8.4) years after ascertainment, BRCA testing, or RRSO (whichever occurred last). Follow up data available through October 14, 2014, were included in the analyses. Censoring occurred at uterine cancer diagnosis, hysterectomy, last follow-up, or death. New cancers were categorized by histologic subtype, and available tumors were analyzed for loss of the wild-type BRCA gene and/or protein expression. MAIN OUTCOMES AND MEASURES Incidence of uterine corpus cancer in BRCA+ women who underwent RRSO without hysterectomy compared with rates expected from the Surveillance, Epidemiology, and End Results database. RESULTS Among the 1083 women women who underwent RRSO without hysterectomy at a median age 45.6 (IQR: 40.9 -52.5), 8 incident uterine cancers were observed (4.3 expected; observed to expected [O:E] ratio, 1.9; 95% CI, 0.8-3.7; P = .09). No increased risk for endometrioid endometrial carcinoma or sarcoma was found after stratifying by subtype. Five serous and/or serous-like (serous/serous-like) endometrial carcinomas were observed (4 BRCA1+ and 1 BRCA2+) 7.2 to 12.9 years after RRSO (BRCA1: 0.18 expected [O:E ratio, 22.2; 95% CI, 6.1-56.9; P <.001]; BRCA2: 0.16 expected [O:E ratio, 6.4; 95% CI, 0.2-35.5; P = .15]). Tumor analyses confirmed loss of the wild-type BRCA1 gene and/or protein expression in all 3 available serous/ serous-like BRCA1+ tumors. CONCLUSIONS AND RELEVANCE Although the overall risk for uterine cancer after RRSO was not increased, the risk for serous/ serous-like endometrial carcinoma was increased in BRCA1+ women. This risk should be considered when discussing the advantages and risks of hysterectomy at the time of RRSO in BRCA1+ women. C1 [Kauff, Noah D.] Duke Canc Inst, Duke Univ Hlth Syst, Clin Canc Genet Program, Box 3607 DUMC, Durham, NC 27710 USA. [Shu, Catherine A.] Columbia Univ, Div Hematol Oncol, Med Ctr, New York, NY USA. [Pike, Malcolm C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA. [Jotwani, Anjali R.; Arnold, Angela G.; Stadler, Zsofia K.; Robson, Mark E.; Offit, Kenneth] Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, 1275 York Ave, New York, NY 10021 USA. [Friebel, Tara M.; Garber, Judy E.; Rebbeck, Timothy R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Gynecol Pathol Serv, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. [Levine, Douglas A.; Bogomolniy, Faina; Dao, Fanny; Olvera, Narciso; Goldfrank, Deborah J.; Brown, Carol L.; Leitao, Mario M., Jr.; Abu-Rustum, Nadeem R.; Barakat, Richard R.] Mem Sloan Kettering Canc Ctr, Gynecol Serv, Dept Surg, 1275 York Ave, New York, NY 10021 USA. [Nathanson, Katherine L.; Domchek, Susan M.] Univ Penn, Perelman Sch Med, Basser Ctr BRCA, Philadelphia, PA 19104 USA. [Nathanson, Katherine L.; Domchek, Susan M.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Konner, Jason A.; Aghajanian, Carol A.] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Bancroft, Elizabeth K.; Eeles, Rosalind A.] Serv Fdn Trust, Royal Marsden Natl Hlth, Inst Canc Res, London, England. [Robson, Mark E.] Mem Sloan Kettering Canc Ctr, Breast Med Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Blum, Joanne L.] Baylor Charles Sammons Canc Ctr, Texas Oncol, Dallas, TX USA. [Neuhausen, Susan L.] City Hope Natl Med Ctr, Dept Populat Sci, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Daly, Mary B.] Fox Chase Canc Ctr, Dept Clin Genet, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Isaacs, Claudine] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol & Med, Washington, DC USA. [Ganz, Patricia A.] Univ Calif Los Angeles, UCLA Schools Publ Hlth & Med, Los Angeles, CA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Ctr Canc Prevent & Control Res, Los Angeles, CA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. [Kauff, Noah D.] Duke Univ Hlth Syst, Duke Canc Inst, Clin Canc Genet Program, Durham, NC USA. RP Kauff, ND (reprint author), Duke Canc Inst, Duke Univ Hlth Syst, Clin Canc Genet Program, Box 3607 DUMC, Durham, NC 27710 USA. EM noah.kauff@duke.edu NR 45 TC 4 Z9 4 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV 1 PY 2016 VL 2 IS 11 BP 1434 EP 1440 DI 10.1001/jamaoncol.2016.1820 PG 7 WC Oncology SC Oncology GA EC6GU UT WOS:000388235300012 PM 27367496 ER PT J AU Spring, LM Gupta, A Reynolds, KL Gadd, MA Ellisen, LW Isakoff, SJ Moy, B Bardia, A AF Spring, Laura M. Gupta, Arjun Reynolds, Kerry L. Gadd, Michele A. Ellisen, Leif W. Isakoff, Steven J. Moy, Beverly Bardia, Aditya TI Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis SO JAMA ONCOLOGY LA English DT Review ID RANDOMIZED PHASE-II; SURGICAL ADJUVANT BREAST; POSTMENOPAUSAL PATIENTS; DOUBLE-BLIND; AROMATASE INHIBITORS; OPTIMAL DURATION; TRIAL; LETROZOLE; ANASTROZOLE; TAMOXIFEN AB IMPORTANCE Estrogen receptor-positive (ER+) tumors of the breast are generally highly responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant treatment for ER+ breast cancer, the role of endocrine therapy in the neoadjuvant setting is unclear. OBJECTIVE To evaluate the effect of neoadjuvant endocrine therapy (NET) on the response rate and the rate of breast conservation surgery (BCS) for ER+ breast cancer. DATA SOURCES Based on PRISMA guidelines, a librarian-led search of PubMed and Ovid MEDLINE was performed to identify eligible trials published from inception to May 15, 2015. The search was performed in May 2015. STUDY SELECTION Inclusion criteria were prospective, randomized, neoadjuvant clinical trials that reported response rates with at least 1 arm incorporating NET (n = 20). Two authors independently analyzed the studies for inclusion. DATA EXTRACTION AND SYNTHESIS Pooled odds ratios (ORs), 95% CIs, and P values were estimated for end points using the fixed-and random-effects statistical model. RESULTS The analysis included 20 studies with 3490 unique patients. Compared with combination chemotherapy, NET as monotherapy with aromatase inhibitors had a similar clinical response rate (OR, 1.08; 95% CI, 0.50-2.35; P =.85; n = 378), radiological response rate (OR, 1.38; 95% CI, 0.92-2.07; P =.12; n = 378), and BCS rate (OR, 0.65; 95% CI, 0.41-1.03; P =.07; n = 334) but with lower toxicity. Aromatase inhibitors were associated with a significantly higher clinical response rate (OR, 1.69; 95% CI, 1.36-2.10; P < .001; n = 1352), radiological response rate (OR, 1.49; 95% CI, 1.18-1.89; P < .001; n = 1418), and BCS rate (OR, 1.62; 95% CI, 1.24-2.12; P < .001; n = 918) compared with tamoxifen. Dual combination therapy with growth factor pathway inhibitors was associated with a higher radiological response rate (OR, 1.59; 95% CI, 1.04-2.43; P =.03; n = 355), but not clinical response rate (OR, 0.76; 95% CI, 0.54-1.07; P = .11; n = 537), compared with endocrine monotherapy. The incidence of pathologic complete response was low (< 10%). CONCLUSIONS AND RELEVANCE Neoadjuvant endocrine therapy, even as monotherapy, is associated with similar response rates as neoadjuvant combination chemotherapy but with significantly lower toxicity, suggesting that NET needs to be reconsidered as a potential option in the appropriate setting. Additional research is needed to develop rational NET combinations and predictive biomarkers to personalize the optimal neoadjuvant strategy for ER+ breast cancer. C1 [Spring, Laura M.; Reynolds, Kerry L.; Gadd, Michele A.; Ellisen, Leif W.; Isakoff, Steven J.; Moy, Beverly; Bardia, Aditya] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, 10 N Grove St,Lawrence House 304, Boston, MA 02114 USA. [Gupta, Arjun] Univ Texas Southwestern Med Ctr, Dept Med, Dallas, TX USA. RP Bardia, A (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, 10 N Grove St,Lawrence House 304, Boston, MA 02114 USA. EM bardia.aditya@mgh.harvard.edu OI Spring, Laura/0000-0001-8904-3514 FU Jerry Younger Grant for Clinical and Translational Breast Cancer Research; National Cancer Institute [5K12CA087723-13, 5T32CA071345-19] FX This study was supported in part by a Jerry Younger Grant for Clinical and Translational Breast Cancer Research. Dr Bardia is supported by National Cancer Institute grant 5K12CA087723-13. Dr Spring is supported by National Cancer Institute grant 5T32CA071345-19. NR 58 TC 1 Z9 2 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV 1 PY 2016 VL 2 IS 11 BP 1477 EP 1486 DI 10.1001/jamaoncol.2016.1897. PG 10 WC Oncology SC Oncology GA EC6GU UT WOS:000388235300018 PM 27367583 ER PT J AU Dryja, TP AF Dryja, Thaddeus P. TI ` Early Insight Into Neovascular Age-Related Macular Degeneration SO JAMA OPHTHALMOLOGY LA English DT Editorial Material C1 [Dryja, Thaddeus P.] Novartis Inst Biomed Res, 22 Windsor St,Fifth Floor, Cambridge, MA 02139 USA. [Dryja, Thaddeus P.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Dryja, TP (reprint author), Novartis Inst Biomed Res, 22 Windsor St,Fifth Floor, Cambridge, MA 02139 USA. EM thaddeus.dryja@novartis.com NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD NOV 1 PY 2016 VL 134 IS 11 BP 1281 EP 1282 DI 10.1001/jamaophthalmol.2016.3031 PG 2 WC Ophthalmology SC Ophthalmology GA EC6GY UT WOS:000388235700018 PM 27657333 ER PT J AU Van Tyne, D Ciolino, JB Wang, J Durand, ML Gilmore, MS AF Van Tyne, Daria Ciolino, Joseph B. Wang, Jay Durand, Marlene L. Gilmore, Michael S. TI Novel Phagocytosis-Resistant Extended-Spectrum beta-Lactamase-Producing Escherichia coli From Keratitis SO JAMA OPHTHALMOLOGY LA English DT Article ID SEQUENCE TYPE 131; MUTATIONS; EMERGENCE; PATTERNS; DOMINANT; STRAIN; GENE AB IMPORTANCE Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are highly antibiotic resistant, and primary ocular infection by ESBL E coli has rarely been reported. A novel mutation conferring phagocytosis resistance would position a strain well to infect the cornea. OBSERVATIONS A woman with recurrent keratitis presented with a corneal ulcer, which was culture positive for ESBL E coli. Resistant to nearly all other antimicrobials, the infection was treated with amikacin and polymyxin B-trimethoprim, and the ulcer resolved over 3 weeks. Analysis of the E coli genome showed it to belong to multilocus sequence type 131 (ST131). This isolate was found to possess a novel deletion in yrfF, an essential regulator of bacterial capsule synthesis. Disruption of yrfF, which confers mucoidy and increased virulence, has not been previously observed in ESBL E coli from any infection site. This novel variant was experimentally proven to cause the mucoid phenotype, and corresponding resistance to phagocytic killing. CONCLUSIONS AND RELEVANCE Increased resistance to immune clearance in an ESBL E coli lineage already known for its virulence is an unsettling development. This phenotype, which likely positioned it as an unusual cause of corneal ulcer, can be easily recognized in the laboratory, which should help limit its spread. C1 [Van Tyne, Daria; Ciolino, Joseph B.; Wang, Jay; Durand, Marlene L.; Gilmore, Michael S.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Harvard Med Sch, 243 Charles St, Boston, MA 02114 USA. [Van Tyne, Daria; Gilmore, Michael S.] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA USA. [Durand, Marlene L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Durand, Marlene L.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Infect Dis Serv, Boston, MA USA. RP Gilmore, MS (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Harvard Med Sch, 243 Charles St, Boston, MA 02114 USA. EM michael_gilmore@meei.harvard.edu FU Public Health Service [EY024285]; Harvard Medical School Department of Ophthalmology for the Massachusetts Eye and Ear Infirmary Infectious Disease Institute; Harvard University-wide Program on Antibiotic Resistance [AI083214]; Research to Prevent Blindness, Inc.; [AI109855] FX This work was supported by Public Health Service grant EY024285, as well as support provided by the Harvard Medical School Department of Ophthalmology for the Massachusetts Eye and Ear Infirmary Infectious Disease Institute. Additional funding was provided by the Harvard University-wide Program on Antibiotic Resistance (AI083214). Dr Van Tyne receives support from grant AI109855, and Dr Ciolino is supported by a Career Development Award from Research to Prevent Blindness, Inc. NR 15 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD NOV 1 PY 2016 VL 134 IS 11 BP 1306 EP 1309 DI 10.1001/jamaophthalmol.2016.3283 PG 4 WC Ophthalmology SC Ophthalmology GA EC6GY UT WOS:000388235700023 PM 27631542 ER PT J AU Gaier, ED Gittinger, JW Cestari, DM Miller, JB AF Gaier, Eric D. Gittinger, John W. Cestari, Dean M. Miller, John B. TI Peripapillary Capillary Dilation in Leber Hereditary Optic Neuropathy Revealed by Optical Coherence Tomographic Angiography SO JAMA OPHTHALMOLOGY LA English DT Letter C1 [Gaier, Eric D.; Gittinger, John W.; Cestari, Dean M.; Miller, John B.] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Miller, JB (reprint author), Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM john_miller@meei.harvard.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD NOV 1 PY 2016 VL 134 IS 11 BP 1332 EP 1334 DI 10.1001/jamaophthalmol.2016.3593 PG 4 WC Ophthalmology SC Ophthalmology GA EC6GY UT WOS:000388235700031 PM 27711925 ER PT J AU Elwy, AR Itani, KMF Bokhour, BG Mueller, NM Glickman, ME Zhao, SB Rosen, AK Lynge, D Perkal, M Brotschi, EA Sanchez, VM Gallagher, TH AF Elwy, A. Rani Itani, Kamal M. F. Bokhour, Barbara G. Mueller, Nora M. Glickman, Mark E. Zhao, Shibei Rosen, Amy K. Lynge, Dana Perkal, Melissa Brotschi, Erica A. Sanchez, Vivian M. Gallagher, Thomas H. TI Surgeons' Disclosures of Clinical Adverse Events SO JAMA SURGERY LA English DT Article ID HARMFUL MEDICAL ERRORS; FALSE DISCOVERY RATE; PHYSICIANS; IMPLEMENTATION; COMMUNICATION; ATTITUDES; PROGRAMS; APOLOGY; BURNOUT; HEALTH AB IMPORTANCE Surgeons are frequently faced with clinical adverse events owing to the nature of their specialty, yet not all surgeons disclose these events to patients. To sustain open disclosure programs, it is essential to understand how surgeons are disclosing adverse events, factors that are associated with reporting such events, and the effect of disclosure on surgeons. OBJECTIVE To quantitatively assess surgeons' reports of disclosure of adverse events and aspects of their experiences with the disclosure process. DESIGN, SETTING, AND PARTICIPANTS An observational study was conducted from January 1, 2011, to December 31, 2013, involving a 21-item baseline questionnaire administered to 67 of 75 surgeons (89%) representing 12 specialties at 3 Veterans Affairs medical centers. Sixty-two surveys of their communication about adverse events and experiences with disclosing such events were completed by 35 of these 67 surgeons (52%). Data were analyzed using mixed linear random-effects and logistic regression models. MAIN OUTCOMES AND MEASURES Self-reports of disclosure assessed by 8 items from guidelines and pilot research, surgeons' perceptions of the adverse event, reported personal effects from disclosure, and baseline attitudes toward disclosure. RESULTS Most of the surgeons completing the web-based surveys (41 responses from men and 21 responses from women) used 5 of the 8 recommended disclosure items: explained why the event happened (55 of 60 surveys [92%]), expressed regret for what happened (52 of 60 [87%]), expressed concern for the patient's welfare (57 of 60 [95%]), disclosed the adverse event within 24 hours (58 of 60 [97%]), and discussed steps taken to treat any subsequent problems (59 of 60 [98%]). Fewer surgeons apologized to patients (33 of 60 [55%]), discussed whether the event was preventable (33 of 60 [55%]), or how recurrences could be prevented (19 of 59 [32%]). Surgeons who were less likely to have discussed prevention (33 of 60 [55%]), those who stated the event was very or extremely serious (40 of 61 surveys [66%]), or reported very or somewhat difficult experiences discussing the event (16 of 61 [26%]) were more likely to have been negatively affected by the event. Surgeons with more negative attitudes about disclosure at baseline reported more anxiety about patients' surgical outcomes or events following disclosure (odds ratio, 1.54; 95% CI, 1.16-2.06). CONCLUSIONS AND RELEVANCE Surgeons who reported they were less likely to discuss preventability of the adverse event, or who reported difficult communication experiences, were more negatively affected by disclosure than others. Quality improvement efforts focused on recognizing the association between disclosure and surgeons' well-beingmay help sustain open disclosure policies. C1 [Elwy, A. Rani; Rosen, Amy K.] Vet Affairs Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Mailstop 152,150 S Huntington Ave, Boston, MA 02130 USA. [Elwy, A. Rani; Bokhour, Barbara G.; Mueller, Nora M.; Glickman, Mark E.; Zhao, Shibei] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Elwy, A. Rani; Bokhour, Barbara G.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA USA. [Itani, Kamal M. F.; Brotschi, Erica A.; Sanchez, Vivian M.] Vet Affairs Boston Healthcare Syst, Dept Surg, West Roxbury, MA USA. [Itani, Kamal M. F.; Rosen, Amy K.; Brotschi, Erica A.; Sanchez, Vivian M.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA. [Mueller, Nora M.] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. [Glickman, Mark E.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA. [Lynge, Dana] Vet Affairs Puget Sound Healthcare Syst, Dept Surg, Seattle, WA USA. [Lynge, Dana] Univ Washington Healthcare Syst, Dept Surg, Seattle, WA USA. [Perkal, Melissa] Vet Affairs Connecticut Healthcare Syst, Dept Surg, West Haven, CT USA. [Perkal, Melissa] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Gallagher, Thomas H.] Univ Washington, Sch Med, Dept Bioeth, Seattle, WA USA. [Gallagher, Thomas H.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Elwy, AR (reprint author), Vet Affairs Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Mailstop 152,150 S Huntington Ave, Boston, MA 02130 USA. EM rani.elwy@va.gov FU Department of Veterans Affairs, Health Services Research and Development Service [IIR07-199] FX This study was funded by grant IIR07-199 from the Department of Veterans Affairs, Health Services Research and Development Service. NR 32 TC 0 Z9 0 U1 4 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD NOV PY 2016 VL 151 IS 11 BP 1015 EP 1021 DI 10.1001/jamasurg.2016.1787 PG 7 WC Surgery SC Surgery GA EC8PM UT WOS:000388404500008 PM 27438083 ER PT J AU Liu, JSB Weber, SM Berian, JR Chen, SL Cohen, ME Ko, CY Bilimoria, KY AF Liu, Jason B. Weber, Sharon M. Berian, Julia R. Chen, Shenglin Cohen, Mark E. Ko, Clifford Y. Bilimoria, Karl Y. TI Role of Operative Complexity Variables in Risk Adjustment for Patients With Cancer SO JAMA SURGERY LA English DT Letter ID OUTCOMES C1 [Liu, Jason B.; Berian, Julia R.; Chen, Shenglin; Cohen, Mark E.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA. [Liu, Jason B.; Berian, Julia R.] Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA. [Weber, Sharon M.] Univ Wisconsin, Carbone Canc Ctr, Dept Surg, Madison, WI 53706 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. RP Liu, JSB (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA. EM jliu@facs.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD NOV PY 2016 VL 151 IS 11 BP 1084 EP 1086 DI 10.1001/jamasurg.2016.2253 PG 4 WC Surgery SC Surgery GA EC8PM UT WOS:000388404500026 PM 27486963 ER PT J AU Mehta, D AF Mehta, Darshan TI Mind-Body Approach to Low Back Pain: A "No-Brainer'' or "All-Brainer,'' Depending on How You Look at It SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Editorial Material C1 [Mehta, Darshan] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Mehta, Darshan] Harvard Med Sch, Educ, Osher Ctr Integrat Med, Boston, MA 02115 USA. [Mehta, Darshan] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Mehta, D (reprint author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.; Mehta, D (reprint author), Harvard Med Sch, Educ, Osher Ctr Integrat Med, Boston, MA 02115 USA.; Mehta, D (reprint author), Brigham & Womens Hosp, Boston, MA 02115 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD NOV PY 2016 VL 22 IS 11 BP 851 EP 852 PG 2 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA EC4QQ UT WOS:000388118900004 ER PT J AU Korzhnev, DM Neculai, D Dhe-Paganon, S Arrowsmith, CH Bezsonova, I AF Korzhnev, Dmitry M. Neculai, Dante Dhe-Paganon, Sirano Arrowsmith, Cheryl H. Bezsonova, Irina TI Solution NMR structure of the HLTF HIRAN domain: a conserved module in SWI2/SNF2 DNA damage tolerance proteins SO JOURNAL OF BIOMOLECULAR NMR LA English DT Article DE DNA replication; DNA damage tolerance; Helicase-like transcription factor; HLTF ID CELL NUCLEAR ANTIGEN; ACTIVATOR INHIBITOR-1 GENE; OB-FOLD; HUMAN SHPRH; EVOLUTIONARY CONSERVATION; POSTREPLICATION REPAIR; GENOMIC INSTABILITY; UBIQUITIN LIGASE; INTERACTIVE TREE; REPLICATION AB HLTF is a SWI2/SNF2-family ATP-dependent chromatin remodeling enzyme that acts in the error-free branch of DNA damage tolerance (DDT), a cellular mechanism that enables replication of damaged DNA while leaving damage repair for a later time. Human HLTF and a closely related protein SHPRH, as well as their yeast homologue Rad5, are multi-functional enzymes that share E3 ubiquitin-ligase activity required for activation of the error-free DDT. HLTF and Rad5 also function as ATP-dependent dsDNA translocases and possess replication fork reversal activities. Thus, they can convert Y-shaped replication forks into X-shaped Holliday junction structures that allow error-free replication over DNA lesions. The fork reversal activity of HLTF is dependent on 3'-ssDNA-end binding activity of its N-terminal HIRAN domain. Here we present the solution NMR structure of the human HLTF HIRAN domain, an OB-like fold module found in organisms from bacteria (as a stand-alone domain) to plants, fungi and metazoan (in combination with SWI2/SNF2 helicase-like domain). The obtained structure of free HLTF HIRAN is similar to recently reported structures of its DNA bound form, while the NMR analysis also reveals that the DNA binding site of the free domain exhibits conformational heterogeneity. Sequence comparison of N-terminal regions of HLTF, SHPRH and Rad5 aided by knowledge of the HLTF HIRAN structure suggests that the SHPRH N-terminus also includes an uncharacterized structured module, exhibiting weak sequence similarity with HIRAN regions of HLTF and Rad5, and potentially playing a similar functional role. C1 [Korzhnev, Dmitry M.; Bezsonova, Irina] Univ Connecticut Hlth, Dept Mol Biol & Biophys, Farmington, CT 06030 USA. [Neculai, Dante] Zhejiang Univ, Sch Med, Hangzhou, Zhejiang, Peoples R China. [Dhe-Paganon, Sirano] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Arrowsmith, Cheryl H.] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada. [Arrowsmith, Cheryl H.] Univ Toronto, Dept Med Biophys, Princess Margaret Canc Ctr, Toronto, ON M5S 1A8, Canada. RP Bezsonova, I (reprint author), Univ Connecticut Hlth, Dept Mol Biol & Biophys, Farmington, CT 06030 USA. EM bezsonova@uchc.edu FU Connecticut Department of Public Health Biomedical Research Grant [DPH-UCHC BIOMED 2013-0203]; Connecticut Innovation Research Grant [13-SCA-UCHC-03]; NSF MCB [1616184, 1615866]; AbbVie [1097737]; Bayer; Boehringer Ingelheim; Genome Canada through the Ontario Genomics Institute [OGI-055]; GlaxoSmithKline; Janssen; Lilly Canada; Novartis Research FoundationOntario Ministry of Economic Development and Innovation; Pfizer; Takeda; Wellcome Trust [092809/Z/10/Z] FX This work was supported by Connecticut Department of Public Health Biomedical Research Grant (DPH-UCHC BIOMED 2013-0203) and Connecticut Innovation Research Grant (13-SCA-UCHC-03). Research in the Bezsonova and Korzhnev labs is supported by NSF MCB (1616184, IB; 1615866, DK). The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer, Boehringer Ingelheim, Genome Canada through the Ontario Genomics Institute [OGI-055], GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and the Wellcome Trust [092809/Z/10/Z]. NR 52 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0925-2738 EI 1573-5001 J9 J BIOMOL NMR JI J. Biomol. NMR PD NOV PY 2016 VL 66 IS 3 BP 209 EP 219 DI 10.1007/s10858-016-0070-9 PG 11 WC Biochemistry & Molecular Biology; Spectroscopy SC Biochemistry & Molecular Biology; Spectroscopy GA EC5NB UT WOS:000388181300006 PM 27771863 ER PT J AU Syrkina, O Hales, CH Bonab, AA Hamrahi, V Paul, K Jung, WJ Tompkins, RG Fischman, AJ Carter, EA AF Syrkina, Olga Hales, Charles H. Bonab, Ali A. Hamrahi, Victoria Paul, Kasie Jung, Walter J. Tompkins, Ronald G. Fischman, Alan J. Carter, Edward A. TI Molecular Imaging of Smoke-Induced Changes in Nuclear Factor-Kappa B Expression in Murine Tissues Including the Lung SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID INHALATION INJURY; JNK ACTIVATION; ENDOTHELIAL-CELLS; INHIBITION; INDUCTION; BURN; APOPTOSIS; SURVIVAL AB Many inflammatory responses are mediated by activation of the transcription factor, nuclear factor-kappa B (NF-kappa B), and a wide variety of human diseases involve abnormal regulation of its expression. In this investigation, we evaluated the effect of smoke inhalation injury on NF-kappa B expression in lung using two strains of NF-kappa B reporter mice. Groups of reporter mice with viral thymidine kinase (TK) or "fire fly" luciferase (Luc) genes under control by the NF-kappa B promoter (TK/NF-kappa B mice and Luc/NF-kappa B mice) were subjected to nonlethal smoke inhalation injury. Sham-treated animals served as controls. Twenty-four hours (each animal was injected intravenously with either 9-(4-18F-fluoro-3-[hydroxymethyl] butyl) guanine ((18)FHBG) (similar to 1.0 mCi) or luciferin (1.0 mg). One hour later, the TK/NF-kappa B mice were studied by micro-positron emission tomography (mu-PET) imaging using a Concord P4 mu-PET camera, and the Luc/NF-kappa B mice were studied by bioluminescence imaging with a charge-coupled device camera. The mu-PET data demonstrated that smoke injury produced massive increases in NF-kappa B expression ((18)FHBG-standardized uptake value: 3.1 vs 0.0) 24 hours after smoke inhalation, which was reduced 48 hours after smoke inhalation, but still significantly different than the control. Qualitative analysis of the bioluminescence data revealed a remarkably similar effect of burn NF-kappa B luciferase expression in vivo. Biodistribution studies of (18)FHBG uptake and luciferase activity in lung tissue demonstrated a similar increase 24 hours after injury, which was reduced 48 hours later, but still significantly higher than the sham. The present data with these models providing longitudinal imaging data on the same mouse may prove useful in the examination of the factors producing lung injury by smoke inhalation, as well as the treatment(s) for the damage produced with and without burn injury. C1 [Syrkina, Olga; Hales, Charles H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Bonab, Ali A.] Massachusetts Gen Hosp, Dept Nucl Med, Boston, MA 02114 USA. [Bonab, Ali A.; Hamrahi, Victoria; Paul, Kasie; Jung, Walter J.; Tompkins, Ronald G.; Fischman, Alan J.] Shriners Hosp Children, Boston, MA USA. [Tompkins, Ronald G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Carter, Edward A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. RP Carter, EA (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 114 16th St 114-3503, Charlestown, MA 02129 USA. EM carter.ea@gmail.com NR 36 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1559-047X EI 1559-0488 J9 J BURN CARE RES JI J. Burn Care Res. PD NOV-DEC PY 2016 VL 37 IS 6 BP 335 EP 342 DI 10.1097/BCR.0000000000000394 PG 8 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA EC7LM UT WOS:000388320400015 PM 27437954 ER PT J AU Marino, M Soley-Bori, M Jette, AM Slavin, MD Ryan, CM Schneider, JC Resnik, L Acton, A Amaya, F Rossi, M Soria-Saucedo, R Kazis, LE AF Marino, Molly Soley-Bori, Marina Jette, Alan M. Slavin, Mary D. Ryan, Colleen M. Schneider, Jeffrey C. Resnik, Linda Acton, Amy Amaya, Flor Rossi, Melinda Soria-Saucedo, Rene Kazis, Lewis E. TI Development of a Conceptual Framework to Measure the Social Impact of Burns SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID PERCEIVED STIGMATIZATION; COMMUNITY INTEGRATION; BODY-IMAGE; QUALITY; REHABILITATION; LIFE; QUESTIONNAIRE; ADJUSTMENT; INJURY; ADULTS AB Measuring community reintegration following burn injury is important to assess the efficacy of therapies designed to optimize recovery. This project aims to develop and validate a conceptual framework for understanding the social impact of burn injuries in adults. The framework is critical for developing the item banks used for a computerized adaptive test. We performed a comprehensive literature review and consulted with clinical experts and burn survivors about social life areas impacted by burn injury. Focus groups with burn survivors and clinicians were conducted to inform and validate the framework. Transcripts were coded using grounded theory methodology. The World Health Organization's International Classification of Functioning, Disability and Health, was chosen to ground the content model. The primary construct identified was social participation, which contains two concepts: societal role and personal relationships. The subdomains chosen for item development were work, recreation and leisure, relating with strangers, and romantic, sexual, family, and informal relationships. Qualitative results strongly suggest that the conceptual model fits the constructs for societal role and personal relationships with the respective subdomains. This conceptual framework has guided the implementation of a large-scale calibration study currently underway which will lead to a computerized adaptive test for monitoring the social impacts of burn injuries during recovery. C1 [Marino, Molly; Jette, Alan M.; Slavin, Mary D.] Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Inst, Boston, MA 02215 USA. [Marino, Molly; Soley-Bori, Marina; Jette, Alan M.; Slavin, Mary D.; Amaya, Flor; Rossi, Melinda; Soria-Saucedo, Rene; Kazis, Lewis E.] Boston Univ, Dept Hlth Law Policy & Management, Ctr Assessment Pharmaceut Practices, Boston, MA 02215 USA. [Ryan, Colleen M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Ryan, Colleen M.; Schneider, Jeffrey C.] Harvard Med Sch, Boston, MA USA. [Ryan, Colleen M.] Shriners Hosp Children, Boston, MA USA. [Schneider, Jeffrey C.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Resnik, Linda] Brown Univ, Providence, RI 02912 USA. [Acton, Amy] Phoenix Soc Burn Survivors, Grand Rapids, MI USA. RP Kazis, LE (reprint author), Boston Univ, Dept Hlth Law Policy & Management, Sch Publ Hlth, 715 Albany St,Talbot Bldg 119W, Boston, MA 02116 USA. EM lek@bu.edu FU NIDRR [H133A130023, H133A120034] FX This study was supported by NIDRR H133A130023 and H133A120034. NR 45 TC 0 Z9 0 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1559-047X EI 1559-0488 J9 J BURN CARE RES JI J. Burn Care Res. PD NOV-DEC PY 2016 VL 37 IS 6 BP E569 EP E578 DI 10.1097/BCR.0000000000000358 PG 10 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA EC7LM UT WOS:000388320400009 PM 27828837 ER PT J AU Siegel, MJ Kaza, RK Bolus, DN Boll, DT Rofsky, NM De Cecco, CN Foley, WD Morgan, DE Schoepf, UJ Sahani, DV Shuman, WP Vrtiska, TJ Yeh, BM Berland, LL AF Siegel, Marilyn J. Kaza, Ravi K. Bolus, David N. Boll, Daniel T. Rofsky, Neil M. De Cecco, Carlo N. Foley, W. Dennis Morgan, Desiree E. Schoepf, U. Joseph Sahani, Dushyant V. Shuman, William P. Vrtiska, Terri J. Yeh, Benjamin M. Berland, Lincoln L. TI White Paper of the Society of Computed Body Tomography and Magnetic Resonance on Dual-Energy CT, Part 1: Technology and Terminology SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE dual-energy CT; CT physics; spectral CT; CT nomenclature ID CLINICAL-APPLICATIONS; ABDOMEN; IMAGES; PRINCIPLES; CONTRAST; SCANNER AB This is the first of a series of 4 white papers that represent Expert Consensus Documents developed by the Society of Computed Body Tomography and Magnetic Resonance through its task force on dual-energy computed tomography (DECT). This article, part 1, describes the fundamentals of the physical basis for DECT and the technology of DECT and proposes uniform nomenclature to account for differences in proprietary terms among manufacturers. C1 [Siegel, Marilyn J.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA. [Kaza, Ravi K.] Univ Michigan Hosp, Dept Radiol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. [Bolus, David N.; Morgan, Desiree E.; Berland, Lincoln L.] Univ Alabama Birmingham, Dept Radiol, 619 S 19th St,N454, Birmingham, AL 35249 USA. [Boll, Daniel T.] Univ Basel Hosp, Dept Radiol, Basel, Switzerland. [Rofsky, Neil M.] UT Southwestern Med Ctr, Dept Radiol, Dallas, TX USA. [De Cecco, Carlo N.; Schoepf, U. Joseph] Med Univ South Carolina, Div Cardiovasc Imaging, Dept Radiol & Radiol Sci, Charleston, SC USA. [Foley, W. Dennis] Med Coll Wisconsin, Dept Radiol, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA. [Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging, Boston, MA USA. [Shuman, William P.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Vrtiska, Terri J.] Mayo Clin, Coll Med, Dept Radiol, Rochester, MN USA. [Yeh, Benjamin M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Berland, LL (reprint author), Univ Alabama Birmingham, Dept Radiol, 619 S 19th St,N454, Birmingham, AL 35249 USA. EM lberland@uabmc.edu RI De Cecco, Carlo N./C-8572-2017 OI De Cecco, Carlo N./0000-0002-2956-3101 NR 22 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD NOV-DEC PY 2016 VL 40 IS 6 BP 841 EP 845 DI 10.1097/RCT.0000000000000531 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EC9YA UT WOS:000388499000001 PM 27841774 ER PT J AU Foley, WD Shuman, WP Siegel, MJ Sahani, DV Boll, DT Bolus, DN De Cecco, CN Kaza, RK Morgan, DE Schoepf, UJ Vrtiska, TJ Yeh, BM Berland, LL AF Foley, W. Dennis Shuman, William P. Siegel, Marilyn J. Sahani, Dushyant V. Boll, Daniel T. Bolus, David N. De Cecco, Carlo N. Kaza, Ravi K. Morgan, Desiree E. Schoepf, U. Joseph Vrtiska, Terri J. Yeh, Benjamin M. Berland, Lincoln L. TI White Paper of the Society of Computed Body Tomography and Magnetic Resonance on Dual-Energy CT, Part 2: Radiation Dose and Iodine Sensitivity SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE dual-energy CT; iodinated contrast; radiation exposure; CT nomenclature ID IMAGE QUALITY; RENAL MASSES; PULMONARY ANGIOGRAPHY; INITIAL-EXPERIENCE; MULTIDETECTOR CT; PANCREATIC ADENOCARCINOMA; ENDOVASCULAR REPAIR; CONTRAST MATERIAL; LOAD; REDUCTION AB This is the second of a series of 4 white papers that represent Expert Consensus Documents developed by the Society of Computed Body Tomography and Magnetic Resonance through its task force on dual-energy computed tomography. This paper, part 2, addresses radiation dose and iodine sensitivity in dual-energy computed tomography. C1 [Foley, W. Dennis] Med Coll Wisconsin, Dept Radiol, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA. [Shuman, William P.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Siegel, Marilyn J.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63130 USA. [Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging, Boston, MA USA. [Boll, Daniel T.] Univ Basel Hosp, Dept Radiol, Basel, Switzerland. [Bolus, David N.; Morgan, Desiree E.; Berland, Lincoln L.] Univ Alabama Birmingham, Dept Radiol, 619S 19th St,N454, Birmingham, AL 35249 USA. [De Cecco, Carlo N.; Schoepf, U. Joseph] Med Univ South Carolina, Dept Radiol & Radiol Sci, Div Cardiovasc Imaging, Charleston, SC USA. [Kaza, Ravi K.] Univ Michigan Hosp, Dept Radiol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. [Vrtiska, Terri J.] Mayo Clin, Dept Radiol, Coll Med, Rochester, MN USA. [Yeh, Benjamin M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Berland, LL (reprint author), Univ Alabama Birmingham, Dept Radiol, 619S 19th St,N454, Birmingham, AL 35249 USA.; Berland, LL (reprint author), Univ Alabama Birmingham, ACR Body Imaging Commiss, 619S 19th St,N454, Birmingham, AL 35249 USA. EM lberland@uabmc.edu RI De Cecco, Carlo N./C-8572-2017 OI De Cecco, Carlo N./0000-0002-2956-3101 NR 52 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD NOV-DEC PY 2016 VL 40 IS 6 BP 846 EP 850 DI 10.1097/RCT.0000000000000539 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EC9YA UT WOS:000388499000002 PM 27768619 ER PT J AU Rahaghi, FN Wells, JM Come, CE De La Bruere, IA Bhatt, SP Ross, JC Vegas-Sanchez-Ferrero, G Diaz, AA Minhas, J Dransfield, MT Estepar, RS Washko, GR AF Rahaghi, Farbod N. Wells, J. Michael Come, Carolyn E. De La Bruere, Isaac A. Bhatt, Surya P. Ross, James C. Vegas-Sanchez-Ferrero, Gonzalo Diaz, Alejandro A. Minhas, Jasleen Dransfield, Mark T. Estepar, Raul San Jose Washko, George R. CA COPDGene Investigators TI Arterial and Venous Pulmonary Vascular Morphology and Their Relationship to Findings in Cardiac Magnetic Resonance Imaging in Smokers SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE 3D reconstruction; arterial; cardiac magnetic resonance imaging; chronic obstructive pulmonary disease; computed tomography; emphysema; pulmonary vascular; venous ID DISEASE; EMPHYSEMA; COPD; HYPERTENSION AB Objective: Prior work has described the relationship between pulmonary vascular pruning on computed tomography (CT) scans and metrics of right-sided heart dysfunction in smokers. In this analysis, we sought to look at pruning on a lobar level, as well as examine the effect of the arterial and venous circulation on this association. Methods: Automated vessel segmentation applied to noncontrast CT scans from the COPDGene Study in 24 subjects with cardiac magnetic resonance imaging scans was used to create a blood volume distribution profile. These vessels were then manually tracked to their origin and characterized as artery or vein. Results: Assessment of pruning on a lobar level revealed associations between pruning and right ventricular function previously not observed on a global level. The right ventricular mass index, the right ventricular endsystolic volume index, and pulmonary arterial-to-aorta ratio were associated with both arterial and venous pruning, whereas right ventricular ejection fraction was associated with only arterial pruning. Conclusions: Lobar assessment and segmentation of the parenchymal vasculature into arterial and venous components provide additional information about the relationship between loss of vasculature on CT scans and right ventricular dysfunction. C1 [Rahaghi, Farbod N.; Come, Carolyn E.; De La Bruere, Isaac A.; Diaz, Alejandro A.; Minhas, Jasleen; Washko, George R.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Div, 75 Francis St,PBB-CA 3, Boston, MA 02115 USA. [Wells, J. Michael; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Wells, J. Michael; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Ross, James C.; Vegas-Sanchez-Ferrero, Gonzalo; Estepar, Raul San Jose] Harvard Sch Med, Dept Radiol, Surg Planning Lab, Boston, MA USA. RP Rahaghi, FN (reprint author), Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Div, 75 Francis St,PBB-CA 3, Boston, MA 02115 USA. EM frahaghi@partners.org FU NHLBI [5T32HL007633, 1R01HL116931, K08 HL123940] FX The authors in this study were supported by NHLBI grants 5T32HL007633 (F.N.R.), 1R01HL116931 (R.S.J.E. and G.R.W), and K08 HL123940 (JMW). NR 24 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD NOV-DEC PY 2016 VL 40 IS 6 BP 948 EP 952 DI 10.1097/RCT.0000000000000465 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EC9YA UT WOS:000388499000019 PM 27636250 ER PT J AU Silverberg, ND Iverson, GL Brubacher, JR Holland, E Hoshino, LC Aquino, A Lange, RT AF Silverberg, Noah D. Iverson, Grant L. Brubacher, Jeffrey R. Holland, Elizabeth Hoshino, Lisa Casagrande Aquino, Angela Lange, Rael T. TI The Nature and Clinical Significance of Preinjury Recall Bias Following Mild Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE brain concussion; good-old-days bias; postconcussion syndrome; psychological models; recall bias ID GOOD-OLD-DAYS; POST-CONCUSSION SYMPTOMS; COGNITIVE-BEHAVIORAL PREVENTION; HEAD-INJURY; POSTCONCUSSION-SYNDROME; ETIOLOGY; EXPECTATION; PERCEPTION; SAMPLE AB Objective: Patients with mild traumatic brain injury (MTBI) often underestimate their preinjury symptoms. This study aimed to clarify the mechanism underlying this recall bias and its contribution to MTBI outcome. Setting: Level I trauma center. Participants: Patients with uncomplicated MTBI (N = 88) and orthopedic injury (N = 67). Design: Prospective longitudinal. Main Measures: Current and retrospective ratings on the British Columbia Postconcussion Symptom Inventory, completed at 6 weeks and 1 year postinjury. Results: Preinjury symptom reporting was comparable across groups, static across time, and associated with compensation-seeking. High preinjury symptom reporting was related to high postinjury symptom reporting in the orthopedic injury group but less so in the MTBI group, indicating a stronger positive recall bias in highly symptomatic MTBI patients. Low preinjury symptom reporting was not a risk factor for poor MTBI outcome. Conclusion: The recall bias was stronger and more likely clinically significant in MTBI patients with high postinjury symptoms. Multiple mechanisms appear to contribute to recall bias after MTBI, including the reattribution of preexisting symptoms to MTBI as well as processes that are not specific to MTBI (eg, related to compensation-seeking). C1 [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada. [Iverson, Grant L.; Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada. [Brubacher, Jeffrey R.] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada. [Aquino, Angela] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada. [Silverberg, Noah D.] GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada. [Iverson, Grant L.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Hoshino, Lisa Casagrande] Simon Fraser Univ, Dept Psychol, Burnaby, BC, Canada. [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA. [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA. RP Silverberg, ND (reprint author), GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada. EM noah.silverberg@vch.ca FU Canadian Institutes of Health Research [200903 MOP-200377-BSB-CAAA-161276]; Vancouver Coastal Health Research Institute; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; MTBI FX Primary funding for this study was provided by the Canadian Institutes of Health Research (200903 MOP-200377-BSB-CAAA-161276); provided to R.T.L. as principal investigator). N.D.S. received salary support from the Vancouver Coastal Health Research Institute. G.L.I. was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The authors thank Jan Buchanan for assistance with patient recruitment.; G.L.I. has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild traumatic brain injury (MTBI) and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained MTBIs. He has received honorariums for serving on research panels that provide scientific peer review of programs. He is a coinvestigator, collaborator, or consultant on grants relating to MTBI funded by several organizations. NR 39 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD NOV-DEC PY 2016 VL 31 IS 6 BP 388 EP 396 DI 10.1097/HTR.0000000000000198 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EC0IW UT WOS:000387784800010 PM 26580693 ER PT J AU Bogdanova, Y Yee, MK Ho, VT Cicerone, KD AF Bogdanova, Yelena Yee, Megan K. Ho, Vivian T. Cicerone, Keith D. TI Computerized Cognitive Rehabilitation of Attention and Executive Function in Acquired Brain Injury: A Systematic Review SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Review DE ABI; attention; cognitive rehabilitation; computerized intervention; executive function; stroke; traumatic brain injury ID OF-THE-LITERATURE; WORKING-MEMORY; TRAINING-PROGRAM; DOUBLE-BLIND; DEFICITS; STROKE; POSTSTROKE; IMPACT; ADULTS; STIMULATION AB Objective: Comprehensive review of the use of computerized treatment as a rehabilitation tool for attention and executive function in adults (aged 18 years or older) who suffered an acquired brain injury. Design: Systematic review of empirical research. Main Measures: Two reviewers independently assessed articles using the methodological quality criteria of Cicerone et al. Data extracted included sample size, diagnosis, intervention information, treatment schedule, assessment methods, and outcome measures. Results: A literature review (PubMed, EMBASE, Ovid, Cochrane, PsychINFO, CINAHL) generated a total of 4931 publications. Twenty-eight studies using computerized cognitive interventions targeting attention and executive functions were included in this review. In 23 studies, significant improvements in attention and executive function subsequent to training were reported; in the remaining 5, promising trends were observed. Conclusions: Preliminary evidence suggests improvements in cognitive function following computerized rehabilitation for acquired brain injury populations including traumatic brain injury and stroke. Further studies are needed to address methodological issues (eg, small sample size, inadequate control groups) and to inform development of guidelines and standardized protocols. C1 [Bogdanova, Yelena; Yee, Megan K.; Ho, Vivian T.] VA Boston Healthcare Syst, Psychol Res Serv, 150 South Huntington Ave, Boston, MA 02130 USA. [Bogdanova, Yelena; Ho, Vivian T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Yee, Megan K.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Cicerone, Keith D.] JFK Johnson Rehabil Inst, Dept Neuropsychol, Edison, NJ USA. [Cicerone, Keith D.] Rutgers Robert Wood Johnson Med Sch, Dept Phys Med & Rehabil, Edison, NJ USA. RP Bogdanova, Y (reprint author), VA Boston Healthcare Syst, Psychol Res Serv 151A, 150 South Huntington Ave, Boston, MA 02130 USA. EM bogdanov@bu.edu FU Rehabilitation Research & Development Service of the Department of Veterans Affairs (VA) [D6996W, I21RX001773-01]; National Institutes of Health; Boston University Clinical & Translational Science Institute [UL1-RR025771]; VA Translation Research Center for TBI & Stress Disorders; VA BHS Psychology Research Service FX This work was supported by the Rehabilitation Research & Development Service of the Department of Veterans Affairs (VA) grants D6996W and I21RX001773-01 to Y.B., the National Institutes of Health and Boston University Clinical & Translational Science Institute grant UL1-RR025771 to Y.B., the VA Translation Research Center for TBI & Stress Disorders [Y.B.], and the VA BHS Psychology Research Service [Y.B.]. The findings were presented in part at the annual meeting of the American Congress of Rehabilitation Medicine, 2014. NR 51 TC 1 Z9 1 U1 13 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD NOV-DEC PY 2016 VL 31 IS 6 BP 419 EP 433 DI 10.1097/HTR.0000000000000203 PG 15 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EC0IW UT WOS:000387784800013 PM 26709580 ER PT J AU Hart, T Novack, TA Temkin, N Barber, J Dikmen, SS Diaz-Arrastia, R Ricker, J Hesdorffer, DC Jallo, J Hsu, NH Zafonte, R AF Hart, Tessa Novack, Thomas A. Temkin, Nancy Barber, Jason Dikmen, Sureyya S. Diaz-Arrastia, Ramon Ricker, Joseph Hesdorffer, Dale C. Jallo, Jack Hsu, Nancy H. Zafonte, Ross TI Duration of Posttraumatic Amnesia Predicts Neuropsychological and Global Outcome in Complicated Mild Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE cognitive function; outcome measures; posttraumatic amnesia; traumatic brain injury ID WORD-ASSOCIATION TEST; GLASGOW COMA SCALE; MINOR HEAD-INJURY; UNCOMPLICATED MILD; STRUCTURED INTERVIEWS; UNITED-STATES; RECOVERY; TRIAL; RELIABILITY; SYMPTOMS AB Objectives: Examine the effects of posttraumatic amnesia (PTA) duration on neuropsychological and global recovery from 1 to 6 months after complicated mild traumatic brain injury (cmTBI). Participants: A total of 330 persons with cmTBI defined as Glasgow Coma Scale score of 13 to 15 in emergency department, with well-defined abnormalities on neuroimaging. Methods: Enrollment within 24 hours of injury with follow-up at 1, 3, and 6 months. Measures: Glasgow Outcome Scale-Extended, California Verbal Learning Test II, and Controlled Oral Word Association Test. Duration of PTA was retrospectively measured with structured interview at 30 days postinjury. Results: Despite all having a Glasgow Coma Scale Score of 13 to 15, a quarter of the sample had a PTA duration of greater than 7 days; half had PTA duration of 1 of 7 days. Both cognitive performance and Extended Glasgow Outcome Scale outcomes were strongly associated with time since injury and PTA duration, with those with PTA duration of greater than 1 week showing residual moderate disability at 6-month assessment. Conclusions: Findings reinforce importance of careful measurement of duration of PTA to refine outcome prediction and allocation of resources to those with cmTBI. Future research would benefit from standardization in computed tomographic criteria and use of severity indices beyond Glasgow Coma Scale to characterize cmTBI. C1 [Hart, Tessa] Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA. [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Temkin, Nancy] Univ Washington, Neurol Surg & Biostat, Seattle, WA 98195 USA. [Barber, Jason] Univ Washington, Neurol Surg, Seattle, WA 98195 USA. [Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA. [Ricker, Joseph] NYU, Sch Med, Dept Rehabil Med, New York, NY USA. [Hesdorffer, Dale C.] Columbia Univ, GH Sergievsky Ctr, New York, NY USA. [Hesdorffer, Dale C.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Jallo, Jack] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Hsu, Nancy H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. [Zafonte, Ross] Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp, 75 Francis St, Boston, MA 02115 USA. [Zafonte, Ross] Harvard Med Sch, Boston, MA USA. RP Hart, T (reprint author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA. EM thart@einstein.edu FU NICHD NIH HHS [U01 HD042687, U01 HD042738] NR 40 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD NOV-DEC PY 2016 VL 31 IS 6 BP E1 EP E9 DI 10.1097/HTR.0000000000000210 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EC0IW UT WOS:000387784800001 PM 26828710 ER PT J AU Francke, JA Penazzato, M Hou, T Abrams, EJ MacLean, RL Myer, L Walensky, RP Leroy, V Weinstein, MC Parker, RA Freedberg, KA Ciaranello, A AF Francke, Jordan A. Penazzato, Martina Hou, Taige Abrams, Elaine J. MacLean, Rachel L. Myer, Landon Walensky, Rochelle P. Leroy, Valeriane Weinstein, Milton C. Parker, Robert A. Freedberg, Kenneth A. Ciaranello, Andrea TI Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE human immunodeficiency virus; early infant HIV diagnosis; birth testing; nucleic acid test; cost-effectiveness ID 1ST-LINE ANTIRETROVIRAL THERAPY; TO-CHILD TRANSMISSION; MORTALITY; AGE; SETTINGS; INTERVENTIONS; OPPORTUNITIES; NEVIRAPINE; PROGRAMS AB Background. Diagnosis of human immunodeficiency virus (HIV) infection during early infancy (commonly known as "early infant HIV diagnosis" [EID]) followed by prompt initiation of antiretroviral therapy dramatically reduces mortality. EID testing is recommended at 6 weeks of age, but many infant infections are missed. Design/Methods.aEuro integral We simulated 4 EID testing strategies for HIV-exposed infants in South Africa: no EID (diagnosis only after illness; hereafter, "no EID"), testing once (at birth alone or at 6 weeks of age alone; hereafter, "birth alone" and "6 weeks alone," respectively), and testing twice (at birth and 6 weeks of age; hereafter "birth and 6 weeks"). We calculated incremental cost-effectiveness ratios (ICERs), using discounted costs and life expectancies for all HIV-exposed (infected and uninfected) infants. Results.aEuro integral In the base case (guideline-concordant care), the no EID strategy produced a life expectancy of 21.1 years (in the HIV-infected group) and 61.1 years (in the HIV-exposed group); lifetime cost averaged $1430/HIV-exposed infant. The birth and 6 weeks strategy maximized life expectancy (26.5 years in the HIV-infected group and 61.4 years in the HIV-exposed group), costing $1840/infant tested. The ICER of the 6 weeks alone strategy versus the no EID strategy was $1250/year of life saved (19% of South Africa's per capita gross domestic product); the ICER for the birth and 6 weeks strategy versus the 6 weeks alone strategy was $2900/year of life saved (45% of South Africa's per capita gross domestic product). Increasing the proportion of caregivers who receive test results and the linkage of HIV-positive infants to antiretroviral therapy with the 6 weeks alone strategy improved survival more than adding a second test. Conclusions.aEuro integral EID at birth and 6 weeks improves outcomes and is cost-effective, compared with EID at 6 weeks alone. If scale-up costs are comparable, programs should add birth testing after strengthening 6-week testing programs. C1 [Francke, Jordan A.; Hou, Taige; MacLean, Rachel L.; Walensky, Rochelle P.; Parker, Robert A.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Gen Internal Med, 50 Staniford St, Boston, MA 02114 USA. [Francke, Jordan A.; Hou, Taige; MacLean, Rachel L.; Walensky, Rochelle P.; Parker, Robert A.; Freedberg, Kenneth A.; Ciaranello, Andrea] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Walensky, Rochelle P.; Freedberg, Kenneth A.; Ciaranello, Andrea] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Parker, Robert A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. [Walensky, Rochelle P.; Parker, Robert A.; Freedberg, Kenneth A.] Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA. [Weinstein, Milton C.; Freedberg, Kenneth A.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Weinstein, Milton C.; Parker, Robert A.] Harvard Med Sch, Boston, MA USA. [Abrams, Elaine J.] Columbia Univ, Int Ctr AIDS Care & Treatment Program, Mailman Sch Publ Hlth, New York, NY USA. [Abrams, Elaine J.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Penazzato, Martina] Med Res Council Clin Trials Unit London, London, England. [Penazzato, Martina] WHO, Geneva, Switzerland. [Myer, Landon] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Rondebosch, South Africa. [Leroy, Valeriane] Univ Toulouse 3, INSERM, U1027, Toulouse, France. RP Ciaranello, A (reprint author), Massachusetts Gen Hosp, Div Gen Internal Med, 50 Staniford St, Boston, MA 02114 USA. EM aciaranello@partners.org FU World Health Organization; National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R01 HD079214]; National Institute of Allergy and Infectious Diseases (NIAID) [K01 AI078754, R01 AI058736, R37 AI093269]; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group; Massachusetts General Hospital Executive Committee on Research FX This work was supported by the World Health Organization (to J. A. F., M. P., T. H., R. A. P., and A. C.); the National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; award R01 HD079214 to J. A. F., T. H., R. L. M., R. P. W., M. C. W., R. A. P., K. A. F., and A. C.) and the National Institute of Allergy and Infectious Diseases (NIAID; awards K01 AI078754 [to A. C.], R01 AI058736 [to J. A. F., T. H., R. L. M., R. P. W., M. C. W., R. A. P., and K. A. F.], and R37 AI093269 [to R. P. W.]); the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group (to A. C., T. H., R. P. W., and K. A. F.); and the Massachusetts General Hospital Executive Committee on Research (to A. C. and R. P. W.). NR 48 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2016 VL 214 IS 9 BP 1319 EP 1328 DI 10.1093/infdis/jiw379 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC3EH UT WOS:000388007700008 PM 27540110 ER PT J AU Srinivasa, S Burdo, TH Williams, KC Mitten, EK Wong, K Fitch, KV Stanley, T Adler, GK Grinspoon, SK AF Srinivasa, Suman Burdo, Tricia H. Williams, Kenneth C. Mitten, Emilie K. Wong, Kimberly Fitch, Kathleen V. Stanley, Takara Adler, Gail K. Grinspoon, Steven K. TI Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices During HIV Infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; immune activation; renin-angiotensin-aldosterone system; mineralocorticoid; sodium restriction ID INSULIN-RESISTANCE; INFLAMMATION; BLOCKADE AB Background. Human immunodeficiency virus (HIV)infected patients demonstrate increased activation of the reninangiotensin-aldosterone system ( RAAS). We evaluated changes in immune markers with physiological RAAS activation. Methods.aEuro integral Immune activation markers were assessed serially in 18 HIV-infected and 7 non-HIV-infected subjects consuming an ad libitum diet followed by a standardized low-sodium diet. Results.aEuro integral Levels of CCL-2 (P = .0004) and soluble CD163 (P = .0001) significantly increased with sodium restriction and RAAS activation, compared with levels in individuals with ad libitum sodium intake, among chronically treated HIV-infected subjects (mean duration of ART [+/- SEM], 11 +/- 1 years), but not among non-HIV-infected subjects of similar age and sex. Conclusions.aEuro integral Dietary sodium restriction, which activates RAAS, uniquely stimulates critical indices of immune activation during HIV infection. Clinical Trials Registration.aEuro integral NCT01407237. C1 [Srinivasa, Suman; Mitten, Emilie K.; Wong, Kimberly; Fitch, Kathleen V.; Stanley, Takara; Grinspoon, Steven K.] Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON207, Boston, MA 02114 USA. [Srinivasa, Suman; Mitten, Emilie K.; Wong, Kimberly; Fitch, Kathleen V.; Stanley, Takara; Adler, Gail K.; Grinspoon, Steven K.] Harvard Med Sch, Boston, MA USA. [Adler, Gail K.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA. [Burdo, Tricia H.; Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA. RP Grinspoon, SK (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON207, Boston, MA 02114 USA. EM sgrinspoon@mgh.harvard.edu FU National Institutes of Health (NIH) [R01DK49302, K24 HL103845, M01RR01066, UL1 RR025758, UL1 TR001102]; National Center for Research Resources; National Center for Advancing Translational Sciences; Harvard cMeRIT; National Institute of Diabetes and Digestive and Kidney Diseases, NIH [P30DK040561] FX This work was supported by the National Institutes of Health (NIH; grants R01DK49302 to S. K. G., K24 HL103845 to G. K. A., and M01RR01066, UL1 RR025758, and UL1 TR001102 to the Harvard Catalyst/Harvard Clinical and Translational Science Center, from the National Center for Research Resources and National Center for Advancing Translational Sciences); Harvard cMeRIT (to S. S.); and the National Institute of Diabetes and Digestive and Kidney Diseases, NIH (pilot and feasibility grant P30DK040561 to the Harvard Nutrition and Obesity Research Center). NR 15 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2016 VL 214 IS 9 BP 1336 EP 1340 DI 10.1093/infdis/jiw392 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC3EH UT WOS:000388007700010 PM 27549584 ER PT J AU Boyce, R Reyes, R Matte, M Ntaro, M Mulogo, E Metlay, JP Band, L Siedner, MJ AF Boyce, Ross Reyes, Raquel Matte, Michael Ntaro, Moses Mulogo, Edgar Metlay, Joshua P. Band, Lawrence Siedner, Mark J. TI Severe Flooding and Malaria Transmission in the Western Ugandan Highlands: Implications for Disease Control in an Era of Global Climate Change SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Malaria; climate change; epidemiology; Uganda; disasters; flooding ID EAST-AFRICAN HIGHLANDS; KENYA HIGHLANDS; HUMAN HEALTH; EL-NINO; VARIABILITY; TOPOGRAPHY; IMPACT AB Background. There are several mechanisms by which global climate change may impact malaria transmission. We sought to assess how the increased frequency of extreme precipitation events associated with global climate change will influence malaria transmission in highland areas of East Africa. Methods.aEuro integral We used a differences-in-differences, quasi-experimental design to examine spatial variability in the incidence rate of laboratory-confirmed malaria cases and malaria-related hospitalizations between villages (1) at high versus low elevations, (2) with versus without rivers, and (3) upstream versus downstream before and after severe flooding that occurred in Kasese District, Western Region, Uganda, in May 2013. Results.aEuro integral During the study period, 7596 diagnostic tests were performed, and 1285 patients were admitted with a diagnosis of malaria. We observed that extreme flooding resulted in an increase of approximately 30% in the risk of an individual having a positive result of a malaria diagnostic test in the postflood period in villages bordering a flood-affected river, compared with villages farther from a river, with a larger relative impact on upstream versus downstream villages (adjusted rate ratio, 1.91 vs 1.33). Conclusions.aEuro integral Extreme precipitation such as the flooding described here may pose significant challenges to malaria control programs and will demand timely responses to mitigate deleterious impacts on human health. C1 [Boyce, Ross] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. [Reyes, Raquel] Univ N Carolina, Sch Med, Div Gen Med & Clin Epidemiol, Chapel Hill, NC USA. [Band, Lawrence] Univ N Carolina, Dept Geog, Chapel Hill, NC USA. [Metlay, Joshua P.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Siedner, Mark J.] Harvard Med Sch, Dept Med, Boston, MA USA. [Siedner, Mark J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Matte, Michael; Ntaro, Moses; Mulogo, Edgar] Mbarara Univ Sci & Technol, Dept Community Hlth, Mbarara, Uganda. RP Boyce, R (reprint author), Univ North Carolina Chapel Hill, Div Infect Dis, 130 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM ross.boyce@unchealth.unc.edu FU Harvard Global Health Initiative and Thrasher Research Fund; National Institutes of Health [K23MH099916] FX We thank Drs Alexander Tsai and Atheendar Venkataramani, along with John Lovette, for their editorial input on manuscript drafts; the Harvard Global Health Initiative and Thrasher Research Fund, for support to R. M. B.; and the National Institutes of Health, for support via grant K23MH099916 to M. J. S. NR 43 TC 1 Z9 1 U1 36 U2 36 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2016 VL 214 IS 9 BP 1403 EP 1410 DI 10.1093/infdis/jiw363 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC3EH UT WOS:000388007700020 PM 27534686 ER PT J AU Won, JS Singh, AK Singh, I AF Won, Je-Seong Singh, Avtar K. Singh, Inderjit TI Biochemical, Cell Biological, Pathological, and Therapeutic Aspects of Krabbe's Disease SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Review DE globoid cell leukodystrophy; Krabbe's disease; myelin; therapy ID CENTRAL-NERVOUS-SYSTEM; BONE-MARROW TRANSPLANTATION; ENZYME REPLACEMENT THERAPY; BLOOD-BRAIN-BARRIER; SECRETORY PHOSPHOLIPASE A(2); PSYCHOSINE-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; FIBER-TYPE DISPROPORTION; AXO-GLIAL INTERACTIONS; TNF-ALPHA PRODUCTION AB Krabbe's disease (KD; also called globoid cell leukodystrophy) is a genetic disorder involving demyelination of the central (CNS) and peripheral (PNS) nervous systems. The disease may be subdivided into three types, an infantile form, which is the most common and severe; a juvenile form; and a rare adult form. KD is an autosomal recessive disorder caused by a deficiency of galactocerebrosidase activity in lysosomes, leading to accumulation of galactoceramide and neurotoxic galactosylsphingosine (psychosine [PSY]) in macrophages (globoid cells) as well as neural cells, especially in oligodendrocytes and Schwann cells. This ultimately results in damage to myelin in both CNS and PNS with associated morbidity and mortality. Accumulation of PSY, a lysolipid with detergent-like properties, over a threshold level could trigger membrane destabilization, leading to cell lysis. Moreover, subthreshold concentrations of PSY trigger cell signaling pathways that induce oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, endothelial/vascular dysfunctions, and neuronal and axonal damage. From the time the "psychosine hypothesis" was proposed, considerable efforts have been made in search of an effective therapy for lowering PSY load with pharmacological, gene, and stem cell approaches to attenuate PSY-induced neurotoxicity. This Review focuses on the recent advances and prospective research for understanding disease mechanisms and therapeutic approaches for KD. (C) 2016 Wiley Periodicals, Inc. C1 [Won, Je-Seong; Singh, Avtar K.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA. [Singh, Inderjit] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ South Carolina, 173 Ashley Ave,DCRI Room 509, Charleston, SC 29425 USA. EM singhi@musc.edu FU National Institutes of Health [NS064195] FX Contract grant sponsor: National Institutes of Health; Contract grant number: NS064195 NR 217 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0360-4012 EI 1097-4547 J9 J NEUROSCI RES JI J. Neurosci. Res. PD NOV PY 2016 VL 94 IS 11 SI SI BP 990 EP 1006 DI 10.1002/jnr.23873 PG 17 WC Neurosciences SC Neurosciences & Neurology GA EC9DE UT WOS:000388443500005 PM 27638584 ER PT J AU Lenoue, SR Wongngamnit, N Thurstone, C AF Lenoue, Sean R. Wongngamnit, Narin Thurstone, Christian TI Practical Aspects of Discussing Marijuana in a New Era SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Editorial Material DE marijuana; evidence-based medicine; informed consent ID POSTTRAUMATIC-STRESS-DISORDER; MULTIPLE-SCLEROSIS; MEDICAL MARIJUANA; CONTROLLED-TRIAL; CANNABIS USE; EPILEPSY; SYMPTOMS; SPASTICITY; EXPOSURE; ALCOHOL AB The use of marijuana for the treatment of medical conditions is a highly controversial topic. Misconceptions by both patients and providers concerning the safety of and evidence-based indications for marijuana can complicate treatment planning and outcomes. Maintaining skills such as motivational interviewing, providing evidence-based informed consent, and increasing access to care remain top priorities for providing quality patient care. The goal of this article is to offer guidance to clinical providers who are adapting to the changing realities of medical marijuana and legalized recreational marijuana. C1 [Lenoue, Sean R.] Univ Colorado, Sch Med, Clin & Res Fellowship Addict Psychiat, Aurora, CO USA. [Wongngamnit, Narin] Denver Vet Affairs Med Ctr, Subst Abuse Treatment Program, Aurora, CO USA. [Wongngamnit, Narin] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Thurstone, Christian] Denver Hlth & Hosp Author, Subst Treatment Educ & Prevent STEP Program, Aurora, CO USA. [Thurstone, Christian] Univ Colorado, Psychiat, Sch Med, Aurora, CO USA. RP Lenoue, SR (reprint author), 13001 E 17th Pl,Campus POB F546,Bldg 500, Aurora, CO 80045 USA. EM sean.lenoue@ucdenver.edu NR 49 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD NOV PY 2016 VL 22 IS 6 BP 471 EP 477 DI 10.1097/PRA.0000000000000189 PG 7 WC Psychiatry SC Psychiatry GA EC5BF UT WOS:000388147400008 PM 27824781 ER PT J AU Haq, A Svobodova, J Imran, S Stanford, C Razzaque, MS AF Haq, Afrozul Svobodova, Jitka Imran, Samira Stanford, Charles Razzaque, Mohammed S. TI Vitamin D deficiency: A single centre analysis of patients from 136 countries SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 18th Workshop on Vitamin D CY APR 21-24, 2015 CL Delft, NETHERLANDS DE Vitamin D deficiency; Electrochemiluminescence; 25(OH)D; 125(OH)2D; United Arab Emirates ID MORTALITY; POPULATION; CANCER; HEALTH; RISK AB Vitamin D deficiency is a global problem, thought to be related to lack of sunlight exposure, and usually accompanied by reduced dietary intake. This study was designed to determine vitamin D status of 60,979 patients admitted to the Burjeel Hospital of VPS healthcare in Abu Dhabi, United Arab Emirates (UAE) from October 2012 to September 2014. The total concentrations of vitamin D [25(OH)D] of all the studied patients were measured in a single laboratory. Of the studied patients, 57.5% were female and 42.5% were male. Serum 25(OH)D (total) measurements showed 82.5% of the studied patients have vitamin D deficiency to insufficiency. 26.4% of females and 18.4% of males have extreme deficiency of 25 (OH)D. There was higher variability of vitamin D in group of females then males according to coefficient of variation. In our studied cohort teenagers (13-19 years) have shown the lowest levels of serum vitamin D (data not shown and will be communicated as a separate publication). The prevalence of hypovitaminosis D is significantly high among population of UAE, Saudi Arabia and many Middle Eastern countries, especially among women, despite abundant sunshine. 86.1% UAE nationals and 78.9% visitors of other nationalities were found <75 nmol/L of 25(OH)D. 28.4% of UAE nationals and 17.5% of visitors of other nationalities have extreme deficiency of 25(OH)D. Our results are significant, as all of our patients are residing permanently in the UAE or visitors that has yearlong sunlight. In addition, measuring 25(OH)D concentrations in a single laboratory minimized test level variations. Our current study formed the basis of further studies to determine if vitamin D deficiency and insufficiency can aggravate systemic diseases, including hypertension, diabetes or obesity that are also wide-spread in the Middle Eastern region. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Haq, Afrozul; Stanford, Charles; Razzaque, Mohammed S.] VPS Healthcare, Res & Dev, Abu Dhabi, U Arab Emirates. [Svobodova, Jitka] Czech Univ Life Sci, Dept Stat, Fac Econ & Management, Kamycka 129, Prague 16521 6, Suchdol, Czech Republic. [Imran, Samira] Monash Univ, Sch Sci, Med Biosci Programme, Subang Jaya, Selangor, Malaysia. [Razzaque, Mohammed S.] Harvard Med Sch, Dept Appl Oral Sci, Forsyth Inst, 245 First St, Cambridge, MA 02142 USA. RP Haq, A (reprint author), VPS Healthcare, Res & Dev, Abu Dhabi, U Arab Emirates. EM haq2000@gmail.com NR 19 TC 1 Z9 1 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD NOV PY 2016 VL 164 SI SI BP 209 EP 213 DI 10.1016/j.jsbmb.2016.02.007 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA EC5EX UT WOS:000388157000036 PM 26877203 ER PT J AU Scragg, R Waayer, D Stewart, AW Lawes, CMM Toop, L Murphy, J Khaw, KT Camargo, CA AF Scragg, Robert Waayer, Debbie Stewart, Alistair W. Lawes, Carlene M. M. Toop, Les. Murphy, Judy Khaw, Kay-Tee Camargo, Carlos A., Jr. TI The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 18th Workshop on Vitamin D CY APR 21-24, 2015 CL Delft, NETHERLANDS DE Acute respiratory infection; Cardiovascular disease; Falls; Fractures; Prevention; Randomized controlled trial; Supplement; Vitamin D ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; SERUM 25-HYDROXYVITAMIN D; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; TRACT INFECTIONS; GENERAL-PRACTICE; PROXIMAL FEMUR; BLOOD-PRESSURE; RISK AB Observational studies have shown that low vitamin D status is associated with an increased risk of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. We recruited 5110 Aucldand adults, aged 50-84 years, into a randomized, double-blind, placebo-controlled trial to test whether vitamin D supplementation protects against these four major outcomes. The intervention is a monthly cholecalciferol dose of 100,000 IU (2.5 mg) for an estimated median 33 years (range 2.5-4.2) during 2011-2015. Participants were recruited primarily from family practices, plus community groups with a high proportion-of Maori, Pacific, or South Asian individuals. The baseline evaluation included medical history, lifestyle, physical measurements (e.g. blood pressure, arterial waveform, lung function, muscle function), and a blood sample (stored at -80 degrees C for later testing). Capsules are being mailed to home addresses with a questionnaire to collect data on non-hospitalized outcomes and to monitor adherence and potential adverse effects. Other data sources include New Zealand Ministry of Health data on mortality, hospitalization, cancer registrations and dispensed pharmaceuticals. A random sample of 438 participants returned for annual collection of blood samples to monitor adherence and safety (hypercalcemia), including repeat physical measurements at 12 months follow-up. The trial will allow testing of a priori hypotheses on several other endpoints including: weight, blood pressure, arterial waveform parameters, heart rate variability, lung function, muscle strength, gait and balance, mood, psoriasis, bone density, and chronic pain. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Scragg, Robert; Waayer, Debbie; Stewart, Alistair W.; Lawes, Carlene M. M.; Murphy, Judy] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand. [Toop, Les.] Univ Otago, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand. [Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth, Cambridge, England. [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. RP Scragg, R (reprint author), Univ Auckland, Sch Populat Hlth, Auckland Mail Ctr, Private Bag 92019, Auckland 1142, New Zealand. EM r.scragg@auckland.ac.nz NR 74 TC 1 Z9 1 U1 4 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD NOV PY 2016 VL 164 SI SI BP 318 EP 325 DI 10.1016/j.jsbmb.2015.09.010 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA EC5EX UT WOS:000388157000054 PM 26365555 ER PT J AU Kohno, M Okita, K Morales, AM Robertson, CL Dean, AC Ghahremani, DG Sabb, FW Rawson, RA Mandelkern, MA Bilder, RM London, ED AF Kohno, M. Okita, K. Morales, A. M. Robertson, C. L. Dean, A. C. Ghahremani, D. G. Sabb, F. W. Rawson, R. A. Mandelkern, M. A. Bilder, R. M. London, E. D. TI Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: link to impulsivity in methamphetamine users SO MOLECULAR PSYCHIATRY LA English DT Article ID INCENTIVE-SENSITIZATION THEORY; REFERENCE TISSUE MODEL; NUCLEUS-ACCUMBENS; RESPONSE-INHIBITION; PREFRONTAL CORTEX; DECISION-MAKING; TRAIT IMPULSIVITY; SEX-DIFFERENCES; BRAIN IMAGES; ADDICTION AB Stimulant use disorders are associated with deficits in striatal dopamine receptor availability, abnormalities in mesocorticolimbic resting-state functional connectivity (RSFC) and impulsivity. In methamphetamine-dependent research participants, impulsivity is correlated negatively with striatal D2-type receptor availability, and mesocorticolimbic RSFC is stronger than that in controls. The extent to which these features of methamphetamine dependence are interrelated, however, is unknown. This question was addressed in two studies. In Study 1, 19 methamphetamine-dependent and 26 healthy control subjects underwent [F-18] fallypride positron emission tomography to measure ventral striatal dopamine D2-type receptor availability, indexed by binding potential (BPND), and functional magnetic resonance imaging (fMRI) to assess mesocorticolimbic RSFC, using a midbrain seed. In Study 2, an independent sample of 20 methamphetamine-dependent and 18 control subjects completed the Barratt Impulsiveness Scale in addition to fMRI. Study 1 showed a significant group by ventral striatal BPND interaction effect on RSFC, reflecting a negative relationship between ventral striatal BPND and RSFC between the midbrain and striatum, orbitofrontal cortex and insula in methamphetamine-dependent participants, but a positive relationship in the control group. In Study 2, an interaction of the group with RSFC on impulsivity was observed. Methamphetamine-dependent users exhibited a positive relationship of midbrain RSFC to the left ventral striatum with cognitive impulsivity, whereas a negative relationship was observed in healthy controls. The results indicate that ventral striatal D2-type receptor signaling may affect the system-level activity within the mesocorticolimbic system, providing a functional link that may help explain high impulsivity in methamphetamine-dependent individuals. C1 [Kohno, M.; Okita, K.; Morales, A. M.; Robertson, C. L.; Dean, A. C.; Ghahremani, D. G.; Sabb, F. W.; Rawson, R. A.; Bilder, R. M.; London, E. D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Okita, K.; Robertson, C. L.; London, E. D.] Univ Calif Irvine, Vet Adm Greater Los Angeles Healthcare Syst, Irvine, CA USA. [Robertson, C. L.; London, E. D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. [Dean, A. C.; London, E. D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Mandelkern, M. A.; Bilder, R. M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA. [Mandelkern, M. A.] Univ Calif Los Angeles, Dept Phys, 405 Hilgard Ave, Los Angeles, CA 90024 USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza,C8-831, Los Angeles, CA 90095 USA. EM elondon@mednet.ucla.edu FU NIH [P20 DA022539, R01 DA020726]; NIDA [R01DA027633, K23DA027734, R21DA034928, UL1TR000124]; Consortium for Neuropsychiatric Phenomics (NIH Roadmap for Medical Research grants) [UL1- DE019580, RL1DA024853]; Marjorie Greene Trust; Thomas P and Katherine P. Pike Chair in Addiction Studies FX The research described here was funded in part by NIH grants P20 DA022539, R01 DA020726 (EDL), NIDA R01DA027633 (RAR), K23DA027734 (ACD), R21DA034928 (ACD), UL1TR000124 (UCLA CTSA), the Consortium for Neuropsychiatric Phenomics (NIH Roadmap for Medical Research grants UL1- DE019580 and RL1DA024853) and endowments from the Thomas P and Katherine P. Pike Chair in Addiction Studies, and the Marjorie Greene Trust. NR 65 TC 1 Z9 1 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD NOV PY 2016 VL 21 IS 11 BP 1554 EP 1560 DI 10.1038/mp.2015.223 PG 7 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA ED2ZU UT WOS:000388719600010 PM 26830141 ER PT J AU Herold, C Hooli, BV Mullin, K Liu, T Roehr, JT Mattheisen, M Parrado, AR Bertram, L Lange, C Tanzi, RE AF Herold, C. Hooli, B. V. Mullin, K. Liu, T. Roehr, J. T. Mattheisen, M. Parrado, A. R. Bertram, L. Lange, C. Tanzi, R. E. TI Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3 SO MOLECULAR PSYCHIATRY LA English DT Article ID SUSCEPTIBILITY LOCI; GENETIC ASSOCIATION; PROTEIN; METAANALYSIS; VARIANTS; LINKAGE; ONSET; SET AB The genetic basis of Alzheimer's disease (AD) is complex and heterogeneous. Over 200 highly penetrant pathogenic variants in the genes APP, PSEN1, and PSEN2 cause a subset of early-onset familial AD. On the other hand, susceptibility to late-onset forms of AD (LOAD) is indisputably associated to the epsilon 4 allele in the gene APOE, and more recently to variants in more than two-dozen additional genes identified in the large-scale genome-wide association studies (GWAS) and meta-analyses reports. Taken together however, although the heritability in AD is estimated to be as high as 80%, a large proportion of the underlying genetic factors still remain to be elucidated. In this study, we performed a systematic family-based genome-wide association and meta-analysis on close to 15 million imputed variants from three large collections of AD families (similar to 3500 subjects from 1070 families). Using a multivariate phenotype combining affection status and onset age, meta-analysis of the association results revealed three single nucleotide polymorphisms (SNPs) that achieved genome-wide significance for association with AD risk: rs7609954 in the gene PTPRG (P-value = 3.98 x 10(-8)), rs1347297 in the gene OSBPL6 (P-value = 4.53 x 10(-8)), and rs1513625 near PDCL3 (P-value = 4.28 x 10(-8)). In addition, rs72953347 in OSBPL6 (P-value = 6.36 x 10(-7)) and two SNPs in the gene CDKAL1 showed marginally significant association with LOAD (rs10456232, P-value = 4.76 x 10(-7); rs62400067, P-value = 3.54 x 10(-7)). In summary, family-based GWAS meta-analysis of imputed SNPs revealed novel genomic variants in (or near) PTPRG, OSBPL6, and PDCL3 that influence risk for AD with genome-wide significance. C1 [Herold, C.] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany. [Herold, C.; Lange, C.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 665 Huntington Ave, Boston, MA 02115 USA. [Hooli, B. V.; Mullin, K.; Tanzi, R. E.] Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Boston, MA 02129 USA. [Liu, T.; Roehr, J. T.; Bertram, L.] Max Planck Inst Mol Genet, Dept Vertebrate Genom, Berlin, Germany. [Mattheisen, M.] Dept Biomed, Bartholins Alle 6, Aarhus, Denmark. [Parrado, A. R.] Pharmaceut Co Johnson & Johnson, Computat Sci Janssen Res & Dev, Spring House, PA USA. [Bertram, L.] Imperial Coll Sci Technol & Med, Sch Publ Hlth, Fac Med, London, England. [Bertram, L.] Univ Lubeck, Inst Neurogenet & Integrat & Expt Genom, Platform Genome Analyt, Lubeck, Germany. RP Lange, C (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, 665 Huntington Ave, Boston, MA 02115 USA.; Tanzi, RE (reprint author), Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Boston, MA 02129 USA.; Tanzi, RE (reprint author), Harvard Med Sch, Dept Neurol, Boston, MA 02114 USA. EM clange@hsph.harvard.edu; tanzi@helix.mgh.harvard.edu RI Bertram, Lars/K-3889-2015 OI Bertram, Lars/0000-0002-0108-124X FU NIA NIH HHS [P50 AG005134, U24 AG021886, P01 AG004953]; NIMH NIH HHS [R01 MH060009, R37 MH060009] NR 33 TC 0 Z9 0 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD NOV PY 2016 VL 21 IS 11 BP 1608 EP 1612 DI 10.1038/mp.2015.218 PG 5 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA ED2ZU UT WOS:000388719600015 PM 26830138 ER PT J AU Emblem, KE Jain, RK AF Emblem, Kyrre E. Jain, Rakesh K. TI Improving treatment of liver metastases by targeting nonangiogenic mechanisms SO NATURE MEDICINE LA English DT Editorial Material ID HYPOXIA; TUMORS AB A recent study confirms an association between vessel co-option and resistance to bevacizumab, an anti-vascular endothelial growth factor-A (VEGFA) antibody, in patients with liver metastases. The authors suggest a combined therapeutic strategy that reduces co-option in mice. C1 [Emblem, Kyrre E.] Oslo Univ Hosp, Intervent Ctr, Dept Diagnost Phys, Oslo, Norway. [Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs Tumor Biol, Boston, MA 02114 USA. [Jain, Rakesh K.] Harvard Med Sch, Boston, MA USA. RP Emblem, KE (reprint author), Oslo Univ Hosp, Intervent Ctr, Dept Diagnost Phys, Oslo, Norway. EM kyrre.eeg.emblem@rr-research.no NR 10 TC 0 Z9 0 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD NOV PY 2016 VL 22 IS 11 BP 1209 EP 1210 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA EB3XK UT WOS:000387302300009 PM 27824818 ER PT J AU Zackular, JP Moore, JL Jordan, AT Juttukonda, LJ Noto, MJ Nicholson, MR Crews, JD Semler, MW Zhang, Y Ware, LB Washington, MK Chazin, WJ Caprioli, RM Skaar, EP AF Zackular, Joseph P. Moore, Jessica L. Jordan, Ashley T. Juttukonda, Lillian J. Noto, Michael J. Nicholson, Maribeth R. Crews, Jonathan D. Semler, Matthew W. Zhang, Yaofang Ware, Lorraine B. Washington, M. Kay Chazin, Walter J. Caprioli, Richard M. Skaar, Eric P. TI Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection SO NATURE MEDICINE LA English DT Article ID ANTIBIOTIC-ASSOCIATED COLITIS; FECAL CALPROTECTIN; EPIDEMIOLOGY; COMMENSALS; INTERFACE AB Clostridium difficile is the most commonly reported nosocomial pathogen in the United States and is an urgent public health concern worldwide(1). Over the past decade, incidence, severity and costs associated with C. difficile infection (CDI) have increased dramatically(2). CDI is most commonly initiated by antibiotic-mediated disruption of the gut microbiota; however, non-antibiotic-associated CDI cases are well documented and on the rise(3,4). This suggests that unexplored environmental, nutrient and host factors probably influence CDI. Here we show that excess dietary zinc (Zn) substantially alters the gut microbiota and, in turn, reduces the minimum amount of antibiotics needed to confer susceptibility to CDI. In mice colonized with C. difficile, excess dietary Zn severely exacerbated C. difficile associated disease by increasing toxin activity and altering the host immune response. In addition, we show that the Zn-binding S100 protein calprotectin has antimicrobial effects against C. difficile and is an essential component of the innate immune response to CDI. Taken together, these data suggest that nutrient Zn levels have a key role in determining susceptibility to CDI and severity of disease, and that calprotectin-mediated metal limitation is an important factor in the host immune response to C. difficile. C1 [Zackular, Joseph P.; Jordan, Ashley T.; Juttukonda, Lillian J.; Noto, Michael J.; Zhang, Yaofang; Ware, Lorraine B.; Washington, M. Kay; Skaar, Eric P.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Moore, Jessica L.; Chazin, Walter J.; Caprioli, Richard M.] Vanderbilt Univ, Dept Chem, Nashville, TN USA. [Moore, Jessica L.; Caprioli, Richard M.] Vanderbilt Univ, Mass Spectrometry Res Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Noto, Michael J.; Semler, Matthew W.; Ware, Lorraine B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Nicholson, Maribeth R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Crews, Jonathan D.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Chazin, Walter J.; Caprioli, Richard M.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA. [Chazin, Walter J.] Vanderbilt Univ, Ctr Struct Biol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Caprioli, Richard M.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.; Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu FU US Department of Veterans Affairs (Merit Review Award) [1I01BX002482]; US National Institutes of Health (NIH) [R01 AI101171, P41 GM103391-05]; Vanderbilt Digestive Disease Research Center (VDDRC) [P30DK058404]; NIH-NIDDK [T32DK007673]; NIH-NIAID [F32AI120553]; NIH-NIGMS [T32GM065086]; Thrasher Research Fund Early Career Award FX We thank P. Schloss and J. Sorg for critical feedback on this study, and D. Aronoff and S. Walk for providing C. difficile strains. This research was supported by the US Department of Veterans Affairs (Merit Review Award no. 1I01BX002482; E.P.S.), the US National Institutes of Health (NIH) (grant no. R01 AI101171 (E.P.S.) and P41 GM103391-05 (R.M.C.)) and the Vanderbilt Digestive Disease Research Center (VDDRC) (grant no. P30DK058404; E.P.S.). J.P.Z. was supported by NIH-NIDDK grant no. T32DK007673 and NIH-NIAID grant no. F32AI120553. J.L.M. was supported by NIH-NIGMS grant no. T32GM065086. M.R.N. was supported by the Thrasher Research Fund Early Career Award. NR 29 TC 2 Z9 2 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD NOV PY 2016 VL 22 IS 11 BP 1330 EP 1334 DI 10.1038/nm.4174 PG 5 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA EB3XK UT WOS:000387302300026 PM 27668938 ER PT J AU Choi, YK Maki, T Mandeville, ET Koh, SH Hayakawa, K Arai, K Kim, YM Whalen, MJ Xing, CH Wang, XY Kim, KW Lo, EH AF Choi, Yoon Kyung Maki, Takakuni Mandeville, Emiri T. Koh, Seong-Ho Hayakawa, Kazuhide Arai, Ken Kim, Young-Myeong Whalen, Michael J. Xing, Changhong Wang, Xiaoying Kim, Kyu-Won Lo, Eng H. TI Dual effects of carbon monoxide on pericytes and neurogenesis in traumatic brain injury SO NATURE MEDICINE LA English DT Article ID ADULT BRAIN; DISEASE AB At low levels, carbon monoxide (CO) has physiological roles as a second messenger and neuromodulator(1,2). Here we assess the effects of CO in a mouse model of traumatic brain injury (TBI). Treatment with CO-releasing molecule (CORM)-3 reduced pericyte death and ameliorated the progression of neurological deficits. In contrast, although treatment with the radical scavenger N-tert-butyl-a-phenylnitrone (PBN) also reduced pericyte death, neurological outcomes were not rescued. As compared to vehicle-treated control and PBN-treated mice, CORM-3-treated mice showed higher levels of phosphorylated neural nitric oxide synthase within neural stem cells (NSCs). Inhibition of nitric oxide synthase diminished the CORM-3-mediated increase in the number of cells that stained positive for both the neuronal marker NeuN and 5-bromo-2'-deoxyuridine (BrdU; a marker for proliferating cells) in vivo, consequently interfering with neurological recovery after TBI. Because NSCs seemed to be in close proximity to pericytes, we asked whether cross-talk between pericytes and NSCs was induced by CORM-3, thereby promoting neurogenesis. In pericyte cultures that were undergoing oxygen and glucose deprivation, conditioned cell culture medium collected after CORM-3 treatment enhanced the in vitro differentiation of NSCs into mature neurons. Taken together, these findings suggest that CO treatment may provide a therapeutic approach for TBI by preventing pericyte death, rescuing cross-talk with NSCs and promoting neurogenesis. C1 [Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA. [Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Koh, Seong-Ho] Hanyang Univ, Dept Neurol, Coll Med, Seoul, South Korea. [Kim, Young-Myeong] Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Gangwon Do, South Korea. [Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Boston, MA USA. [Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, SNU Harvard NeuroVasc Protect Res Ctr, Seoul, South Korea. RP Choi, YK; Lo, EH (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA.; Choi, YK; Lo, EH (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. EM yoonkyung@kangwon.ac.kr; lo@helix.mgh.harvard.edu OI Koh, Seong-Ho/0000-0001-5419-5761 FU US National Institutes of Health; Rappaport Foundation; National Research Foundation of Korea; Global Research Laboratory Program of Korea FX This work was supported in part by grants from the US National Institutes of Health (K.H., K.A., M.J.W., C.X., X.W. and E.H.L.), the Rappaport Foundation (E.H.L.), the Research Abroad grant from the National Research Foundation of Korea (Y.K.C., S.-H.K., Y.-M.K. and K.-W.K.) and the Global Research Laboratory Program of Korea (K.-WK.). The vector expressing the HIF-1 alpha double mutant was kindly provided by G.L. Semenza (Johns Hopkins University School of Medicine). NR 17 TC 1 Z9 1 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD NOV PY 2016 VL 22 IS 11 BP 1335 EP 1341 DI 10.1038/nm.4188 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA EB3XK UT WOS:000387302300027 PM 27668935 ER PT J AU Crous-Bou, M Harrington, LB Kabrhel, C AF Crous-Bou, Marta Harrington, Laura B. Kabrhel, Christopher TI Environmental and Genetic Risk Factors Associated with Venous Thromboembolism SO SEMINARS IN THROMBOSIS AND HEMOSTASIS LA English DT Review DE venous thromboembolism; epidemiology; genetics; risk factors ID FACTOR-V-LEIDEN; DEEP-VEIN THROMBOSIS; ABO BLOOD-GROUP; PLASMINOGEN-ACTIVATOR INHIBITOR-1; VON-WILLEBRAND-FACTOR; INHERITED ANTITHROMBIN DEFICIENCY; PROTHROMBIN G20210A MUTATION; PARTICULATE AIR-POLLUTION; GENOME-WIDE ASSOCIATION; TOTAL HIP-ARTHROPLASTY AB Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism, and a combination of environmental and genetic risk factors contributes to VTE risk. Within environmental risk factors, some are provoking (e.g., cancer, surgery, trauma or fracture, immobilization, pregnancy and the postpartum period, long-distance travel, hospitalization, catheterization, and acute infection) and others are nonprovoking (e.g., age, sex, race/ethnicity, body mass index and obesity, oral contraceptive or hormone therapy use, corticosteroid use, statin use, diet, physical activity, sedentary time, and air pollution). Additionally, VTE has a strong genetic basis, with approximately 50 to 60% of the variance in VTE incidence attributed to genetic effects. Some genetic susceptibility variants that contribute to risk have been identified in candidate genes, mostly related to the clotting system and responsible for inherited hypercoagulable states (e.g., factor V Leiden, prothrombin, fibrinogen gamma, or blood group non-O). Other susceptibility single-nucleotide polymorphisms have been identified from genome-wide association studies, such as the two new loci in TSPAN15 (rs78707713) and SCL44A2 (rs2288904) genes. Risk factors are not always associated with VTE in isolation; however, and an understanding of how environmental and genetic factors interact may provide insight into the pathophysiology of VTE, possibly identifying opportunities for targeted prevention and treatment. C1 [Crous-Bou, Marta] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA USA. [Crous-Bou, Marta] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Harrington, Laura B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Kabrhel, Christopher] Massachusetts Gen Hosp, Ctr Vasc Emergencies, Dept Emergency Med, Boston, MA 02114 USA. RP Kabrhel, C (reprint author), Massachusetts Gen Hosp, Ctr Vasc Emergencies, Dept Emergency Med, Boston, MA 02114 USA. EM ckabrhel@partners.org FU National Heart, Lung, and Blood Institute; [T32 HL098048]; [R01 HL116854] FX This work was conducted with support from the National Heart, Lung, and Blood Institute. Support for Harrington: T32 HL098048, PI: Eric B. Rimm. Support for Crous-Bou and Kabrhel: R01 HL116854, PI Christopher Kabrhel. NR 151 TC 1 Z9 1 U1 10 U2 10 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0094-6176 EI 1098-9064 J9 SEMIN THROMB HEMOST JI Semin. Thromb. Hemost. PD NOV PY 2016 VL 42 IS 8 BP 808 EP 820 DI 10.1055/s-0036-1592333 PG 13 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EC5YV UT WOS:000388214100002 PM 27764878 ER PT J AU White, B Rosovsky, R Parry, BA Kabrhel, C AF White, Benjamin Rosovsky, Rachel Parry, Blair Alden Kabrhel, Christopher TI The Outpatient Treatment of Venous Thromboembolism: Operational Impact and the Role of Novel Anticoagulants SO SEMINARS IN THROMBOSIS AND HEMOSTASIS LA English DT Article DE pulmonary embolism; venous thromboembolism; anticoagulation; emergency department operations; outpatient treatment ID ACUTE PULMONARY-EMBOLISM; DEEP-VEIN THROMBOSIS; BRAIN NATRIURETIC PEPTIDE; CLINICAL PROGNOSTIC MODEL; CARDIAC TROPONIN-T; LOW-RISK PATIENTS; HOME-TREATMENT; UNFRACTIONATED HEPARIN; ORAL RIVAROXABAN; EARLY DISCHARGE AB Pulmonary embolism (PE) and venous thromboembolism (VTE) are common diagnoses in the emergency department (ED), with significant potential morbidity and mortality. As a result, historically nearly all patients with PE have been admitted to the hospital for observation and treatment. In recent years, the ability to rapidly and accurately risk stratify patients with VTE according to their risk of short-term clinical deterioration has supported outpatient treatment, and non-vitamin K antagonist oral anticoagulants (NOACs) have further facilitated this approach. This review details the historical context and operational impact of managing VTE in the outpatient setting, describes a model for outpatient management of VTE, and suggests potential areas of further inquiry. C1 [White, Benjamin; Parry, Blair Alden; Kabrhel, Christopher] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Rosovsky, Rachel] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA. RP Kabrhel, C (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Ctr Vasc Emergencies, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. EM ckabrhel@partners.org NR 70 TC 1 Z9 1 U1 1 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0094-6176 EI 1098-9064 J9 SEMIN THROMB HEMOST JI Semin. Thromb. Hemost. PD NOV PY 2016 VL 42 IS 8 BP 846 EP 856 DI 10.1055/s-0036-1593542 PG 11 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EC5YV UT WOS:000388214100005 PM 27764882 ER PT J AU Witkin, AS Harshbarger, S Kabrhel, C AF Witkin, Alison S. Harshbarger, Savanah Kabrhel, Christopher TI Pulmonary Embolism Response Teams SO SEMINARS IN THROMBOSIS AND HEMOSTASIS LA English DT Article DE pulmonary embolism; deep vein thrombosis; rapid response team; thrombosis; thrombolysis ID DEEP-VEIN THROMBOSIS; ACUTE VENOUS THROMBOEMBOLISM; RIGHT-VENTRICULAR FUNCTION; QUALITY-OF-LIFE; THROMBOLYTIC THERAPY; RANDOMIZED-TRIAL; CAUSE MORTALITY; CLINICAL-TRIAL; UNITED-STATES; TASK-FORCE AB Pulmonary embolism is a common and often life-threatening event. Treatment options include anticoagulation alone, catheter-directed therapies, and surgical thromboembolectomy. While guidelines exist, there is often controversy over which treatment is most appropriate, particularly for intermediate-risk patients. The traditional care model, in which the primary team is responsible for consulting the appropriate specialists, may be inadequate and inefficient for emergent situations, as ensuring coordination and communication between various consulting services can be a time consuming and confusing process. The Pulmonary Embolism Response Team (PERT) model was developed to improve the quality and efficiency of care for patient with intermediate- and high-risk pulmonary embolism. Activation of the PERT allows for rapid, multidisciplinary discussion among dedicated specialists, which typically includes members of the cardiology, emergency medicine, hematology, pulmonary/critical care, and surgical services. While the majority of patients are still treated with anticoagulation alone, in the event that a more invasive approach is deemed necessary, the team expedites this process. Over the last several years, the PERT model has been adopted at more than 75 health care institutions and may represent a new standard of care. C1 [Witkin, Alison S.] Harvard Med Sch, Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Boston, MA USA. [Witkin, Alison S.; Harshbarger, Savanah; Kabrhel, Christopher] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Ctr Vasc Emergencies, Boston, MA USA. RP Kabrhel, C (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Ctr Vasc Emergencies, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. EM ckabrhel@partners.org NR 47 TC 1 Z9 1 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0094-6176 EI 1098-9064 J9 SEMIN THROMB HEMOST JI Semin. Thromb. Hemost. PD NOV PY 2016 VL 42 IS 8 BP 857 EP 864 DI 10.1055/s-0036-1593541 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EC5YV UT WOS:000388214100006 PM 27769084 ER PT J AU Artola, RT Mihos, CG Santana, O AF Artola, Rosa T. Mihos, Christos G. Santana, Orlando TI Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE HMG-CoA reductase inhibitors; meta-analysis; systemic lupus erythematosus; statins ID DISEASE-ACTIVITY; CONTROLLED-TRIAL; DOUBLE-BLIND; TASK-FORCE; ATORVASTATIN; RECOMMENDATIONS; INHIBITORS; REDUCTASE AB Objectives Systemic lupus erythematosus (SLE) is associated with a significant risk of cardiovascular mortality. The use of statins for lipid modulation and the prevention of cardiovascular disease in this population also may impart pleiotropic anti-inflammatory and immunomodulatory effects. Our aim was to identify studies that compared the use of statins and placebo or no statin therapy in patients with SLE. Methods A meta-analysis was conducted on the follow-up measures of serum lipid levels, inflammatory markers, and disease activity, which was measured using the SLE Disease Activity Index (SLEDAI) score. The mean difference (MD) was calculated by the inverse variance method under a fixed or random-effects model, as appropriate. Results A total of eight studies met our inclusion criteria, including five randomized controlled trials. The total number of patients was 814 (statins 446, placebo/no statins 368), and follow-up ranged from 1 month to 7 years. The total cholesterol (MD -23.48 mg/dL, 95% confidence interval [CI] -34.57 to -12.39, P < 0.0001), low-density lipoprotein (MD -20.7 mg/dL, 95% CI -30.51 to -10.89, P < 0.0001), and high-sensitivity C-reactive protein (MD -0.40 mg/dL, 95% CI -0.64 to -0.16, P = 0.001) levels were significantly reduced by statin therapy. There was no change with statin use in serum levels of high-density lipoprotein and conventional C-reactive protein, and there was no difference in the SLEDAI score. Conclusions The use of statins in SLE reduced the serum lipid and high-sensitivity C-reactive protein levels, which suggests a role for the primary prevention of cardiovascular disease. Statins did not affect the SLEDAI score, and therefore their use for modifying SLE disease activity levels is not presently supported. C1 Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthoped & Rheumatol, Cambridge Hosp,Cardiac Ultrasound Lab, Boston, MA USA. Columbia Univ, Mt Sinai Heart Inst, Div Cardiol, Miami Beach, FL USA. RP Mihos, CG (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Blake 255, Boston, MA 02114 USA. EM cmihos@mgh.harvard.edu NR 24 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD NOV PY 2016 VL 109 IS 11 BP 705 EP 711 DI 10.14423/SMJ.0000000000000561 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EC0IE UT WOS:000387782500011 PM 27812716 ER PT J AU Nelson, M Abdi, A Adhikari, S Boniface, M Bramante, RM Egan, DJ Fields, JM Leo, MM Liteplo, AS Liu, R Nomura, JT Pigott, DC Raio, CC Ruskis, J Strony, R Thom, C Lewiss, RE AF Nelson, Mathew Abdi, Amin Adhikari, Srikar Boniface, Michael Bramante, Robert M. Egan, Daniel J. Fields, J. Matthew Leo, Megan M. Liteplo, Andrew S. Liu, Rachel Nomura, Jason T. Pigott, David C. Raio, Christopher C. Ruskis, Jennifer Strony, Robert Thom, Chris Lewiss, Resa E. TI Goal-directed Focused Ultrasound Milestones Revised: A Multiorganizational Consensus SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID EMERGENCY-MEDICINE MILESTONES; CONTROLLED CLINICAL-TRIAL; POINT-OF-CARE; LIMITED ULTRASONOGRAPHY; ECTOPIC PREGNANCY; SONOGRAPHY; PHYSICIANS; EDUCATION; ECHOCARDIOGRAPHY; SCHOOLS AB In 2012 the Accreditation Council for Graduate Medical Education and the American Board of Emergency Medicine released the emergency medicine milestones. The Patient Care 12 (PC12) subcompetency delineates staged and progressive accomplishment in emergency ultrasound. While valuable as an initial framework for ultrasound resident education, there are limitations to PC12. This consensus paper provides a revised description of criteria to define the subcompetency. A multiorganizational task force was formed between the American College of Emergency Physicians Ultrasound Section, the Council of Emergency Medicine Residency Directors, and the Academy of Emergency Ultrasound of the Society for Academic Emergency Medicine. Representatives from each organization created this consensus document and revision. C1 [Nelson, Mathew] North Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA. [Abdi, Amin] Los Angeles Cty Univ Southern Calif, Med Ctr, Dept Emergency Med, Los Angeles, CA USA. [Adhikari, Srikar] Univ Arizona, Dept Emergency Med, Tucson, AZ USA. [Boniface, Michael] Univ Florida, Dept Emergency Med, Gainesville, FL USA. [Bramante, Robert M.; Raio, Christopher C.] Good Samaritan Hosp, Med Ctr, Dept Emergency Med, Islip, NY USA. [Egan, Daniel J.] Mt Sinai St Lukes Roosevelt, Dept Emergency Med, New York, NY USA. [Fields, J. Matthew] Thomas Jefferson Hosp, Dept Emergency Med, Philadelphia, PA USA. [Leo, Megan M.] Boston Univ, Sch Med, Dept Emergency Med, Boston, MA 02118 USA. [Liteplo, Andrew S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Liu, Rachel] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. [Nomura, Jason T.] Christiana Care Hlth Syst, Dept Emergency Med, Newark, DE USA. [Pigott, David C.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA. [Ruskis, Jennifer] Cook Cty Hosp, Dept Emergency Med, Chicago, IL 60612 USA. [Strony, Robert] Geisinger Med Ctr, Dept Emergency Med, Danville, PA 17822 USA. [Thom, Chris] Univ Virginia Hlth Syst, Dept Emergency Med, Charlottesville, VA USA. [Lewiss, Resa E.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. RP Nelson, M (reprint author), North Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA. EM Mnelson9@optonline.net NR 30 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD NOV PY 2016 VL 23 IS 11 BP 1274 EP 1279 DI 10.1111/acem.13069 PG 6 WC Emergency Medicine SC Emergency Medicine GA EB8AX UT WOS:000387614400010 PM 27520068 ER PT J AU Walker, N Bullen, C Barnes, J McRobbie, H Tutka, P Raw, M Etter, JF Siddiqi, K Courtney, RJ Castaldelli-Maia, JM Selby, P Sheridan, J Rigotti, NA AF Walker, Natalie Bullen, Chris Barnes, Joanne McRobbie, Hayden Tutka, Piotr Raw, Martin Etter, Jean-Francois Siddiqi, Kamran Courtney, Ryan J. Castaldelli-Maia, Joao Mauricio Selby, Peter Sheridan, Janie Rigotti, Nancy A. TI Getting cytisine licensed for use world-wide: a call to action SO ADDICTION LA English DT Editorial Material DE Affordable; cost-effective; cytisine; regulatory approval; smoking cessation; treatment ID RECEPTOR PARTIAL AGONIST; SMOKING-CESSATION; VARENICLINE; EFFICACY; METAANALYSIS; NICOTINE; HEALTH C1 [Walker, Natalie; Bullen, Chris] Univ Auckland, Natl Inst Hlth Innovat, Sch Populat Hlth, Auckland, New Zealand. [Walker, Natalie] Univ Auckland, Addict Res Ctr, Sch Populat Hlth, Auckland, New Zealand. [Barnes, Joanne] Univ Auckland, Sch Pharm, Auckland, New Zealand. [McRobbie, Hayden] Queen Mary Univ London, London, England. [Tutka, Piotr] Univ Rzeszow, Dept Pharmacol, Ctr Innovat Res Med & Nat Sci, Rzeszow, Poland. [Raw, Martin] Univ Nottingham, UK Ctr Tobacco Control Studies, Nottingham, England. [Etter, Jean-Francois] Univ Geneva, Fac Med, Geneva, Switzerland. [Siddiqi, Kamran] Univ York, Dept Hlth Sci, York, N Yorkshire, England. [Courtney, Ryan J.] Univ New South Wales, Res Ctr, Natl Drug & Alcohol, Sydney, NSW, Australia. [Castaldelli-Maia, Joao Mauricio] Fundacao ABC, Sch Med, Dept Neurosci, Santo Andre, Brazil. [Selby, Peter] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada. [Selby, Peter] Univ Toronto, Dept Psychiat & Publ Hlth Sci, Toronto, ON, Canada. [Sheridan, Janie] Univ Auckland, Sch Pharm, Auckland, New Zealand. [Sheridan, Janie] Univ Auckland, Addict Res Ctr, Auckland, New Zealand. [Rigotti, Nancy A.] Harvard Med Sch, Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA USA. RP Walker, N (reprint author), Univ Auckland, Natl Inst Hlth Innovat, Sch Populat Hlth, Auckland, New Zealand.; Walker, N (reprint author), Univ Auckland, Addict Res Ctr, Sch Populat Hlth, Auckland, New Zealand. EM n.walker@auckland.ac.nz RI Bullen, Chris/E-4594-2017 OI Bullen, Chris/0000-0001-6807-2930 NR 19 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD NOV PY 2016 VL 111 IS 11 BP 1895 EP 1898 DI 10.1111/add.13464 PG 4 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DZ8WR UT WOS:000386153700001 PM 27426482 ER PT J AU Bradley, KA Rubinsky, AD Lapham, GT Berger, D Bryson, C Achtmeyer, C Hawkins, EJ Chavez, LJ Williams, EC Kivlahan, DR AF Bradley, Katharine A. Rubinsky, Anna D. Lapham, Gwen T. Berger, Douglas Bryson, Christopher Achtmeyer, Carol Hawkins, Eric J. Chavez, Laura J. Williams, Emily C. Kivlahan, Daniel R. TI Predictive validity of clinical AUDIT-C alcohol screening scores and changes in scores for three objective alcohol-related outcomes in a Veterans Affairs population SO ADDICTION LA English DT Article DE Alcohol drinking; alcohol-induced disorders; alcohol-related disorders; alcohol screening; biomarkers; prevention ID IDENTIFICATION TEST AUDIT; HIGH-DENSITY-LIPOPROTEIN; US GENERAL-POPULATION; SELF-CARE BEHAVIORS; SERVICES TASK-FORCE; PRIMARY-HEALTH-CARE; USE DISORDERS; BRIEF INTERVENTION; SUBSTANCE-ABUSE; GLOBAL BURDEN AB AimsTo evaluate the association between Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) alcohol screening scores, collected as part of routine clinical care, and three outcomes in the following year (Aim 1), and the association between changes in AUDIT-C risk group at 1-year follow-up and the same outcomes in the subsequent year (Aim 2). DesignCohort study. SettingTwenty-four US Veterans Affairs (VA) healthcare systems (2004-07), before systematic implementation of brief intervention. ParticipantsA total of 486115 out-patients with AUDIT-Cs documented in their electronic health records (EHRs) on two occasions 12months apart (baseline' and follow-up'). MeasurementsIndependent measures were baseline AUDIT-C scores and change in standard AUDIT-C risk groups (no use, low-risk use and mild, moderate, severe misuse) from baseline to follow-up. Outcome measures were (1) high-density lipoprotein cholesterol (HDL), (2) alcohol-related gastrointestinal hospitalizations (GI hospitalizations') and (3) physical trauma, each in the years after baseline and follow-up. FindingsBaseline AUDIT-C scores had a positive association with outcomes in the following year. Across AUDIT-C scores 0-12, mean HDL ranged from 41.4 [95% confidence interval (CI)=41.3-41.5] to 53.5 (95% CI=51.4-55.6) mg/l, and probabilities of GI hospitalizations from 0.49% (95% CI=0.48-0.51%) to 1.8% (95% CI=1.3-2.3%) and trauma from 3.0% (95% CI=2.95-3.06%) to 6.0% (95% CI=5.2-6.8%). At follow-up, patients who increased to moderate or severe alcohol misuse had consistently higher mean HDL and probabilities of subsequent GI hospitalizations or trauma compared with those who did not (P-values all <0.05). For example, among those with baseline low-risk use, in those with persistent low-risk use versus severe misuse at follow-up, the probabilities of subsequent trauma were 2.65% (95% CI=2.54-2.75%) versus 5.15% (95% CI=3.86-6.45%), respectively. However, for patients who decreased to lower AUDIT-C risk groups at follow-up, findings were inconsistent across outcomes, with only mean HDL decreasing in most groups that decreased use (P-values all <0.05). ConclusionsWhen AUDIT-C screening is conducted in clinical settings, baseline AUDIT-C scores and score increases to moderate-severe alcohol misuse at follow-up screening appear to have predictive validity for HDL cholesterol, alcohol-related gastrointestinal hospitalizations and physical trauma. Decreasing AUDIT-C scores collected in clinical settings appear to have predictive validity for only HDL. C1 [Bradley, Katharine A.; Rubinsky, Anna D.; Lapham, Gwen T.; Bryson, Christopher; Achtmeyer, Carol; Hawkins, Eric J.; Chavez, Laura J.; Williams, Emily C.; Kivlahan, Daniel R.] Seattle Ctr Innovat Veteran Ctr & Value Driven Ca, HSR&D, Seattle, WA USA. [Bradley, Katharine A.; Rubinsky, Anna D.; Achtmeyer, Carol; Hawkins, Eric J.; Kivlahan, Daniel R.] Vet Affairs VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. [Bradley, Katharine A.; Lapham, Gwen T.] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [Berger, Douglas; Bryson, Christopher; Achtmeyer, Carol] Dept Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Bradley, Katharine A.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bradley, Katharine A.; Berger, Douglas; Kivlahan, Daniel R.] Univ Washington, Dept Med, Seattle, WA USA. [Hawkins, Eric J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rubinsky, Anna D.] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA. [Rubinsky, Anna D.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Bradley, KA (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM bradley.k@ghc.org FU Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development, Health Services Research and Development Merit Review Award [IIR 08-314]; Group Health Research Institute; Career Development Award from VA Health Services Research Development [CDA 12-276] FX This work was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development, Health Services Research and Development Merit Review Award #IIR 08-314 and Group Health Research Institute. Support for VA/CMS data for this project is provided by the VA Information Resource Center. E.C.W. is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 66 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD NOV PY 2016 VL 111 IS 11 BP 1975 EP 1984 DI 10.1111/add.13505 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DZ8WR UT WOS:000386153700016 PM 27349855 ER PT J AU Banerjee, G Edelman, EJ Barry, DT Becker, WC Cerda, M Crystal, S Gaither, JR Gordon, AJ Gordon, KS Kerns, RD Martins, SS Fiellin, DA Marshall, BDL AF Banerjee, Geetanjoli Edelman, E. Jennifer Barry, Declan T. Becker, William C. Cerda, Magdalena Crystal, Stephen Gaither, Julie R. Gordon, Adam J. Gordon, Kirsha S. Kerns, Robert D. Martins, Silvia S. Fiellin, David A. Marshall, Brandon D. L. TI Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study SO ADDICTION LA English DT Article DE Heroin; longitudinal study; non-medical prescription drug use; opioid-related disorders; polysubstance use; veterans ID POSTTRAUMATIC-STRESS-DISORDER; UNITED-STATES; VIETNAM VETERANS; CHRONIC PAIN; INVERSE PROBABILITY; UNINFECTED PATIENTS; MILITARY PERSONNEL; THERAPEUTIC-USE; MENTAL-ILLNESS; MEDICAL USE AB AimsTo estimate the influence of non-medical use of prescription opioids (NMUPO) on heroin initiation among US veterans receiving medical care. DesignUsing a multivariable Cox regression model, we analyzed data from a prospective, multi-site, observational study of HIV-infected and an age/race/site-matched control group of HIV-uninfected veterans in care in the United States. Approximately annual behavioral assessments were conducted and contained self-reported measures of NMUPO and heroin use. SettingVeterans Health Administration (VHA) infectious disease and primary care clinics in Atlanta, Baltimore, New York, Houston, Los Angeles, Pittsburgh and Washington, DC. ParticipantsA total of 3396 HIV-infected and uninfected patients enrolled into the Veterans Aging Cohort Study who reported no life-time NMUPO or heroin use, had no opioid use disorder diagnoses at baseline and who were followed between 2002 and 2012. MeasurementsThe primary outcome measure was self-reported incident heroin use and the primary exposure of interest was new-onset NMUPO. Our final model was adjusted for socio-demographics, pain interference, prior diagnoses of post-traumatic stress disorder and/or depression and self-reported other substance use. FindingsUsing a multivariable Cox regression model, we found that non-medical use of prescription opioids NMUPO was associated positively and independently with heroin initiation [adjusted hazard ratio (AHR)=5.43, 95% confidence interval (CI)=4.01, 7.35]. ConclusionsNew-onset non-medical use of prescription opioids (NMUPO) is a strong risk factor for heroin initiation among HIV-infected and uninfected veterans in the United States who reported no previous history of NMUPO or illicit opioid use. C1 [Banerjee, Geetanjoli; Marshall, Brandon D. L.] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI USA. [Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA. [Edelman, E. Jennifer; Gaither, Julie R.; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Barry, Declan T.] Yale Univ, Sch Med, New Haven, CT USA. [Barry, Declan T.] APT Fdn Pain Treatment Serv, New Haven, CT USA. [Becker, William C.; Kerns, Robert D.] VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Cerda, Magdalena] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA. [Gaither, Julie R.] Yale Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Kirsha S.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Kerns, Robert D.] Yale Univ, Dept Neurol, New Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychol, New Haven, CT USA. [Martins, Silvia S.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. RP Marshall, BDL (reprint author), Brown Univ, Dept Epidemiol, 121 South Main St, Providence, RI 02912 USA. EM brandon_marshall@brown.edu OI Fiellin, David/0000-0002-4006-010X FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794, P01-AA019072]; National Institute of Allergy and Infectious Diseases US Department of Veterans Affairs; National Institute on Drug Abuse [F31-DA035567, R03-DA037770, R01-DA037866]; AHRQ [1U19HS021112, R18-HS023258]; Center of Innovation grant from the Health Services Research and Development Service of the Department of Veterans Affairs [CIN 13-047] FX This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA: U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794, U10-AA013566, and P01-AA019072), the National Institute of Allergy and Infectious Diseases (P30-AI042853), and in kind by the US Department of Veterans Affairs. J.R.G. is supported by the National Institute on Drug Abuse (F31-DA035567). E.J.E. is a Yale-Drug Abuse, Addiction, and HIV research scholar (K12-DA033312). B.D.L.M. is supported by the National Institute on Drug Abuse (R03-DA037770). S.S.M. is supported by the National Institute on Drug Abuse (R01-DA037866). S.C. is supported by AHRQ awards 1U19HS021112 and R18-HS023258. R.D.K. is supported by a Center of Innovation grant from the Health Services Research and Development Service of the Department of Veterans Affairs (CIN 13-047). The sponsors had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; and in the decision to submit the article for publication. We would like to acknowledge the veterans who participate in the Veterans Aging Cohort Study (VACS) and the study coordinators and staff at each VACS site and at the West Haven Coordinating Center. We would also like to thank Melissa Skanderson for her assistance and support during data acquisition. The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 57 TC 3 Z9 3 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD NOV PY 2016 VL 111 IS 11 BP 2021 EP 2031 DI 10.1111/add.13491 PG 11 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DZ8WR UT WOS:000386153700022 PM 27552496 ER PT J AU Fargo, KN Carrillo, MC Weiner, MW Potter, WZ Khachaturian, Z Vradenburg, G Weiner, MW AF Fargo, Keith N. Carrillo, Maria C. Weiner, Michael W. Potter, William Z. Khachaturian, Zaven Vradenburg, George Weiner, Michael W. TI The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions SO ALZHEIMERS & DEMENTIA LA English DT Editorial Material ID PREVENTION TRIALS; DRUG TRIALS; TASK-FORCE; DISEASE C1 [Fargo, Keith N.; Carrillo, Maria C.] Alzheimers Assoc, Chicago, IL USA. [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Potter, William Z.] NIMH, Bethesda, MD USA. [Khachaturian, Zaven] Journal Alzheimers Assoc, Rockville, MD USA. RP Khachaturian, Z (reprint author), Journal Alzheimers Assoc, Rockville, MD USA. EM zaven@kra.net NR 15 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2016 VL 12 IS 11 BP 1113 EP 1115 DI 10.1016/j.jalz.2016.19.001 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EC1AJ UT WOS:000387835600001 PM 27836052 ER PT J AU Shi, M Kovac, A Korff, A Cook, TJ Ginghina, C Bullock, KM Yang, L Stewart, T Zheng, DF Aro, P Atik, A Kerr, KF Zabetian, CP Peskind, ER Hu, SC Quinn, JF Galasko, DR Montine, TJ Banks, WA Zhang, J AF Shi, Min Kovac, Andrej Korff, Ane Cook, Travis J. Ginghina, Carmen Bullock, Kristin M. Yang, Li Stewart, Tessandra Zheng, Danfeng Aro, Patrick Atik, Anzari Kerr, Kathleen F. Zabetian, Cyrus P. Peskind, Elaine R. Hu, Shu-Ching Quinn, Joseph F. Galasko, Douglas R. Montine, Thomas J. Banks, William A. Zhang, Jing TI CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Article DE Central nervous system protein efflux; Central nervous system-derived exosomes; Tau; Blood plasma; Alzheimer's disease; Parkinson's disease; Biomarkers ID BLOOD-BRAIN-BARRIER; CELL-ADHESION MOLECULE; ALPHA-SYNUCLEIN; CEREBROSPINAL-FLUID; PATHOLOGY; PLASMA; PROTEINS; L1; ASSOCIATION; DJ-1 AB Introduction: Alzheimer's disease (AD) and Parkinson's disease (PD) involve tau pathology. Tau is detectable in blood, but its clearance from neuronal cells and the brain is poorly understood. Methods: Tau efflux from the brain to the blood was evaluated by administering radioactively labeled and unlabeled tau intracerebroventricularly in wild-type and tau knock-out mice, respectively. Central nervous system (CNS) derived tau in L1CAM-containing exosomes was further characterized extensively in human plasma, including by single molecule array technology with 303 subjects. Results: The efflux of Tau, including a fraction via CNS-derived L1CAM exosomes, was observed in mice. In human plasma, tau was explicitly identified within L1CAM exosomes. In contrast to AD patients, L1CAM exosomal tau was significantly higher in PD patients than controls and correlated with cerebrospinal fluid tau. Conclusions: Tau is readily transported from the brain to the blood. The mechanisms of CNS tau efflux are likely different between AD and PD. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Shi, Min; Korff, Ane; Cook, Travis J.; Ginghina, Carmen; Yang, Li; Stewart, Tessandra; Zheng, Danfeng; Aro, Patrick; Atik, Anzari; Montine, Thomas J.; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Kovac, Andrej; Bullock, Kristin M.; Zabetian, Cyrus P.; Hu, Shu-Ching; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Kovac, Andrej; Bullock, Kristin M.; Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kovac, Andrej] Slovak Acad Sci, Inst Neuroimmunol, Bratislava, Slovakia. [Zheng, Danfeng; Zhang, Jing] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing, Peoples R China. [Zheng, Danfeng; Zhang, Jing] Peking Univ, Hosp 3, Beijing, Peoples R China. [Kerr, Kathleen F.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Galasko, Douglas R.] Univ Calif San Diego, Shiley Marcos Alzheimers Dis Res Ctr, La Jolla, CA 92093 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.; Zhang, J (reprint author), Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing, Peoples R China.; Zhang, J (reprint author), Peking Univ, Hosp 3, Beijing, Peoples R China. EM zhangj@uw.edu FU National Institutes of Health (NIH) [U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, P50 NS062684-6221, R21 NS085425, R01 NS065070, P50 AG05131]; Alzheimer's Association grant [2015-NIRG-342009]; Department of Veterans Affairs [1I01BX000531, 5I01BX002113]; University of Washington's Proteomics Resource [UWPR95794] FX We deeply appreciate the participants for their generous donation of samples. This study was supported by grants from the National Institutes of Health (NIH) (U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221 to JZ, R21 NS085425 to M.S., R01 NS065070 to C.P.Z., and P50 AG05131 to D.R.G.), partially by an Alzheimer's Association grant (2015-NIRG-342009) to M.S., and by grants from the Department of Veterans Affairs (to Parkinson's Disease, Mental illness, and Geriatric Research, Education, and Clinical Centers, VA Puget Sound Health Care System - C.P.Z., E.R.P., and W.A.B.; 1I01BX000531 to C.P.Z., and 5I01BX002113 to J.F.Q.). It was also supported in part by the University of Washington's Proteomics Resource (UWPR95794). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; or decision to submit the manuscript for publication. NR 29 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2016 VL 12 IS 11 BP 1125 EP 1131 DI 10.1016/j.jalz.2016.04.003 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EC1AJ UT WOS:000387835600003 PM 27234211 ER PT J AU Schopfer, DW Regan, M Heidenreich, PA Whooley, MA AF Schopfer, David W. Regan, Mathilda Heidenreich, Paul A. Whooley, Mary A. TI Depressive Symptoms, Cardiac Disease Severity, and Functional Status in Patients With Coronary Artery Disease (from the Heart and Soul Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIOVASCULAR EVENTS; ANGINA-PECTORIS; PRIMARY-CARE; ASSOCIATION; RISK; MORTALITY; FAILURE; REHABILITATION; CLASSIFICATION; EPIDEMIOLOGY AB Patient-reported health status is highly valued as a key measure of health care quality, yet little is known about the extent to which it is determined by subjective perception compared with objective measures of disease severity. We sought to compare the associations of depressive symptoms and objective measures of cardiac disease severity with perceived functional status in patients with stable coronary artery disease. We assessed depressive symptoms, severity of cardiovascular disease, and perceived functional status in a cross-sectional study of 1,023 patients with stable coronary artery disease. We compared the extent to which patient-reported functional status was influenced by depressive symptoms versus objective measures of disease severity. We then evaluated perceived functional status as a predictor of subsequent cardiovascular hospitalizations during 8.8 years of follow-up. Patients with depressive symptoms were more likely to report poor functional status than those without depressive symptoms (44% vs 17%; p <0.001). After adjustment for traditional risk factors and co-morbid conditions, independent predictors of poor functional status were depressive symptoms (odds ratio [OR] 2.68, 95% confidence interval [CI] 1.89 to 3.79), poor exercise capacity (OR 2.30, 95% CI 1.65 to 3.19), and history of heart failure (OR 1.61, 95% CI 1.12 to 2.29). Compared with patients who had class I functional status, those with class II functional status had a 96% greater rate (hazard ratio 1.96, 95% CI 1.15 to 3.34) and those with class III or IV functional status had a 104% greater rate (hazard ratio 2.04, 95% CI 1.12 to 3.73) of hospitalization for HF, adjusted for baseline demographic characteristics, co-morbidities, cardiac disease severity, and depressive symptoms. In conclusion, depressive symptoms and cardiac disease severity were independently associated with patient-reported functional status. This suggests that perceived functional status may be as strongly influenced by depressive symptoms as it is by cardiovascular disease severity. Published by Elsevier Inc. C1 [Schopfer, David W.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schopfer, David W.; Regan, Mathilda; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Heidenreich, Paul A.] Stanford Univ, Dept Cardiol, Palo Alto, CA 94304 USA. [Heidenreich, Paul A.] VA Palo Alto Healthcare Syst, Dept Cardiol, Palo Alto, CA USA. RP Schopfer, DW (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Schopfer, DW (reprint author), San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. EM david.schopfer@ucsf.edu FU National Center for Advancing Translational Sciences, Bethesda; Maryland of the National Institutes of Health, Bethesda, Maryland [KL2TR000143]; Department of Veterans Affairs, Washington, DC (Epidemiology Merit Review Program); National Heart, Lung, and Blood Institute, Bethesda, Maryland [R01 HL079235]; Robert Wood Johnson Foundation, Princeton, New Jersey (Generalist Physician Faculty Scholars Program); American Federation for Aging Research, New York, New York (Paul Beeson Faculty Scholars in Aging Regearch Program); Ischemia Research and Education Foundation, South San Francisco, California; Nancy Kirwan Heart Research Fund, San Francisco, California FX Dr. Schopfer is supported by the National Center for Advancing Translational Sciences, Bethesda, Maryland of the National Institutes of Health, Bethesda, Maryland under award number KL2TR000143. The Heart and Soul Study was supported by grants from the Department of Veterans Affairs, Washington, DC (Epidemiology Merit Review Program), the National Heart, Lung, and Blood Institute, Bethesda, Maryland (R01 HL079235), the Robert Wood Johnson Foundation, Princeton, New Jersey (Generalist Physician Faculty Scholars Program), the American Federation for Aging Research, New York, New York (Paul Beeson Faculty Scholars in Aging Regearch Program), the Ischemia Research and Education Foundation, South San Francisco, California, and Nancy Kirwan Heart Research Fund, San Francisco, California. NR 29 TC 0 Z9 0 U1 2 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 1 PY 2016 VL 118 IS 9 BP 1287 EP 1292 DI 10.1016/j.amjcard.2016.07.062 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC2JJ UT WOS:000387937700003 PM 27665203 ER PT J AU Leslie-Mazwi, TM Bello, JA Tu, R Nicola, GN Donovan, WD Barr, RM Hirsch, JA AF Leslie-Mazwi, T. M. Bello, J. A. Tu, R. Nicola, G. N. Donovan, W. D. Barr, R. M. Hirsch, J. A. TI Current Procedural Terminology: History, Structure, and Relationship to Valuation for the Neuroradiologist SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID CODES AB The year 1965 was critical for US health care policy. In that year, Medicare was created as part of the Social Security Act under President Lyndon B. Johnson after several earlier attempts by Presidents Franklin Roosevelt and Harry Truman. In 1966, the American Medical Association first published a set of standard terms and descriptors to document medical procedures, known as Current Procedural Terminology, or CPT. Fifty years later, though providers have certainly heard the term CPT code, most would benefit from an enhanced understanding of the historical basis, current structure, and relationship to valuation of Current Procedural Terminology. This article will highlight this evolution, particularly as it relates to neuroradiology. C1 [Leslie-Mazwi, T. M.; Hirsch, J. A.] Massachusetts Gen Hosp, Neuroendovasc Program, Boston, MA 02114 USA. [Bello, J. A.] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA. [Tu, R.] George Washington Univ, Progress Radiol, Falls Church, VA USA. [Nicola, G. N.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Donovan, W. D.] Norwich Diagnost Imaging Associates, Norwich, CT USA. [Barr, R. M.] Mecklenburg Radiol Associates PA, Charlotte, NC USA. RP Leslie-Mazwi, TM (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Neuroendovasc Program, Boston, MA 02114 USA. EM tleslie-mazwi@mgh.harvard.edu NR 19 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD NOV PY 2016 VL 37 IS 11 BP 1972 EP 1976 DI 10.3174/ajnr.A4863 PG 5 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA EC2PI UT WOS:000387965400009 ER PT J AU Clark, LR Koscik, RL Nicholas, CR Okonkwo, OC Engelman, CD Bratzke, LC Hogan, KJ Mueller, KD Bendlin, BB Carlsson, CM Asthana, S Sager, MA Hermann, BP Johnson, SC AF Clark, Lindsay R. Koscik, Rebecca L. Nicholas, Christopher R. Okonkwo, Ozioma C. Engelman, Corinne D. Bratzke, Lisa C. Hogan, Kirk J. Mueller, Kimberly D. Bendlin, Barbara B. Carlsson, Cynthia M. Asthana, Sanjay Sager, Mark A. Hermann, Bruce P. Johnson, Sterling C. TI Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Mild cognitive impairment; Alzheimer's disease; Norms/normative studies; Elderly/Geriatrics/Aging; Dementia; Learning and Memory ID INFORMANT QUESTIONNAIRE; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; HEALTHY-ADULTS; ELDERLY IQCODE; DISEASE; DECLINE; DEMENTIA; CRITERIA AB Objective: Detecting cognitive decline in presymptomatic Alzheimer's disease (AD) and early mild cognitive impairment (MCI) is challenging, but important for treatments targeting AD-related neurodegeneration. The current study aimed to investigate the utility and performance of internally developed robust norms and standard norms in identifying cognitive impairment in late middle-age (baseline age range = 36-68; M = 54). Method: Robust norms were developed for neuropsychological measures based on longitudinally confirmed cognitively normal (CN) participants (n = 476). Seven hundred and seventy-nine participants enriched for AD risk were classified as psychometric MCI (pMCI) or CN based on standard and robust norms and "single-test" versus "multi-test" criteria. Results: Prevalence of pMCI ranged from 3% to 49% depending on the classification scheme used. Those classified as pMCI using robust norms exhibited greater subjective cognitive complaints, diagnostic stability, and mild clinical symptoms at follow-up. Conclusions: Results suggest that identifying early clinically relevant cognitive decline in late middle-age is feasible using robust norms and multi-test criteria. C1 [Clark, Lindsay R.; Koscik, Rebecca L.; Okonkwo, Ozioma C.; Engelman, Corinne D.; Bratzke, Lisa C.; Hogan, Kirk J.; Mueller, Kimberly D.; Carlsson, Cynthia M.; Asthana, Sanjay; Sager, Mark A.; Hermann, Bruce P.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53705 USA. [Clark, Lindsay R.; Nicholas, Christopher R.; Okonkwo, Ozioma C.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53705 USA. [Nicholas, Christopher R.; Okonkwo, Ozioma C.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Engelman, Corinne D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53705 USA. [Bratzke, Lisa C.] Univ Wisconsin, Sch Nursing, Madison, WI 53705 USA. [Hogan, Kirk J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI 53705 USA. [Hermann, Bruce P.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53705 USA. RP Johnson, SC (reprint author), William S Middleton Mem VA Hosp, GRECC, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Bratzke, Lisa/0000-0002-0321-4501 FU Clinical Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS) [UL1TR00427]; National Institutes of Health (NIH) [R01 AG027161, R01 AG021155, ADRC P50 AG033514]; Wisconsin Alzheimer's Institute (WAI) Holland Research Fund FX This work was supported by the Clinical Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS), and grant UL1TR00427. Funding support was also provided by the National Institutes of Health (NIH) (R01 AG027161 to S.C.J., R01 AG021155 to S.C.J., ADRC P50 AG033514 to S.A.) and the Wisconsin Alzheimer's Institute (WAI) Holland Research Fund. The content is solely the responsibility of the authors and does not represent the official views of NIH. NR 48 TC 3 Z9 3 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD NOV PY 2016 VL 31 IS 7 BP 675 EP 688 DI 10.1093/arclin/acw024 PG 14 WC Psychology, Clinical; Psychology SC Psychology GA EC2PH UT WOS:000387965300001 ER PT J AU Woodbury, ML Anderson, K Finetto, C Fortune, A Dellenbach, B Grattan, E Hutchison, S AF Woodbury, Michelle L. Anderson, Kelly Finetto, Christian Fortune, Andrew Dellenbach, Blair Grattan, Emily Hutchison, Scott TI Matching Task Difficulty to Patient Ability During Task Practice Improves Upper Extremity Motor Skill After Stroke: A Proof-of-Concept Study SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Occupational therapy; Rehabilitation; Stroke ID FUGL-MEYER ASSESSMENT; ADULT SQUIRREL-MONKEYS; MOVEMENT REPRESENTATIONS; THERAPY; CORTEX; RECOVERY; STRATEGIES AB Objective: To test the feasibility of the Fugl-Meyer Assessment of the Upper Extremity "keyform," derived from Rasch analysis, as a method for systematically planning and progressing rehabilitation. Design: Feasibility study, single group design. Setting: University rehabilitation research laboratory. Participants: Participants (N=10; mean age, 59.70 +/- 9.96y; 24.1 +/- 30.54mo poststroke) with ischemic or hemorrhagic stroke >3 months prior, voluntarily shoulder flexion >= 30 degrees, and simultaneous elbow extension >= 20 degrees. Interventions: The keyform method defined initial rehabilitation targets (goals) and progressed the rehabilitation program after every third session. Targets were repetitively practiced within the context of client-selected functional tasks not in isolation. Main Outcome Measures: Feasibility was defined by subject's pain or fatigue, upper extremity motor function (Wolf Motor Function Test), and movement patterns (kinematics). Assessments were administered pre- and posttreatment and compared using paired t tests. Task-difficulty and patient-ability measures were calculated using Rasch analysis and compared using paired t tests (P<.05). Results: Ten participants completed 9 sessions, 200 movement repetitions per session in <2 hours without pain or fatigue. Participants gained upper extremity motor function (Wolf Motor Function Test: pretreatment, 22.23 +/- 24.26s; posttreatment, 15.46 +/- 22.12s; P=.01), improved shoulder elbow coordination (index of curvature: pretreatment, 1.30 +/- 0.15; posttreatment, 1.21 +/- 0.11; P =.01), and exhibited reduced trunk compensatory movement (trunk displacement: pretreatment, 133.97 +/- 74.15mm; posttreatment, 108.08 +/- 64.73mm; P=.02). Task-difficulty and patient-ability measures were not statistically different throughout the program (person-ability measures of 1.01 +/- 0.05, 1.64 +/- 0.45, and 2.22 +/- 0.65 logits and item-difficulty measures of 0.93 +/- 0.37, 1.70 +/- 0.20, and 2.06 +/- 0.24 logits at the 3 testing time points, respectively; P>.05). Conclusions: The Fugl-Meyer Assessment of the Upper Extremity keyform is a feasible method to ensure that the difficulty of tasks practiced were well matched to initial and evolving levels of upper extremity motor ability. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Woodbury, Michelle L.; Fortune, Andrew; Hutchison, Scott] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Woodbury, Michelle L.; Anderson, Kelly; Finetto, Christian; Fortune, Andrew; Dellenbach, Blair; Grattan, Emily; Hutchison, Scott] Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Woodbury, Michelle L.; Hutchison, Scott] Med Univ South Carolina, Dept Hlth Profess, Div Occupat Therapy, Charleston, SC 29425 USA. RP Woodbury, ML (reprint author), Med Univ South Carolina, Coll Hlth Profess, 77 President St, Charleston, SC 29425 USA. EM WoodbuML@musc.edu FU Ralph H. Johnson Veterans Affairs Medical Center; Office of Research and Development, Rehabilitation Research and Development, Department of Veterans Affairs, Career Development-2 Award [B-6332W]; Veterans Affairs Merit Review Awards [N0799-R]; Medical University of South Carolina Center of Biomedical Research Excellence for Stroke Recovery, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM12345] FX Supported in part by the Ralph H. Johnson Veterans Affairs Medical Center and the Office of Research and Development, Rehabilitation Research and Development, Department of Veterans Affairs, Career Development-2 Award (award no. B-6332W); and Veterans Affairs Merit Review Awards (award no. N0799-R). Also supported by the Medical University of South Carolina Center of Biomedical Research Excellence for Stroke Recovery, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (grant no. P20GM12345). NR 30 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2016 VL 97 IS 11 BP 1863 EP 1871 DI 10.1016/j.apmr.2016.03.022 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA EB8IK UT WOS:000387634500005 PM 27117385 ER PT J AU Rolfson, O Wissig, S van Maasakkers, L Stowell, C Ackerman, I Ayers, D Barber, T Benzakour, T Bozic, K Budhiparama, N Caillouette, J Conaghan, PG Dahlberg, L Dunn, J Grady-Benson, J Ibrahim, SA Lewis, S Malchau, H Manzary, M March, L Nassif, N Nelissen, R Smith, N Franklin, PD AF Rolfson, Ola Wissig, Stephanie van Maasakkers, Lisa Stowell, Caleb Ackerman, Ilana Ayers, David Barber, Thomas Benzakour, Thami Bozic, Kevin Budhiparama, Nicolaas Caillouette, James Conaghan, Philip G. Dahlberg, Leif Dunn, Jennifer Grady-Benson, John Ibrahim, Said A. Lewis, Sally Malchau, Henrik Manzary, Mojieb March, Lyn Nassif, Nader Nelissen, Rob Smith, Noel Franklin, Patricia D. TI Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group SO ARTHRITIS CARE & RESEARCH LA English DT Article ID REPORTED OUTCOMES; PHYSICAL-FUNCTION; ARTHROPLASTY REGISTER; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; REPLACEMENT; PAIN; QUESTIONNAIRE; MANAGEMENT; QUALITY AB ObjectiveTo define a minimum Standard Set of outcome measures and case-mix factors for monitoring, comparing, and improving health care for patients with clinically diagnosed hip or knee osteoarthritis (OA), with a focus on defining the outcomes that matter most to patients. MethodsAn international working group of patients, arthroplasty register experts, orthopedic surgeons, primary care physicians, rheumatologists, and physiotherapists representing 10 countries was assembled to review existing literature and practices for assessing outcomes of pharmacologic and nonpharmacologic OA therapies, including surgery. A series of 8 teleconferences, incorporating a modified Delphi process, were held to reach consensus. ResultsThe working group reached consensus on a concise set of outcome measures to evaluate patients' joint pain, physical functioning, health-related quality of life, work status, mortality, reoperations, readmissions, and overall satisfaction with treatment result. To support analysis of these outcome measures, pertinent baseline characteristics and risk factor metrics were defined. Annual outcome measurement is recommended for all patients. ConclusionWe have defined a Standard Set of outcome measures for monitoring the care of people with clinically diagnosed hip or knee OA that is appropriate for use across all treatment and care settings. We believe this Standard Set provides meaningful, comparable, and easy to interpret measures ready to implement in clinics and/or registries globally. We view this set as an initial step that, when combined with cost data, will facilitate value-based health care improvements in the treatment of hip and knee OA. C1 [Rolfson, Ola; Wissig, Stephanie; van Maasakkers, Lisa; Stowell, Caleb] Int Consortium Hlth Outcomes Measurement, Cambridge, MA USA. [Rolfson, Ola; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Rolfson, Ola; Malchau, Henrik] Harvard Med Sch, Boston, MA USA. [Rolfson, Ola; Malchau, Henrik] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden. [Ackerman, Ilana] Univ Melbourne, Melbourne, Vic, Australia. [Ayers, David; Franklin, Patricia D.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Barber, Thomas] Kaiser Permanente, Oakland, CA USA. [Benzakour, Thami] Zerktouni Orthoped Clin, Casablanca, Morocco. [Bozic, Kevin] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA. [Budhiparama, Nicolaas] Medistra Hosp, Fdn Arthroplasty & Sports Med, Nicolaas Inst Construct Orthopaed Res & Educ, Jakarta, Indonesia. [Caillouette, James; Nassif, Nader] Hoag Orthoped Inst, Newport Beach, CA USA. [Conaghan, Philip G.] Univ Leeds, Leeds, W Yorkshire, England. [Conaghan, Philip G.] Natl Inst Hlth Res, Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Dahlberg, Leif] Lund Univ, Lund, Sweden. [Dunn, Jennifer] Univ Otago, Dunedin, New Zealand. [Grady-Benson, John] Connecticut Joint Replacement Inst, Hartford, CT USA. [Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lewis, Sally] Aneurin Bevan Hlth Board, Newport, Gwent, Wales. [Manzary, Mojieb] Johns Hopkins Aramco Hlth Care Ctr, Dhahran, Saudi Arabia. [March, Lyn] North Sydney Orthopaed & Sports Med Ctr, Sydney, NSW, Australia. [March, Lyn] Univ Sydney, Inst Bone & Joint, Royal North Shore Hosp, Sydney, NSW, Australia. [Nelissen, Rob] Leiden Univ, Leiden, Netherlands. [Smith, Noel] Arthrit Victoria, Elsternwick, Vic, Australia. RP Rolfson, O (reprint author), Sahlgrens Univ Hosp, Dept Orthopaed, S-43180 Molndal, Sweden. EM ola.rolfson@vgregion.se OI Dunn, Jennifer/0000-0002-2894-7533; Rolfson, Ola/0000-0001-6534-1242 FU Hoag Orthopedic Institute; Connecticut Joint Replacement Institute; Harvard Pilgrim Health Care; Zimmer Biomet; DePuy Synthes FX Supported by the Hoag Orthopedic Institute, the Connecticut Joint Replacement Institute, and the Harvard Pilgrim Health Care.; Dr. Budhiparama sits on the advisory boards of DePuy Synthes, Roche, and Sanofi Aventis and has received grants from Zimmer Biomet (less than $10,000). Dr. Malchau has received institutional grants from DePuy Synthes and Zimmer Biomet (more than $10,000 each) and is a board member and shareholder in RSA Biomedical. NR 49 TC 3 Z9 3 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2016 VL 68 IS 11 BP 1631 EP 1639 DI 10.1002/acr.22868 PG 9 WC Rheumatology SC Rheumatology GA EB0TN UT WOS:000387058800007 PM 26881821 ER PT J AU Kozora, E Ulug, AM Erkan, D Vo, A Filley, CM Ramon, G Burleson, A Zimmerman, R Lockshin, MD AF Kozora, E. Ulug, A. M. Erkan, D. Vo, A. Filley, C. M. Ramon, G. Burleson, A. Zimmerman, R. Lockshin, M. D. TI Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients SO ARTHRITIS CARE & RESEARCH LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; CLINICAL-DISEASE ACTIVITY; NEUROPSYCHIATRIC LUPUS; COGNITIVE DEFICITS; BRAIN; MANIFESTATIONS; ABNORMALITIES; INDEX; TASK; CLASSIFICATION AB ObjectiveStandardized cognitive tests and functional magnetic resonance imaging (fMRI) studies of systemic lupus erythematosus (SLE) patients demonstrate deficits in working memory and executive function. These neurobehavioral abnormalities are not well studied in antiphospholipid syndrome, which may occur independently of or together with SLE. This study compares an fMRI paradigm involving motor skills, working memory, and executive function in SLE patients without antiphospholipid antibody (aPL) (the SLE group), aPL-positive non-SLE patients (the aPL-positive group), and controls. MethodsBrain MRI, fMRI, and standardized cognitive assessment results were obtained from 20 SLE, 20 aPL-positive, and 10 healthy female subjects with no history of neuropsychiatric abnormality. ResultsAnalysis of fMRI data showed no differences in performance across groups on bilateral motor tasks. When analysis of variance was used, significant group differences were found in 2 executive function tasks (word generation and word rhyming) and in a working memory task (N-Back). Patients positive for aPL demonstrated higher activation in bilateral frontal, temporal, and parietal cortices compared to controls during working memory and executive function tasks. SLE patients also demonstrated bilateral frontal and temporal activation during working memory and executive function tasks. ConclusionCompared to controls, both aPL-positive and SLE patients had elevated cortical activation, primarily in the frontal lobes, during tasks involving working memory and executive function. These findings are consistent with cortical overactivation as a compensatory mechanism for early white matter neuropathology in these disorders. C1 [Kozora, E.; Burleson, A.] Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. [Kozora, E.; Filley, C. M.] Univ Colorado, Sch Med, Denver, CO USA. [Kozora, E.; Erkan, D.; Lockshin, M. D.] Cornell Univ, Hosp Special Surg, New York, NY 10021 USA. [Kozora, E.; Erkan, D.; Zimmerman, R.; Lockshin, M. D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Ulug, A. M.; Vo, A.] Feinstein Inst Med Res, Manhasset, NY USA. [Ulug, A. M.] Hofstra Univ, Hempstead, NY 11550 USA. [Ulug, A. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ulug, A. M.] Bogazici Univ, Inst Biomed Engn, Istanbul, Turkey. [Filley, C. M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ramon, G.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. RP Kozora, E (reprint author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. EM kozorae@njhealth.org FU Mary Kirkland Center, Hospital for Special Surgery, New York, New York FX Supported by the Mary Kirkland Center, Hospital for Special Surgery, New York, New York. NR 49 TC 1 Z9 1 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2016 VL 68 IS 11 BP 1655 EP 1663 DI 10.1002/acr.22873 PG 9 WC Rheumatology SC Rheumatology GA EB0TN UT WOS:000387058800010 PM 26946337 ER PT J AU Dzierba, AL Roberts, R Muir, J Alhammad, A Schumaker, G Clark, J Ruthazer, R Devlin, JW AF Dzierba, Amy L. Roberts, Russel Muir, Justin Alhammad, Abdullah Schumaker, Greg Clark, Jacqueline Ruthazer, Robin Devlin, John W. TI Severe Thrombocytopenia in Adults with Severe Acute Respiratory Distress Syndrome: Impact of Extracorporeal Membrane Oxygenation Use SO ASAIO JOURNAL LA English DT Article DE platelet; acute respiratory distress syndrome; extracorporeal membrane oxygenation; intensive care unit ID CRITICALLY-ILL PATIENTS; 2009 INFLUENZA A(H1N1); RISK-FACTORS; ORGANIZATION; SUPPORT AB Extracorporeal membrane oxygenation (ECMO) use is perceived to cause thrombocytopenia (T), but the role of non-ECMO factors in the development of T remains unclear. We sought to evaluate the incidence and factors associated with severe T (platelet count <= 50,000/mu l) in adults with severe acute respiratory distress syndrome (ARDS) managed with or without ECMO. The ECMO (n = 32) versus the non-ECMO (n = 53) groups had a similar baseline platelet count (214,000 vs. 179,000/mu l), Acute Physiology and Chronic Health Evaluation (APACHE) II score (p = 0.13), unfractionated heparin (UFH) exposure (p = 0.62), and severe T incidence (25 vs. 19%, p = 0.5). Although the APACHE II score (p = 0.01), presence of liver failure (p = 0.08), and platelet transfusion (p = 0.0009) were different between the severe T (18/85 [21%]) and non-severe T groups (67/85 [79%]), the incidence of septic shock (p = 0.64), heparin infusion use (p = 0.41), exposure to non-heparin T-causing medications (p = 0.77) and ECMO use (p = 0.5) were not. An adjusted multivariate linear regression model revealed that only the APACHE II score was independently associated with the development of severe T (p = 0.01) but use of ECMO was not (p = 0.32) ECMO use may not affect the incidence of severe T among adults with severe ARDS. Larger studies that are prospective in nature are required to confirm this finding. C1 [Dzierba, Amy L.; Muir, Justin] NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA. [Roberts, Russel; Devlin, John W.] Northeastern Univ, Sch Pharm, 360 Huntington Ave,140TF RD218F, Boston, MA 02115 USA. [Roberts, Russel] Massachusetts Gen Hosp, Dept Pharm Serv, Boston, MA 02114 USA. [Alhammad, Abdullah] King Saud Univ, Coll Pharm, Riyahd, Saudi Arabia. [Schumaker, Greg; Devlin, John W.] Tufts Med Ctr, Div Pulm Crit Care Med & Sleep Med, Boston, MA USA. [Clark, Jacqueline] Univ Maryland, Med Ctr, Dept Pharm Serv, Baltimore, MD 21201 USA. [Ruthazer, Robin] Tufts Med Ctr, Tufts CTSI Biostat & Epidemiol Res Design Ctr, Boston, MA USA. RP Devlin, JW (reprint author), Northeastern Univ, Sch Pharm, 360 Huntington Ave,140TF RD218F, Boston, MA 02115 USA. EM j.devlin@neu.edu NR 23 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1058-2916 EI 1538-943X J9 ASAIO J JI Asaio J. PD NOV-DEC PY 2016 VL 62 IS 6 BP 710 EP 714 DI 10.1097/MAT.0000000000000415 PG 5 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA EC1OX UT WOS:000387876500017 PM 27442855 ER PT J AU Tabet, R Vitale, N Moine, H AF Tabet, Ricardos Vitale, Nicolas Moine, Herve TI Fragile X syndrome: Are signaling lipids the missing culprits? SO BIOCHIMIE LA English DT Review DE Fragile X syndrome; FMRP; Diacylglycerol kinase; Diacylglycerol; Phosphatidic acid; Lipid signaling ID MENTAL-RETARDATION PROTEIN; METABOTROPIC GLUTAMATE RECEPTORS; LONG-TERM DEPRESSION; DIACYLGLYCEROL KINASE-ZETA; CENTRAL-NERVOUS-SYSTEM; SYNAPTIC PLASTICITY; DENDRITIC SPINES; MOUSE MODEL; TRANSLATIONAL CONTROL; PHOSPHATIDIC-ACID AB Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability and autism. FXS results from the absence of FMRP, an RNA binding protein associated to ribosomes that influences the translation of specific mRNAs in post-synaptic compartments of neurons. The main molecular consequence of the absence of FMRP is an excessive translation of neuronal protein in several areas of the brain. This local protein synthesis deregulation is proposed to underlie the defect in synaptic plasticity responsible for FXS. Recent findings in neurons of the fragile X mouse model (Fmr1-KO) uncovered another consequence of the lack of FMRP: a deregulation of the diacylglycerol (DAG)/phosphatidic acid (PA) homeostasis. DAG and PA are two interconvertible lipids that influence membrane architecture and that act as essential signaling molecules that activate various downstream effectors, including master regulators of local protein synthesis and actin polymerization. As a consequence, DAG and PA govern a variety of cellular processes, including cell proliferation, vesicle/membrane trafficking and cytoskeletal organization. At the synapse, the level of these lipids is proposed to influence the synaptic activation status. FMRP appears as a master regulator of this neuronal process by controlling the translation of a diacylglycerol kinase enzyme that converts DAG into PA. The deregulated levels of DAG and PA caused by the absence of FMRP could represent a novel therapeutic target for the treatment of FXS. (C) 2016 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved. C1 [Tabet, Ricardos] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Mass Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. [Vitale, Nicolas] Univ Strasbourg, CNRS UPR3212, Inst Neurosci Cellulaires & Integrat, F-67084 Strasbourg, France. [Moine, Herve] Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France. [Moine, Herve] CNRS, UMR7104, F-67404 Illkirch Graffenstaden, France. [Moine, Herve] INSERM, U964, F-67404 Illkirch Graffenstaden, France. [Moine, Herve] Univ Strasbourg, F-67084 Strasbourg, France. RP Moine, H (reprint author), Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France. EM moine@igbmc.fr OI Moine, Herve/0000-0002-6250-7902 FU Agence Nationale de la Recherche [ANR-12-BSV8-0022]; Fondation Jerome Lejeune funding; FRAXA Research Foundation; gence Nationale de la Recherche [ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02]; APLM FX We wish to thank the other members of the laboratory for discussions and comments. We apologize to colleagues whose work could not be cited here due to space limitations. Our work is supported by Agence Nationale de la Recherche (ANR-12-BSV8-0022), Fondation Jerome Lejeune funding, FRAXA Research Foundation and grant ANR-10-LABX-0030-INRT, a French State fund managed by the Agence Nationale de la Recherche under the frame program Investissements d'Avenir ANR-10-IDEX-0002-02. to H.M., and by APLM to RT. NR 81 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0300-9084 EI 1638-6183 J9 BIOCHIMIE JI Biochimie PD NOV PY 2016 VL 130 SI SI BP 188 EP 194 DI 10.1016/j.biochi.2016.09.002 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EB8IC UT WOS:000387633700022 PM 27597551 ER PT J AU Ma, J Koster, J Qin, Q Hu, SG Li, W Chen, CH Cao, QY Wang, JZ Mei, SL Liu, Q Xu, H Liu, XS AF Ma, Jian Koster, Johannes Qin, Qian Hu, Shengen Li, Wei Chen, Chenhao Cao, Qingyi Wang, Jinzeng Mei, Shenglin Liu, Qi Xu, Han Liu, Xiaole Shirley TI CRISPR-DO for genome-wide CRISPR design and optimization SO BIOINFORMATICS LA English DT Article ID SGRNA DESIGN; HUMAN-CELLS; CAS9; ENDONUCLEASE; SPECIFICITY; SYSTEM; TOOL AB Motivation: Despite the growing popularity in using CRISPR/Cas9 technology for genome editing and gene knockout, its performance still relies on well-designed single guide RNAs (sgRNA). In this study, we propose a web application for the Design and Optimization (CRISPR-DO) of guide sequences that target both coding and non-coding regions in spCas9 CRISPR system across human, mouse, zebrafish, fly and worm genomes. CRISPR-DO uses a computational sequence model to predict sgRNA efficiency, and employs a specificity scoring function to evaluate the potential of off-target effect. It also provides information on functional conservation of target sequences, as well as the overlaps with exons, putative regulatory sequences and single-nucleotide polymorphisms (SNPs). The web application has a user-friendly genome-browser interface to facilitate the selection of the best target DNA sequences for experimental design. C1 [Ma, Jian; Qin, Qian; Hu, Shengen; Wang, Jinzeng; Mei, Shenglin; Liu, Qi; Liu, Xiaole Shirley] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China. [Koster, Johannes; Li, Wei; Chen, Chenhao; Xu, Han; Liu, Xiaole Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Koster, Johannes; Li, Wei; Chen, Chenhao; Xu, Han; Liu, Xiaole Shirley] Harvard Sch Publ Hlth, Boston, MA 02115 USA. [Koster, Johannes; Li, Wei; Chen, Chenhao; Xu, Han; Liu, Xiaole Shirley] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA. [Koster, Johannes] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA. [Koster, Johannes] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Koster, Johannes] Harvard Med Sch, Boston, MA 02115 USA. [Cao, Qingyi] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1,Coll Med, Hangzhou 310003, Zhejiang, Peoples R China. RP Liu, Q; Liu, XS (reprint author), Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.; Xu, H; Liu, XS (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.; Xu, H; Liu, XS (reprint author), Harvard Sch Publ Hlth, Boston, MA 02115 USA.; Xu, H; Liu, XS (reprint author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA. EM qiliu@tongji.edu.cn; hanxu@jimmy.harvard.edu; xsliu@jimmy.harvard.edu FU National Natural Science Foundation of China [31329003]; NIH [R01 HG008728]; Claudia Adams Barr Award in Innovative Basic Cancer Research from Dana-Farber Cancer Institute FX The project was partially supported by the National Natural Science Foundation of China [31329003], NIH R01 HG008728, and the Claudia Adams Barr Award in Innovative Basic Cancer Research from Dana-Farber Cancer Institute. NR 19 TC 0 Z9 0 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1367-4803 EI 1460-2059 J9 BIOINFORMATICS JI Bioinformatics PD NOV 1 PY 2016 VL 32 IS 21 BP 3336 EP 3338 DI 10.1093/bioinformatics/btw476 PG 3 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics GA EC2VZ UT WOS:000387983700019 PM 27402906 ER PT J AU van IJzendoorn, DGP Glass, K Quackenbush, J Kuijjer, ML AF van IJzendoorn, David G. P. Glass, Kimberly Quackenbush, John Kuijjer, Marieke L. TI PyPanda: a Python package for gene regulatory network reconstruction SO BIOINFORMATICS LA English DT Article AB PANDA (Passing Attributes between Networks for Data Assimilation) is a gene regulatory network inference method that uses message-passing to integrate multiple sources of 'omics data. PANDA was originally coded in C++. In this application note we describe PyPanda, the Python version of PANDA. PyPanda runs considerably faster than the C++version and includes additional features for network analysis. Availability and implementation: The open source PyPanda Python package is freely available at http://github.com/davidvi/pypanda. Contact: mkuijjer@jimmy.harvard.edu or d.g.p.van_ijzendoorn@lumc.nl C1 [van IJzendoorn, David G. P.] Leiden Univ, Dept Pathol, Med Ctr, NL-2300 RC Leiden, Netherlands. [Glass, Kimberly] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA 02215 USA. [Quackenbush, John; Kuijjer, Marieke L.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Quackenbush, John; Kuijjer, Marieke L.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Quackenbush, John] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. RP Kuijjer, ML (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.; Kuijjer, ML (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. EM d.g.p.van_ijzendoorn@lumc.nl; mkuijjer@jimmy.harvard.edu FU National Institutes of Health [R01 HL111759, P01 HL105339]; Leiden University Fund [5259/4-6-2015/Gg] FX This work has been supported by the National Institutes of Health (R01 HL111759 to J.Q., K.G., P01 HL105339 to J.Q., K.G., M.L.K.) and Leiden University Fund (5259/4-6-2015/Gg to D.G.P.IJ). NR 11 TC 0 Z9 0 U1 6 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1367-4803 EI 1460-2059 J9 BIOINFORMATICS JI Bioinformatics PD NOV 1 PY 2016 VL 32 IS 21 BP 3363 EP 3365 DI 10.1093/bioinformatics/btw422 PG 3 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics GA EC2VZ UT WOS:000387983700028 PM 27402905 ER PT J AU Vos, JM Gustine, J Rennke, HG Hunter, Z Manning, RJ Dubeau, TE Meid, K Minnema, MC Kersten, MJ Treon, SP Castillo, JJ AF Vos, Josephine M. Gustine, Joshua Rennke, Helmut G. Hunter, Zachary Manning, Robert J. Dubeau, Toni E. Meid, Kirsten Minnema, Monique C. Kersten, Marie-Jose Treon, Steven P. Castillo, Jorge J. TI Renal disease related to Waldenstrom macroglobulinaemia: incidence, pathology and clinical outcomes SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE Waldenstrom macroglobulinaemia; renal medicine; amyloidosis; haemodialysis; epidemiology ID CHAIN DEPOSITION DISEASE; INTERNATIONAL WORKSHOP; LYMPHOCYTIC-LEUKEMIA; INVOLVEMENT; CONSENSUS; RECOMMENDATIONS; NEPHROPATHY; DEFINITION; DISORDERS; LYMPHOMA AB The incidence and prognostic impact of nephropathy related to Waldenstrom macroglobulinaemia (WM) is currently unknown. We performed a retrospective study to assess biopsy-confirmed WM-related nephropathy in a cohort of 1391 WM patients seen at a single academic institution. A total of 44 cases were identified, the estimated cumulative incidence was 51% at 15years. There was a wide variation in kidney pathology, some directly related to the WM: amyloidosis (n=11, 25%), monoclonal-IgM deposition disease/cryoglobulinaemia (n=10, 23%), lymphoplasmacytic lymphoma infiltration (n=8, 18%), light-chain deposition disease (n=4, 9%) and light-chain cast nephropathy (n=4, 9%), and some probably related to the WM: thrombotic microangiopathy (TMA) (n=3, 7%), minimal change disease (n=2, 5%), membranous nephropathy (n=1, 2%) and crystal-storing tubulopathy (n=1, 2%). The median overall survival in patients with biopsy-confirmed WM-related nephropathy was 115years, shorter than for the rest of the cohort (16years, P=003). Survival was better in patients with stable or improved renal function after treatment (P=005). Based on these findings, monitoring for renal disease in WM patients should be considered and a kidney biopsy pursued in those presenting with otherwise unexplained renal failure and/or nephrotic syndrome. C1 [Vos, Josephine M.; Gustine, Joshua; Hunter, Zachary; Manning, Robert J.; Dubeau, Toni E.; Meid, Kirsten; Treon, Steven P.; Castillo, Jorge J.] Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, Boston, MA 02115 USA. [Vos, Josephine M.] St Antonius Hosp, Dept Internal Med Haematol, Nieuwegein, Netherlands. [Rennke, Helmut G.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Rennke, Helmut G.; Treon, Steven P.; Castillo, Jorge J.] Harvard Med Sch, Boston, MA USA. [Minnema, Monique C.] Acad Med Ctr, Dept Haematol, Amsterdam, Netherlands. [Kersten, Marie-Jose] UMC Utrecht Canc Ctr, Dept Haematol, Utrecht, Netherlands. RP Vos, JM (reprint author), St Antonius Hosp, Internist Haematol, Dept Internal Med, Postbus 2500, NL-3430 EM Nieuwegein, Netherlands. EM jm.vos@antoniusziekenhuis.nl OI Castillo, Jorge/0000-0001-9490-7532; Hunter, Zachary/0000-0002-1689-1691 NR 33 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD NOV PY 2016 VL 175 IS 4 BP 623 EP 630 DI 10.1111/bjh.14279 PG 8 WC Hematology SC Hematology GA EC0RB UT WOS:000387807300009 PM 27468978 ER PT J AU Kakiuchi, T Takahara, T Kasugai, Y Arita, K Yoshida, N Karube, K Suguro, M Matsuo, K Nakanishi, H Kiyono, T Nakamura, S Osada, H Sekido, Y Seto, M Tsuzuki, S AF Kakiuchi, Tatsuo Takahara, Taishi Kasugai, Yumiko Arita, Kotaro Yoshida, Noriaki Karube, Kennosuke Suguro, Miyuki Matsuo, Keitaro Nakanishi, Hayao Kiyono, Tohru Nakamura, Shigeo Osada, Hirotaka Sekido, Yoshitaka Seto, Masao Tsuzuki, Shinobu TI Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation SO CARCINOGENESIS LA English DT Article ID MALIGNANT PLEURAL MESOTHELIOMA; NEUROFIBROMATOSIS TYPE-2; EPITHELIAL-CELLS; LUNG-CANCER; MOUSE MODEL; PROTEIN; IDENTIFICATION; ESTABLISHMENT; TRANSCRIPTION; INACTIVATION AB Mesotheliomas are frequently characterized by disruption of Hippo pathway due to deletion and/or mutation in genes, such as neurofibromin 2 (NF2). Hippo disruption attenuates yes-associated protein (YAP) phosphorylation allowing YAP to translocate to the nucleus and regulate gene expression. The role of disrupted Hippo pathway in maintenance of established mesotheliomas has been extensively investigated using cell lines; however, its involvement in development of human mesothelioma has not been explored much. Here, we employed immortalized human mesothelial cells to disrupt Hippo pathway. YAP phosphorylation was reduced on NF2 knockdown and the cells exhibited altered growth in vitro, developing tumors when transplanted into nude mice. Similar results were obtained from enforced expression of wild-type or constitutively active (S127A) YAP, indicating the crucial role of activated YAP in the transformation of mesothelial cells. Gene expression analysis comparing control- and YAP-transduced immortalized human mesothelial cells revealed phospholipase-C beta 4 (PLCB4) to be among the genes highly upregulated by YAP. PLCB4 was upregulated by YAP in immortalized human mesothelial cells and downregulated on YAP knockdown in Hippo-disrupted mesothelioma cell lines. PLCB4 knockdown attenuated the growth of YAP-transduced immortalized mesothelial cells and YAP-active, but not YAP-nonactive, mesothelioma cell lines. Our model system thus provides a versatile tool to investigate the mechanisms underlying mesothelioma development. We suggest that PLCB4 may be an attractive drug target for the treatment of mesothelioma. C1 [Kakiuchi, Tatsuo; Takahara, Taishi; Kasugai, Yumiko; Suguro, Miyuki; Matsuo, Keitaro; Tsuzuki, Shinobu] Aichi Canc Ctr Res Inst, Div Mol Med, Nagoya, Aichi 4648681, Japan. [Kakiuchi, Tatsuo; Takahara, Taishi; Nakamura, Shigeo] Nagoya Univ Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi 4660065, Japan. [Arita, Kotaro] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Internal Med 3, Toyama 9300194, Japan. [Yoshida, Noriaki; Seto, Masao] Kurume Univ, Dept Pathol, Sch Med, Kurume, Fukuoka 8300011, Japan. [Karube, Kennosuke] Univ Ryukyus, Lab Cytopathol, Fac Med, Okinawa 9030215, Japan. [Nakanishi, Hayao] Aichi Hosp, Aichi Canc Ctr, Lab Pathol & Clin Res, Okazaki, Aichi 4440011, Japan. [Kiyono, Tohru] Natl Canc Ctr, Div Carcinogenesis & Canc Prevent, Tokyo 1040045, Japan. [Osada, Hirotaka; Sekido, Yoshitaka] Aichi Canc Ctr Res Inst, Div Mol Oncol, Nagoya, Aichi 4648681, Japan. [Osada, Hirotaka; Sekido, Yoshitaka] Nagoya Univ, Dept Canc Genet, Program Funct Construct Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan. [Tsuzuki, Shinobu] Aichi Med Univ, Dept Biochem, Sch Med, Nagakute, Aichi 4801195, Japan. [Yoshida, Noriaki] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Tsuzuki, S (reprint author), Aichi Canc Ctr Res Inst, Div Mol Med, Nagoya, Aichi 4648681, Japan.; Tsuzuki, S (reprint author), Aichi Med Univ, Dept Biochem, Sch Med, Nagakute, Aichi 4801195, Japan. EM stsuzuki@aichi-cc.jp OI Matsuo, Keitaro/0000-0003-1761-6314 FU KAKENHI [25290053]; Ministry of Health; Labor and Welfare of Japan; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [14-24617]; P-DIRECT FX This work was supported by KAKENHI (25290053 to Y.S.); Grant-in-Aid for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health; Labor and Welfare of Japan, the Takeda Science Foundation; Research Grant of the Princess Takamatsu Cancer Research Fund (14-24617 to Y.S.); and P-DIRECT. NR 50 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD NOV PY 2016 VL 37 IS 11 BP 1098 EP 1109 DI 10.1093/carcin/bgw084 PG 12 WC Oncology SC Oncology GA EC2WH UT WOS:000387984500008 ER PT J AU Bednash, JS Mallampalli, RK AF Bednash, Joseph S. Mallampalli, Rama K. TI Regulation of inflammasomes by ubiquitination SO CELLULAR & MOLECULAR IMMUNOLOGY LA English DT Review DE deubiquitinase; E3 ligase; inflammasome; innate immunity; ubiqutin ID NF-KAPPA-B; NLRP3 INFLAMMASOME; CUTTING EDGE; CELL-DEATH; ASSEMBLY COMPLEX; E3 LIGASE; ACTIVATION; PROTEASOME; IL-1-BETA; MACROPHAGES AB Inflammasomes are multi-protein complexes that regulate the innate immune response by facilitating the release of inflammatory cytokines in response to pathogen exposure or cellular damage. Pro-inflammatory inflammasome signaling is vital to host defense and helps initiate the process of tissue repair following an insult to the host, but can be injurious, when excessive or chronic. As such, inflammasome activity is tightly regulated. Here we discuss one critical mechanism of inflammasome regulation, ubiquitination, that functions as a universal modulator of protein stability and trafficking. Recent studies have provided important insights into the regulation of inflammasome activation by protein ubiquitination. We review the molecular regulation of inflammasome function, specifically, as it relates to ubiquitination, and discuss the implications for the development of therapeutics to specifically target aberrant inflammasome signaling. C1 [Bednash, Joseph S.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Div Pulm Allergy & Crit Care Med, 930 Scaife Hall, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Div Pulm Allergy & Crit Care Med,UPMC Montefiore, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU Flight Attendant Medical Research Institute FX This work was supported by the Flight Attendant Medical Research Institute. NR 62 TC 1 Z9 1 U1 5 U2 5 PU CHIN SOCIETY IMMUNOLOGY PI BEING PA 5 DONGDAN SANTIAO, DONGCHEN DISTRICT, BEING, 100005, PEOPLES R CHINA SN 1672-7681 EI 2042-0226 J9 CELL MOL IMMUNOL JI Cell. Mol. Immunol. PD NOV PY 2016 VL 13 IS 6 BP 722 EP 728 DI 10.1038/cmi.2016.15 PG 7 WC Immunology SC Immunology GA EC2SN UT WOS:000387974300002 PM 27063466 ER PT J AU Hasegawa, K Tsugawa, Y Camargo, CA AF Hasegawa, Kohei Tsugawa, Yusuke Camargo, Carlos A., Jr. TI 30-Day Readmissions in Hospitalized Adults With Asthma Exacerbations: Insights From the Nationwide Readmission Database Response SO CHEST LA English DT Letter C1 [Hasegawa, Kohei; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Tsugawa, Yusuke] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 125 Nashua St,Ste 920, Boston, MA 02114 USA. EM khasegawa1@partners.org NR 4 TC 0 Z9 0 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2016 VL 150 IS 5 BP 1165 EP 1166 DI 10.1016/j.chest.2016.07.042 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EB2RD UT WOS:000387208600027 PM 27832887 ER PT J AU Herzberg, B Fisher, DE AF Herzberg, Benjamin Fisher, David E. TI Metastatic melanoma and immunotherapy SO CLINICAL IMMUNOLOGY LA English DT Article DE Melanoma; Immunotherapy; T cell; Checkpoint; Vitiligo ID CELL LUNG-CANCER; DOSE RECOMBINANT INTERLEUKIN-2; TUMOR-INFILTRATING LYMPHOCYTES; TERM SURVIVAL UPDATE; REGULATORY T-CELLS; CTLA-4 BLOCKADE; ADVERSE EVENTS; PD-1 BLOCKADE; SOLID TUMORS; PHASE-II AB Harnessing the immune system to attack cancer cells has represented a holy grail for greater than 100 years. While prospects of tumor-selective durable immune based therapies have provided small clinical signals for many decades, recent years have demonstrated a virtual explosion in progress. Melanoma has led the field of cancers in which immunotherapy has produced major clinical inroads. The most significant and impactful immunotherapies for melanoma utilize immune checkpoint inhibition to stimulate T cell mediated tumor killing. The major targets of checkpoint blockade have thus far been CTLA4 and PD1, two key receptors for central and peripheral immune tolerance. This review discusses current understanding of how these checkpoint blockade therapeutics have led to major clinical responses in patients with advanced melanoma. It is likely that we are poised to see significantly greater anti-cancer immunotherapy efficacy, both in improving response rates and durability for melanoma, and for other less immunogenic malignancies. (C) 2016 Elsevier Inc. All rights reserved. C1 [Herzberg, Benjamin] Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA. [Fisher, David E.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Fisher, David E.] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA. RP Herzberg, B (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA. EM bherzberg@partners.org NR 89 TC 1 Z9 1 U1 4 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD NOV PY 2016 VL 172 SI SI BP 105 EP 110 DI 10.1016/j.clim.2016.07.006 PG 6 WC Immunology SC Immunology GA EC3VW UT WOS:000388056200018 PM 27430520 ER PT J AU Mantopoulos, D Bouzika, P Tsakris, A Pawlyk, BS Sandberg, MA Miller, JW Rizzo, JF Vavvas, DG Cestari, DM AF Mantopoulos, Dimosthenis Bouzika, Peggy Tsakris, Athanassios Pawlyk, Basil S. Sandberg, Michael A. Miller, Joan W. Rizzo, Joseph F., III Vavvas, Demetrios G. Cestari, Dean M. TI An Experimental Animal Model of Photodynamic Optic Nerve Head Injury (PONHI) SO CURRENT EYE RESEARCH LA English DT Article DE Animal model; mesoporphyrin IX; neuroprotection; optic nerve head injury; photodynamic treatment ID RETINAL GANGLION-CELLS; COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; RODENT MODEL; NEUROPATHY; MICE; NEOVASCULARIZATION; MESOPORPHYRIN; INDUCTION; APOPTOSIS AB Purpose: Anterior ischemic optic neuropathy (AION) is the most common cause of non-glaucomatous optic nerve head (ONH) injury among older adults. AION results from a sudden ischemic insult to the proximal portion of the optic nerve, typically leading to visual impairment. Here, we present an experimental model of photodynamically induced ONH injury that can be used to study neuroprotective modalities.Methods: Intraperitoneal injection of mesoporphyrin IX was followed by photodynamic treatment of the ONH in one eye of Brown-Norway rats; the fellow eye received the reverse sequence as a sham control. Fluorescein angiography (FA), spectral domain optical coherence tomography (SD-OCT), and visual evoked potential (VEP) recordings were performed at different time points following laser treatment. Immunohistochemistry was used to monitor apoptotic cell death (TUNEL) and macrophage infiltration (CD68). Cytokine levels were evaluated using enzyme-linked immunosorbent assay (ELISA).Results: FA showed early hyperfluorescence and late leakage of the ONH, while SD-OCT revealed optic nerve edema. No leakage or other abnormalities were detected in control eyes. VEPs were significantly reduced in amplitude and showed prolonged responses compared to sham eyes. The number of apoptotic retinal ganglion cells was elevated one day after laser treatment (13.77 4.49, p < 0.01) and peaked on day 7 (57.22 +/- 11.34, p < 0.01). ONH macrophage infiltration also peaked on day 7 (101.8 +/- 9.8, p < 0.05). ELISAs performed showed upregulation of macrophage chemoattractant protein-1 and macrophage inflammatory protein-2 on days 3 and 1, respectively.Conclusions: Photodynamic treatment of the ONH after administration of mesoporphyrin IX leads to macroscopic, histologic, and physiologic evidence of ONH injury. Given the long half-life of mesoporphyrin IX and the ease of intraperitoneal injections, this new model of photodynamically induced ONH injury may be a useful tool for studying optic nerve injury and possible neuroprotective treatments. C1 [Mantopoulos, Dimosthenis; Bouzika, Peggy; Rizzo, Joseph F., III; Cestari, Dean M.] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Neuroophthalmol Serv, Boston, MA USA. [Mantopoulos, Dimosthenis; Bouzika, Peggy; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Pawlyk, Basil S.; Sandberg, Michael A.] Harvard Med Sch, Dept Ophthalmol, Berman Gund Lab Study Retinal Degenerat, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Tsakris, Athanassios] Univ Athens, Sch Med, Dept Microbiol, Athens, Greece. RP Cestari, DM (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM dean_cestari@meei.harvard.edu FU NEI NIH HHS [R01 EY025362] NR 39 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0271-3683 EI 1460-2202 J9 CURR EYE RES JI Curr. Eye Res. PD NOV PY 2016 VL 41 IS 11 BP 1498 EP 1506 DI 10.3109/02713683.2015.1135960 PG 9 WC Ophthalmology SC Ophthalmology GA EC2GR UT WOS:000387928300017 PM 27158920 ER PT J AU Shen, FX AF Shen, Francis X. TI THE OVERLOOKED HISTORY OF NEUROLAW SO FORDHAM LAW REVIEW LA English DT Article ID LAW; NEUROSCIENCE; EPILEPSY; SOCIETY C1 [Shen, Francis X.] Univ Minnesota, Law, Minneapolis, MN 55455 USA. [Shen, Francis X.] Shen Neurolaw Lab, Minneapolis, MN 55455 USA. [Shen, Francis X.] MacArthur Fdn Res Network Law & Neurosci, Educ & Outreach, Nashville, TN 37203 USA. [Shen, Francis X.] Massachusetts Gen Hosp, Ctr Law Brain & Behaivor, Boston, MA 02114 USA. RP Shen, FX (reprint author), Univ Minnesota, Law, Minneapolis, MN 55455 USA.; Shen, FX (reprint author), Shen Neurolaw Lab, Minneapolis, MN 55455 USA.; Shen, FX (reprint author), MacArthur Fdn Res Network Law & Neurosci, Educ & Outreach, Nashville, TN 37203 USA.; Shen, FX (reprint author), Massachusetts Gen Hosp, Ctr Law Brain & Behaivor, Boston, MA 02114 USA. NR 182 TC 1 Z9 1 U1 5 U2 5 PU FORDHAM UNIV SCHOOL LAW PI NEW YORK PA 140 W 62ND STREET, NEW YORK, NY 10023 USA SN 0015-704X J9 FORDHAM LAW REV JI Fordham Law Rev. PD NOV PY 2016 VL 85 IS 2 BP 667 EP 695 PG 29 WC Law SC Government & Law GA EC3BP UT WOS:000387999800013 ER PT J AU Ughi, GJ Wang, H Gerbaud, E Gardecki, JA Fard, AM Hamidi, E Vacas-Jacques, P Rosenberg, M Jaffer, FA Tearney, GJ AF Ughi, Giovanni J. Wang, Hao Gerbaud, Edouard Gardecki, Joseph A. Fard, Ali M. Hamidi, Ehsan Vacas-Jacques, Paulino Rosenberg, Mireille Jaffer, Farouc A. Tearney, Guillermo J. TI Clinical Characterization of Coronary Atherosclerosis With Dual-Modality OCT and Near-Infrared Autofluorescence Imaging SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE first-in-human; multimodality imaging; near-infrared fluorescence; optical coherence tomography ID OPTICAL COHERENCE TOMOGRAPHY; INDUCED FLUORESCENCE SPECTROSCOPY; IN-VIVO; PLAQUE; CATHETER; NM AB OBJECTIVES The authors present the clinical imaging of human coronary arteries in vivo using a multimodality optical coherence tomography (OCT) and near-infrared autofluorescence (NIRAF) intravascular imaging system and catheter. BACKGROUND Although intravascular OCT is capable of providing microstructural images of coronary atherosclerotic lesions, it is limited in its capability to ascertain the compositional/molecular features of plaque. A recent study in cadaver coronary plaque showed that endogenous NIRAF is elevated in necrotic core lesions. The combination of these 2 technologies in 1 device may therefore provide synergistic data to aid in the diagnosis of coronary pathology in vivo. METHODS We developed a dual-modality intravascular imaging system and 2.6-F catheter that can simultaneously acquire OCT and NIRAF data from the same location on the artery wall. This technology was used to obtain volumetric OCT-NIRAF images from 12 patients with coronary artery disease undergoing percutaneous coronary intervention. Images were acquired during a brief, nonocclusive 3-to 4-ml/s contrast purge at a speed of 100 frames/s and a pullback rate of 20 or 40 mm/s. OCT-NIRAF data were analyzed to determine the distribution of the NIRAF signal with respect to OCT-delineated plaque morphological features. RESULTS High-quality intracoronary OCT and NIRAF image data (> 50-mm pullback length) were successfully acquired without complication in all patients (17 coronary arteries). The maximum NIRAF signal intensity of each plaque was compared with OCT-defined type, showing a statistically significant difference between plaque types (1-way analysis of variance, p < 0.0001). Interestingly, coronary arterial NIRAF intensity was elevated only focally in plaques with a high-risk morphological phenotype (p < 0.05), including OCT fibroatheroma, plaque rupture, and fibroatheroma associated with in-stent restenosis. CONCLUSIONS This OCT-NIRAF study demonstrates that dual-modality microstructural and fluorescence intracoronary imaging can be safely and effectively conducted in human patients. Our findings show that NIRAF is associated with a high-risk morphological plaque phenotype. The focal distribution of NIRAF in these lesions furthermore suggests that this endogenous imaging biomarker may provide complementary information to that obtained by structural imaging alone. (C) 2016 by the American College of Cardiology Foundation. C1 [Ughi, Giovanni J.; Wang, Hao; Gerbaud, Edouard; Gardecki, Joseph A.; Fard, Ali M.; Hamidi, Ehsan; Vacas-Jacques, Paulino; Rosenberg, Mireille; Jaffer, Farouc A.; Tearney, Guillermo J.] Harvard Med Sch, Wellman Ctr Photomed, Boston, MA USA. [Ughi, Giovanni J.; Wang, Hao; Gerbaud, Edouard; Gardecki, Joseph A.; Fard, Ali M.; Hamidi, Ehsan; Vacas-Jacques, Paulino; Rosenberg, Mireille; Jaffer, Farouc A.; Tearney, Guillermo J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jaffer, Farouc A.] Harvard Med Sch, Cardiovasc Res Ctr, Boston, MA USA. [Jaffer, Farouc A.] Harvard Med Sch, Div Cardiol, Boston, MA USA. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Tearney, Guillermo J.] Harvard Med Sch, Boston, MA USA. [Tearney, Guillermo J.] Harvard MIT Hlth Sci & Technol, Boston, MA USA. RP Tearney, GJ (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St,BHX 604A, Boston, MA 02114 USA.; Jaffer, FA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Simches Res Bldg,Room 3206,55 Fruit St, Boston, MA 02114 USA. EM fjaffer@mgh.harvard.edu; gtearney@partners.org OI Ughi, Giovanni J./0000-0003-3354-0698 FU Canon USA; NIH [R01HL093717, R01HL HL122388]; AHA [13GRNT1760040]; Bullock-Wellman Fellowship Award, Harvard Medical School; Merck; Kowa; Siemens; Boston Scientific; Canon FX Massachusetts General Hospital has a patent licensing arrangement with Terumo and Canon Corporations. Dr. Tearney (Terumo, Canon), Dr. Gardecki (Canon), and Dr. Jaffer (Canon) have the right to receive royalties as part of these licensing arrangements. The authors have received financial support from Canon USA (support of new technology advancement in OCT-NIRAF), NIH grant R01HL093717 (to Dr. Tearney for the development of the imaging system and imaging of the first 2 patients), NIH grant R01HL HL122388 (to Dr. Jaffer), AHA Grant-in-Aid 13GRNT1760040 (to Dr. Jaffer), and Bullock-Wellman Fellowship Award, Harvard Medical School (to Dr. Ughi). Dr. Jaffer has received research grants from Merck, Kowa, and Siemens; served as a consultant for Abbott Vascular and Boston Scientific; and has received nonfinancial support from Boston Scientific. Dr. Tearney has received royalties from MIT; has received sponsored research from Canon; and has received catheter components from Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Jaffer and Tearney are joint senior authors. NR 23 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD NOV PY 2016 VL 9 IS 11 BP 1304 EP 1314 DI 10.1016/j.jcmg.2015.11.020 PG 11 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EC1GE UT WOS:000387852100011 PM 26971006 ER PT J AU Cohen, LS Nonacs, R AF Cohen, Lee S. Nonacs, Ruta TI Neurodevelopmental Implications of Fetal Exposure to Selective Serotonin Reuptake Inhibitors and Untreated Maternal Depression Weighing Relative Risks SO JAMA PSYCHIATRY LA English DT Editorial Material ID ANTIDEPRESSANT USE; PREGNANCY; NEWBORN C1 [Cohen, Lee S.; Nonacs, Ruta] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Ammon Pinizzotto Ctr Womens Mental Hlth, Boston, MA USA. RP Cohen, LS (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, 185 Cambridge St,Simches Res Blg, Boston, MA 02114 USA. EM lcohen2@mgh.harvard.edu FU Cephalon; Takeda/Lundbeck Pharmaceuticals; GlaxoSmithKline; JayMac Pharmaceuticals; Alkermes Biopharmaceuticals; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb/Otsuka Pharmaceuticals; Forest/Actavis Pharmaceuticals; Ortho-McNeil Janssen Pharmaceuticals; Sunovion Pharmaceuticals FX Dr Cohen has received research support from Cephalon, Takeda/Lundbeck Pharmaceuticals, GlaxoSmithKline, and JayMac Pharmaceuticals and support for the National Pregnancy Registry for Atypical Antipsychotics from Alkermes Biopharmaceuticals, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb/Otsuka Pharmaceuticals, Forest/Actavis Pharmaceuticals, Ortho-McNeil Janssen Pharmaceuticals, and Sunovion Pharmaceuticals. No other disclosures were reported. NR 7 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2016 VL 73 IS 11 BP 1170 EP 1172 DI 10.1001/jamapsychiatry.2016.2705 PG 4 WC Psychiatry SC Psychiatry GA EC2GJ UT WOS:000387927400012 PM 27732715 ER PT J AU Roussos, P Guennewig, B Kaczorowski, DC Barry, G Brennand, KJ AF Roussos, Panos Guennewig, Boris Kaczorowski, Dominik C. Barry, Guy Brennand, Kristen J. TI Activity-Dependent Changes in Gene Expression in Schizophrenia Human-Induced Pluripotent Stem Cell Neurons SO JAMA PSYCHIATRY LA English DT Article ID DE-NOVO MUTATIONS; AUTISM SPECTRUM DISORDER; SEVERE INTELLECTUAL DISABILITY; EPILEPTIC ENCEPHALOPATHIES; PATTERNS AB IMPORTANCE Schizophrenia candidate genes participate in common molecular pathways that are regulated by activity-dependent changes in neurons. One important next step is to further our understanding on the role of activity-dependent changes of gene expression in the etiopathogenesis of schizophrenia. OBJECTIVE To examine whether neuronal activity-dependent changes of gene expression are dysregulated in schizophrenia. DESIGN, SETTING, AND PARTICIPANTS Neurons differentiated from human-induced pluripotent stem cells derived from 4 individuals with schizophrenia and 4 unaffected control individuals were depolarized using potassium chloride. RNA was extracted followed by genome-wide profiling of the transcriptome. Neurons were planted on June 21, 2013, and harvested on August 2, 2013. MAIN OUTCOMES AND MEASURES We performed differential expression analysis and gene coexpression analysis to identify activity-dependent or disease-specific changes of the transcriptome. Gene expression differences were assessed with linear models. Furthermore, we used gene set analyses to identify coexpressed modules that are enriched for schizophrenia risk genes. RESULTS We identified 1669 genes that were significantly different in schizophreniaassociated vs control human-induced pluripotent stem cell-derived neurons and 1199 genes that are altered in these cells in response to depolarization (linear models at false discovery rate <= 0.05). The effect of activity-dependent changes of gene expression in schizophrenia-associated neurons (59 significant genes at false discovery rate <= 0.05) was attenuated compared with control samples (594 significant genes at false discovery rate <= 0.05). Using gene coexpression analysis, we identified 2 modules (turquoise and brown) that were associated with diagnosis status and 2 modules (yellow and green) that were associated with depolarization at a false discovery rate of <= 0.05. For 3 of the 4 modules, we found enrichment with schizophrenia-associated variants: brown (chi(2) = 20.68; P =.002), turquoise (chi(2) = 12.95; P =.04), and yellow (chi(2) = 15.34; P =.02). CONCLUSIONS AND RELEVANCE In this analysis, candidate genes clustered within gene networks that were associated with a blunted effect of activity-dependent changes of gene expression in schizophrenia-associated neurons. Overall, these findings link schizophrenia candidate genes with specific molecular functions in neurons, which could be used to examine underlying mechanisms and therapeutic interventions related to schizophrenia. C1 [Roussos, Panos; Brennand, Kristen J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Guennewig, Boris] Univ New South Wales, St Vincents Clin Sch, Kensington, NSW, Australia. [Guennewig, Boris] Univ New South Wales, Sch Biotechnol & Biomol Sci, Kensington, NSW, Australia. [Guennewig, Boris; Kaczorowski, Dominik C.] Garvan Inst Med Res, Sydney, NSW, Australia. [Barry, Guy] Res Berghofer Med Res Inst, Queensland Inst Med, Herston, Qld, Australia. [Brennand, Kristen J.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA. RP Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, 1470 Madison Ave, New York, NY 10029 USA.; Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Genet, 1470 Madison Ave, New York, NY 10029 USA.; Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Genom Sci, 1470 Madison Ave, New York, NY 10029 USA. EM panagiotis.roussos@mssm.edu RI Brennand, Kristen/J-8704-2012 OI Brennand, Kristen/0000-0003-0993-5956 FU National Institutes of Health [R01AG050986, R01MH109677, R01MH101454, R01MH106056]; New York Stem Cell Foundation; Brain Behavior Research Foundation; Alzheimer's Association grant [NIRGf-340998]; Veterans Affairs merit grant [BX002395]; Swiss National Science Foundation [P2EZP3_152143]; Geoff and Dawn Dixon fellowship; Office of Research Infrastructure of the National Institutes of Health [S10OD018522] FX This work was supported by the National Institutes of Health grants R01AG050986 and R01MH109677 (Dr Roussos) and R01MH101454 and R01MH106056 (Dr Brennand), New York Stem Cell Foundation (Dr Brennand), Brain Behavior Research Foundation (Drs Roussos and Brennand), Alzheimer's Association grant NIRGf-340998 (Dr Roussos), the Veterans Affairs merit grant BX002395 (Dr Roussos), the Swiss National Science Foundation grant P2EZP3_152143 (Dr Guennewig), and a Geoff and Dawn Dixon fellowship (Dr Guennewig). This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this article was supported by the Office of Research Infrastructure of the National Institutes of Health award S10OD018522. NR 31 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2016 VL 73 IS 11 BP 1180 EP 1188 DI 10.1001/jamapsychiatry.2016.2575 PG 9 WC Psychiatry SC Psychiatry GA EC2GJ UT WOS:000387927400014 PM 27732689 ER PT J AU Friedman, MJ Kilpatrick, DG Schnurr, PP AF Friedman, Matthew J. Kilpatrick, Dean G. Schnurr, Paula P. TI Changes to the Definition of Posttraumatic Stress Disorder in the DSM-5 Reply SO JAMA PSYCHIATRY LA English DT Letter C1 [Friedman, Matthew J.; Schnurr, Paula P.] US Dept Vet Affairs, Natl Ctr PTSD, White River Jct, VT USA. [Friedman, Matthew J.; Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Kilpatrick, Dean G.] Med Univ South Carolina, Charleston, SC USA. RP Friedman, MJ (reprint author), VA Med Ctr, Natl Ctr PTSD 116D, 215 N Main St, White River Jct, VT 05009 USA. EM matthew.j.friedman@dartmouth.edu FU National Institute of Mental Health; Department of Veterans Affairs; Department of Defense FX Dr Kilpatrick receives funding from the National Institute of Mental Health. Dr Schnurr receives research funding from the Department of Veterans Affairs, Department of Defense, and National Institute of Mental Health. NR 4 TC 1 Z9 1 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2016 VL 73 IS 11 BP 1203 EP 1203 DI 10.1001/jamapsychiatry.2016.2401 PG 1 WC Psychiatry SC Psychiatry GA EC2GJ UT WOS:000387927400021 PM 27732695 ER PT J AU Konstam, MA Kiernan, M Chandler, A Dhingra, R Mody, F Eisen, H Haught, WH Wagoner, L Gupta, D Patten, R Gordon, P Korr, K Fileccia, R Gregory, D Wedge, P Romeling, M Konstam, JM Udelson, JE AF Konstam, Marvin A. Kiernan, Michael Chandler, Arthur Dhingra, Ravi Mody, Freny Eisen, Howard Haught, W. Herbert Wagoner, Lynne Gupta, Divya Patten, Richard Gordon, Paul Korr, Kenneth Fileccia, Russell Gregory, Douglas Wedge, Patricia Romeling, Matthew Konstam, Jeremy M. Udelson, James E. CA SECRET CHF Investigators TI Acute Effect of the V-2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized with Heart Failure: Results of the SECRET of CHF SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 20th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 17-20, 2016 CL Kissimmee, FL SP Heart Failure Soc Amer C1 [Konstam, Marvin A.; Kiernan, Michael; Udelson, James E.] Tufts Med Ctr, Boston, MA USA. [Chandler, Arthur] Univ Cardiol Associates, Augusta, GA USA. [Dhingra, Ravi] Univ Wisconsin, Madison, WI USA. [Mody, Freny] VA Greater Los Angeles, Los Angeles, CA USA. [Eisen, Howard] Drexel Univ, Philadelphia, PA 19104 USA. [Haught, W. Herbert] Heart Ctr Res, Huntsville, AL USA. [Wagoner, Lynne] Mercy Hosp, Fairfield, OH USA. [Gupta, Divya] Emory Univ, Atlanta, GA 30322 USA. [Patten, Richard] Lahey Med Ctr, Burlington, MA USA. [Gordon, Paul; Korr, Kenneth] Miriam Hosp, Providence, RI 02906 USA. [Fileccia, Russell] Ark La Tex Cardiol, Shreveport, LA USA. [Gregory, Douglas; Wedge, Patricia; Romeling, Matthew; Konstam, Jeremy M.] Cardiovasc Clin Sci Fdn, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD NOV PY 2016 VL 22 IS 11 BP 939 EP 939 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC3XA UT WOS:000388059200020 ER PT J AU Abraham, WT Adamson, PB Costanzo, MR Eigler, N Gold, M Klapholz, M Maurer, M Saxon, L Singh, J Troughton, R AF Abraham, William T. Adamson, Philip B. Costanzo, Maria Rosa Eigler, Neal Gold, Michael Klapholz, Marc Maurer, Mathew Saxon, Leslie Singh, Jagmeet Troughton, Richard TI Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 20th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 17-20, 2016 CL Kissimmee, FL SP Heart Failure Soc Amer C1 [Abraham, William T.] Ohio State Univ, Columbus, OH 43210 USA. [Adamson, Philip B.; Eigler, Neal] St Jude Med, St Paul, MN USA. [Costanzo, Maria Rosa] Midwest Heart, Downers Grove, IL USA. [Gold, Michael] Med Univ South Carolina, Newark, NJ USA. [Klapholz, Marc] UMDNJ, Newark, NJ USA. [Maurer, Mathew] Columbia Univ, New York, NY 10027 USA. [Saxon, Leslie] Univ Southern Calif, Los Angeles, CA 90089 USA. [Singh, Jagmeet] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Troughton, Richard] Christchurch Hosp, Christchurch, New Zealand. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD NOV PY 2016 VL 22 IS 11 BP 940 EP 940 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC3XA UT WOS:000388059200023 ER PT J AU O'Donnell, AE Schaefer, KG Stevenson, LW Mehra, MR Desai, AS AF O'Donnell, Arden E. Schaefer, Kristen G. Stevenson, Lynne W. Mehra, Mandeep R. Desai, Akshay S. TI A Randomized Controlled Trial of a Social Worker-Aided Palliative Care Intervention in High Risk Patients with Heart Failure (SWAP-HF) SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 20th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 17-20, 2016 CL Kissimmee, FL SP Heart Failure Soc Amer C1 [O'Donnell, Arden E.; Stevenson, Lynne W.; Mehra, Mandeep R.; Desai, Akshay S.] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA. [Schaefer, Kristen G.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD NOV PY 2016 VL 22 IS 11 BP 940 EP 940 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC3XA UT WOS:000388059200024 ER PT J AU Waks, JW Tereshchenko, LG AF Waks, Jonathan W. Tereshchenko, Larisa G. TI Global electrical heterogeneity: A review of the spatial ventricular gradient SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE Spatial ventricular gradient; Vectorcardiogram ID T-WAVE MORPHOLOGY; ORTHOGONAL ELECTROCARDIOGRAM; ACTIVATION SEQUENCE; FRONT DIRECTION; NORMAL MEN; QRS; RECOVERY; ANGLE; VECTORCARDIOGRAM; REPOLARIZATION AB The ventricular gradient, an electrocardiographic concept calculated by integrating the area under the QRS complex and T-wave, represents the degree and direction of myocardial electrical heterogeneity. Although the concept of the ventricular gradient was first introduced in the 1930s, it has not yet found a place in routine electrocardiography. In the modern era, it is relatively simple to calculate the ventricular gradient in three dimensions (the spatial ventricular gradient (SVG)), and there is now renewed interest in using the SVG as a tool for risk stratification of ventricular arrhythmias and sudden cardiac death. This manuscript will review the history of the ventricular gradient, describe its electrophysiological meaning and significance, and discuss its clinical utility. (C) 2016 Elsevier Inc. All rights reserved. C1 [Waks, Jonathan W.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Harvard Thorndike Electrophysiol Inst, Div Cardiovasc Med, Boston, MA USA. [Tereshchenko, Larisa G.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. RP Waks, JW (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, 185 Pilgrim Rd,Baker 4, Boston, MA 02215 USA. EM jwaks@bidmc.harvard.edu OI Tereshchenko, Larisa/0000-0002-6976-1313 FU NHLBI NIH HHS [R01 HL118277] NR 44 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD NOV-DEC PY 2016 VL 49 IS 6 BP 824 EP 830 DI 10.1016/j.jelectrocard.2016.07.025 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB8IA UT WOS:000387633500010 PM 27539162 ER PT J AU Waks, JW Tereshchenko, LG Parekh, RS AF Waks, Jonathan W. Tereshchenko, Larisa G. Parekh, Rulan S. TI Electrocardiographic predictors of mortality and sudden cardiac death in patients with end stage renal disease on hemodialysis SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE Electrocardiogram; Hemodialysis; End stage renal disease; Sudden cardiac death; Arrhythmia; Conduction abnormality; Cardiovascular disease ID CHRONIC KIDNEY-DISEASE; QRS-T ANGLE; SIGNAL-AVERAGED ELECTROCARDIOGRAM; HEART-RATE-VARIABILITY; QT INTERVAL; PROGNOSTIC VALUE; DIALYSIS PATIENTS; UREMIC CARDIOMYOPATHY; RISK STRATIFICATION; DISPERSION AB Patients with end stage renal disease (ESRD) on hemodialysis experience a high incidence of cardiovascular mortality, and sudden cardiac death (SCD) accounts for approximately 25% of all deaths in this patient population. Despite this high risk of SCD, many non-invasive SCD risk stratification tools that are frequently applied to other patient populations (such as those with prior myocardial infarction and reduced left ventricular systolic function) may be less useful markers of increased SCD risk in ESRD. Improved SCD risk stratification tools for use specifically in patients on hemodialysis are therefore necessary to optimally target use of primary prevention interventions aimed at decreasing SCD incidence. Electrocardiography is an effective, non-invasive SCD risk stratification tool in hemodialysis patients. This article reviews data supporting the association between various ECG parameters (QT interval, spatial QRS-T angle, signal averaged ECG, heart rate variability, and T-wave alternans) and mortality/SCD in the dialysis population. Despite the association between abnormal ECG parameters and SCD, it remains unclear if these abnormal parameters (such as prolonged QT interval) are mechanistically related to SCD and/or ventricular arrhythmias, or if they are simply markers for more severe cardiac disease, such as left ventricular hypertrophy, that may independently predispose to SCD. Current obstacles that impair widespread implementation of ECG risk stratification in the hemodialysis population are also discussed. (C) 2016 Published by Elsevier Inc. C1 [Waks, Jonathan W.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA USA. [Tereshchenko, Larisa G.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. [Parekh, Rulan S.] Hosp Sick Children, Univ Hlth Network, Div Nephrol, Toronto, ON, Canada. [Parekh, Rulan S.] Univ Toronto, Toronto, ON, Canada. RP Parekh, RS (reprint author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM rulan.parekh@sickkids.ca OI Tereshchenko, Larisa/0000-0002-6976-1313 FU NHLBI NIH HHS [R01 HL118277] NR 52 TC 0 Z9 0 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD NOV-DEC PY 2016 VL 49 IS 6 BP 848 EP 854 DI 10.1016/j.jelectrocard.2016.07.020 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB8IA UT WOS:000387633500014 PM 27554424 ER PT J AU Matsuda, S Movila, A Suzuki, M Kajiya, M Wisitrasameewong, W Kayal, R Hirshfeld, J Al-Dharrab, A Savitri, IJ Mira, A Kurihara, H Taubman, MA Kawai, T AF Matsuda, Shinji Movila, Alexandru Suzuki, Maiko Kajiya, Mikihito Wisitrasameewong, Wichaya Kayal, Rayyan Hirshfeld, Josefine Al-Dharrab, Ayman Savitri, Irma J. Mira, Abdulghani Kurihara, Hidemi Taubman, Martin A. Kawai, Toshihisa TI A novel method of sampling gingival crevicular fluid from a mouse model of periodontitis SO JOURNAL OF IMMUNOLOGICAL METHODS LA English DT Article DE Periodontal disease; Gingival crevicular fluid; Ligature-induced periodontal disease; Mice ID TUMOR-NECROSIS-FACTOR; KAPPA-B LIGAND; RECEPTOR ACTIVATOR; TISSUE DESTRUCTION; BONE-RESORPTION; MARKERS; DISEASE; INVOLVEMENT; INDUCTION; RISK AB Using a mouse model of silk ligature-induced periodontal disease (PD), we report a novel method of sampling mouse gingival crevicular fluid (GCF) to evaluate the time-dependent secretion patterns of bone resorption related cytokines. GCF is a serum transudate containing host-derived biomarkers which can represent cellular response in the periodontium. As such, human clinical evaluations of PD status rely on sampling this critical secretion. At the same time, a method of sampling GCF from mice is absent, hindering the translational value of mouse models of PD. Therefore, we herein report a novel method of sampling GCF from a mouse model of periodontitis, involving a series of easy steps. First, the original ligature used for induction of PD was removed, and a fresh ligature for sampling GCF was placed in the gingival crevice for 10 min. Immediately afterwards, the volume of GCF collected in the sampling ligature was measured using a high precision weighing balance. The sampling ligature containing GCF was then immersed in a solution of PBS-Tween 20 and subjected to ELISA. This enabled us to monitor the volume of GCF and detect time-dependent changes in the expression of such cytokines as IL-lb, TNF-alpha, IL-6, RANKL, and OPG associated with the levels of alveolar bone loss, as reflected in GCF collected from a mouse model of PD. Therefore, this novel GCF sampling method can be used to measure various cytokines in GCF relative to the dynamic changes in periodontal bone loss induced in a mouse model of PD. (C) 2016 Published by Elsevier B.V. C1 [Matsuda, Shinji; Movila, Alexandru; Suzuki, Maiko; Kajiya, Mikihito; Wisitrasameewong, Wichaya; Hirshfeld, Josefine; Savitri, Irma J.; Taubman, Martin A.; Kawai, Toshihisa] Forsyth Inst, Dept Immunol & Infect Dis, 245 First St, Cambridge, MA 02142 USA. [Matsuda, Shinji; Kajiya, Mikihito; Kurihara, Hidemi] Hiroshima Univ, Fac Dent, Dept Periodontol, Hiroshima, Japan. [Suzuki, Maiko] Ohio State Univ, Coll Dent, Columbus, OH 43210 USA. [Wisitrasameewong, Wichaya; Kawai, Toshihisa] Harvard Univ, Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Wisitrasameewong, Wichaya] Chulalongkorn Univ, Dept Periodontol, Fac Dent, Bangkok, Thailand. [Kayal, Rayyan; Al-Dharrab, Ayman; Mira, Abdulghani] King Abdulaziz Univ, Fac Dent, Jeddah, Saudi Arabia. [Hirshfeld, Josefine] Univ Birmingham, Dept Restorat Dent, Birmingham, W Midlands, England. [Savitri, Irma J.] Univ Airlangga, Fac Med Dent, Dept Periodontol, Jawa Timur, Indonesia. RP Kawai, T (reprint author), Forsyth Inst, Dept Immunol & Infect Dis, 245 First St, Cambridge, MA 02142 USA. EM tkawai@forsyth.org FU National Institute of Dental and Craniofacial Research (NIDCR) [DE-03420, DE-18499, DE-19917, T32 DE 7327-12]; Brain Circulation Program to Develop New Leaders for International Dental Education Course through International Collaborative Dental Research; King Abdulaziz University of Saudi Arabia FX This study was supported by grants DE-03420, DE-18499, DE-19917, and T32 DE 7327-12 from the National Institute of Dental and Craniofacial Research (NIDCR), Brain Circulation Program to Develop New Leaders for International Dental Education Course through International Collaborative Dental Research and a research fund from King Abdulaziz University of Saudi Arabia. NR 20 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-1759 EI 1872-7905 J9 J IMMUNOL METHODS JI J. Immunol. Methods PD NOV PY 2016 VL 438 BP 21 EP 25 DI 10.1016/j.jim.2016.08.008 PG 5 WC Biochemical Research Methods; Immunology SC Biochemistry & Molecular Biology; Immunology GA EA6KS UT WOS:000386738700003 PM 27589925 ER PT J AU Subbarayal, B Chauhan, SK Di Zazzo, A Dana, R AF Subbarayal, Brinda Chauhan, Sunil K. Di Zazzo, Antonio Dana, Reza TI IL-17 Augments B Cell Activation in Ocular Surface Autoimmunity SO JOURNAL OF IMMUNOLOGY LA English DT Article ID DRY EYE DISEASE; TH17 CELLS; IFN-GAMMA; BXD2 MICE; RESPONSES; INFLAMMATION; SUPPRESSION; EXPRESSION; IL-21 AB Accumulating evidence shows that IL-17 is critically involved in diverse autoimmune diseases. However, its effect on the induction and progression of the humoral immune response is not fully understood. Using a preclinical model of IL-17 mediated dry eye disease, we demonstrate that upon encountering both the BCR and a secondary T cell signal, IL-17 can enhance B cell proliferation and germinal center formation in dry eye disease mice, suggesting that a stable Ag-dependent T B cell interaction is required. Additionally, IL-17 also promotes the differentiation of B cells into isotype-switched B cells and plasma cells. Furthermore, we show that Th17 cells are more effective than Thl cells to provide B cell help. Reduced B cell response correlates with significant reduction in clinical disease after in vivo IL-17A neutralization. In conclusion, our findings demonstrate a new role of IL-17 in promoting autoimmunity in part through directly enhancing B cell proliferation, differentiation, and plasma cell generation. The Journal of Immunology, 2016, 197: 3464-3470. C1 [Subbarayal, Brinda; Chauhan, Sunil K.; Di Zazzo, Antonio; Dana, Reza] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA. RP Dana, R (reprint author), Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA. EM Reza_Dana@meei.harvard.edu FU National Institutes of Health [EY20889] FX This work was supported by National Institutes of Health Grant EY20889 (to R.D.). NR 22 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD NOV 1 PY 2016 VL 197 IS 9 BP 3464 EP 3470 DI 10.4049/jimmunol.1502641 PG 7 WC Immunology SC Immunology GA EC2PN UT WOS:000387965900006 PM 27655846 ER PT J AU Agboola, S Jethwani, K Lopez, L Searl, M O'Keefe, S Kvedar, J AF Agboola, Stephen Jethwani, Kamal Lopez, Lenny Searl, Meghan O'Keefe, Sandra Kvedar, Joseph TI Text to Move: A Randomized Controlled Trial of a Text-Messaging Program to Improve Physical Activity Behaviors in Patients With Type 2 Diabetes Mellitus SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE type 2 diabetes; text messaging; mobile phones; physical activity; engagement; pedometers ID SELF-MANAGEMENT; INTERVENTION; TECHNOLOGY; OUTCOMES; WALKING; ADULTS AB Background: Text messages are increasingly being used because of the low cost and the ubiquitous nature of mobile phones to engage patients in self-care behaviors. Self-care is particularly important in achieving treatment outcomes in type 2 diabetes mellitus (T2DM). Objective: This study examined the effect of personalized text messages on physical activity, as measured by a pedometer, and clinical outcomes in a diverse population of patients with T2DM. Methods: Text to Move (TTM) incorporates physical activity monitoring and coaching to provide automated and personalized text messages to help patients with T2DM achieve their physical activity goals. A total of 126 English-or Spanish-speaking patients with glycated hemoglobin A(1c) (HbA(1c)) >7 were enrolled in-person to participate in the study for 6 months and were randomized into either the intervention arm that received the full complement of the intervention or a control arm that received only pedometers. The primary outcome was change in physical activity. We also assessed the effect of the intervention on HbA1c, weight, and participant engagement. Results: All participants (intervention: n=64; control: n=62) were included in the analyses. The intervention group had significantly higher monthly step counts in the third (risk ratio [RR] 4.89, 95% CI 1.20 to 19.92, P=.03) and fourth (RR 6.88, 95% CI 1.21 to 39.00, P=.03) months of the study compared to the control group. However, over the 6-month follow-up period, monthly step counts did not differ statistically by group (intervention group: 9092 steps; control group: 3722 steps; RR 2.44, 95% CI 0.68 to 8.74, P=.17). HbA(1c) decreased by 0.07% (95% CI -0.47 to 0.34, P=.75) in the TTM group compared to the control group. Within groups, HbA1c decreased significantly from baseline in the TTM group by -0.43% (95% CI -0.75 to -0.12, P=.01), but nonsignificantly in the control group by -0.21% (95% CI -0.49 to 0.06, P=.13). Similar changes were observed for other secondary outcomes. Conclusion: Personalized text messaging can be used to improve outcomes in patients with T2DM by employing optimal patient engagement measures. C1 [Agboola, Stephen; Jethwani, Kamal; Kvedar, Joseph] Partners Connected Hlth, Suite 300,25 New Chardon St, Boston, MA 02114 USA. [Agboola, Stephen; Jethwani, Kamal; O'Keefe, Sandra; Kvedar, Joseph] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Agboola, Stephen; Jethwani, Kamal; Kvedar, Joseph] Harvard Med Sch, Boston, MA USA. [Lopez, Lenny] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Searl, Meghan] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Agboola, S (reprint author), Partners Connected Hlth, Suite 300,25 New Chardon St, Boston, MA 02114 USA. EM sagboola@partners.org FU McKesson Foundation; RWJ Foundation Harold Amos Faculty Development Program; NIDDK [1K23DK098280-01] FX The investigators would like to gratefully acknowledge the following for their invaluable support: the Text to Move Study team (Misbah Mohammed, Meaghan Doherty, Clare Flanagan, Suzanne Rossov, Ellen Murachver, Shiyi Zan, Julie Kvedar, Caitlin Masters, Kurleigh Henry, Rob Havasy, Alyssa Woulfe, Bianca Porneala, and Sara Golas), the McKesson Foundation for funding this project, and Dr Lopez thanks the RWJ Foundation Harold Amos Faculty Development Program and NIDDK 1K23DK098280-01 for their support. NR 27 TC 0 Z9 0 U1 4 U2 4 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD NOV PY 2016 VL 18 IS 11 AR e307 DI 10.2196/jmir.6439 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA EC4OC UT WOS:000388111100009 PM 27864165 ER PT J AU Sadasivam, RS Borglund, EM Adams, R Marlin, BM Houston, TK AF Sadasivam, Rajani Shankar Borglund, Erin M. Adams, Roy Marlin, Benjamin M. Houston, Thomas K. TI Impact of a Collective Intelligence Tailored Messaging System on Smoking Cessation: The Perspect Randomized Experiment SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE recommender system; health communication; computer tailoring; smoking cessation ID PHYSICAL-ACTIVITY; BEHAVIOR-CHANGE; QUIT-PRIMO; INTERVENTIONS; ENGAGEMENT; PROGRAMS; ENHANCE; TRIAL AB Background: Outside health care, content tailoring is driven algorithmically using machine learning compared to the rule-based approach used in current implementations of computer-tailored health communication (CTHC) systems. A special class of machine learning systems ("recommender systems") are used to select messages by combining the collective intelligence of their users (ie, the observed and inferred preferences of users as they interact with the system) and their user profiles. However, this approach has not been adequately tested for CTHC. Objective: Our aim was to compare, in a randomized experiment, a standard, evidence-based, rule-based CTHC (standard CTHC) to a novel machine learning CTHC: Patient Experience Recommender System for Persuasive Communication Tailoring (PERSPeCT). We hypothesized that PERSPeCT will select messages of higher influence than our standard CTHC system. This standard CTHC was proven effective in motivating smoking cessation in a prior randomized trial of 900 smokers (OR 1.70, 95% CI 1.03-2.81). Methods: PERSPeCT is an innovative hybrid machine learning recommender system that selects and sends motivational messages using algorithms that learn from message ratings from 846 previous participants (explicit feedback), and the prior explicit ratings of each individual participant. Current smokers (N=120) aged 18 years or older, English speaking, with Internet access were eligible to participate. These smokers were randomized to receive either PERSPeCT (intervention, n=74) or standard CTHC tailored messages (n=46). The study was conducted between October 2014 and January 2015. By randomization, we compared daily message ratings (mean of smoker ratings each day). At 30 days, we assessed the intervention's perceived influence, 30-day cessation, and changes in readiness to quit from baseline. Results: The proportion of days when smokers agreed/strongly agreed (daily rating >= 4) that the messages influenced them to quit was significantly higher for PERSPeCT (73%, 23/30) than standard CTHC (44%, 14/30, P=.02). Among less educated smokers (n=49), this difference was even more pronounced for days strongly agree (intervention: 77%, 23/30; comparison: 23%, 7/30, P<.001). There was no significant difference in the frequency which PERSPeCT randomized smokers agreed or strongly agreed that the intervention influenced them to quit smoking (P=.07) and use nicotine replacement therapy (P=.09). Among those who completed follow-up, 36% (20/55) of PERSPeCT smokers and 32% (11/34) of the standard CTHC group stopped smoking Conclusions: Compared to standard CTHC with proven effectiveness, PERSPeCT outperformed in terms of influence ratings and resulted in similar cessation rates. C1 [Sadasivam, Rajani Shankar; Borglund, Erin M.; Houston, Thomas K.] Univ Massachusetts Med Scool, Quantitat Hlth Sci, Div Hlth Informat & Implementat Sci, Worcester, MA USA. [Adams, Roy; Marlin, Benjamin M.] Univ Massaachusttes Amherst, Coll Informat & Comp Sci, Amherst, MA USA. [Houston, Thomas K.] Bedford VA Med Ctr, US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. RP Sadasivam, RS (reprint author), Univ Massachusetts Med Scool, Albert Sherman Ctr, Div Hlth Informat & Implementat Sci, Quantitat Hlth Sci, 368 Plantat St, Worcester, MA 01605 USA. EM rajani.sadasivam@umassmed.edu OI Borglund, Erin/0000-0003-0492-1803; Sadasivam, Rajani/0000-0001-8406-6207 FU Patient-Centered Outcomes Research Institute [PI12-001]; National Cancer Institute [R01 CA129091, K07CA172677]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000161]; National Science Foundation CAREER award [1350522] FX Funding for these studies was received from the Patient-Centered Outcomes Research Institute (PI12-001), the National Cancer Institute grants R01 CA129091, and the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000161. Dr Sadasivam is funded by a National Cancer Institute Career Development Award (K07CA172677). Dr Marlin is also funded by a National Science Foundation CAREER award (1350522). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health, or the Department of Veterans Affairs or the United States government. NR 34 TC 0 Z9 0 U1 8 U2 8 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD NOV PY 2016 VL 18 IS 11 AR e285 DI 10.2196/jmir.6465 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA EC4OC UT WOS:000388111100002 PM 27826134 ER PT J AU Teichert, T Gurnsey, K Salisbury, D Sweet, RA AF Teichert, Tobias Gurnsey, Kate Salisbury, Dean Sweet, Robert A. TI Contextual processing in unpredictable auditory environments: the limited resource model of auditory refractoriness in the rhesus SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE auditory deficits; EEG; habituation; response suppression; rhesus ID EVENT-RELATED POTENTIALS; NEOCORTICAL PYRAMIDAL NEURONS; PRIMARY VISUAL-CORTEX; MISMATCH NEGATIVITY; RECEPTIVE-FIELD; EVOKED-POTENTIALS; CORTICAL-NEURONS; SENSORY MEMORY; MACAQUE MONKEY; IN-VIVO AB Auditory refractoriness refers to the finding of smaller electroencephalographic (EEG) responses to tones preceded by shorter periods of silence. To date, its physiological mechanisms remain unclear, limiting the insights gained from findings of abnormal refractoriness in individuals with schizophrenia. To resolve this roadblock, we studied auditory refractoriness in the rhesus, one of the most important animal models of auditory function, using grids of up to 32 chronically implanted cranial EEG electrodes. Four macaques passively listened to sounds whose identity and timing was random, thus preventing animals from forming valid predictions about upcoming sounds. Stimulus onset asynchrony ranged between 0.2 and 12.8 s, thus encompassing the clinically relevant timescale of refractoriness. Our results show refractoriness in all 8 previously identified middle-and long-latency components that peaked between 14 and 170 ms after tone onset. Refractoriness may reflect the formation and gradual decay of a basic sensory memory trace that may be mirrored by the expenditure and gradual recovery of a limited physiological resource that determines generator excitability. For all 8 components, results were consistent with the assumption that processing of each tone expends similar to 65% of the available resource. Differences between components are caused by how quickly the resource recovers. Recovery time constants of different components ranged between 0.5 and 2 s. This work provides a solid conceptual, methodological, and computational foundation to dissect the physiological mechanisms of auditory refractoriness in the rhesus. Such knowledge may, in turn, help develop novel pharmacological, mechanism-targeted interventions. C1 [Teichert, Tobias; Gurnsey, Kate; Salisbury, Dean; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Teichert, Tobias] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Teichert, T (reprint author), Univ Pittsburgh, BST W 1658,200 Lothrop St, Pittsburgh, PA 15261 USA. EM teichert@pitt.edu FU National Institute of Mental Health [R01 MH094328, R01 MH071533] FX This work was supported by National Institute of Mental Health Grants R01 MH094328 (to D. Salisbury) and R01 MH071533 (to R.A. Sweet). NR 67 TC 0 Z9 0 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD NOV PY 2016 VL 116 IS 5 BP 2125 EP 2139 DI 10.1152/jn.00419.2016 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA EC2VV UT WOS:000387983300012 PM 27512021 ER PT J AU Mitchell, CM Epstein-Peterson, ZD Bandini, J Amobi, A Cahill, J Enzinger, A Noveroske, S Peteet, J Balboni, T Balboni, MJ AF Mitchell, Christine M. Epstein-Peterson, Zachary D. Bandini, Julia Amobi, Ada Cahill, Jonathan Enzinger, Andrea Noveroske, Sarah Peteet, John Balboni, Tracy Balboni, Michael J. TI Developing a Medical School Curriculum for Psychological, Moral, and Spiritual Wellness: Student and Faculty Perspectives SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Religion; spirituality; curriculum development; medical school; wellness ID CANCER-PATIENTS; FAMILY MEDICINE; OF-LIFE; PHYSICIANS; CARE; RELIGION; END; ATTITUDES; EDUCATION; QUALITY AB Context. Although many studies have addressed the integration of a religion and/or spirituality curriculum into medical school training, few describe the process of curriculum development based on qualitative data from students and faculty. Objectives. The aim of this study is to explore the perspectives of medical students and chaplaincy trainees regarding the development of a curriculum to facilitate reflection on moral and spiritual dimensions of caring for the critically ill and to train students in self-care practices that promote professionalism. Methods. Research staff conducted semiscripted and one-on-one interviews and focus groups. Respondents also completed a short and self-reported demographic questionnaire. Participants included 44 students and faculty members from Harvard Medical School and Harvard Divinity School, specifically senior medical students and divinity school students who have undergone chaplaincy training. Results. Two major qualitative themes emerged: curriculum format and curriculum content. Inter-rater reliability was high (kappa = 0.75). With regard to curriculum format, most participants supported the curriculum being longitudinal, elective, and experiential. With regard to curriculum content, five subthemes emerged: personal religious and/or spiritual (R/S) growth, professional integration of R/S values, addressing patient needs, structural and/or institutional dynamics within the health care system, and controversial social issues. Conclusion. Qualitative findings of this study suggest that development of a future medical school curriculum on R/S and wellness should be elective, longitudinal, and experiential and should focus on the impact and integration of R/S values and self-care practices within self, care for patients, and the medical team. Future research is necessary to study the efficacy of these curricula once implemented. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Mitchell, Christine M.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Epstein-Peterson, Zachary D.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Bandini, Julia] Brandeis Univ, Dept Sociol, Waltham, MA USA. [Amobi, Ada; Peteet, John; Balboni, Tracy; Balboni, Michael J.] Harvard Med Sch, Boston, MA USA. [Cahill, Jonathan] Boston Coll, Dept Theol, Chestnut Hill, MA 02167 USA. [Enzinger, Andrea] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Noveroske, Sarah; Peteet, John; Balboni, Tracy; Balboni, Michael J.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Dana 1009,450 Brookline Ave, Boston, MA 02115 USA. [Balboni, Tracy] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Balboni, MJ (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Dana 1009,450 Brookline Ave, Boston, MA 02115 USA. EM Michael_Balboni@dfci.harvard.edu FU John Templeton Foundation FX The John Templeton Foundation. NR 45 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2016 VL 52 IS 5 BP 727 EP 736 DI 10.1016/j.jpainsymman.2016.05.018 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EC2OE UT WOS:000387961500017 PM 27693904 ER PT J AU Vance, CG Kopacz, MS AF Vance, C. Garland Kopacz, Marek S. TI After the Spiritual Assessment SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Letter C1 [Vance, C. Garland] Charles George VA Med Ctr, Asheville, NC USA. [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. EM marekskopacz@hotmail.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2016 VL 52 IS 5 BP E3 EP E4 DI 10.1016/j.jpainsymman.2016.09.001 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EC2OE UT WOS:000387961500004 PM 27660083 ER PT J AU Shulman, DS Lee, MA Lehmann, LE Margossian, SP AF Shulman, David S. Lee, Michelle A. Lehmann, Leslie E. Margossian, Steven P. TI Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY LA English DT Article DE chronic myelogenous leukemia; bone marrow transplant; hematopoietic cell transplant; tyrosine kinase inhibitor ID CHRONIC MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; IMATINIB MESYLATE; ALLOGENEIC TRANSPLANTATION; CML; PATTERNS AB The management of chronic myelogenous leukemia (CML) in children changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs). Unfortunately, outcomes for patients presenting in an advanced stageaccelerated phase or blast crisis CMLcontinues to be poor, requiring chemotherapy and allogeneic hematopoietic stem cell transplant (HSCT) to attempt cure. Integration of TKIs in the therapy of advanced CML is still an area of active investigation. There are little published data on TKI use in children with advanced stage CML. We performed a retrospective review of all children treated at our institution between January 1, 2010 and June 30, 2013, and identified 5 children, age 12 to 18 years, with advanced stage CML. All patients were treated with a TKI before HSCT and TKIs were restarted post-HSCT in 4/5 with a goal of continuing until 2 years posttransplant. At time of HSCT all were in a morphologic and cytogenetic remission; 1 patient had also achieved molecular remission. All patients are alive and in molecular remission at an average of 38 months (range, 14 to 51 mo) following transplant. Our experience indicates that TKIs are safe and well tolerated in children both pretransplant and posttransplant and may improve outcomes in this aggressive disease. C1 [Shulman, David S.] Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02215 USA. [Lee, Michelle A.; Lehmann, Leslie E.; Margossian, Steven P.] Boston Childrens Hosp, Dana Farber Canc Inst, Pediat Stem Cell Transplantat Ctr, Boston, MA USA. RP Shulman, DS (reprint author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02215 USA. EM david.shulman@childrens.harvard.edu NR 22 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1077-4114 EI 1536-3678 J9 J PEDIAT HEMATOL ONC JI J. Pediatr. Hematol. Oncol. PD NOV PY 2016 VL 38 IS 8 BP 610 EP 614 DI 10.1097/MPH.0000000000000636 PG 5 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA EC3GY UT WOS:000388015600021 PM 27403776 ER PT J AU Friedman, GN Grannan, BL Yanamadala, V Shankar, GM Dewitt, JC Puthenpura, V Koffie, RM Macdonald, SM Ebb, DH Frosch, MP Duhaime, AC AF Friedman, Gabriel N. Grannan, Benjamin L. Yanamadala, Vijay Shankar, Ganesh M. Dewitt, John C. Puthenpura, Vidya Koffie, Robert M. Macdonald, Shannon M. Ebb, David H. Frosch, Matthew P. Duhaime, Ann-Christine TI Rapid Neurological Recovery Following Partial Surgical Resection of Spinal Glioblastoma Multiforme in a Pediatric Patient Presenting With Complete Paraplegia SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY LA English DT Article DE glioblastoma multiforme; pediatric; spinal; oncology ID CORD ASTROCYTOMA; SURVIVAL; RADIOTHERAPY; STRATEGIES; CCG-945 AB Pediatric spinal cord glioblastoma multiforme is a rare entity with a poor prognosis often presenting with lower extremity weakness or paralysis. Previous literature suggests that aggressive surgical resection may provide overall survival benefit; however, there is limited concurrent analysis demonstrating neurological recovery following surgical resection. We report the case of a 9-year-old boy who presented with complete paraplegia and regained the ability to ambulate independently following subtotal surgical resection, radiation, and chemotherapy. The case demonstrates the balance between meaningful neurological recovery and overall survival when deciding on the extent of resection in cases of pediatric spinal glioblastoma multiforme. C1 [Friedman, Gabriel N.; Grannan, Benjamin L.; Yanamadala, Vijay; Shankar, Ganesh M.; Puthenpura, Vidya; Koffie, Robert M.; Duhaime, Ann-Christine] Massachusetts Gen Hosp, Dept Neurosurg, Wang Bldg,Suite 027,55 Fruit St, Boston, MA 20114 USA. [Dewitt, John C.; Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Ebb, David H.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Macdonald, Shannon M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Friedman, Gabriel N.; Grannan, Benjamin L.; Yanamadala, Vijay; Shankar, Ganesh M.; Koffie, Robert M.; Macdonald, Shannon M.; Ebb, David H.; Frosch, Matthew P.; Duhaime, Ann-Christine] Harvard Med Sch, Boston, MA USA. RP Grannan, BL (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Wang Bldg,Suite 027,55 Fruit St, Boston, MA 20114 USA. EM bgrannan@partners.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1077-4114 EI 1536-3678 J9 J PEDIAT HEMATOL ONC JI J. Pediatr. Hematol. Oncol. PD NOV PY 2016 VL 38 IS 8 BP E286 EP E290 DI 10.1097/MPH.0000000000000637 PG 5 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA EC3GY UT WOS:000388015600005 PM 27403775 ER PT J AU Tatmatsu-Rocha, JC Ferraresi, C Hamblin, MR Maia, FD do Nascimento, NRF Driusso, P Parizotto, NA AF Tatmatsu-Rocha, Jose Carlos Ferraresi, Cleber Hamblin, Michael R. Maia, Flavio Damasceno Falcao do Nascimento, Nilberto Robson Driusso, Patricia Parizotto, Nivaldo Antonio TI Low-level laser therapy (904 nm) can increase collagen and reduce oxidative and nitrosative stress in diabetic wounded mouse skin SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY LA English DT Article DE Catalase; Diabetes mellitus; Oxidative stress; Collagen production; Nitric oxide; TBARS; Photobiomodulation ID CONTACT HYPERSENSITIVITY; HEALING PATHOPHYSIOLOGY; REACTIVE OXYGEN; DRUG-DELIVERY; RADIATION; ACTIVATION; MECHANISMS; CELLS; PHOTOTHERAPY; ANTIOXIDANTS AB Background and Objective: Over the last decade we have seen an increased interest in the use of Low-Level Laser Therapy (LLLT) in diseases that involve increased oxidative stress. It is well established that hyperglycemia in diabetes elicits a rise in reactive oxygen species (ROS) production but the effect of LLLT remains unclear. This study aimed to investigate whether LLLT was able to improve oxidative/nitrosative stress parameters in the wound healing process in diabetic mice. Study Design/Materials and Methods: Twenty male mice were divided into four groups: non-irradiated control (NIC), irradiated control (IC), non-irradiated and diabetic (NID), irradiated and diabetic (ID). Diabetes was induced by administration of streptozotocin. Wounds were created 120 days after the induction of diabetes in groups IC and ID and these groups were irradiated daily for 5 days (superpulsed 904 nm laser, average power 40 mW, 60 s). All animals were sacrificed 1 day after the last irradiation and histology, collagen amount, catalase activity, nitrite and thiobarbituric acid reactive substances (TBARS) were measured. Results: Histology showed that collagen fibers were more organized in IC and ID when compared to NID group, and significant differences in collagen content were found in group ID versus NID. Catalase activity was higher in IC group compared to other groups (p < 0.001). TBARS levels were higher in IC versus NIC, but were lower in ID versus NID (p < 0.001). Nitrite was lower in both irradiated groups versus the respective non-irradiated groups (p < 0.001). Conclusions: Delayed wound healing in diabetes is still a challenge in clinical practice with high social costs. The increased production of collagen and decreased oxidative and nitrosative stress suggests that LLLT may be a viable therapeutic alternative in diabetic wound healing. (C) 2016 Elsevier B.V. All rights reserved. C1 [Tatmatsu-Rocha, Jose Carlos; Ferraresi, Cleber; Driusso, Patricia; Parizotto, Nivaldo Antonio] Univ Fed Sao Carlos, Phys Therapy Dept, Sao Carlos, SP, Brazil. [Tatmatsu-Rocha, Jose Carlos] Univ Fed Ceara, Phys Therapy Dept, Fortaleza, Ceara, Brazil. [Maia, Flavio Damasceno] Univ Fed Ceara, Dept Pharmacol, Fortaleza, Ceara, Brazil. [Falcao do Nascimento, Nilberto Robson] Univ Estadual Ceara, Super Inst Biomed, Lab Renal & Cardiovasc Pharmacol, Fortaleza, Ceara, Brazil. [Tatmatsu-Rocha, Jose Carlos; Ferraresi, Cleber; Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA USA. [Tatmatsu-Rocha, Jose Carlos; Ferraresi, Cleber; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Tatmatsu-Rocha, JC (reprint author), 304 Tappan St, Brookline, MA 02445 USA. EM tatmatsu@gmail.com RI Ferraresi, Cleber/B-2458-2014 FU CAPES/PDSE (Coordenacao de Aperfeicoamento de Pessoal) [006648/2015-00]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) in Brazil [2010/07194-7]; US NIH [R01AI050875] FX The authors declare no conflicts of interest in this research. JCTR was supported by CAPES/PDSE (Coordenacao de Aperfeicoamento de Pessoal-Process no. 006648/2015-00). CF was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Process no. 2010/07194-7) in Brazil. MRH was supported by US NIH (grant R01AI050875). The authors express their thanks to professors Walberto dos Santos Conceicao A Dornelas, Geanne Matos and Tatiana Sato and to the Laboratory of Pharmacology, Federal University of Ceara for all support with chemical reagents. NR 48 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE SA PI LAUSANNE PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND SN 1011-1344 J9 J PHOTOCH PHOTOBIO B JI J. Photochem. Photobiol. B-Biol. PD NOV PY 2016 VL 164 BP 96 EP 102 DI 10.1016/j.jphotobiol.2016.09.017 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA EB8FH UT WOS:000387626400012 PM 27661759 ER PT J AU Shubert, CR Ferrone, CR Fernandez-del Castillo, C Kendrick, ML Farnell, MB Smoot, RL Truty, MJ Que, FG AF Shubert, Christopher R. Ferrone, Christina R. Fernandez-del Castillo, Carlos Kendrick, Michael L. Farnell, Michael B. Smoot, Rory L. Truty, Mark J. Que, Florencia G. TI A multicenter randomized controlled trial comparing pancreatic leaks after TissueLink versus SEAMGUARD after distal pancreatectomy (PLATS) NCT01051856 SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Distal pancreatectomy; TissueLink; SEAMGUARD; Postoperative pancreatic fistula ID FISTULA; REINFORCEMENT AB Background: Pancreatic leak is common after distal pancreatectomy. This trial sought to compare TissueLink closure of the pancreatic stump to that of SEAMGUARD. Methods: A multicenter, prospective, trial of patients undergoing distal pancreatectomy randomized to either TissueLink or SEAMGUARD. Results: Enrollment was closed early due to poor accrual. Overall, 67 patients were enrolled, 35 TissueLink and 32 SEAMGUARD. The two groups differed in American Society of Anesthesiologist class and diagnosis at baseline and were relatively balanced otherwise. Overall, 37 of 67 patients (55%) experienced a leak of any grade, 15 (46.9%) in the SEAMGUARD arm and 22 (62.9%) in the TissueLink arm (P = 0.19). The clinically significant leak rate was 17.9%; 22.9% for TissueLink and 12.5% for SEAMGUARD (P = 0.35). There were no statistically significant differences in major or any pancreatic fistulaerelated morbidity between the two groups. Conclusions: This is the first multicentered randomized trial evaluating leak rate after distal pancreatectomy between two common transection methods. Although a difference in leak rates was observed, it was not statistically significant and therefore does not provide evidence of the superiority of one technique over the other. Choice should remain based on surgeon comfort, experience, and pancreas characteristics. (C) 2016 Elsevier Inc. All rights reserved. C1 [Shubert, Christopher R.; Kendrick, Michael L.; Farnell, Michael B.; Smoot, Rory L.; Truty, Mark J.; Que, Florencia G.] Mayo Clin, Dept Surg, Div Subspecialty Gen Surg, Sect Hepatobiliary & Pancreas Surg, Rochester, MN USA. [Ferrone, Christina R.; Fernandez-del Castillo, Carlos] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Ferrone, Christina R.; Fernandez-del Castillo, Carlos] Harvard Med Sch, Gen & Gastrointestinal Surg, Boston, MA USA. RP Que, FG (reprint author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA. EM que.florencia@mayo.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD NOV PY 2016 VL 206 IS 1 BP 32 EP 40 DI 10.1016/j.jss.2016.06.034 PG 9 WC Surgery SC Surgery GA EC2VR UT WOS:000387982900007 PM 27916372 ER PT J AU Morgan, AE Pantoja, JL Grossi, EA Ge, L Weinsaft, JW Ratcliffe, MB AF Morgan, Ashley E. Pantoja, Joe L. Grossi, Eugene A. Ge, Liang Weinsaft, Jonathan W. Ratcliffe, Mark B. TI Neochord placement versus triangular resection in mitral valve repair: A finite element model SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Finite element modeling; Mitral valve repair; Cardiac mechanics; Surgical simulation ID POSTERIOR LEAFLET PROLAPSE; VENTRICULAR-WALL STRESS; EXPANDED POLYTETRAFLUOROETHYLENE; CHORDAE TENDINEAE; REGURGITATION; REPLACEMENT; SIMULATION; DISEASE; SHAPE AB Background: Recurrent mitral regurgitation after mitral valve repair is common, occurring in nearly 50% of patients within 10 years of surgery. Durability of repair is partly related to stress distribution over the mitral leaflets. We hypothesized that repair with neochords (NCs) results in lower stress than leaflet resection (LR). Materials and methods: Magnetic resonance imaging and 3D echocardiography were performed before surgical repair of P2 prolapse in a single patient. A finite element model of the left ventricle and mitral valve was created previously, and the modeling program LS-DYNA was used to calculate leaflet stress for the following repairs: Triangular LR; LR with ring annuloplasty (LR + RA); One NC; Two NCs; and 2NC + RA. Results: (1) NC placement resulted in stable posterior leaflet stress: Baseline versus 2 NC at end diastole (ED), 12.1 versus 12.0 kPa, at end systole (ES) 20.3 versus 21.7 kPa. (2) In contrast, LR increased posterior leaflet stress: Baseline versus LR at ED 12.1 versus 40.8 kPa, at ES 20.3 versus 46.1 kPa. (3) All repair types reduced anterior leaflet stress: Baseline versus 2 NC versus LR 34.2 versus 25.8 versus 20.6 kPa at ED and 80.8 versus 76.8 versus 67.8 kPa at ES. (4) The addition of RA reduced leaflet stress relative to repair without RA. Conclusions: Neochord repair restored normal leaflet coaptation without creating excessive leaflet stress, whereas leaflet resection more than doubled stress across the posterior leaflet. The excess stress created by leaflet resection was partially, but not completely, mitigated by ring annuloplasty. (C) 2016 Elsevier Inc. All rights reserved. C1 [Morgan, Ashley E.] Univ Calif San Francisco, East Bay Surg Residency, San Francisco, CA 94143 USA. [Pantoja, Joe L.] Univ Calif San Francisco, Coll Med, San Francisco, CA 94143 USA. [Grossi, Eugene A.] NYU, Dept Cardiothorac Surg, New York, NY USA. [Grossi, Eugene A.] New York Harbor Vet Affairs Med Ctr, Dept Cardiothorac Surg, New York, NY USA. [Ge, Liang; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Ge, Liang; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. [Ge, Liang; Ratcliffe, Mark B.] Vet Affairs Med Ctr, Dept Surg, San Francisco, CA 94121 USA. [Weinsaft, Jonathan W.] Weill Cornell Med Coll, Dept Med Cardiol, New York, NY USA. [Weinsaft, Jonathan W.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@med.va.gov OI GROSSI, eugene/0000-0002-2066-7035 FU NIH-R01 [HL128278-01] FX Funding support provided by NIH-R01 HL128278-01, Dr. Weinsaft. NR 26 TC 0 Z9 0 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD NOV PY 2016 VL 206 IS 1 BP 98 EP 105 DI 10.1016/j.jss.2016.07.011 PG 8 WC Surgery SC Surgery GA EC2VR UT WOS:000387982900016 PM 27916382 ER PT J AU Benedict, LA Bairdain, S Paulus, JK Jackson, CC Chen, C Kelleher, C AF Benedict, Leo Andrew Bairdain, Sigrid Paulus, Jessica K. Jackson, Carl-Christian Chen, Catherine Kelleher, Cassandra TI Esophageal duplication cysts and closure of the muscle layer SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Esophageal duplication cysts; Esophagus; Diverticulum ID THORACOSCOPIC RESECTION AB Background: Foregut duplication cysts are rare congenital anomalies that require surgical intervention with approximately 10%-15% of all gastrointestinal duplication cysts originating from the esophagus. Consensus is lacking among surgeons regarding closure of the esophageal muscle layer after resection of an esophageal duplication cyst and long-term outcomes are poorly documented. Therefore, we conducted the first study comparing complication rates in patients undergoing closure versus nonclosure of the esophageal muscle layer after esophageal duplication cyst resection. Materials and methods: A retrospective cohort study at Boston Children's Hospital, Massachusetts General Hospital, Brigham and Women's Hospital, and the Floating Hospital for Children at Tufts Medical Center was conducted. Patients undergoing resection of esophageal duplication cysts between 1990 and 2012 were classified according to whether the esophageal muscle layer was closed or left open. Demographic data, surgical technique, preoperative symptoms, and both short-term (<30 d) and long-term (>= 30 d) complication rates were abstracted from patient medical records. Results: Twenty-five patients were identified with a median age of 15-y old (range, 2 mo to 68-y old) and an average follow-up of 1 y. Eleven patients had the esophageal muscle layer closed after surgical resection (44%). Of those 11 patients, one developed a short-term complication, dysphagia (9%, 95% CI: 2%, 38%). Only one patient returned to the operating room, after 30 d, for an upper endoscopy after developing symptoms of gastro-esophageal reflux disease. Of the 14 patients who had their muscle layer left open, three patients (21%, 95% CI: 8%, 48%) developed short-term complications, two of whom required surgical intervention within 30 d. Furthermore, two additional patients required surgical intervention after 30 d for a long-term complication (diverticulum and cyst recurrence). Conclusions: Surgical complications occurred more frequently in patients who had the muscle layer left open after resection of an esophageal duplication cyst. In addition, most patients requiring reoperation for both short-term and long-term complications occurred in this group. Though small, this study is the first to evaluate the complications after resecting esophageal duplication cysts. Our results suggest that closing the esophageal muscle layer after removal of an esophageal duplication cyst may be indicated to prevent both complications and the need for reoperations. (C) 2016 Elsevier Inc. All rights reserved. C1 [Benedict, Leo Andrew; Jackson, Carl-Christian] Tufts Med Ctr, Floating Hosp Children, Dept Pediat Surg, Boston, MA USA. [Bairdain, Sigrid; Chen, Catherine] Boston Childrens Hosp, Dept Surg, Boston, MA USA. [Paulus, Jessica K.] Tufts Univ, Sch Med, Tufts Clin & Translat Sci Inst, Dept Med, Boston, MA USA. [Kelleher, Cassandra] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. [Kelleher, Cassandra] Harvard Med Sch, Boston, MA USA. RP Benedict, LA (reprint author), Tufts Med Ctr, Dept Surg, 800 Washington St, Boston, MA 02111 USA. EM andrew.benedict99@gmail.com NR 8 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD NOV PY 2016 VL 206 IS 1 BP 231 EP 234 DI 10.1016/j.jss.2016.07.024 PG 4 WC Surgery SC Surgery GA EC2VR UT WOS:000387982900034 PM 27916367 ER PT J AU Brink, JA AF Brink, James A. TI Serving Up Incidental Findings: Just the Way You Like 'Em SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Brink, James A.] Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA. RP Brink, JA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA. EM jabrink@partners.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2016 VL 13 IS 11 BP 1285 EP 1286 DI 10.1016/j.jacr.2016.09.019 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB8JX UT WOS:000387638400001 PM 27814828 ER PT J AU Shishehbor, MH Aronow, HD Bartholomew, JR Beckman, JA Froehlich, JB Lookstein, R Misra, S Roberts, AC Rosenfield, K Jaff, MR AF Shishehbor, Mehdi H. Aronow, Herbert D. Bartholomew, John R. Beckman, Joshua A. Froehlich, James B. Lookstein, Robert Misra, Sanjay Roberts, Anne C. Rosenfield, Kenneth Jaff, Michael R. TI Vascular Specialist Response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) Panel on Peripheral Artery Disease of the Lower Extremities SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Peripheral artery disease; intermittent claudication; critical limb ischema; recommendations; MEDCAC ID CRITICAL LIMB ISCHEMIA; INTERMITTENT CLAUDICATION; NUTRITION EXAMINATION; COST-EFFECTIVENESS; NATIONAL-HEALTH; REVASCULARIZATION; MANAGEMENT; EXERCISE; AMPUTATION; METAANALYSIS C1 [Shishehbor, Mehdi H.; Bartholomew, John R.] Cleveland Clin, Cleveland, OH 44106 USA. [Aronow, Herbert D.] Brown Univ, Providence, RI 02912 USA. [Beckman, Joshua A.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. [Froehlich, James B.] Univ Michigan, Ann Arbor, MI 48109 USA. [Lookstein, Robert] Mt Sinai, New York, NY USA. [Misra, Sanjay] Mayo Clin, Rochester, MN USA. [Roberts, Anne C.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Rosenfield, Kenneth; Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Shishehbor, MH (reprint author), Cleveland Clin, Inst Heart & Vasc, 9500 Euclid Ave,J3-5, Cleveland, OH 44195 USA. EM shishem@ccf.org OI Beckman, Joshua/0000-0001-8332-8439 FU National Institute of Health; Astra Zeneca; Jansson pharmaceuticals; Pfizer; Blue Cross Blue Shield of Michigan; Fibromuscular Disease Society of America; Venite; Boston Scientific; Spectranetics; Philips Healthcare Clinical Events Committee: Shockwave; Boehringer Ingelheim; Abbott Vascular; Atrium; NIH; LutonixBard; Cardinal Health FX Mehdi H. Shishehbor: Non-compensated advisor and educator without any personal compensation from Medtronic, Boston Scientific, Abbott Vascular, Spectranetics, Cardiovascular System Inc, Cook Medical, Merck, and Terumo. Research grant from National Institute of Health and Astra Zeneca.; James B. Froehlich: Consultant: Pfizer; Merck; Boehringer Ingelheim; Janssen pharmaceuticals; Johnson & Johnson; Novartis. Grant support: Jansson pharmaceuticals; Pfizer; Blue Cross Blue Shield of Michigan; Fibromuscular Disease Society of America.; Robert Lookstein: Consultant: Boston Scientific, Bayer Healthcare, The Medicines Company, Research Support: Venite, Boston Scientific, Spectranetics, Philips Healthcare Clinical Events Committee: Shockwave.; Sanjay Misra: Consultant: Boston Scientific; DSMB Chair Flexstent Cordis J and J, Research Grants: National Institute of Health, Boehringer Ingelheim.; Kenneth Rosenfield: Consultant/Scientific Advisory Board: Abbott Vascular, Cardinal Health, Inari Medical, InspireMD, Surmodics, Volcano/Philips. Consultant/Scientific Advisory Board with Equity or Stock Options: Capture Vascular, Contego, CRUZAR Systems, Endo span, Eximo, MD Insider, Micell, Shockwave, Silk Road Medical, Valcare; Personal Equity: CardioMEMs, Contego, CRUZAR Systems, Embolitech, Icon, Janacare, MD Insider, Primacea, PQ Bypass. Research or Fellowship Support: Abbott Vascular, Atrium, NIH, LutonixBard; Board Member: VIVA Physicians.; Michael R. Jaff: Non-Compensated Advisor: Abbott Vascular; Boston Scientific; Cordis; Medtronic; Paid Consultant: Cardinal Health; Equity Shareholder: PQ Bypass, Primacea; Board Member: VIVA Physicians, a 501 c 3 not-for-profit education and research organization; The Society for Cardiovascular Angiography and Interventions. NR 33 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2016 VL 13 IS 11 BP 1296 EP 1301 DI 10.1016/j.jacr.2016.03.008 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB8JX UT WOS:000387638400005 PM 27075208 ER PT J AU Hardy, SM AF Hardy, Seth M. TI Engaging Employees and Improving Care at the Veterans Health Administration SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Hardy, Seth M.] VA Maine Healthcare Syst, VA Ctr 1, US Dept Vet Affairs, Serv Radiol, Augusta, ME 04330 USA. RP Hardy, SM (reprint author), VA Maine Healthcare Syst, VA Ctr 1, US Dept Vet Affairs, Serv Radiol, Augusta, ME 04330 USA. EM sethmhardy@gmail.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2016 VL 13 IS 11 BP 1322 EP 1323 DI 10.1016/j.jacr.2016.06.039 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB8JX UT WOS:000387638400010 PM 27526973 ER PT J AU Gyftopoulos, S Rosenberg, ZS Roberts, CC Bencardino, JT Appel, M Baccei, SJ Cassidy, RC Chang, EY Fox, MG Greenspan, BS Hochman, MG Jacobson, JA Mintz, DN Newman, JS Shah, NA Small, KM Weissman, BN AF Gyftopoulos, Soterios Rosenberg, Zehava S. Roberts, Catherine C. Bencardino, Jenny T. Appel, Marc Baccei, Steven J. Cassidy, R. Carter Chang, Eric Y. Fox, Michael G. Greenspan, Bennett S. Hochman, Mary G. Jacobson, Jon A. Mintz, Douglas N. Newman, Joel S. Shah, Nehal A. Small, Kirstin M. Weissman, Barbara N. TI ACR Appropriateness Criteria Imaging After Shoulder Arthroplasty SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness Criteria; shoulder arthroplasty; aseptic loosening; periprosthetic infection; MRI; CT ID POLYETHYLENE WEAR DEBRIS; TOTAL-HIP-ARTHROPLASTY; BRACHIAL-PLEXUS; ROTATOR CUFF; COMPUTED-TOMOGRAPHY; GLENOID COMPONENT; QUANTITATIVE ASSESSMENT; FATTY DEGENERATION; JOINT ASPIRATION; CT-SCAN AB There has been a rapid increase in the number of shoulder arthroplasties, including partial or complete humeral head resurfacing, hemiarthroplasty, total shoulder arthroplasty, and reverse total shoulder arthroplasty, performed in the United States over the past two decades. Imaging can play an important role in diagnosing the complications that can occur in the setting of these shoulder arthroplasties. This review is divided into two parts. The first part provides a general discussion of various imaging modalities, comprising radiography, CT, MRI, ultrasound, and nuclear medicine, and their role in providing useful, treatment-guiding information. The second part focuses on the most appropriate imaging algorithms for shoulder arthroplasty complications such as aseptic loosening, infection, fracture, rotator cuff tendon tear, and nerve injury. The evidence-based ACR Appropriateness Criteria guidelines offered in this report were reached via an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (the RAND/UCLA Appropriateness Method and the Grading of Recommendations Assessment, Development, and Evaluation) for rating the appropriateness of imaging and treatment procedures for specific clinical scenarios. Further analysis and review of the guidelines were performed by a multidisciplinary expert panel. In those instances in which there was insufficient or equivocal data for recommending the appropriate imaging algorithm, expert opinion may have supplemented the available evidence. C1 [Gyftopoulos, Soterios] NYU, Med Ctr, 550 1St Ave, New York, NY 10016 USA. [Rosenberg, Zehava S.] Hosp Joint Dis & Med Ctr, New York, NY USA. [Roberts, Catherine C.] Mayo Clin, Phoenix, AZ USA. [Bencardino, Jenny T.] NYU, Sch Med, New York, NY USA. [Appel, Marc] James J Peters VA Med Ctr, Bronx, NY USA. [Appel, Marc; Cassidy, R. Carter] Amer Acad Orthopaed Surg, Rosemont, IL USA. [Baccei, Steven J.] UMass Mem Med Ctr, Worcester, MA USA. [Cassidy, R. Carter] UK Healthcare Spine & Total Joint Serv, Lexington, KY USA. [Chang, Eric Y.] VA San Diego Healthcare Syst, San Diego, CA USA. [Fox, Michael G.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Greenspan, Bennett S.] Augusta Univ, Med Coll Georgia, Augusta, GA USA. [Hochman, Mary G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Jacobson, Jon A.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Mintz, Douglas N.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Newman, Joel S.] New England Baptist Hosp, Boston, MA USA. [Shah, Nehal A.; Small, Kirstin M.; Weissman, Barbara N.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Gyftopoulos, S (reprint author), NYU, Hosp Joint Dis, Dept Radiol, 301 E 7th St, New York, NY 10003 USA. EM soterios.gyftopoulos@nyumc.org OI Rosenberg MD, Zehava/0000-0003-1902-6350 NR 67 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2016 VL 13 IS 11 BP 1324 EP 1336 DI 10.1016/j.jacr.2016.07.028 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB8JX UT WOS:000387638400011 PM 27814833 ER PT J AU McCloud, RF Okechukwu, CA Sorensen, G Viswanath, K AF McCloud, Rachel F. Okechukwu, Cassandra A. Sorensen, Glorian Viswanath, K. TI Beyond access: barriers to internet health information seeking among the urban poor SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article DE communication barriers; internet; information seeking behavior; healthcare disparities; vulnerable populations ID LOW SOCIOECONOMIC POSITION; EHEALTH LITERACY; COMMUNICATION INEQUALITIES; DIGITAL DIVIDE; CARE; US; INTERVENTIONS; SERVICES; OUTCOMES; ADULTS AB Objective Communication inequalities deepen health disparities even when internet access is achieved. The goal of this study is to understand how a range of barriers may inhibit individuals from low socioeconomic position (SEP) from engaging with online health information even when it is freely available. Materials and methods Detailed data were collected from 118 low-SEP individuals from a randomized controlled trial providing internet access. Measures triangulated the health-seeking experience through internet use tracked in real-time, call log data, and self-reported barriers. Negative binomial regression models were fitted with technology and perceived predictors, and our outcome, health information seeking, and then stratified by medical status. Results Participants experienced a median of two computer issues (median 6 days) and two internet issues (median 6.5 days). Duration of internet problems was associated with a decrease in the rate of internet health information seeking by a factor of 0.990 (P = .03) for each additional day. Participants with a medical problem who were frustrated in their search for health information had half the rate of health information seeking of those who were not frustrated (incidence rate ratio = 0.395, P = .030). Discussion Despite IT support, participants still experienced internet connectivity issues that negatively impacted their health information seeking. Frustration in their search to find information may serve as an additional barrier to those who have medical issues. Conclusion After initial internet access, a second-level digital divide emerged due to connectivity issues, highlighting the need to understand the complex network of barriers experienced by low-SEP internet users. C1 [McCloud, Rachel F.; Sorensen, Glorian; Viswanath, K.] Dana Farber Canc Inst, Ctr Commun Based Res, 450 Brookline Ave,LW 601, Boston, MA 02115 USA. [Okechukwu, Cassandra A.; Viswanath, K.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. RP McCloud, RF (reprint author), Dana Farber Canc Inst, Ctr Commun Based Res, 450 Brookline Ave,LW 601, Boston, MA 02115 USA. EM Rachel_Faulkenberry@dfci.harvard.edu FU NIH [R25 CA057711, R01 CA122894] FX This work was supported by NIH grant number R25 CA057711 and R01 CA122894. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 41 TC 2 Z9 2 U1 16 U2 16 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2016 VL 23 IS 6 BP 1053 EP 1059 DI 10.1093/jamia/ocv204 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA EC3DZ UT WOS:000388006800004 PM 27206459 ER PT J AU Burket, MW Brodmann, M Metzger, C Tan, KT Jaff, MR AF Burket, Mark W. Brodmann, Marianne Metzger, Christopher Tan, Kongteng Jaff, Michael R. TI Twelve-Month Results of the Nitinol Astron Stent in Iliac Artery Lesions SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID DISEASE; ANGIOPLASTY; TRIAL AB Purpose:To evaluate the safety and efficacy of a self-expanding bare-metal nitinol stent (Astron; BIOTRONIK AG, Bulach, Switzerland) for the treatment of atherosclerotic lesions in the common and external iliac arteries. This study tested the hypothesis that the major adverse event (MAE) rate at 12 months was less than or equal to a performance goal of 15%. Materials and Methods: In a prospective study that began in November 2011, 161 patients with symptomatic iliac lesions were treated, with an Astron stent in the United States, Canada, and Austria. The primary endpoint was a composite rate of procedure- and stent-related MAEs at 12 months that included 30-day mortality, clinically indicated target lesion revascularization (TLR), and index limb amputation. Results: The MAE rate at 12 months was 2.1% (3/146; [95% CI: 0.4% to 5.9%]; p < 0.001). The acute procedural success and 30-day clinical success outcomes were both 95% (153/161). The primary patency rate at 12 months was 89.8% (115/128). The comparison of baseline and 12-month Ankle Brachial Index (ABI) measurements showed a mean increase of 0.23 +/- 0.19 (p < 0.001). The Walking Impairment Questionnaire (WIQ) PAD specific score, walking distance score, walking speed score and stair climbing score paired each showed a significant increase from baseline to 12 months (p < 0.001). Conclusions: The Astron stent system was shown to be safe and effective in the treatment of patients with atherosclerotic disease. The observed MAE rate met the pre-specified performance goal of 15%. The stent demonstrated a high 12-month primary patency rate and showed improvement in quality of life measures. C1 [Burket, Mark W.] Univ Toledo, Med Ctr, 3000 Arlington Ave, Toledo, OH 43614 USA. [Brodmann, Marianne] Med Univ Graz, Clin Div Angiol, Graz, Austria. [Metzger, Christopher] Wellmont CVA Heart Inst, Kingsport, TN USA. [Tan, Kongteng] Univ Toronto, Toronto Gen Hosp, Toronto, ON, Canada. [Jaff, Michael R.] Massachusetts Gen Phys Org, VasCore, Boston, MA USA. RP Burket, MW (reprint author), Univ Toledo, Med Ctr, 3000 Arlington Ave, Toledo, OH 43614 USA. EM mark.burket@utoledo.edu FU BIOTRONIK AG (Bulach, Switzerland); BIOTRONIK, Inc. (Lake Oswego, Oregon) FX The study sponsors are BIOTRONIK AG (Bulach, Switzerland) and BIOTRONIK, Inc. (Lake Oswego, Oregon). The authors would like to acknowledge the writing assistance of Manju Morrissey, MD, MPH, consultant to BIOTRONIK, Inc. NR 14 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD NOV PY 2016 VL 27 IS 11 BP 1650 EP 1656 DI 10.1016/j.jvir.2016.06.008 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA EC2IK UT WOS:000387935200004 PM 27542591 ER PT J AU Frenk, NE Chao, TE Cui, J Fagenholz, PJ Irani, Z AF Frenk, Nathan E. Chao, Tiffany E. Cui, Jie Fagenholz, Peter J. Irani, Zubin TI Staged Particle and Ethanol Embolotherapy of a Symptomatic Pancreatic Arteriovenous Malformation SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Letter C1 [Frenk, Nathan E.; Irani, Zubin] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Div Intervent Radiol, 55 Fruit St, Boston, MA 02119 USA. [Chao, Tiffany E.; Fagenholz, Peter J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 55 Fruit St, Boston, MA 02119 USA. [Cui, Jie] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Nephrol, 55 Fruit St, Boston, MA 02119 USA. RP Frenk, NE (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Div Intervent Radiol, 55 Fruit St, Boston, MA 02119 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD NOV PY 2016 VL 27 IS 11 BP 1734 EP 1735 DI 10.1016/j.jvir.2016.06.015 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA EC2IK UT WOS:000387935200025 PM 27926402 ER PT J AU Kuyumcu, G Gordon, R Ott, H Ganguli, S AF Kuyumcu, Gokhan Gordon, Robert Ott, Harald Ganguli, Suvranu TI CT-Guided Thoracic Duct Embolization SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Letter ID EXPERIENCE C1 [Kuyumcu, Gokhan] Rush Univ, Med Ctr, Dept Radiol, 1653 W Congress Pkwy, Chicago, IL 60612 USA. [Gordon, Robert; Ganguli, Suvranu] Harvard Med Sch, Massachusetts Gen Hosp, Div Intervent Radiol, Dept Radiol, Boston, MA USA. [Ott, Harald] Harvard Med Sch, Massachusetts Gen Hosp, Div Intervent Radiol, Dept Thorac Surg, Boston, MA USA. RP Kuyumcu, G (reprint author), Rush Univ, Med Ctr, Dept Radiol, 1653 W Congress Pkwy, Chicago, IL 60612 USA. NR 4 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD NOV PY 2016 VL 27 IS 11 BP 1753 EP 1755 DI 10.1016/j.jvir.2016.08.002 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA EC2IK UT WOS:000387935200035 PM 27926412 ER PT J AU Mazzola, P Rea, F Merlino, L Bellelli, G Dubner, L Corrao, G Pasinetti, GM Annoni, G AF Mazzola, Paolo Rea, Federico Merlino, Luca Bellelli, Giuseppe Dubner, Lauren Corrao, Giovanni Pasinetti, Giulio M. Annoni, Giorgio TI Hip Fracture Surgery and Survival in Centenarians SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Centenarians; Hip fracture; Hip fracture surgery; Orthogeriatric; Survival ID EXCESS MORTALITY; AGE; OLDER; MANAGEMENT; WOMEN; RISK; HOME AB Background: Hip fracture (HF) is increasingly frequent with advancing age. Studies describing the HF incidence rate and survival after surgery in centenarians are scanty. To fill this gap, we performed a large population-based investigation on Lombardy centenarians (Italy). Methods: Retrospective observational cohort study based on information from the Healthcare Utilization Database. Among the cohort of 7,830 residents that reached 100 years of age between 2004 and 2011, incidence rate of HF was calculated. Two hundred fifty-nine patients were discharged alive from a hospital after HF and surgical repair (HF cohort). For each HF cohort member, a control was randomly selected from the initial cohort to be matched for gender and date of birth, and who did not experience HF from the date of their hundredth birthday until the date of hospital discharge of the corresponding HF cohort member. The survival curves and the hazard functions of HF and control cohort were calculated within 2 years. Results: Over a mean follow-up of 1.85 years, HF incidence rate was 23.1 per 1,000 centenarians per year. Survival probability was significantly lower in HF cohort than in control cohort (31.5 vs 48.1%, p < .001). Hazard functions showed an increased risk of death in HF cohort than in control cohort, especially in the 3 months after surgery. Conclusion: Survival analysis exhibited an excess mortality in the first 3 months among HF cohort members, but not beyond this period. Every effort to counteract HF is warranted, including prevention of falls and high quality of care, especially in the early postsurgical time. C1 [Mazzola, Paolo; Bellelli, Giuseppe; Annoni, Giorgio] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy. [Mazzola, Paolo; Bellelli, Giuseppe] San Gerardo Univ Hosp, Geriatr Clin, Monza, Italy. [Mazzola, Paolo; Bellelli, Giuseppe; Dubner, Lauren; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Mazzola, Paolo; Bellelli, Giuseppe; Annoni, Giorgio] NeuroMI Milan Ctr Neurosci, Clin Neurosci Res Area, Milan, Italy. [Rea, Federico; Corrao, Giovanni] Univ Milano Bicocca, Div Biostat Epidemiol & Publ Hlth, Dept Stat & Quantitat Methods, Milan, Italy. [Merlino, Luca] Operat Unit Terr Hlth Serv, Milan, Italy. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Mazzola, P (reprint author), Geriatr Unit, 7 C,Via Pergolesi 33, I-20900 Monza, MB, Italy. EM paolo.mazzola@unimib.it OI Bellelli, Giuseppe/0000-0001-5430-0947 FU Career Scientist Award in the Research and Development unit FX Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 27 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD NOV PY 2016 VL 71 IS 11 BP 1514 EP 1518 DI 10.1093/gerona/glw016 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EC3AG UT WOS:000387995800018 PM 26883679 ER PT J AU Das, DS Ray, A Das, A Song, Y Tian, Z Oronsky, B Richardson, P Scicinski, J Chauhan, D Anderson, KC AF Das, D. S. Ray, A. Das, A. Song, Y. Tian, Z. Oronsky, B. Richardson, P. Scicinski, J. Chauhan, D. Anderson, K. C. TI A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells SO LEUKEMIA LA English DT Article ID PROTEIN S-NITROSYLATION; VIVO SYNERGISTIC CYTOTOXICITY; DNA METHYLATION; NITRIC-OXIDE; MOLECULAR PATHOGENESIS; TUMOR RESENSITIZATION; THERAPEUTIC TARGET; ANTICANCER AGENT; CANCER; INHIBITOR AB The hypoxic bone marrow (BM) microenvironment confers growth/survival and drug resistance in multiple myeloma (MM) cells. Novel therapies targeting the MM cell in its hypoxic BM milieu may overcome drug resistance. Recent studies led to the development of a novel molecule RRx-001 with hypoxia-selective epigenetic and nitric oxide-donating properties. Here, we demonstrate that RRx-001 decreases the viability of MM cell lines and primary patient cells, as well as overcomes drug resistance. RRx-001 inhibits MM cell growth in the presence of BM stromal cells. RRx-001-induced apoptosis is associated with: (i) activation of caspases; (ii) release of ROS and nitrogen species; (iii) induction of DNA damage via ATM/.-H2AX; and (iv) decrease in DNA methyltransferase (DNMT) and global methylation. RNA interference study shows a predominant role of DNMT1 in MM cell survival versus DNMT3a or DNMT3b. The deubiquitylating enzyme USP7 stimulates DNMT1 activity, and conversely, USP7-siRNA reduced DNMT1 activity and decreased MM cell viability. RRx-001 plus USP7 inhibitor P5091 triggered synergistic anti-MM activity. MM xenograft studies show that RRx-001 is well tolerated, inhibits tumor growth and enhances survival. Combining RRx-001 with pomalidomide, bortezomib or SAHA induces synergistic anti-MM activity. Our results provide the rationale for translation of RRx001, either alone or in combination, to clinical evaluation in MM. C1 [Das, D. S.; Ray, A.; Song, Y.; Tian, Z.; Richardson, P.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, M 553 450 Brookline Ave, Boston, MA 02215 USA. [Das, D. S.; Ray, A.; Song, Y.; Tian, Z.; Richardson, P.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, M 553 450 Brookline Ave, Boston, MA 02215 USA. [Das, A.] Childrens Hosp, Program Cellular & Mol Med, 300 Longwood Ave, Boston, MA 02115 USA. [Oronsky, B.; Scicinski, J.] EpicentRx Inc, Mountain View, CA USA. RP Chauhan, D; Anderson, KC (reprint author), Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, M 553 450 Brookline Ave, Boston, MA 02215 USA.; Chauhan, D; Anderson, KC (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, M 553 450 Brookline Ave, Boston, MA 02215 USA. EM Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu FU National Institutes of Health Specialized Programs of Research Excellence (SPORE) [P50100707, PO1-CA078378, RO1 CA050947] FX This investigation was supported by National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant P50100707, PO1-CA078378, and RO1 CA050947. KCA is an American Cancer Society Clinical Research Professor. NR 60 TC 4 Z9 4 U1 7 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD NOV PY 2016 VL 30 IS 11 BP 2187 EP 2197 DI 10.1038/leu.2016.96 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA EC0PM UT WOS:000387803100009 PM 27118403 ER PT J AU Eisfeld, AK Kohlschmidt, J Mrozek, K Blachly, JS Nicolet, D Kroll, K Orwick, S Carroll, AJ Stone, RM de la Chapelle, A Byrd, JC Bloomfield, CD AF Eisfeld, A-K Kohlschmidt, J. Mrozek, K. Blachly, J. S. Nicolet, D. Kroll, K. Orwick, S. Carroll, A. J. Stone, R. M. de la Chapelle, A. Byrd, J. C. Bloomfield, C. D. TI Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2 SO LEUKEMIA LA English DT Letter ID PARTIAL TANDEM DUPLICATION; POOR-PROGNOSIS; HIGH-FREQUENCY; GROUP-B; SUBGROUP; CANCER; ALL1 C1 [Eisfeld, A-K; Kohlschmidt, J.; Mrozek, K.; Nicolet, D.; Orwick, S.; de la Chapelle, A.; Bloomfield, C. D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Kohlschmidt, J.; Nicolet, D.] Mayo Clin, Alliance Clin Trials Oncol Stat & Data Ctr, Rochester, MN USA. [Blachly, J. S.; Kroll, K.; Byrd, J. C.] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Carroll, A. J.] Univ Alabama Birmingham, Birmingham, AL USA. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Eisfeld, AK (reprint author), Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. EM ann-kathrin.eisfeld@osumc.edu; clara.bloomfield@osumc.edu FU NCI NIH HHS [U10 CA180850, P30 CA016058, P50 CA140158, U10 CA077658, U10 CA180821, U10 CA180855, U10 CA180861, U10 CA180867, U10 CA180882, U24 CA196171] NR 15 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD NOV PY 2016 VL 30 IS 11 BP 2254 EP 2258 DI 10.1038/leu.2016.196 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA EC0PM UT WOS:000387803100021 PM 27435003 ER PT J AU Li, XH Yang, K Liu, B AF Li, Xinhua Yang, Kai Liu, Bob TI A study of the midpoint dose to CTDIvol ratio: Implications for CT dose evaluation SO MEDICAL PHYSICS LA English DT Article DE computed tomography (CT); volume CT dose index; midpoint dose; conversion factor; scan length ID TUBE CURRENT MODULATION; MONTE-CARLO; DOSIMETRY; FEASIBILITY AB Purpose: In multidetector CT, the volume CT dose index (CTDIvol) is reported for each scan series and dose conversion factors are used for the size-specific dose estimate (SSDE) and scanner-independent organ dose evaluation. This study aimed at examining the dependencies of conversion factors on scan length, tube voltage, and subject size. The results may be insightful for evaluating the dose from CT examinations with large variations in patient size and scan length. Methods: A previously developed Monte Carlo simulation program was used to simulate single rotation axial scans of two standard CTDI phantoms [material polymethyl methacrylate (PMMA), diameters 16 and 32 cm] and multiple water cylinders at five tube voltages (70, 80, 100, 120, and 140 kV). The resultant longitudinal dose profiles were used to calculate CTDIL(water)/CTDIw , (PMMA), where L was dose integration length. The ratio was equal to the midpoint dose D-L(0) (water) to CTDIvol ratio in a CT scan series with a scan length equal to L. Results: For water phantom diameters from 11 to 50 cm and scan lengths from 15 to 30 cm, the changes of D-L(0)/CTDIvol from that of 120 kV and 20-cm scan length were between -18.4% and 11.7%. This was consistent with the CTDIvol to SSDE conversion factors of AAPM Report No. 204. For scan lengths less than 15 cm, D-L(0)/CTDIvol decreased considerably as L decreased. D-L(0)/CTDIvol was shown to be 17.3%-31.4% lower for L = 5 cm than for L = 15 cm, when the tube voltage was 120 kV and phantom diameter ranged from 11 to 50 cm. As tube voltage increased from 80 to 140 kV, D-L(0)/CTDIvol decreased at small diameters while it increased at large diameters. The change was 9.4% with a diameter of 18 cm and a scan length of 20 cm and 17.6% with a diameter of 40 cm and a scan length of 30 cm. Conclusions: The midpoint dose to CTDIvol ratio varies widely across the clinical scan lengths from a few millimeters to about 1 m and varies moderately across tube voltages from 70 to 140 kV. The comprehensive data provided in the Appendix can be used for assessing the dose from short-length scans and improving the dose evaluation in CT. (C) 2016 American Association of Physicists in Medicine. C1 [Li, Xinhua; Yang, Kai; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. RP Li, XH (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. EM XLI16@mgh.harvard.edu NR 26 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD NOV PY 2016 VL 43 IS 11 BP 5878 EP 5888 DI 10.1118/1.4963811 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB0BD UT WOS:000387007500009 PM 27806599 ER PT J AU Moriarty, H Winter, L True, G Robinson, K Short, TH AF Moriarty, Helene Winter, Laraine True, Gala Robinson, Keith Short, Thomas H. TI Depressive Symptomatology Mediates Associations With Community Reintegration in Veterans With TBI SO MILITARY PSYCHOLOGY LA English DT Article DE traumatic brain injury; veterans; community reintegration; depression; posttraumatic stress disorder ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; REHABILITATION OUTCOMES; TEMPORAL RELATIONSHIP; SOCIAL SUPPORT; INTEGRATION; MODERATORS; SYMPTOMS; IRAQ; WAR AB Community reintegration (CR) is a challenge for military veterans with traumatic brain injury (TBI). Posttraumatic stress disorder (PTSD), depression, bodily pain, and limitations in physical functioning-common comorbidities with TBI in veterans-have all been associated with problems in CR, but their interrelationships are unclear. The role of depression as a possible mediator of effects on CR has not been examined. We tested depressive symptoms as a possible mediator of CR's associations with physical limitations, PTSD, and bodily pain. This cross-sectional study used baseline data from a larger randomized controlled trial that evaluated the impact of an in-home intervention for veterans with TBI and their families. Eighty-three military veterans with TBI recruited from a medical rehabilitation service at an urban U.S. Department of Veterans Affairs medical center participated in the study. Interview instruments measured CR, depressive symptoms, physical limitations (limitations in physical functioning), bodily pain, quality of the relationship with key family members, and sociodemographic characteristics. PTSD was determined through review of the electronic medical record. Interview data were collected in veterans' homes. Depressive symptoms totally mediated the association between physical limitations and CR and the association between PTSD and CR. The bodily pain-CR association was not significant after quality of relationship had been entered into the regression models. Findings suggest that interventions to increase CR of veterans with TBI should address depression, a treatable condition. Replication of our mediation findings in larger veteran and civilian samples with TBI is needed. C1 [Moriarty, Helene] Villanova Univ, Coll Nursing, Driscoll Hall,800 Lancaster Ave, Villanova, PA 19085 USA. [Moriarty, Helene] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA. [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA. [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA USA. [True, Gala] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [True, Gala; Robinson, Keith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Robinson, Keith] Corporal Michael J Crescenz VA Med Ctr, Rehabil Med Serv, Polytrauma Network Site Vet Integrated Serv Netwo, Philadelphia, PA USA. [Short, Thomas H.] John Carroll Univ, Dept Math & Comp Sci, University Hts, OH USA. RP Moriarty, H (reprint author), Villanova Univ, Coll Nursing, Driscoll Hall,800 Lancaster Ave, Villanova, PA 19085 USA. EM helene.moriarty@villanova.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [R21 HD068857-01] FX The project described was supported by Award R21 HD068857-01 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. NR 74 TC 0 Z9 0 U1 5 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0899-5605 EI 1532-7876 J9 MIL PSYCHOL JI Milit. Psychol. PD NOV PY 2016 VL 28 IS 6 BP 376 EP 389 DI 10.1037/mil0000122 PG 14 WC Psychology, Multidisciplinary SC Psychology GA EC2PJ UT WOS:000387965500002 ER PT J AU Brown, W Grubaugh, AL Knapp, RG Acierno, RE AF Brown, Wilson Grubaugh, Anouk L. Knapp, Rebecca G. Acierno, Ronald E. TI Interplay Between Service Era, PTSD Symptom Expression, and Treatment Completion Among Veterans SO MILITARY PSYCHOLOGY LA English DT Article DE PTSD; service era; veterans; exposure therapy ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; PROLONGED EXPOSURE THERAPY; MENTAL-HEALTH; PROCESSING THERAPY; VIETNAM VETERANS; WAR VETERANS; AFGHANISTAN; IRAQ; PSYCHOTHERAPY AB The current veteran population has grown significantly as a result of 3 recent major conflicts: Vietnam, Persian Gulf War, and Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Despite a strong presence in VA PTSD specialty clinics nationwide, little is known about how these veteran cohort groups differ in PTSD symptom presentation. Additionally, it is unclear how variations in PTSD symptom presentation may in turn affect treatment adherence and completion. Understanding factors associated with treatment dropout from exposure-based therapy for PTSD is an important area of study, as individuals who drop out of treatment are likely to remain symptomatic and experience significant impairment across a number of psychosocial domains. The present study examined the relationship between service theater affiliation and pretreatment symptom expression as predictors of treatment completion in a sample of 164 veterans. Although treatment completion did not differ by service era, study data revealed statistically significant differences in initial PTSD symptom expression. Implications of the results and future directions are discussed. C1 [Brown, Wilson; Grubaugh, Anouk L.; Knapp, Rebecca G.; Acierno, Ronald E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Brown, Wilson] Summa St Thomas Hosp, Ctr Treatment & Study Traumat Stress, Akron, OH USA. [Grubaugh, Anouk L.; Acierno, Ronald E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Brown, W (reprint author), St Thomas Hosp, Ctr Treatment & Study Traumat Stress, Summa Hlth Syst, 444 North Main St,Suite 426, Akron, OH 44310 USA. EM brownwj@summahealth.org FU Department of Defense (DoD) [W81XWH-08-2-0047] FX This study was supported by Department of Defense (DoD) grant W81XWH-08-2-0047 awarded to Ronald E. Acierno. NR 42 TC 0 Z9 0 U1 4 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0899-5605 EI 1532-7876 J9 MIL PSYCHOL JI Milit. Psychol. PD NOV PY 2016 VL 28 IS 6 BP 418 EP 428 DI 10.1037/mil0000133 PG 11 WC Psychology, Multidisciplinary SC Psychology GA EC2PJ UT WOS:000387965500005 ER PT J AU Boeve, BF Dickson, DW Duda, JE Ferman, TJ Galasko, DR Galvin, JE Goldman, JG Growdon, JH Hurtig, HI Kaufer, DI Kantarci, K Leverenz, JB Lippa, CF Lopez, OL McKeith, IG Singleton, AB Taylor, A Tsuang, D Weintraub, D Zabetian, CP AF Boeve, Bradley F. Dickson, Dennis W. Duda, John E. Ferman, Tanis J. Galasko, Douglas R. Galvin, James E. Goldman, Jennifer G. Growdon, John H. Hurtig, Howard I. Kaufer, Daniel I. Kantarci, Kejal Leverenz, James B. Lippa, Carol F. Lopez, Oscar L. McKeith, Ian G. Singleton, Andrew B. Taylor, Angela Tsuang, Debby Weintraub, Daniel Zabetian, Cyrus P. TI Arguing against the proposed definition changes of PD SO MOVEMENT DISORDERS LA English DT Article DE Dementia with Lewy bodies; dementia; Parkinson's disease; parkinsonism ID PARKINSON-DISEASE DEMENTIA; LEWY BODIES; DIAGNOSIS; RISK; DLB; CONSORTIUM; APOE AB As members of the Lewy Body Dementia Association Scientific Advisory Council, we aim to address some of the issues raised in the article titled Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease. In particular, we suggest that the 1-year rule distinguishing Parkinson's disease dementia from dementia with Lewy bodies is worth maintaining because it serves an important purpose in clinical practice and clinical and basic science research and when helping the lay community understand the complexity of these different clinical phenotypes. Furthermore, we believe that adding an additional diagnostic label, PD (dementia with Lewy bodies subtype), will confuse rather than clarify the distinction between dementia with Lewy bodies and PD or PD dementia, and will not improve management or expedite therapeutic development. We present arguments supporting our contentions. (c) 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. C1 [Boeve, Bradley F.] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55895 USA. [Dickson, Dennis W.] Mayo Clin, Jacksonville, FL 32224 USA. [Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA. [Duda, John E.; Hurtig, Howard I.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Ferman, Tanis J.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Jacksonville, FL 32224 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Galvin, James E.] Florida Atlantic Univ, Marcus Neurosci Inst, Boca Raton, FL 33431 USA. [Goldman, Jennifer G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Growdon, John H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Kaufer, Daniel I.] Univ North Carolina Chapel Hill, Dept Neurol, Chapel Hill, NC USA. [Kantarci, Kejal] Mayo Clin, Coll Med, Dept Radiol, Rochester, MN 55895 USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Lippa, Carol F.] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA. [Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [McKeith, Ian G.] Newcastle Univ, Inst Ageing, Newcastle Upon Tyne, Tyne & Wear, England. [Singleton, Andrew B.] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. [Taylor, Angela] Lewy Body Dementia Assoc, Lilburn, GA USA. [Tsuang, Debby] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. RP Boeve, BF (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55895 USA. EM bboeve@mayo.edu FU Intramural NIH HHS [Z01 AG000932-01]; NIA NIH HHS [P50 AG005131, P50 AG005136] NR 24 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2016 VL 31 IS 11 BP 1619 EP 1622 DI 10.1002/mds.26721 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA EB5LK UT WOS:000387415700004 PM 27492190 ER PT J AU Berman, BD Smucny, J Wylie, KP Shelton, E Kronberg, E Leehey, M Tregellas, JR AF Berman, Brian D. Smucny, Jason Wylie, Korey P. Shelton, Erika Kronberg, Eugene Leehey, Maureen Tregellas, Jason R. TI Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson disease; resting-state fMRI; graph theory; levodopa ID RATING-SCALE; CONNECTIVITY; ORGANIZATION; EFFICIENCY; DISORDER AB BackgroundPD is associated with disrupted connectivity to a large number of distributed brain regions. How the disease alters the functional topological organization of the brain, however, remains poorly understood. Furthermore, how levodopa modulates network topology in PD is largely unknown. The objective of this study was to use resting-state functional MRI and graph theory to determine how small-world architecture is altered in PD and affected by levodopa administration. MethodsTwenty-one PD patients and 20 controls underwent functional MRI scanning. PD patients were scanned off medication and 1 hour after 200mg levodopa. Imaging data were analyzed using 226 nodes comprising 10 intrinsic brain networks. Correlation matrices were generated for each subject and converted into cost-thresholded, binarized adjacency matrices. Cost-integrated whole-brain global and local efficiencies were compared across groups and tested for relationships with disease duration and severity. ResultsData from 2 patients and 4 controls were excluded because of excess motion. Patients off medication showed no significant changes in global efficiency and overall local efficiency, but in a subnetwork analysis did show increased local efficiency in executive (P=0.006) and salience (P=0.018) networks. Levodopa significantly decreased local efficiency (P=0.039) in patients except within the subcortical network, in which it significantly increased local efficiency (P=0.007). ConclusionsLevodopa modulates global and local efficiency measures of small-world topology in PD, suggesting that degeneration of nigrostriatal neurons in PD may be associated with a large-scale network reorganization and that levodopa tends to normalize the disrupted network topology in PD. (c) 2016 International Parkinson and Movement Disorder Society C1 [Berman, Brian D.; Shelton, Erika; Leehey, Maureen] Univ Colorado Anschutz Med Campus, Dept Neurol, 12631 E 17th Ave,Mail Stop B-185, Aurora, CO 80045 USA. [Berman, Brian D.] Denver VA Med Ctr, Neurol Sect, Denver, CO USA. [Smucny, Jason; Wylie, Korey P.; Kronberg, Eugene; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Berman, BD (reprint author), Univ Colorado Anschutz Med Campus, Dept Neurol, 12631 E 17th Ave,Mail Stop B-185, Aurora, CO 80045 USA. EM brian.berman@ucdenver.edu FU NIH/NCATS Colorado CTSI grant [KL2 TR001080]; University of Colorado Department of Neurology; University of Colorado Center for NeuroScience FX This work was supported by NIH/NCATS Colorado CTSI grant number KL2 TR001080, the University of Colorado Department of Neurology, and the University of Colorado Center for NeuroScience. NR 47 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2016 VL 31 IS 11 BP 1676 EP 1684 DI 10.1002/mds.26713 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA EB5LK UT WOS:000387415700015 PM 27461405 ER PT J AU Alibiglou, L Videnovic, A Planetta, PJ Vaillancourt, DE MacKinnon, CD AF Alibiglou, Laila Videnovic, Aleksandar Planetta, Peggy J. Vaillancourt, David E. MacKinnon, Colum D. TI Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: A harbinger of freezing of gait? SO MOVEMENT DISORDERS LA English DT Article DE PD; RBD; freezing; gait; sleep ID DEEP BRAIN-STIMULATION; PARKINSONS-DISEASE; REM-SLEEP; PEDUNCULOPONTINE NUCLEUS; BRADYKINESIA; MEDICATION; FEATURES; IMPAIRMENT; PATTERNS; POSTURE AB BackgroundMuscle activity during rapid eye movement sleep is markedly increased in people with rapid eye movement sleep behavior disorder and people with Parkinson's disease (PD) who have freezing of gait. This study examined whether individuals with rapid eye movement sleep behavior disorder who do not have a diagnosis of PD show abnormalities in gait initiation that resemble the impairments observed in PD and whether there is a relationship between these deficits and the level of rapid eye movement sleep without atonia. MethodsGait initiation and polysomnography studies were conducted in 4 groups of 10 participants: rapid eye movement sleep behavior disorder, PD with and without freezing of gait, and controls. ResultsSignificant reductions were seen in the posterior shift of the center of pressure during the propulsive phase of gait initiation in the groups with rapid eye movement sleep behavior disorder and PD with freezing of gait when compared with controls and PD nonfreezers. These reductions negatively correlated with the amount of rapid eye movement sleep without atonia. The duration of the initial dorsiflexor muscle burst during gait initiation was significantly reduced in both PD groups and the rapid eye movement sleep behavior disorder cohort. ConclusionsThese results provide evidence that people with rapid eye movement sleep behavior disorder, prior to a diagnosis of a degenerative neurologic disorder, show alterations in the coupling of posture and gait similar to those seen in PD. The correlation between increased rapid eye movement sleep without atonia and deficits in forward propulsion during the push-off phase of gait initiation suggests that abnormities in the regulation of muscle tone during rapid eye movement sleep may be related to the pathogenesis of freezing of gait. (c) 2016 International Parkinson and Movement Disorder Society C1 [Alibiglou, Laila] Rosalind Franklin Univ Med & Sci, Dept Phys Therapy, N Chicago, IL 60064 USA. [Alibiglou, Laila] Rosalind Franklin Univ Med & Sci, Dept Neurosci, N Chicago, IL 60064 USA. [Videnovic, Aleksandar] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Neurol Clin Res Inst, Boston, MA USA. [Planetta, Peggy J.; Vaillancourt, David E.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA. [Vaillancourt, David E.] Univ Florida, Dept Biomed Engn, Gainesville, FL USA. [MacKinnon, Colum D.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA. [MacKinnon, Colum D.] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA. RP Alibiglou, L (reprint author), Rosalind Franklin Univ Med & Sci, Dept Phys Therapy, Dept Neurosci, 3333 Green Bay Rd, N Chicago, IL 60064 USA. EM laila.alibiglou@rosalindfranklin.edu FU Michael J. Fox Foundation for Parkinson's Research FX The study was funded and supported by a grant from the Michael J. Fox Foundation for Parkinson's Research. NR 49 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2016 VL 31 IS 11 BP 1711 EP 1719 DI 10.1002/mds.26665 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA EB5LK UT WOS:000387415700019 PM 27250871 ER PT J AU Sullivan, LB Gui, DY Heiden, MGV AF Sullivan, Lucas B. Gui, Dan Y. Heiden, Matthew G. Vander TI Altered metabolite levels in cancer: implications for tumour biology and cancer therapy SO NATURE REVIEWS CANCER LA English DT Review ID PYRUVATE-KINASE M2; HEREDITARY TYROSINEMIA TYPE-1; BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER; MAGNETIC-RESONANCE-SPECTROSCOPY; REDUCTIVE GLUTAMINE-METABOLISM; FUMARATE HYDRATASE DEFICIENCY; PEGYLATED ARGININE DEIMINASE; GLYOXALASE-I-INHIBITION; SUCCINATE-DEHYDROGENASE; ALPHA-KETOGLUTARATE AB Altered cell metabolism is a characteristic feature of many cancers. Aside from well-described changes in nutrient consumption and waste excretion, altered cancer cell metabolism also results in changes to intracellular metabolite concentrations. Increased levels of metabolites that result directly from genetic mutations and cancer-associated modifications in protein expression can promote cancer initiation and progression. Changes in the levels of specific metabolites, such as 2-hydroxyglutarate, fumarate, succinate, aspartate and reactive oxygen species, can result in altered cell signalling, enzyme activity and/or metabolic flux. In this Review, we discuss the mechanisms that lead to changes in metabolite concentrations in cancer cells, the consequences of these changes for the cells and how they might be exploited to improve cancer therapy. C1 [Sullivan, Lucas B.; Gui, Dan Y.; Heiden, Matthew G. Vander] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Sullivan, Lucas B.; Gui, Dan Y.; Heiden, Matthew G. Vander] MIT, Dept Biol, Cambridge, MA 02139 USA. [Heiden, Matthew G. Vander] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Heiden, MGV (reprint author), MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.; Heiden, MGV (reprint author), MIT, Dept Biol, Cambridge, MA 02139 USA.; Heiden, MGV (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM mvh@mit.edu FU American Cancer Society [PF-15-096-01-TBE]; US National Institutes of Health (NIH) [T32 GM007753]; Burroughs Wellcome Fund, the Ludwig Center at the Massachusetts Institute of Technology (MIT); NIH [P30CA1405141, GG006413, R01CA168653] FX This work was supported by a postdoctoral fellowship, PF-15-096-01-TBE from the American Cancer Society to L.B.S., US National Institutes of Health (NIH) (T32 GM007753) to D.Y.G., the Burroughs Wellcome Fund, the Ludwig Center at the Massachusetts Institute of Technology (MIT), and the NIH (P30CA1405141, GG006413 and R01CA168653) to M.G.V.H. NR 189 TC 4 Z9 4 U1 19 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-175X EI 1474-1768 J9 NAT REV CANCER JI Nat. Rev. Cancer PD NOV PY 2016 VL 16 IS 11 BP 680 EP 693 DI 10.1038/nrc.2016.85 PG 14 WC Oncology SC Oncology GA EB3XJ UT WOS:000387302100006 PM 27658530 ER PT J AU Nipp, R Goyal, L AF Nipp, Ryan Goyal, Lipika TI Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma SO ONCOLOGIST LA English DT Editorial Material ID CANCER CLINICAL-TRIALS; ELDERLY-PATIENTS; SORAFENIB; PARTICIPATION; OLDER; PROGRAM; AGE C1 [Nipp, Ryan; Goyal, Lipika] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA. [Nipp, Ryan; Goyal, Lipika] Harvard Med Sch, Boston, MA USA. RP Goyal, L (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA. EM lgoyal@partners.org NR 19 TC 0 Z9 0 U1 2 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD NOV PY 2016 VL 21 IS 11 BP 1283 EP 1285 DI 10.1634/theoncologist.2016-0349 PG 3 WC Oncology SC Oncology GA EC0IF UT WOS:000387782600002 ER PT J AU Olszewski, AJ Treon, SP Castillo, JJ AF Olszewski, Adam J. Treon, Steven P. Castillo, Jorge J. TI Evolution of Management and Outcomes in Waldenstrom Macroglobulinemia: A Population-Based Analysis SO ONCOLOGIST LA English DT Article DE Waldenstrom macroglobulinemia; Rituximab; Bortezomib; Bendamustine; Cost of therapy; Health services research ID LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA; END RESULTS DATABASE; LYMPHOMA STUDY-GROUP; UNITED-STATES; MARGINAL ZONE; HEMATOLOGIC MALIGNANCIES; INTERNATIONAL WORKSHOP; INCIDENCE-PATTERNS; OBSERVATIONAL DATA; PROGNOSTIC-FACTORS AB Introduction. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM) is a rare lymphoma affecting older patients. Its management largely relies on small phase II trials and it is unclear how their results translate into clinical practice in the community. Method. We evaluated changes in the presentation, management, and survival among 2,666 Medicare beneficiaries diagnosed with WM between 1994 and 2011, using Medicare claims linked to Surveillance, Epidemiology and End Results data. Results. Prevalence of transfusions, anemia, thrombocytopenia, and neuropathy at diagnosis significantly increased over time, whereas the use of plasmapheresis was low (2.5%) and stable. The proportion of patients starting chemotherapy within 1 year of WM diagnosis increased from 39% in 1994 to 62% in 2011(p<.0001). Treatments based on classic alkylators and purine analogs predominated in the 1990s, but were quickly replaced by rituximab-containing regimens after 2000. Rituximab monotherapy has been prescribed for >50% of patients since 2004, and combination chemoimmunotherapy for a further 30%. Mostpatients initiating multiagent regimens in 2012-2013 received rituximab with bortezomib or bend-amustine. These changes were accompanied by significant improvementsin overall and WM-related survival, but also by a significant increase in cost of chemotherapy. Mean Medicare payments for chemotherapy drugs accrued in the first year of treatment rose from $9,464 in 1994-2000 to $29,490 after 2008. Conclusion. Hematologists have rapidly adopted innovative, expensive the rapies for WM before completion of randomizedtrials. This under scores the need to assess the comparative value of such therapies in rare malignancies through a combination of clinical and observational data. C1 [Olszewski, Adam J.] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA. [Olszewski, Adam J.] Rhode Isl Hosp, Div Hematol Oncol, Providence, RI USA. [Treon, Steven P.; Castillo, Jorge J.] Harvard Med Sch, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA USA. RP Olszewski, AJ (reprint author), Brown Univ, Alpert Med Sch, Comprehens Canc Ctr, Rhode Isl Hosp, 593 Eddy St, Providence, RI 02903 USA. EM adam_olszewski@brown.edu OI Castillo, Jorge/0000-0001-9490-7532 FU American Society of Hematology Research Scholar Award FX This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute, the Office of Research, Development and Information, Centers for Medicare & Medicaid Services, Information Management Services, Inc., and the SEER Program tumor registries in the creation of the SEER-Medicare database. This study was funded by the American Society of Hematology Research Scholar Award to A.J.O. NR 62 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD NOV PY 2016 VL 21 IS 11 BP 1377 EP 1386 DI 10.1634/theoncologist.2016-0126 PG 10 WC Oncology SC Oncology GA EC0IF UT WOS:000387782600016 ER PT J AU Wallner, PE Gerdeman, A Willis, JM Zietman, AL AF Wallner, Paul E. Gerdeman, Anthony Willis, Jennifer M. Zietman, Anthony L. TI The American Board of Radiology radiation oncology Maintenance of Certification Part 3 Modular Examination: Evaluation of the first administration SO PRACTICAL RADIATION ONCOLOGY LA English DT Article AB Based on data obtained from clinical practice analysis (CPA) surveys performed in 2010 and 2013, and with input from its maintenance of certification (MOC) advisory committee, the American Board of Radiology (ABR) recognized that the changing nature of radiation oncology practice patterns warranted revisions of its MOC Part III cognitive examination. One significant revision was the introduction of a modular examination that allowed diplomates to select specific areas of clinical interest. The module-based items represented 30% (60 of 200) of total examination content. The new modular examination was administered for the first time in October 2015. Logistics of examination development, administration, and diplomate post-examination survey responses are reviewed. (C) 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. C1 [Wallner, Paul E.] 21st Century Oncol Inc, Ft Myers, FL USA. [Gerdeman, Anthony; Willis, Jennifer M.] Amer Board Radiol, Tucson, AZ USA. [Zietman, Anthony L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wallner, PE (reprint author), 5013 Cedar Croft Lane, Bethesda, MD 20814 USA. EM pwallner@theabr.org NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1879-8500 J9 PRACT RADIAT ONCOL JI Pract. Radiat. Oncol. PD NOV-DEC PY 2016 VL 6 IS 6 BP 436 EP 438 DI 10.1016/j.prro.2016.04.007 PG 3 WC Oncology SC Oncology GA EC2UZ UT WOS:000387981000031 PM 27687188 ER PT J AU Batin, E Depauw, N MacDonald, S Lu, HM AF Batin, Estelle Depauw, Nicolas MacDonald, Shannon Lu, Hsiao-Ming TI Can surface imaging improve the patient setup for proton postmastectomy chest wall irradiation? SO PRACTICAL RADIATION ONCOLOGY LA English DT Article ID RADIOTHERAPY; BREAST; SYSTEM; RADIATION; ACCURACY AB Purposes/Objectives: For postmastectomy radiation therapy by proton beams, the usual bony landmark based radiograph setup technique is indirect because the target volumes are generally superficial and far away from major bony structures. The surface imaging setup technique of matching chest wall surface directly to treatment planning computed tomography was evaluated and compared to the traditional radiograph-based technique. Methods and materials: Fifteen postmastectomy radiation therapy patients were included, with the first 5 patients positioned by standard radiograph-based technique; radiopaque makers, however, were added on the patient's skin surface to improve the relevance of the setup. AlignRT was used to capture patient surface images at different time points along the process, with the calculated position corrections recorded but not applied. For the remaining 10 patients, the orthogonal x-ray imaging was replaced by the AlignRT setup procedure followed by a beamline radiograph at the treatment gantry angle only as confirmation. The position corrections recorded during all fractions for all patients (28-31 each) were analyzed to evaluate the setup accuracy. The time spent on patient setup and treatment delivery was also analyzed. Results: The average position discrepancy over the treatment course relative to the planning computed tomography was significantly larger in the radiograph only group, particularly in translations (3.2 +/- 2.0 mm in vertical, 3.1 +/- 3.0 mm in longitudinal, 2.6 +/- 2.5 mm in lateral), than AlignRT assisted group (1.3 +/- 1.3 mm in vertical, 0.8 +/- 1.2 mm in longitudinal, 1.5 +/- 1.4 mm in lateral). The latter was well within the robustness limits (perpendicular to 3 mm) of the pencil beam scanning treatment established in our previous studies. The setup time decreased from an average of 11 minutes using orthogonal x-rays to an average of 6 minutes using AlignRT surface imaging. Conclusions: The use of surface imaging allows postmastectomy chest wall patients to be positioned more accurately and substantially more efficiently than radiograph only-based techniques. (C) 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. C1 [Batin, Estelle; Depauw, Nicolas; MacDonald, Shannon; Lu, Hsiao-Ming] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Dept Radiat Oncol, Boston, MA USA. RP Batin, E (reprint author), Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, 30 Fruit St, Boston, MA 02114 USA. EM ebatin@mgh.harvard.edu NR 14 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1879-8500 J9 PRACT RADIAT ONCOL JI Pract. Radiat. Oncol. PD NOV-DEC PY 2016 VL 6 IS 6 BP E235 EP E241 DI 10.1016/j.prro.2016.02.001 PG 7 WC Oncology SC Oncology GA EC2UZ UT WOS:000387981000002 PM 27025165 ER PT J AU Paly, JJ Lin, CC Gray, PJ Hallemeier, CL Beard, C Sineshaw, H Jemal, A Efstathiou, JA AF Paly, Jonathan J. Lin, Chun Chieh Gray, Phillip J. Hallemeier, Christopher L. Beard, Clair Sineshaw, Helmneh Jemal, Ahmedin Efstathiou, Jason A. TI Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012 SO PRACTICAL RADIATION ONCOLOGY LA English DT Article ID GERM-CELL CANCER; TESTICULAR SEMINOMA; UNITED-STATES; CHEMOTHERAPY; RADIOTHERAPY; THERAPY; TUMORS AB Purpose/objective: Disease-specific survival for testicular seminoma approaches 100%, even for those with node-positive disease. We sought to describe modern practice patterns, survival outcomes, and factors associated with postoperative therapy for patients with clinical stage (CS) IIA/B disease. Methods and materials: Data on patients diagnosed with CS IIA/B seminoma from 1998 to 2012 were extracted from the National Cancer Data Base. Demographic, clinical, treatment, and payer characteristics were evaluated using multivariate regression to identify factors associated with receipt of chemotherapy or radiation therapy (RT) within 6 months of orchiectomy. Five-year Kaplan-Meier overall survival (OS) by CS and treatment was calculated. A Cox proportional hazards regression for 5-year OS was performed. Results: A total of 1885 patients were included; 38.5% received chemotherapy and 61.5% received RT. On multivariate analysis, factors associated with receipt of postorchiectomy RT rather than chemotherapy included CS IIA (odds ratio [OR], 3.04; P<.01) and community treatment setting (OR, 1.81-2.76; P<.01). Reduced likelihood of receiving RT was associated with Medicaid insurance (OR, 0.50; P<.01), more recent year of diagnosis (continuous OR, 0.93; P<.01), and primary pathologic tumor 3/4 stage (OR, 0.47; P<.01). On multivariate Cox regression, decreased 5-year OS was associated with receipt of chemotherapy in CS IIA patients (hazard ratio, 13.33; P<.01) but not in CS IIB patients (hazard ratio, 1.39; P=.45). For CS IIA, 5-year OS was 99.4% for orchiectomy and RT versus 91.2% for orchiectomy and chemotherapy (log-rank P<.01). For CS IIB, 5-year OS was 96.1% for orchiectomy and RT versus 92.8% for orchiectomy and chemotherapy (log-rank P=.08). Conclusions: Consistent with national guideline recommendations, our analysis supports preferred status for RT in CS IIA. In addition, these data also support use of RT for CS IIB. CS, treatment year, primary pathologic tumor stage, insurance, and facility type were associated with type of postoperative therapy. Longer follow-up to account for potential late effects of treatment is needed. (C) 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. C1 [Paly, Jonathan J.; Gray, Phillip J.; Efstathiou, Jason A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02214 USA. [Lin, Chun Chieh; Sineshaw, Helmneh; Jemal, Ahmedin] Amer Canc Soc, Surveillance & Hlth Serv Res Program, Atlanta, GA USA. [Hallemeier, Christopher L.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. [Beard, Clair] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. RP Efstathiou, JA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02214 USA. EM jefstathiou@partners.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1879-8500 J9 PRACT RADIAT ONCOL JI Pract. Radiat. Oncol. PD NOV-DEC PY 2016 VL 6 IS 6 BP E249 EP E258 DI 10.1016/j.prro.2016.05.002 PG 10 WC Oncology SC Oncology GA EC2UZ UT WOS:000387981000004 PM 27345128 ER PT J AU Murphy, M Kontos, N Freudenreich, O AF Murphy, Michael Kontos, Nicholas Freudenreich, Oliver TI Electronic Support Groups: An Open Line of Communication in Contested Illness SO PSYCHOSOMATICS LA English DT Article DE somatization; Consultation-Liaison psychiatry; health; internal medicine; quality of life ID RANDOMIZED CONTROLLED-TRIAL; MEDICALLY UNEXPLAINED SYMPTOMS; DOCTOR-PATIENT-RELATIONSHIP; INTERNET USE; DISEASE; FIBROMYALGIA; SOMATIZATION; CONSEQUENCES; CONSULTATION; COMMUNITIES AB Patients with functional somatic syndromes are often difficult to treat. The relationship between doctors and patients can be strained, which limits communication. Instead, patients often communicate with each other over the Internet in electronic support groups. Objective: This perspective summarizes studies of patient-to-patient communication over the Internet and uses the concept of contested illness to provide insights into the experiences of patients with functional somatic disorders. Discussion: Conflict between a patient and their physician is a key feature of functional somatic syndromes. Physicians and patients do not have a shared understanding or appreciation of the patient's experiences. Patients with functional somatic syndromes often value their own embodied experience over medical knowledge. At the same time, they remain deeply invested in finding a "good doctor" who believes that the patient is suffering, agrees with their conception of the cause, and assents to the treatment as directed by the patient. Electronic support groups reinforce these beliefs. Conclusion: Patients may benefit from a compromising, collaborative approach that is realistic about the limitations of medical knowledge. However, physicians should not engage in unsafe treatment practices. Electronic support groups exist for a wide range of illnesses and the issues that rise to the surface in functional somatic syndromes likely occur to some extent with almost every patient. C1 [Murphy, Michael; Kontos, Nicholas; Freudenreich, Oliver] Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA. [Murphy, Michael] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA. [Kontos, Nicholas; Freudenreich, Oliver] Harvard Med Sch, Boston, MA USA. RP Murphy, M (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA. EM mmurphy56@partners.org OI Murphy, Michael/0000-0002-8014-763X NR 52 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD NOV-DEC PY 2016 VL 57 IS 6 BP 547 EP 555 PG 9 WC Psychiatry; Psychology SC Psychiatry; Psychology GA EC3YY UT WOS:000388064200001 PM 27421707 ER PT J AU Gan, JJ Lin, A Samimi, MS Mendez, MF AF Gan, Joanna J. Lin, Andrew Samimi, Mersal S. Mendez, Mario F. TI Somatic Symptom Disorder in Semantic Dementia: The Role of Alexisomia SO PSYCHOSOMATICS LA English DT Article DE semantic dementia; alexisomia; alexithymia; somatization; somatic symptom disorder ID PRIMARY PROGRESSIVE APHASIA; FRONTAL-LOBE DEGENERATION; NON-ALZHEIMER TYPE; FRONTOTEMPORAL DEMENTIA; DIAGNOSIS; KNOWLEDGE; ATROPHY AB Background: Semantic dementia (SD) is a neurodegenerative disorder characterized by loss of semantic knowledge. SD may be associated with somatic symptom disorder due to excessive preoccupation with unidentified somatic sensations. Objective: To evaluate the frequency of somatic symptom disorder among patients with SD in comparison to comparably demented patients with Alzheimer's disease. Methods: A retrospective cohort study was conducted using clinical data from a referral-based behavioral neurology program. Fifty-three patients with SD meeting criteria for imaging-supported semantic variant primary progressive aphasia (another term for SD) were compared with 125 patients with clinically probable Alzheimer disease. Logistic regression controlled for sex, age, disease duration, education, overall cognitive impairment, and depression. Results: The prevalence of somatic symptom disorder was significantly higher among patients with SD (41.5%) compared to patients with Alzheimer disease (11.2%) (odds ratio = 6:1; p < 0.001). Somatic symptom disorder was associated with misidentification and preoccupation with normal bodily sensations such as hunger, bladder filling, borborygmi, rhinorrhea, and reflux; excessive concern over the incompletely understood meaning or source of pain or other symptoms; and Cotard syndrome or the delusion that unidentified somatic symptoms signify death or deterioration. Conclusions: SD, a disorder of semantic knowledge, is associated with somatic symptom disorder from impaired identification of somatic sensations. Their inability to read and name somatic sensations, or "alexisomia," results in disproportionate and persistent concern about somatic sensations with consequent significant disability. C1 [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA. [Gan, Joanna J.; Lin, Andrew; Samimi, Mersal S.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU U.S. National Institutes of Health, United States, National Institute on Aging, United States [R01AG050967, R01 AG034499] FX This work was supported by the U.S. National Institutes of Health, United States, National Institute on Aging, United States (Grants R01AG050967 and R01 AG034499). NR 25 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD NOV-DEC PY 2016 VL 57 IS 6 BP 598 EP 604 PG 7 WC Psychiatry; Psychology SC Psychiatry; Psychology GA EC3YY UT WOS:000388064200006 PM 27647568 ER PT J AU Herold, S Freudenreich, O AF Herold, Sarah Freudenreich, Oliver TI Hepatitis C Virus and Schizophrenia: Expanding the Role of the Community Psychiatrist SO PSYCHOSOMATICS LA English DT Article ID INTERFERON-ALPHA; UNITED-STATES; DEPRESSION; METAANALYSIS; PREVENTION; PREVALENCE; INFECTION; CARE C1 [Herold, Sarah; Freudenreich, Oliver] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Herold, Sarah; Freudenreich, Oliver] Erich Lindemann Mental Hlth Ctr, 25 Staniford St, Boston, MA 02114 USA. [Freudenreich, Oliver] Harvard Med Sch, Boston, MA USA. RP Herold, S (reprint author), Erich Lindemann Mental Hlth Ctr, 25 Staniford St, Boston, MA 02114 USA. EM sherold@partners.org NR 20 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD NOV-DEC PY 2016 VL 57 IS 6 BP 634 EP 637 PG 4 WC Psychiatry; Psychology SC Psychiatry; Psychology GA EC3YY UT WOS:000388064200010 PM 27418108 ER PT J AU Fullard, JF Halene, TB Giambartolomei, C Haroutunian, V Akbarian, S Roussos, P AF Fullard, John F. Halene, Tobias B. Giambartolomei, Claudia Haroutunian, Vahram Akbarian, Schahram Roussos, Panos TI Understanding the genetic liability to schizophrenia through the neuroepigenome SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Postmortem; Brain; Gene expression; Chromatin; Epigenetics ID DNA-METHYLATION CHANGES; DORSOLATERAL PREFRONTAL CORTEX; CHROMATIN STATE DYNAMICS; HUMAN BRAIN-TISSUE; HUMAN CELL-TYPES; BIPOLAR DISORDER; CHIP-SEQ; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; REGULATORY ELEMENTS AB The Psychiatric Genomics Consortium-Schizophrenia Workgroup (PGC-SCZ) recently identified 108 loci associated with increased risk for schizophrenia (SCZ). The vast majority of these variants reside within non-coding sequences of the genome and are predicted to exert their effects by affecting the mechanism of action of cis regulatory elements (CREs), such as promoters and enhancers. Although a number of large-scale collaborative efforts (e.g. ENCODE) have achieved a comprehensive mapping of CREs in human cell lines or tissue homogenates, it is becoming increasingly evident that many risk-associated variants are enriched for expression Quantitative Trait Loci (eQTLs) and CREs in specific tissues or cells. As such, data derived from previous research endeavors may not capture fully cell-type and/or region specific changes associated with brain diseases. Coupling recent technological advances in genomics with cell-type specific methodologies, we are presented with an unprecedented opportunity to better understand the genetics of normal brain development and function and, in turn, the molecular basis of neuropsychiatric disorders. In this review, we will outline ongoing efforts towards this goal and will discuss approaches with the potential to shed light on the mechanism(s) of action of cell-type specific cis regulatory elements and their putative roles in disease, with particular emphasis on understanding the manner in which the epigenome and CREs influence the etiology of SCZ. Published by Elsevier B.V. C1 [Fullard, John F.; Halene, Tobias B.; Giambartolomei, Claudia; Haroutunian, Vahram; Akbarian, Schahram; Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, New York, NY 10029 USA. [Haroutunian, Vahram; Akbarian, Schahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Halene, Tobias B.; Haroutunian, Vahram; Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. RP Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Dept Genet & Genom Sci, One Gustave L Levy Pl, New York, NY 10029 USA.; Roussos, P (reprint author), Inst Multiscale Biol, One Gustave L Levy Pl, New York, NY 10029 USA. EM Panagiotis.roussos@mssm.edu FU Office of Academic Affiliations; Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; National Institutes of Health [R01AG050986]; Brain Behavior Research Foundation [20540]; Alzheimer's Association [NIRG-340998]; Veterans Affairs (Merit grant) [BX002395] FX Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (Halene), the National Institutes of Health (R01AG050986 Roussos), Brain Behavior Research Foundation (20540 Roussos), Alzheimer's Association (NIRG-340998 Roussos) and the Veterans Affairs (Merit grant BX002395 Roussos). NR 150 TC 3 Z9 3 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2016 VL 177 IS 1-3 BP 115 EP 124 DI 10.1016/j.schres.2016.01.039 PG 10 WC Psychiatry SC Psychiatry GA EC2OR UT WOS:000387963200016 PM 26827128 ER PT J AU Saadi, A Patenaude, B Nirola, DK Deki, S Tshering, L Clark, S Shaull, L Sorets, T Fink, G Mateen, F AF Saadi, Altaf Patenaude, Bryan Nirola, Damber Kumar Deki, Sonam Tshering, Lhab Clark, Sarah Shaull, Lance Sorets, Tali Fink, Guenther Mateen, Farrah TI Quality of life in epilepsy in Bhutan (vol 39, pg 44, 2016) SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Correction C1 [Saadi, Altaf] Massachusetts Gen Hosp, Partners Neurol Residency, Boston, MA 02114 USA. [Saadi, Altaf] Brigham & Womans Hosp, Boston, MA USA. [Patenaude, Bryan; Fink, Guenther] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Nirola, Damber Kumar; Deki, Sonam; Tshering, Lhab] Jigme Dorji Wangchuck Natl Referral Hosp, Thimphu, Bhutan. [Clark, Sarah; Shaull, Lance; Sorets, Tali; Mateen, Farrah] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mateen, Farrah] Harvard Med Sch, Boston, MA USA. RP Mateen, F (reprint author), Massachusetts Gen Hosp, Dept Neurol, 165 Cambridge St,627, Boston, MA 02114 USA. EM asaadi@partners.org; bryanpatenaude@gmail.com; drnirola@yahoo.com; somkey90@gmail.com; tsheringlhab999@gmail.com; sclark0929@gmail.com; lrshaull@gmail.com; tsorets@bbns.org; gfink@hsph.harvard.edu; fmateen@mgh.harvard.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1059-1311 EI 1532-2688 J9 SEIZURE-EUR J EPILEP JI Seizure PD NOV PY 2016 VL 42 BP 14 EP 14 DI 10.1016/j.seizure.2016.09.001 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EC3TL UT WOS:000388049100003 PM 27639029 ER PT J AU Bauman, WA La Fountaine, MF Cirnigliaro, CM Kirshblum, SC Spungen, AM AF Bauman, W. A. La Fountaine, M. F. Cirnigliaro, C. M. Kirshblum, S. C. Spungen, A. M. TI Provocative stimulation of the hypothalamic-pituitary-testicular axis in men with spinal cord injury SO SPINAL CORD LA English DT Article ID TESTOSTERONE REPLACEMENT THERAPY; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; BODY-COMPOSITION; HEALTH; PAIN; INDIVIDUALS; PREVALENCE; MORTALITY; MALES AB Study design: Prospective study. Objective: To determine the integrity of the hypothalamic-pituitary-testicular axis in healthy men with spinal cord injury (SCI). Methods: Thirty healthy men with chronic SCI (37 +/- 10 years) and thirty-eight able-bodied (AB) controls (36 +/- 10 years) participated. Gonadotropin-releasing hormone (GnRH; 100 mu g IV) was administered to determine gonadotropin release, and human chorionic gonadotropin (hCG; 4000 IU IM) was administered to determine testosterone (T) secretion. Responses to stimulation were categorized as 'responder' or 'non-responder' by clinical criteria. Single factor ANOVA with repeated measures was performed to identify group differences. Results: The proportion of responders to pituitary GnRH stimulation was similar in the SCI group (22 subjects (73%) for the follicular-stimulating hormone (FSH) and 23 subjects (76%) for the luteinizing hormone (LH) to that of the AB group. The SCI-responder group had an increased FSH response after stimulation compared with the AB-responder group (P<0.05). The SCI-responder group had a greater LH area under the curve to GnRH stimulation than the AB-responder group (P=0.06). The peak FSH response was at 60 min and the peak LH response at 30min, regardless of group designation. All groups had similar increases in serum T concentration to hCG stimulation. Conclusions: The pituitary response to stimulation in healthy men with SCI revealed an augmented FSH response; LH response only trended higher. The testicular response to provocative stimulation was similar in hypogonadal and eugondal subjects and in GnRH responders and non-responders. These findings suggest a lack of hypothalamic drive of pituitary gonadotropin release in healthy people with chronic SCI. C1 [Bauman, W. A.; La Fountaine, M. F.; Cirnigliaro, C. M.; Spungen, A. M.] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs, Rehabil Res & Dev Serv, Bronx, NY USA. [Bauman, W. A.; La Fountaine, M. F.; Spungen, A. M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, W. A.; Spungen, A. M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [La Fountaine, M. F.] Seton Hall Univ, Sch Hlth & Med Sci, S Orange, NJ 07079 USA. [Kirshblum, S. C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, S. C.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. RP Bauman, WA (reprint author), James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, 130 West Kingsbridge Rd,Room 7A-13, Bronx, NY 10468 USA. EM william.bauman@va.gov FU James J Peters VA Medical Center, Bronx, NY; Department of Veterans Affairs Rehabilitation Research and Development Service; Kessler Institute for Rehabilitation, West Orange, NJ; Veteran Affairs Rehabilitation Research and Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B2648-C, B4162-C, B9212-C] FX We thank the James J Peters VA Medical Center, Bronx, NY, the Department of Veterans Affairs Rehabilitation Research and Development Service and the Kessler Institute for Rehabilitation, West Orange, NJ, for their support. This work was funded by the Veteran Affairs Rehabilitation Research and Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B2648-C, #B4162-C and #B9212-C). NR 35 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD NOV PY 2016 VL 54 IS 11 BP 961 EP 966 DI 10.1038/sc.2016.50 PG 6 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EC2OO UT WOS:000387962900009 PM 27112842 ER PT J AU Reddy, SM Rose, DE Burgess, JF Charns, MP Yano, EM AF Reddy, Shivani M. Rose, Danielle E. Burgess, James F., Jr. Charns, Martin P. Yano, Elizabeth M. TI The Role of Organizational Factors in the Provision of Comprehensive Women's Health in the Veterans Health Administration SO WOMENS HEALTH ISSUES LA English DT Article ID PRIMARY-CARE; NATIONAL CENTERS; PATCHWORK QUILT; VA; AVAILABILITY; INNOVATION; AFFAIRS; EXCELLENCE; SERVICES; DELIVERY AB Background: Increasing numbers of women veterans present an organizational challenge to a health care system that historically has served men. Women veterans require comprehensive women's health services traditionally not provided by the Veterans Health Administration. Objective: Examine the association of organizational factors and adoption of comprehensive women's health care. Study Design: Cross-sectional analysis of the 2007 Veterans Health Administration National Survey of Women Veterans Health Programs and Practices. Methods: Dependent measures included a) model of women's health care: separate women's health clinic (WHC), designated women's health provider in primary care (DWHP), both(WHC+DWHP), or neither and b) the availability of five women's health services: cervical cancer screening and evaluation and management of vaginitis, menstrual disorders, contraception, and menopause. Exposure variables were organizational factors drawn from the Greenhalgh model of diffusion of innovations including measures of structure, absorptive capacity, and system readiness for innovation. Results: The organizational factors of a gynecology clinic, an academic affiliation with a medical school, a women's health representative on one or more high-impact committees, and a greater caseload of women veterans were more common at sites with WHCs and WHC+DWHPs, compared with sites relying on general primary care with or without a DWHP. Academic affiliation and high-impact committee involvement remained significant in multivariable analysis. Sites with WHCs or WHC+DWHPs were more likely to offer all five women's health services. Conclusion: Facilities with greater apparent absorptive capacity (academic affiliation and women's health representation on high-impact committees) are more likely to adopt WHCs. Facilities with separate WHCs are more likely to deliver a package of women's health services, promoting comprehensive care for women veterans. (C) 2016 Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Reddy, Shivani M.] VA Boston Healthcare Syst, Dept Gen Internal Med, Boston, MA USA. [Reddy, Shivani M.] RTI Int, Ctr Adv Methods Dev, Waltham, MA USA. [Rose, Danielle E.; Yano, Elizabeth M.] VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Burgess, James F., Jr.; Charns, Martin P.] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Burgess, James F., Jr.; Charns, Martin P.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. RP Reddy, SM (reprint author), RTI Int, Ctr Adv Methods Dev, VA Boston Healthcare Syst, Dept Gen Internal Med, 307 Waverly Oaks Rd, Waltham, MA 02452 USA. EM reddy.shivani@gmail.com FU VA-OAA Advanced Fellowship Program in Health Issues of Women Veterans; VA HSR&D Senior Research Career Scientist award [RCS 05-195]; VA HSRD project [IIR 04-036, IAE 07-170, CRE 12-038] FX Dr. Reddy's efforts were funded by the VA-OAA Advanced Fellowship Program in Health Issues of Women Veterans. Dr. Yano's efforts were funded by a VA HSR&D Senior Research Career Scientist award (Project # RCS 05-195). The project was supported by several VA HSR&D projects, for the original survey (Project # IIR 04-036), linkages to additional data sources (Project # IAE 07-170), and current secondary analyses (Project # CRE 12-038). NR 34 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2016 VL 26 IS 6 BP 648 EP 655 DI 10.1016/j.whi.2016.09.001 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA EC3OU UT WOS:000388036300010 PM 27745998 ER PT J AU Davis, TD Campbell, DG Bonner, LM Bolkan, CR Lanto, A Chaney, EF Waltz, T Zivin, K Yano, EM Rubenstein, LV AF Davis, Teri D. Campbell, Duncan G. Bonner, Laura M. Bolkan, Cory R. Lanto, Andrew Chaney, Edmund F. Waltz, Thomas Zivin, Kara Yano, Elizabeth M. Rubenstein, Lisa V. TI Women Veterans with Depression in Veterans Health Administration Primary Care: An Assessment of Needs and Preferences SO WOMENS HEALTH ISSUES LA English DT Article ID QUALITY IMPROVEMENT PROGRAMS; RANDOMIZED CONTROLLED-TRIAL; AFFAIRS PRIMARY-CARE; COLLABORATIVE CARE; GENDER-DIFFERENCES; AFGHANISTAN VETERANS; CLINICAL-PRACTICE; WAR VETERANS; PTSD; DIAGNOSES AB Objective: Depression is the most prevalent mental health condition in primary care (PC). Yet as the Veterans Health Administration increases resources for PC/mental health integration, including integrated care for women, there is little detailed information about depression care needs, preferences, comorbidity, and access patterns among women veterans with depression followed in PC. Methods: We sampled patients regularly engaged with Veterans Health Administration PC. We screened 10,929 (10,580 men, 349 women) with the two-item Patient Health Questionnaire. Of the 2,186 patients who screened positive (2,092 men, 94 women), 2,017 men and 93 women completed the full Patient Health Questionnaire-9 depression screening tool. Ultimately, 46 women and 715 men with probable major depression were enrolled and completed a baseline telephone survey. We conducted descriptive statistics to provide information about the depression care experiences of women veterans and to examine potential gender differences at baseline and at seven month follow-up across study variables. Results: Among those patients who agreed to screening, 20% of women (70 of 348) had probable major depression, versus only 12% of men (1,243 of 10,505). Of the women, 48% had concurrent probable posttraumatic stress disorder and 65% reported general anxiety. Women were more likely to receive adequate depression care than men (57% vs. 39%, respectively; p <.05); 46% of women and 39% of men reported depression symptom improvement at the 7-monthfollow-up. Women veterans were less likely than men to prefer care from a PC physician ( p < .01) at baseline and were more likely than men to report mental health specialist care ( p < .01) in the 6 months before baseline. Conclusion and Implications for Practice: PC/mental health integration planners should consider methods for accommodating women veterans unique care needs and preferences for mental health care delivered by health care professionals other than physicians. C1 [Davis, Teri D.; Lanto, Andrew; Yano, Elizabeth M.; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Davis, Teri D.] Univ Calif Los Angeles, Sch Med, Div Psychiat & Behav Sci, Semel Inst, Los Angeles, CA USA. [Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. [Bonner, Laura M.] VA Puget Sound Healthcare Syst, VA HSR&D Northwest Ctr Outcomes Res Older Adults, Seattle, WA USA. [Bonner, Laura M.] GRECC, Seattle, WA USA. [Bonner, Laura M.; Chaney, Edmund F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bolkan, Cory R.] Washington State Univ, Dept Human Dev, Vancouver, WA USA. [Waltz, Thomas] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA. [Waltz, Thomas] VA Ann Arbor Hlth Care Syst, Ctr Clin Management Res, Hlth Serv Res & Dev Serv, Ann Arbor, MI USA. [Zivin, Kara] VA Ann Arbor Med Ctr, CCMR, Ann Arbor, MI USA. [Zivin, Kara] Univ Michigan, Dept Psychiat, Sch Med, Ann Arbor, MI 48109 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND Corp, RAND Hlth Program, Santa Monica, CA USA. RP Davis, TD (reprint author), VA Greater Los Angeles Healthcare Syst, West Los Angeles VAMC, 11301 Wilshire Blvd 111G,Bldg 500,Room 3233, Los Angeles, CA 90073 USA. EM davis127@yahoo.com FU Department of Veterans Affairs (VA) Health Services Research and Development Service (HSRD); VA Quality Enhancement Research Initiative (QUERI) [MHI 99-375, MNT 01-027, MHQ 10-06, RRP 12-175] FX This project was funded by the Department of Veterans Affairs (VA) Health Services Research and Development Service (HSR&D) and the VA Quality Enhancement Research Initiative (QUERI) (Project nos. MHI 99-375, MNT 01-027, MHQ 10-06, RRP 12-175). The views expressed here are those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs, the United States Government, and the authors' other institutions. NR 58 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2016 VL 26 IS 6 BP 656 EP 666 DI 10.1016/j.whi.2016.08.001 PG 11 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA EC3OU UT WOS:000388036300011 PM 27697494 ER PT J AU Milan, PB Lotfibakhshaiesh, N Joghataie, MT Ai, J Pazouki, A Kaplan, DL Kargozar, S Amini, N Hamblin, MR Mozafari, M Samadikuchaksaraei, A AF Milan, P. Brouki Lotfibakhshaiesh, N. Joghataie, M. T. Ai, J. Pazouki, A. Kaplan, D. L. Kargozar, S. Amini, N. Hamblin, M. R. Mozafari, M. Samadikuchaksaraei, A. TI Accelerated wound healing in a diabetic rat model using decellularized dermal matrix and human umbilical cord perivascular cells SO ACTA BIOMATERIALIA LA English DT Article DE Wound healing; Decellularization; Scaffold; Stem cell; Dermal tissue engineering ID THICKNESS EXCISIONAL WOUNDS; MESENCHYMAL STROMAL CELLS; ENDOTHELIAL GROWTH-FACTOR; HUMAN AMNIOTIC MEMBRANE; MARROW-DERIVED CELLS; STEM-CELLS; FULL-THICKNESS; IN-VITRO; EXTRACELLULAR-MATRIX; TISSUE REGENERATION AB There is an unmet clinical need for novel wound healing strategies to treat full thickness skin defects, especially in diabetic patients. We hypothesized that a scaffold could perform dual roles of a biomechanical support and a favorable biochemical environment for stem cells. Human umbilical cord perivascular cells (HUCPVCs) have been recently reported as a type of mesenchymal stem cell that can accelerate early wound healing in skin defects. However, there are only a limited number of studies that have incorporated these cells into natural scaffolds for dermal tissue engineering. The aim of the present study was to promote angiogenesis and accelerate wound healing by using HUCPVCs and decellularized dermal matrix (DDM) in a rat model of diabetic wounds. The DDM scaffolds were prepared from harvested human skin samples and histological, ultrastructural, molecular and mechanical assessments were carried out. In comparison with the control (without any treatment) and DDM alone group, full thickness excisional wounds treated with HUCPVCs-loaded DDM scaffolds demonstrated an accelerated wound closure rate, faster re-epithelization, more granulation tissue formation and decreased collagen deposition. Furthermore, immunofluorescence analysis showed that the VEGFR-2 expression and vascular density in the HUCPVCs-loaded DDM scaffold treated group were also significantly higher than the other groups at 7 days post implantation. Since the rates of angiogenesis, re-epithelization and formation of granulation tissue are directly correlated with full thickness wound healing in patients, the proposed HUCPVCsloaded DDM scaffolds may fulfil a role neglected by current treatment strategies. This pre-clinical proof-of-concept study warrants further clinical evaluation. Statement of Significance The aim of the present study was to design a novel tissue-engineered system to promote angiogenesis, re-epithelization and granulation of skin tissue using human umbilical cord perivascular stem cells and decellularized dermal matrix natural scaffolds in rat diabetic wound models. The authors of this research article have been working on stem cells and tissue engineering scaffolds for years. According to our knowledge, there is a lack of an efficient system for the treatment of skin defects using tissue engineering strategy. Since the rates of angiogenesis, re-epithelization and granulation tissue are directly correlated with full thickness wound healing, the proposed HUCPVCs-loaded DDM scaffolds perfectly fills the niche neglected by current treatment strategies. This pre-clinical study demonstrates the proof-of concept that necessitates clinical evaluations. (C) 2016 Published by Elsevier Ltd on behalf of Acta Materialia Inc. C1 [Milan, P. Brouki; Lotfibakhshaiesh, N.; Joghataie, M. T.; Ai, J.; Kargozar, S.] Tehran Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran. [Joghataie, M. T.; Amini, N.; Mozafari, M.; Samadikuchaksaraei, A.] IUMS, Cellular & Mol Res Ctr, Tehran, Iran. [Pazouki, A.] IUMS, Minimally Invas Surg Res Ctr, Tehran, Iran. [Kaplan, D. L.] Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA. [Hamblin, M. R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA. [Hamblin, M. R.] Harvard Med Sch, Dept Dermatol, 25 Shattuck St, Boston, MA 02115 USA. [Hamblin, M. R.] Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Mozafari, M.] MERC, Nanotechnol & Adv Mat Dept, Bioengn Res Grp, Tehran, Iran. [Mozafari, M.; Samadikuchaksaraei, A.] IUMS, Fac Adv Technol Med, Dept Tissue Engn & Regenerat Med, Tehran, Iran. [Samadikuchaksaraei, A.] IUMS, Fac Allied Med, Dept Med Biotechnol, Tehran, Iran. RP Lotfibakhshaiesh, N; Joghataie, MT (reprint author), Tehran Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran. EM peiman.brouki@gmail.com; n-lotfiba@tums.ac.ir; mt.joghataei@yahoo.com; jafar_ai@tums.ac.ir; pazouki@minisergury.com; david.kaplan@tufts.edu; kargozarsaeid@gmail.com; amini_ot@yahoo.com; hamblin@helix.mgh.harvard.edu; mozafari.masoud@gmail.com; samadikuchaksaraei@yahoo.com OI Kargozar, Saeid/0000-0002-3785-1322 FU Iran National Science Foundation (INSF) [92031133]; US NIH [R01AI050875] FX This work was financially supported by Iran National Science Foundation (INSF) through research Grant No. 92031133. Michael R Hamblin was supported by US NIH grant R01AI050875. NR 67 TC 2 Z9 2 U1 9 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1742-7061 EI 1878-7568 J9 ACTA BIOMATER JI Acta Biomater. PD NOV PY 2016 VL 45 BP 234 EP 246 DI 10.1016/j.actbio.2016.08.053 PG 13 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA EB3VZ UT WOS:000387298300017 PM 27591919 ER PT J AU Riedl, MA Lumry, WR Li, HH Banerji, A Bernstein, JA Bas, M Bjorkander, J Magerl, M Maurer, M Rockich, K Chen, HZ Schranz, J AF Riedl, Marc A. Lumry, William R. Li, H. Henry Banerji, Aleena Bernstein, Jonathan A. Bas, Murat Bjorkander, Janne Magerl, Markus Maurer, Marcus Rockich, Kevin Chen, Hongzi Schranz, Jennifer TI Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article ID QUALITY-OF-LIFE; C1-INHIBITOR CONCENTRATE; DEFICIENCY; THERAPY; TOLERABILITY; PROPHYLAXIS; ATTACKS; CHILD; HOME AB Background: The currently approved method of C1 inhibitor (C1 INH) administration for patients with hereditary angioedema with C1 INH deficiency (HAE) is by intravenous injection. A C1 INH subcutaneous formulation may provide an attractive mode of administration for some patients. Objective: To evaluate efficacy and safety of two doses of subcutaneous, plasma-derived C1 INH with the dispersing agent, recombinant human hyaluronidase (rHuPH20) to prevent angioedema attacks in patients with HAE. Methods: A randomized, double-blind, dose-ranging, crossover study, patients >= 12 years of age (n = 47) with a confirmed diagnosis of HAE were randomly assigned to receive subcutaneous injections of 1000 U C1 INH with 24,000 U rHuPH20 or 2000 U C1 INH with 48,000 U rHuPH20 every 3 or 4 days for 8 weeks and then crossed-over for another 8-week period. The primary efficacy end point was the number of angioedema attacks during each treatment period. Results: The study was terminated early as a precaution related to non-neutralizing antibodies to rHuPH20 in 45% of patients. The mean +/- standard deviation number of angioedema attacks during the 8-week treatment periods were 1.58 +/- 1.59 with 1000 U C1 INH and 0.97 +/- 1.26 with 2000 U. The mean (95% confidence interval [CI]) within-patient difference (2000 U-1000 U, respectively) was -0.61 (95% CI, -1.23 to 0.01) attacks per month (p = 0.0523), and -0.56 (95% CI, -1.06 to -0.05) attacks that required acute treatment, (p = 0.0315). No deaths or other serious adverse events were reported. Injection-site reaction was the most common adverse event. Conclusion: Despite early termination, this study demonstrated a clinically and statistically significant difference in burden of disease, which favored 2000 U C1 INH, without associated serious adverse events. C1 [Riedl, Marc A.] Univ Calif San Diego, Sch Med, US HAEA Angioedema Ctr, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA. [Lumry, William R.] Allergy & Asthma Res Associates Res Ctr, Dallas, TX USA. [Li, H. Henry] Inst Asthma & Allergy, Chevy Chase, MD USA. [Banerji, Aleena] Massachusetts Gen Hosp, Dept Med Allergy & Clin Immunol, Boston, MA 02114 USA. [Bernstein, Jonathan A.] Univ Cincinnati, Med Ctr, Dept Med Immunol & Allergy, Cincinnati, OH 45267 USA. [Bas, Murat] Tech Univ Munich, Dept Otorhinolaryngol, Munich, Germany. [Bjorkander, Janne] Futurum Acad Hlth & Care, Reg Jonkoping Cty, Jonkoping, Sweden. [Magerl, Markus; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Berlin, Germany. [Rockich, Kevin; Chen, Hongzi; Schranz, Jennifer] Shire, Wayne, NJ USA. RP Riedl, MA (reprint author), Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92122 USA. EM mriedl@ucsd.edu NR 28 TC 1 Z9 1 U1 0 U2 0 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 EI 1539-6304 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD NOV-DEC PY 2016 VL 37 IS 6 BP 489 EP 500 DI 10.2500/aap.2016.37.4006 PG 12 WC Allergy SC Allergy GA EB7MR UT WOS:000387572300017 PM 27931305 ER PT J AU Steinberg, BA Shrader, P Kim, S Thomas, L Fonarow, GC Ansell, J Kowey, PR Singer, DE Gersh, BJ Mahaffey, KW Peterson, ED Piccini, JP AF Steinberg, Benjamin A. Shrader, Peter Kim, Sunghee Thomas, Laine Fonarow, Gregg C. Ansell, Jack Kowey, Peter R. Singer, Daniel E. Gersh, Bernard J. Mahaffey, Kenneth W. Peterson, Eric D. Piccini, Jonathan P. CA ORBIT-AF Investigators Patients TI How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) SO AMERICAN HEART JOURNAL LA English DT Article ID NET CLINICAL BENEFIT; ANTITHROMBOTIC THERAPY; PREVENT STROKE; ANTICOAGULATION; METAANALYSIS; WARFARIN; VALIDATION; SCORES; COHORT AB Background Assessments of stroke and bleeding risks are essential to selecting oral anticoagulation in patients with atrial fibrillation (AF). We aimed to assess outcomes according to physician assessed risk, with comparison to empirical risk scores. Methods This was a prospective, observational study of 9,715 outpatients with AF enrolled in ORBIT-AF, a US national registry. Stroke and bleeding risks were quantified by physician assignment, CHADS(2) and CHA(2)DS(2)-VASc stroke scores, and ATRIA and HAS-BLED bleeding scores. Outcomes were stroke or systemic embolism and major bleeding during a median follow-up of 28 months. Results Physician-assigned risk was associated with thromboembolic events: low risk (0.71 per 100 patient-years [95% CI 0.56-0.91], n = 3,991), intermediate risk (0.98 [95% CI 0.79-1.20], n = 4,148), and high risk (1.84 [95% CI 1.43-2.37], n = 1,576, P < .0001), and major bleeding: low (3.43 [95% CI 3.07-3.82], n = 4,250), intermediate (4.55 [95% CI 4.03-5.15], n = 2,702), and high (5.76 [95% CI 4.42-7.50], n = 468; P <.0001). Discrimination of stroke risk was similar with CHADS(2) (c = 0.59, 95% CI 0.57-0.61) vs physician assessment (c = 0.58, 95% CI 0.55-0.62). Among patients on oral anticoagulation, bleeding risk discrimination was higher with ATRIA (c = 0.63, 95% CI 0.61-0.65) and HAS-BLED (c = 0.60, 95% CI 0.59-0.62) than with physician assessment (0.55, 95% CI 0.53-0.57). Physician-assessed risk categories did not add significantly to empirical risk scores, in Cox models for outcomes (P-adjusted >.05 for all physician assessments vs P-adjusted <.05 for empirical scores). Conclusion Physician-assigned risk showed a graded relationship with outcomes, and both physician-based and empirical scores yielded only moderate discrimination. Although empirical scores provided valuable risk stratification information (with or without physician judgment), physician assessment added little to existing scores. These data support the use of empirical scores for stroke and bleeding risk stratification, and the need for novel approaches to risk stratification in this population. C1 [Steinberg, Benjamin A.; Peterson, Eric D.; Piccini, Jonathan P.] Duke Univ, Med Ctr, Durham, NC USA. [Steinberg, Benjamin A.; Shrader, Peter; Kim, Sunghee; Thomas, Laine; Peterson, Eric D.; Piccini, Jonathan P.] Duke Clin Res Inst, Durham, NC USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Ansell, Jack] NYU, Sch Med, Lenox Hill Hosp, New York, NY USA. [Kowey, Peter R.] Lankenau Inst Med Res, Wynnewood, PA USA. [Singer, Daniel E.] Harvard Med Sch, Boston, MA USA. [Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gersh, Bernard J.] Mayo Clin, Rochester, MN USA. [Mahaffey, Kenneth W.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. RP Steinberg, BA (reprint author), Duke Univ, Electrophysiol Sect, Duke Clin Res Inst, Med Ctr, POB 17969, Durham, NC 27715 USA. EM benjamin.steinberg@duke.edu FU Johnson and Johnson; Eli Lilly Company; Janssen Pharmaceuticals; American Heart Association; Johnson & Johnson/Janssen Pharmaceuticals; Bayer HealthCare Pharmaceuticals; Boston Scientific Corporation; Johnson & Johnson Pharmaceutical Research Development FX Dr Steinberg reports modest educational support from Medtronic. Mr Shrader, Dr Kim, and Dr Thomas report no disclosures. Dr Fonarow reports modest consultant/advisory board support from Ortho McNeil. Dr Ansell reports modest consultant/advisory board from Bristol Myers Squibb, Pfizer, Janssen, Daiichi, Boehringer Ingelheim, and Alere. Dr Kowey reports modest consultant/advisory board support from Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Portola, Merck, Sanofi, and Daiichi Sankyo. Dr Singer reports significant research grant support from Johnson and Johnson; modest consultant/advisory board support from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson and Johnson, and Pfizer; and significant consultant/advisory board support from Daiichi Sankyo. Dr Gersh reports modest DSMB/advisory board support from Medtronic, Baxter Healthcare Corporation, InspireMD, Cardiovascular Research Foundation, PPD Development, LP, Boston Scientific, and St Jude. Dr Mahaffey's financial disclosures before August 1, 2013 can be viewed at https://www.dcri.org/about-us/conflict-of-interest/Mahaffey-COI_2011-201 3.pdf; disclosures after August 1, 2013 can be viewed at http://med.stanford.edu/profiles/kenneth_mahaffey. Dr Peterson reports significant research grant support from Eli Lilly & Company, Janssen Pharmaceuticals, and the American Heart Association, and modest consultant/advisory board support from Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Pharmaceuticals, Pfizer, and Genentech. Dr Piccini reports significant research grant support from Johnson & Johnson/Janssen Pharmaceuticals; significant other research support from Bayer HealthCare Pharmaceuticals (formerly Berlex Labs), Boston Scientific Corporation, Johnson & Johnson Pharmaceutical Research & Development; modest consultant/advisory board support from Forest Laboratories and Medtronic; and significant consultant/advisory board support from Johnson & Johnson/Janssen Pharmaceuticals. NR 22 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD NOV PY 2016 VL 181 BP 145 EP 152 DI 10.1016/j.ahj.2016.07.026 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB3HE UT WOS:000387253900020 PM 27823686 ER PT J AU Roth, SH Miller, KW Orser, BA Urban, BW AF Roth, Sheldon H. Miller, Keith W. Orser, Beverley A. Urban, Bernd W. TI Unlocking the Mechanisms of Anesthesia SO ANESTHESIA AND ANALGESIA LA English DT Editorial Material C1 [Roth, Sheldon H.] Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada. [Roth, Sheldon H.] Univ Calgary, Cumming Sch Med, Dept Anaesthesia, Calgary, AB, Canada. [Miller, Keith W.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA USA. [Orser, Beverley A.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada. [Orser, Beverley A.] Univ Toronto, Dept Physiol, Toronto, ON, Canada. [Urban, Bernd W.] Univ Klinikum Bonn, Klin Anaesthesiol, Bonn, Germany. RP Roth, SH (reprint author), Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada. EM shroth@ucalgary.ca NR 1 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2016 VL 123 IS 5 BP 1070 EP 1071 DI 10.1213/ANE.0000000000001427 PG 2 WC Anesthesiology SC Anesthesiology GA EB1GM UT WOS:000387097600001 PM 27454067 ER PT J AU Kenny, JD Chemali, JJ Cotten, JF Van Dort, CJ Kim, SE Ba, D Taylor, NE Brown, EN Solt, K AF Kenny, Jonathan D. Chemali, Jessica J. Cotten, Joseph F. Van Dort, Christy J. Kim, Seong-Eun Ba, Demba Taylor, Norman E. Brown, Emery N. Solt, Ken TI Physostigmine and Methylphenidate Induce Distinct Arousal States During Isoflurane General Anesthesia in Rats SO ANESTHESIA AND ANALGESIA LA English DT Article ID BISPECTRAL INDEX; SEVOFLURANE ANESTHESIA; PROPOFOL ANESTHESIA; BURST SUPPRESSION; EMERGENCE; CONSCIOUSNESS; SLEEP; MICROINJECTION; STIMULATION; ANTAGONISM AB BACKGROUND: Although emergence from general anesthesia is clinically treated as a passive process driven by the pharmacokinetics of drug clearance, agents that hasten recovery from general anesthesia may be useful for treating delayed emergence, emergence delirium, and postoperative cognitive dysfunction. Activation of central monoaminergic neurotransmission with methylphenidate has been shown to induce reanimation (active emergence) from general anesthesia. Cholinergic neurons in the brainstem and basal forebrain are also known to promote arousal. The objective of this study,was to test the hypothesis that physostigmine, a centrally acting cholinesterase inhibitor, induces reanimation from isoflurane anesthesia in adult rats. METHODS: The dose-dependent effects of physostigmine on time to emergence from a standardized isoflurane general anesthetic were tested. It was then determined whether physostigmine restores righting during continuous isoflurane anesthesia. In a separate group of rats with implanted extradural electrodes, physostigmine was administered during continuous inhalation of 1.0% isoflurane, and the electroencephalogram changes were recorded. Finally, 2.0% isoflurane was used to induce burst suppression, and the effects of physostigmine and methylphenidate on burst suppression probability (BSP) were tested. RESULTS: Physostigmine delayed time to emergence from isoflurane anesthesia at doses >= 0.2 mg/kg (n = 9). During continuous isoflurane anesthesia (0.9% +/- 0.1%), physostigmine did not restore righting (n = 9). Blocking the peripheral side effects of physostigmine with the coad-ministration of glycopyrrolate (a muscarinic antagonist that does not cross the blood brain barrier) produced similar results (n = 9 each). However, during inhalation of 1.0% isoflurane, physostigmine shifted peak electroencephalogram power from delta (<4 Hz) to theta (4-8 Hz) in 6 of 6 rats. During continuous 2.0% isoflurane anesthesia, physostigmine induced large, statistically significant decreases in BSP in 6 of 6 rats, whereas methylphenidate did not. CONCLUSIONS: Unlike methylphenidate, physostigmine does not accelerate time to emergence from isoflurane anesthesia and does not restore righting during continuous isoflurane anesthesia. However, physostigmine consistently decreases BSP during deep isoflurane anesthesia, whereas methylphenidate does not. These findings suggest that activation of cholinergic neurotransmission during isoflurane anesthesia produces arousal states that are distinct from those induced by monoaminergic activation. C1 [Kenny, Jonathan D.; Chemali, Jessica J.; Cotten, Joseph F.; Van Dort, Christy J.; Taylor, Norman E.; Brown, Emery N.; Solt, Ken] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA. [Kim, Seong-Eun; Ba, Demba; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA. RP Solt, K (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA. EM ksolt@mgh.harvard.edu OI Solt, Ken/0000-0001-5328-2062 FU National Institutes of Health [TR01-GM104948, DP1-OD003646, K08-GM094394] FX This work was supported by National Institutes of Health grant numbers TR01-GM104948, DP1-OD003646, and K08-GM094394. NR 40 TC 2 Z9 2 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2016 VL 123 IS 5 BP 1210 EP 1219 DI 10.1213/ANE.0000000000001234 PG 10 WC Anesthesiology SC Anesthesiology GA EB1GM UT WOS:000387097600020 PM 26991753 ER PT J AU Amlong, CA Perkins, MG Houle, TT Miller, KW Pearce, RA AF Amlong, Corey A. Perkins, Mark G. Houle, Timothy T. Miller, Keith W. Pearce, Robert A. TI Contrasting Effects of the gamma-Aminobutyric Acid Type A Receptor beta 3 Subunit N265M Mutation on Loss of Righting Reflexes Induced by Etomidate and the Novel Anesthetic Barbiturate R-mTFD-MPAB SO ANESTHESIA AND ANALGESIA LA English DT Article ID GABA(A) RECEPTOR; POINT MUTATION; MICE AB BACKGROUND: Previous studies have shown that etomidate modulates gamma-aminobutyric acid type A receptors by binding at the beta(+)-alpha(-) subunit interface within the transmembrane domain of receptors that incorporate beta 2 or beta 3 subunits. Introducing an asparagine-to-methionine (N265M) mutation at position 265 of the beta 3 subunit, which sits within the etomidate-binding site, attenuates the hypnotic effect of etomidate in vivo. It was reported recently that the photoactivatable barbiturate R-mTFD-MPAB also acts on gamma-aminobutyric acid type A receptors primarily by binding to a homologous site at the gamma-beta interface. Given this difference in drug-binding sites established by the in vitro experiments, we hypothesized that the beta 3-N265M-mutant mice would not be resistant to the anesthetic effects of R-mTFD-MPAB in vivo, whereas the same mutant mice would be resistant to the anesthetic effects of R-etomidate. METHODS: We measured the effects of IV injection of etomidate and R-mTFD-MPAB on loss and recovery of righting reflex in wild-type mice and in mice carrying the beta 3-N265M mutation. RESULTS: Etomidate-induced hypnosis, as measured by the duration of loss of righting reflex, was attenuated in the N265M knock-in mice, confirming prior results. By contrast, recovery of balance and coordinated movement, as measured by the ability to maintain all 4 paws on the ground, was unaffected by the mutation. Neither hypnosis nor impairment of coordinated movement produced by the barbiturate R-mTFD-MPAB was affected by the mutation. CONCLUSIONS: The findings confirmed our hypothesis that mutating the etomidate-binding site would not alter the response to the barbiturate R-mTFD-MPAB. Furthermore, we confirmed previous studies indicating that etomidate-induced hypnosis is mediated in part by beta 3-containing receptors. We also extended previous findings by showing that etomidate-impaired balance and coordinated movement are not mediated by beta 3-containing receptors, thus implicating beta 2-containing receptors in this end point. C1 [Amlong, Corey A.; Perkins, Mark G.; Pearce, Robert A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, 600 Highland Ave,B6-319 CSC, Madison, WI 53792 USA. [Houle, Timothy T.; Miller, Keith W.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Pearce, RA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, 600 Highland Ave,B6-319 CSC, Madison, WI 53792 USA. EM rapearce@wisc.edu FU National Institutes of Health [GM 58448, GM 101497]; Department of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital; Department of Anesthesiology, University of Wisconsin, Madison FX National Institutes of Health grants: GM 58448 (KWM) and GM 101497 (RAP). Additional support came from the Department of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital, as well as the Department of Anesthesiology, University of Wisconsin, Madison. NR 22 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2016 VL 123 IS 5 BP 1241 EP 1246 DI 10.1213/ANE.0000000000001358 PG 6 WC Anesthesiology SC Anesthesiology GA EB1GM UT WOS:000387097600023 PM 27331778 ER PT J AU Forman, SA Miller, KW AF Forman, Stuart A. Miller, Keith W. TI Mapping General Anesthetic Sites in Heteromeric gamma-Aminobutyric Acid Type A Receptors Reveals a Potential For Targeting Receptor Subtypes SO ANESTHESIA AND ANALGESIA LA English DT Article ID GATED ION-CHANNEL; PROPOFOL BINDING-SITE; NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA(A) RECEPTORS; TRANSMEMBRANE DOMAIN; AMINO-ACID; ETOMIDATE BINDING; BETA-3 SUBUNIT; ANALOG; IDENTIFICATION AB IV general anesthetics, including propofol, etomidate, alphaxalone, and barbiturates, produce important actions by enhancing gamma-raminobutyric acid type A (GABA(A)) receptor activation. In this article, we review scientific studies that have located and mapped IV anesthetic sites using photoaffinity labeling and substituted cysteine modification protection. These anesthetics bind in transmembrane pockets between subunits of typical synaptic GABA(A) receptors, and drugs that display stereoselectivity also show remarkably selective interactions with distinct interfacial sites. These results suggest strategies for developing new drugs that selectively modulate distinct GABA(A) receptor subtypes. C1 [Forman, Stuart A.; Miller, Keith W.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 5 Fruit St, Boston, MA 02114 USA. RP Forman, SA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 5 Fruit St, Boston, MA 02114 USA. EM saforman@partners.org FU National Institute of General Medical Sciences [GM058448, GM089745]; National Institutes of Health (NIH) [P41 RR-01081] FX National Institute of General Medical Sciences (GM058448, GM089745), and National Institutes of Health (NIH) P41 RR-01081. NR 73 TC 2 Z9 2 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2016 VL 123 IS 5 BP 1263 EP 1273 DI 10.1213/ANE.0000000000001368 PG 11 WC Anesthesiology SC Anesthesiology GA EB1GM UT WOS:000387097600026 PM 27167687 ER PT J AU Mirzakhani, H Nozari, A AF Mirzakhani, Hooman Nozari, Ala TI Muscle Relaxation With Succinylcholine in Electroconvulsive Therapy Response SO ANESTHESIA AND ANALGESIA LA English DT Letter C1 [Mirzakhani, Hooman] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. Harvard Med Sch, Anesthesia Crit Care & Pain Med, Boston, MA USA. RP Mirzakhani, H (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. EM hoomi@post.harvard.edu OI Mirzakhani, Hooman/0000-0002-2290-4436 NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2016 VL 123 IS 5 BP 1329 EP 1330 DI 10.1213/ANE.0000000000001476 PG 2 WC Anesthesiology SC Anesthesiology GA EB1GM UT WOS:000387097600035 PM 27551738 ER PT J AU Cheng, GS Storer, B Chien, JW Jagasia, M Hubbard, JJ Burns, L Ho, VT Pidala, J Palmer, J Johnston, L Mayer, S Crothers, K Pusic, I Lee, SJ Williams, KM AF Cheng, Guang-Shing Storer, Barry Chien, Jason W. Jagasia, Madan Hubbard, Jesse J. Burns, Linda Ho, Vincent T. Pidala, Joseph Palmer, Jeanne Johnston, Laura Mayer, Sebastian Crothers, Kristina Pusic, Iskra Lee, Stephanie J. Williams, Kirsten M. TI Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment and also for the rational design of prospective studies. Objectives: To describe the longitudinal trajectory of lung function parameters, including FEV1, in patients with BOS after hematopoietic cell transplant. Methods: Subjects with BOS defined by National Institutes of Health consensus guidelines criteria from a recent multicenter prospective trial of combination treatment with fluticasone, azithromycin and montelukast and a retrospective cohort from Fred Hutchinson Cancer Research Center were included. Longitudinal change in FEV1 for each patient was calculated on the basis of available pulmonary function tests in three periods: pre-BOS, from BOS diagnosis to 6 months, and 6-18 months after diagnosis. The effect of treatment on FEV1 trajectory was analyzed by univariate and multivariate linear regression. The Kaplan-Meier method was used to estimate survival. Measurements and Main Results: The FEV1 percent predicted value at diagnosis was 46% (interquartile range, 35-57%) for trial participants and 53% (interquartile range, 41-64%) for the retrospective cohort. There was a concomitant mild reduction in FVC, as well as a marked reduction in forced expiratory flow, midexpiratory phase, at diagnosis. While there was individual heterogeneity, the overall FEV1 trajectory was characterized by a marked decline within 6 months prior to BOS diagnosis, followed by stability of FEV1 early after diagnosis and a slow rate of decline beyond 6 months. The effect of the trial medications on FEV1 trajectory after BOS diagnosis was a mean rate of change of 0.92% predicted per month (95% confidence interval, -0.53 to 2.37) compared with the retrospective cohort, but this was not statistically significant. Two-year overall survival rates were 76% and 72% for the study participants and the retrospective cohort patients, respectively. Earlier time to diagnosis after hematopoietic cell transplant and severity of FVC at diagnosis were significantly associated with reduced survival. Conclusions: The FEV1 trajectory in patients with BOS after hematopoietic cell transplant in a contemporary era of management follows a predominant pattern of rapid FEV1 decline in the 6 months prior to diagnosis, followed by FEV1 stabilization after diagnosis. C1 [Cheng, Guang-Shing; Storer, Barry; Hubbard, Jesse J.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,D5-360, Seattle, WA 98109 USA. [Cheng, Guang-Shing; Chien, Jason W.; Crothers, Kristina] Univ Washington, Sch Med, Pulm & Crit Care Med, Seattle, WA USA. [Chien, Jason W.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Jagasia, Madan] Vanderbilt Univ, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Burns, Linda] Natl Marrow Donor Program, Minneapolis, MN USA. [Ho, Vincent T.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Pidala, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. [Palmer, Jeanne] Mayo Clinic Scottsdale, Div Hematol Oncol, Scottsdale, AZ USA. [Johnston, Laura] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Mayer, Sebastian] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Pusic, Iskra] Washington Univ, Div Med & Oncol, St Louis, MO USA. [Williams, Kirsten M.] Childrens Natl Hlth Syst, Childrens Res Inst, Washington, DC USA. RP Cheng, GS (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,D5-360, Seattle, WA 98109 USA. EM gcheng2@fredhutch.org OI Cheng, Guang-Shing/0000-0003-4324-9634 FU Chronic Graft-versus-Host Disease Consortium [U54 CA163438]; National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network; NCATS; National Cancer Institute; Cancer Center Support Grant New Investigator Award; Cancer Consortium of the Fred Hutchinson Cancer Research Center; University of Washington FX Funding for this study was provided by the Chronic Graft-versus-Host Disease Consortium (grant U54 CA163438), which is part of the National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network, funded through a collaboration between NCATS and the National Cancer Institute (S.J.L., principal investigator). Additional funding was provided by a Cancer Center Support Grant New Investigator Award, funded by the Cancer Consortium of the Fred Hutchinson Cancer Research Center and the University of Washington (G.-S.C., principal investigator). NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1932 EP 1939 DI 10.1513/AnnalsATS.201604-262OC PG 8 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900013 PM 27513368 ER PT J AU Schapira, MM Aggarwal, C Akers, S Aysola, J Imbert, D Langer, C Simone, CB Strittmatter, E Vachani, A Fraenkel, L AF Schapira, Marilyn M. Aggarwal, Charu Akers, Scott Aysola, Jaya Imbert, Diana Langer, Corey Simone, Charlie B., II Strittmatter, Emily Vachani, Anil Fraenkel, Liana TI How Patients View Lung Cancer Screening The Role of Uncertainty in Medical Decision Making SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Radiographic lung cancer screening guidelines and coverage requirements warrant a shared decision-making process. Guidance is needed regarding how to conduct shared decision making effectively. A useful organizing theme should include consideration of a patient's response to and tolerance of uncertainty associated with lung cancer screening. Objectives: The objectives of this study are to: (1) describe how patients respond to specific categories of uncertainty in the context of lung cancer screening, and (2) inform strategies for addressing concerns about uncertainty as part of the shared decision making. Methods: We performed two series of structured interviews on participants in a convenience sample of current or former cigarette smokers recruited from primary care and pulmonary practices in Philadelphia. An interview guide included prompts related to benefits, harms, and responses to general and specific types of uncertainty (stochastic, statistical, and evidentiary) associated with lung cancer screening. Interviews were audio-recorded, transcribed, and independently coded by two investigators. An inductive analysis was conducted, and major themes were identified. Measurements and Main Results: Twenty-two adults participated in the study. Sixty-eight percent were men, 72% were black or African American, and 50% met U.S. Preventive Services Task Force criteria for lung cancer screening. The primary themes to emerge from our study were: (1) the desire to decrease uncertainty may motivate lung cancer screening decisions; (2) uncertainty is an attribute of health states that impacts how patients weigh benefits and harms of lung cancer screening; (3) patient understanding and tolerance of uncertainty varies across stochastic, statistical, and evidentiary uncertainty; and (4) provider-patient communication may mitigate intolerance of uncertainty in the context of lung cancer screening. Conclusions: A systematic approach to understanding and addressing patients' concerns about uncertainty in the context of lung cancer screening can guide a patient-centered approach to shared decision making. The results of this study can inform provider-patient communication strategies regarding the decision to perform radiographic lung cancer screening. C1 [Schapira, Marilyn M.; Aysola, Jaya; Imbert, Diana; Strittmatter, Emily] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Aggarwal, Charu; Langer, Corey] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA. [Vachani, Anil] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Dept Med, Philadelphia, PA 19104 USA. [Akers, Scott] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104 USA. [Simone, Charlie B., II] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Akers, Scott; Vachani, Anil] Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA. [Fraenkel, Liana] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Fraenkel, Liana] Yale Univ, Dept Med, New Haven, CT 06520 USA. RP Schapira, MM (reprint author), Univ Penn, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mschap@upenn.edu FU National Institutes of Health [P30 CA016520]; Department of Veterans Affairs Health Services Research and Development Service Program [HX001334-01A1] FX Supported by National Institutes of Health grant P30 CA016520 and the Department of Veterans Affairs Health Services Research and Development Service Program grant HX001334-01A1. NR 0 TC 1 Z9 1 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1969 EP 1976 DI 10.1513/AnnalsATS.201604-290OC PG 8 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900018 PM 27676595 ER PT J AU Kanodra, NM Pope, C Halbert, CH Silvestri, GA Rice, LJ Tanner, NT AF Kanodra, Neeti M. Pope, Charlene Halbert, Chanita H. Silvestri, Gerard A. Rice, LaShanta J. Tanner, Nichole T. TI Primary Care Provider and Patient Perspectives on Lung Cancer Screening A Qualitative Study SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: The U.S. Preventive Services Task Force recommends annual low-dose computed tomography (LDCT) for lung cancer screening in high-risk individuals. Preventive healthcare is provided predominantly by primary care providers (PCPs). Successful implementation of a screening program requires acceptance and participation by both providers and patients, with available collaboration with pulmonologists. Objectives: To identify perceptions of and perspectives on lung cancer screening and implementation among PCPs and eligible veteran patients at high risk for lung cancer. Methods: We conducted a qualitative study using grounded theory in which 28 veterans and 13 PCPs completed a questionnaire and participated in focus groups. Sessions were recorded, transcribed verbatim, and analyzed with NVivo 10 software. Counts and percentages were used to report questionnaire results. Measurements and Main Results: While 58% percent of providers were aware of lung cancer screening guidelines, many could not recall the exact patient eligibility criteria. Most patients were willing to undergo LDCT screening and identified smoking as a risk factor for lung cancer, but they did not recall their PCP explaining the reason for the testing. All providers assessed smoking behavior, but only 23% referred active smokers for formal cessation services. Patients volunteered information regarding their hurdles with smoking cessation while discussing risk factors for cancer. PCPs cited time constraints as a reason for lack of appropriate counseling and shared decision making. Both parties were willing to explore modalities and decision aid tools to improve shared decision making; however, while patients were interested in individual risk prediction, few PCPs believed statistical approaches to counseling would confuse patients. Conclusions: While patients and providers are receptive to LDCT screening, efforts are needed to improve guideline knowledge and adherence among providers. System-level interventions are necessary to facilitate time and resources for shared decision making and smoking cessation counseling and treatment. Further research is needed to identify optimal strategies for effective lung cancer screening in the community. C1 [Kanodra, Neeti M.; Silvestri, Gerard A.; Tanner, Nichole T.] Med Univ South Carolina, Dept Med, Div Pulm Crit Care & Sleep Med, 96 Jonathan Lucas St,CSB 816, Charleston, SC 29425 USA. [Pope, Charlene] Med Univ South Carolina, Coll Nursing, Charleston, SC 29425 USA. [Halbert, Chanita H.; Rice, LaShanta J.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Hollings Canc Ctr, Charleston, SC 29425 USA. [Pope, Charlene; Halbert, Chanita H.; Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, HEROIC, Charleston, SC USA. RP Tanner, NT (reprint author), Med Univ South Carolina, Dept Med, Div Pulm Crit Care & Sleep Med, 96 Jonathan Lucas St,CSB 816, Charleston, SC 29425 USA. EM tripici@musc.edu FU Veterans Affairs (VA) Health Equity and Rural Outreach Innovation Center (HEROIC) at the Ralph H. Johnson VA Medical Center, Charleston, SC FX Supported by the Veterans Affairs (VA) Health Equity and Rural Outreach Innovation Center (HEROIC) at the Ralph H. Johnson VA Medical Center, Charleston, SC. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1977 EP 1982 DI 10.1513/AnnalsATS.201604-286OC PG 6 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900019 PM 27676369 ER PT J AU Slatore, CG Wiener, RS Golden, SE Au, DH Ganzini, L AF Slatore, Christopher G. Wiener, Renda Soylemez Golden, Sara E. Au, David H. Ganzini, Linda TI Longitudinal Assessment of Distress among Veterans with Incidental Pulmonary Nodules SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Millions of patients are diagnosed with pulmonary nodules every year. Increased distress may be a common harm, but methods of mitigating this distress are unclear. Objectives: We aimed to determine whether high-quality communication regarding the discovery of a pulmonary nodule is associated with a lower level of patient distress. Methods: We conducted a prospective, repeated-measures cohort study of 121 patients with newly reported, incidentally detected pulmonary nodules. The primary exposure was participant-reported quality of communication regarding the nodule. Secondary exposures included communication measures regarding participants' values, preferences, and decision making. The main outcome was nodule-related distress measured using the Impact of Event Scale. We used adjusted generalized estimating equations to measure the association between nodule communication quality and at least mild distress. Measurements and Main Results: Most participants (57%) reported at least mild distress at least once. While average distress scores decreased over time, one-fourth still had elevated distress after 2 years of surveillance for a nodule. The average calculated risk of cancer at baseline was 10% (SD, 13%), but 52.4% believed they had a greater than 30% risk of lung cancer at baseline, and this percentage remained fairly constant at all visits. High-quality nodule communication was associated with decreased odds of distress (adjusted odds ratio, 0.42; 95% confidence interval, 0.24-0.73). Lower-quality communication processes regarding participants' values and preferences were also associated with increased odds of distress, but concordance between the actual and preferred decision-making roles was not. Conclusions: Among patients with incidentally discovered pulmonary nodules, distress is common and persistent for about 25%. Many participants substantially overestimate their risk of lung cancer. Incorporating patients' values and preferences into communication about a pulmonary nodule and its evaluation may mitigate distress. C1 [Slatore, Christopher G.; Golden, Sara E.; Ganzini, Linda] VA Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA. [Slatore, Christopher G.] VA Portland Hlth Care Syst, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Dept Med, Portland, OR 97201 USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. RP Slatore, CG (reprint author), Portland VA Med Ctr, Hlth Serv Res & Dev, 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Slatore, Christopher/0000-0003-0958-8122 FU VA Health Services Research & Development career development award [CDA 09-025, CDP 11-227]; VA Portland Health Care System, Portland, Oregon; VA Puget Sound Healthcare System, Seattle, Washington; Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts FX This study was sponsored by a VA Health Services Research & Development career development award (CDA 09-025 and CDP 11-227) (C.G.S.). It was also supported by resources from the VA Portland Health Care System, Portland, Oregon; the VA Puget Sound Healthcare System, Seattle, Washington; and the Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts. The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1983 EP 1991 DI 10.1513/AnnalsATS.201607-555OC PG 9 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900020 PM 27599153 ER PT J AU Crothers, K Kross, EK Reisch, LM Shahrir, S Slatore, C Zeliadt, SB Triplette, M Meza, R Elmore, JG AF Crothers, Kristina Kross, Erin K. Reisch, Lisa M. Shahrir, Shahida Slatore, Christopher Zeliadt, Steven B. Triplette, Matthew Meza, Rafael Elmore, Joann G. TI Patients' Attitudes Regarding Lung Cancer Screening and Decision Aids A Survey and Focus Group Study SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Little is known about vulnerable patients' perceptions and understanding of, and preferences for, lung cancer screening decision aids. Objectives: To determine, in a low-income, racially diverse population, (1) participants' experience, preferences, and reactions to web-based and paper decision aids, and (2) their understanding of harms and benefits of lung cancer screening. Methods: We enrolled outpatients at an urban county hospital in six focus group discussions that included review of a web-based and a paper-based lung-cancer screening decision aid. Participants completed surveys before and after the focus groups. Measurements and Main Results: Forty-five patients participated (mean age, 61 yr; 76% current smokers; 24% former smokers); 27% had not completed high school; 50% had an annual income not exceeding $ 15,000; 42% were nonwhite; and 96% reported chronic illness requiring at least three health care visits yearly. Comparing the proportion with correct answers on pre- and postsurveys, participants' understanding of lung cancer screening increased, particularly of the harms of screening including the potential for false positives, extra testing, and complications. However, after conclusion of the focus groups, more than 50% believed that screening lowered the chance of getting lung cancer. Five major themes emerged from qualitative analyses. Participants (1) were not aware of the purpose of lung cancer screening; (2) wanted to know about the benefits and harms; (3) believed physicians need to communicate more effectively; (4) found decision aids helpful and influential for decision-making about screening; and (5) wanted the discussion to be personalized and tailored. Participants expressed surprise that the magnitude of their lung cancer risk and benefits of screening were lower than anticipated. Conclusions: Vulnerable patients find lung cancer screening decision aids helpful and generally show increased knowledge after reviewing decision aids, particularly of harms. Our results can inform future implementation efforts. C1 [Crothers, Kristina; Kross, Erin K.; Reisch, Lisa M.; Shahrir, Shahida; Triplette, Matthew; Elmore, Joann G.] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. [Slatore, Christopher] Vet Affairs Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA. [Slatore, Christopher] Vet Affairs Portland Hlth Care Syst, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Zeliadt, Steven B.] Vet Affairs Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Zeliadt, Steven B.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Meza, Rafael] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359765, Seattle, WA 98104 USA. EM crothk@uw.edu OI Meza, Rafael/0000-0002-1076-5037; Slatore, Christopher/0000-0003-0958-8122; Crothers, Kristina/0000-0001-9702-0371 FU Lung Cancer Discovery Grant from the American Lung Association [K05 CA104699]; VA Portland Health Care System FX Supported by a Lung Cancer Discovery Grant from the American Lung Association (K.C.), K05 CA104699 (J.G.E.), and by resources from the VA Portland Health Care System (C.S.). The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 BP 1992 EP 2001 DI 10.1513/AnnalsATS.201604-289OC PG 10 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900021 PM 27652509 ER PT J AU Sibila, O Mateus, EF Restrepo, MI Chalmers, JD Vidal, S AF Sibila, Oriol Mateus, Eder F. Restrepo, Marcos I. Chalmers, James D. Vidal, Silvia TI Measuring Airway Mucin 2 in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization Reply SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Letter C1 [Sibila, Oriol; Mateus, Eder F.; Vidal, Silvia] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Sibila, Oriol; Mateus, Eder F.; Vidal, Silvia] Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chalmers, James D.] Univ Dundee, Dundee, Scotland. RP Sibila, O (reprint author), Hosp Santa Creu & Sant Pau, Barcelona, Spain.; Sibila, O (reprint author), Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD NOV PY 2016 VL 13 IS 11 PG 2 WC Respiratory System SC Respiratory System GA EB4GQ UT WOS:000387328900039 ER PT J AU Vergallo, R Uemura, S Soeda, T Minami, Y Cho, JM Ong, DS Aguirre, AD Gao, L Biasucci, LM Crea, F Yu, B Lee, H Kim, CJ Jang, IK AF Vergallo, Rocco Uemura, Shiro Soeda, Tsunenari Minami, Yoshiyasu Cho, Jin-Man Ong, Daniel S. Aguirre, Aaron D. Gao, Lei Biasucci, Luigi M. Crea, Filippo Yu, Bo Lee, Hang Kim, Chong-Jin Jang, Ik-Kyung TI Prevalence and Predictors of Multiple Coronary Plaque Ruptures In Vivo 3-Vessel Optical Coherence Tomography Imaging Study SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE atherosclerosis; fibroatheroma; incidence; optical coherence tomography; phenotype ID ACUTE MYOCARDIAL-INFARCTION; CULPRIT LESION MORPHOLOGY; THIN-CAP FIBROATHEROMA; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC LESIONS; RANDOMIZED-TRIAL; ANGINA-PECTORIS; ISCHEMIC DEATH; KIDNEY-DISEASE; STABLE ANGINA AB Objective-Plaque rupture may be the local expression of a widespread coronary instability. This study aimed to investigate: (1) the prevalence and characteristics of nonculprit plaque rupture; (2) the pancoronary atherosclerotic phenotype in patients with and without nonculprit plaque rupture; and (3) the prevalence and predictors of multiple plaque ruptures. Approach and Results-Six hundred and seventy-five nonculprit plaques from 261 patients (34 acute myocardial infarction, 73 unstable angina pectoris, and 154 stable angina pectoris) were analyzed by 3-vessel optical coherence tomography. Nonculprit plaque ruptures were identified in 51 patients (20%). Patients with nonculprit plaque ruptures had higher prevalence of thin-cap fibroatheroma (51% versus 13%; P<0.001) in the 3 major epicardial coronary vessels. Multiple plaque ruptures were observed in 20% of patients (38% acute myocardial infarction versus 10% unstable angina pectoris versus 19% stable angina pectoris; P=0.042). Thin-cap fibroatheroma, intimal vasculature, and macrophages were independent morphological predictors of multiple plaque ruptures, whereas acute myocardial infarction and chronic kidney disease were independent clinical predictors. Patients with nonculprit plaque ruptures showed higher 1-year rates of nontarget lesion revascularization (11.8% versus 4.4%; P=0.039). Conclusions-Nonculprit plaque ruptures were observed in 20% of patients with coronary artery disease and were associated with pancoronary vulnerability and higher 1-year revascularization rate. C1 [Vergallo, Rocco; Soeda, Tsunenari; Minami, Yoshiyasu; Ong, Daniel S.; Gao, Lei; Jang, Ik-Kyung] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA. [Vergallo, Rocco; Biasucci, Luigi M.; Crea, Filippo] Univ Cattolica Sacro Cuore, Div Cardiol, Rome, Italy. [Uemura, Shiro] Nara Med Univ, Kashihara, Nara, Japan. [Cho, Jin-Man; Kim, Chong-Jin; Jang, Ik-Kyung] Kyung Hee Univ, Div Cardiol, Seoul, South Korea. [Aguirre, Aaron D.] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA USA. [Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China. [Lee, Hang] Harvard Med Sch, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA. RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA.; Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin 150086, Peoples R China. EM yubodr@163.com; ijang@mgh.harvard.edu FU Italian Society of Cardiology Award for Research Abroad; Enrico ed Enrica Sovena Foundation, Rome, Italy FX Dr Jang's research was supported by Michael and Kathryn Park and by Allan and Gillian Gray. Dr Vergallo was supported by the 2013 Italian Society of Cardiology Award for Research Abroad and the Enrico ed Enrica Sovena Foundation, Rome, Italy. NR 38 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1079-5642 EI 1524-4636 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD NOV PY 2016 VL 36 IS 11 BP 2229 EP + DI 10.1161/ATVBAHA.116.307891 PG 23 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EB0RC UT WOS:000387051500018 PM 27634834 ER PT J AU Liu, G Ding, M Chiuve, SE Rimm, EB Franks, PW Meigs, JB Hu, FB Sun, Q AF Liu, Gang Ding, Ming Chiuve, Stephanie E. Rimm, Eric B. Franks, Paul W. Meigs, James B. Hu, Frank B. Sun, Qi TI Plasma Levels of Fatty Acid-Binding Protein 4, Retinol-Binding Protein 4, High-Molecular-Weight Adiponectin, and Cardiovascular Mortality Among Men With Type 2 Diabetes A 22-Year Prospective Study SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE adipokines; adiponectin; cardiovascular disease; fatty acid-binding proteins; heart failure ID CORONARY-HEART-DISEASE; HUMAN THP-1 MACROPHAGES; CHRONIC KIDNEY-DISEASE; BODY-MASS INDEX; ADIPOSE-TISSUE; NATRIURETIC PEPTIDE; INSULIN-RESISTANCE; COLORECTAL-CANCER; GENETIC-VARIANTS; ALL-CAUSE AB Objective-To examine select adipokines, including fatty acid-binding protein 4, retinol-binding protein 4, and high-molecular-weight (HMW) adiponectin in relation to cardiovascular disease (CVD) mortality among patients with type 2 diabetes mellitus. Approach and Results-Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, and HMW adiponectin were measured in 950 men with type 2 diabetes mellitus in the Health Professionals Follow-up Study. After an average of 22 years of follow-up (1993-2015), 580 deaths occurred, of whom 220 died of CVD. After multivariate adjustment for covariates, higher levels of fatty acid-binding protein 4 were significantly associated with a higher CVD mortality: comparing extreme tertiles, the hazard ratio and 95% confidence interval of CVD mortality was 1.78 (1.22-2.59; P trend=0.001). A positive association was also observed for HMW adiponectin: the hazard ratio (95% confidence interval) was 2.07 (1.42-3.06; P trend=0.0002), comparing extreme tertiles, whereas higher retinol-binding protein 4 levels were nonsignificantly associated with a decreased CVD mortality with an hazard ratio (95% confidence interval) of 0.73 (0.50-1.07; P trend=0.09). A Mendelian randomization analysis suggested that the causal relationships of HMW adiponectin and retinol-binding protein 4 would be directionally opposite to those observed based on the biomarkers, although none of the Mendelian randomization associations achieved statistical significance. Conclusions-These data suggest that higher levels of fatty acid-binding protein 4 and HMW adiponectin are associated with elevated CVD mortality among men with type 2 diabetes mellitus. Biological mechanisms underlying these observations deserve elucidation, but the associations of HMW adiponectin may partially reflect altered adipose tissue functionality among patients with type 2 diabetes mellitus. C1 [Liu, Gang; Ding, Ming; Chiuve, Stephanie E.; Rimm, Eric B.; Franks, Paul W.; Hu, Frank B.; Sun, Qi] Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA. [Rimm, Eric B.; Hu, Frank B.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Chiuve, Stephanie E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Rimm, Eric B.; Hu, Frank B.; Sun, Qi] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Meigs, James B.] Harvard Med Sch, Boston, MA USA. [Franks, Paul W.] Lund Univ, Dept Clin Sci, Genet & Mol Epidemiol Unit, Lund, Sweden. [Franks, Paul W.] Skane Univ Hosp Malmo, Malmo, Sweden. [Franks, Paul W.] Umea Univ, Fac Med, Dept Publ Hlth & Clin Med, Umea, Sweden. [Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA. [Meigs, James B.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP Sun, Q (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA. EM qisun@hsph.harvard.edu FU National Institutes of Health [CA167552, HL35464, R00HL098459, DK058845]; NIH [ES022981, ES021372]; NIDDK [K24 DK080140]; International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council FX This study was funded by research grants CA167552, HL35464, R00HL098459, and DK058845 from the National Institutes of Health. Q. Sun is supported by NIH grants ES022981 and ES021372. J.B. Meigs is supported by NIDDK K24 DK080140. G. Liu was supported by the International Postdoctoral Exchange Fellowship Program 2015 by the Office of China Postdoctoral Council. NR 87 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1079-5642 EI 1524-4636 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD NOV PY 2016 VL 36 IS 11 BP 2259 EP + DI 10.1161/ATVBAHA.116.308320 PG 24 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EB0RC UT WOS:000387051500022 PM 27609367 ER PT J AU Sencan, I Huang, BK Bian, Y Mis, E Khokha, MK Cao, H Choma, M AF Sencan, Ikbal Huang, Brendan K. Bian, Yong Mis, Emily Khokha, Mustafa K. Cao, Hui Choma, Michael TI Ultrahigh-speed, phase-sensitive full-field interferometric confocal microscopy for quantitative microscale physiology SO BIOMEDICAL OPTICS EXPRESS LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; DRIVEN FLUID-FLOW; INCOHERENT ILLUMINATION; SPECKLE ILLUMINATION; MUCUS CLEARANCE; VELOCIMETRY; MECHANISM; LIGHT; LASER AB We developed ultra-high-speed, phase-sensitive, full-field reflection interferometric confocal microscopy (FFICM) for the quantitative characterization of in vivo microscale biological motions and flows. We demonstrated 2D frame rates in excess of 1 kHz and pixel throughput rates up to 125 MHz. These fast FFICM frame rates were enabled by the use of a low spatial coherence, high-power laser source. Specifically, we used a dense vertical cavity surface emitting laser (VCSEL) array that synthesized low spatial coherence light through a large number of narrowband, mutually-incoherent emitters. Off-axis interferometry enabled single-shot acquisition of the complex-valued interferometric signal. We characterized the system performance (similar to 2 mu m lateral resolution, similar to 8 mu m axial gating depth) with a well-known target. We also demonstrated the use of this highly parallelized confocal microscopy platform for visualization and quantification of cilia-driven surface flows and cilia beat frequency in an important animal model (Xenopus embryos) with > 1 kHz frame rate. Such frame rates are needed to see large changes in local flow velocity over small distance (high shear flow), in this case, local flow around a single ciliated cell. More generally, our results are an important demonstration of low-spatial coherence, high-power lasers in high-performance, quantitative biomedical imaging. (C) 2016 Optical Society of America C1 [Sencan, Ikbal; Bian, Yong; Choma, Michael] Yale Univ, Dept Radiol & Biomed Imaging, New Haven, CT 06511 USA. [Sencan, Ikbal] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, MGH HST Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Huang, Brendan K.; Choma, Michael] Yale Univ, Biomed Engn, New Haven, CT 06511 USA. [Bian, Yong] Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. [Mis, Emily; Khokha, Mustafa K.; Choma, Michael] Yale Univ, Pediat, New Haven, CT 06511 USA. [Cao, Hui; Choma, Michael] Yale Univ, Appl Phys, New Haven, CT 06511 USA. RP Sencan, I (reprint author), Yale Univ, Dept Radiol & Biomed Imaging, New Haven, CT 06511 USA.; Sencan, I (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, MGH HST Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM isencan@mgh.harvard.edu; michael.choma@yale.edu FU National Institutes of Health (NIH) [1R21EB016163-01A1, 1R01HL118419-01, 1R21HL125125-01A1]; Office of Naval Research (ONR) [MURI N00014-13-1-0649] FX This work is supported by the National Institutes of Health (NIH) (1R21EB016163-01A1,1R01HL118419-01,1R21HL125125-01A1); Office of Naval Research (ONR) (MURI N00014-13-1-0649). NR 34 TC 0 Z9 0 U1 13 U2 13 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2156-7085 J9 BIOMED OPT EXPRESS JI Biomed. Opt. Express PD NOV 1 PY 2016 VL 7 IS 11 BP 4674 EP 4684 DI 10.1364/BOE.7.004674 PG 11 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA EB7HM UT WOS:000387557600028 PM 27896006 ER PT J AU Brunner, AM Fathi, AT Chen, YB AF Brunner, A. M. Fathi, A. T. Chen, Y. B. TI Life after transplant: are we becoming high maintenance in AML? SO BONE MARROW TRANSPLANTATION LA English DT Review ID ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; WT1 PEPTIDE VACCINATION; VERSUS-HOST-DISEASE; DONOR LYMPHOCYTE INFUSIONS; ACUTE MYELOGENOUS LEUKEMIA; ADVANCED HEMATOLOGIC MALIGNANCIES; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE INHIBITORS AB Allogeneic hematopoietic cell transplantation (allo-HCT) for patients with AML is increasingly able to impact the historically poor outcomes in this disease. Nonetheless, even with transplant, the rates of post-HCT relapse are unacceptably high, and remain a great challenge in the treatment of patients with AML. Maintenance therapies after allo-HCT, given to patients at high risk of relapse or with evidence of minimal residual disease (MRD), may provide a way to reduce relapse rates and improve survival. New therapies may offer acceptable toxicity profiles in the post-HCT setting, and investigations are ongoing using hypomethylating agents, histone deacetylase inhibitors, immunomodulatory drugs, targeted tyrosine kinase inhibitors, drug-antibody conjugates and cellular therapies. Future directions in the field of post-HCT therapies may include better risk stratification with MRD, as well as the exploitation of novel mechanisms such as immune checkpoint inhibition and modified chimeric antigen receptor (CAR) T cells. In this mini review, we discuss the current landscape of clinical research in post-HCT maintenance therapies, as well as future therapeutic strategies of interest. Although there is great potential for post-HCT agents to improve AML outcomes, these will need to be evaluated prospectively through well-designed randomized clinical trials. C1 [Brunner, A. M.; Fathi, A. T.; Chen, Y. B.] Massachusetts Gen Hosp, Div Hematol Oncol, Yawkey 9E-9052,55 Fruit St, Boston, MA 02114 USA. RP Chen, YB (reprint author), Massachusetts Gen Hosp, Div Hematol Oncol, Yawkey 9E-9052,55 Fruit St, Boston, MA 02114 USA. EM ychen6@partners.org FU National Institutes of Health (NIH) [T32 CA 71345-18] FX AMB is supported in part by National Institutes of Health (NIH) grant T32 CA 71345-18. NR 87 TC 0 Z9 0 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD NOV PY 2016 VL 51 IS 11 BP 1423 EP 1430 DI 10.1038/bmt.2016.160 PG 8 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA EB3DW UT WOS:000387243700004 PM 27322850 ER PT J AU Rotenstein, L Nathan, A Ghobrial, I Antin, J Parnes, A AF Rotenstein, L. Nathan, A. Ghobrial, I. Antin, J. Parnes, A. TI Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation SO BONE MARROW TRANSPLANTATION LA English DT Letter ID COLD AGGLUTININ DISEASE; WALDENSTROMS MACROGLOBULINEMIA; RITUXIMAB; DEXAMETHASONE; ECULIZUMAB; INHIBITOR; THERAPY C1 [Rotenstein, L.] Harvard Med Sch, Boston, MA USA. [Nathan, A.] Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02115 USA. [Ghobrial, I.; Antin, J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Parnes, A.] Brigham & Womens Hosp, Dept Med, Div Hematol, 75 Francis St, Boston, MA 02115 USA. RP Parnes, A (reprint author), Brigham & Womens Hosp, Dept Med, Div Hematol, 75 Francis St, Boston, MA 02115 USA. EM APARNES@PARTNERS.ORG NR 15 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD NOV PY 2016 VL 51 IS 11 BP 1504 EP 1506 DI 10.1038/bmt.2016.152 PG 3 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA EB3DW UT WOS:000387243700017 PM 27272445 ER PT J AU Tat, MJ Soonsawat, A Nagle, CB Deason, RG O'Connor, MK Budson, AE AF Tat, Michelle J. Soonsawat, Anothai Nagle, Corinne B. Deason, Rebecca G. O'Connor, Maureen K. Budson, Andrew E. TI The influence of strategic encoding on false memory in patients with mild cognitive impairment and Alzheimer's disease dementia SO BRAIN AND COGNITION LA English DT Article DE Alzheimer's disease; False memory; Memory strategies; Mild cognitive impairment ID HEALTHY OLDER-ADULTS; RECALL-TO-REJECT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; CATEGORIZED PICTURES; NATIONAL INSTITUTE; RECOGNITION; GIST; YOUNGER; RECOMMENDATIONS AB Patients with Alzheimer's disease (AD) dementia exhibit high rates of memory distortions in addition to their impairments in episodic memory. Several investigations have demonstrated that when healthy individuals (young and old) engaged in an encoding strategy that emphasized the uniqueness of study items (an item-specific encoding strategy), they were able to improve their discrimination between old items and unstudied critical lure items in a false memory task. In the present study we examined if patients with AD could also improve their memory discrimination when engaging in an item specific encoding strategy. Healthy older adult controls, patients with mild cognitive impairment (MCI) due to AD, and patients with mild AD dementia were asked to study lists of categorized words. In the Item-Specific condition, participants were asked to provide a unique detail or personal experience with each study item. In the Relational condition, they were asked to determine how each item in the list was related to the others. To assess the influence of both strategies, recall and recognition memory tests were administered. Overall, both patient groups exhibited poorer memory in both recall and recognition tests compared to controls. In terms of recognition, healthy older controls and patients with MCI due to AD exhibited improved memory discrimination in the Item-Specific condition compared to the Relational condition, whereas patients with AD dementia did not. We speculate that patients with MCI due to AD use intact frontal networks to effectively engage in this strategy. Published by Elsevier Inc. C1 [Tat, Michelle J.; Soonsawat, Anothai; Nagle, Corinne B.; O'Connor, Maureen K.; Budson, Andrew E.] VA Boston Healthcare Syst, Ctr Translat Cognit Neurosci, Boston, MA USA. [Tat, Michelle J.; Soonsawat, Anothai; Nagle, Corinne B.; O'Connor, Maureen K.; Budson, Andrew E.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA. [Deason, Rebecca G.] Texas State Univ, Dept Psychol, San Marcos, TX USA. [O'Connor, Maureen K.] Edith Nourse Rogers Vet Mem Hosp, Bedford, MA USA. RP Tat, MJ (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave Mailstop 151C, Boston, MA 02130 USA. EM mjtat@bu.edu FU U.S. Veterans Affairs Clinical Science, Research & and Development [ICX000736A]; Boston University Alzheimer's Disease Center FX This research was supported by a U.S. Veterans Affairs Clinical Science, Research & and Development Merit Review Award ICX000736A (AEB) and a Boston University Alzheimer's Disease Center Pilot Grant Award to MJT. Anothai Soonsawat's current affiliation is with the University of California-Los Angeles Department of Psychiatry and Biobehavioral Sciences. This material is also result of work supported with resources and use of facilities at the VA Boston Healthcare System, Boston, MA. NR 46 TC 0 Z9 0 U1 4 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0278-2626 EI 1090-2147 J9 BRAIN COGNITION JI Brain Cogn. PD NOV PY 2016 VL 109 BP 50 EP 58 DI 10.1016/j.bandc.2016.08.003 PG 9 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA EB3XM UT WOS:000387302500007 PM 27643951 ER PT J AU Williams, NR Short, EB Hopkins, T Bentzle, BS Sahlem, GL Pannu, J Schmidt, M Borckardt, JJ Korte, JE George, MS Takacs, I Nahas, Z AF Williams, Nolan R. Short, E. Baron Hopkins, Thomas Bentzle, Brandon S. Sahlem, Greg L. Pannu, Jaspreet Schmidt, Matt Borckardt, Jeff J. Korte, Jeffrey E. George, Mark S. Takacs, Istvan Nahas, Ziad TI Five Year Follow-Up of Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression SO BRAIN STIMULATION LA English DT Article DE Deep brain stimulation; Treatment-resistant depression; Epidural cortical stimulation; Brain stimulation; Interventional psychiatry ID DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX STIMULATION; MAJOR DEPRESSION; RATING-SCALE; INTERVENTIONAL PSYCHIATRY; FUNCTIONAL CONNECTIVITY; NEUROPATHIC PAIN; CONTROLLED-TRIAL; THERAPY AB Background: Epidural prefrontal cortical stimulation (EpCS) represents a novel therapeutic approach with many unique benefits that can be used for treatment-resistant depression (TRD). Objective: To examine the long-term safety and efficacy of EpCS of the frontopolar cortex (FPC) and dorsolateral prefrontal cortex (DLPFC) for treatment of TRD. Methods: Adults (N = 5) who were 21-80 years old with severe TRD [failure to respond to adequate courses of at least 4 antidepressant medications, psychotherapy and >= 20 on the Hamilton Rating Scale for Depression (HRSD24)] were recruited. Participants were implanted with bilateral EpCS over the FPC and DLPFC and received constant, chronic stimulation throughout the five years with Medtronic IPGs. They were followed for 5 years (2/1/2008-10/14/2013). Efficacy of EpCS was assessed with the HRSD24 in an open-label design as the primary outcome measure at five years. Results: All 5 patients continued to tolerate the therapy. The mean improvements from pre-implant baseline on the HRSD24 were [7 months] 54.9% (+/- 37.7), [1 year] 41.2% (+/- 36.6), [2 years] 53.8% (+/- 21.7), and [5 years] 45% (+/- 47). Three of 5 (60%) subjects continued to be in remission at 5 years. There were 5 serious adverse events: 1 electrode 'paddle' infection and 4 device malfunctions, all resulting in suicidal ideation and/or hospitalization. Conclusion: These results suggest that chronic bilateral EpCS over the FPC and DLPFC is a promising and potentially durable new technology for treating TRD, both acutely and over 5 years. (C) 2016 Elsevier Inc. All rights reserved. C1 [Williams, Nolan R.; Bentzle, Brandon S.; Pannu, Jaspreet] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Short, E. Baron; Hopkins, Thomas; Sahlem, Greg L.; Schmidt, Matt; Borckardt, Jeff J.; George, Mark S.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Korte, Jeffrey E.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [George, Mark S.; Takacs, Istvan] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Nahas, Ziad] Amer Univ, Beirut Med Ctr, Beirut, Lebanon. RP Williams, NR (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. EM nolanw@stanford.edu OI Williams, Nolan/0000-0003-4368-3203; Bentzley, Brandon/0000-0001-6014-4514 FU NIH [F30 DA035065, T32 GM008716, R25 DA020537]; National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award FX Medtronic, Inc. (Minneapolis, MN) donated the devices but was otherwise not involved in the study, particularly data acquisition, analysis, or drafting the article. Ziad Nahas, MD, declares no conflict of interest in relation to the work described and was funded by a National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award. Brandon Bentzley, MD, PhD, declares no conflict of interest in relation to the work described and was supported by NIH grants F30 DA035065 and T32 GM008716. Nolan Williams, MD, and Thomas Hopkins, BA, declare no conflict of interest in relation to the work described and were supported by NIH grant R25 DA020537. No other contributors declare a conflict of interest in relation to the work described. NR 72 TC 1 Z9 1 U1 10 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV-DEC PY 2016 VL 9 IS 6 BP 897 EP 904 DI 10.1016/j.brs.2016.06.054 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB2MW UT WOS:000387197500013 PM 27443912 ER PT J AU Badran, BW Glusman, CE Austelle, CW Jenkins, S DeVries, WH Galbraith, V Thomas, T Adams, TG George, MS Revuelta, GJ AF Badran, Bashar W. Glusman, Chloe E. Austelle, Chris W. Jenkins, Shonna DeVries, William H. Galbraith, Virginia Thomas, Tiffani Adams, Thomas G., Jr. George, Mark S. Revuelta, Gonzalo J. TI A Double-Blind, Sham-Controlled Pilot Trial of Pre-Supplementary Motor Area (Pre-SMA) 1 Hz rTMS to Treat Essential Tremor SO BRAIN STIMULATION LA English DT Letter ID TRANSCRANIAL MAGNETIC STIMULATION; CORTEX C1 [Badran, Bashar W.; Glusman, Chloe E.; Austelle, Chris W.; DeVries, William H.; Galbraith, Virginia; George, Mark S.] Med Univ South Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Jenkins, Shonna; George, Mark S.; Revuelta, Gonzalo J.] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA. [Thomas, Tiffani; Revuelta, Gonzalo J.] Med Univ South Carolina, Coll Med, Charleston, SC USA. [Adams, Thomas G., Jr.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Adams, Thomas G., Jr.] VA Natl Ctr PTSD, Clin Neurosci Div, Washington, DC USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Badran, BW (reprint author), MUSC Inst Psychiat, 67 President St,504N, Charleston, SC 29425 USA. EM basharwbadran@gmail.com NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV-DEC PY 2016 VL 9 IS 6 BP 945 EP 947 DI 10.1016/j.brs.2016.08.003 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB2MW UT WOS:000387197500020 PM 27567469 ER PT J AU Whittemore, AS Wang, W Jorgenson, E Asgari, MM AF Whittemore, Alice S. Wang, Wei Jorgenson, Eric Asgari, Maryam M. TI A GWAS of Cutaneous Squamous Cell Carcinoma-Letter SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Letter C1 [Whittemore, Alice S.; Wang, Wei] Stanford Univ, Sch Med, Dept Hlth Res & Policy, HRP Redwood Bldg,Room T204,259 Campus Dr, Stanford, CA 94305 USA. [Jorgenson, Eric; Asgari, Maryam M.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Asgari, Maryam M.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Whittemore, AS (reprint author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, HRP Redwood Bldg,Room T204,259 Campus Dr, Stanford, CA 94305 USA. EM alicesw@stanford.edu FU NCI NIH HHS [R01 CA166672] NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2016 VL 25 IS 11 BP 1534 EP 1534 DI 10.1158/1055-9965.EPI-16-0502 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EB7AI UT WOS:000387537000011 PM 27803070 ER PT J AU Roemer, MGM Advani, RH Redd, RA Pinkus, GS Natkunam, Y Ligon, AH Connelly, CF Pak, CJ Carey, CD Daadi, SE Chapuy, B De Jong, D Hoppe, RT Neuberg, DS Shipp, MA Rodig, SJ AF Roemer, Margaretha G. M. Advani, Ranjana H. Redd, Robert A. Pinkus, Geraldine S. Natkunam, Yasodha Ligon, Azra H. Connelly, Courtney F. Pak, Christine J. Carey, Christopher D. Daadi, Sarah E. Chapuy, Bjoern De Jong, Daphne Hoppe, Richard T. Neuberg, Donna S. Shipp, Margaret A. Rodig, Scott J. TI Classical Hodgkin Lymphoma with Reduced beta M-2/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status SO CANCER IMMUNOLOGY RESEARCH LA English DT Article ID REED-STERNBERG CELLS; MHC CLASS-I; HLA-CLASS-I; PD-1 BLOCKADE; CANCER; RESISTANCE; NIVOLUMAB AB In classical Hodgkin lymphoma (cHL), malignant Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the PD-1 ligands is attributable, in part, to copy number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2). Amplification of PD-L1/PD-L2 is associated with advanced clinical stage and inferior progression-free survival (PFS) following first-line (induction) therapy. The relationships between altered expression of beta(2)-microglobulin (beta M-2), MHC class I, and MHC class II by HRS cells, PD-L1/PD-L2 amplification, and clinical outcome in cHL are poorly defined. We assessed these variables in diagnostic biopsy specimens from 108 patients with cHL who received uniform treatment and had long-term follow-up and found decreased/absent expression of beta M-2/MHC class I in 79% (85/108) and decreased/absent expression of MHC class II in 67% (72/108) of cases. Patients with decreased/absent beta M-2/MHC class I had shorter PFS, independent of PD-L1/PD-L2 amplification and advanced stage. Decreased or absent MHC class II was unrelated to outcome. These results suggest that MHC class I-mediated antigen presentation by HRS cells is an important component of the biological response to standard chemo/radiotherapy. The paucity of beta M-2/MHC class I expression on HRS cells also prompts speculation regarding alternative mechanisms of action of PD-1 blockade in cHL. (C) 2016 AACR. C1 [Roemer, Margaretha G. M.; Connelly, Courtney F.; Pak, Christine J.; Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Roemer, Margaretha G. M.; De Jong, Daphne] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands. [Advani, Ranjana H.; Natkunam, Yasodha; Daadi, Sarah E.; Hoppe, Richard T.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Redd, Robert A.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Pinkus, Geraldine S.; Ligon, Azra H.; Carey, Christopher D.; Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Amory 3rd Floor,75 Francis St, Boston, MA 02115 USA. RP Rodig, SJ (reprint author), Brigham & Womens Hosp, Dept Pathol, Amory 3rd Floor,75 Francis St, Boston, MA 02115 USA. EM srodig@partners.org FU NCI NIH HHS [R01 CA161026] NR 22 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD NOV PY 2016 VL 4 IS 11 BP 910 EP 916 DI 10.1158/2326-6066.CIR-16-0201 PG 7 WC Oncology; Immunology SC Oncology; Immunology GA EB6ZH UT WOS:000387533800003 PM 27737878 ER PT J AU Dou, RX Nishihara, R Cao, Y Mima, THK Masuda, A Masugi, Y Shi, Y Gu, MC Li, WW da Silva, A Nosho, K Zhang, XH Meyerhardt, JA Giovannucci, EL Chan, AT Fuchs, CS Qian, ZR Ogino, S AF Dou, Ruoxu Nishihara, Reiko Cao, Yin Mima, Tsuyoshi Hamada Kosuke Masuda, Atsuhiro Masugi, Yohei Shi, Yan Gu, Mancang Li, Wanwan da Silva, Annacarolina Nosho, Katsuhiko Zhang, Xuehong Meyerhardt, Jeffrey A. Giovannucci, Edward L. Chan, Andrew T. Fuchs, Charles S. Qian, Zhi Rong Ogino, Shuji TI MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer SO CANCER IMMUNOLOGY RESEARCH LA English DT Article ID ISLAND METHYLATOR PHENOTYPE; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; COLON-CANCER; MICROSATELLITE INSTABILITY; BRAF MUTATION; TUMOR MICROENVIRONMENT; EXPRESSION PROFILES; PIK3CA MUTATION; ASPIRIN USE; PROGNOSIS AB Experimental evidence suggests that the let-7 family of non-coding RNAs suppresses adaptive immune responses, contributing to immune evasion by the tumor. We hypothesized that the amount of let-7a and let-7b expression in colorectal carcinoma might be associated with limited T-lymphocyte infiltrates in the tumor microenvironment and worse clinical outcome. Utilizing the molecular pathological epidemiology resources of 795 rectal and colon cancers in two U.S.-nationwide prospective cohort studies, we measured tumor-associated let-7a and let-7b expression levels by quantitative reverse-transcription PCR, and CD3(+), CD8(+), CD45RO (PTPRC)(+), and FOXP3(+) cell densities by tumor tissue microarray immunohistochemistry and computer-assisted image analysis. Logistic regression analysis and Cox proportional hazards regression were used to assess associations of let-7a (and let-7b) expression (quartile predictor variables) with T-cell densities (binary outcome variables) and mortality, respectively, controlling for tumor molecular features, including microsatellite instability, CpG island methylator phenotype, LINE-1 methylation, and KRAS, BRAF, and PIK3CA mutations. Compared with cases in the lowest quartile of let-7a expression, those in the highest quartile were associated with lower densities of CD3_ [multivariate odds ratio (OR), 0.40; 95% confidence interval (CI), 0.23-0.67; P-trend = 0.003] and CD45RO(+) cells (multivariate OR, 0.31; 95% CI, 0.17-0.58; P-trend = 0.0004), and higher colorectal cancer-specific mortality (multivariate hazard ratio, 1.82; 95% CI, 1.42-3.13; P-trend = 0.001). In contrast, let-7b expression was not significantly associated with T-cell density or colorectal cancer prognosis. Our data support the role of let-7a in suppressing antitumor immunity in colorectal cancer and suggest let-7a as a potential target of immunotherapy. (C) 2016 AACR. C1 [Dou, Ruoxu; Nishihara, Reiko; Mima, Tsuyoshi Hamada Kosuke; Masuda, Atsuhiro; Masugi, Yohei; Shi, Yan; Gu, Mancang; Li, Wanwan; da Silva, Annacarolina; Nosho, Katsuhiko; Zhang, Xuehong; Meyerhardt, Jeffrey A.; Giovannucci, Edward L.; Qian, Zhi Rong; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Dou, Ruoxu; Nishihara, Reiko; Mima, Tsuyoshi Hamada Kosuke; Masuda, Atsuhiro; Masugi, Yohei; Shi, Yan; Gu, Mancang; Li, Wanwan; da Silva, Annacarolina; Nosho, Katsuhiko; Zhang, Xuehong; Meyerhardt, Jeffrey A.; Chan, Andrew T.; Fuchs, Charles S.; Qian, Zhi Rong; Ogino, Shuji] Harvard Med Sch, Boston, MA 02115 USA. [Dou, Ruoxu] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China. [Nishihara, Reiko; Cao, Yin; Giovannucci, Edward L.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Nishihara, Reiko; Cao, Yin; Giovannucci, Edward L.; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Nishihara, Reiko; Giovannucci, Edward L.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA. [Nosho, Katsuhiko] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan. [Chan, Andrew T.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ogino, Shuji] Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, 75 Francis St, Boston, MA 02115 USA. RP Qian, ZR (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Qian, ZR (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Ogino, S (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM zhirong_qian@dfci.harvard.edu; shuji_ogino@dfci.harvard.edu OI Masugi, Yohei/0000-0002-6952-4043 FU NCI NIH HHS [R01 CA151993, K07 CA190673, P01 CA055075, P01 CA087969, P50 CA127003, R01 CA118553, R01 CA137178, R35 CA197735, UM1 CA167552, UM1 CA186107]; NIDDK NIH HHS [K24 DK098311] NR 50 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD NOV PY 2016 VL 4 IS 11 BP 927 EP 935 DI 10.1158/2326-6066.CIR-16-0112 PG 9 WC Oncology; Immunology SC Oncology; Immunology GA EB6ZH UT WOS:000387533800005 PM 27737877 ER PT J AU Johnson, DB Frampton, GM Rioth, MJ Yusko, E Xu, YM Guo, XY Ennis, RC Fabrizio, D Chalmers, ZR Greenbowe, J Ali, SM Balasubramanian, S Sun, JX He, YT Frederick, DT Puzanov, I Balko, JM Cates, JM Ross, JS Sanders, C Robins, H Shyr, Y Miller, VA Stephens, PJ Sullivan, RJ Sosman, JA Lovly, CM AF Johnson, Douglas B. Frampton, Garrett M. Rioth, Matthew J. Yusko, Erik Xu, Yaomin Guo, Xingyi Ennis, Riley C. Fabrizio, David Chalmers, Zachary R. Greenbowe, Joel Ali, Siraj M. Balasubramanian, Sohail Sun, James X. He, Yuting Frederick, Dennie T. Puzanov, Igor Balko, Justin M. Cates, Justin M. Ross, Jeffrey S. Sanders, Catherine Robins, Harlan Shyr, Yu Miller, Vincent A. Stephens, Philip J. Sullivan, Ryan J. Sosman, Jeffrey A. Lovly, Christine M. TI Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade SO CANCER IMMUNOLOGY RESEARCH LA English DT Article ID METASTATIC MELANOMA; CTLA-4 BLOCKADE; CANCER; IPILIMUMAB; SENSITIVITY; MUTATIONS; ANTIBODY AB Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce durable responses in a substantial fraction of melanoma patients. We sought to determine whether the number and/or type of mutations identified using a next-generation sequencing (NGS) panel available in the clinic was correlated with response to anti-PD-1 in melanoma. Using archival melanoma samples from anti-PD-1/PD-L1-treated patients, we performed hybrid capture-based NGS on 236-315 genes and T-cell receptor (TCR) sequencing on initial and validation cohorts from two centers. Patients who responded to anti-PD-1/PD-L1 had higher mutational loads in an initial cohort (median, 45.6 vs. 3.9 mutations/MB; P = 0.003) and a validation cohort (37.1 vs. 12.8 mutations/MB; P = 0.002) compared with nonresponders. Response rate, progression-free survival, and overall survival were superior in the high, compared with intermediate and low, mutation load groups. Melanomas with NF1 mutations harbored highmutational loads (median, 62.7 mutations/ MB) and high response rates (74%), whereas BRAF/ NRAS/ NF1 wild-type melanomas had a lower mutational load. In these archival samples, TCR clonality did not predict response. Mutation numbers in the 315 genes in the NGS platform strongly correlated with those detected by whole-exome sequencing in The Cancer Genome Atlas samples, but was not associated with survival. In conclusion, mutational load, as determined by an NGS platform available in the clinic, effectively stratified patients by likelihood of response. This approach may provide a clinically feasible predictor of response to anti-PD-1/ PD-L1. (C) 2016 AACR. C1 [Johnson, Douglas B.; Rioth, Matthew J.; Puzanov, Igor; Balko, Justin M.; Sosman, Jeffrey A.; Lovly, Christine M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Johnson, Douglas B.; Rioth, Matthew J.; Xu, Yaomin; Guo, Xingyi; Puzanov, Igor; Balko, Justin M.; Cates, Justin M.; Shyr, Yu; Sosman, Jeffrey A.; Lovly, Christine M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Rioth, Matthew J.] Vanderbilt Univ, Med Ctr, Dept Bioinformat, Nashville, TN USA. [Xu, Yaomin; Guo, Xingyi; Shyr, Yu] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA. [Balko, Justin M.; Lovly, Christine M.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA. [Cates, Justin M.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. [Frampton, Garrett M.; Ennis, Riley C.; Fabrizio, David; Chalmers, Zachary R.; Greenbowe, Joel; Ali, Siraj M.; Balasubramanian, Sohail; Sun, James X.; He, Yuting; Ross, Jeffrey S.; Miller, Vincent A.; Stephens, Philip J.] Fdn Med Inc, Cambridge, MA USA. [Yusko, Erik; Sanders, Catherine; Robins, Harlan] Adapt Biotechnol, Seattle, WA USA. [Frederick, Dennie T.; Sullivan, Ryan J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Johnson, DB (reprint author), Vanderbilt Univ, Med Ctr, 777 PRB,2220 Pierce Ave, Nashville, TN 37232 USA. EM Douglas.b.johnson@vanderbilt.edu FU NCI NIH HHS [K23 CA204726] NR 27 TC 1 Z9 1 U1 4 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD NOV PY 2016 VL 4 IS 11 BP 959 EP 967 DI 10.1158/2326-6066.CIR-16-0143 PG 9 WC Oncology; Immunology SC Oncology; Immunology GA EB6ZH UT WOS:000387533800008 PM 27671167 ER PT J AU Yokoyama, Y Zhu, HR Lee, JH Kossenkov, AV Wu, SY Wickramasinghe, JM Yin, XF Palozola, KC Gardini, A Showe, LC Zaret, KS Liu, Q Speicher, D Conejo-Garcia, JR Bradner, JE Zhang, ZG Sood, AK Ordog, T Bitler, BG Zhang, RG AF Yokoyama, Yuhki Zhu, Hengrui Lee, Jeong Heon Kossenkov, Andrew V. Wu, Sherry Y. Wickramasinghe, Jayamanna M. Yin, Xiangfan Palozola, Katherine C. Gardini, Alessandro Showe, Louise C. Zaret, Kenneth S. Liu, Qin Speicher, David Conejo-Garcia, Jose R. Bradner, James E. Zhang, Zhiguo Sood, Anil K. Ordog, Tamas Bitler, Benjamin G. Zhang, Rugang TI BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer SO CANCER RESEARCH LA English DT Article ID STEM-CELLS; BROMODOMAIN INHIBITION; SELECTIVE-INHIBITION; TRANSCRIPTION; GENES; RESISTANCE; REVEALS; PROLIFERATION; GLIOBLASTOMA; CARCINOMA AB The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stem-related genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable small-molecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer. C1 [Yokoyama, Yuhki; Zhu, Hengrui; Gardini, Alessandro; Bitler, Benjamin G.; Zhang, Rugang] Wistar Inst Anat & Biol, Gene Express & Regulat Program, 3601 Spruce St, Philadelphia, PA 19104 USA. [Lee, Jeong Heon; Zhang, Zhiguo] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA. [Kossenkov, Andrew V.; Wickramasinghe, Jayamanna M.; Showe, Louise C.] Wistar Inst Anat & Biol, Ctr Syst & Computat Biol, 3601 Spruce St, Philadelphia, PA 19104 USA. [Wu, Sherry Y.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA. [Wu, Sherry Y.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNAi & Noncoding RNA, Houston, TX 77030 USA. [Yin, Xiangfan; Showe, Louise C.; Liu, Qin; Speicher, David] Wistar Inst Anat & Biol, Mol & Cellular Oncol Program, 3601 Spruce St, Philadelphia, PA 19104 USA. [Palozola, Katherine C.; Zaret, Kenneth S.] Univ Penn, Perelman Sch Med, Epigenet Program, Inst Regenerat Med, Philadelphia, PA 19104 USA. [Palozola, Katherine C.; Zaret, Kenneth S.] Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA. [Conejo-Garcia, Jose R.] Wistar Inst Anat & Biol, Tumor Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA. [Bradner, James E.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Zhang, Zhiguo] Mayo Clin, Rochester, MN USA. [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA. RP Zhang, RG (reprint author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA. EM bbitler@wistar.org; rzhang@wistar.org FU NCI NIH HHS [K99 CA194318, P30 CA010815, P50 CA083639, R01 CA160331, R01 CA163377, R01 CA202919] NR 40 TC 0 Z9 0 U1 6 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD NOV 1 PY 2016 VL 76 IS 21 BP 6320 EP 6330 DI 10.1158/0008-5472.CAN-16-0854 PG 11 WC Oncology SC Oncology GA EB5US UT WOS:000387446700021 PM 27803105 ER PT J AU Zheng, BH Jarugumilli, GK Chen, BE Wu, X AF Zheng, Baohui Jarugumilli, Gopala K. Chen, Baoen Wu, Xu TI Chemical Probes to Directly Profile Palmitoleoylation of Proteins SO CHEMBIOCHEM LA English DT Article DE chemical probes; fatty acids; palmitoylation; palmitoleoylation; Wnt ID STEAROYL-COA DESATURASE; S-ACYLTRANSFERASES; WNT PROTEINS; PALMITOYLATION; ACID; INHIBITION; SECRETION; ACYLATION; CANCER; CELLS AB Palmitoleoylation is a unique fatty acylation of proteins in which a monounsaturated fatty acid, palmitoleic acid (C16:1), is covalently attached to a protein. Wnt proteins are known to be palmitoleoylated by cis-9 palmitoleate at conserved serine residues. O-palmitoleoylation plays a critical role in regulating Wnt secretion, binding to the receptors, and in the dynamics of Wnt signaling. Therefore, protein palmitoleoylation is important in tissue homeostasis and tumorigenesis. Chemical probes based on saturated fatty acids, such as -alkynyl palmitic acid (Alk-14 or Alk-C-16), have been used to study Wnt palmitoleoylation. However, such probes require prior conversion to the unsaturated fatty acid by stearoyl-CoA desaturase (SCD) in cells, significantly decreasing their selectivity and efficiency for studying protein palmitoleoylation. We synthesized and characterized -alkynyl cis- and trans-palmitoleic acids (cis- and trans-Alk-14:1) as chemical probes to directly study protein palmitoleoylation. We found that cis-Alk-14:1 could more efficiently label Wnt proteins in cells. Interestingly, the DHHC family of palmitoyl acyltransferases can charge both saturated and unsaturated fatty acids, potentially using both as acyl donors in protein palmitoylation and palmitoleoylation. Furthermore, proteomic analysis of targets labeled by these probes revealed new cis- and trans-palmitoleoylated proteins. Our studies provided new chemical tools and revealed new insights into palmitoleoylation in cell signaling. C1 [Zheng, Baohui; Jarugumilli, Gopala K.; Chen, Baoen; Wu, Xu] Harvard Med Sch, Cutaneous Biol Res Ctr, Massachusetts Gen Hosp, Bldg 149,13th St, Charlestown, MA 02129 USA. RP Wu, X (reprint author), Harvard Med Sch, Cutaneous Biol Res Ctr, Massachusetts Gen Hosp, Bldg 149,13th St, Charlestown, MA 02129 USA. EM xwu@cbrc2.mgh.harvard.edu FU American Cancer Society [124929-RSG-13-291-01-TBE]; National Institutes of Health [R01 CA181537, R01 DK107651] FX This work was supported by a Research Scholar Award from the American Cancer Society (124929-RSG-13-291-01-TBE), and grants from the National Institutes of Health (R01 CA181537 and R01 DK107651) to X.W. We thank Dr. Masaki Fukata for the expression vectors of DHHC proteins, Dr. Marilyn Resh for the plasmid of Porcupine, and the Taplin Mass Spec Core at Harvard Medical School for proteomic studies. NR 33 TC 0 Z9 0 U1 8 U2 8 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA POSTFACH 101161, 69451 WEINHEIM, GERMANY SN 1439-4227 EI 1439-7633 J9 CHEMBIOCHEM JI ChemBioChem PD NOV PY 2016 VL 17 IS 21 BP 2022 EP 2027 DI 10.1002/cbic.201600403 PG 6 WC Biochemistry & Molecular Biology; Chemistry, Medicinal SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA EB1WN UT WOS:000387147100005 PM 27558878 ER PT J AU Palevsky, PM Zhang, JH Seliger, SL Emanuele, N Fried, LF AF Palevsky, Paul M. Zhang, Jane H. Seliger, Stephen L. Emanuele, Nicholas Fried, Linda F. CA VA NEPHRON-D Study TI Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CONVERTING ENZYME-INHIBITOR; GLOMERULAR-FILTRATION-RATE; DOUBLE-BLIND CROSSOVER; ACUTE KIDNEY INJURY; DIABETIC-NEPHROPATHY; RECEPTOR BLOCKER; CONTROLLED-TRIAL; RENAL-DISEASE; METAANALYSIS; TELMISARTAN AB Background and objectives The benefit of dual blockade of the renin-angiotensin system is limited by adverse effects. We performed a secondary analysis of the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) Study to describe the effect of increased intensity Of renin-angiotensin system blockade on the incidence, risk factors, and outcomes of AKI. Design, setting, participants, & measurements In the VA NEPHRON-D Study, we randomized 1148 veterans receiving outpatient care with type 2 diabetes mellitus, eGFR of between 30 and 89.9 ml/min per 1.73 m(2), and urinary albumin excretion of at least 300 mu g/mg creatinine (or a urinary total protein of at least 0.5 mg/mg creatinine) to either combination therapy with losartan and lisinopril or monotherapy with losartan. We identified hospitalized AKI events and their outcomes during a median follow-up of 2.2 years through systematic reporting of serious adverse events. Results The incidence of AKI was 12.2 (95% confidence interval, 10.5 to 14.0) versus 6.7 (95% confidence interval, 5.6 to 8.2) per 100 patient-years in the combination arm versus monotherapy arms (P<0.001). Individuals with AKI were more likely to develop the primary study end point of death, ESRD, or decline in kidney function (hazard ratio; 1.78; 95% confidence interval, 1.34 to 2.26; P<0.001). Patients with AKI in the combination arm had greater recovery of kidney function (75.9% versus 66.3%; P=0.04), lower 30-day mortality (4.7% versus 15.0%; P<0.01), and lower hazard for development of the primary study end point (hazard ratio, 0.60; 95% confidence interval, 0.37 to 0.98). Conclusions Dual renin-angiotensin system blockade was associated with an increased risk of AKI compared with monotherapy, but AKI in the setting of monotherapy was associated with lower rates of recovery of kidney function, higher mortality, and higher risk of progression of kidney disease. C1 [Palevsky, Paul M.; Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv, Pittsburgh, PA USA. [Palevsky, Paul M.; Fried, Linda F.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Zhang, Jane H.] Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Seliger, Stephen L.] Vet Affairs Maryland Healthcare Syst, Med Serv, Baltimore, MD USA. [Seliger, Stephen L.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Emanuele, Nicholas] Edward Hines Jr Vet Affairs Hosp, Med Serv, Hines, IL USA. [Emanuele, Nicholas] Loyola Univ, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Room 7E123,111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM Palevsky@pitt.edu FU Department of Veterans Affairs (VA) Office of Research and Development FX This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs (VA) Office of Research and Development. The Investigator Initiated Studies Program of Merck GmbH donated the study medications losartan and lisinopril/placebo for the study. NR 29 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2016 VL 11 IS 11 BP 1944 EP 1953 DI 10.2215/CJN.03470316 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA EA8DA UT WOS:000386864300007 PM 27679519 ER PT J AU Portale, AA Wolf, MS Messinger, S Perwad, F Juppner, H Warady, BA Furth, SL Salusky, IB AF Portale, Anthony A. Wolf, Myles S. Messinger, Shari Perwad, Farzana Juppner, Harald Warady, Bradley A. Furth, Susan L. Salusky, Isidro B. TI Fibroblast Growth Factor 23 and Risk of CKD Progression in Children SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; VITAMIN-D METABOLISM; CARDIOVASCULAR EVENTS; 25-HYDROXYVITAMIN D; MINERAL METABOLISM; CKID COHORT; MORTALITY AB Background and objectives Plasma fibroblast growth factor 23 (FGF23) concentrations increase early in the course of CKD in children. High FGF23 levels associate with progression of CKD in adults. Whether FGF23 predicts CKD progression in children is unknown. Design, setting, participants, & measurements We tested the hypothesis that high plasma FGF23 is an independent risk factor for CKD progression in 419 children, aged 1-16 years, enrolled in the Chronic Kidney Disease in Children (CKiD) cohort study. We measured plasma FGF23 concentrations at baseline and determined GFR annually using plasma disappearance of iohexol or the CKiD study estimating equation. We analyzed the association of baseline FGF23 with risk of progression to the composite end point, defined as start of dialysis or kidney transplantation or 50% decline from baseline GFR, adjusted for demographics, baseline GFR, proteinuria, other CKD-specific factors, and other mineral metabolites. Results At enrollment, median age was 11 years [interquartile range (IQR), 8-15], GFR was 44 ml/min per 1.73 m(2) (IQR, 33-57), and FGF23 was 132 RU/ml (IQR, 88-200). During a median follow-up of 5.5 years (IQR, 3.5-6.6), 32.5% of children reached the progression end point. Higher FGF23 concentrations were independently associated with higher risk of the composite outcome (fully adjusted hazard ratio, 2.52 in the highest versus lowest FGF23 tertile; 95% confidence interval, 1.44 to 4.39, P=0.002; fully adjusted hazard ratio, 1.33 per doubling of FGF23; 95% confidence interval, 1.13 to 1.56, P=0.001). The time to progression was 40% shorter for participants in the highest compared with the lowest FGF23 tertile. In contrast, serum phosphorus, vitamin D metabolites, and parathyroid hormone did not consistently associate with progression in adjusted analyses. Conclusions High plasma FGF23 is an independent risk factor for CKD progression in children. C1 [Portale, Anthony A.; Perwad, Farzana] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Wolf, Myles S.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Messinger, Shari] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [Juppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA. [Juppner, Harald] Harvard Med Sch, Boston, MA USA. [Warady, Bradley A.] Univ Missouri, Sch Med, Dept Pediat, Kansas City, MO 64108 USA. [Furth, Susan L.] Univ Penn, Dept Pediat, Philadelphia, PA USA. [Salusky, Isidro B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. RP Portale, AA (reprint author), Univ Calif San Francisco, Dept Pediat, Div Pediat Nephrol, 550 16th St,Box 3214, San Francisco, CA 94143 USA. EM anthony.portale@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK) [R01-DK-084978, PO1-DK-11794]; AbbVie; Genzyme Corporation; Pediatric Nephrology Innovative Research Fund; NIDDK; Eunice Kenney Shriver National Institute of Child Health and Human Development; National Heart, Lung and Blood Institute [UO1-DK-66143, UO1-DK-66174, U01-DK-082194, UO1-DK-66116] FX This study was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK; R01-DK-084978 to A.A.P., PO1-DK-11794 (subproject IV) to H.J.], grants from AbbVie and Genzyme Corporation (to A.A.P.), and the Pediatric Nephrology Innovative Research Fund (to A.A.P.). The CKiD study is funded by the NIDDK, Eunice Kenney Shriver National Institute of Child Health and Human Development, and National Heart, Lung and Blood Institute [UO1-DK-66143, UO1-DK-66174, U01-DK-082194, and UO1-DK-66116 (Principal Investigators: S.L.F. and B.A.W.)]. NR 49 TC 1 Z9 1 U1 2 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2016 VL 11 IS 11 BP 1989 EP 1998 DI 10.2215/CJN.02110216 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA EA8DA UT WOS:000386864300012 PM 27561289 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; WARFARIN; APIXABAN; EFFICACY; STROKE; RIVAROXABAN; OUTCOMES; RISK; METAANALYSIS AB Warfarin has had a thin margin of benefit over risk for the prevention of stroke and systemic embolism in patients with ESRD because of higher bleeding risks and complications of therapy. The successful use of warfarin has been dependent on the selection of patients with nonvalvular atrial fibrillation at relatively high risk of stroke and systemic embolism and lower risks of bleeding over the course of therapy. Without such selection strategies, broad use of warfarin has not proven to be beneficial to the broad population of patients with ESRD and nonvalvular atrial fibrillation. In a recent meta-analysis of use of warfarin in patients with nonvalvular atrial fibrillation and ESRD, warfarin had no effect on the risks of stroke (hazard ratio, 1.12; 95% confidence interval, 0.69 to 1.82; P=0.65) or mortality (hazard ratio, 0.96; 95% confidence interval, 0.81 to 1.13; P=0.60) but was associated with increased risk of major bleeding (hazard ratio, 1.30; 95% confidence interval, 1.08 to 1.56; P<0.01). In pivotal trials, novel oral anticoagulants were generally at least equal to warfarin for efficacy and safety in nonvalvular atrial fibrillation and mild to moderate renal impairment. Clinical data for ESRD are limited, because pivotal trials excluded such patients. Given the very high risk of stroke and systemic embolism and the early evidence of acceptable safety profiles of novel oral anticoagulants, we think that patients with ESRD should be considered for treatment with chronic anticoagulation provided that there is an acceptable bleeding profile. Apixaban is currently indicated in ESRD for this application and may be preferable to warfarin given the body of evidence for warfarin and its difficulty of use and attendant adverse events. C1 [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst & Renal El, Renal Sect, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Div, Renal Sect 111F U, Pittsburgh, PA 15240 USA. EM palevsky@cjasn.org FU Baylor Healthcare System Foundation FX This paper was supported, in part, by the Baylor Healthcare System Foundation. NR 34 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2016 VL 11 IS 11 BP 2078 EP 2084 DI 10.2215/CJN.09700916 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA EA8DA UT WOS:000386864300025 PM 27821638 ER PT J AU Naples, JG Gellad, WF Hanlon, JT AF Naples, Jennifer Greene Gellad, Walid F. Hanlon, Joseph T. TI The Role of Opioid Analgesics in Geriatric Pain Management SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Opioid; Aged; Pharmacokinetics; Adverse drug event ID NURSING-HOME RESIDENTS; CHRONIC NONCANCER PAIN; OLDER-ADULTS; RISK; MEDICATIONS; AGE; PEOPLE; PHARMACOKINETICS; FRACTURES; OSTEOARTHRITIS AB When possible, chronic noncancer pain (CNCP) in older adults should be managed by nonpharmacologic modalities in conjunction with nonopioid analgesics. If moderate-to-severe pain persists despite these approaches, however, nonparenteral opioids may be considered as adjunctive therapy. This article reviews the epidemiology of opioid use and their effectiveness for CNCP in older adults and summarizes important age-related changes in opioid pharmacokinetics and pharmacodynamics that increase the risks of adverse effects in the elderly. Finally, to assist clinicians with selecting appropriate therapy, the article concludes with an evidence-based approach to optimize opioid prescribing in older adults with CNCP. C1 [Naples, Jennifer Greene] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Med, Univ Dr,151C, Pittsburgh, PA 15240 USA. [Hanlon, Joseph T.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU National Institute on Aging [T32AG021885, P30AG024827, R01AG037451]; Donoghue Foundation; Agency for Healthcare Research and Quality [R18 HS023779]; VA Health Services Research and Development (HSR&D) Service Merit awards [IIR 12-379, 1 I01 HX001765]; VA HSRD award [I01 HX001765] FX Dr J.G. Naples's fellowship is supported by a National Institute on Aging grant (T32AG021885). Dr J.T. Hanlon is supported by National Institute of Aging grants (P30AG024827 and R01AG037451), a grant from the Donoghue Foundation, a grant from the Agency for Healthcare Research and Quality (R18 HS023779), and VA Health Services Research and Development (HSR&D) Service Merit awards (IIR 12-379 and 1 I01 HX001765). Dr W.F. Gellad is supported by VA HSR&D award I01 HX001765. NR 50 TC 0 Z9 0 U1 8 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2016 VL 32 IS 4 BP 725 EP + DI 10.1016/j.cger.2016.06.006 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA EB2OT UT WOS:000387202400008 PM 27741966 ER PT J AU Chun, BY Rizzo, JF AF Chun, Bo Y. Rizzo, Joseph F., III TI Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation SO CURRENT OPINION IN OPHTHALMOLOGY LA English DT Review DE dominant optic atrophy; mitochondrial dysfunction; optic atrophy 1 gene mutation; retinal ganglion cells ID RETINAL GANGLION-CELLS; CYTOCHROME-C RELEASE; M-AAA PROTEASE; MITOCHONDRIAL FUSION; OPA1 MUTATIONS; PROTEOLYTIC CLEAVAGE; MOUSE MODEL; APOPTOSIS; NEUROPATHIES; MORPHOLOGY AB Purpose of reviewReview recent advances in clinical and experimental studies of dominant optic atrophy (DOA) to better understand the complexities of pathophysiology caused by the optic atrophy 1 (OPA1) mutation.Recent findingsDOA is the most commonly diagnosed inherited optic atrophy, causing progressive bilateral visual loss that begins early in life. During the past 25 years, there has been substantial progress in the understanding of the clinical, genetic, and pathophysiological basis of this disease. The histopathological hallmark of DOA is the primary degeneration of retinal ganglion cells, preferentially in the papillomacular bundle, which results temporal optic disc pallor and cecocentral scotomata in patients with DOA. Loss of OPA1 protein function by OPA1 gene mutations causes mitochondrial dysfunction because of the loss of mitochondrial fusion, impaired mitochondrial oxidative phosphorylation, increases in reactive oxygen species, and altered calcium homeostasis. These factors lead to apoptosis of retinal ganglion cells by a haploinsufficiency mechanism.SummaryImproved understanding of the pathophysiology of DOA provides insights that can be used to develop therapeutic approaches to the DOA. C1 [Chun, Bo Y.; Rizzo, Joseph F., III] Harvard Med Sch, Dept Ophthalmol, Neuroophthalmol Serv, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. [Chun, Bo Y.] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea. RP Rizzo, JF (reprint author), Harvard Med Sch, Dept Ophthalmol, Neuroophthalmol Serv, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM joseph_rizzo@meei.harvard.edu FU Biomedical Research Institute, Kyungpook National University Hospital FX Research on DOA in Korea (B.Y.C.) was supported by Biomedical Research Institute grant, Kyungpook National University Hospital (2012). NR 61 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-8738 EI 1531-7021 J9 CURR OPIN OPHTHALMOL JI Curr. Opin. Ophthalmol. PD NOV PY 2016 VL 27 IS 6 BP 475 EP 480 DI 10.1097/ICU.0000000000000314 PG 6 WC Ophthalmology SC Ophthalmology GA EA1JN UT WOS:000386348500001 PM 27585216 ER PT J AU Gilbert, AL Heidary, G AF Gilbert, Aubrey L. Heidary, Gena TI Update on the evaluation of pediatric idiopathic intracranial hypertension SO CURRENT OPINION IN OPHTHALMOLOGY LA English DT Review DE idiopathic intracranial hypertension; MRI; ocular coherence tomography; optic nerve sheath ultrasound; pseudotumor cerebri ID PSEUDOTUMOR CEREBRI; COHERENCE TOMOGRAPHY; HEALTHY CONTROLS; IMAGING FINDINGS; CHILDREN; ULTRASONOGRAPHY AB Purpose of reviewPapilledema associated with idiopathic intracranial hypertension (IIH) may result in irreversible, progressive visual loss. The development of tools for the evaluation of pediatric patients with IIH is particularly relevant as many patients may not be able to comply with the detailed clinical evaluation utilized in adults for the treatment and management of this disease. The purpose of this review is to summarize relevant articles on the diagnostic tools used in evaluation and management of pediatric IIH.Recent findingsStudies suggest that characteristic pediatric IIH MRI findings include empty sella turcica, decreased pituitary gland size, optic nerve tortuosity, perioptic subarachnoid space enlargement, posterior globe flattering, and intraocular protrusion of the optic nerve head. On optical coherence tomography (OCT), increased retinal nerve fiber layer and macular thickness may be observed in children with IIH compared with controls. The retinal nerve fiber layer thickness seems to coincide with the severity of papilledema and may be more sensitive than funduscopy for detecting optic nerve head elevation. Research on ultrasound of the optic nerve shows increased size of the optic nerve sheath diameter in pediatric IIH patients, and this may correlate with increased opening pressure on lumbar puncture.SummaryThere appears to be characteristic findings on MRI, OCT, and ultrasound studies in pediatric IIH patients. Although ultrasound is rarely used for monitoring these patients nowadays, MRI and OCT can be useful in the evaluation and management of these individuals. C1 [Gilbert, Aubrey L.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. [Gilbert, Aubrey L.] Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. RP Gilbert, AL (reprint author), Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.; Gilbert, AL (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM aubrey_gilbert@meei.harvard.edu OI Heidary, Gena/0000-0002-3557-0420 FU Heed Foundation FX A.L.G. receives research support from the Heed Foundation. NR 13 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-8738 EI 1531-7021 J9 CURR OPIN OPHTHALMOL JI Curr. Opin. Ophthalmol. PD NOV PY 2016 VL 27 IS 6 BP 493 EP 497 DI 10.1097/ICU.0000000000000317 PG 5 WC Ophthalmology SC Ophthalmology GA EA1JN UT WOS:000386348500004 PM 27585209 ER PT J AU Gaier, ED Torun, N AF Gaier, Eric D. Torun, Nurhan TI The enigma of nonarteritic anterior ischemic optic neuropathy: an update for the comprehensive ophthalmologist SO CURRENT OPINION IN OPHTHALMOLOGY LA English DT Review DE ischemic optic neuropathy; neuro-ophthalmology; optic nerve ID SYSTEMIC CORTICOSTEROID-THERAPY; OBSTRUCTIVE SLEEP-APNEA; PHOSPHODIESTERASE-5 INHIBITORS; INTRAVITREAL INJECTION; RECENT-ONSET; VISION LOSS; FELLOW EYE; NEURITIS; NAION; AMIODARONE AB Purpose of reviewNonarteritic anterior ischemic optic neuropathy (NAION) is the most common cause of acute optic nerve injury, and frequently presents to comprehensive ophthalmologists. We review the typical and atypical clinical features and current literature on various treatment modalities for NAION.Recent findingsThe epidemiology and clinical presentation of this disease can be variable, making a definitive diagnosis difficult in many cases. In addition, the differential diagnoses for this disorder, although comprising much less prevalent entities, are quite broad and can have substantial systemic implications if these alternatives go unrecognized. NAION has many systemic associations and comorbidities that deserve inquiry when the diagnosis is made. There are currently no widely accepted, evidence-based treatments for NAION. All recommendations made to patients to reduce their risk of sequential eye involvement, including avoidance of potential nocturnal hypotension, erectile dysfunction medication, and treatment of obstructive sleep apnea, have theoretical bases.SummaryNAION is a common cause of acute vision loss in adult and older patients, and thus, comprehensive ophthalmologists need to be able to diagnose and appropriately manage this disorder. We anticipate fruitful results from current and future trials aimed at neuroprotection in the affected eye and prevention of sequential eye involvement. C1 [Gaier, Eric D.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. [Gaier, Eric D.; Torun, Nurhan] Harvard Med Sch, Boston, MA USA. [Torun, Nurhan] Beth Israel Deaconess Med Ctr, Div Ophthalmol, Boston, MA 02215 USA. RP Gaier, ED (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM Eric_Gaier@meei.harvard.edu NR 43 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-8738 EI 1531-7021 J9 CURR OPIN OPHTHALMOL JI Curr. Opin. Ophthalmol. PD NOV PY 2016 VL 27 IS 6 BP 498 EP 504 DI 10.1097/ICU.0000000000000318 PG 7 WC Ophthalmology SC Ophthalmology GA EA1JN UT WOS:000386348500005 PM 27585212 ER PT J AU Saeed, HN Chodosh, J AF Saeed, Hajirah N. Chodosh, James TI Ocular manifestations of Stevens-Johnson syndrome and their management SO CURRENT OPINION IN OPHTHALMOLOGY LA English DT Review DE amniotic membrane; ocular surface; Stevens-Johnson syndrome; toxic epidermal necrolysis ID TOXIC EPIDERMAL NECROLYSIS; OSTEO-ODONTO-KERATOPROSTHESIS; AMNIOTIC MEMBRANE TRANSPLANTATION; BOSTON KERATOPROSTHESIS; ERYTHEMA MULTIFORME; DISEASE; COMPLICATIONS; INVOLVEMENT; THERAPY; ENDOPHTHALMITIS AB Purpose of reviewRecent advances and outcomes data in the management of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) demonstrate the need for a universal standard of care for patients admitted with the disease.Recent findingsAmniotic membrane transplantation, aggressive topical corticosteroids, and lubrication in the acute stage are necessary to prevent or mitigate long-term ocular sequelae. If chronic ocular disease does occur, several interventions can be employed to prevent progressive vision loss and discomfort. The earliest interventions are the ones most likely to prevent chronic complications.SummaryThe literature overwhelmingly describes acute intervention for ocular involvement in SJS/TEN as improving long-term outcomes. All patients admitted for SJS/TEN or suspicion of SJS/TEN should be evaluated and then closely followed by ophthalmologists. As the disease progresses, the interventions needed for visual rehabilitation become more invasive and higher risk. C1 [Saeed, Hajirah N.; Chodosh, James] Harvard Med Sch, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. RP Saeed, HN (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Hajirah_Saeed@meei.harvard.edu FU Research to Prevent Blindness, New York, New York, USA FX This work was supported by an unrestricted grant from Research to Prevent Blindness, New York, New York, USA. NR 49 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-8738 EI 1531-7021 J9 CURR OPIN OPHTHALMOL JI Curr. Opin. Ophthalmol. PD NOV PY 2016 VL 27 IS 6 BP 522 EP 529 DI 10.1097/ICU.0000000000000312 PG 8 WC Ophthalmology SC Ophthalmology GA EA1JN UT WOS:000386348500008 PM 27585215 ER PT J AU Forster, SE Finn, PR Brown, JW AF Forster, Sarah E. Finn, Peter R. Brown, Joshua W. TI A preliminary study of longitudinal neuroadaptation associated with recovery from addiction SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE fMRI; Treatment outcome; Decision-making; Balloon analogue risk task; Anterior cingulate cortex; Ventromedial prefrontal cortex; Monetary reward ID MEDIAL PREFRONTAL CORTEX; RISK-TASK BART; METHAMPHETAMINE-DEPENDENT INDIVIDUALS; SUBSTANCE USE DISORDERS; COCAINE DEPENDENCE; COGNITIVE CONTROL; TEST-RETEST; FOLLOW-UP; ABSTINENT ALCOHOLICS; NEURAL ACTIVATION AB Background: Few studies have explored longitudinal change in event-related brain responses during early recovery from addiction. Moreover, existing findings yield evidence of both increased and decreased signaling within reward and control centers over time. The current study explored reward- and control related signals in a risky decision-making task and specifically investigated parametric modulations of the BOLD signal, rather than signal magnitude alone. It was hypothesized that risk-related signals during decision-making and outcome evaluation would reflect recovery and that change in specific signals would correspond with improved treatment outcomes. Methods: Twenty-one substance dependent individuals were recruited upon enrollment in community based substance use treatment programs, wherein they received treatment-as-usual. Participants completed functional neuroimaging assessments at baseline and 3-month follow-up while performing the Balloon Analogue Risk Task (BART). Risk- and reward-sensitive signals were identified using parametric modulators. Substance use was tracked throughout the 3-month study interval using the timeline follow-back procedure. Results: Longitudinal contrasts of parametric modulators suggested improved formation of risk-informed outcome expectations at follow-up. Specifically, a greater response to high risk (low-likelihood) positive feedback was identified in caudal anterior cingulate cortex (ACC) and a greater response to low risk (low-likelihood) negative feedback was identified in caudal ACC and inferior frontal gyrus. In addition, attenuation of a ventromedial prefrontal cortex (vmPFC) "reward-seeking" signal (i.e., increasing response with greater reward) during risky decisions at follow-up was associated with less substance use during the study interval. Conclusions: Changes in risk- and reward-related signaling in ACC/vmPFC appear to reflect recovery and may support sobriety. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Forster, Sarah E.; Finn, Peter R.; Brown, Joshua W.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA. [Forster, Sarah E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Forster, Sarah E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. RP Brown, JW (reprint author), Indiana Univ, 1101 E 10th St, Bloomington, IN 47405 USA. EM jwmbrown@indiana.edu FU NIH [DA026457, AA13650]; [TL1 RR025759] FX This research was supported by NIH R01 grant DA026457 to JWB and NIH R01 grant AA13650 to PRF. SEF was partly supported by TL1 RR025759 (A. Shekhar, PI) during early stages of the project. The authors would also like to thank William Hetrick, PhD and Brian O'Donnell, PhD for helpful comments on the dissertation of which this work was a part. NR 45 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2016 VL 168 BP 52 EP 60 DI 10.1016/j.drugalcdep.2016.08.626 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EB6VN UT WOS:000387523800008 PM 27620345 ER PT J AU McGinnis, KA Tate, JP Williams, EC Skanderson, M Bryant, KJ Gordon, AJ Kraemer, KL Maisto, SA Crystal, S Fiellin, DA Justice, AC AF McGinnis, Kathleen A. Tate, Janet P. Williams, Emily C. Skanderson, Melissa Bryant, Kendall J. Gordon, Adam J. Kraemer, Kevin L. Maisto, Stephen A. Crystal, Steven Fiellin, David A. Justice, Amy C. TI Comparison of AUDIT-C collected via electronic medical record and self-administered research survey in HIV infected and uninfected patients SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol consumption; Population-based screening; AUDIT-C; Electronic health record; Veterans; HIV ID RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE; PRIMARY-CARE; HEAVY DRINKING; BRIEF INTERVENTION; UNHEALTHY ALCOHOL; SCREENING-TEST; DRUG-USE; VETERANS; QUALITY AB Background: Using electronic medical record (EMR) data for clinical decisions, quality improvement, and research is common. While unhealthy alcohol use is particularly risky among HIV infected individuals (HIV+), the validity of EMR data for identifying unhealthy alcohol use among HIV+ is unclear. Among HIV+ and uninfected, we: (1) assess agreement of EMR and research AUDIT-C at validated cutoffs for unhealthy alcohol use; (2) explore EMR cutoffs that maximize agreement; and (3) assess subpopulation variation in agreement. Methods: Using data from the Veterans Aging Cohort Study (VACS), EMR AUDIT-C cutoffs of 2+, 3+, and 4+ for men (2+ and 3+ for women) were compared to research AUDIT-C 4+ for men (3+ for women). Agreement was compared by demographics, HIV, hepatitis C infection, and alcohol related diagnosis. Results: Among 1082 HIV+ and 1160 uninfected men, 14% and 22% had an EMR and research AUDIT-C 4+, respectively. Among 32 HIV+ and 115 uninfected women, 9% and 14% had an EMR and research AUDIT-C 3+. For men, EMR agreement with the research AUDIT-C 4+ was highest at a cutoff of 3+ (kappa = 0.49). For women, EMR agreement with AUDIT-C 3+ was highest at a cutoff of 2+ (kappa =0.46). Moderate agreement was consistent across subgroups. Conclusions: EMR AUDIT-C underestimates unhealthy alcohol use compared to research AUDIT-C in both HIV+ and uninfected individuals. Methods for improving quality of clinical screening may be in need of investigation. Researchers and clinicians may consider alternative EMR cutoffs that maximize agreement given limitations of clinical screening. Published by Elsevier Ireland Ltd. C1 [McGinnis, Kathleen A.; Tate, Janet P.; Skanderson, Melissa; Fiellin, David A.; Justice, Amy C.] VA CT Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. [Tate, Janet P.; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA. [Williams, Emily C.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Williams, Emily C.] VA Hlth Serv Res & Dev, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Seattle, WA USA. [Bryant, Kendall J.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Gordon, Adam J.; Kraemer, Kevin L.] Natl Inst Alcohol Abuse & Alcoholism, Bethesda, MD USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Maisto, Stephen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Crystal, Steven] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Fiellin, David A.; Justice, Amy C.] Rutgers State Univ, Hlth Serv Res, New Brunswick, NJ USA. RP McGinnis, KA (reprint author), VA CT Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. EM kathleen.mcginnis3@va.gov OI Fiellin, David/0000-0002-4006-010X FU National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism [U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U10 AA013566]; Career Development Award from VA Health Services Research Development [CDA 12-276] FX The views are not those of the Department of Veterans Affairs or the United States Government. COMpAAAS/Veterans Aging Cohort Study, a CHAART Cooperative Agreement, is supported by the National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799; U10 AA013566-completed) and in kind by the US Department of Veterans Affairs. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). NR 39 TC 0 Z9 0 U1 10 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2016 VL 168 BP 196 EP 202 DI 10.1016/j.drugalcdep.2016.09.015 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EB6VN UT WOS:000387523800028 PM 27694059 ER PT J AU Antonny, B Burd, C De Camilli, P Chen, E Daumke, O Faelber, K Ford, M Frolov, VA Frost, A Hinshaw, JE Kirchhausen, T Kozlov, MM Lenz, M Low, HH McMahon, H Merrifield, C Pollard, TD Robinson, PJ Roux, A Schmid, S AF Antonny, Bruno Burd, Christopher De Camilli, Pietro Chen, Elizabeth Daumke, Oliver Faelber, Katja Ford, Marijn Frolov, Vadim A. Frost, Adam Hinshaw, Jenny E. Kirchhausen, Tom Kozlov, Michael M. Lenz, Martin Low, Harry H. McMahon, Harvey Merrifield, Christien Pollard, Thomas D. Robinson, Phillip J. Roux, Aurelien Schmid, Sandra TI Membrane fission by dynamin: what we know and what we need to know SO EMBO JOURNAL LA English DT Review DE dynamin; membrane fission; endocytosis; GTPase; molecular motor ID CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; DEPENDENT CONFORMATIONAL-CHANGES; DOMAIN-CONTAINING PROTEINS; MITOCHONDRIAL FISSION; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; BAR DOMAINS; COATED-PIT; MECHANOCHEMICAL ENZYME AB The large GTPase dynamin is the first protein shown to catalyze membrane fission. Dynamin and its related proteins are essential to many cell functions, from endocytosis to organelle division and fusion, and it plays a critical role in many physiological functions such as synaptic transmission and muscle contraction. Research of the past three decades has focused on understanding how dynamin works. In this review, we present the basis for an emerging consensus on how dynamin functions. Three properties of dynamin are strongly supported by experimental data: first, dynamin oligomerizes into a helical polymer; second, dynamin oligomer constricts in the presence of GTP; and third, dynamin catalyzes membrane fission upon GTP hydrolysis. We present the two current models for fission, essentially diverging in how GTP energy is spent. We further discuss how future research might solve the remaining open questions presently under discussion. C1 [Antonny, Bruno] Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, Valbonne, France. [Burd, Christopher] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA. [De Camilli, Pietro] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, New Haven, CT 06510 USA. [De Camilli, Pietro] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA. [De Camilli, Pietro] Yale Univ, Sch Med, Kavli Inst Neurosci, New Haven, CT USA. [Chen, Elizabeth] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA. [Daumke, Oliver; Faelber, Katja] Max Delbruck Ctr Mol Med, Dept Crystallog, Berlin, Germany. [Ford, Marijn] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA USA. [Frolov, Vadim A.] Univ Basque Country, CSIC, Biofis Inst, Leioa, Spain. [Frolov, Vadim A.] Univ Basque Country, Dept Biochem & Mol Biol, Leioa, Spain. [Frolov, Vadim A.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain. [Frost, Adam] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. [Hinshaw, Jenny E.] NIDDK, Lab Cell & Mol Biol, NIH, Bethesda, MD 20892 USA. [Kirchhausen, Tom] Harvard Med Sch, Dept Cell Biol, Boston, MA USA. [Kirchhausen, Tom] Harvard Med Sch, Dept Pediat, Boston, MA USA. [Kirchhausen, Tom] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Kozlov, Michael M.] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Tel Aviv, Israel. [Lenz, Martin] Univ Paris Saclay, Univ Paris Sud, CNRS, LPTMS, Orsay, France. [Low, Harry H.] Imperial Coll, Dept Life Sci, London, England. [McMahon, Harvey] MRC Lab Mol Biol, Cambridge, England. [Merrifield, Christien] Inst Integrat Biol Cell, Gif Sur Yvette, France. [Pollard, Thomas D.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA. [Robinson, Phillip J.] Univ Sydney, Childrens Med Res Inst, Cell Signalling Unit, Westmead, NSW, Australia. [Roux, Aurelien] Univ Geneva, Dept Biochem, Geneva 4, Switzerland. [Roux, Aurelien] Univ Geneva, Swiss NCCR Chem Biol, Geneva 4, Switzerland. [Schmid, Sandra] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA. RP Roux, A (reprint author), Univ Geneva, Dept Biochem, Geneva 4, Switzerland.; Roux, A (reprint author), Univ Geneva, Swiss NCCR Chem Biol, Geneva 4, Switzerland. EM aurelien.roux@unige.ch OI Robinson, Phillip J./0000-0002-7878-0313; Lenz, Martin/0000-0002-2307-1106 FU Medical Research Council [MC_U105178795] NR 114 TC 3 Z9 3 U1 24 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0261-4189 EI 1460-2075 J9 EMBO J JI Embo J. PD NOV PY 2016 VL 35 IS 21 BP 2270 EP 2284 DI 10.15252/embj.201694613 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EB1VA UT WOS:000387142500003 PM 27670760 ER PT J AU Morotti, A Goldstein, JN AF Morotti, Andrea Goldstein, Joshua N. TI Diagnosis and Management of Acute Intracerebral Hemorrhage SO EMERGENCY MEDICINE CLINICS OF NORTH AMERICA LA English DT Article DE Intracerebral hemorrhage; Hemorrhagic stroke; Neurocritical care; Blood pressure; Coagulopathy; Hematoma expansion ID ASSOCIATION/AMERICAN STROKE ASSOCIATION; PROTHROMBIN COMPLEX CONCENTRATE; MINIMALLY INVASIVE SURGERY; HEALTH-CARE PROFESSIONALS; ACUTE ISCHEMIC-STROKE; INITIAL CONSERVATIVE TREATMENT; RANDOMIZED CONTROLLED-TRIAL; INTRAVENTRICULAR HEMORRHAGE; ORAL ANTICOAGULANTS; HEMATOMA EXPANSION AB Intracerebral hemorrhage (ICH) is the deadliest type of stroke and up to half of patients die in hospital. Blood pressure management, coagulopathy reversal, and intracranial pressure control are the mainstays of acute ICH treatment. Prevention of hematoma expansion and minimally invasive hematoma evacuation are promising therapeutic strategies under investigation. This article provides an updated review on ICH diagnosis and management in the emergency department. C1 [Morotti, Andrea; Goldstein, Joshua N.] Harvard Med Sch, Massachusetts Gen Hosp, JP Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. [Goldstein, Joshua N.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. RP Goldstein, JN (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. EM jgoldstein@partners.org FU NINDS [5R01NS073344] FX NINDS award 5R01NS073344. NR 88 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8627 EI 1558-0539 J9 EMERG MED CLIN N AM JI Emerg. Med. Clin. N. Am. PD NOV PY 2016 VL 34 IS 4 BP 883 EP + DI 10.1016/j.emc.2016.06.010 PG 18 WC Emergency Medicine SC Emergency Medicine GA EB1EL UT WOS:000387092300012 PM 27741993 ER PT J AU Edlow, AG Edlow, BL Edlow, JA AF Edlow, Andrea G. Edlow, Brian L. Edlow, Jonathan A. TI Diagnosis of Acute Neurologic Emergencies in Pregnant and Postpartum Women SO EMERGENCY MEDICINE CLINICS OF NORTH AMERICA LA English DT Article DE Eclampsia; Posterior reversible encephalopathy syndrome; Reversible cerebrovascular constriction syndrome; Cerebral venous sinus thrombosis; Pregnancy ID REVERSIBLE ENCEPHALOPATHY SYNDROME; CEREBRAL VASOCONSTRICTION SYNDROME; CERVICAL ARTERY DISSECTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; INTRACRANIAL VENOUS THROMBOSIS; AMNIOTIC-FLUID EMBOLISM; OF-THE-LITERATURE; RISK-FACTORS; UNITED-STATES AB Acute neurologic symptoms in pregnant and postpartum women may be caused by exacerbation of a preexisting neurologic condition, the initial presentation of a non pregnancy-related problem, or a new neurologic problem. Pregnant and postpartum patients with headache and neurologic symptoms are often diagnosed with preeclampsia or eclampsia; however, other etiologies must also be considered. A team approach with close communication between emergency physicians, neurologists, maternal fetal medicine specialists, and radiologists is the key to obtaining best outcomes. This article reviews the clinical features and differential diagnosis of acute serious neurologic conditions in pregnancy and the puerperium, focusing on diagnosis. C1 [Edlow, Andrea G.] Tufts Med Ctr, Mother Infant Res Inst, Dept Obstet & Gynecol, Div Maternal Fetal Med, 800 Washington St,Box 394, Boston, MA 02111 USA. [Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. [Edlow, Jonathan A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Emergency Med, One Deaconess Pl,West Clin Ctr,2nd Floor, Boston, MA 02215 USA. RP Edlow, JA (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Emergency Med, One Deaconess Pl,West Clin Ctr,2nd Floor, Boston, MA 02215 USA. EM jedlow@bidmc.harvard.edu NR 153 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8627 EI 1558-0539 J9 EMERG MED CLIN N AM JI Emerg. Med. Clin. N. Am. PD NOV PY 2016 VL 34 IS 4 BP 943 EP + DI 10.1016/j.emc.2016.06.014 PG 24 WC Emergency Medicine SC Emergency Medicine GA EB1EL UT WOS:000387092300015 PM 27741996 ER PT J AU Findling, JW Fleseriu, M Newell-Price, J Petersenn, S Pivonello, R Kandra, A Pedroncelli, AM Biller, BMK AF Findling, James W. Fleseriu, Maria Newell-Price, John Petersenn, Stephan Pivonello, Rosario Kandra, Albert Pedroncelli, Alberto M. Biller, Beverly M. K. TI Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study SO ENDOCRINE LA English DT Article DE Pasireotide; Cushing's disease; Salivary cortisol; Urinary free cortisol ID URINARY FREE CORTISOL; PITUITARY SURGERY; DIAGNOSIS; HYPERCORTISOLISM; UPDATE; TOOL AB Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism. This analysis reports changes in late-night salivary cortisol (LNSC) during a 12-month, multicentre, Phase III study of patients with Cushing's disease who were randomized to pasireotide 600 or 900 mu g sc bid. LNSC assessment was an exploratory objective based on a single, optional measurement at midnight +/- A 1 h on the same day as one of the 24-h urinary free cortisol (UFC) measurements. Of 162 enrolled patients, baseline LNSC was measured in 93. Sixty-seven patients had levels above the upper limit of normal (ULN); median baseline levels were 19.7 and 20.7 nmol/L in the groups subsequently randomized to 600 mu g (n = 40) and 900 mu g (n = 27), respectively. Median LNSC levels decreased from baseline to month 12; median changes in patients who had baseline LNSC > ULN in the 600 and 900 mu g groups were -13.4 nmol/L (-52.6 %; n = 19) and -11.8 nmol/L (-56.1 %; n = 14), respectively. LNSC normalized at months 6 and 12 in 25/67 (37.3 %) and 13/67 (19.4 %) patients, respectively; 10/25 and 8/13 patients also had normalized UFC, and 7/25 and 4/13 had partial UFC control (UFC > ULN and aeyen50 % decrease from baseline). There was a moderate correlation (r = 0.55) on the log scale between individual patient LNSC and UFC values when all time points were pooled. Pasireotide decreased LNSC levels during 12 months of treatment. Salivary cortisol may be a simple, convenient biomarker for assessing treatment response in patients with Cushing's disease. C1 [Findling, James W.] Med Coll Wisconsin, Div Endocrinol Metab & Clin Nutr, W129 N7055 Northfield Dr Suite A 203,Menomonee Fa, Milwaukee, WI 53051 USA. [Fleseriu, Maria] Oregon Hlth & Sci Univ, Dept Med & Neurol Surg, NW Pituitary Ctr, Portland, OR 97239 USA. [Newell-Price, John] Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England. [Petersenn, Stephan] ENDOC Ctr Endocrine Tumors, Hamburg, Germany. [Pivonello, Rosario] Univ Naples Federico II, Dipartimento Med Clin & Chirurgia, Endocrinol & Metabol, Naples, Italy. [Kandra, Albert; Pedroncelli, Alberto M.] Novartis Pharma AG, Basel, Switzerland. [Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA. RP Findling, JW (reprint author), Med Coll Wisconsin, Div Endocrinol Metab & Clin Nutr, W129 N7055 Northfield Dr Suite A 203,Menomonee Fa, Milwaukee, WI 53051 USA. EM jfindling@mcw.edu FU Novartis Pharma AG; Novartis Pharmaceuticals Corporation FX This study was funded by Novartis Pharma AG. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. NR 35 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD NOV PY 2016 VL 54 IS 2 BP 516 EP 523 DI 10.1007/s12020-016-0978-6 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EB3BD UT WOS:000387235500024 PM 27209465 ER PT J AU Meijers, WC de Boer, RA Ho, JE AF Meijers, Wouter C. de Boer, Rudolf A. Ho, Jennifer E. TI Biomarkers to identify and prevent new-onset heart failure in the community SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Editorial Material ID REDUCED EJECTION FRACTION; COLLABORATIVE CARE; RISK; POPULATION; COHORT C1 [Meijers, Wouter C.; de Boer, Rudolf A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands. [Ho, Jennifer E.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP de Boer, RA (reprint author), Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands. EM r.a.de.boer@umcg.nl NR 13 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD NOV PY 2016 VL 18 IS 11 BP 1351 EP 1352 DI 10.1002/ejhf.636 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB4LS UT WOS:000387343900008 PM 27813301 ER PT J AU de Vries, YA Roest, AM Beijers, L Turner, EH de Jonge, P AF de Vries, Ymkje Anna Roest, Annelieke M. Beijers, Lian Turner, Erick H. de Jonge, Peter TI Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Article DE Bias; Antidepressants; Depression; Anxiety; Harms ID RANDOMIZED CONTROLLED-TRIAL; CONTROLLED-RELEASE FLUVOXAMINE; DOUBLE-BLIND; PANIC DISORDER; MAJOR DEPRESSION; SERTRALINE TREATMENT; EXTENDED-RELEASE; RESULTS DATABASE; VENLAFAXINE ER; PLACEBO AB Previous research has shown that reporting bias has inflated the apparent efficacy of antidepressants. We investigated whether apparent safety was also affected. We included 133 trials, involving 31,296 patients, of second-generation antidepressants for the treatment of major depressive disorder (MDD) or anxiety disorders, obtained from Food and Drug Administration (FDA) reviews. We extracted data on overall discontinuation, discontinuation due to adverse events, and serious adverse events (SAEs). Meta-analysis was used to compare discontinuation rates between FDA reviews and matching journal articles, while SAEs were compared qualitatively. The odds ratio for overall discontinuation, comparing drug to placebo, was 1.0 for both sources, while that for discontinuation due to adverse events was 2.4 for both sources. Seventy-seven of 97 (79%) journal articles provided incomplete information on SAEs; sixty-one (63%) articles made no mention of SAEs at all. Of 21 articles which could be compared to the FDA, only 6 (29%) had full reporting without discrepancies. Nine (43%) articles reported a discrepant number of SAEs. Descriptions were absent or discrepant in 6 (29%) additional articles, even for important SAEs such as suicide attempts. In conclusion, reporting bias has not affected average discontinuation rates over trials. However, SAE reporting is not only very poor, with over half of articles failing to discuss SAEs altogether, but discrepancies between the FDA and articles were common and often led to a more favorable drug-placebo comparison.These findings suggest that journal articles are an unreliable source of data on SAEs in antidepressant trials. (C) 2016 Elsevier B.V. and ECNP. All rights reserved. C1 [de Vries, Ymkje Anna; Roest, Annelieke M.; Beijers, Lian; de Jonge, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands. [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [de Jonge, Peter] Univ Groningen, Dept Psychol, Dev Psychol, Groningen, Netherlands. RP de Vries, YA (reprint author), Univ Med Ctr Groningen, Dept Psychiat, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM y.a.de.vries@umcg.nl NR 50 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X EI 1873-7862 J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD NOV PY 2016 VL 26 IS 11 BP 1752 EP 1759 DI 10.1016/j.euroneuro.2016.09.370 PG 8 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA EB6VL UT WOS:000387523600003 PM 27659240 ER PT J AU Kim, J Nafiujjaman, M Nurunnabi, M Lee, YK Park, HK AF Kim, Jeongho Nafiujjaman, Md Nurunnabi, Md Lee, Yong-Kyu Park, Hun-Kuk TI Hemorheological characteristics of red blood cells exposed to surface functionalized graphene quantum dots SO FOOD AND CHEMICAL TOXICOLOGY LA English DT Article DE Toxicology; Graphene quantum dot; Red blood cell; Haemolysis; Aggregation; Deformability ID IN-VITRO; PHOTOVOLTAIC DEVICES; SILVER NANOPARTICLES; NANOMATERIALS; TOXICITY; OXIDE; CYTOTOXICITY; AGGREGATION; SYSTEM AB Graphene quantum dots (GQDs) are potential candidates for various biomedical applications such as drug delivery, bioimaging, cell labeling, and biosensors. However, toxicological information on their effects on red blood cells (RBCs) and the mechanisms involved remain unexplored. To the best of our knowledge, our study is the first to investigate the toxicity effects of three GQDs with different surface functionalizations on the hemorheological characteristics of human RBCs, including hemolysis, deformability, aggregation, and morphological changes. RBCs were exposed to three different forms of GQDs (non-functionalized, hydroxylated, and carboxylated GQDs) at various concentrations (0, 500, 750, and 1000 mu g/mL) and incubation times (0, 1, 2, 3, or 4 h). The rheological characteristics of the RBCs were measured using microfluidic-laser diffractometry and aggregometry. Overall, the hemolysis rate and rheological alterations of the RBCs were insignificant at a concentration less than 500 mu g/mL. Carboxylated GQDs were observed to have more substantial hemolytic activity and caused abrupt changes in the deformability and aggregation of the RBCs than the non-functionalized or hydroxylated GQDs at concentrations >750 mu g/mL. Our findings indicate that hemorheological assessments could be utilized to estimate the degree of toxicity to cells and to obtain useful information on safety sheets for nanomaterials. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Kim, Jeongho; Park, Hun-Kuk] Kyung Hee Univ, Coll Med, Dept Biomed Engn, 26 Kyungheedae Ro, Seoul 02447, South Korea. [Nafiujjaman, Md; Lee, Yong-Kyu] Korea Natl Univ Transportat, Dept Green Bioengn, Chungju Si 380702, Chunbuk, South Korea. [Nurunnabi, Md] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Nurunnabi, Md] Harvard Med Sch, Boston, MA 02114 USA. [Lee, Yong-Kyu] Korea Natl Univ Transportat, Dept Chem & Biol Engn, Chungju Si 380702, Chunbuk, South Korea. RP Park, HK (reprint author), Kyung Hee Univ, Coll Med, Dept Biomed Engn, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Lee, YK (reprint author), Korea Natl Univ Transportat, Dept Green Bioengn, Chungju Si 380702, Chunbuk, South Korea. EM leeyk@ut.ac.kr; sigmoidus@khu.ac.kr OI Nurunnabi, Md/0000-0003-4457-3401 FU Technology Innovation Program - Ministry of Trade, Industry and Energy (MI, Korea) [10054687] FX This research was supported by the Technology Innovation Program (No. 10054687) funded by the Ministry of Trade, Industry and Energy (MI, Korea). NR 34 TC 0 Z9 0 U1 19 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-6915 EI 1873-6351 J9 FOOD CHEM TOXICOL JI Food Chem. Toxicol. PD NOV PY 2016 VL 97 BP 346 EP 353 DI 10.1016/j.fct.2016.09.034 PG 8 WC Food Science & Technology; Toxicology SC Food Science & Technology; Toxicology GA EB8FN UT WOS:000387627000036 PM 27697543 ER PT J AU Nam, H Guinan, JJ AF Nam, Hui Guinan, John J., Jr. TI Low-frequency bias tone suppression of auditory-nerve responses to low-level clicks and tones SO HEARING RESEARCH LA English DT Article DE Auditory nerve; Cochlear mechanics; Micromechanics; Peak splitting ID GUINEA-PIG COCHLEA; LOW-SIDE SUPPRESSORS; OUTER HAIR-CELLS; 2-TONE SUPPRESSION; BASILAR-MEMBRANE; MAMMALIAN COCHLEA; FIBERS; INNER; MODULATION; SENSITIVITY AB We used low-frequency "bias" tones (BT's) to explore whether click and tone responses are affected in the same way by cochlear active processes. In nonlinear systems the responses to clicks are not always simply related to the responses to tones. Cochlear amplifier gain depends on the incremental slope of the outer-hair-cell (OHC) stereocilia mechano-electric transduction (MET) function. BTs transiently change the operating-point of OHC MET channels and can suppress cochlear-amplifier gain by pushing OHC METs into low-slope saturation regions. BT effects on single auditory-nerve (AN) fibers have been studied on tone responses but not on click responses. We recorded from AN fibers in anesthetized cats and compared tone and click responses using 50 Hz BTs at 70-120 dB SPL to manipulate OHC stereocilia position. BTs can also excite and thereby obscure the BT suppression. We measured AN-fiber response synchrony to BTs alone so that we could exclude suppression measurements when the BT synchrony might obscure the suppression. BT suppression of low-level tone and click responses followed the traditional pattern of twice-a-BT-cycle suppression with more suppression at one phase than the other. The major suppression phases of most fibers were tightly grouped with little difference between click and tone suppressions, which is consistent with low-level click and tone responses being amplified in the same way. The data are also consistent with the operating point of the OHC MET function varying smoothly from symmetric in the base to offset in the apex, and, in contrast, with the IHC MET function being offset throughout the cochlea. As previously reported, bias-tones presented alone excited AN fibers at one or more phases, a phenomena termed "peak splitting" with most BT excitation phases similar to 1/4 cycle before or after the major suppression phase. We explain peak splitting as being due to distortion in multiple fluid drives to inner-hair-cell stereocilia. (C) 2016 Elsevier B.V. All rights reserved. C1 [Nam, Hui; Guinan, John J., Jr.] Eaton Peabody Lab, Mass Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. [Nam, Hui; Guinan, John J., Jr.] Harvard MIT HST Speech & Hearing Biosci & Technol, Cambridge, MA USA. [Guinan, John J., Jr.] Harvard Med Sch, Boston, MA USA. RP Guinan, JJ (reprint author), Eaton Peabody Lab, Mass Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM hnam@alum.mit.edu; john_guinan@meei.harvard.edu OI Guinan, John/0000-0003-1774-4738 FU NIH NIDCD [RO1 DC000235, T32 DC00038, P30 DC005209] FX We thank Dr. M.C. Brown, Dr. D.C. Mountain and Dr. C.A. Shera for comments on earlier versions of the manuscript. This work was supported by NIH NIDCD grants: RO1 DC000235, T32 DC00038 and P30 DC005209 and was part H.N's PhD thesis. NR 40 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD NOV PY 2016 VL 341 BP 66 EP 78 DI 10.1016/j.heares.2016.08.007 PG 13 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA EB6TN UT WOS:000387518600007 PM 27550413 ER PT J AU Chhatwal, J Wang, XJ Ayer, T Kabiri, M Chung, RT Hur, C Donohue, JM Roberts, MS Kanwal, F AF Chhatwal, Jagpreet Wang, Xiaojie Ayer, Turgay Kabiri, Mina Chung, Raymond T. Hur, Chin Donohue, Julie M. Roberts, Mark S. Kanwal, Fasiha TI Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals SO HEPATOLOGY LA English DT Article ID VIRUS-INFECTION; COST-EFFECTIVENESS; HEPATOCELLULAR-CARCINOMA; MORTALITY; TRANSPLANTATION; PREVALENCE; SOFOSBUVIR; CIRRHOSIS; REGIMENS; FIBROSIS AB Oral direct-acting antivirals (DAAs) represent a major advance in hepatitis C virus (HCV) treatment. Along with recent updates in HCV screening policy and expansions in insurance coverage, treatment demand in the United States is changing rapidly. Our objective was to project the characteristics and number of people needing antiviral treatment and HCV-associated disease burden in the era of oral DAAs. We used a previously developed and validated Hepatitis C Disease Burden Simulation model (HEP-SIM). HEP-SIM simulated the actual clinical management of HCV from 2001 onward, which included antiviral treatment with pegylated interferon (Peg-IFN)-based therapies as well as the recent oral DAAs, risk-based and birth-cohort HCV screening, and the impact of the Affordable Care Act. We also simulated two hypothetical scenariosno treatment and treatment with Peg-IFN-based therapies only. We estimated that in 2010, 2.5 (95% confidence interval [CI], 1.9-3.1) million noninstitutionalized people were viremic, which dropped to 1.9 (95% CI, 1.4-2.6) million in 2015, and projected to drop below 1 million by 2020. A total of 1.8 million HCV patients will receive HCV treatment from the launch of oral DAAs in 2014 until 2030. Based on current HCV management practices, it will take 4-6 years to treat the majority of patients aware of their disease. However, 560,000 patients would still remain unaware by 2020. Even in the oral DAA era, 320,000 patients will die, 157,000 will develop hepatocellular carcinoma, and 203,000 will develop decompensated cirrhosis in the next 35 years. Conclusions: HCV-associated disease burden will still remain substantial in the era of oral DAAs. Increasing HCV screening and treatment capacity is essential to further decreasing HCV burden in the United States. (Hepatology 2016;64:1442-1450) C1 [Chhatwal, Jagpreet; Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. [Chhatwal, Jagpreet; Chung, Raymond T.; Hur, Chin] Harvard Med Sch, Boston, MA USA. [Chhatwal, Jagpreet; Chung, Raymond T.; Hur, Chin] Massachusetts Gen Hosp, Liver Ctr, Boston, MA 02114 USA. [Chhatwal, Jagpreet; Chung, Raymond T.; Hur, Chin] Massachusetts Gen Hosp, Gastrointestinal Div, Boston, MA 02114 USA. [Wang, Xiaojie; Ayer, Turgay] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA. [Wang, Xiaojie] Univ Florida, Dept Ind & Syst Engn, Gainesville, FL 32611 USA. [Kabiri, Mina; Donohue, Julie M.; Roberts, Mark S.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Houston, TX USA. [Kanwal, Fasiha] Baylor Coll Med, Dept Med Gastroenterol & Hepatol, Houston, TX 77030 USA. RP Chhatwal, J (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM jagchhatwal@mgh.harvard.edu OI Hur, Chin/0000-0002-2819-7576 FU National Institutes of Health [KL2TR000146]; Gilead Sciences, Inc. FX This project was, in parts, funded by the National Institutes of Health under award number KL2TR000146 and Gilead Sciences, Inc. NR 36 TC 9 Z9 9 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD NOV PY 2016 VL 64 IS 5 BP 1442 EP 1450 DI 10.1002/hep.28571 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EB6AX UT WOS:000387464200012 PM 27015107 ER PT J AU Ruggiero, NA Chang, M Brown, S AF Ruggiero, Nicole A. Chang, Mei Brown, Sheldon TI Pseudomonas mendocina Bacteremia, A Case Study and Review of Literature SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Review DE Pseudomonas mendocina; bacteremia; cellulitis ID INFECTIVE ENDOCARDITIS; PATIENT AB Infections with Pseudomonas mendocina have rarely been reported. P. mendocina seems to be a less virulent and less resistant organism compared to P. aeruginosa. We present a case of P. mendocina bacteremia likely secondary to cellulitis and a brief review of P. mendocina infections reported in the literature. C1 [Ruggiero, Nicole A.; Chang, Mei] James J Peters VA Med Ctr, Dept Pharm, Bronx, NY USA. [Brown, Sheldon] James J Peters VA Med Ctr, Dept Infect Dis, Bronx, NY USA. RP Ruggiero, NA (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd 119, Bronx, NY 10468 USA. EM nicole.ruggiero@va.gov NR 9 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1056-9103 EI 1536-9943 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD NOV PY 2016 VL 24 IS 6 BP 314 EP 317 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EB6CJ UT WOS:000387468200023 ER PT J AU Rosenfeld, EA Marx, J Terry, MA Stall, R Flatt, J Borrero, S Miller, E AF Rosenfeld, E. A. Marx, J. Terry, M. A. Stall, R. Flatt, J. Borrero, S. Miller, E. TI Perspectives on expedited partner therapy for chlamydia: a survey of health care providers SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Expedited partner therapy; providers; survey; sexually transmitted infection; treatment ID SEXUALLY-TRANSMITTED INFECTIONS; VIOLENCE; NOTIFICATION; KNOWLEDGE; ATTITUDES; ADOLESCENTS; PHYSICIANS; TRIAL AB There is a lack of research on health care providers' use of and perspectives on expedited partner therapy in a state where expedited partner therapy is not prohibited or explicitly allowed. The aim of our study was to understand if and how health care providers use expedited partner therapy, if specific demographic factors and knowledge contribute to increased use of expedited partner therapy, and to describe barriers and facilitators to the use of expedited partner therapy in Pittsburgh, Pennsylvania. A convenience sample of 112 health care providers from diverse disciplines who treat young women at risk for chlamydia completed an online survey. About 11% of health care providers used expedited partner therapy consistently. Those who self-reported that they were knowledgeable about expedited partner therapy were more likely to use expedited partner therapy (73% vs. 49%, p=.009) as were those who said no or were unsure about their institution's guidelines for expedited partner therapy (35% vs. 22%, p=0.01) (62% vs. 57%, p=0.01). The most commonly reported facilitator of expedited partner therapy was having clear legal guidelines (86%). This study finds that in a setting where expedited partner therapy is not expressly permitted, health care providers still use the practice but also experience barriers that limit uptake. Legislation expressly endorsing expedited partner therapy in the state and in medical institutions is needed to increase expedited partner therapy use. C1 [Rosenfeld, E. A.] VA Pittsburgh Healthcare Syst, VA Womens Hlth, Pittsburgh, PA USA. [Marx, J.; Terry, M. A.; Stall, R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Flatt, J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Borrero, S.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Miller, E.] Univ Pittsburgh, UPMC, Childrens Hosp Pittsburgh, Div Adolescent Med, Pittsburgh, PA USA. RP Rosenfeld, EA (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C 151C Bldg 30, Pittsburgh, PA 15240 USA. EM Elian.rosenfeld@va.gov NR 29 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD NOV PY 2016 VL 27 IS 13 BP 1180 EP 1186 DI 10.1177/0956462415610689 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA9XX UT WOS:000386999100005 PM 26446138 ER PT J AU Gandhi, PU Gaggin, HK Redfield, MM Chen, HH Stevens, SR Anstrom, KJ Semigran, MJ Liu, P Januzzi, JL AF Gandhi, Parul U. Gaggin, Hanna K. Redfield, Margaret M. Chen, Horng H. Stevens, Susanna R. Anstrom, Kevin J. Semigran, Marc J. Liu, Peter Januzzi, James L., Jr. TI Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction Results From the RELAX Trial SO JACC-HEART FAILURE LA English DT Article DE biomarkers; diastolic function; heart failure with preserved ejection fraction; insulin-like growth factor-binding protein 7 ID EXERCISE CAPACITY; CLINICAL STATUS; INHIBITION AB OBJECTIVES This study sought to investigate relationships between insulin-like growth factor-binding protein-7 (IGFBP7) and parameters of diastolic function or functional capacity in patients with heart failure and preserved ejection fraction (HFpEF) who were randomized to receive sildenafil or placebo. BACKGROUND IGFBP7 was previously found to be associated with diastolic function in heart failure with reduced ejection fraction, but it is unclear whether these associations are present in HFpEF. METHODS At baseline and 24 weeks, IGFBP7, imaging studies, and peak oxygen consumption (Vo(2max)) were obtained and compared in 160 patients with HFpEF who were randomized to receive sildenafil or placebo. RESULTS Patients with supramedian baseline IGFBP7 concentrations were older, had signs of systemic congestion and worse renal function, and had higher concentrations of prognostic heart failure biomarkers including amino-terminal pro-B-type natriuretic peptide (p < 0.05). Higher baseline IGFBP7 was modestly correlated with worse diastolic function: higher E velocity (Spearman correlation [rho] = 0.40), E/E' (rho = 0.40), left atrial volume index (rho = 0.39), and estimated right ventricular systolic pressure (rho = 0.41; all p < 0.001) and weakly correlated with transmitral E/A (rho = 0.26; p = 0.006). Notably, change in IGFBP7 was significantly correlated with change in E, E/A, E/E', and right ventricular systolic pressure. Elevated baseline IGFBP7 was associated with lower baseline Vo(2max) (13.2 vs. 11.1 ml/min/kg; p < 0.001), and change in IGFBP7 was weakly inversely correlated with change in Vo(2max) (rho = 0.19; p = 0.01). Subjects receiving sildenafil had a decrease in IGFBP7 over 24 weeks, in contrast to placebo-treated patients (median change in IGFBP7 -1.5 vs. +13.6 ng/ml; p < 0.001). CONCLUSIONS In patients with HFpEF, IGFBP7 may be a novel biomarker of diastolic function and exercise capacity. (C) 2016 by the American College of Cardiology Foundation. C1 [Gandhi, Parul U.] VA CT Healthcare Syst, West Haven, CT USA. [Gandhi, Parul U.] Yale Univ, Sch Med New Haven, New Haven, CT 06520 USA. [Gaggin, Hanna K.; Semigran, Marc J.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Redfield, Margaret M.; Chen, Horng H.] Mayo Clin Rochester, Rochester, MN USA. [Stevens, Susanna R.; Anstrom, Kevin J.] Duke Clin Res Inst, Durham, NC USA. [Liu, Peter] Univ Ottawa, Inst Heart, Ottawa, ON, Canada. RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Dept Cardiol Internal Med, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA. EM jjanuzzi@partners.org NR 25 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD NOV PY 2016 VL 4 IS 11 BP 860 EP 869 DI 10.1016/j.jchf.2016.08.002 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB5PR UT WOS:000387429000005 PM 27744089 ER PT J AU Savarese, G Giugliano, RP Rosano, GMC McMurray, J Magnani, G Filippatos, G Dellegrottaglie, S Lund, LH Trimarco, B Perrone-Filardi, P AF Savarese, Gianluigi Giugliano, Robert P. Rosano, Giuseppe M. C. McMurray, John Magnani, Giulia Filippatos, Gerasimos Dellegrottaglie, Santo Lund, Lars H. Trimarco, Bruno Perrone-Filardi, Pasquale TI Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure A Meta-Analysis SO JACC-HEART FAILURE LA English DT Article DE atrial fibrillation; heart failure; meta-analysis; novel oral anticoagulants; trials ID RISK STRATIFICATION SCHEMES; RANDOMIZED-TRIALS; PREDICTING STROKE; ROCKET AF; WARFARIN; THROMBOEMBOLISM; RIVAROXABAN; DYSFUNCTION; INSIGHTS; QUALITY AB OBJECTIVES This study investigated the efficacy and safety of novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and heart failure (HF) by a meta-analysis. BACKGROUND AF is quite prevalent in patients with HF. METHODS Four phase III clinical trials comparing NOACs to warfarin in patients with AF were included. Each patient was defined as affected by HF according to the criteria of the trial in which the patient was enrolled. Pre-specified outcomes were the composite of stroke/systemic embolism (SSE); major, intracranial, and any bleeding; and cardiovascular (CV) and all-cause death. RESULTS A total of 55,011 patients were enrolled, 26,384 (48%) with HF, and 28,627 (52%) without HF; 27,518 receiving NOACs and 27,493 receiving warfarin (median, 70 years of age; 36% females; follow-up: 1.5 to 2.8 years). Rates of SSE (relative risk [RR]: 0.98; 95% confidence interval [CI]: 0.90 to 1.07]; p = 0.68) and major bleeding (RR: 0.95; 95% Cl: 0.88 to 1.03; p = 0.21) were comparable in patients with and without HF. HF patients had reduced rates of any (RR: 0.86; 95% Cl: 0.81 to 0.91; p < 0.01) and intracranial (RR: 0.74 95% CI: 0.63 to 0.88; p < 0.01) bleeding but increased rates of all-cause (RR: 1.70 95% Cl: 1.31 to 2.19; p < 0.01) and CV death (RR: 2.05 95% CI: 1.66 to 2.55; p < 0.01). NOACs, compared with warfarin significantly reduced SSE and major, intracranial, and any bleeding, regardless of the presence or absence of HF (P-interaction > 0.05 for each). CONCLUSIONS Patients with AF and HF had increased mortality but reduced rates of intracranial and any bleeding compared with the no-HF patients, with no differences in rates of SSE and major bleeding. NOACs significantly reduced SSE, major bleeding, and intracranial hemorrhage in HF patients. No interactions in efficacy and safety of NOACs were observed between AF patients with and without HF. (C) 2016 by the American College of Cardiology Foundation. C1 [Savarese, Gianluigi; Trimarco, Bruno; Perrone-Filardi, Pasquale] Univ Naples Federico II, Dept Adv Biomed Sci, Via Pansini 5, I-80131 Naples, Italy. [Savarese, Gianluigi; Lund, Lars H.] Karolinska Inst, Dept Med, Cardiol Unit, Stockholm, Sweden. [Giugliano, Robert P.; Magnani, Giulia] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA. [Giugliano, Robert P.; Magnani, Giulia] Harvard Med Sch, Boston, MA USA. [Rosano, Giuseppe M. C.] St Georges Univ, Cardiovasc & Cell Sci Res Inst, London, England. [McMurray, John] IRCCS San Raffaele Pisana, Rome, Italy. [Filippatos, Gerasimos] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. [Filippatos, Gerasimos] Univ Athens, Hosp Attikon, Athens, Greece. [Dellegrottaglie, Santo] Villa Fiori, Naples, Italy. [Dellegrottaglie, Santo] Mt Sinai Sch Med, New York, NY USA. RP Perrone-Filardi, P (reprint author), Univ Naples Federico II, Dept Adv Biomed Sci, Via Pansini 5, I-80131 Naples, Italy. EM fpperron@unina.it OI mcmurray, john/0000-0002-6317-3975 NR 23 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD NOV PY 2016 VL 4 IS 11 BP 870 EP 880 DI 10.1016/j.jchf.2016.07.012 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB5PR UT WOS:000387429000006 PM 27614940 ER PT J AU Gaither, JR Goulet, JL Becker, WC Crystal, S Edelman, EJ Gordon, K Kerns, RD Rimland, D Skanderson, M Justice, AC Fiellin, DA AF Gaither, Julie R. Goulet, Joseph L. Becker, William C. Crystal, Stephen Edelman, E. Jennifer Gordon, Kirsha Kerns, Robert D. Rimland, David Skanderson, Melissa Justice, Amy C. Fiellin, David A. TI The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE mortality; opioid analgesics; practice guideline; quality of health care; substance use disorders ID CHRONIC NONCANCER PAIN; VETERANS AGING COHORT; OF-HEALTH PATHWAYS; PRESCRIPTION OPIOIDS; CLINICAL GUIDELINES; ANTIRETROVIRAL THERAPY; PREVENTION WORKSHOP; UNINFECTED VETERANS; UNITED-STATES; MENTAL-HEALTH AB Objective:Patients with substance use disorders (SUDs) prescribed long-term opioid therapy (LtOT) are at risk for overdose and mortality. Prior research has shown that receipt of LtOT in accordance with clinical practice guidelines has the potential to mitigate these outcomes. Our objective was to determine whether the presence of a SUD modifies the association between guideline-concordant care and 1-year all-cause mortality among patients receiving LtOT for pain.Methods:Among HIV+ and HIV- patients initiating LtOT (90 days opioids) between 2000 and 2010 as part of the Veterans Aging Cohort Study, we used time-updated Cox regression and propensity-score matching to examinestratified by SUD statusthe association between 1-year all-cause mortality and 3 quality indicators derived from national opioid-prescribing guidelines. Specifically, we examined whether patients received psychotherapeutic cointerventions (2 outpatient mental health visits), benzodiazepine coprescriptions (7 days), and SUD treatment (1 inpatient day or outpatient visit). These indicators were among those found in a previous study to have a strong association with mortality.Results:Among 17,044 patients initiating LtOT, there were 1048 (6.1%) deaths during 1 year of follow-up. Receipt of psychotherapeutic cointerventions was associated with lower mortality in the overall sample and was more protective in patients with SUDs (adjusted hazard ratio [AHR] 0.43, 95% confidence interval [CI] 0.33-0.56 vs AHR 0.65, 95% CI 0.53-0.81; P for interaction=0.002). Benzodiazepine coprescribing was associated with higher mortality in the overall sample (AHR 1.41, 95% CI 1.22-1.63), but we found no interaction by SUD status (P for interaction=0.11). Among patients with SUDs, receipt of SUD treatment was associated with lower mortality (AHR 0.43, 95% CI 0.33-0.57).Conclusions:For clinicians prescribing LtOT to patients with untreated SUDs, engaging patients with psychotherapeutic and SUD treatment services may reduce mortality. Clinicians should also avoid, when possible, prescribing opioids with benzodiazepines. C1 [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, New Haven, CT USA. [Gaither, Julie R.; Goulet, Joseph L.; Becker, William C.; Gordon, Kirsha; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Gaither, Julie R.; Justice, Amy C.] Yale Univ, Yale Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gaither, Julie R.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Yale Sch Med, Dept Psychiat, New Haven, CT USA. [Becker, William C.; Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA. [Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gaither, JR (reprint author), 950 Campbell Ave, West Haven, CT 06516 USA. EM julie.gaither@yale.edu OI Goulet, Joseph/0000-0002-0842-804X FU National Institute on Drug Abuse [F31DA035567, K12DA033312]; National Institute on Alcohol Abuse and Alcoholism [U10AA013566, U01AA020790, U24AA020794]; National Institute of Mental Health [P30MH062294]; Agency for Healthcare Research and Quality [U19HS21112]; VA Health Services Research and Development Center of Innovation [CIN13047] FX Research reported in this paper was supported by grants from the National Institute on Drug Abuse (grant nos. F31DA035567, K12DA033312), National Institute on Alcohol Abuse and Alcoholism (grant nos. U10AA013566, U01AA020790, U24AA020794), National Institute of Mental Health (grant no. P30MH062294), the Agency for Healthcare Research and Quality (grant no. U19HS21112), and the VA Health Services Research and Development Center of Innovation (grant no. CIN13047). NR 72 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2016 VL 10 IS 6 BP 418 EP 428 DI 10.1097/ADM.0000000000000255 PG 11 WC Substance Abuse SC Substance Abuse GA EB3PB UT WOS:000387276500008 PM 27610580 ER PT J AU Singh, SM D'Avila, A Aryana, A Kim, YH Mangrum, JM Michaud, GF Dukkipati, SR Heist, EK Barrett, CD Thorpe, KE Reddy, VY AF Singh, Sheldon M. D'Avila, Andre Aryana, Arash Kim, Young-Hoon Mangrum, J. Michael Michaud, Gregory F. Dukkipati, Srinivas R. Heist, E. Kevin Barrett, Conor D. Thorpe, Kevin E. Reddy, Vivek Y. TI Persistent Atrial Fibrillation Ablation in Females: Insight from the MAGIC-AF Trial SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE arrhythmia; atrial fibrillation; atrioesophageal fistula; catheter ablation; dofetilide; gender ID CATHETER ABLATION; PROCEDURAL COMPLICATIONS; GENDER; SEX; MANAGEMENT; IBUTILIDE; SOCIETY; DESIGN; RISK; RACE AB Gender and Persistent AF IntroductionAtrial fibrillation (AF) ablation is less frequently performed in women when compared to men. There are conflicting data on the safety and efficacy of AF ablation in women. The objective of this study was to compare the clinical characteristics and outcomes in a contemporary cohort of men and women undergoing persistent AF ablation procedures. Methods and ResultsA total of 182 men and 53 women undergoing a first-ever persistent AF catheter ablation procedure in The Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation (MAGIC-AF) trial were evaluated. Clinical and procedural characteristics were compared between each gender. The primary efficacy endpoint was the 1-year single procedure freedom from atrial arrhythmia off anti-arrhythmic drugs. Women undergoing catheter ablation procedures were older than men (P < 0.001). The duration of AF and associated co-morbidities were similar between both genders. Single procedure drug-free atrial arrhythmia recurrence occurred in 53% of the cohort with no difference based on gender (men = 54%, women = 53%; P = 1.0). Procedural (P = 0.04), fluoroscopic (P = 0.02), and ablation times (P = 0.003) were shorter in women compared to men. Periprocedural complications and postablation improvement in quality of life were similar between men and women. ConclusionWomen undergoing a first-ever persistent AF ablation procedure were older but had similar clinical outcomes and complications when compared with men. C1 [Singh, Sheldon M.] Univ Toronto, Schulich Heart Program, Sunnybrook Hlth Sci Ctr, Fac Med, Toronto, ON, Canada. [D'Avila, Andre; Dukkipati, Srinivas R.; Reddy, Vivek Y.] Icahn Sch Med Mt Sinai, Helmsley Cardiac Arrhythmia Serv, New York, NY 10029 USA. [D'Avila, Andre] Hosp Cardiol, Inst Pesquisa Arritmia Cardiaca, Florianopolis, SC, Brazil. [Aryana, Arash] Mercy Gen Hosp, Sacramento, CA USA. [Aryana, Arash] Dign Hlth Heart & Vasc Inst, Sacramento, CA USA. [Kim, Young-Hoon] Korea Univ, Med Ctr, Cardiovasc Div, Seoul, South Korea. [Mangrum, J. Michael] Univ Virginia, Cardiovasc Med, Charlottesville, VA USA. [Michaud, Gregory F.] Harvard Univ, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA. [Heist, E. Kevin; Barrett, Conor D.] Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA. [Thorpe, Kevin E.] Univ Toronto, Dalla Lana Sch Publ Hlth, Keenan Res Ctr, Li Ka Shing Knowledge Inst,St Michaels Hosp, Toronto, ON, Canada. RP Singh, SM (reprint author), Sunnybrook HSC, Schulich Heart Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada. EM sheldon.singh@sunnybrook.ca FU St. Jude Medical FX The MAGIC-AF study was funded by St. Jude Medical. NR 27 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD NOV PY 2016 VL 27 IS 11 BP 1259 EP 1263 DI 10.1111/jce.13051 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB5DN UT WOS:000387393800001 ER PT J AU Rav-Acha, M Ng, CY Heist, EK Rozen, G Chalhoub, F Kostis, WJ Ruskin, J Mansour, M AF Rav-Acha, Moshe Ng, Chee Yuan Heist, E. Kevin Rozen, Guy Chalhoub, Fadi Kostis, William J. Ruskin, Jeremy Mansour, Moussa TI A Novel Annotation Technique During Mapping to Facilitate the Termination of Atrial Tachycardia Following Ablation for Atrial Fibrillation SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE atrial fibrillation; atrial tachycardia; atypical atrial flutter; electronatomic activation mapping; pulmonary vein isolation ID VENTRICULAR-TACHYCARDIA; CRITICAL ISTHMUS; ELECTROANATOMIC CHARACTERIZATION; MACROREENTRANT TACHYCARDIA; CATHETER ABLATION; IDENTIFICATION; ARRHYTHMIAS; ENTRAINMENT; MECHANISMS; CONDUCTION AB A Novel Annotation Technique During Mapping to Facilitate the Termination of AT IntroductionThe treatment of atrial tachycardia (AT) occurring after ablation for atrial fibrillation (AF) is challenging. The most common ablation strategy relies on entrainment, and electroanatomic activation mapping (EAM) using a conventional window of interest (WOI), centered on the easily detectable atrial signal on the coronary sinus catheter. We describe a novel EAM annotation technique that uses a WOI starting 40 milliseconds prior to the P wave in order to detect the reentrant AT exit site. This WOI timing is based on the similarity between scar-related reentrant AT and scar-related ventricular tachycardia. MethodsPatients with AT after prior ablation for AF were included. The EAM of the AT was performed using the novel mapping annotation technique. The ablation was considered successful if the AT terminated during ablation at the site identified by this strategy. ResultsTwenty-eight patients with 36 ATs were included. The ATs were classified as follows: mitral annulus (13/36), roof (11/36), anterior/posterior/lateral left atrial wall (10/36), and RA (2/36). A complete EAM using the novel annotation technique was achieved in 34 of 36 AT's, encompassing 94 6.5% of the cycle length. Low amplitude pre-P fractionated electrograms were found in 34 of 36 (94%) ATs and these occurred at a mean distance of 1.8 +/- 1.2 mm from the early-meets-late line. Ablation at these areas resulted in termination of 34 of 36 ATs (94%). ConclusionThe novel EAM annotation allows the accurate detection of the critical isthmus of post-AF ablation AT. Ablation of these isthmuses results in termination of the AT in the vast majority of patients. C1 [Rav-Acha, Moshe; Ng, Chee Yuan; Heist, E. Kevin; Rozen, Guy; Chalhoub, Fadi; Kostis, William J.; Ruskin, Jeremy; Mansour, Moussa] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Corrigan Minehan Heart Ctr, 55 Fruit St, Boston, MA 02114 USA. RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Corrigan Minehan Heart Ctr, 55 Fruit St, Boston, MA 02114 USA. EM mmansour@partners.org FU Deane Institute for Stroke and Atrial Fibrillation; St. Jude Medical; Biosense Webster FX This work was made possible because of support of the Deane Institute for Stroke and Atrial Fibrillation.; E. Kevin Heist reports research grants from St. Jude Medical and serving as consultant to Biosense Webster and St. Jude Medical. Jeremy Ruskin reports fellowship support from St. Jude Medical; serving as: consultant to Advanced Medical Education, Cardiome, Daiichi Sankyo, Portola Pharmaceuticals (equity interest); scientific advisory board member for Medtronic; steering committee member for Pfizer; data monitoring committee member for Gilead Sciences and Laguna Medical. Moussa Mansour reports research grants from Biosense Webster and St. Jude Medical, and serving as consultant for Biosense Webster, St. Jude Medical, and Boston Scientific. Other authors: No disclosures. NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD NOV PY 2016 VL 27 IS 11 BP 1274 EP 1281 DI 10.1111/jce.13063 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EB5DN UT WOS:000387393800004 ER PT J AU Sprich, SE Safren, SA Finkelstein, D Remmert, JE Hammerness, P AF Sprich, Susan E. Safren, Steven A. Finkelstein, Daniel Remmert, Jocelyn E. Hammerness, Paul TI A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents SO JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY LA English DT Article DE ADHD; adolescence; behavior therapy; cognitive therapy ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PROSPECTIVE FOLLOW-UP; III-R DIAGNOSES; PSYCHOSOCIAL TREATMENTS; PERSISTENT SYMPTOMS; RESEARCH CRITERIA; ADULTS; CHILDREN; PSYCHOPATHOLOGY AB ObjectiveTo test cognitive behavioral therapy (CBT) for persistent attention-deficit hyperactivity disorder (ADHD) symptoms in a sample of medication-treated adolescents. MethodsForty-six adolescents (ages 14-18), with clinically significant ADHD symptoms despite stable medication treatment were randomly assigned to receive CBT for ADHD or wait list control in a cross-over design. Twenty-four were randomized to CBT, 22 to wait list, and 15 crossed-over from wait list to CBT. A blind independent evaluator (IE) rated symptom severity on the ADHD Current Symptom Scale, by adolescent and parent report, and rated each subject using the Clinical Global Impression Severity Scale (CGI), a global measure of distress and impairment. These assessments were performed at baseline, 4-months (post-CBT or post wait list), and 8-months (post-treatment for those originally assigned to the wait list condition and 4-month follow-up for those originally assigned to CBT). Trial Registration: . ResultsUsing all available data, mixed effects modeling, and pooling for the wait list cross-over, participants who received CBT received a mean score 10.93 lower on the IE-rated parent assessment of symptom severity (95% CI: -12.93, -8.93; p<.0001), 5.24 lower on the IE-rated adolescent assessment of symptom severity (95% CI: -7.21, -3.28; p<.0001), and 1.17 lower IE-rated CGI (95% CI: -1.39, -.94; p<.0001). Results were consistent across 100 multiple imputations (all p<.0001). There was a greater proportion of responders after CBT by parent (50% vs. 18%, p=.00) and adolescent (58% vs. 18% p=.02) report. ConclusionsThis study demonstrates initial efficacy of CBT for adolescents with ADHD who continued to exhibit persistent symptoms despite medications. C1 [Sprich, Susan E.; Safren, Steven A.; Remmert, Jocelyn E.] Massachusetts Gen Hosp, Dept Psychiat, Behav Med Serv, Boston, MA 02114 USA. [Sprich, Susan E.; Safren, Steven A.; Finkelstein, Daniel; Hammerness, Paul] Harvard Med Sch, Boston, MA USA. [Safren, Steven A.] Univ Miami, Dept Psychol, Miami, FL USA. [Finkelstein, Daniel] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Hammerness, Paul] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA. RP Safren, SA (reprint author), Univ Miami, Dept Psychol, 5665 Ponce De Leon Blvd,POB 248185, Coral Gables, FL 33124 USA. EM ssafren@miami.edu FU NIMH [R34MH083063]; Harvard Catalyst, Harvard Clinical and Translational Science Center by NIH [1 UL1 RR025758-03] FX This project was supported by NIMH grant R34MH083063; Additional support for data analysis came from the Harvard Catalyst, Harvard Clinical and Translational Science Center by NIH grant 1 UL1 RR025758-03. S.A.S. and S.E.S. receive royalties from Oxford University Press for their published therapist guide and client workbook. S.A.S. receives royalties from Guilford Publications for authored books. S.E.S. receives royalties from Springer for an edited book and S.A.S will receive royalties from Springer for an edited book. The rest of the authors have declared that they have no potential or competing conflicts of interest in relation to the work reported. The authors thank the following individuals who assisted with the project: Christine Cooper-Vince, Meghan Groves Cromer, and Aleksandra Margolina, for research assistance; Jennifer Burbridge, Aude Henin, Laura Knouse, and Jonathan Lerner, for study intervention and assessing; Steven Evans, for consultation at the start of the study on the design and implementation of the trial; Hang Lee, for consulting on the data analysis. NR 43 TC 1 Z9 1 U1 14 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9630 EI 1469-7610 J9 J CHILD PSYCHOL PSYC JI J. Child Psychol. Psychiatry PD NOV PY 2016 VL 57 IS 11 BP 1218 EP 1226 DI 10.1111/jcpp.12549 PG 9 WC Psychology, Developmental; Psychiatry; Psychology SC Psychology; Psychiatry GA EB1PL UT WOS:000387125800003 PM 26990084 ER PT J AU Della-Torre, E Stone, JH AF Della-Torre, Emanuel Stone, John H. TI "How I manage" IgG4-Related Disease SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Article DE IgG4-related disease; autoimmune pancreatitis; sialoadenitis; retroperitoneal fibrosis; SLAM-F7; cytotoxic T cell; plasmablast; glucocorticoid ID REGULATORY IMMUNE-REACTIONS; AUTOIMMUNE PANCREATITIS; SYSTEMIC-DISEASE; SCLEROSING PANCREATITIS; RITUXIMAB; CHOLANGITIS; TH2; STATEMENT; THERAPY; ATOPY AB IgG4-related disease (IgG4-RD) is an immune-mediated disease driven by interactions on several levels between cells of the B and T lineages. A key driver of IgG4-RD is believed to be a novel CD4+ cytotoxic T lymphocyte that bears SLAM-F7 on its surface. This cell is presumed to be sustained by continuous antigen presentation by cells of the B cell lineage, particularly plasmablasts. Because IgG4-RD has been recognized for fewer than 15 years as a unified diagnostic entity, no controlled clinical trials or few prospective studies of any sort have been performed. Although progress in understanding disease pathophysiology will likely lead in due course to disease-specific therapies-undoubtedly with implications for other immune-mediated diseases-at this juncture, the management of IgG4-RD remains more an art than a science, driven largely by the published clinical experience of only a few centers of expertise. We identify here six common management dilemmas in IgG4-RD and describe our typical approach to the management of each one. C1 [Della-Torre, Emanuel] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Unit Med & Clin Immunol, Milan, Italy. [Stone, John H.] Harvard Med Sch, Boston, MA 02114 USA. [Stone, John H.] Massachusetts Gen Hosp, Edward Fox Chair Med, Boston, MA 02114 USA. [Stone, John H.] Massachusetts Gen Hosp, Rheumatol Clin Yawkey 2, 55 Fruit St, Boston, MA 02114 USA. RP Stone, JH (reprint author), Harvard Med Sch, Boston, MA 02114 USA.; Stone, JH (reprint author), Massachusetts Gen Hosp, Edward Fox Chair Med, Boston, MA 02114 USA.; Stone, JH (reprint author), Massachusetts Gen Hosp, Rheumatol Clin Yawkey 2, 55 Fruit St, Boston, MA 02114 USA. EM jhstone@mgh.harvard.edu NR 34 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 EI 1573-2592 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD NOV PY 2016 VL 36 IS 8 BP 754 EP 763 DI 10.1007/s10875-016-0331-0 PG 10 WC Immunology SC Immunology GA EB5RD UT WOS:000387437100005 PM 27667138 ER PT J AU Taft, CT Creech, SK Gallagher, MW Macdonald, A Murphy, CM Monson, CM AF Taft, Casey T. Creech, Suzannah K. Gallagher, Matthew W. Macdonald, Alexandra Murphy, Christopher M. Monson, Candice M. TI Strength at Home Couples Program to Prevent Military Partner Violence: A Randomized Controlled Trial SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE violence; veterans; partner aggression; domestic abuse; prevention ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-USE DISORDERS; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; TACTICS-SCALES CTS2; INTIMATE PARTNER; RELATIONSHIP SATISFACTION; PSYCHOMETRIC PROPERTIES; IDENTIFICATION TEST; DSM-IV; RELIABILITY AB Objective: We evaluated the efficacy of Strength at Home Couples, a cognitive-behavioral trauma-informed intimate partner violence (IPV) preventive intervention for married or partnered military service members or veterans. No prior randomized controlled trial had supported the efficacy of such an intervention in this population. Method: Participants included 69 male service members or veterans and their female partners. Recruitment was conducted from February 2010 through August 2013, and participation occurred within 2 Department of Veterans Affairs hospitals. All couples completed an initial assessment including diagnostic interviews and measures of physical and psychological IPV and were randomized by cohort to a supportive prevention couples group or Strength at Home Couples. All couples were reassessed at postintervention and at 6 and 12 months follow-ups. Results: Both service members or veterans and their female partners engaged in fewer acts of reported physical and psychological IPV in the Strength at Home Couples condition relative to supportive prevention, and relative risk of physical violence was lower for both members of the dyad in Strength at Home Couples at follow-up assessments (male service member or veteran IPV relative risk [RR] = .53; female IPV RR = .43). Those in Strength at Home Couples evidenced significantly greater program completion than did those in supportive prevention (RR = 1.73; 95% confidence interval [1.00, 2.99]). Exploratory analyses did not find differences between groups on relationship satisfaction. Conclusion: Results provide support for the efficacy of Strength at Home Couples in preventing physical IPV and reducing psychological IPV. These results have important implications for preventing violence and associated physical and mental health problems. Clinical Trials Registration: Trial Registry Name: Strength at Home Couples Program; Registration Number: NCT00827879; URL: https://clinicaltrials.gov/ct2/show/NCT00827879?term=strength+at+home& rank=1 What is the public health significance of this article? This study suggests that the Strength at Home Couples program, a cognitive-behavioral trauma-informed intimate partner violence (IPV) preventive intervention for married or partnered military service members or veterans, is efficacious in preventing physical IPV and reducing psychological IPV. C1 [Taft, Casey T.; Macdonald, Alexandra] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Taft, Casey T.; Macdonald, Alexandra] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Creech, Suzannah K.] Providence VA Med Ctr, Providence, RI USA. [Creech, Suzannah K.] VHA VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX USA. [Gallagher, Matthew W.] Univ Houston, Dept Psychol, Houston, TX 77004 USA. [Gallagher, Matthew W.] Univ Houston, Texas Inst Measurement Evaluat & Stat, Houston, TX 77004 USA. [Murphy, Christopher M.] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA. [Monson, Candice M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. RP Taft, CT (reprint author), VA Boston Healthcare Syst 116B 4, Natl Ctr PTSD, 150 South Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov OI Creech, Suzannah/0000-0002-6582-1673 FU Centers for Disease Control and Prevention [RFA-CDC-CE07-002] FX This work was supported by a cooperative agreement from the Centers for Disease Control and Prevention (RFA-CDC-CE07-002) and through the use of the facilities and resources of the Providence VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 48 TC 0 Z9 0 U1 9 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD NOV PY 2016 VL 84 IS 11 BP 935 EP 945 DI 10.1037/ccp0000129 PG 11 WC Psychology, Clinical SC Psychology GA EA8YS UT WOS:000386926800002 PM 27599224 ER PT J AU Reger, GM Koenen-Woods, P Zetocha, K Smolenski, DJ Holloway, KM Rothbaum, BO Difede, J Rizzo, AA Edwards-Stewart, A Skopp, NA Mishkind, M Reger, MA Gahm, GA AF Reger, Greg M. Koenen-Woods, Patricia Zetocha, Kimberlee Smolenski, Derek J. Holloway, Kevin M. Rothbaum, Barbara O. Difede, JoAnn Rizzo, Albert A. Edwards-Stewart, Amanda Skopp, Nancy A. Mishkind, Matthew Reger, Mark A. Gahm, Gregory A. TI Randomized Controlled Trial of Prolonged Exposure Using Imaginal Exposure vs. Virtual Reality Exposure in Active Duty Soldiers With Deployment-Related Posttraumatic Stress Disorder (PTSD) SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE exposure therapy; virtual reality; military; posttraumatic stress disorder; Army ID MENTAL-HEALTH PROBLEMS; COGNITIVE-PROCESSING THERAPY; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL HELP; BEHAVIORAL THERAPY; ANXIETY DISORDERS; CLINICAL-TRIALS; D-CYCLOSERINE; RAPE VICTIMS; VETERANS AB Objective: Prolonged exposure (PE) is an evidence-based psychotherapy for posttraumatic stress disorder (PTSD) but there is limited research with active-duty military populations. Virtual reality exposure (VRE) has shown promise but randomized trials are needed to evaluate efficacy relative to existing standards of care. This study evaluated the efficacy of VRE and PE for active duty soldiers with PTSD from deployments to Iraq and Afghanistan. Method: Active-duty soldiers (N = 162) were randomized to 10-sessions of PE, VRE, or a minimal attention waitlist (WL). Blinded assessors evaluated symptoms at baseline, halfway through treatment, at posttreatment, and at 3- and 6-month follow-ups using the Clinician Administered PTSD Scale (CAPS). Results: Intent-to-treat analyses found that both PE and VRE resulted in significant reductions in PTSD symptoms relative to those in the WL. The majority of patients demonstrated reliable change in PTSD symptoms. There was no difference between PE and VRE regarding treatment drop out before completing 10 sessions (44 and 41% for VRE and PE, respectively). Contrary to hypotheses, analyses at posttreatment did not show that VRE was superior to PE. Post hoc analyses found that PE resulted in significantly greater symptom reductions than VRE at 3- and 6-month follow-up. Both treatments significantly reduced self-reported stigma. Conclusions: PE is an efficacious treatment for active-duty Army soldiers with PTSD from deployments to Iraq or Afghanistan. Results extend previous evidence supporting the efficacy of PE to active-duty military personnel and raise important questions for future research on VRE. What is the public health significance of this article? Results provide convergent evidence suggesting that exposure therapy is an effective treatment for active duty U.S. Army soldiers with posttraumatic stress disorder from deployments to Iraq and Afghanistan. C1 [Reger, Greg M.; Koenen-Woods, Patricia; Zetocha, Kimberlee; Smolenski, Derek J.; Holloway, Kevin M.; Edwards-Stewart, Amanda; Skopp, Nancy A.; Mishkind, Matthew; Reger, Mark A.; Gahm, Gregory A.] Natl Ctr Telehlth & Technol, Tacoma, WA USA. [Reger, Greg M.] VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. [Reger, Greg M.; Reger, Mark A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Holloway, Kevin M.] Ctr Deployment Psychol, Bethesda, MD USA. [Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. [Difede, JoAnn] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Rizzo, Albert A.] Univ So Calif, Inst Creat Technol, Los Angeles, CA USA. [Mishkind, Matthew] Univ Colorado, Arthur E Johnson Depress Ctr, Sch Med, Anschutz Med Campus, Boulder, CO 80309 USA. RP Reger, GM (reprint author), VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. EM greg.reger@va.gov FU Genentech; U.S. Army Medical Research and Materiel Command Military Operational Medicine Research Program [W81XWH-08-2-0015] FX Dr. Barbara Rothbaum owns equity in Virtually Better, Inc., which is developing products related to virtual reality, and Dr. Rothbaum is a consultant for Virtually Better, Inc. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. However, the virtual reality used in this study was created by Dr. Skip Rizzo and the ICT lab at USC, not Virtually Better, Inc. Dr. Rothbaum receives royalties from Oxford University Press, Guilford, APPI, and Emory University and received one advisory board payment from Genentech.; This research was supported by Grant W81XWH-08-2-0015 from the U.S. Army Medical Research and Materiel Command Military Operational Medicine Research Program. Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of Army, the Department of Defense, or the Department of Veterans Affairs. The authors would like to acknowledge Emily Fantelli, Amber Shaw, Lauren Bartlett, and Elizabeth Bullock for extensive assistance coordinating this study. We would also like to thank Russell McCann, Erin O'brien, Erika Ast, and Charnette Munroe for their efforts treating and assessing soldiers. We also thank Colette Candy, Jay Earles, Vicki Ingram, and the providers at the two respective Departments of Psychology for their support. Finally, we are grateful to Frank Andrasik and the late Andrew Leon for their consultation. NR 76 TC 0 Z9 0 U1 25 U2 25 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD NOV PY 2016 VL 84 IS 11 BP 946 EP 959 DI 10.1037/ccp0000134 PG 14 WC Psychology, Clinical SC Psychology GA EA8YS UT WOS:000386926800003 PM 27606699 ER PT J AU Shipherd, JC Salters-Pedneault, K Fordiani, J AF Shipherd, Jillian C. Salters-Pedneault, Kristalyn Fordiani, Joanne TI Evaluating Postdeployment Training for Coping With Intrusive Cognition: A Comparison of Training Approaches SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE acceptance; mindfulness; intrusive cognitions; trauma; soldiers ID POSTTRAUMATIC-STRESS-DISORDER; COMPREHENSIVE SOLDIER FITNESS; THOUGHT SUPPRESSION; PSYCHOMETRIC PROPERTIES; BEHAVIORAL THERAPY; COMMITMENT THERAPY; EMOTION DYSREGULATION; IRAQ RANDOMIZATION; PAIN TOLERANCE; ACCEPTANCE AB Objective: Although intrusive cognition (IC) is remarkably common in soldiers postdeployment and successful coping with ICs may predict better long-term psychological health, few elements of current programmatic postdeployment trainings have directly addressed adaptive strategies for managing intrusive deployment-related cognitions. The current study explored the efficacy of a brief acceptance-based skills training for coping with ICs relative to a change-based skills training, a psychoeducation-only training, or training as usual. Method: Participants were 1,524 (1,372 men) active-duty U.S. Army soldiers between 3 and 12 months' postdeployment. Results: Soldiers who received acceptance-based training demonstrated larger reductions in distress and impairment related to ICs about deployment at 1 month follow-up and larger reductions in symptoms of PTSD and general psychopathology relative to other training conditions. In contrast, participants in the change-oriented skills training showed relatively fewer benefits than did those in the acceptance-based training. In addition, soldiers who received the psychoeducation-only training showed no benefits relative to training as usual. Conclusions: Results suggest that brief trainings focused on postdeployment ICs may have benefits for soldiers up to 1 month later and may be a useful addition to a broader postdeployment transition program. Findings also indicate that an acceptance-based training approach may be more beneficial than a change-oriented approach for helping soldiers manage ICs and that psychoeducation alone may be insufficient for helping soldiers manage these cognitions. What is the public health significance of this article? This study suggests that a brief, targeted, acceptance-based training may be beneficial in helping soldiers manage postdeployment intrusive cognitions. C1 [Shipherd, Jillian C.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA. [Shipherd, Jillian C.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Salters-Pedneault, Kristalyn] Eastern Connecticut State Univ, Dept Psychol, Willimantic, CT 06226 USA. [Fordiani, Joanne] Gulf Coast Vet Hlth Care Syst, Behav Hlth Serv Line, Biloxi, MS USA. RP Shipherd, JC (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div 116B 3, 150 South Huntington Ave, Boston, MA 02130 USA. EM jillian.shipherd@va.gov FU U.S. Army Medical Research and Materiel Command Award [W81XWH-09-1-0535] FX This research was supported by U.S. Army Medical Research and Materiel Command Award W81XWH-09-1-0535. This trial is registered in the Defense Technical Information Database (Accession 579178). NR 69 TC 0 Z9 0 U1 10 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD NOV PY 2016 VL 84 IS 11 BP 960 EP 971 DI 10.1037/ccp0000136 PG 12 WC Psychology, Clinical SC Psychology GA EA8YS UT WOS:000386926800004 PM 27599228 ER PT J AU Alcantara, C Li, XL Wang, Y Canino, G Alegria, M AF Alcantara, Carmela Li, Xinliang Wang, Ye Canino, Glorisa Alegria, Margarita TI Treatment Moderators and Effectiveness of Engagement and Counseling for Latinos Intervention on Worry Reduction in a Low-Income Primary Care Sample SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE comparative effectiveness; transdiagnostic; Hispanic/Latinos; primary care; anxiety ID DEPRESSION AB Objective: We conducted a secondary analysis of randomized controlled trial data to determine if the Engagement and Counseling for Latinos (ECLA) intervention, a brief, evidence-based, and culturally adapted cognitive-behavioral intervention specifically designed for and effective at treating depression, also reduced co-occurring worry symptoms. We also explored whether delivery modality (telephone, face-to-face) and sociodemographic patient characteristics moderated treatment effectiveness. Method: Between May 2011 and September 2012, low-income Latino primary care patients (N = 257) with depression from Boston and San Juan were randomized to usual care (n = 86), face-to-face ECLA (n = 84), or telephone ECLA (n = 87) and completed a psychosocial assessment at baseline and 4 months after randomization. We used intention-to-treat analyses with linear regression models with change in worry (4 months from randomization) as the primary outcome and treatment condition as the primary predictor. Results: Patients in ECLA experienced significant reductions in worry at 4 months from randomization than those in usual care (PSWQ Delta = -3.28, p < .05). Among patients receiving ECLA, those in the telephone condition exhibited greater worry reductions than those in the face-to-face condition (telephone: M = -7.83, SD = 11.45; face-to-face: M = -6.73, SD = 12.23; p < .05). Employment status was the only significant treatment moderator. Unemployed patients did not exhibit any changes in worry irrespective of condition, whereas employed patients exhibited the greatest worry reductions across conditions. Conclusions: Although worry was not a treatment target in ECLA, it also reduced worry among low-income Latinos, which suggests ECLA may have transdiagnostic clinical implications. Telephone-delivered ECLA might hold promise for increasing the uptake of mental health care among employed low-income Latinos. What is the public health significance of this article? This study suggests that a brief, culturally adapted, cognitive-behavioral intervention (Engagement and Counseling for Latinos, ECLA) for depression also reduces worry, especially among employed and low-income Latino primary care patients. Our results also suggest that telephone-delivered ECLA, in comparison to face-to-face-delivered ECLA, may hold strong promise as a method to increase access to effective and high-quality mental health treatments for Latino populations. C1 [Alcantara, Carmela] Columbia Univ, Sch Social Work, 1255 Amsterdam Ave,Room 810,MC 4600, New York, NY 10027 USA. [Li, Xinliang; Wang, Ye; Alegria, Margarita] Massachusetts Gen Hosp, Dept Med, Dispar Res Unit, Boston, MA 02114 USA. [Canino, Glorisa] Univ Puerto Rico, Sch Med, Behav Sci Res Inst, San Juan, PR 00936 USA. RP Alcantara, C (reprint author), Columbia Univ, Sch Social Work, 1255 Amsterdam Ave,Room 810,MC 4600, New York, NY 10027 USA. EM ca2543@columbia.edu FU National Institute on Minority Health and Health Disparities [P60MD002261-S1]; National Heart Lung and Blood Institute [K23 HL125748-01]; National Center for Advancing Translational Sciences, National Institutes of Health [KL2 TR000081-10] FX This research was supported by the National Institute on Minority Health and Health Disparities, Grant P60MD002261-S1. Carmela Alcantara was supported by the National Heart Lung and Blood Institute, Grant K23 HL125748-01, and by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR000081-10. We thank Sarah Hayes-Skelton, PhD, for her helpful comments. NR 19 TC 0 Z9 0 U1 2 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD NOV PY 2016 VL 84 IS 11 BP 1016 EP 1022 DI 10.1037/ccp0000146 PG 7 WC Psychology, Clinical SC Psychology GA EA8YS UT WOS:000386926800009 PM 27631958 ER PT J AU Percac-Lima, S Singer, DE Cronin, PR Chang, YC Zai, AH AF Percac-Lima, Sanja Singer, Daniel E. Cronin, Patrick R. Chang, Yuchiao Zai, Adrian H. TI Can Text Messages Improve Attendance to Primary Care Appointments in Underserved Populations? SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Text messaging; underserved; appointment reminder; primary care; health disparities ID RANDOMIZED CONTROLLED-TRIAL; NO-SHOW RATES; SERVICE REMINDERS; TELEPHONE; ADHERENCE; SYSTEMS; URBAN AB We explored whether text message (TM) reminders could be used at a community health center (CHC) to improve primary care appointment attendance in adult patients. Over six months, we allocated 8,425 appointments to intervention and 2,679 to control. The proportion of no-shows in the intervention was 18.0% vs. 19.8% in control (p = .106). Among intervention appointments, 1,431 did not have a cell phone, 4,955 did not respond to the consent TM, and 231 declined TMs. The proportion of no-shows for the 1,309 appointments who received TM was 13.7% compared with 20.2% in a matched control group (p = .001). However, of 81 surveyed patients who did not respond to the consent TM, 64 (93%) wished to receive TMs. In conclusion, patients who received TM demonstrated improved attendance to their appointments. TM might be an effective supplemental appointment reminder method in a subpopulation of CHC patients and it should be explored in future research. C1 [Percac-Lima, Sanja] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA. [Percac-Lima, Sanja; Singer, Daniel E.; Chang, Yuchiao] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Percac-Lima, Sanja; Singer, Daniel E.; Chang, Yuchiao; Zai, Adrian H.] Harvard Med Sch, Boston, MA USA. [Cronin, Patrick R.; Zai, Adrian H.] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. RP Percac-Lima, S (reprint author), Massachusetts Gen Hosp, Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA. EM Spercaclima@mgh.harvard.org NR 42 TC 0 Z9 0 U1 2 U2 2 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2016 VL 27 IS 4 BP 1709 EP 1725 PG 17 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EB1EQ UT WOS:000387092800008 PM 27818433 ER PT J AU Manalo, T May, A Quinn, J Lafontant, DS Shifatu, O He, W Gonzalez-Rosa, JM Burns, GC Burns, CE Burns, AR Lafontant, PJ AF Manalo, Trina May, Adam Quinn, Joshua Lafontant, Dominique S. Shifatu, Olubusola He, Wei Gonzalez-Rosa, Juan M. Burns, Geoffrey C. Burns, Caroline E. Burns, Alan R. Lafontant, Pascal J. TI Differential Lectin Binding Patterns Identify Distinct Heart Regions in Giant Danio (Devario aequipinnatus) and Zebrafish (Danio rerio) Hearts SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE bulbus; concanavalin A; coronary; development; giant danio; heart; lectin; regeneration; WGA; zebrafish ID WHEAT-GERM-AGGLUTININ; LASER-CAPTURE MICRODISSECTION; CONCANAVALIN-A; ULTRASTRUCTURAL-LOCALIZATION; CARDIOVASCULAR DEVELOPMENT; ENDOTHELIAL-CELLS; IMAGE-ANALYSIS; FISH HEART; RAT-HEART; ADULT AB Lectins are carbohydrate-binding proteins commonly used as biochemical and histochemical tools to study glycoconjugate (glycoproteins, glycolipids) expression patterns in cells, tissues, including mammalian hearts. However, lectins have received little attention in zebrafish (Danio rerio) and giant danio (Devario aequipinnatus) heart studies. Here, we sought to determine the binding patterns of six commonly used lectinswheat germ agglutinin (WGA), Ulex europaeus agglutinin, Bandeiraea simplicifolia lectin (BS lectin), concanavalin A (Con A), Ricinus communis agglutinin I (RCA I), and Lycopersicon esculentum agglutinin (tomato lectin)in these hearts. Con A showed broad staining in the myocardium. WGA stained cardiac myocyte borders, with binding markedly stronger in the compact heart and bulbus. BS lectin, which stained giant danio coronaries, was used to measure vascular reconstruction during regeneration. However, BS lectin reacted poorly in zebrafish. RCA I stained the compact heart of both fish. Tomato lectin stained the giant danio, and while low reactivity was seen in the zebrafish ventricle, staining was observed in their transitional cardiac myocytes. In addition, we observed unique staining patterns in the developing zebrafish heart. Lectins' ability to reveal differential glycoconjugate expression in giant danio and zebrafish hearts suggests they can serve as simple but important tools in studies of developing, adult, and regenerating fish hearts. C1 [Manalo, Trina; May, Adam; Quinn, Joshua; Lafontant, Dominique S.; Shifatu, Olubusola; He, Wei; Lafontant, Pascal J.] Depauw Univ, Dept Biol, 1 E Hanna St,Olin 258, Greencastle, IN 46135 USA. [Gonzalez-Rosa, Juan M.; Burns, Geoffrey C.; Burns, Caroline E.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Cardiovasc Res Ctr, Charlestown, MA USA. [Burns, Alan R.] Univ Houston, Coll Optometry, Houston, TX USA. RP Lafontant, PJ (reprint author), Depauw Univ, Dept Biol, 1 E Hanna St,Olin 258, Greencastle, IN 46135 USA. EM pascallafontant@depauw.edu FU NIH [1 R15 HD084262-01]; Donald E. Town Faculty Fellowship; Faculty Development Funds at DePauw University; EMBO Long-term Fellowship [ALTF 253-2014]; Fund for Medical Discovery Fellowship - Executive Committee on Research at Massachusetts General Hospital; National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NLBLI) [5R01HL127067]; [NEI P30EY007551] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: P.J.L. is supported by NIH 1 R15 HD084262-01, Donald E. Town Faculty Fellowship, and Faculty Development Funds at DePauw University. A.R.B. is supported by grant NEI P30EY007551. J.M.G.-R. was supported by EMBO Long-term Fellowship ALTF 253-2014 and a Fund for Medical Discovery Fellowship awarded by the Executive Committee on Research at Massachusetts General Hospital. G.C.B. and C.E.B. were supported by National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NLBLI) grant 5R01HL127067. NR 55 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD NOV PY 2016 VL 64 IS 11 BP 687 EP 714 DI 10.1369/0022155416667928 PG 28 WC Cell Biology SC Cell Biology GA EB2BK UT WOS:000387161700003 PM 27680670 ER PT J AU Cubo-Romano, P Torres-Macho, J Soni, NJ Reyes, LF Rodriguez-Almodovar, A Fernandez-Alonso, JM Gonzalez-Davia, R Casas-Rojo, JM Restrepo, MI de Casasola, GG AF Cubo-Romano, Pilar Torres-Macho, Juan Soni, Nilam J. Reyes, Luis F. Rodriguez-Almodovar, Ana Manuel Fernandez-Alonso, Juan Gonzalez-Davia, Rosa Manuel Casas-Rojo, Jose Restrepo, Marcos I. Garcia de Casasola, Gonzalo TI Admission inferior vena cava measurements are associated with mortality after hospitalization for acute decompensated heart failure SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID HAND-CARRIED ULTRASOUND; RIGHT ATRIAL PRESSURE; NATRIURETIC PEPTIDE LEVELS; NATIONAL REGISTRY ADHERE; EUROPEAN-SOCIETY; PROGNOSTIC-SIGNIFICANCE; MEDICARE BENEFICIARIES; DIAGNOSTIC-ACCURACY; AMERICAN-SOCIETY; RE-ADMISSION AB BACKGROUNDPrognostication of patients hospitalized with acute decompensated heart failure (ADHF) is important to patients, providers, and healthcare systems. Few bedside tools exist to prognosticate patients hospitalized with ADHF. OBJECTIVEThe objective of this study was to assess the relationship between inferior vena cava (IVC) diameter and postdischarge mortality in patients hospitalized with ADHF. DESIGNProspective observational study. SETTINGA 247-bed urban teaching hospital in Spain PATIENTSNinety-seven patients hospitalized with ADHF. INTERVENTIONNone. MEASUREMENTSThe IVC diameter and collapsibility were measured by a hospitalist at the time of admission and discharge. Primary outcome was 90-day all-cause mortality. Secondary outcomes were readmission rates at 90 and 180 days, and 180-day all-cause mortality. Patients were followed for 180 days. RESULTSData from 80 patients were analyzed. From admission to discharge, a significant improvement in IVC maximum (IVCmax) diameter (2.12 vs 1.87 cm; P < 0.001) and IVC collapsibility (25.7% vs 33.1%; P < 0.001) was seen in the total study cohort. During the 90-day follow-up period, 11 patients (13.7%) died. An admission IVCmax diameter 1.9 cm was associated with a higher mortality rate at 90 days (25.4% vs 3.4%; P = 0.009) and 180 days (29.3% vs 3.4%; P = .003). In a multivariate Cox proportional hazards regression analysis, admission IVCmax diameter was an independent predictor of 90-day mortality (hazard ratio [HR]: 5.88; 95% confidence interval [CI]: 1.21-28.10; P = 0.025) and 90-day readmission (HR: 3.20; 95% CI: 1.24-8.21; P = 0.016). CONCLUSIONIn patients hospitalized with acute decompensated heart failure, a dilated IVC by bedside ultrasound at the time of admission is associated with a higher 90-day mortality after hospitalization. Journal of Hospital Medicine 2016;11:778-784. (c) 2016 Society of Hospital Medicine C1 [Cubo-Romano, Pilar; Torres-Macho, Juan; Manuel Casas-Rojo, Jose; Garcia de Casasola, Gonzalo] Infanta Cristina Univ Hosp, Dept Internal Med & Emergency Med, Madrid, Spain. [Cubo-Romano, Pilar; Torres-Macho, Juan; Rodriguez-Almodovar, Ana; Gonzalez-Davia, Rosa; Manuel Casas-Rojo, Jose; Garcia de Casasola, Gonzalo] Univ Complutense, Dept Med, Madrid, Spain. [Soni, Nilam J.; Reyes, Luis F.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Sect Pulm & Crit Care Med, San Antonio, TX USA. [Soni, Nilam J.; Reyes, Luis F.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Soni, Nilam J.] Univ Texas Sch Med San Antonio, Div Hosp Med, San Antonio, TX USA. [Rodriguez-Almodovar, Ana; Gonzalez-Davia, Rosa] Infanta Cristina Univ Hosp, Dept Cardiol, Madrid, Spain. [Manuel Fernandez-Alonso, Juan] Infanta Cristina Univ Hosp, Dept Biochem, Madrid, Spain. RP Soni, NJ (reprint author), 7703 Floyd Curl Dr,MC 7982, San Antonio, TX 78229 USA. EM sonin@uthscsa.edu FU Madrid-Castilla la Mancha Society of Internal Medicine; National Heart, Lung, and Blood Institute [K23HL096054] FX This study was supported by a grant from the Madrid-Castilla la Mancha Society of Internal Medicine. Dr. Restrepo is partially supported by award number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The authors report no conflicts of interest. NR 42 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD NOV PY 2016 VL 11 IS 11 BP 778 EP 784 DI 10.1002/jhm.2620 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EB0ZH UT WOS:000387075100007 PM 27264844 ER PT J AU Andolfi, C Wiesel, O Fisichella, PM AF Andolfi, Ciro Wiesel, Ory Fisichella, P. Marco TI Surgical Treatment of Epiphrenic Diverticulum: Technique and Controversies SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES LA English DT Article DE epiphrenic diverticulum; esophageal function test; gastroesophageal reflux disease; laparoscopic antireflux surgery; laparoscopic repair; thoracoscopic repair ID ESOPHAGEAL DIVERTICULA; MANAGEMENT; FUNDOPLICATION; ACHALASIA; OUTCOMES AB The goal of this article is to illustrate the current minimal invasive approaches to patients with epiphrenic diverticulum in terms of preoperative evaluation, surgical technique, and outcomes. Two techniques will be presented: a laparoscopic and a video-assisted thoracic repair. Indications for each technique will be discussed as well as proper patient selection and management. Current controversies in the treatment of patients with this rare disease will be addressed. C1 [Andolfi, Ciro] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Wiesel, Ory] Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA. [Fisichella, P. Marco] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. [Fisichella, P. Marco] Boston VA, Boston, MA USA. RP Fisichella, PM (reprint author), Harvard Med Sch, Boston VA Healthcare Syst, Brigham & Womens Hosp, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM piero.fisichella@va.gov NR 25 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1092-6429 EI 1557-9034 J9 J LAPAROENDOSC ADV S JI J. Laparoendosc. Adv. Surg. Tech. PD NOV PY 2016 VL 26 IS 11 BP 905 EP 910 DI 10.1089/lap.2016.0365 PG 6 WC Surgery SC Surgery GA EB2QR UT WOS:000387207400010 PM 27631419 ER PT J AU Andolfi, C Fisichella, PM AF Andolfi, Ciro Fisichella, P. Marco TI Laparoscopic Heller Myotomy and Dor Fundoplication for Esophageal Achalasia: Technique and Perioperative Management SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES LA English DT Article DE achalasia; Heller myotomy; esophageal function testing; laparoscopic repair; partial fundoplication ID PERORAL ENDOSCOPIC MYOTOMY; PNEUMATIC DILATION; SURGERY; CANCER; RISK; POEM; DILATATION; MANOMETRY AB Surgical correction of achalasia using laparoscopic Heller myotomy with Dor fundoplication is argued to be the gold standard treatment for patients with achalasia. The goal of this technical report is to illustrate our preferred approach to patients with achalasia and to provide the reader with a detailed description of our operative technique, its rationale, and our pre and postoperative management. C1 [Andolfi, Ciro] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Fisichella, P. Marco] Brigham & Womens Hosp, Dept Surg, Boston VA, 75 Francis St, Boston, MA 02115 USA. RP Fisichella, PM (reprint author), Harvard Med Sch, Boston VA Healthcare Syst, Brigham & Womens Hosp, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM piero.fisichella@va.gov NR 25 TC 0 Z9 0 U1 2 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1092-6429 EI 1557-9034 J9 J LAPAROENDOSC ADV S JI J. Laparoendosc. Adv. Surg. Tech. PD NOV PY 2016 VL 26 IS 11 BP 916 EP 920 DI 10.1089/lap.2016.0407 PG 5 WC Surgery SC Surgery GA EB2QR UT WOS:000387207400012 PM 27606723 ER PT J AU Melton, DW Roberts, AC Wang, HZ Sarwar, Z Wetzel, MD Wells, JT Porter, L Berton, MT McManus, LM Shireman, PK AF Melton, David W. Roberts, Alexander C. Wang, Hanzhou Sarwar, Zaheer Wetzel, Michael D. Wells, Jason T. Porter, Laurel Berton, Michael T. McManus, Linda M. Shireman, Paula K. TI Absence of CCR2 results in an inflammaging environment in young mice with age-independent impairments in muscle regeneration SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE sarcopenia; monocytes/macrophages; TLRs; myogenic progenitor cells ID SKELETAL-MUSCLE; SATELLITE CELLS; STEM-CELLS; FIBRO/ADIPOGENIC PROGENITORS; ALTERED INFLAMMATION; SIGNALING PATHWAY; INJURY; RECEPTOR; CHEMOKINES; MONOCYTES AB Skeletal muscle regeneration requires coordination between dynamic cellular populations and tissue microenvironments. Macrophages, recruited via CCR2, are essential for regeneration; however, the contribution of macrophages and the role of CCR2 on nonhematopoietic cells has not been defined. In addition, aging and sex interactions in regeneration and sarcopenia are unclear. Muscle regeneration was measured in young (3-6 mo), middle (11-15 mo), old (24-32 mo) male and female CCR2(-/-) mice. Whereas age-related muscle atrophy/sarcopenia was present, regenerated myofiber cross-sectional area (CSA) in CCR2(-/-) mice was comparably impaired across all ages and sexes, with increased adipocyte area compared with wild-type (WT) mice. CCR2(-/-) mice myofibers achieved approximately one third of baseline CSA even 84 d after injury. Regenerated CSA and clearance of necrotic tissue were dependent on bone marrow-derived cellular expression of CCR2. Myogenic progenitor cells isolated from WT and CCR2(-/-) mice exhibited comparable proliferation and differentiation capacity. The most striking cellular anomaly in injured muscle of CCR2(-/-) mice was markedly decreased macrophages, with a predominance of Ly6C2 anti-inflammatory monocytes/macrophages. Ablation of proinflammatory TLR signaling did not affect muscle regeneration or resolution of necrosis. Of interest, many proinflammatory, proangiogenic, and chemotactic cytokines were markedly elevated in injured muscle of CCR2(-/-) relative to WT mice despite impairments in macrophage recruitment. Collectively, these results suggest that CCR2 on bone marrow-derived cells, likely macrophages, were essential to muscle regeneration independent of TLR signaling, aging, and sex. Decreased proinflammatory monocytes/macrophages actually promoted a proinflammatory microenvironment, which suggests that inflammaging was present in young CCR2(-/-) mice. C1 [Melton, David W.; Roberts, Alexander C.; Sarwar, Zaheer; Wetzel, Michael D.; Wells, Jason T.; Porter, Laurel; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Wang, Hanzhou] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Berton, Michael T.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Melton, David W.; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Melton, David W.; Roberts, Alexander C.; Wang, Hanzhou; Sarwar, Zaheer; Wetzel, Michael D.; Wells, Jason T.; Porter, Laurel; Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wetzel, Michael D.] Shriners Hosp Children, Houston, TX USA. [Wells, Jason T.] Lahey Hosp & Med Ctr, Burlington, MA USA. [Porter, Laurel] Bexar Cty Med Examiners Off, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc & Endovasc Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [HL074236, HL110743]; NIH National Institute of Allergy and Infectious Diseases [AI095951]; Nathan Shock Centers of Excellence in Basic Biology of Aging [AG013319]; Veterans Administration Merit Review [1I01BX001186]; NIH National Cancer Institute [UL1-TR001120] FX We thank Joel Michalek, Ph.D., and Ken Ouyang for expert assistance in performing statistical analyses for these studies. These studies were supported, in part, by grants from the U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (HL074236 and HL110743), NIH National Institute of Allergy and Infectious Diseases (AI095951), Nathan Shock Centers of Excellence in Basic Biology of Aging AG013319, and Veterans Administration Merit Review 1I01BX001186. Data was generated in the Flow Cytometry Shared Resource Facility, which is supported by the University of Texas Health Science Center at San Antonio (UTHSCSA), NIH National Cancer Institute P30-CA054174-20 (Cancer Therapy & Research Center at UTHSCSA) and UL1-TR001120 (Clinical and Translational Science Award). NR 78 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD NOV PY 2016 VL 100 IS 5 BP 1011 EP 1025 DI 10.1189/jlb.3MA0316-104R PG 15 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA DZ6YA UT WOS:000386007500020 PM 27531927 ER PT J AU Xia, D Reardon, DA Bruce, JL Lindeman, NI AF Xia, Daniel Reardon, David A. Bruce, Jacqueline L. Lindeman, Neal I. TI The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID PROMOTER METHYLATION; ADJUVANT TEMOZOLOMIDE; RADIOTHERAPY; GLIOMAS; HYPERMETHYLATION; INACTIVATION; CONCOMITANT; ASSAY AB The methylation status of the promoter of the O-6-methylguanine DNA methyltransferase gene (MGMT) is an established prognostic and predictive biomarker of glioblastoma (GBM). At the Center for Advanced Molecular Diagnostics, MGMT testing is performed by methylation-specific PCR with multiple replicates, Leading to three types of reportable results: methylated, unmethylated, and inconsistently methylated. An inconsistently methylated result is reported when a methylated peak is seen in some but not all of the PCR replicates from a single DNA sample. To better understand the clinical implications of these results, we performed a retrospective review of all MGMT testing at our laboratory over a 5-year period, and correlated test results with outcome and specimen-quality data. This review yielded several novel findings. First, inconsistent MGMT methylation on replicate methylation-specific PCR is not uncommon, composes 12% (58/465) of our GBM results. Second, inconsistently methylated GBM cases are associated with relatively poor overall survival (more similar to unmethylated than to methylated cases). Third and interestingly, there appears to be a dose response relationship between patient survival and the extent of methylation in inconsistently methylated GBMs. Finally, our analyses of specimen-quality data suggest that a combination of technical factors (eg, small samples) and tumor biology may explain inconsistent MGMT results on replicate methylation-specific PCR testing. C1 [Xia, Daniel; Bruce, Jacqueline L.; Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02114 USA. [Reardon, David A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. RP Xia, D (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02114 USA. EM yxia8@partners.org NR 15 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 BP 864 EP 871 DI 10.1016/j.jmoldx.2016.06.009 PG 8 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000009 PM 27639200 ER PT J AU O'Leary, T Muralidhar, S Przygodzki, R Gaziano, JM Concato, J AF O'Leary, T. Muralidhar, S. Przygodzki, R. Gaziano, J. M. Concato, J. TI The Department of Veterans Affairs Million Veteran Program: An Update SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [O'Leary, T.; Muralidhar, S.; Przygodzki, R.] US Dept Vet Affairs, Washington, DC USA. [Gaziano, J. M.] US Dept Vet Affairs, Boston, MA USA. [Concato, J.] US Dept Vet Affairs, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA G19 BP 941 EP 941 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000037 ER PT J AU Ritterhouse, L Lafrate, A Le, LP Lennerz, JK AF Ritterhouse, L. Lafrate, A. Le, L. P. Lennerz, J. K. TI HFE Genotyping Test-Order Practice: A 10-Year Institutional Experience of 1840 Cases SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Ritterhouse, L.; Lafrate, A.; Le, L. P.; Lennerz, J. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA G27 BP 943 EP 943 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000045 ER PT J AU Jan, M Mar, BG Li, LS Johnson, LA Robinson, HE Raymond, AN Kudlow, BA Weinstock, DM Silverman, LB Harris, MH Lafrate, AJ Le, LP Nardi, V AF Jan, M. Mar, B. G. Li, L. S. Johnson, L. A. Robinson, H. E. Raymond, A. N. Kudlow, B. A. Weinstock, D. M. Silverman, L. B. Harris, M. H. Lafrate, A. J. Le, L. P. Nardi, V. TI A Novel Multiplex Next-Generation Sequencing Assay to Detect Actionable Kinase Fusions and Point Mutations in Philadelphia-Like Acute Lymphoblastic Leukemia SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Jan, M.; Robinson, H. E.; Raymond, A. N.; Lafrate, A. J.; Le, L. P.; Nardi, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mar, B. G.; Li, L. S.; Weinstock, D. M.; Silverman, L. B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Johnson, L. A.; Kudlow, B. A.] ArcherDX Inc, Boulder, CO USA. [Harris, M. H.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA H20 BP 955 EP 956 PG 2 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000097 ER PT J AU Pattanayak, V Duraisamy, S Lennerz, JK Dias-Santagata, D Le, LP Iafrate, AJ Nardi, V AF Pattanayak, V. Duraisamy, S. Lennerz, J. K. Dias-Santagata, D. Le, L. P. Iafrate, A. J. Nardi, V. TI Concomitant RAS Variants in Hematological Malignancies SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Pattanayak, V.; Duraisamy, S.; Lennerz, J. K.; Dias-Santagata, D.; Le, L. P.; Iafrate, A. J.; Nardi, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA H48 BP 962 EP 963 PG 2 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000125 ER PT J AU Liu, Y Geyer, JT Hasserjian, RP Wang, SA Bueso-Ramos, E Oak, J Arber, DA Hsi, E Levinson, KB Bagg, A Tam, W Orazi, A AF Liu, Y. Geyer, J. T. Hasserjian, R. P. Wang, S. A. Bueso-Ramos, E. Oak, J. Arber, D. A. Hsi, E. Levinson, K. B. Bagg, A. Tam, W. Orazi, A. TI Oligomonocytic Chronic Myelomonocytic Leukemia (CMML without Absolute Monocytosis) Displays a Similar Mutational Profile to Classical CMML with Frequent ASXL1, TET2 and SRSF2 Mutations SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Liu, Y.; Geyer, J. T.; Tam, W.; Orazi, A.] Weill Cornell Med Coll, New York, NY USA. [Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hasserjian, R. P.] Harvard Med Sch, Boston, MA USA. [Wang, S. A.; Bueso-Ramos, E.] MD Anderson Canc Ctr, Houston, TX USA. [Oak, J.; Arber, D. A.] Stanford Univ, Stanford, CA 94305 USA. [Hsi, E.] Cleveland Clin, Cleveland, OH 44106 USA. [Levinson, K. B.; Bagg, A.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA H51 BP 963 EP 963 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000128 ER PT J AU Nasrallah, MP Binder, ZA Zhao, J Martinez-Lage, M Oldridge, D Desai, A Maloney, E June, C O'Rourke, DM Maus, MV Morrissette, JJ AF Nasrallah, M. P. Binder, Z. A. Zhao, J. Martinez-Lage, M. Oldridge, D. Desai, A. Maloney, E. June, C. O'Rourke, D. M. Maus, M. V. Morrissette, J. J. TI Supporting Brain Tumor Clinical Trials: EGFRvIII-Directed CART Therapy in Glioblastoma SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Nasrallah, M. P.; Martinez-Lage, M.; Desai, A.; Maloney, E.; June, C.; O'Rourke, D. M.; Morrissette, J. J.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. [Binder, Z. A.] Univ Penn, Philadelphia, PA 19104 USA. [Zhao, J.] BioReference Labs, Philadelphia, PA USA. [Oldridge, D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Maus, M. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA S49 BP 1009 EP 1010 PG 2 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000317 ER PT J AU Wang, C McLaughlin, PJ Batten, JM Nielsen, GP Chebib, I Le, LP Iafrate, AJ Nardi, V AF Wang, C. McLaughlin, P. J. Batten, J. M. Nielsen, G. P. Chebib, I. Le, L. P. Iafrate, A. J. Nardi, V. TI AMP Technology Reveals EWSR1 Rearrangements in EWSR1 FISH Negative Cases SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Wang, C.; McLaughlin, P. J.; Batten, J. M.; Nielsen, G. P.; Chebib, I.; Le, L. P.; Iafrate, A. J.; Nardi, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA S68 BP 1014 EP 1014 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000336 ER PT J AU Wang, CI Sadow, PM Nardi, V Lennerz, JK Lynch, KD Cao, Y Zheng, Z Le, LP Iafrate, AJ Dias-Santagata, D AF Wang, C. I. Sadow, P. M. Nardi, V. Lennerz, J. K. Lynch, K. D. Cao, Y. Zheng, Z. Le, L. P. Iafrate, A. J. Dias-Santagata, D. TI Recurrent Oncogenic Fusions in Salivary Duct Carcinoma SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Wang, C. I.; Sadow, P. M.; Nardi, V.; Lennerz, J. K.; Lynch, K. D.; Cao, Y.; Le, L. P.; Iafrate, A. J.; Dias-Santagata, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zheng, Z.] City Univ Hong Kong, Kowloon, Hong Kong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA S81 BP 1017 EP 1017 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000348 ER PT J AU Sholl, LM Bruce, JL Alden, RS Lydon, CA Feeney, NB Paweletz, CP Oxnard, GR Lindeman, NI AF Sholl, L. M. Bruce, J. L. Alden, R. S. Lydon, C. A. Feeney, N. B. Paweletz, C. P. Oxnard, G. R. Lindeman, N. I. TI Clinical Validation of Plasma Cell Free DNA Mutation Detection in Patients with EGFR-Mutated Lung Cancer SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Sholl, L. M.; Bruce, J. L.; Lindeman, N. I.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Alden, R. S.; Lydon, C. A.; Feeney, N. B.; Paweletz, C. P.; Oxnard, G. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA S118 BP 1026 EP 1027 PG 2 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000385 ER PT J AU Costa-Mallen, P Zabetian, CP Hu, SC Agarwal, P Yearout, D Checkoway, H AF Costa-Mallen, Paola Zabetian, Cyrus P. Hu, Shu-Ching Agarwal, Pinky Yearout, Dora Checkoway, Harvey TI Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE Tobacco smoking; Haptoglobin concentration; Ferritin concentration; Haptoglobin phenotype; Parkinson's disease ID HEMOGLOBIN-BINDING; SUBSTANTIA-NIGRA; NEURODEGENERATIVE DISEASES; CIGARETTE-SMOKING; IRON; ASSOCIATION; SMOKERS; SUSCEPTIBILITY; ECHOGENICITY; POLYMORPHISM AB The phenotype Hp 2-1 of haptoglobin has been previously associated with increased risk of Parkinson disease (PD) and with serum iron abnormalities in PD patients. Tobacco smoking has been consistently observed in epidemiology studies to be inversely related to PD risk, with mechanisms that remain uncertain. We recently observed that the protective effect of smoking on PD risk is stronger among subjects of haptoglobin Hp 2-2 and Hp 1-1 phenotypes, and weaker among subjects of haptoglobin Hp 2-1 phenotype. In this PD case-control study, we investigated whether tobacco smoking was associated with changes in serum haptoglobin and ferritin concentration that depended on haptoglobin phenotype among 106 PD patients and 238 controls without PD or other neurodegenerative disorders. Serum ferritin concentration, serum haptoglobin concentration, haptoglobin phenotype, and smoking data information of cases and controls were obtained. Differences in haptoglobin and ferritin concentration by smoking status and pack-years of smoking were calculated as well as regression between pack-years and haptoglobin and ferritin concentration, and the effect of haptoglobin phenotype on these parameters. Tobacco smoking was associated with an elevation in serum haptoglobin concentration, especially among healthy controls of haptoglobin Hp 2-2 phenotype, and with an elevation in ferritin concentration especially among PD patients of haptoglobin Hp 2-1 phenotype. These findings suggest that an elevation in haptoglobin concentration, preferentially among subjects of haptoglobin Hp 2-2 phenotype, could be a contributing factor to the protective effect of smoking on PD risk. C1 [Costa-Mallen, Paola] Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA 98028 USA. [Zabetian, Cyrus P.; Yearout, Dora] Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Univ Washington, Dept Neurol, 325 Ninth Ave,3EH70, Seattle, WA 98104 USA. [Agarwal, Pinky] Evergreen Hlth, Booth Gardner Parkinsons Care Ctr, 12040 NE 128th St,Mailstop 11, Kirkland, WA 98034 USA. [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Publ Hlth, 9500 Gilman Dr 0725, La Jolla, CA 92093 USA. RP Costa-Mallen, P (reprint author), Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA 98028 USA. EM pcostamallen@bastyr.edu FU NIH [R21 NS070202, P50 NS062684, R01 NS065070]; Department of Veteran Affairs [1I01BX000531]; Bastyr University [4 2009-2011] FX The authors would like to thank all the individual study participants. This study was funded by grants from NIH (Grants # R21 NS070202, P50 NS062684, R01 NS065070), the Department of Veteran Affairs (Grant # 1I01BX000531), and Bastyr University (Faculty Seed Grants # 3 and # 4 2009-2011). NR 33 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 EI 1435-1463 J9 J NEURAL TRANSM JI J. Neural Transm. PD NOV PY 2016 VL 123 IS 11 BP 1319 EP 1330 DI 10.1007/s00702-016-1590-x PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DZ7TD UT WOS:000386068700007 PM 27349967 ER PT J AU Catafau, AM Bullich, S Seibyl, JP Barthel, H Ghetti, B Leverenz, J Ironside, JW Schulz-Schaeffer, WJ Hoffmann, A Sabri, O AF Catafau, Ana M. Bullich, Santiago Seibyl, John P. Barthel, Henryk Ghetti, Bernardino Leverenz, James Ironside, James W. Schulz-Schaeffer, Walter J. Hoffmann, Anja Sabri, Osama TI Cerebellar Amyloid-beta Plaques: How Frequent Are They, and Do They Influence F-18-Florbetaben SUV Ratios? SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE Alzheimer disease; florbetaben; positron emission tomography ID PRESENILIN-1 MUTATION CARRIERS; POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; REFERENCE REGION; SENILE PLAQUES; COMPOUND-B; PET SCANS; DEPOSITION; BRAIN; IMPACT AB SUV ratios (SUVRs) are used for relative quantification of F-18-florbetaben scans. The cerebellar cortex can be used as a reference region for quantification. However, cerebellar amyloid-beta (A beta) plaques may be present in Alzheimer disease (AD). The aim of this study was to assess the influence of A beta pathology, including neuritic plaques, diffuse plaques, and vascular deposits, in F-18-florbetaben SUVR when cerebellum is used as the reference. Methods: Using immunohistochemistry to demonstrate A beta plaques and vascular deposits, and using the Bielschowsky method to demonstrate neuritic plaques, we performed a neuropathologic assessment of the frontal, occipital, anterior cingulate, and posterior cingulate cerebral cortices and the cerebellar cortex of 87 end-of-life patients (64 with AD, 14 with other types of dementia, and 9 nondemented aged volunteers; mean age +/- SD, 80.4 +/- 10.2 y) who had undergone F-18-florbetaben PET before death. The lesions were rated as absent (none or sparse) or present (moderate or frequent). Mean cortical SUVRs were compared among cases with different cerebellar A beta loads. Results: None of the 83 evaluable cerebellar samples showed frequent diffuse A beta or neuritic plaques; 8 samples showed frequent vascular A beta deposits. Diffuse A beta plaques were rated as absent in 78 samples (94%) and present in 5 samples (6%). Vascular A beta was rated as absent in 62 samples (74.7%) and present in 21 samples (25.3%). No significant differences in cerebellar SUVs were found among cases with different amounts or types of A beta deposits in the cerebral cortex. Both diffuse and neuritic plaques were found in the cerebral cortex of 26-44 cases. No significant SUVR differences were found between these brains with different cerebellar A beta loads. Conclusion: The effect of cerebellar plaques on cortical F-18-florbetaben SUVRs appears to be negligible even in advanced stages of AD with a higher cerebellar A beta load. C1 [Catafau, Ana M.; Bullich, Santiago] Piramal Imaging GmbH, Tegelerstr 6-7, D-13353 Berlin, Germany. [Seibyl, John P.] Mol Neuroimaging, New Haven, CT USA. [Barthel, Henryk; Sabri, Osama] Univ Leipzig, Leipzig, Germany. [Ghetti, Bernardino] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Leverenz, James] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leverenz, James] Univ Washington, Seattle, WA 98195 USA. [Ironside, James W.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Schulz-Schaeffer, Walter J.] Georg August Univ Gottingen, Gottingen, Germany. [Hoffmann, Anja] Bayer Pharma AG, Berlin, Germany. RP Bullich, S (reprint author), Piramal Imaging GmbH, Tegelerstr 6-7, D-13353 Berlin, Germany. EM santi.bullich@piramal.com FU Bayer Pharma AG, Berlin (Germany); Piramal Imaging S.A., Matran (Switzerland) FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. The trial was funded by Bayer Pharma AG, Berlin (Germany), and Piramal Imaging S.A., Matran (Switzerland). No other potential conflict of interest relevant to this article was reported. NR 34 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD NOV PY 2016 VL 57 IS 11 BP 1740 EP 1745 DI 10.2967/jnumed.115.171652 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EB1GG UT WOS:000387097000020 PM 27363836 ER PT J AU Yambo, TW Johnson, ME Delaney, KR Hamilton, R Miller, AM York, JA AF Yambo, Teresa W. Johnson, Mary E. Delaney, Kathleen R. Hamilton, Rebekah Miller, Arlene Michaels York, Janet A. TI Experiences of Military Spouses of Veterans With Combat-Related Posttraumatic Stress Disorder SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Article DE Spouse; posttraumatic stress disorder; phenomenology; military; Colaizzi ID MALE VIETNAM VETERANS; SECONDARY TRAUMATIZATION; MENTAL-HEALTH; PARTNERS; WAR; SATISFACTION; PRISONERS; SYMPTOMS AB PurposeTo explore the experiences of military spouses living with veterans with combat-related posttraumatic stress disorder (PTSD). DesignHusserlian phenomenology was chosen as the theoretical framework because it allowed a deeper understanding of the unfolding of the spouses' daily experience. MethodsA purposive sample of 14 spouses living with veterans with symptoms of PTSD participated in unstructured interviews. Data were analyzed using a modification of the Colaizzi phenomenological method. FindingsSpouses recognized that the veteran was no longer the same person, with life becoming one of living with the unpredictability of PTSD. The spouses bore the burden to maintain normalcy in the family and eventually created a new life. ConclusionsMilitary spouses endure psychological stress and strain, while living with a veteran with PTSD. There is a need for more programs to support the resilience of military spouses. Clinical RelevanceLife for military spouses of veterans with PTSD is ever-changing and unpredictable. Practitioners need to be aware of the stress that spouses experience and develop programs and interventions that bolster the resilience of military families. C1 [Yambo, Teresa W.] Air Force Aid Soc, Spouse Employment Program, Osan Air Base, South Korea. [Johnson, Mary E.; Hamilton, Rebekah] Rush Univ, Specialty Educ, Chicago, IL 60612 USA. [Johnson, Mary E.] Rush Univ, Dept Community Syst & Mental Hlth Nursing, Chicago, IL 60612 USA. [Delaney, Kathleen R.] Rush Univ, PMH NP Program, Chicago, IL 60612 USA. [Delaney, Kathleen R.] Rush Univ, Grad Nursing Educ Demonstrat, Chicago, IL 60612 USA. [Hamilton, Rebekah] Rush Univ, Women Children & Family Hlth Nursing, Chicago, IL 60612 USA. [Miller, Arlene Michaels] Rush Univ, Commun Syst & Mental Hlth Nursing, Chicago, IL 60612 USA. [York, Janet A.] Med Univ South Carolina, PMHNP Residency Program, Mental Hlth Serv Line, Ralph H Johnson VAMC, Charleston, SC USA. [York, Janet A.] Med Univ South Carolina, Nursing, Charleston, SC USA. RP Yambo, TW (reprint author), Rush Univ, Coll Nursing, 600 S Paulina St, Chicago, IL 60612 USA. EM Teresa_w_yambo@rush.edu FU Jonas Center for Nursing and Veterans Healthcare; Bob Woodruff Foundation; National Military Family Association FX We appreciate the Jonas Center for Nursing and Veterans Healthcare, Bob Woodruff Foundation, and the National Military Family Association, which partially funded this research. NR 39 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6546 EI 1547-5069 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PD NOV PY 2016 VL 48 IS 6 BP 543 EP 551 DI 10.1111/jnu.12237 PG 9 WC Nursing SC Nursing GA EB2DB UT WOS:000387166400003 PM 27518829 ER EF